<SEC-DOCUMENT>0000939767-20-000035.txt : 20200225
<SEC-HEADER>0000939767-20-000035.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200225161332
ACCESSION NUMBER:		0000939767-20-000035
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20200103
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		20650766

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exel2019123110-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:eb39fec5d67043059b39f9b13440d630,x:757fa6a7ffe942ea9b8be091c709a45a-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:exel="http://www.exelixis.com/20200103" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-3E0DE728E16A9835DC307F5F58881B11-wk-Fact-3E0DE728E16A9835DC307F5F58881B11" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-772E0FB5EED22B7A48097F5F58899E96-wk-Fact-772E0FB5EED22B7A48097F5F58899E96">--01-03</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-590004BBBC8151568AA6B1BFC5E60A6E-wk-Fact-590004BBBC8151568AA6B1BFC5E60A6E">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-C18039D1514D550D81F4A4A79C72A647-wk-Fact-C18039D1514D550D81F4A4A79C72A647">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-7CDF3EA17DADF3C127F17F5F58871AE7-wk-Fact-7CDF3EA17DADF3C127F17F5F58871AE7">0000939767</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" name="exel:CollaborativeArrangementAchievedMilestoneAmount" id="Fact-E6DECAC2D7A91EB87DE015BA6907B36C-wk-Fact-E6DECAC2D7A91EB87DE015BA6907B36C">20000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q4" name="exel:InventoryManufacturedBeforeRegulatoryApproval" id="Fact-2E98D7A638AE54319B51C7BD70F4AF10-wk-Fact-2E98D7A638AE54319B51C7BD70F4AF10">0</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q1YTD" name="exel:MedicarePartDFundingMandate" id="Fact-A377A412DB6A11A0A1BC649AF7319F76-wk-Fact-A377A412DB6A11A0A1BC649AF7319F76">0.50</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" id="Fact-E0F0D75714C198CF36B9DD2CB6A9FB27-wk-Fact-E0F0D75714C198CF36B9DD2CB6A9FB27">P6M</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-48C0C2D323AC546C9E0D7675C1D85853-wk-Fact-48C0C2D323AC546C9E0D7675C1D85853">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-0931248BC90E584D87ECEE5C77E9F5F1-wk-Fact-0931248BC90E584D87ECEE5C77E9F5F1">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-E02155D2139E5CC2947BA59B216F4A51-wk-Fact-E02155D2139E5CC2947BA59B216F4A51">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-C90D9143603D53C99C1C5F927C170EAB-wk-Fact-C90D9143603D53C99C1C5F927C170EAB">400000000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-5BA1BB968A9A524F8A0C020D2AEC35D5-wk-Fact-5BA1BB968A9A524F8A0C020D2AEC35D5">299876000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-CD42DA9BAFC254CEAD51295F80503451-wk-Fact-CD42DA9BAFC254CEAD51295F80503451">304831000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-C7DD8DC68CF25A699E5794F8B3C09B00-wk-Fact-C7DD8DC68CF25A699E5794F8B3C09B00">299876000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-5640D752D09C5E98BBF57450E6989067-wk-Fact-5640D752D09C5E98BBF57450E6989067">304831000</ix:nonFraction><ix:nonNumeric contextRef="FI2019Q4_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-6CE0FCE5C266BE2D59E470505A81F3C0-wk-Fact-6CE0FCE5C266BE2D59E470505A81F3C0">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FI2019Q4_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-7D947BE1EC78C1C3F83B704C99E9BD1F-wk-Fact-7D947BE1EC78C1C3F83B704C99E9BD1F">P5Y</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2017Q4FYYTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-9F06C2B7C23632DAECF4C754417C14D6-wk-Fact-9F06C2B7C23632DAECF4C754417C14D6">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-CCDF6C015C347E142B5DC7544179CBA8-wk-Fact-CCDF6C015C347E142B5DC7544179CBA8" sign="-">156000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q4YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-913C1AF8854955839A99B9E5063CD579-wk-Fact-913C1AF8854955839A99B9E5063CD579">1049000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2017Q4FYYTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-5D33F43624FB0D5C31E07F5F58926AC7-wk-Fact-5D33F43624FB0D5C31E07F5F58926AC7">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-E48D6712496480715A727F5F58DFB6D0-wk-Fact-E48D6712496480715A727F5F58DFB6D0">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-CE2044CCF8405CFA8A83A89588D712F6-wk-Fact-CE2044CCF8405CFA8A83A89588D712F6">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-1FF457A008955FBFB8C24E73D2BC50FC-wk-Fact-1FF457A008955FBFB8C24E73D2BC50FC">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-EF960E95643A512E9C1F47E2F51D4E39-wk-Fact-EF960E95643A512E9C1F47E2F51D4E39">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-938BEFB6D1B8595C9B03636833CBE85C-wk-Fact-938BEFB6D1B8595C9B03636833CBE85C">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-AA61665A7D8F5B258AE1766E2557517F-wk-Fact-AA61665A7D8F5B258AE1766E2557517F">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-A6327BDDDC1F5EE6B1204EE4B3F2E950-wk-Fact-A6327BDDDC1F5EE6B1204EE4B3F2E950">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-295A53780EBAC7DDA118125838E9B588-wk-Fact-295A53780EBAC7DDA118125838E9B588">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-CE6B9ECAD44394412B84125838AEB4A5-wk-Fact-CE6B9ECAD44394412B84125838AEB4A5">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-7DABC88CC728E3D5959612583915F158-wk-Fact-7DABC88CC728E3D5959612583915F158">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-B4A8BFFF1FB3025574E07F5F58C2586E-wk-Fact-B4A8BFFF1FB3025574E07F5F58C2586E">P15Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-246047967E0F105CD9E4125838CD9F75-wk-Fact-246047967E0F105CD9E4125838CD9F75">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="D2010Q4Jan02-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-07143095F83750495D89A84F45F2B52A-wk-Fact-07143095F83750495D89A84F45F2B52A">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-2539F3C03FD9A5D5B0B0A84EA270C9BF-wk-Fact-2539F3C03FD9A5D5B0B0A84EA270C9BF">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-D162C5A3C48A883EC907A84FEA89ACC0-wk-Fact-D162C5A3C48A883EC907A84FEA89ACC0">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact-9B56F2ABD4F151A9AFA2A84ECDB8F3D5-wk-Fact-9B56F2ABD4F151A9AFA2A84ECDB8F3D5">P7Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="exel-20200103.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q4feb18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-03-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:ProductCommercializationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:GlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAFilingAcceptanceHCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_MINNEBROMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:MINNEBROMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:AdditionalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:FirstProductToReachMarketMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesSecondProductApprovalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_StatusAxis_exel_VestedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:VestedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2010Q4Jan02-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-01-02</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Fiscal">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-28</xbrli:startDate>
			<xbrli:endDate>2020-01-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="cad">
		<xbrli:measure>iso4217:CAD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="program">
		<xbrli:measure>exel:program</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit><xbrli:unit id="renewal_option">
		<xbrli:measure>exel:renewal_option</xbrli:measure>
	</xbrli:unit><xbrli:unit id="USD_PER_sqft">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>utreg:sqft</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s6E0BE5D548D95F178F5467AE05DD453F"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:31%;"></td><td style="width:34%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:20px;text-align:left;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s157DCB801066550D9CF101D9851EB093"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:14pt;"><span style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:14pt;"><span style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:266px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-top:2px;text-align:right;font-size:14pt;"><span style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">FORM </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:14pt;"><span style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e594-wk-Fact-334E1EB9C0A03C0912D480153F31FC1B" name="dei:DocumentType" contextRef="FD2019Q4YTD">10-K</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:0px;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e597-wk-Fact-9C37EE5ABBD184F149F785DD3F26E085" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Wingdings;font-size:8.5pt;">&#9746;</span></ix:nonNumeric></span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">For the fiscal year ended </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d21809722e607-wk-Fact-CD72CF5A1602EDBAAAFA80158BAFD5D0" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">January 3, 2020</ix:nonNumeric></span></span></span></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">or</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:0px;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e613-wk-Fact-F6C98F8C5F0A2CCFCCB485DE2C30FE9A" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Wingdings;font-size:8.5pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d21809722e623-wk-Fact-B10BE84969D35B5B81C8B6C7AB139976" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">000-30235</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:267px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:266px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo19q4.jpg" alt="exellogo19q4.jpg" style="height:49px;width:148px;"></img></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:14pt;"><span style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e644-wk-Fact-45472465F2265347A9FAB2F03814D0BD" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD">EXELIXIS, INC.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Calibri,sans-serif;font-size:7pt;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:8.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e664-wk-Fact-6768AACFEFB655EAA9B01700DF1BDC4C" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e669-wk-Fact-92F714AE241352969A54530EB430CA78" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">04-3257395</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">(I.R.S. Employer Identification Number)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e684-wk-Fact-D0DB7D9C6F1B56FDA6B9837538B59FBD" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">1851 Harbor Bay Parkway</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e690-wk-Fact-AF229F23A7145D5A8B242638F0E7B29C" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">Alameda,</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d21809722e695-wk-Fact-452C5D454C415C75A72B70F2ABF7E8F0" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">CA</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d21809722e700-wk-Fact-AD7E79C0C42058799D5323E488704C8E" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">94502</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d21809722e708-wk-Fact-8F56829B12BD5730A1ABB662433C42E7" name="dei:CityAreaCode" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">650</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d21809722e713-wk-Fact-B2A470547A4F5F29B3C7DC4542C2C63B" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">837-7000</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:7pt;"><span style="font-family:Calibri,sans-serif;font-size:7pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:8.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e753-wk-Fact-49A629C1E38BCE0BFCD18016B29A039F" name="dei:Security12bTitle" contextRef="FD2019Q4YTD">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e758-wk-Fact-D8358DCC00834A5E7ADB8016B34029A9" name="dei:TradingSymbol" contextRef="FD2019Q4YTD">EXEL</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;"><span><ix:nonNumeric id="d21809722e763-wk-Fact-93BC9FEDBBF93708F6568016B3F2D990" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:0px;text-align:center;text-indent:0px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">None</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;</span><span><ix:nonNumeric id="d21809722e774-wk-Fact-279776635351ED02FDAF80176ECA9987" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9746;</span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span><ix:nonNumeric id="d21809722e794-wk-Fact-5A16BE4B83D07955FC1680178B2DE859" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">No</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9746;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;</span><span><ix:nonNumeric id="d21809722e804-wk-Fact-1200FC4AADB4FA21D03B8017C48C9340" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9746;</span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span><ix:nonNumeric id="d21809722e821-wk-Fact-5B367E39302947E872108017E259329E" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9746;</span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:26%;"></td><td style="width:4%;"></td><td style="width:20%;"></td><td style="width:27%;"></td><td style="width:3%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e853-wk-Fact-2C128E49E7CEC8C5BBE180180D1AF64A" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Arial Unicode MS;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e904-wk-Fact-A2B823EB5BF5CC388A06801830D406F2" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Arial Unicode MS;font-size:8.5pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><span style="font-family:Arial Unicode MS;font-size:8.5pt;"><span><ix:nonNumeric id="d21809722e934-wk-Fact-C49BA09681A919C246AC700E176109AE" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  </span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d21809722e949-wk-Fact-BF9EF909BA31256CDCF48019426621DD" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Wingdings;font-size:8.5pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8.5pt;">&#9746;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;"><span>$<ix:nonFraction id="d21809722e961-wk-Fact-BF3ED92059334E0694147F5F588D8D17" name="dei:EntityPublicFloat" contextRef="FI2019Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,731,439,777</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">. Excludes shares of the registrant&#8217;s common stock held by persons who were directors and/or executive officers of the registrant at&#160;June&#160;28, 2019&#160;on the basis that such persons may be deemed to have been affiliates of the registrant at such date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">Number shares of the registrant&#8217;s common stock outstanding as of </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">February&#160;18, 2020</span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;">: </span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;"><span><ix:nonFraction id="d21809722e972-wk-Fact-7AC819A676D755CF992E403B349646BA" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q4feb18" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">305,393,240</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:8.5pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:8.5pt;"><span style="font-family:Calibri,sans-serif;font-size:8.5pt;"><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="TextSelection-D8A4E2CE2E75F1A4FA437F8790007DF6-0-wk-Fact-C5E2B66FF15BA3C16E5B7F89598D643D" escape="true">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than May 4, 2020, in connection with the registrant&#8217;s 2020 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric> </span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s87685C8EE92A570B9E53D6B24B688B3E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sF9173CA4F8835037985115CB97642435"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9BD3F292CF0C55618CCC67C55B2F13B9"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Business</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9BD3F292CF0C55618CCC67C55B2F13B9">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6BB0A72870AF585282857140811BFEB5"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6BB0A72870AF585282857140811BFEB5">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1B.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6F3F417146BC55B9BA3191ACEC7E3500"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unresolved Staff Comments</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6F3F417146BC55B9BA3191ACEC7E3500">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF6787D5D80E157BA997F06A41794DA12"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Properties</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF6787D5D80E157BA997F06A41794DA12">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s91EA716305D8589299136DD3D9E26A14"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s91EA716305D8589299136DD3D9E26A14">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF2E7B3BFB9FD551683D71DE28E4E362A"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF2E7B3BFB9FD551683D71DE28E4E362A">53</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sF583C12D45C25431AD1D45765DE78AFD"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;5.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1091D77BA5DC53069A746A183F45F8AC"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1091D77BA5DC53069A746A183F45F8AC">54</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s7E42650AABFF522F9B29FDD3D34E4EB7"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selected Financial Data</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s7E42650AABFF522F9B29FDD3D34E4EB7">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;7.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s05D5A4F917E45FBDBA3385867F10DAFD"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s05D5A4F917E45FBDBA3385867F10DAFD">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;7A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s87FEDAF3557056BFA250D81B91DAA331"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s87FEDAF3557056BFA250D81B91DAA331">71</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;8.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC9EB9003094150519FFA3C18EBD86BBC"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC9EB9003094150519FFA3C18EBD86BBC">72</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA41E8B4C5C2E50448F3A9AB9C85E1DC8"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA41E8B4C5C2E50448F3A9AB9C85E1DC8">109</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s26B22B0521AB572D8679D12318C8B17C"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s26B22B0521AB572D8679D12318C8B17C">109</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9B.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s57A887B8024B5C17A96344A5BD991423"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s57A887B8024B5C17A96344A5BD991423">111</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s82D46CABF09B5926BFBCE1FE1C860E10"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;10.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s80FFD497F2D85865AB2F4C0F88CE5554"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s80FFD497F2D85865AB2F4C0F88CE5554">111</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;11.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s34EC3EA7F54852A3A20A380592688726"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Compensation</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s34EC3EA7F54852A3A20A380592688726">111</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;12.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0D686A2674325BEE918EDD6CBB721CBA"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0D686A2674325BEE918EDD6CBB721CBA">112</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;13.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA72B55362B8B5BE0A2ECF505489EFBED"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA72B55362B8B5BE0A2ECF505489EFBED">112</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;14.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s22680314FC065C869068EEF38728EA37"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s22680314FC065C869068EEF38728EA37">112</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s5C16DEA372FE579991D4BD78F836B0FD"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART IV</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;15.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sCF69B1826B725C41B7DC9565A4010D92"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits, Financial Statement Schedules</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sCF69B1826B725C41B7DC9565A4010D92">113</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;16.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5E1E09DE6DA658BFA7AF47A662EFBB17"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form 10-K Summary</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5E1E09DE6DA658BFA7AF47A662EFBB17">119</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sD36375C21DEA5EECA0257D49077E197F"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD36375C21DEA5EECA0257D49077E197F">120</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF9173CA4F8835037985115CB97642435"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Some of the statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; and elsewhere in this Annual Report on Form&#160;10-K are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div><a id="s9BD3F292CF0C55618CCC67C55B2F13B9"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Business</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers. The growth that we have experienced in recent years is largely attributable to cabozantinib&#8217;s clinical and commercial success; consistent with our values and legal obligations, we are committed to ensuring that all patients who are prescribed cabozantinib are able to access this essential medicine.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). For additional information about these products, see &#8220;&#8212;Collaborations&#8212;Other Collaborations.&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Over the course of 2019, revenues from CABOMETYX and COMETRIQ sales and from the royalties and milestone payments we have received pursuant to collaboration agreements with our partners, coupled with disciplined expense management, have fueled the growth of our organization. We believe in our long-term growth prospects</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which are s</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upported by a healthy cash position and profitability over the past three fiscal years. We are utilizing our cash and investments to enable potential future success by expanding the development program for cabozantinib and by building a pipeline of new drug candidates through internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug development and commercialization expertise. The following report details the progress we made executing our growth strategy.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exelixis Marketed Products: CABOMETYX and COMETRIQ</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#160;was first approved by the U.S. Food and Drug Administration (FDA) on April 25, 2016, for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy and by the European Commission (EC) on September 9, 2016, similarly for the treatment of advanced RCC in adults in the European Union (EU) following prior VEGF-targeted therapy. On December 19, 2017, the FDA approved the expanded indication for CABOMETYX to include previously untreated patients with advanced RCC, and the EC approved CABOMETYX on May 17, 2018 as a first-line treatment for adults with intermediate- or poor-risk advanced RCC. Most recently, CABOMETYX was approved by the FDA on January 14, 2019, for the treatment of patients with HCC who have been previously treated with sorafenib, which followed the EC&#8217;s earlier approval of CABOMETYX on November 15, 2018, for the treatment of HCC in adults previously treated with sorafenib. COMETRIQ, our first marketed cabozantinib product, was approved by the FDA on November 29, 2012, for the treatment of patients with progressive, metastatic MTC, and in March 2014, the EC granted COMETRIQ a conditional marketing authorization for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. In 2019, 2018 and 2017, we generated </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$760.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$619.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$349.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in net product revenues from sales of CABOMETYX and COMETRIQ in the U.S. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Outside the U.S. and Japan, CABOMETYX and COMETRIQ are marketed by our collaboration partner Ipsen Pharma SAS (Ipsen). Should CABOMETYX be approved in Japan, it will be marketed by our collaboration partner Takeda Pharmaceutical Company Limited (Takeda). In 2019, 2018 and 2017, we earned $62.4 million, $32.3 million and $3.8 million, respectively, of royalties on net sales of cabozantinib products outside of the U.S. For additional information on the terms of our collaboration agreements with Ipsen and Takeda, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Commercial Collaborations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Renal Cell Carcinoma - CABOMETYX is a Leading Tyrosine Kinase Inhibitor (TKI) Treatment Option for Patients with Advanced RCC</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Kidney cancer is among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S. Estimates suggest that approximately 32,000 patients in the U.S. and 71,000 worldwide will require systemic treatment for kidney cancer in 2020. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A growing number of these patients with RCC have been or will be treated with CABOMETYX, which has become a standard of care for the treatment of patients suffering from this difficult-to-treat disease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since CABOMETYX was first approved, our promotional and medical affairs teams have been focused on educating physicians about CABOMETYX&#8217;s unique clinical profile. We believe that the success of CABOMETYX is attributable to this clinical profile, derived from the results of our clinical trials, METEOR and CABOSUN. CABOMETYX is the first and only single-agent therapy approved for previously treated advanced RCC to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters in a global pivotal trial: overall survival (OS); progression-free survival (PFS); and objective response rate (ORR). In addition, in previously untreated patients with advanced RCC, CABOMETYX is the only approved single-agent therapy to improve PFS and ORR compared with sunitinib, a first-generation TKI that was the previous standard of care. It is also noteworthy that on September 7, 2018, the National Comprehensive Cancer Network (NCCN), the nation&#8217;s foremost non-profit alliance of leading cancer centers, updated its Clinical Practice Guidelines to recommend CABOMETYX as the only TKI with preferred status for advanced RCC patients who have progressed on prior therapy and for the treatment of advanced RCC regardless of patient risk status (favorable-, intermediate-, and poor risk). These updated recommendations strengthened the differentiation of CABOMETYX from other TKIs approved for this indication, leading many physicians to consider CABOMETYX a therapeutic option, despite numerous competing products approved to treat advanced RCC. For additional information about CABOMETYX&#8217;s profile as expressed in the METEOR and CABOSUN clinical trial data, see &#8220;&#8212;Cabozantinib Development Program&#8212;Clinical Trials Supporting Regulatory Approvals.&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In markets outside the U.S. in 2019, we continued to work closely with Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX as a treatment for advanced RCC. As a result of the approvals of CABOMETYX for RCC indications in 51 countries outside of the U.S., including the Member States of the EU, Canada, Brazil, Taiwan, South Korea and Australia, CABOMETYX has continued to grow both in sales revenue and the number of RCC patients benefiting from its clinical effect. Additionally, with respect to the Japanese market, Takeda achieved an important regulatory milestone in April 2019 with its application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable and metastatic RCC in Japan</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Hepatocellular Carcinoma - the CABOMETYX Label Expanded to Include Previously Treated HCC</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">According to published studies, liver cancer is a leading cause of cancer death worldwide, accounting for more than 700,000 deaths and 800,000 new cases each year. In the U.S., the incidence of liver cancer has more than tripled since 1980. Although HCC is the most common form of liver cancer, making up about three-fourths of the nearly 43,000 cases of liver cancer estimated to be diagnosed in the U.S. during 2020, this patient population has long been underserved. Prior to 2017, there was only one approved systemic therapy for the treatment of HCC. Then, in 2017 and 2018, four new therapies were </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">approved in the U.S. for HCC, one for previously untreated patients and three for patients previously treated with sorafenib. Given the introduction of new and more effective therapies, including immune checkpoint inhibitor (ICI) combination therapies if approved, we believe the second- and later-line HCC market has the potential to grow significantly in coming years, as these new treatment options are expected to result in an increasing number of patients receiving multiple lines of therapy. With the approval of CABOMETYX in January 2019 for HCC patients previously treated with sorafenib, we aim to play a key role in the advancement of therapeutic options for these patients.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA&#8217;s approval of CABOMETYX for this HCC indication was based on our phase 3 pivotal study, CELESTIAL. The CELESTIAL study met its primary endpoint, demonstrating that cabozantinib significantly improved OS, as compared to placebo. For additional information on CELESTIAL, see &#8220;&#8212;Cabozantinib Development Program&#8212;Clinical Trials Supporting Regulatory Approvals&#8212;HCC - CELESTIAL.&#8221; Upon FDA approval, we were immediately prepared to offer CABOMETYX to all eligible HCC patients in the U.S. who may benefit from this treatment option. We were able to take action quickly due to the strength of our existing commercial and medical affairs organizations, in addition to our well-established distribution network and our ability to leverage our RCC commercialization experience. The NCCN&#8217;s inclusion of CABOMETYX in its Clinical Practice Guidelines for Hepatobiliary Cancers as a Category 1 option for the treatment of patients with HCC (Child-Pugh Class A only) who have been previously treated with sorafenib further supports CABOMETYX as an important treatment option for eligible HCC patients.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Outside the U.S., the EC&#8217;s approval of CABOMETYX provided physicians in the EU with a second approved therapy for the second-line treatment of this aggressive and difficult-to-treat cancer</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Health Canada&#8217;s November 2019 approval brought a much-needed therapy to Canadian patients with HCC. In addition to the Member States of the EU and Canada, CABOMETYX is also approved for previously treated HCC indications in Taiwan, South Korea</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Australia and Hong Kong, among other countries. With respect to the Japanese market, in January 2020, Takeda applied to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable HCC who progressed after prior systemic therapy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Medullary Thyroid Cancer - COMETRIQ, the First Commercial Approval of Cabozantinib</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Estimates suggest that there will be approximately 900 MTC cases diagnosed in the U.S. in 2020. The FDA&#8217;s approval of COMETRIQ for this MTC indication was based on our phase 3 trial, EXAM. The EXAM trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for cabozantinib, as compared to placebo. For additional information on EXAM, see &#8220;&#8212;Cabozantinib Development Program&#8212;Clinical Trials Supporting Regulatory Approvals&#8212;MTC - EXAM.&#8221; In 2019, 2018 and 2017, we generated </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$26.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$19.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and $25.0 million, respectively, in net product revenues from sales of COMETRIQ in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Program</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib inhibits the activity of tyrosine kinases, including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance and maintenance of the tumor microenvironment. Objective tumor responses have been observed in patients treated with cabozantinib in more than 20 individual tumor types investigated in phase 1 and 2 clinical trials to date, reflecting the medicine&#8217;s broad clinical potential. We are currently evaluating cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">85</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of those trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. In addition to co-funding select trials with us, our collaboration partners Ipsen and Takeda also conduct trials in their territories through similar independently-sponsored programs.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following two tables summarize select cabozantinib clinical development activities, one describing studies that evaluate the potential of cabozantinib as a single-agent, and the other describing studies that evaluate the potential of cabozantinib in combination with other therapies, including ICIs:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, SINGLE-AGENT</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Thyroid Cancer</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Progressive, metastatic medullary thyroid cancer</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (EXAM)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Progressive, metastatic medullary thyroid cancer</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Post-marketing study (EXAMINER)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Differentiated thyroid cancer (DTC)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (COSMIC-311)</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Renal Cell Carcinoma (RCC)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (METEOR and CABOSUN)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First- or second-line papillary RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Randomized phase 2&#8224; (PAPMET)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic Variant Histology RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* (CABOSUN II)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Locally Advanced Non-Metastatic Clear Cell RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Hepatocellular Carcinoma (HCC)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line HCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (CELESTIAL)</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Small Cell Lung Cancer (NSCLC)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">EGFR wild-type</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Molecular alterations in RET, ROS1, MET, AXL, or NTRK1</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Trials </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">High-risk prostate cancer</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* (SPARC)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic urothelial carcinoma (UC)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* (ATLANTIS)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Colorectal cancer (CRC)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">High-grade uterine sarcomas</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#167;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic gastrointestinal stromal tumor</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#167; (CABOGIST)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pancreatic neuroendocrine tumors and carcinoid tumors</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* and Phase 3&#8224; (CABINET)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Plexiform neurofibromas (pediatric and adult cohorts)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Relapsed osteosarcoma or Ewing sarcoma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Soft-tissue sarcomas</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through our IST program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8224; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through collaboration with NCI-CTEP.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#167; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial sponsored by the European Organization for Research and Treatment of Cancer.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, IN COMBINATION WITH OTHER THERAPIES</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combination Regimen</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Genitourinary Cancers</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First-line advanced RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (CheckMate 9ER)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First-line advanced or metastatic RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab + ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (COSMIC-313)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First-line metastatic RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab vs. nivolumab after 4 cycles of nivolumab + ipilimumab </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3&#8224; randomized (PDIGREE)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced or metastatic RCC with a clear-cell component</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ CB-839 (telaglenastat)</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2 pivotal trial (CANTATA)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced or metastatic non-clear cell RCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced RCC with bone metastasis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ radium-223 dichloride</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224; (RadiCal)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cisplatin-Ineligible advanced UC</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ pembrolizumab</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* (PemCab)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Genitourinary tumors</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b&#8224;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Genitourinary tumors</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab + ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224; (ICONIC)</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Gastrointestinal Cancers</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First-line advanced HCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (COSMIC-312), including a single-agent cabozantinib arm</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line advanced HCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1/2 (CheckMate 040)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Neoadjuvant locally advanced HCC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; nivolumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">KRAS wild-type metastatic CRC and cMET amplified metastatic CRC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; panitumumab</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1* (CaboMAb)</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Thyroid Cancers</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced DTC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab + ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Lung Cancers</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">NSCLC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Gynecologic Cancers</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced or metastatic endometrial cancer</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic, triple negative breast cancer</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Breast cancer with brain metastases</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; trastuzumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Neuroendocrine Tumors (NET) and Carcinoid</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced carcinoid tumors</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Head and Neck Cancers</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Recurrent, metastatic squamous cell carcinoma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ cetuximab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Recurrent, metastatic squamous cell carcinoma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ pembrolizumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Melanoma</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unresectable, advanced melanoma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab + ipilimumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced, metastatic melanoma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ pembrolizumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Sarcoma</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ temozolomide</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Sarcomas of the extremities</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ radiation therapy</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Trials in Multiple Tumor Types</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced solid tumors</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b with 20 cabozantinib and atezolizumab expansion cohorts, including metastatic castration-resistant prostate cancer (mCRPC) (pivotal cohort), RCC, UC, HCC, colorectal adenocarcinoma, DTC, NSCLC, endometrial cancer, ovarian cancer, breast cancer, gastric or gastroesophageal junction adenocarcinoma and head and neck cancer (COSMIC-021), and three single-agent cabozantinib exploratory cohorts (UC, NSCLC and mCRPC), and one single-agent atezolizumab exploratory cohort (mCRPC)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced CRC, HCC, gastric, gastroesophageal or esophageal adenocarcinoma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ durvalumab</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1* (CAMILLA)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced non-squamous NSCLC, UC and advanced malignant mesothelioma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">+ pemetrexed</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1*</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through our IST program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8224; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through collaboration with NCI-CTEP.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#167; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial sponsored by the European Organization for Research and Treatment of Cancer.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trials Supporting Regulatory Approvals</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">RCC - METEOR</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2015, we announced positive results of METEOR, a phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC who have experienced disease progression following treatment with at least one prior VEGF receptor inhibitor. METEOR met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in PFS for CABOMETYX. The median PFS was 7.4 months for the CABOMETYX arm versus 3.8 months for the everolimus arm. CABOMETYX also significantly improved ORR, a secondary endpoint, compared with everolimus. In September 2015,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">The New England Journal of Medicine (NEJM)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;published the complete, detailed positive results from the primary analysis of METEOR, and these results were also presented at the European Society for Medical Oncology (ESMO) 2015 Congress. After additional follow up, METEOR also met its other secondary endpoint of OS, as presented in June 2016 at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting and published in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Lancet Oncology</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The median OS was 21.4 months for patients receiving CABOMETYX versus 16.5 months for those receiving everolimus. The safety profile in the study and in later analyses was consistent with the established profile of cabozantinib and other TKIs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the METEOR trial, the FDA approved CABOMETYX for the treatment of patients with advanced RCC following prior antiangiogenic therapy, and the European Medicines Agency (EMA) approved CABOMETYX for the treatment of advanced RCC in adults following prior VEGF-targeted therapy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">RCC - CABOSUN</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2016, we announced positive results from CABOSUN, a randomized, open-label, active-controlled phase 2 trial comparing cabozantinib with sunitinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease conducted by The Alliance for Clinical Trials in Oncology (The Alliance) under our CRADA with NCI-CTEP. These results were presented at the ESMO 2016 Congress in October 2016 and subsequently published in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Clinical Oncology</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in November 2016. CABOSUN met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in investigator-assessed PFS compared with sunitinib.&#160;The median PFS for cabozantinib was 8.2 months versus 5.6 months for sunitinib. Investigator-assessed</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ORR, a secondary endpoint, was also significantly improved, at 33% for cabozantinib versus 12% for sunitinib, and median OS, another secondary endpoint, showed a trend favoring cabozantinib with 30.3 months versus 21.8 months for sunitinib. Updated results from CABOSUN were presented at the ESMO 2017&#160;Congress in September 2017 and subsequently published in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">European Journal of Cancer </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in May 2018. The updated results included the analysis from a blinded independent radiology review committee (IRRC), which confirmed the primary efficacy endpoint results of investigator-assessed PFS, as well as an updated investigator-assessed analysis. Per the IRRC analysis, the median PFS for cabozantinib was 8.6 months versus 5.3 months for sunitinib, and both the updated investigator assessment and IRRC analysis demonstrated consistent and statistically significant improvement of PFS with cabozantinib as compared to sunitinib. The updated OS analysis had a data cut-off of&#160;July 1, 2017, and showed a favorable trend for patients randomized to cabozantinib compared to sunitinib that was not statistically significant. Median OS was 26.6 months for patients receiving cabozantinib versus 21.2 months for those receiving sunitinib. The safety profile in the study and in later analyses was consistent with the established profile of cabozantinib and other TKIs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the CABOSUN trial, the FDA approved CABOMETYX for the treatment of patients with previously untreated, advanced or metastatic RCC on December 19, 2017, and we commenced our commercial launch of CABOMETYX for this new indication immediately upon such approval. Additionally, on May 17, 2018, the EC approved cabozantinib as a first-line treatment for adults with intermediate- or poor-risk advanced RCC.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">RCC - Retrospective Analyses of CABOSUN and METEOR</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As the advanced RCC treatment landscape continues to evolve and include multiple ICI treatment options, biomarker analyses are of increasing importance to help select for advanced RCC patients who would potentially derive the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">most clinical benefit from CABOMETYX. Two relevant retrospective analyses were presented at the ESMO 2018 Congress in October 2018 that described the potential utility of CABOMETYX in patients with advanced RCC regardless of their PD-L1 status, as well as in those patients with advanced RCC who progressed on previous ICI monotherapy or combination treatment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The first analysis of data from the CABOSUN and METEOR trials evaluated the effect of PD-L1 expression on clinical outcomes with cabozantinib in advanced RCC and demonstrated that cabozantinib improved clinical outcomes regardless of PD-L1 status, relative to sunitinib or everolimus, the respective comparator arms for each trial. The findings showed that PD-L1 expression was associated with shorter median PFS and OS in both METEOR and CABOSUN. Treatment with cabozantinib, however, improved PFS and OS compared with everolimus (METEOR) and sunitinib (CABOSUN) in both PD-L1 positive and PD-L1 negative patients. An additional retrospective analysis found that cabozantinib was active in patients previously treated with ICIs, either alone or in combination with anti-VEGF or other therapies. At a median follow-up of 12 months, ORR was 33%, disease control rate (DCR) was 79% and the one-year OS rate was 53%. Together, these analyses evaluating data from the CABOSUN and METEOR clinical trials contribute to cabozantinib&#8217;s unique product profile, as well as its value as a treatment option for patients with advanced RCC within an evolving and competitive treatment landscape that includes multiple ICI treatment options.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">HCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> CELESTIAL</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, we announced positive results of CELESTIAL, our phase 3 pivotal trial comparing cabozantinib to placebo in patients with HCC who had received previous treatment with sorafenib. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CELESTIAL had met its primary endpoint, with cabozantinib providing a statistically significant and clinically meaningful improvement versus placebo in OS, at which time the independent data monitoring committee, recommended CELESTIAL be stopped for efficacy. In January 2018,&#160;statistically significant and clinically meaningful positive results from the second interim analysis of CELESTIAL were presented during an oral session at the 2018 ASCO&#8217;s Gastrointestinal Cancers Symposium. In July 2018,&#160;the</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> NEJM</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;also published the complete, detailed positive results from CELESTIAL. In the total population of second- and third-line patients, median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (hazard ratio 0.76; 95% confidence interval 0.63-0.92; p=0.0049). Median PFS was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo. ORR was 4% with cabozantinib and 0.4% with placebo. Disease control (partial response (PR) or stable disease (SD)) was achieved by 64% of patients in the cabozantinib group compared with 33% in the placebo group. In a subgroup analysis of patients whose only prior therapy for HCC was sorafenib (70% of patients in the study), median OS was 11.3 months with cabozantinib versus 7.2 months with placebo. PFS in the subgroup was 5.5 months with cabozantinib versus 1.9 months with placebo. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The safety profile of cabozantinib observed in the study was consistent with the established profile of cabozantinib and other TKIs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the CELESTIAL trial, the FDA approved CABOMETYX on January 14, 2019 for the treatment of patients with HCC who have been previously treated with sorafenib, and we commenced our commercial launch of CABOMETYX for this new indication immediately upon such approval. Additionally, on November 15, 2018, our collaboration partner Ipsen received EC approval of CABOMETYX as a monotherapy for HCC in adults who have previously been treated with sorafenib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">MTC - EXAM</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2011, we announced positive results from EXAM, a phase 3 international, multicenter, randomized double-blinded controlled trial of COMETRIQ in patients with progressive, metastatic MTC. EXAM met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for COMETRIQ-treated patients compared to those receiving placebo, with median PFS of 11.2 months in the COMETRIQ arm versus 4.0 months in the placebo arm. In addition, the ORR was 27% with PRs observed only among patients in the COMETRIQ arm, and the median duration of objective response was 14.7 months for patients treated with COMETRIQ. These primary results were presented at the ASCO 2012 Annual Meeting in June 2012 and subsequently published in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Clinical Oncology</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in October 2013. In November 2014, we announced completion of the OS analysis, a secondary endpoint of the study. Consistent with an earlier interim analysis, there was no statistically significant difference in OS between the treatment arms. The median OS was 26.6 months for the COMETRIQ arm and 21.1 months for the placebo arm. We presented the final results at the ASCO 2015 Annual Meeting and submitted the results to regulatory authorities to satisfy post-marketing commitments. The safety profile in the study was consistent with the established profile of cabozantinib and other TKIs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the EXAM trial, the FDA approved COMETRIQ on November 29, 2012, for the treatment of patients with progressive, metastatic MTC. In March 2014, the EC granted COMETRIQ a conditional marketing authorization for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. COMETRIQ is marketed and commercialized in the EU by Ipsen. In connection with the approval of COMETRIQ for the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">treatment of progressive, metastatic MTC, we were subject to post-marketing requirements, all of which have been satisfied, other than a requirement to conduct the EXAMINER clinical study, comparing a lower dose of cabozantinib with the labeled dose of 140 mg. EXAMINER is evaluating safety and PFS in progressive, metastatic MTC patients, and we expect top-line results from the trial in 2020. The study is also comparing COMETRIQ capsules with CABOMETYX tablets and, if positive, could facilitate the transition of metastatic MTC patients being treated with COMETRIQ to CABOMETYX.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Late-Stage Exelixis Sponsored Trial Evaluating Cabozantinib as a Monotherapy</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Differentiated Thyroid Cancer (DTC) - COSMIC-311</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Published studies indicate that approximately 53,000 new cases of thyroid cancer will be diagnosed in the U.S. in 2020. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Differentiated thyroid tumors, which make up about 90% of all thyroid cancers, are typically treated with surgery followed by ablation of the remaining thyroid with radioiodine (RAI). Approximately 5% to 15% of differentiated thyroid tumors are resistant to radioiodine treatment. With limited treatment options, these patients have a life expectancy of only three to six years from the time metastatic lesions are detected. New treatment options are therefore urgently needed.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2018 we initiated COSMIC-311, a multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two prior VEGFR-targeted therapies. The trial aims to enroll approximately 300 patients at approximately 150 sites globally, and patients enrolled in the trial will be randomized in a 2:1 ratio to receive either cabozantinib 60 mg or placebo once daily. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We completed enrollment of the first 100 patients in the trial in February 2020 and plan to conduct an analysis in these first 100 patients for the co-primary endpoint of ORR, and an interim analysis of PFS in the second half of 2020. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We further expect to reach total enrollment of 300 patients for the trial in the second half of 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">COSMIC-311 was informed by cabozantinib&#8217;s encouraging clinical activity in phase 1 and 2 trials in patients with RAI-refractory DTC, including: an Exelixis-sponsored phase 1 open-label trial assessing the safety, tolerability and antitumor activity of cabozantinib in patients with DTC; a phase 2 single-arm, open-label trial evaluating cabozantinib for the first-line treatment of metastatic RAI-refractory DTC, conducted by the Center for Rare Cancers and Personalized Therapy&#160;at the&#160;Abramson Cancer Center&#160;of the&#160;University of Pennsylvania (Abramson Cancer Center); and a phase 2 single-arm trial evaluating cabozantinib </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in patients with RAI-refractory DTC who had been previously treated with at least one VEGFR-targeted therapy, conducted by the International Thyroid Oncology Group</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Among the 15 RAI-refractory DTC patients enrolled in the Exelixis-sponsored phase 1 trial, PR was achieved by 53% of patients, and SD was reported in 40% of patients. Among the 35 patients in the Abramson Cancer Center phase 2 study who were evaluable for response, PR was achieved by 54% of patients, and SD was reported in 43% of patients. All but one evaluated patient in the Abramson Cancer Center trial experienced a decrease in tumor target lesions, and with a median follow up of 35 weeks, the median PFS had not been reached as of the data cut-off date. Among the 25 RAI-refractory DTC patients in the International Thyroid Oncology Group Study, PR was achieved by 40% of patients, and SD was reported in 52% of patients. Median PFS was 12.7 months, and median OS was 34.7 months. The safety profile in all three studies were consistent with the established profile of cabozantinib and other TKIs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trials Conducted Under our Clinical Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib has shown clinical anti-tumor activity with objective responses observed in more than 20 forms of cancer in phase 1 and 2 evaluation; we are, therefore, focused on advancing a broad cabozantinib clinical development program to fully investigate its therapeutic potential, both alone and in combination with other therapies. In particular, given that clinical observations from early-stage clinical trials evaluating cabozantinib in combination with ICIs have shown preliminary promising activity across a diverse range of tumors, and that patients have been able to tolerate these drug combinations, we are focused on exploring the potential of cabozantinib in combination with ICI&#8217;s in late-stage or other potentially label-enabling trials. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Combination Studies with Bristol-Myers Squibb Company (BMS)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Preclinical data and clinical observations from an ongoing phase 1 trial evaluating cabozantinib in combination with nivolumab, with or without ipilimumab, in patients with previously treated genitourinary tumors suggest that cabozantinib may result in a more immune-permissive tumor environment. In consideration of those results, in February 2017, we entered into a clinical collaboration agreement with BMS for the purpose of conducting clinical studies combining cabozantinib with BMS&#8217; PD-1 ICI, nivolumab, both with or without BMS&#8217; CTLA-4 ICI, ipilimumab.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of the collaboration, we are evaluating these combinations in a phase 3 pivotal trial in previously untreated or metastatic advanced RCC and in a phase 1/2 trial in both previously treated and previously untreated advanced HCC. We may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. Pursuant to our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreements with BMS, each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each trial will be determined on a trial-by-trial basis. For additional information on the terms of the clinical trial collaboration agreement, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Development Collaborations&#8212;BMS</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">RCC - CheckMate 9ER</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 9ER is an open-label, randomized, multi-national phase 3 pivotal trial evaluating nivolumab in combination with cabozantinib versus sunitinib in patients with previously untreated, advanced or metastatic RCC. The original trial protocol required patients to be randomized 1:1:1 to one of three arms: cabozantinib and nivolumab; cabozantinib, nivolumab and ipilimumab; or sunitinib. However, following the positive results of CheckMate 214, BMS&#8217;s phase 3 trial evaluating nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic RCC and in an effort to accelerate the development of the cabozantinib and nivolumab combination, the trial protocol was amended to remove the triplet combination. In accordance with the terms of the modified CheckMate 9ER protocol, patients are being randomized 1:1 to receive either 40 mg of cabozantinib daily and 240 mg of nivolumab every 2 weeks, or 50 mg of sunitinib daily on a 4-weeks-on/2-weeks-off schedule, while the primary endpoint for the trial remains PFS, and the secondary endpoint is OS. The triplet combination continues to be evaluated in COSMIC-313, an ongoing phase 3 pivotal trial being conducted pursuant to our clinical collaboration with BMS. CheckMate 9ER completed enrollment in May 2019, and BMS announced that top-line results are expected in the first half of 2020. The trial is supported financially through the co-funding of both of our collaboration partners, Ipsen and Takeda.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">RCC - COSMIC-313</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we initiated COSMIC-313, a multicenter, randomized, double-blinded, controlled phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. The study aims to enroll approximately 676 patients at up to 150 sites globally. Patients are being randomized 1:1 to the experimental arm of the triplet combination of cabozantinib, nivolumab and ipilimumab and to the control arm of nivolumab and ipilimumab in combination with matched placebo. The primary endpoint for the trial is PFS, and the secondary endpoint is OS. We expect to complete enrollment for COSMIC-313 in early 2021 and to report top-line results of the event-driven analyses from the trial in the 2022 timeframe.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are sponsoring COSMIC-313, and BMS is providing nivolumab and ipilimumab free of charge.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">HCC - CheckMate 040</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 040 is a large, multi-cohort phase 1/2 trial in patients with previously treated and previously untreated advanced HCC, including a cohort evaluating treatment regimens that include cabozantinib in combination with nivolumab or in combination with both nivolumab and ipilimumab. This cohort containing the cabozantinib combination treatment regimens was designed to enroll approximately 30 patients into each of two groups in accordance with the trial protocol, with one group receiving 40 mg of cabozantinib daily and 3 mg/kg of nivolumab every two weeks, and the other group receiving 40 mg of cabozantinib daily, 3 mg/kg of nivolumab every two weeks and 1 mg/kg ipilimumab every six weeks. The primary endpoints for the cohorts are safety and tolerability and ORR; secondary endpoints include duration of response (DOR), PFS and OS.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for CheckMate 040 were presented at ASCO&#8217;s Gastrointestinal Cancers Symposium in January 2020. For the 36 patients treated with the combination of cabozantinib and nivolumab, ORR was 19%, and DCR was 75%. Median PFS was 5.4 months, and median OS was 21.5 months. For the 35 patients treated with the combination of cabozantinib, nivolumab and ipilimumab, ORR was 29%, and DCR was 83%. Median PFS was 6.8 months, and median OS had not yet been reached as of the data cut-off date. The safety profile for the combinations in the trial was consistent with the established profile of each agent, and no new safety signals have emerged.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Combination Studies with F. Hoffmann-La Roche Ltd. (Roche)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Diversifying our exploration of cabozantinib combinations with ICIs, in February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s anti-PD-L1 ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of the clinical supply agreement, we are evaluating this combination in a phase 1b trial in locally advanced or metastatic tumors and a phase 3 pivotal trial in previously untreated advanced HCC. Informed by the data generated from the phase 1b trial, COSMIC-021, we also entered into a joint clinical research agreement with Roche in December 2019, pursuant to which we plan to evaluate this combination in various late-stage clinical trials, including in non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC) and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RCC. For additional information on the terms of the master clinical supply agreement and joint clinical research agreement, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Development Collaborations&#8212;Roche</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Locally Advanced or Metastatic Solid Tumors - COSMIC-021</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. We are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The study is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion cohort phase, which is ongoing. The dose-escalation phase of the trial enrolled 12 patients with advanced RCC, and results were presented at the ESMO 2018 Congress</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The primary objective was to determine the optimal dose and schedule of daily oral administration of cabozantinib when given in combination with atezolizumab to inform the trial&#8217;s subsequent expansion stage. Cabozantinib doses of 40 mg daily and 60 mg daily were evaluated. All patients received the standard atezolizumab dosing regimen of 1200 mg infusion once every 3 weeks. The dose-escalation phase of the study determined the optimal dose of cabozantinib as 40 mg daily when given in combination with the standard atezolizumab dosing regimen of 1200 mg infusion once every 3 weeks. No dose-limiting toxicities or serious adverse events (AEs) were noted. Dose reductions and higher-grade AEs were less frequent with the 40 mg cabozantinib dosing cohort. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Encouraging clinical activity was also observed. The safety profile for the combination in the dose-escalation phase of the trial was consistent with the established profile of each combination agent, and no new safety signals have emerged.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Enrollment in the expansion stage of this study, which is currently ongoing, includes the following 20 combination tumor expansion cohorts:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with advanced non-squamous NSCLC without a defined tumor genetic alteration (EGFR, ALK, ROS1, or BRAF) who have not received prior therapy with an ICI;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with NSCLC without a defined tumor genetic alteration who have progressed following treatment with an ICI;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with NSCLC with an EGFR mutation who have progressed following treatment with an EGFR-targeting TKI for metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who have progressed following treatment with an ICI;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">with mCRPC who have previously received enzalutamide and/or abiraterone acetate without prior docetaxel for mCRPC and experienced radiographic disease progression in soft tissue;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">with mCRPC who have previously received enzalutamide and/or abiraterone acetate with prior docetaxel therapy for mCRPC;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">mCRPC who have previously received enzalutamide and/or abiraterone acetate without prior docetaxel therapy for mCRPC;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with RCC with clear cell histology who have not had prior systemic anticancer therapy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with RCC with non-clear cell histology who have not had prior systemic anticancer therapy for inoperable, locally advanced, recurrent or metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who have progressed on or after platinum-containing chemotherapy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced or metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who are eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced or metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with triple-negative breast cancer who have progressed following treatment with at least one prior systemic therapy for inoperable, locally advanced, recurrent or metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with epithelial ovarian cancer who have platinum-resistant or refractory disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with endometrial cancer who have progressed following treatment with at least one prior systemic therapy for inoperable, locally advanced, recurrent or metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with advanced HCC who have a Child-Pugh score of A and have not had prior systemic anticancer therapy for inoperable, locally advanced, recurrent or metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with gastric or gastroesophageal junction adenocarcinoma who have progressed following treatment with platinum-containing or fluoropyrimidine-containing chemotherapy for inoperable locally advanced, recurrent or metastatic disease;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with colorectal adenocarcinoma who have progressed following treatment with systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan for metastatic disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with head and neck cancer of squamous cell histology who have progressed following treatment with platinum-containing chemotherapy for inoperable locally advanced, recurrent or metastatic disease; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with DTC who are radio-refractory or deemed ineligible for treatment with iodine-131.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Each expansion cohort was designed to initially enroll approximately 30 patients. However, based on continuing encouraging efficacy and safety data, certain cohorts have been or may be further expanded, including the cohorts of patients with NSCLC who have been previously treated with an ICI and mCRPC who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. In addition, in order to address the contribution of components, there are three exploratory cohorts that will evaluate cabozantinib as a single-agent therapy in 1) patients with NSCLC without a defined tumor genetic alteration who have progressed following treatment with an ICI, 2) patients with UC who have progressed following treatment with an ICI and 3) patients with mCRPC, as well as a fourth exploratory cohort that will evaluate atezolizumab as a single-agent therapy in patients with mCRPC. We anticipate completing enrollment of up to 1,732 patients in the trial in late 2020, which timing is subject to the initiation of additional cohorts or expansion of selected existing cohorts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since its initiation, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312 and other planned pivotal trials in NSCLC, mCRPC and RCC. In particular, data from the mCRPC cohort of the trial were presented at ASCO&#8217;s Genitourinary Cancers Symposium in February 2020. Based on an interim analysis of 44 enrolled patients treated with the combination of cabozantinib and atezolizumab, the ORR was 32% (2 CRs and 12 PRs) and the DCR was 80%.&#160;Among the 36 patients with high-risk clinical features, the ORR was 33%.&#160;The safety profile for the combination was consistent with the established profile of each agent, and no new safety signals have emerged. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication as early as in 2021.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">HCC - COSMIC-312</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. The trial also includes a third arm evaluating cabozantinib monotherapy in this first-line setting in order to address the contribution of components. The study has a target enrollment of 740 patients at up to 250 sites globally. Patients are being randomized to one of three arms: cabozantinib and atezolizumab (40 mg); sorafenib; or cabozantinib (60 mg). The co-primary endpoints for the trial are PFS and OS.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are sponsoring COSMIC-312, and&#160;Ipsen&#160;will co-fund the trial.&#160;Ipsen&#160;will have access to the results to support potential future regulatory submissions outside of the U.S. and&#160;Japan. Roche is providing atezolizumab free of charge.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trials Conducted through our CRADA with NCI-CTEP and our IST Program</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2011, we entered into a CRADA with NCI-CTEP for the clinical development of cabozantinib. Through our CRADA with NCI-CTEP and our IST program we have been able to expand the cabozantinib development program while avoiding over-burdening our internal development resources. Our CRADA reflects a major commitment by NCI-CTEP to support the broad exploration of cabozantinib&#8217;s potential in a wide variety of cancers, each representing a substantial unmet medical need. Through this mechanism, NCI-CTEP provides funding for as many as 20 active clinical trials of cabozantinib each year for a five-year period. The term of the CRADA was extended in October 2016 for an additional five-year period through October 2021, provided that both parties maintain the right to terminate the CRADA for any reason upon sixty days&#8217; notice, for an uncured material breach upon thirty days&#8217; notice and immediately for safety concerns. Investigational New Drug (IND) applications for trials under the CRADA are held by NCI-CTEP. NCI-CTEP also retains rights to any inventions made in whole or in part by NCI-CTEP investigators.&#160;However, for inventions that claim the use and/or the composition of cabozantinib, we have an automatic option to elect a worldwide, non-exclusive license to cabozantinib inventions for commercial purposes, with the right to sublicense to affiliates or collaborators working on our behalf, as well as an additional, separate option to negotiate an exclusive license to cabozantinib inventions.&#160;Further, before any trial proposed under the CRADA may commence, the protocol is subject to our review and approval, and the satisfaction of certain other conditions. As reflected by the results from completed trials and summaries of ongoing trials below, we believe our CRADA with NCI-CTEP has and will enable us to continue to expand the cabozantinib development program broadly in a cost-efficient manner.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Advanced Genitourinary Tumors</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results from a phase 1b study conducted under our CRADA with NCI-CTEP evaluating cabozantinib in combination with nivolumab with or without ipilimumab in patients with previously treated genitourinary tumors guided the choice of dose for the ongoing CheckMate 9ER trial in previously untreated advanced RCC. The study evaluated 78 patients; 49 were treated with the doublet combination of cabozantinib and nivolumab and 29 were treated with the triplet combination of cabozantinib, nivolumab and ipilimumab. Among the 13 patients with metastatic RCC who were evaluable for response, ORR was 54 percent (7 PRs of 13 patients) and the DCR was 100%. In the overall study the ORR in 64 evaluable patients was 36% (3 CRs and 20 PRs) with a median DOR of 24 months. Based on general tolerability, the recommended cabozantinib dose for the expanded dose cohorts and for future late-stage evaluation was determined as cabozantinib at 40 mg daily oral dose combined with nivolumab at 3 mg/kg every 2 weeks and ipilimumab at 1 mg/kg every 3 weeks for 4 doses. The safety profile for the combination in the trial was consistent with the established profile of each agent, and no new safety signals have emerged.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">PDIGREE is a phase 3 trial led by The Alliance which plans to enroll 1,046 intermediate- or poor-risk advanced RCC patients who have a clear cell component in their tumors. All patients are initially treated with up to 4 cycles of induction ipilimumab combined with nivolumab. Subsequently, patients are treated based on their response to the induction therapy. Patients achieving a complete response (CR) continue on maintenance nivolumab, while patients with progressive disease (PD) are switched to cabozantinib monotherapy. Patients who neither achieve a CR nor develop PD during induction are randomized 1:1 to either maintenance nivolumab or nivolumab in combination with cabozantinib 40 mg daily. The primary endpoint is OS, while PFS, CR rate, ORR and safety are among the secondary endpoints.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">PAPMET is a 4-arm randomized phase 2 trial being conducted by the Southwest Oncology Group in patients with locally advanced or metastatic papillary RCC. The study was designed to enroll 180 patients with either type I or type II papillary RCC. Patients may have received up to one prior line of therapy. The trial compares a control arm of sunitinib with 3 independent investigational arms of single-agent MET inhibitors: cabozantinib; crizotinib; and savolitinib. The primary endpoint is PFS. An IA led to the closing of accrual to the crizotinib and savolitinib arms due to lack of efficacy. The cabozantinib arm continues as the only remaining investigational arm. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RADICAL is a randomized phase 2 trial being conducted by The Alliance which plans to enroll up to 210 patients with advanced RCC. All patients must have at least 2 sites of bone metastases and may have received up to 2 prior lines of systemic therapy. Patients are randomized 1:1 to be treated with cabozantinib in combination with radium-223 dichloride or cabozantinib as a single agent. The primary endpoint is symptomatic skeletal event-free survival, while secondary endpoints include PFS, OS, ORR and safety.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Neuroendocrine Tumors</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Alliance is leading the CABINET study which treats patients with well- or moderately-differentiated neuroendocrine tumors (NETs). CABINET includes 2 separate randomized studies, one for patients with pancreatic NETs and the other for patients with carcinoid tumors. The planned enrollment for the pancreatic NET study is 185 patients and for the carcinoid study is 210 patients. Both studies randomize previously treated patients 2:1 to cabozantinib 60 mg daily or placebo. The primary endpoint for both studies is PFS per Response Evaluation Criteria in Solid Tumors 1.1 as determined by a blinded IRRC. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Cancer Indications</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are 46 ongoing and 28 planned externally sponsored trials evaluating the clinical and therapeutic potential of cabozantinib, including those administered through our CRADA with NCI-CTEP and our IST program.&#160;Like our CRADA with NCI-CTEP, our IST program helps us to continue to evaluate cabozantinib across a broad range of tumor types.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These externally sponsored trials include signal seeking studies of single-agent cabozantinib, novel combinations, and randomized trials.&#160;The monotherapy trials are focused on solid tumors including genitourinary neoplasms, gastrointestinal malignancies, lung cancer and a variety of less common tumor types.&#160;The combination studies include trials combining cabozantinib with several different ICIs, as well as studies adding cabozantinib to various other anti-cancer therapies, including monoclonal antibodies, chemotherapeutic agents, small molecules which target specific cellular pathways, or radiation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to the various trials described above, our CRADA includes ongoing randomized phase 2 studies in endometrial cancer and NSCLC, both in combination with an ICI.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A complete listing of all ongoing cabozantinib trials can be found at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:underline;">www.ClinicalTrials.gov</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">XL092 Development Program</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XL092 is the first internally-discovered compound to enter the clinic following our re-initiation of internal drug discovery activities. XL092 is a next-generation oral TKI that targets VEGF receptors, MET, and other kinases implicated in cancer&#8217;s growth and spread. The molecule is the subject of an active IND that we submitted to the FDA in December 2018, and that the FDA accepted in January 2019. XL092 is being studied in a multicenter phase 1 clinical trial designed to evaluate its pharmacokinetics, safety and tolerability. The trial is divided into dose-escalation and expansion phases. The dose-escalation phase of the trial is enrolling patients with advanced solid tumors, with the primary objective of determining a dose for daily oral administration of XL092 suitable for further evaluation. We anticipate that dose expansion cohorts and potential combination cohorts with ICIs will begin to enroll in 2020.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Assuming positive data from the initial phase of the trial, the expansion phase is designed to further explore the selected dose of XL092 in individual tumor cohorts, where safety, tolerability, and initial clinical activity would be evaluated.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Expansion of the Exelixis Pipeline: Internal Drug Discovery and Business Development Programs</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are actively focused on expanding our pipeline through internal drug discovery and targeted business development activities. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Internal Drug Discovery</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. From 2000 until 2012, we had an active internal drug discovery group that advanced 22 compounds to the IND stage, either independently or with collaboration partners, including cabozantinib and cobimetinib. We built significant infrastructure, including a library of 4.6 million compounds, and gained extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current internal drug discovery organization is leveraging that history in a focused and measured manner. Notably, these efforts are led by some of the same experienced scientists that led the efforts to discover cabozantinib, cobimetinib and esaxerenone, which have been approved for commercialization. We are concentrating our in-house work on the most demanding and time-sensitive aspects of lead optimization and use contract research organizations to support more routine activities, thereby minimizing our internal footprint while still maintaining an agile, competitive approach. We are and will continue to be judicious in the selection of targets, focusing on those with robust preclinical validation datasets. We remain focused on oncology as a therapeutic area, and prioritize those targets that we believe, for example, are key components of signaling pathways frequently deregulated in human cancers or are components of mechanisms that contribute to tumor-mediated immune suppression. We anticipate that our experience identifying high quality lead compounds against a variety of target classes through use of our propriety compound library, coupled with our expertise in medicinal chemistry, tumor biology and pharmacology, will permit us to prosecute competitive and productive discovery programs in areas of high potential. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthest along in these efforts is XL092. For additional information on XL092, see &#8220;-XL092 Development Program</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; We have also advanced an additional compound, XL265, an inhibitor of MET and TAM kinases, into preclinical development, and are conducting multiple additional lead optimization programs for inhibitors of a variety of targets that we believe play significant roles in tumor growth. We anticipate that some of these programs will yield preclinical development candidates during 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Development</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We augment our internal discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. In furtherance of this strategy, we have entered into multiple collaboration and license agreements, including with:&#160;Aurigene Discovery Technologies Limited (Aurigene), which is&#160;focused on&#160;the discovery and development of novel small molecules as therapies for cancer; Iconic Therapeutics, Inc. (Iconic), which is focused on the advancement of a next-generation antibody-drug conjugate (ADC) program targeting tissue factor in solid tumors; Invenra, Inc. (Invenra), which is&#160;focused on the discovery and development of multispecific antibodies for the treatment of cancer; and&#160;StemSynergy Therapeutics, Inc. (StemSynergy), which is focused on</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha (CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">). We</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have already made progress under our collaborations with these partners and believe we will continue to do so in 2020. Both the tissue factor (ADC) program with Iconic and the lead Aurigene program targeting CDK7 are in preclinical development and could result in IND filings in 2020. For additional information on each of these collaborations, see &#8220;&#8212;Collaborations&#8212;In-licensing Collaborations.&#8221;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are seeking additional, external collaborative relationships around assets at all stages of development and technologies that complement our internal drug discovery and clinical development efforts. These collaborative relationships are aimed at expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, Daiichi Sankyo and BMS for other compounds and programs in our portfolio. Under each of our collaborations, we are entitled to receive milestones and royalties or, in the case of cobimetinib, royalties from sales outside the U.S. and a share of profits (or losses) from commercialization in the U.S.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cabozantinib Commercial Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Ipsen Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in 2016</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of December 31, 2019, we achieved aggregate milestone payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$330.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">including milestone payments during 2019 of 1) $50.0 million upon Ipsen&#8217;s achievement of $250.0 million in net sales of cabozantinib in its territories over four consecutive fiscal quarters, 2) $3.0 million upon the approval by Health Canada of cabozantinib for the first-line treatment of adults with advanced RCC, and 3) $2.0 million upon the approval by Health Canada of cabozantinib for the treatment of patients with advanced HCC who have been previously treated with sorafenib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$79.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$470.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with future sales volume milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. We were initially entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial $</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales; this amount was reached in the second quarter of 2018. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the year ended December&#160;31, 2019 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and going forward, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales, with separate tiers for Canada; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD$30.0 million of annual net sales and a tiered royalty thereafter to</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers for Canada also reset each calendar year. As of December 31, 2019, we have earned royalties of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$98.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on net sales of cabozantinib by Ipsen since the inception of the collaboration agreement. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Consistent with our historical agreement with GlaxoSmithKline (GSK), we are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding: CheckMate 9ER; CheckMate 040 (though Ipsen has opted not to co-fund the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); the dose escalation phase and first 20 expansion cohorts of COSMIC-021; and COSMIC-312.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished and labeled drug product to Ipsen for distribution in the territories outside of the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a pharmacovigilance agreement, which defines each partner&#8217;s responsibilities for safety reporting. The pharmacovigilance agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of 1) the expiration of patent claims related to cabozantinib, 2) the expiration of regulatory exclusivity covering cabozantinib or 3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018 and May 2019, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from Takeda in 2017. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have also achieved regulatory and development milestones in the aggregate of $26.0 million since the inception of the collaboration agreement, including a $16.0 million milestone achieved during the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upon Takeda&#8217;s submission of a regulatory application to the Japanese MHLW for Manufacturing and Marketing Approval of cabozantinib as a treatment for patients in Japan with unresectable and metastatic RCC. We also earned a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone in the first quarter of 2020 for the January 2020 submission of a regulatory application </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to the Japanese MHLW for Manufacturing and Marketing Approval of cabozantinib as a treatment for patients in Japan with unresectable HCC who progressed after prior systemic therapy</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the collaboration agreement, as amended, as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are eligible to receive regulatory and development milestone payments from Takeda of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to first-line RCC and second-line HCC, including the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we earned for the submission of a regulatory application in 2020 described above</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are also eligible to receive additional regulatory and development milestone payments, without limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$155.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also receive </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on the initial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and following this initial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales thereafter; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Consistent with our historical agreement with GSK, we are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In accordance with the collaboration agreement, Takeda has opted into and is co-funding CheckMate 9ER.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of 1) two years after first generic entry with respect to such product in Japan or 2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application (MAA) in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cabozantinib Development Collaborations </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">BMS</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s ICIs, nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate 9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. We also intend to evaluate these combinations in other phase 3 pivotal trials in various other tumor types. For descriptions of the CheckMate 9ER, COSMIC-313 and CheckMate 040 trials, see &#8220;&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with Bristol-Myers Squibb Company (BMS).&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination IND application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Roche</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021 and in December 2018, we initiated COSMIC-312. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge. For descriptions of the COSMIC-021 and COSMIC-312 trials, see &#8220;&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with F. Hoffmann-La Roche Ltd. (Roche).&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Building upon encouraging clinical activity observed in COSMIC-021, in December 2019 we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal trials in advanced NSCLC, mCRPC and RCC. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond the initial three planned phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">In-licensing Collaborations </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Aurigene Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six&#160;programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> pre-existing programs. We are also responsible for up to&#160;$32.6&#160;million&#160;in research funding for the discovery and preclinical development work on these programs.&#160;During the year ended December 31, 2019, we incurred&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in expense for the discovery and preclinical development funding commitment. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each option we decide to exercise, we will be required to pay an exercise fee of either $10.0 million or $12.0 million, depending on the program, and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to&#160;$148.8&#160;million&#160;per program in potential development and regulatory milestone payments, $280.0 million&#160;per program in potential commercial milestone payments, as well as royalties on potential sales.&#160;Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Iconic Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we&#160;entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#8217;s expertise in targeting tissue factor in solid tumors. Tissue factor is highly expressed on tumor cells and in the tumor microenvironment, and tissue factor overexpression, while not oncogenic itself, facilitates angiogenesis, metastasis and other processes important to tumor development and progression. ICON-2, Iconic&#8217;s lead oncology ADC program, is a rationally designed second-generation ADC with potential for an improved therapeutic index and safety profile. Under the terms of the agreement, we gained an exclusive option to license ICON-2 in exchange for an upfront payment to Iconic of&#160;$7.5&#160;million&#160;and a commitment for preclinical development funding. During the year ended December 31, 2019, we incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in expense for the preclinical development funding commitment. If we exercise the option, we will be required to make an option exercise fee payment of&#160;$20.0&#160;million&#160;to Iconic; we would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic would become eligible for up to&#160;$190.6&#160;million&#160;in potential development, regulatory and first-sale milestone payments,&#160;$262.5&#160;million&#160;in potential commercial milestone payments, as well as royalties on potential sales. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Invenra Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> technology platform, or with other platforms and formats at our option. As of December 31, 2019, we have initiated three additional discovery projects and two binder projects, and in total we incurred an aggregate of $7.0 million and $4.0 million in expense during the years ended December 31, 2019 and 2018, respectively, in consideration of the upfront licensing and project initiation fees. Invenra is eligible to receive up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$131.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$43.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;$325.0 million as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;$2.0 million&#160;for each B-Body project and four additional binder projects subject to an upfront payment of $1.5 million for each project, as well as additional milestone payments and royalties for any products that arise from these efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">StemSynergy Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery and development of novel oncology compounds targeting CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, a component of the Wnt signaling pathway implicated in key oncogenic processes. Activation of &#946;-catenin, a key downstream component of the pathway, is increas</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ed in multiple tumors, inclu</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ding a majority of colorectal cancers, where mutations in the APC gene that result in &#946;-catenin stabilization are prevalent. Compounds targeting CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have also been shown to induce degradation of &#946;-catenin and pygopus, another member of the pathway, in pre</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">clinical CRC models, and to inhibit the growth of tumors. Importantly, their GI-sparing qualities may help overcome limitations of other approaches targeting the Wnt pathway. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct pre</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">clinical and clinical studies with compounds targeting CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We paid&#160;StemSynergy an upfront payment of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in initial research and development funding during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December&#160;31, 2018 and provided </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. StemSynergy is eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding on an as needed basis. StemSynergy will also be eligible for up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to the commercialization of our first product, COMETRIQ, our primary business strategy was focused on the development and out-license of compounds to pharmaceutical and biotechnology companies under collaboration agreements that allowed us to retain economic participation in compounds and support additional development of our proprietary products.&#160;Our collaboration agreements with Genentech and Daiichi Sankyo described below are representative of this historical strategy. We have since evolved and are now a fully-integrated biopharmaceutical company focused on driving the expansion and depth of our product offerings through the continued development of cabozantinib, internal drug discovery and execution of strategic transactions that align with our oncology drug development and commercialization expertise, all to improve care and outcomes for people with cancer around the world. While the historical collaboration agreements described below have the potential to provide future revenue, and while we have already received some collaboration revenues from these arrangements, we do not expect to receive significant revenues from these historical collaboration agreements unless and until our partnered compounds generate substantial sales in the territories and indications where they are approved. If these events occur, then the milestone payments, royalties or other rights and benefits under our historical collaboration agreements could become substantial.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Genentech - Cobimetinib</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the RAS/RAF/MEK/ERK pathway. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and in March 2009, granted Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S.; however, following a review of the commercial landscape, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. in January 2018. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Cobimetinib Profit Sharing and Royalty Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive 50% of profits and losses from the first $200.0 million of U.S. actual sales, decreasing to 30% of profits and losses from U.S. actual sales in excess of $400.0 million. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. During 2019, we earned royalties of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on net sales of COTELLIC outside the U.S. and a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> profit on the profit and loss sharing of U.S. actual sales which are recorded in Collaboration revenues. Since the inception of the collaboration agreement, we have also received aggregate upfront and milestone payments of&#160;$50.0&#160;million and are not eligible for any additional milestone payments.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Cobimetinib Clinical Development Program </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to its established commercialization of COTELLIC, Genentech continues to make progress with respect to the clinical development, regulatory status and commercial potential of cobimetinib. Cobimetinib is being evaluated in a broad development program consisting of more than 50 clinical trials by Genentech or through Genentech&#8217;s IST program, including an ongoing phase 3 pivotal trial exploring the combination of cobimetinib with atezolizumab and vemurafenib in BRAF V600 mutant melanoma (IMspire150), which we announced had met its primary endpoint in December 2019, and a series of early-stage clinical trials investigating the combination of cobimetinib and atezolizumab in multiple tumor settings. Should these trials prove positive and Genentech obtain regulatory approvals based on such positive results, we believe that cobimetinib could provide us with an additional source of revenue in the future.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Melanoma - coBRIM. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2014, we announced positive top-line results from coBRIM, the phase 3 pivotal trial conducted by Genentech evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600E or V600K mutation. The primary endpoint was investigator-determined PFS, and secondary endpoints included OS, ORR, IRRC-determined PFS and DOR. coBRIM met its primary endpoint, demonstrating a statistically significant increase in investigator-determined PFS. The median PFS was 9.9 months for the combination of cobimetinib and vemurafenib versus 6.2 months for vemurafenib alone. The median PFS as established by an IRRC, a secondary endpoint, was 11.3 months for the combination arm compared to 6.0 months for the control arm. ORR, another secondary endpoint, was 68% for the combination versus 45% for vemurafenib alone. Data were published in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">NEJM </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and presented at the ESMO 2014 Congress in September 2014.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Updated results for PFS and ORR from coBRIM were then presented at the ASCO 2015 Annual Meeting in June 2015 and showed a median PFS of 12.3 months for the combination of cobimetinib and vemurafenib versus 7.2 months for vemurafenib alone, and an ORR of 70% for the combination of vemurafenib and cobimetinib versus 50% for vemurafenib alone. In November 2015, we announced that the coBRIM trial also met its OS secondary endpoint, demonstrating a statistically significant increase in OS for the combination of cobimetinib and vemurafenib compared to vemurafenib monotherapy. The median OS was 22.3 months for the combination of cobimetinib and vemurafenib versus 17.4 months for vemurafenib alone. The safety profile of the combination was consistent with that observed in a previous study.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CoBRIM served as the basis for the regulatory approval of COTELLIC in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma in the U.S., Switzerland, the EU, Canada, Australia, Brazil and other countries.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Melanoma - IMspire150. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, Genentech initiated IMspire150, a phase 3 pivotal trial evaluating the combination of cobimetinib, vemurafenib and atezolizumab vs. cobimetinib plus vemurafenib in previously untreated BRAF V600 mutation positive patients with metastatic or unresectable locally advanced melanoma. This trial, which has a primary endpoint of PFS, was based on the results of Genentech&#8217;s ongoing phase 1b trial in the same patient population. In December 2019, IMspire150 met its primary endpoint, demonstrating a significant and clinically meaningful improvement in PFS. Results will be presented at an upcoming medical meeting and discussed with healthcare authorities around the world, including the FDA and the EMA.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Daiichi Sankyo - Esaxerenone</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below. During the research term, which concluded in November 2007, we jointly identified drug candidates with Daiichi Sankyo for further development. Esaxerenone is the only remaining drug candidate identified under the collaboration that continues to be developed by Daiichi Sankyo, and we are entitled to receive payments upon attainment of pre-specified development, regulatory and commercialization milestones for esaxerenone.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2017, Daiichi Sankyo reported positive top-line results from ESAX-HTN, a phase 3 pivotal trial of esaxerenone, and submitted a Japanese regulatory application for esaxerenone for an essential hypertension indication in February 2018, for which we received a $20.0 million milestone payment, which we recorded in the first quarter of 2018. Data from ESAX-HTN were published in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Hypertension </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in June 2018. Daiichi Sankyo&#8217;s application was then approved by the MHLW in January 2019, and the first commercial sale of the branded esaxerenone product MINNEBRO in Japan in May 2019 triggered the payment of a $20.0 million milestone payment to us. As of December 31, 2019, and after giving effect to the milestone payment associated with the Japanese regulatory application for esaxerenone, we have achieved an aggregate of $65.5 million in development, regulatory and commercialization milestone payments related to MINNEBRO over the life of the collaboration agreement and are eligible to receive commercialization milestone payments of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$90.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Daiichi Sankyo may terminate the agreement upon 90 days&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO. As of December 31, 2019, we have earned royalties of $0.1 million on net sales of MINNEBRO by Daiichi Sankyo since the approval of MINNEBRO in January 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo also continues to advance the development program for esaxerenone, and in November 2019, Daiichi Sankyo announced positive results from a phase 3 pivotal trial evaluating esaxerenone as a treatment option for patients in Japan with diabetic nephropathy. Should Daiichi Sankyo obtain regulatory approval based on these positive results, and taking into account the approval of MINNEBRO by the MHLW for the treatment of hypertension and Daiichi Sankyo&#8217;s subsequent commercial sales of MINNEBRO, we believe that esaxerenone will provide an additional source of revenue in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Manufacturing and Product Supply</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for clinical or commercial production and distribution of our products. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations who, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. As our operations continue to expand through our clinical development and commercial progress, we continue to appropriately expand our supply chain through secondary third-party contract manufacturers and suppliers. We have selected well-established and reputable global third-party contract manufacturers for our drug substance and drug product manufacturing that have good regulatory standing, large manufacturing capacities and multiple manufacturing sites within their business footprint. These third parties must comply with applicable regulatory requirements, including the FDA&#8217;s Current Good Manufacturing Practice (GMP), the EC&#8217;s Guidelines on Good Distribution Practice (GDP), as well as other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies, as applicable, and are subject to routine inspections by such regulatory agencies. In addition, through our third-party contract manufacturers and data service </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We monitor and evaluate the performance of our third-party contract manufacturers on an ongoing basis for compliance with these requirements and to affirm their continuing capabilities to meet both our commercial and clinical needs. We also have contracted with a third-party logistics provider, with multiple distribution locations, to provide shipping and warehousing services for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our third-party contract manufacturers, and our quality department audits them on a periodic basis.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We source raw materials that are used to manufacture our drug substance from multiple third-party suppliers in Asia and Europe. We stock sufficient quantities of these materials and provide them to our third-party drug substance contract manufacturers so they can manufacture adequate drug substance quantities per our requirements, for both clinical and commercial purposes. We then store drug substance at third-party facilities and provide appropriate amounts to our third-party drug product contract manufacturers, who then manufacture, package and label our specified quantities of finished goods for COMETRIQ and CABOMETYX, respectively. In addition, we rely on our third-party contract manufacturers to source materials such as excipients, components and reagents, which are required to manufacture our drug substance and finished drug product.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Within our supply chain, we have established safety stock amounts for both our drug substance and drug products, and we store these quantities in multiple locations. The quantities that we store are based on our business needs and take into account scenarios for market demand, production lead times, potential supply interruptions and shelf life for our drug substance and drug products. In parallel, for business continuity reasons, we will continue to enhance our supply chain by incrementally adding additional suppliers for our drug substance and drug product manufacturers where needed. We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of CABOMETYX to support the currently approved advanced RCC and HCC indications, as well as potential additional indications if trials evaluating CABOMETYX in those indications prove to be successful and gain regulatory approval in the future. Our manufacturing footprint also enables us to fulfill our supply obligations for CABOMETYX and COMETRIQ to our collaboration partners for global development and commercial purposes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Marketing, Sales and Distribution</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes CABOMETYX and COMETRIQ in the U.S. In addition, although we currently do not co-promote COTELLIC alongside Genentech, we have the right to do so and will do so if we, in consultation with Genentech, deem it useful and appropriate to realize COTELLIC&#8217;s commercial objectives. We use customary pharmaceutical company practices to market our products in the U.S. and concentrate our efforts on oncologists, oncology nurses and pharmacists.&#160;Our commercial products, CABOMETYX and COMETRIQ, are sold initially through wholesale distribution and specialty pharmacy channels and then, if applicable, resold to hospitals and other organizations that provide CABOMETYX and COMETRIQ to end-user patients. To facilitate our commercial activities in the U.S., we also employ various third-party vendors, such as advertising agencies, market research firms and other sales-support related services as needed. We believe that our commercial team and distribution practices are sufficient to facilitate our marketing efforts in reaching our target audience and our delivery of our products to patients in a timely and compliant fashion.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we rely on Ipsen and Takeda for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ongoing and further</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs or similar programs with the effect of introducing earlier patient access to CABOMETYX, and we also rely on Ipsen for these same activities with respect to the commercialization and distribution of COMETRIQ outside of the U.S. For COTELLIC, we rely on Genentech, as our collaboration partner, for all current and future commercialization and marketing activities, with the exception of the limited co-promotion activities highlighted above.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help ensure that all eligible patients in the U.S. have appropriate access to CABOMETYX and COMETRIQ, we have established a comprehensive reimbursement and patient support program called Exelixis Access Services (EASE). Through EASE, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria. In addition, EASE provides comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Seasonal Operations and Backlog</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Sales of our marketed products do not reflect any significant degree of seasonality.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The markets in which we operate are characterized by short lead times and the absence of significant backlogs. We do not believe that backlog information is material to our business as a whole.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Environment, Health and Safety</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In support of the development and expansion of our product pipeline, we have resumed and expanded our internal drug discovery activities. Our research and development processes involve the controlled use of certain hazardous materials and chemicals. We are subject to federal, state and local environmental, health and workplace safety laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials. While we have incurred, and may continue to incur, expenditures to maintain compliance with these laws and regulations, we do not expect the cost of complying with these laws and regulations to be material.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Government Regulation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Development</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing, marketing approval, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, post-marketing safety reporting, export, import, record keeping, advertising and promotion of our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The process required by the FDA before product candidates may be marketed in the U.S. generally involves the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nonclinical laboratory and animal tests, some of which must be conducted in accordance with Good Laboratory Practice;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">submission of an IND, which must become effective before human clinical trials may begin;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the investigational drug candidate for its proposed intended use;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for drug products, submission of a New Drug Application (NDA) to the FDA for commercial marketing, or generally of a supplemental New Drug Application (sNDA), for approval of a new indication if the product is already approved for another indication;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for biological products, submission of a Biologics License Application (BLA) to the FDA for commercial marketing, or generally a supplemental Biologics License Application (sBLA) for approval of a new indication if the product is already approved for another indication;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with GMP and Good Clinical Practice (GCP), respectively;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDA approval of the NDA or sNDA, or BLA or sBLA.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The testing and approval process requires substantial time, effort and financial resources. Prior to commencing the first human clinical trial with a product candidate, we must submit an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development. Further, an independent institutional review board for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial and provide its informed consent form before the trial commences at that center. Regulatory authorities or an institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 1 - Studies, which involve the initial introduction of a new drug product candidate into humans, are initially conducted in a limited number of subjects to test the product candidate for safety, tolerability, absorption, metabolism, distribution and excretion in healthy humans or patients. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In rare cases, a Phase 1 study that is designed to assess effectiveness may serve as the basis for FDA marketing approval of a drug or for a label expansion. For instance, at FDA&#8217;s discretion, a product may receive approval based on a Phase 1b study if </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:12px;text-align:left;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">effectiveness results from the study are extremely compelling, approval of the drug would address a significant unmet patient need, and the drug is being approved through the Accelerated Approval pathway.&#160;As discussed below, Accelerated Approval generally requires a post-approval study to confirm clinical benefit.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 2 - Studies are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, optimal dosage, and common short-term side effect and risks associated with the drug. Multiple phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive phase 3 clinical trials. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. In some cases, a sponsor may decide to run what is referred to as a &#8220;phase 2b&#8221; evaluation, which is a second, confirmatory phase 2 trial that could, if positive, serve as a pivotal trial in the approval of a product candidate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 3 - When earlier phase evaluations provide preliminary evidence suggesting that a dosage range of the product is effective and has an acceptable safety profile, phase 3 trials are performed to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called phase 4 studies may be deemed a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FDA Review and Approval</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For approval of a new drug or changes to an approved drug, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA, or as part of an sNDA. The submission of an NDA requires payment of a substantial user fee to the FDA. The FDA may convene an advisory committee to provide clinical insight on NDA review questions. Although the FDA is not required to follow the recommendations of an advisory committee, the agency usually does so. The FDA may deny approval of an NDA or sNDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data and/or an additional phase 3 pivotal clinical trial. Even if such data are submitted, the FDA may ultimately decide that the NDA or sNDA does not satisfy the criteria for approval. An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy. Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Satisfaction of FDA development and approval requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Government regulation may delay or prevent marketing of product candidates for new diseases for a considerable period of time and impose costly procedures upon our activities. The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all. Success in early-stage clinical trials does not ensure success in late-stage or other potentially label-enabling clinical trials. Even if a product candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market, including withdrawal of the NDA approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including obtaining prior FDA approval of certain changes to the approved NDA, record-keeping requirements, and reporting of adverse experiences with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies. Thus, we and our third-party contract manufacturing organizations are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain manufacturing requirements (including procedural and documentation requirements) upon us and our third-party contract manufacturing organizations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the Orphan Drug Act of 1983, as amended, provides incentives for the development of drugs and biological products for rare diseases or conditions that affect fewer than 200,000 people in the U.S. (or for which there is no reasonable expectation that the cost of developing and making available the drug in the U.S. for such disease or condition will be recovered from sales of the drug in the U.S.). Certain of the incentives turn on the drug first being designated as an orphan drug. To be eligible for designation as an orphan drug (Orphan Drug Designation), the FDA must not have previously approved a drug considered the &#8220;same drug,&#8221; as defined in the FDA&#8217;s orphan drug regulations, for the same orphan-</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">designated indication or the sponsor of the subsequent drug must provide a plausible hypothesis of clinical superiority over the previously approved same drug. Upon receipt of Orphan Drug Designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses and waiver of the Prescription Drug User Fee Act application fee. In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity if no drug considered the same drug was previously approved for the same orphan condition (or if the subsequent drug is demonstrated to be clinically superior to any such previously approved same drug). Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication. Moreover, a subsequent same drug could break an approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA has various programs that are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. Examples of such programs included Fast Track designation, breakthrough therapy designation, priority review and accelerated approval, and the eligibility criteria of and benefits for each program vary: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Fast Track</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">is a process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases or conditions that demonstrate the potential to fill unmet medical needs, by providing, among other things, eligibility for accelerated approval if relevant criteria are met, and rolling review, which allows submission of individually completed sections of an NDA or for FDA review before the entire submission is completed. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Breakthrough therapy</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> designation is a process designed to expedite the development and review of drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives: intensive guidance on an efficient drug development program; intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review; and rolling review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Priority review</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is designed to shorten the review period for drugs that treat serious conditions and that, if approved, would offer significant advances in safety or effectiveness or would provide a treatment where no adequate therapy exists. Under priority review, the FDA aims to take action on application within six months as compared to a standard review time of 10 months. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Accelerated approval</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint, or a certain intermediate clinical endpoint, reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act) established two abbreviated approval pathways for drug products in which potential competitors may rely upon the FDA&#8217;s prior approval of the same or similar drug product.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Abbreviated New Drug Application (ANDA).</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> An ANDA may be approved by the FDA if the applicant demonstrates that the proposed generic product is the same as the approved drug, which is referred to as the Reference Listed Drug (RLD).&#160;Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (1)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (2)&#160;are intended for the same uses, and (3)&#160;are bioequivalent.&#160;This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA previously found to be safe and effective. Furthermore, conducting bioequivalence testing is generally less time consuming and costly than conducting a full set of clinical trials in humans. In this regard, the FDA has published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active pharmaceutical ingredient in CABOMETYX and COMETRIQ, as it does for many FDA-approved therapeutic products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">505(b)(2)&#160;NDAs.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;A 505(b)(2) application is one for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Under Section 505(b)(2) of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Federal </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Food, Drug, and Cosmetic Act (</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDCA), an applicant may rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. If the 505(b)(2) applicant establishes that reliance on FDA&#8217;s prior findings of safety and efficacy for an approved product is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies. The FDA may require additional studies or measurements, including comparability studies.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unlike a full NDA for which the sponsor has conducted or obtained a right of reference to all the data essential to approval, the filing of both an ANDA application and a 505(b)(2) application may be delayed due to patent or exclusivity protections covering an approved product. The Hatch-Waxman Act provides (a) up to five years of exclusivity for the first approval of a new chemical entity (NCE) exclusivity and (b) three years of exclusivity for approval of an NDA or supplemental application for a product that is not an NCE but rather where the application contains new clinical studies considered essential to the approval of the NDA or sNDA (three-year &#8220;changes&#8221; exclusivity). NCE exclusivity runs from the time of approval of the NDA and bars FDA from accepting for review of any ANDA or 505(b)(2) application for a drug containing the same active moiety for five years (or for four years if the application contains a Paragraph IV certification that a reference product patent is invalid or not infringed by the ANDA/505(b)(2) product). The three-year &#8220;changes&#8221; exclusivity generally bars the FDA from approving any ANDA or 505(b)(2) application that relies on the information supporting the approval of the drug or the change to the drug for which the information was submitted and the exclusivity granted.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book Listing.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is referred to as the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the RLD that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. An ANDA or 505(b)(2) applicant may also submit a statement that it intends to carve-out from the labeling of its product an RLD&#8217;s use that is protected by exclusivity or a method of use patent. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. Filing such a lawsuit within 45 days of the receipt of the Paragraph IV certification notice prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant. The ANDA or 505(b)(2) application also will not receive final approval until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired. We intend to defend vigorously any patents for our approved products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2019, we received a Paragraph IV certification notice letter from MSN Pharmaceuticals, Inc. (MSN), that it had filed an ANDA with the FDA for a generic version of CABOMETYX tablets, and we subsequently filed a patent infringement lawsuit against MSN on&#160;October 29, 2019. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Regulatory Approval Outside of the United States </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The way clinical trials are conducted in the EU will undergo a major change when Regulation (EU) 536/2014 governing clinical trials in the EU, repealing the existing Directive 2001/20/EC, comes into application. Once fully implemented, this regulation will harmonize the assessment and supervision processes for clinical trials throughout the EU, via an EU portal and database. The EMA will set up and maintain the portal and database, in collaboration with the Member States and the EC. Although Regulation (EU) 536/2014 was adopted and entered into force in 2014, the timing of its application depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit. Regulation (EU) 536/2014 will then become applicable six months after the EC publishes notice of this confirmation. In December 2015, the EMA's Management Board endorsed a delivery timeframe with a projected application date in September 2018. However, the system's go-live date has been postponed several times due to technical difficulties with the development of the information technology systems. At its meeting in October 2019, the EMA&#8217;s Management Board </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not provide the firm date for the audit to be carried out in order for Regulation (EU) 536/2014 to be applied. The application of Regulation (EU) 536/2014 will likely be further delayed. Until CTIS is confirmed to be fully functional based on an independent audit, there is uncertainty about the date of application of Regulation 536/2014. In the interim, Directive 2001/20 continues to be applicable for regulating clinical trials conducted in the Member States of the EU.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under EU regulatory systems, a company may submit MAAs either under centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the EMA for scientific review by the Committee for Medicinal Products for Human Use (CHMP) so that an opinion is issued on product approvability. The opinion is considered by the EC which is responsible for granting the centralized marketing authorization in the form of a binding EC decision. If the application is approved, the EC grants a single marketing authorization that is valid for all EU member states as well as Iceland, Liechtenstein and Norway, collectively the European Economic Area. The decentralized and mutual recognition procedures, as well as national authorization procedure are available for products for which the centralized procedure is not compulsory. The mutual recognition procedure provides for the EU member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State (RMS). The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state. Under this procedure the applicant can select the member state that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States. Within 90 days of receiving the application and assessment report, each Concerned Member State must decide whether to recognize the RMS assessment. If a member state does not agree with the assessment, and the disputed points cannot be resolved the matter is eventually referred to the Coordination Group on Mutual Recognition and Decentralised procedures in the first instance to reach an agreement and failing to reach such an agreement, a referral to the EMA and the CHMP for arbitration that will result in an opinion to form the basis of a decision to be issued by the EC binding on all member states. If the application is successful during the decentralized or mutual recognition procedure, national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Conditional marketing authorizations may be granted in the centralized procedure for a limited number of medicinal products for human use referenced in EU law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required. Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. In the EU, orphan designation is available for products in development which are either: (a) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU; or (b) intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant for a similar medicinal product can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Healthcare and Privacy Regulation </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute (AKS), which prohibits, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce or reward for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare and Medicaid; the FDCA and its </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded; and federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a governmental healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. For example, the California Consumer Privacy Act of 2018, as amended (CCPA), went into operation on January 1, 2020 and broadly defines personal information, affords California residents expanded privacy rights and protections and provides for civil penalties for violations and a private right of action related to certain data security breaches. There are similar legislative proposals being advanced in other states, as well as in Congress. In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act (HIPAA). Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly encourage, assist or otherwise facilitate a HIPAA-covered entity (or its business associate) to use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including laws in all 50 states requiring security breach notification in some circumstances. CCPA, HIPAA, and these other laws could create liability for us or increase our cost of doing business. International laws, such as the EU General Data Protection Regulation 2016/679 (GDPR), could also apply to our operations. Failure to provide adequate privacy protections and maintain compliance with applicable privacy laws could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, the Patient Protection and Affordable Care Act of 2010, as amended (PPACA) created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare &amp; Medicaid Services annually certain payments and other transfers of value provided to physicians (as defined by such law) and teaching hospitals made in the previous calendar year. In addition, there are also an increasing number of state laws that control pharmaceutical product pricing or require manufacturers to make reports to states on pricing and marketing information. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Because our products are covered in the U.S. by the Medicaid programs, we have various obligations, including government price reporting and rebate requirements, which generally require us to pay substantial rebates or offer our drugs at substantial discounts to certain purchasers (including &#8220;covered entities&#8221; purchasing under the 340B Drug Discount Program). We are also required to discount our products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas and regulatory guidance, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources. Failure to properly calculate prices, or to offer required discounts or rebates could subject us to substantial penalties.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Coverage and Reimbursement </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Sales of our approved products and any future products of ours will depend, in part, on the extent to which their costs will be covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. Each third-party payer may have its own policy regarding what products it will cover, the conditions under which it will cover such products, and how much it will pay for such products. Third-party payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a third-party payer&#8217;s decision to provide coverage for a drug product does not guarantee what reimbursement rate, if any, will be approved. Patients may be less likely to use our products if coverage is not provided and reimbursement may not cover a significant portion of the cost of our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S. and other potentially significant markets for our products, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">products and therapies, which may result in lower average selling prices. In some cases, for example, third-party payers try to encourage the use of less expensive generic products through their prescription benefits coverage and reimbursement and co-pay policies. Further, the increased emphasis on managed healthcare in the U.S. and on country-specific and national pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing coverage and/or reimbursement controls and measures, could have a material adverse impact on our net product revenues and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Healthcare Reform</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering proposals or have enacted legislative and regulatory changes to the healthcare system that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices. In particular, there have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients; reform the structure of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; and facilitate the importation of certain lower-cost drugs from other countries, expedite the development and approval of generic drugs and biosimilars. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. For example, in October 2017, California as adopted SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide notice of price increases above a defined threshold to certain purchasers and related reports to the government.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. pharmaceutical industry has already been significantly impacted by major legislative initiatives and related political contests, including, for example, efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. Notably, in December 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the penalty enforcing the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Then, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld this District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. It is unclear how this decision, future decisions, subsequent appeals and other efforts will impact the PPACA. Additionally, the 2019 year-end federal spending package permanently repealed, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device taxes, and, effective January 1, 2021, also eliminates the health insurer tax.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. Insurers are also pursuing means of contracting for pharmaceutical &#8220;value&#8221; or &#8220;outcomes.&#8221; These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of value-based contracting, which could adversely affect product sales. Due to the volatility in the current regulatory and market dynamics, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before its cost may be funded within the respective national healthcare system. The requirements governing drug pricing vary widely from country to country. For example, EU Member States may restrict the range of medicinal products for which their national healthcare systems provide reimbursement and may control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profits </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the medicinal product generates for the company placing it on the market. Pricing and reimbursement negotiations with governmental authorities or payers in EU member states can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. To obtain reimbursement and/or pricing approval in some countries, drug manufacturers and collaboration partners may also be required to conduct a study that seeks to establish the cost effectiveness of a new drug compared with other available established therapies. There can be no assurance that any country that has price controls, reimbursement limitations or other requirements for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products on cost-effectiveness grounds. Historically, products launched in countries in the EU do not follow the price structures of the U.S. and they generally tend to be priced significantly lower.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Competition </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are many companies focused on the development of small molecules and antibodies for cancer. Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition for Cabozantinib</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that our ability to successfully compete will depend on, among other things:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">efficacy, safety and reliability of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">timing and scope of regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the speed at which we develop cabozantinib for the treatment of additional tumor types beyond its approved indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to complete clinical development and obtain regulatory approvals for cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to manufacture and sell commercial quantities of cabozantinib product to the market;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to successfully commercialize cabozantinib and secure coverage and adequate reimbursement in approved indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product acceptance by physicians and other health care providers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our collaboration partners&#8217; investments in the resources necessary to successfully commercialize cabozantinib in&#160;territories where it is approved outside of the U.S.;&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">skills of our employees and our ability to recruit and retain skilled employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">protection of our intellectual property, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">including our ability to enforce our intellectual property rights against potential generic competition</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the availability of substantial capital resources to fund development and commercialization activities</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that the quality and breadth of activity observed with cabozantinib, the skill of our employees and our ability to recruit and retain skilled employees, our patent portfolio and our capabilities for research and drug development are competitive strengths. However, many large pharmaceutical and biotechnology companies have significantly larger intellectual property estates than we do, more substantial capital resources than we have, and greater capabilities and experience than we do in preclinical and clinical development, sales, marketing, manufacturing and regulatory affairs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The markets for which we intend to pursue regulatory approval of cabozantinib are highly competitive. We are aware of products in research or development by our competitors that are intended to treat all of the tumor types we are targeting, and should they demonstrate suitable clinical evidence, any of these products may compete with cabozantinib. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. While we have adapted our cabozantinib development strategy to address the expanding role of therapies that combine ICIs with other targeted agents in indications for which CABOMETYX is approved or being evaluated in clinical studies, we cannot ensure that our clinical trials will show efficacy in comparison to competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Competition in Approved Cabozantinib Indications</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">CABOMETYX - RCC:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We believe the principal competition for CABOMETYX in advanced RCC includes: the combination of Merck&#8217;s pembrolizumab and Pfizer&#8217;s axitinib; the combination of Pfizer&#8217;s avelumab and axitinib; BMS&#8217; nivolumab; the combination of BMS&#8217;s ipilimumab and nivolumab; Pfizer&#8217;s axitinib, sunitinib and temsirolimus, each as single-agent therapies; Novartis&#8217; everolimus and pazopanib, each as single-agent therapies; Bayer&#8217;s and Amgen&#8217;s sorafenib; Roche&#8217;s bevacizumab; the combination of Eisai&#8217;s lenvatinib and Novartis&#8217; everolimus; and generic versions of everolimus and aldesleukin. Additionally, there are a variety of therapies being developed for advanced RCC, including: the combination of Merck&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; the combination of Calithera&#8217;s CB-839 and Novartis&#8217; everolimus; AVEO Pharmaceutical&#8217;s tivozanib; the combination of BMS&#8217; nivolumab and Nektar Therapeutics&#8217; NKTR-214; and generic versions of sorafenib and sunitinib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> The competitive landscape for RCC is evolving rapidly, especially given the entrance of ICI and ICI-TKI combination therapies into the RCC treatment landscape, particularly in the first-line setting. This will lead to new trends in prescribing and sequencing of certain drugs and combinations across different lines of therapy. It is therefore difficult to predict how these changes will affect sales of CABOMETYX during 2020 and going forward.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">CABOMETYX - HCC: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe the principal competition for CABOMETYX in previously treated HCC includes: Bayer&#8217;s regorafenib; Bayer&#8217;s and Onyx&#8217;s sorafenib; BMS&#8217; nivolumab; Eisai&#8217;s levantinib; Merck&#8217;s pembrolizumab; and Eli Lilly&#8217;s ramucirumab. Additionally, there are a variety of therapies being developed for previously treated HCC, including: the combination of BMS&#8217;s ipilimumab and nivolumab; and generic versions of sorafenib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">COMETRIQ:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We believe that the principal competing anti-cancer therapy&#160;to COMETRIQ in progressive, metastatic MTC is Genzyme&#8217;s vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease. We believe that COMETRIQ also faces competition as a treatment for progressive, metastatic MTC from off-label use of certain treatments, including: Bayer&#8217;s and Onyx&#8217;s sorafenib; Pfizer&#8217;s sunitinib; Takeda&#8217;s ponatinib; Novartis&#8217; pazopanib; and Eisai&#8217;s lenvatinib. Additionally, there are a variety of compounds being developed for MTC with early-stage clinical trials in progress, including: Blueprint Medicine&#8217;s pralsetinib (for certain subsets of MTC patients); and Loxo Oncology&#8217;s (a wholly owned subsidiary of Eli Lilly) selpercatinib (which was recently granted Breakthrough Therapy Designation by the FDA for the treatment of patients with RET-mutant MTC who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options). </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Competition in Potential Cabozantinib Indications</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have initiated COSMIC-311, a phase 3 pivotal trial evaluating cabozantinib in patients with DTC who have progressed after up to two prior VEGFR-targeted therapies, and COSMIC-312, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with previously untreated HCC. However, we face a rapidly evolving treatment landscape for the treatment of both of these indications, as other therapies have recently received regulatory approval or are in advanced stages of clinical development, which may impair the relative value of CABOMETYX or a combination of CABOMETYX with an ICI in DTC and previously untreated HCC, respectively. Should cabozantinib be approved for this indication of DTC, we believe its principal competition may include: Bayer&#8217;s and Onyx&#8217;s sorafenib; and Eisai&#8217;s lenvatinib. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with previously untreated advanced HCC, we believe its principal competition may include: Eisai&#8217;s levantinib; Bayer&#8217;s and Onyx&#8217;s sorafenib; BMS&#8217; nivolumab; the combination of Merck&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; BeiGen and Celgene&#8217;s tislelizumab; the combination of Roche&#8217;s bevacizumab and atezolizumab; AstraZeneca&#8217;s durvalumab; the combination of AstraZeneca&#8217;s durvalumab and tremelimumab; and generic versions of sorafenib. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we are evaluating the combination of cabozantinib and atezolizumab in COSMIC-021, a phase 1b trial in locally advanced or metastatic solid tumors, including mCRPC. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication as early as 2021. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with mCRPC, we believe its principal competition may include: Janssen Biotech&#8217;s (a wholly owned subsidiary of Johnson &amp; Johnson) abiraterone; Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; Janssen Biotech&#8217;s apalutamide; Bayer&#8217;s darolutamide; Sanofi&#8217;s docetaxel; Sanofi&#8217;s cabazitaxel; Dendreon&#8217;s Sipuleucel-T; Bayer&#8217;s radium-223 dichloride; AstraZeneca&#8217;s and Merck&#8217;s olaparib; Clovis Oncology&#8217;s rucaparib; the combination of Merck&#8217;s pembrolizumab and Sanofi&#8217;s docetaxel; the combination of Merck&#8217;s pembrolizumab and Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; the combination of BMS&#8217; nivolumab and Sanofi&#8217;s docetaxel; the combination of Merck&#8217;s pembrolizumab and AstraZeneca&#8217;s and Merck&#8217;s olaparib; the combination of AB Science&#8217;s masitinib and Sanofi&#8217;s docetaxel; and Novartis&#8217; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">177</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lu-PSMA-617.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Examples of potential competition for cabozantinib in other cancer indications include: other VEGF pathway inhibitors, including Genentech&#8217;s bevacizumab and Pfizer&#8217;s axitinib; other RET inhibitors, including Takeda&#8217;s ponatinib, Loxo Oncology&#8217;s selpercatinib, Blueprint Medicine&#8217;s pralsetinib, Turning Point Therapeutics&#8217; TPX-0046 and Daiichi Sankyo&#8217;s and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Boston Pharmaceuticals&#8217; DS 5010 (also known as BOS172738)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; other MET inhibitors, including AstraZeneca&#8217;s savolitinib, Pfizer&#8217;s crizotinib, Mirati&#8217;s glesatinib and Novartis&#8217; and Incyte&#8217;s capmatinib; other inhibitors of multiple tyrosine kinases, including Eisai&#8217;s lenvatinib, Mirati&#8217;s sitravatinib and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Boehringer Ingelheim&#8217;s nintedanib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; and ICIs, including BMS&#8217; ipilimumab and nivolumab, Merck&#8217;s pembrolizumab, Roche&#8217;s atezolizumab, Pfizer&#8217;s avelumab and AstraZeneca&#8217;s durvalumab and tremelimumab.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition for Cobimetinib</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that cobimetinib&#8217;s principal competition amongst targeted agents includes: the combination of Array&#8217;s encorafenib and binimetinib; and the combination of Novartis&#8217; trametinib and dabrafenib. Within the class of ICIs, we believe that cobimetinib&#8217;s principal competition includes: the combination of BMS&#8217;s ipilimumab and nivolumab; and Merck&#8217;s pembrolizumab. The second category, ICIs, are of particular competitive importance vis-a-vis cobimetinib in advanced melanoma as they are already FDA approved in melanoma patient populations that overlap with those that may be eligible for cobimetinib, they have been rapidly incorporated into the NCCN treatment guidelines, and they are viewed with a high degree of enthusiasm by physicians and key opinion leaders. Ongoing and future trials incorporating ICIs, including combination trials, may further impact usage of cobimetinib in melanoma and potentially in additional tumor types in which cobimetinib may ultimately gain approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Competition for Esaxerenone</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that esaxerenone&#8217;s principal competition for the treatment of hypertension in Japan will be Bayer&#8217;s MR antagonist, finerenone, if and when it is approved by the MHLW. Finerenone is still in development for this indication, and results from ongoing clinical studies are expected during 2020. Other potential competitors for the treatment of hypertension in Japan, if and when they are approved by the MHLW, include: Janssen Pharmaceuticals&#8217; canagliflozin; Reata Pharmaceuticals&#8217; bardoxolone methyl; and Gilead Sciences&#8217; selonsertib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that esaxerenone&#8217;s principal competition for the treatment of diabetic nephropathy in Japan will be finerenone, if and when it is approved by the MHLW. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Significant Customers</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate as a single business segment and have operations solely in the U.S. During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we derived </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our revenues from Ipsen, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our revenues from affiliates of CVS Health Corporation, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our revenues from affiliates of McKesson Corporation and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our revenues from affiliates of AmerisourceBergen Corporation. See &#8220;Note 2. Revenues&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K for information about significant customers in prior years. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patents and Proprietary Rights </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We actively seek patent protection in the U.S., Europe and selected other foreign countries to cover our drug candidates and related technologies. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country. We have numerous patents and pending patent applications that relate to methods of screening drug targets, compounds that modulate drug targets, as well as methods of making and using such compounds.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">While many patent applications have been filed relating to the drug candidates that we have developed, the majority of these are not yet issued or allowed. We own all global patents associated with cabozantinib, cobimetinib and our other drug candidates referenced below.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cabozantinib</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib is covered by 10 issued patents in the U.S., building from U.S. Pat. No.&#160;7,579,473, for the composition-of-matter of cabozantinib (the &#8216;473 Patent) and pharmaceutical compositions thereof. This composition of matter patent would expire in September 2024, but we have been granted a patent term extension to extend the term to August 2026. The following table describes the US patents that cover our marketed cabozantinib products, and which are listed in the Orange Book. Except as otherwise noted, the stated expiration dates include any patent term extensions already granted. In addition to the composition of matter patent referenced above, the table includes patents directed to, among other things, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. We continue to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our cabozantinib products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4251968503937%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:13%;"></td><td style="width:14%;"></td><td style="width:52%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent No.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">General Subject Matter</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent Expiration</span></div></td></tr><tr><td rowspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,579,473</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2026</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,497,284</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Methods of treatment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2024</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,877,776</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2030</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,724,342</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Formulations of cabozantinib</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2033</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,039,757</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Methods of treatment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2031</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,034,873</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Methods of treatment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2031</span></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,579,473</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2026</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,877,776</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2030</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,717,720</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Formulations of cabozantinib</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2032</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To our knowledge after extensive investigation, no other company possesses a portfolio of broad and exclusive rights to the patents and patent applications required for the commercialization of medicines containing cabozantinib. Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise in this area. For example, in September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets.&#160;The notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;MSN&#8217;s notice letter does not provide a Paragraph IV certification against the &#8216;473 Patent, which expires on August 16, 2026, or U.S. Patent No. 8,497,284, which expires on September 24, 2024; therefore, neither the &#8216;473 Patent nor U.S. Patent No. 8,497,284 are presently at issue. On October 29, 2019, we filed a complaint for patent infringement against MSN asserting U.S. Patent No. 8,877,776 in the United States District Court for the District of Delaware (the Delaware District Federal Court) arising from MSN&#8217;s ANDA filing with the FDA. We cannot predict the outcome of this lawsuit or assure you that the lawsuit will prevent the introduction of a generic version of CABOMETYX for any particular length of time, or at all.&#160;For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In Europe, cabozantinib is protected by issued patents covering the composition-of-matter and methods of use. The issued patent would expire in September 2024, but we have applied for and either have obtained, or expect to obtain Supplementary Protection Certificates in Europe to extend the term to 2029. In addition to the composition of matter patent, the table below includes later-expiring patents directed to the commercial product, including, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4251968503937%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:13%;"></td><td style="width:14%;"></td><td style="width:52%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent No.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">General Subject Matter</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent Expiration</span></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2213661</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter and methods of treatment</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2029</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2387563</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib and methods of treatment</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2030</span></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2213661</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter and methods of treatment</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2029</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2387563</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib and methods of treatment</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2030</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Similarly in Japan, cabozantinib is protected by an issued patent covering the composition-of-matter, and salts thereof, as well as pharmaceutical compositions and related methods of use. We intend to apply for patent term extension in Japan to extend the term to 2029. Foreign counterparts of the issued U.S. and European composition of matter patents have been issued in Australia and Canada, and are anticipated to expire in 2024. We have other filed patent applications and issued patents in the U.S. and other selected countries covering certain synthetic methods, salts, polymorphs, formulations, prodrugs, metabolites and combinations of cabozantinib that, if issued, are anticipated to expire as late as 2035</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Outside the U.S. and Japan, cabozantinib is licensed to Ipsen; in Japan cabozantinib is licensed to Takeda, each in accordance with the respective collaboration agreements. A discussion of risks and uncertainties that may affect our patent position and other proprietary rights is set forth in &#8220;Risk Factors,&#8221; contained in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Drug Candidates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also have pending patent applications, and will continue to file new patent applications, in the U.S., Europe and other selected countries covering the composition-of-matter of our other drug candidates in clinical and/or preclinical development. We intend to describe these patents in more detail once it is determined that a particular drug candidate warrants further development.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained licenses from various parties that give us rights to technologies that we deem to be necessary or desirable for our research and development. These licenses (both exclusive and non-exclusive) may require us to pay royalties as well as upfront and milestone payments.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We require our scientific personnel to maintain laboratory notebooks and other research records in accordance with our policies, which are designed to strengthen and support our intellectual property protection. In addition to our patented intellectual property, we also rely on trade secrets and other proprietary information, especially when we do not believe that&#160;patent</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">protection is appropriate or can be obtained. We also require all of our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive proprietary information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all proprietary information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Furthermore, our agreements with employees and, in most circumstances, our agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors expressly provide that all inventions, concepts, developments, copyrights, trademarks or other intellectual property developed by an employee during the employment period, or developed by a service provider during the service period or utilizing our proprietary drugs or information, shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Employees</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had 617 full-time equivalent employees, all of which are located in the U.S. None of our employees are represented by a labor union, and we consider our employee relations to be good.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Corporate Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc. and changed our name to Exelixis, Inc. in February 2000. Our principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502. Our telephone number is (650) 837-7000. We maintain a site on the worldwide web at www.exelixis.com; however, information found on our website is not incorporated by reference into this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We make available free of charge on or through our website our Securities and Exchange Commission (SEC) filings, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</span></div><div><a id="s6BB0A72870AF585282857140811BFEB5"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the risks discussed elsewhere in this report, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advanced RCC and previously treated HCC, and possibly for other indications for which cabozantinib is being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from such trials. In this regard, part of our strategy is to pursue additional indications for cabozantinib to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We rely heavily upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, foreign sales of CABOMETYX by our collaboration partners could be adversely affected by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or otherwise. If our collaboration partners are unable to, or do not invest the resources necessary to successfully commercialize CABOMETYX in the EU and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government health care payers such as Medicare and Medicaid, commercial health care plans and the medical community. Market acceptance for CABOMETYX could depend on numerous factors, including the effectiveness and safety profile, or perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts, and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by rapid technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy following the advent of ICIs. While we have adapted our cabozantinib development strategy to address the use of therapies that combine ICIs with other targeted agents in indications for which CABOMETYX is approved, we cannot ensure that our clinical trials will show efficacy in comparison to competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or increase our internal sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and pre-commercial-stage oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to enter into or maintain agreements with third parties to store, distribute and commercialize our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize our products will depend, in part, on the extent to which we are able to adequately distribute the products to eligible patients. We currently rely on third-party providers for storage and collaboration partners for ongoing and further commercialization and distribution of CABOMETYX and COMETRIQ in their respective territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply CABOMETYX and COMETRIQ on a timely and competitive basis. These third parties may not provide timely services, and we may be unable to maintain or renew our arrangements with these third parties or enter into new arrangements, on acceptable terms or at all. If we are unable to contract for these third-party services on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper conduct or inaccurate reporting, the laws that could impact our operations include, without limitation:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal AKS, which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the FDCA and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HIPAA and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the PPACA Open Payments program, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by such law) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities, as well as state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state pharmaceutical price and price reporting laws and regulations that require us to provide notice of price increases or the introduction of new high-cost products, and/or file complex ancillary reports concerning prices and pricing and discount practices.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These federal and state healthcare laws and regulations govern pharmaceutical marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. Under the False Claims Act, these individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the civil False Claims Act, or settles a lawsuit brought pursuant to the False Claims Act to avoid further prosecution, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant financial and personnel resources. Therefore, if any such action is brought against us, our business may be impaired, even if we are ultimately successful in our defense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The pharmaceutical industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We face related uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. Notably, in December 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the penalty enforcing the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Then, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld this District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. It is unclear how this decision, future decisions, subsequent appeals and other efforts will impact the PPACA. Additionally, the 2019 year-end federal spending package permanently repealed, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device taxes, and, effective January 1, 2021, also eliminates the health insurer tax. There is no assurance that the repeal or modification of some or all of the provisions of the PPACA in the future, will not have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. Insurers are also pursuing means of contracting for pharmaceutical &#8220;value&#8221; or &#8220;outcomes.&#8221; These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of value-based contracting, which could adversely affect product sales. Furthermore, the expansion of the 340B Drug Discount Program has increased the number of purchasers eligible for significant discounts on branded drugs, including our marketed products</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Due to the volatility in the current regulatory and market dynamics, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, any such measures could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients; reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; and facilitate the importation of certain lower-cost drugs from other countries. While we cannot know the final form of any such legislative, regulatory and/or administrative measures, some of the pending legislative proposals, such as those incorporating International Pricing Index models, if enacted, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with its evaluation of proposals concerning the pricing of, and access to, pharmaceutical products, many companies in our industry have received governmental requests for documents and information relating to drug </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pricing and patient support programs. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, these findings could further harm our business, reputation and/or prospects. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For example, California adopted SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide notice of price increases above a defined threshold to certain purchasers and related reports to the government. Such obligations to provide notices of price increases to purchasers may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of drug pricing transparency regulations, and our associated compliance obligations, may increase general and administrative costs and/or diminish our revenues as a result of the imposition of caps on pricing and price increases. Therefore, the implementation of these cost-containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products resulting in a decrease in revenue.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Outside the U.S., particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner Ipsen may also be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and Ipsen might establish for CABOMETYX, which would result in lower license revenues to us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The U.S. Department of Health and Human Services Office of Inspector General established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. If we are deemed not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. A variety of entities, including pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Regardless of whether we have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection continues to evolve globally and in the U.S. For example, the CCPA went into operation on January 1, 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">breaches. Similar legislative proposals being advanced in other states and Congress is also considering federal privacy legislation. In addition, most healthcare providers are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly encourage, assist or otherwise facilitate a HIPAA-covered entity (or its business associate) to use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the GDPR regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also restricts transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Legislation and regulatory action designed to facilitate the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the commercial potential of our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve an NDA under section 505(b)(2) of the FDCA that relies in whole or in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail above in &#8220;Item 1. Business&#8221; under the heading &#8220;Government Regulation&#8212;FDA Review and Approval.&#8221; In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our marketed products prior to the expiry of one or more our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in significant expenses, distraction for our management team, and could have an adverse impact on our stock price. For example, in September 2019, we received a Paragraph IV certification notice letter from MSN that it had filed an ANDA with the FDA for a generic version of CABOMETYX tablets, and we subsequently filed a patent infringement lawsuit against MSN on October 29, 2019. It is possible that MSN or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which reauthorized the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which applicants for such products partially pay for the FDA&#8217;s pre-market review of their product candidates and pay other specified fees. The legislation also includes, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. In addition, the FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; health care costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019, recently signed into law as part of the 2019 year-end federal spending package, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing generic manufacturers access to branded drug samples. While we cannot predict the specific outcome or impact on our business of such regulatory actions or legislation, they do have the potential to facilitate the development and future approval of generic versions of our products, or otherwise limit or reduce the term for our market exclusivity, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of cabozantinib for new indications, or of new potential product candidates, is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new potential product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval in a particular indication. Moreover, the results of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of cabozantinib in new indications, or of our other product candidates, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of efficacy or a tolerable safety profile;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lower-than-anticipated patient registration or enrollment in our clinical testing</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including in China as a result of the recent coronavirus outbreak</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If there are significant delays in or termination of the clinical testing of cabozantinib or our other product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of cabozantinib or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to pursue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up ; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable authorities in other countries. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a MAA to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual additional indications. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-approval studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. For example, based on the regulatory feedback from the FDA, and if supported by the clinical data from COSMIC-021, we i</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ntend to file with the FDA for accelerated approval of cabozantinib in an mCRPC indication as early as 2021</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We expect that as a condition of any potential approval under the FDA's accelerated approval pathway, the FDA will require us to perform confirmatory post-marketing clinical trials to confirm the clinical benefit, if any, of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, such as mCRPC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in any additional indications. Further, these regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply successfully with regulatory requirements, including withdrawal of product approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. These efforts may initially show promise in identifying product candidates, yet ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160;We may also be unable to in-license or acquire additional product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If our internal drug discovery or business development efforts do not result in suitable product candidates, our business and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although we do not intend to disclose material, nonpublic information through these means. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements, Accounting and Financial Results</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our profitability could be negatively impacted by our extensive clinical development, business development and commercialization activities for cabozantinib and pipeline expansion efforts relative to the revenues we generate.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$321.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$690.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the&#160;years ended December 31, 2019 and 2018, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; other collaboration revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We expect to continue to spend significant additional amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of additional partnerships through business development activities or strategic transactions that align with our oncology drug development</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, regulatory and commercial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial outlook may not be realized.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">From time to time, in press releases and otherwise, we may publish estimates, forecasts or other forward-looking statements regarding our future financial or operating results, including estimated revenues, expenses and earnings. Any forecast of our future performance reflects various assumptions. These assumptions are subject to significant risks and uncertainties, and as a matter of course, any number of them may prove to be incorrect. Further, the achievement of any forecast depends on numerous assumptions and other factors (including those described in this discussion), many of which are beyond our control. As a result, we cannot be certain that our performance will be consistent with any management estimates or forecasts or that the variation from such estimates or forecasts will not be material and adverse. Current and potential stockholders are cautioned not to base their entire analysis of our business and prospects upon isolated estimates or forecasts, but instead are encouraged to utilize our entire publicly available mix of historical and forward-looking information, as well as other available information regarding us, our products, the competitive landscape for our products, our commercialization, development and regulatory efforts, as well as those of our collaboration partners, and the biotechnology and pharmaceutical industry generally when evaluating our prospective financial or operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments. Our business operations grew substantially during 2019. In order to maintain business growth in 2020, we plan to continue to execute on our U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib and our other product candidates, internal discovery activities and the execution of strategic transactions. Our ability to achieve these business objectives will depend on many factors including but not limited to: </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number and size of clinical trials we conduct and the cost of drug supply for such clinical trials evaluating our products with other therapeutic agents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib and increasing internal drug discovery activities, as well as through the execution of strategic transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including any disruptions resulting from government shutdowns, rising interest rate environments, actual or threatened public health emergencies and outbreak of disease (including for example, the recent coronavirus outbreak), increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160;Accordingly, we do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and stock-based compensation reflect the more significant estimates and judgments used in the preparation of our Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements from the Financial Accounting Standards Board and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">again in the future and, as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, our other results of operations or our current financial position. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to income tax in the U.S. as well as numerous U.S. states and territories, municipalities, and other local jurisdictions. As a result, our effective tax rate is derived from various factors including the mix of earnings and applicable tax rates in the various places that we operate, the accounting for stock options and stock-based awards, and research and development spending. In preparing our financial statements, we estimate the amount of tax that will become payable in each jurisdiction. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in tax laws, changes in the mix of our earnings from state to state, the results of examinations and audits of our tax filings, or our inability to secure or sustain acceptable agreements with tax authorities. Any of these factors could cause our effective tax rate to fluctuate. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses and tax credits to offset future taxable income may be subject to limitations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2019, we had federal and state net operating loss carryforwards of approximately $675 million. The federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2035 for federal income tax purposes and 2020 for state income tax purposes. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code (the Code) and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2019, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses is conditioned upon our maintaining profitability and generating U.S. federal taxable income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The UK&#8217;s withdrawal from the EU&#160;may have a negative effect on global economic conditions, financial markets and our business. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Following the ratification of the Withdrawal Agreement by the European Parliament and UK Parliament, the UK left the EU on January 31, 2020 (commonly referred to as &#8220;Brexit&#8221;). The Withdrawal Agreement provides for a transition period until December 31, 2020, during which the UK remains in the single market and customs union and the free movement of people will continue, in order to ensure frictionless trade and business continuity until a long-term relationship is agreed. At the end of transition, the UK&#8217;s relationship with the EU will be determined by the new agreements it has entered into on trade and other areas of cooperation. The new agreements must be reached before the transition period ends. If not, the UK would have to rely on previous international conventions for security cooperation and would trade with the EU on World Trade Organization terms. The exception is Northern Ireland, whose trade in goods with the EU would be covered by the provisions in the Northern Ireland Protocol.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications Brexit will have and how it might affect us. For example, we rely on third-party contract manufacturing organization facilities located in the UK, responsible for packaging, labeling, storing and subsequently distributing supplies of our product to the EU. Any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the UK and the EU that ultimately result from Brexit may have an adverse impact on this part of our supply chain. Trade restrictions, changes to the regulatory approval or drug cost reimbursement systems, and additional administrative costs may impede the ability of our collaboration partner Ipsen to market our products in Europe. Furthermore, the initial announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations; therefore, the Brexit transition may continue to adversely affect European and global economic and market conditions, which may cause third-party payers, including governmental organizations, to closely monitor their costs and reduce their spending budgets, and which could contribute to instability in the global financial and foreign exchange markets. Any of these effects of Brexit could have a material adverse impact on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subject us to a number of risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies, including, Ipsen, Takeda, Roche and Genentech, BMS and Daiichi Sankyo, for the development and ultimate commercialization of our products. Our dependence on our relationships with collaboration partners for the development and commercialization of compounds subjects us to, a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the amount and timing of resources that our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners or potential future </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> partners will devote to the development or commercialization of drug candidates or to their marketing and distribution;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial, deliver product that fails to meet appropriate quality and regulatory standards and results in a market recall or withdrawal, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes that may arise between us and our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners may experience financial difficulties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners&#8217; lack of success in their efforts to obtain regulatory approvals in a timely manner, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners&#8217; failure to comply with the terms of our collaboration agreements and related ancillary agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">related to GMP, GCP, GDP and Good Pharmacovigilance Practice;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners could independently move forward with competing drug candidates, developed either independently or in collaboration with others, including our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to enter into additional collaboration arrangements with third parties in an area or field of exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that future </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> partners may require us to relinquish some important rights, such as marketing and distribution rights; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of, development of our drug candidates.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations and our product development efforts could be delayed, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our internal drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce our products for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for clinical or commercial production and distribution of our products. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. As our operations continue to expand through our clinical development and commercial progress, we continue to appropriately expand our supply chain through secondary third-party contract manufacturers and suppliers. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude our ability to meet our commercial supply requirements, or our supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the DSCSA. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the supply of CABOMETYX and COMETRIQ for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our partners&#8217; ability to successfully develop and commercialize CABOMETYX and COMETRIQ and generate revenues to which we are entitled under the collaborations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in internal drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, they may be impacted by external factors, including, without limitation, actual or threatened public health emergencies and outbreak of disease. In fact, certain of our contractors located in China have been affected by the recent coronavirus outbreak, which has restricted their ability to perform their contractually obligated services to us. In any of these circumstances, we have or may continue to experience delays in the receipt of services, lose work performed by these scientific advisors and contractors or be unable to engage them in the first place, and our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Information Technology, Data Privacy and Intellectual Property</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches, cyber attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous companies have been subject to a wide variety of security incidents, cyber attacks (including through use of ransomware) and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber attacks on our operations and financial condition has not been material to date, we and our third-party vendors have frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack, and such threats can also vary in motive (including corporate espionage). Cyber attacks continue to become more prevalent and much harder to detect and defend against, and it is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information (or sensitive business information of our collaboration partners, which may lead to significant liability for us). A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter partes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, in September 2019, we received a Paragraph IV certification notice letter from MSN that it has filed an ANDA with the FDA for a generic version of CABOMETYX tablets, and we subsequently filed a patent infringement lawsuit against MSN on October 29, 2019. Should MSN or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical personnel, in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to develop or commercialize certain product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for cabozantinib and our other product candidates, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our headquarters in Alameda, California is located in the San Francisco Bay Area, and therefore our facilities are vulnerable to damage from earthquakes. We have limited earthquake insurance, which may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fires and floods, which have become a significant danger in California during recent years, as well as power loss, communications failures, aircraft disasters (due to the proximity of our headquarters to a major international airport), terrorism and similar events, and any insurance we may maintain may be inadequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired, causing significant delays in our programs and making it difficult for us to recover due to the unique nature of our research activities. Accordingly, an earthquake or other disaster could have a material adverse impact on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability or otherwise have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials, and such liability may exceed our insurance coverage and our total assets. In addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the biotechnology, biopharmaceutical and pharmaceutical industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse or inconclusive results or announcements related to our or our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> partners&#8217; clinical trials or delays in those clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for cabozantinib or any of our other programs or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to make future investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products or clinical trial data by our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications, such as MSN&#8217;s ANDA, seeking approval of generic versions of our marketed products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in our relationships with our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners, including the termination or modification of our agreements, or other events or conflicts that may affect our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel or board members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the disposition of any of our technologies or compounds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, actual or threatened public health emergencies and outbreak of disease (including for example, the recent coronavirus outbreak), policies governing foreign trade and health care spending and delivery, or future U.S. federal government shutdowns, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><a id="s6F3F417146BC55B9BA3191ACEC7E3500"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1B. Unresolved Staff Comments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">None.</span></div><div><a id="sF6787D5D80E157BA997F06A41794DA12"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Properties</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our corporate headquarters is located in Alameda, California, where&#160;we lease a total of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">228,941</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7,477</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space that we expect to take possession of on or prior to April 30, 2020. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The lease expires in October 2031. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have two five-year options to extend the lease. In October 2019, we entered into a build-to-suit lease agreement (the Build-to-Suit Lease) for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">220,000</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of additional office facilities adjacent to our current corporate headquarters. The term of the Build-to-Suit Lease is for a period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">242</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> months, which will begin on the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the term will begin in October 2021. We believe these leased facilities are sufficient to accommodate our current and near-term needs.</span></div><div><a id="s91EA716305D8589299136DD3D9E26A14"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets.&#160;The notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">MSN&#8217;s notice letter does not provide a Paragraph IV certification against the &#8216;473 Patent, which expires on August 16, 2026, or U.S. Patent No. 8,497,284, which expires on September 24, 2024; therefore, neither the &#8216;473 Patent nor U.S. Patent No. 8,497,284 are presently at issue. On October 29, 2019, we filed a complaint for patent infringement against MSN asserting U.S. Patent No. 8,877,776 in the Delaware District Federal Court arising from MSN&#8217;s ANDA filing with the FDA. Based on the information we have received to date, our complaint does not allege infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. We are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of U.S. Patent No. 8,877,776 on October 8, 2030 and equitable relief enjoining MSN from infringing this patent. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. A date for a bench trial in this case has been tentatively scheduled for April 2022</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div><a id="sF2E7B3BFB9FD551683D71DE28E4E362A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF583C12D45C25431AD1D45765DE78AFD"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II</span></div><div><a id="s1091D77BA5DC53069A746A183F45F8AC"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;EXEL&#8221; since April 11, 2000.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Holders</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">February&#160;18, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were 381 holders of record of our common stock. The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dividends</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since inception, we have not paid dividends on our common stock. We currently intend to retain all future earnings, if any, for use in our business and currently do not plan to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unregistered Sales of Equity Securities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no unregistered sales of equity securities by us during the year ended December&#160;31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Repurchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no repurchases&#160;of our common stock </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the year ended December&#160;31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act of 1933, as amended.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following graph compares, for the five-year period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested on December&#160;31, 2014 in each of our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;"><img src="fiveyearchart2019.jpg" alt="fiveyearchart2019.jpg" style="height:353px;width:672px;"></img></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:29%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">342</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">904</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,842</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,178</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,031</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Nasdaq Composite Index</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">107</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">117</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">146</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">202</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Nasdaq Biotechnology Index</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">111</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">87</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">106</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">95</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">119</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><a id="s7E42650AABFF522F9B29FDD3D34E4EB7"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Selected Financial Data</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following Selected Financial Data has been derived from our audited Consolidated Financial Statements and should be read in conjunction with Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Part II, Item 8. &#8220;Financial Statements and Supplementary Data&#8221; contained in this Annual Report on Form 10-K. The consolidated financial information as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and for the years ended, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from audited Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K. The consolidated financial information as of December&#160;31, 2017, 2016 and 2015, and for each of the years ended December&#160;31, 2016 and 2015, are derived from audited Consolidated Financial Statements not included in this Annual Report on Form 10-K. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020; fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018; fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017; fiscal year 2016, which was a 52-week fiscal year, ended on December 30, 2016; and fiscal year 2015, which was a 53-week fiscal year, ended on January 1, 2016.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">(in thousands, except per share data)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consolidated Statements of Income Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">967,775</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">37,172</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">598,305</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">286,567</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">219,578</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">158,593</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">369,470</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">438,855</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">165,910</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(28,124</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(121,421</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">77,097</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(237,978</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">55</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">321,012</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1.06</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1.02</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">302,584</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">315,009</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,388,628</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">851,621</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">457,176</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">479,554</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">253,310</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Working capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">868,444</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">791,544</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">369,704</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">200,215</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">126,414</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,885,670</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,422,286</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">595,739</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">332,223</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term obligations </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">56,954</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,361</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">255,163</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">237,635</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">420,897</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity (deficit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,685,970</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,287,453</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">89,318</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(140,806</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Revenues for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> are presented under Accounting Standards Update No. 2014-09, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, while revenues for the years ended December&#160;31, 2017, 2016 and 2015 continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification Topic 605: </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;">Revenue Recognition</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of this Annual Report on Form 10-K for additional discussion of our operating results. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Net income for the year ended December 31, 2018 included a $244.1 million income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The decreases in long-term obligations were primarily due to the repayment of the Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. in 2017, the repayment of the $80.0 million term loan with Silicon Valley Bank in 2017, and the conversions and redemption in 2016 of the 4.25% convertible senior subordinated notes due 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</span></div></div><hr style="page-break-after:always"></hr><div><a id="s05D5A4F917E45FBDBA3385867F10DAFD"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Some of the statements under in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This discussion and analysis generally discusses 2019 and 2018 items and year-to-year comparisons between 2019 and 2018. Discussions of 2017 items and year-to-year comparisons between 2018 and 2017 that are not included in this Annual Report on Form 10-K can be found in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">, filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX tablets approved for advanced RCC and previously treated HCC; and COMETRIQ capsules approved for progressive, metastatic MTC. For these types of cancer, cabozantinib has become or is becoming a standard of care. The other two products resulting from our discovery efforts are: COTELLIC, an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech; and MINNEBRO, an oral, non-steroidal, selective blocker of the MR, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA first approved CABOMETYX for previously treated patients with advanced RCC in April 2016, and in December 2017 the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib. This approval was based on results from CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC, which demonstrated a statistically significant and clinically meaningful improvement in OS versus placebo.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen rights to cabozantinib outside of the U.S. and Japan, and to Takeda rights to cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the EU and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. Additionally, with respect to the Japanese market, Takeda achieved important regulatory milestones with its applications to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable and metastatic RCC in April 2019, and more recently in January 2020, as a treatment for patients with unresectable HCC who progressed after prior systemic therapy.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest of world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine.&#160;We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising&#160;over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">85</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our CRADA with NCI-CTEP or our IST program. Informed by the available data from these clinical trials, we continue to advance cabozantinib&#8217;s development program with potentially label-enabling trials. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are particularly interested in examining cabozantinib&#8217;s potential in combination with ICIs to determine if such combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. The most advanced of these combination studies include CheckMate 9ER, a phase 3 pivotal trial evaluating cabozantinib in combination with nivolumab in previously untreated advanced or metastatic RCC, for which our collaboration partner BMS has announced top-line results are expected in the first half of 2020, and CheckMate 040, a phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, also in collaboration with BMS and for which initial clinically meaningful results were presented at ASCO&#8217;s Gastrointestinal Cancers Symposium in January 2020. Additionally in May 2019, as part of our clinical collaboration with BMS, we initiated COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We expect to complete enrollment for COSMIC-313 in early 2021 and to report top-line results of the event-driven analyses from the trial in the 2022 timeframe. We also intend to evaluate the combination of cabozantinib and nivolumab, with or without ipilimumab, in other phase 3 trials in various other tumor types. In an effort to diversify our exploration of combinations with ICIs, we also initiated COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with the Roche&#8217;s ICI, atezolizumab, versus sorafenib in previously untreated advanced HCC, and COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. COSMIC-021 is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion phase, which is ongoing. Findings from the dose-escalation stage of COSMIC-021 demonstrated that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. The expansion phase of COSMIC-021 comprises 24 total cohorts, with 20 cohorts evaluating the combination of cabozantinib and atezolizumab and four cohorts evaluating cabozantinib or atezolizumab as single-agent therapies. Based on continuing encouraging efficacy and safety data certain cohorts have been or may be further expanded, including the cohorts of patients with NSCLC who have been previously treated with an ICI and mCRPC who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. We anticipate enrolling up to 1,732 patients in the trial in late 2020, which timing is subject to the initiation of additional cohorts or expansion of selected existing cohorts. Since its initiation, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting planned pivotal trials in NSCLC, mCRPC and RCC. Encouraging results from an interim analysis of the mCRPC cohort of COSMIC-021 were presented at ASCO&#8217;s Genitourinary Cancer Symposium in February 2020. For additional information on the COSMIC-021 results, see &#8220;Business&#8212;Cabozantinib Development Program&#8212;Trials Conducted under our Clinical Collaboration Agreements&#8212;Combination Studies with F. Hoffmann-La Roche Ltd. (Roche)&#8221; in Part I, Item 1 of this Annual Report on Form 10-K. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication as early as 2021.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. Notably, these efforts are led by some of the same experienced scientists that led the efforts to discover cabozantinib, cobimetinib and esaxerenone, which have been approved for commercialization. Using our expertise in medicinal chemistry, tumor biology and pharmacology, we are advancing drug candidates toward and through preclinical development. Furthest along in these internal drug discovery efforts is XL092, a next-generation oral tyrosine kinase inhibitor that is currently in a phase 1 clinical trial in patients with advanced solid malignancies. We anticipate that dose expansion cohorts and potential combination cohorts with ICIs of this phase 1 trial will begin to enroll in 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">development infrastructure. In furtherance of this strategy, in 2019, we entered into collaboration and license agreements with&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene, which is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on the discovery and development of novel small molecules as therapies for cancer, and Iconic, which is focused on the advancement of a next-generation ADC program targeting the tissue factor in solid tumors. Both the lead Aurigene program targeting CDK7 and tissue factor ADC program with Iconic are in preclinical development and could result in IND filings in 2020. We have also made progress under our 2018 collaborations with Invenra, which is focused on the discovery and development of multispecific antibodies for the treatment of cancer, and StemSynergy, which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting CK1&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To further enhance our early-stage pipeline, we expect to enter into additional, external collaborative relationships around assets and technologies that complement our internal drug discovery and development efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019 Business Updates and Financial Highlights</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2019, we continued to execute on our business objectives, generating significant revenue from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for 2019 and subsequent to year end include:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Updates</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2019, following the FDA&#8217;s acceptance of our IND for XL092, a next-generation oral TKI, we initiated a phase 1 dose escalation trial, evaluating the pharmacokinetics, safety and tolerability of XL092 in patients with advanced solid tumors, with the primary objective of determining a dose for daily oral administration suitable for further evaluation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2019, Takeda applied</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable and metastatic RCC.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we announced the initiation of COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, which will be conducted in collaboration with BMS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, following the Japanese MHLW&#8217;s approval, we announced that Daiichi Sankyo launched MINNEBRO as a treatment for patients with hypertension in Japan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we announced an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2019, Genentech informed us that IMspire170, Genentech&#8217;s phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab in patients with previously untreated BRAF V600 wild-type advanced melanoma, did not meet its primary endpoint.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, to expand patient enrollment in certain existing mCRPC and NSCLC cohorts and to add new expansion and exploratory cohorts in mCRPC (</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an aggregate of 24 total cohorts, with 20 expansion cohorts evaluating the combination of cabozantinib and atezolizumab </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and four exploratory cohorts </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluating cabozantinib or atezolizumab as single-agent therapies</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we announced an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six programs to discover and develop small molecules as therapies for cancer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, Ipsen received regulatory approval from Health Canada for CABOMETYX for the first-line treatment of adults with advanced RCC.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we expanded our collaboration with Invenra focused on the discovery and development of multispecific antibodies for the treatment of cancer to include the development of novel binders against six additional targets which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body&#8482; technology platform, or with other platforms and formats at our option.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we filed a patent infringement lawsuit against MSN, following receipt of a Paragraph IV certification notice letter from MSN that it had filed an ANDA with the FDA requesting approval to market a generic version of CABOMETYX tablets, following expiration of the &#8216;473 Patent, which expires on August 14, 2026. For a </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-left:48px;padding-bottom:0px;padding-top:4px;text-align:left;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2019, Daiichi Sankyo reported positive results from a phase 3 pivotal trial of esaxerenone in patients with diabetic nephropathy.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2019, Ipsen received regulatory approval from Health Canada for CABOMETYX for treatment of patients with HCC who have been previously treated with sorafenib.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, we announced that IMspire150, the phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab and vemurafenib in patients with previously untreated BRAF V600 mutant melanoma, met its primary endpoint. Results will be presented at an upcoming medical meeting and discussed with healthcare authorities around the world, including the FDA and EMA.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, we announced a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal trials in advanced NSCLC, mCRPC and RCC. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2020, we announced an amendment to the protocol for COSMIC-021 to further expand patient enrollment in an existing mCRPC cohort to up to 130 patients.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2020, clinically meaningful data from CheckMate 040, the phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, were presented at ASCO&#8217;s Gastrointestinal Cancers Symposium. For additional information on the CheckMate 040 results, see &#8220;Business&#8212;Cabozantinib Development Program&#8212;Trials Conducted under our Clinical Collaboration Agreements&#8212;Combination Studies with Bristol-Myers Squibb Company (BMS)&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2020, Takeda applied to the Japanese MHLW for approval to manufacture and sell CABOMETYX as a treatment for patients with unresectable HCC who progressed after prior systemic therapy in Japan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2020, we presented clinically meaningful results from the mCRPC cohort of COSMIC-021 at ASCO&#8217;s Genitourinary Cancers Symposium. For additional information on the COSMIC-021 results, see &#8220;Business&#8212;Cabozantinib Development Program&#8212;Trials Conducted under our Clinical Collaboration Agreements&#8212;Co</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">mbination Studies with F. Hoffmann-La Roche Ltd. (Roche)&#8221; in Part I, Item 1 of this Annual Report on Form 10-K</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2020, we announced the enrollment of the first 100 patients in COSMIC-311, the phase 3 pivotal trial of cabozantinb versus placebo in patients with RAI-refractory DTC who have progressed after up to two prior VEGF receptor-targeted therapies.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2019 Financial Highlights</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues for 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$760.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$619.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$967.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$853.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses for 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$337.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$182.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses for 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$228.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$206.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for 2019 was </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$77.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to an income tax benefit of </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$238.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income for 2019 was </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$321.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1.06</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1.02</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, diluted, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$690.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$2.32</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$2.21</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share diluted, for 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1.4 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.9 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will continue to face challenges and risks that may impact our ability to execute on our 2020 business objectives. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and possibly for other indications for which cabozantinib is being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from such trials. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Achievement of our 2020 business objectives and the continued success of CABOMETYX will also depend on the success of our development and commercialization strategies to navigate increased competition, including that from, but not limited to, the use of therapies that combine an ICI with another targeted agent to treat cancer. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of CABOMETYX tablets that is the subject of the ANDA submitted to the FDA by MSN, which if approved following the expiration of our composition of matter patent in 2026, could result in significant decreases in the revenue derived from the U.S. sales of CABOMETYX and thereby materially harm our business and financial condition. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with internal drug discovery operations. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. For a complete discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div><a id="sF4790628F16C54D79146D374E4A4095A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Impact of the Duration of Our Fiscal Year</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Accordingly, 2019 was a 53-week fiscal year and 2018 was a 52-week fiscal year. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">T</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">he 53-week fiscal year in 2019, as compared to the 52-week fiscal year in 2018, contributed to the year-over-year increases in certain revenues and expenses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">759,950</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">207,825</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(11</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">967,775</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">957,621</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">738,529</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">30</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(197,671</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(119,250</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">66</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">759,950</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">733,421</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">599,946</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">22</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">26,529</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">19,333</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">37</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">759,950</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in product revenues for CABOMETYX for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily due to a 17% increase in the number of units of CABOMETYX sold and, to a lesser extent, an increase in the average selling price of the product. The increase in CABOMETYX sales volume reflects the continued growth of CABOMETYX for the treatment of patients with advanced RCC as well as the launch of CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib, following FDA approval for that indication in January 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in product revenues for COMETRIQ for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily due to a 24% increase in the number of units of COMETRIQ sold and, to a lesser extent, an increase in the average selling price of the product. The increase in COMETRIQ sales volume was entirely due to a comparator purchase of the product for use in a clinical trial. Excluding the comparator purchase, COMETRIQ sales volume has continued to decrease since the launch of CABOMETYX in April 2016. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our 2020 net product revenues to remain in-line with 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, reflecting the continued evolution of the metastatic RCC and HCC treatment landscapes.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances as described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K. The increase in discounts and allowances for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily the result of the overall increase in product sales volume and increases in Public Health Service hospital utilization and the dollar amount of the related chargebacks, and, to a lesser extent, increases in utilization and the dollar amount of chargebacks associated with Veterans Affairs hospitals and Group Purchasing Organizations, as well as increases to other government and commercial rebates. We expect a moderate increase in our discounts and allowances as a percentage of gross product revenues during 2020 as the number of patients participating in government programs continues to increase, and as the discounts given and rebates paid to government payers also increase.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">161,299</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">192,188</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">49,965</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">39,501</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">26</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(3,439</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,858</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">207,825</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">License Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and a significant reversal of revenues would not occur, as well as royalty revenues. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues, which are allocated between license revenues and research and development services revenues, were $96.2 million for the year ended December&#160;31, 2019, as compared to $164.4 million for the comparable periods in 2018. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the nature and timing of m</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ilestone events, their achievement can vary significantly from year to year. Milestone revenues by period primarily included the following:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">primarily </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">included: 1) recognition of a $50.0 million milestone from Ipsen upon their achievement of $250.0 million in net sales of cabozantinib in their territories over four consecutive quarters; 2) recognition of a $20.0 million milestone from Daiichi Sankyo for the first commercial sale of MINNEBRO tablets as a treatment for patients with hypertension in Japan; 3) recognition of $9.9 million in revenues related to a $16.0 million milestone from Takeda for the submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese MHLW; 4) recognition of $9.1 million in revenues related to a $10.0 million milestone from Takeda for the submission of a regulatory application in January 2020 for cabozantinib as a treatment for patients with advanced HCC to the Japanese MHLW; and 5) recognition of two milestones totaling $5.0 million from Ipsen on the approvals by Health Canada of cabozantinib for the treatment of adults with first-line RCC and for the treatment of adults with advanced HCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">who have been previously treated with sorafenib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">primarily </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">included: 1) recognition of $46.5 million in revenue related to a $50.0 million milestone from Ipsen for the approval of cabozantinib for the first-line treatment of adults with intermediate- or poor-risk advanced RCC by the EC; 2) recognition of $37.2 million in revenue related to a $40.0 million milestone from Ipsen for the approval by the EC of cabozantinib for previously-treated HCC; 3) recognition of a $25.0 million milestone from Ipsen upon their achievement of $100.0 million in net sales of cabozantinib in their territories over four consecutive quarters; 4) recognition of a $20.0 million milestone upon Daiichi Sankyo&#8217;s submission to the Japanese MHLW of a regulatory application for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esaxerenone</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as a treatment for patients with hypertension; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5) recognition of $18.6 million of a $20.0 million </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone from Ipsen for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the initiation of COSMIC-312; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and 6) recognition of a $5.0 million milestone from Ipsen on the approval by Health Canada of cabozantinib for the treatment of adults with advanced RCC.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties increased primarily as a result of an increase in royalties on Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $62.4 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to $32.3 million in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to increased demand of CABOMETYX, which, as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, is approved and commercially available in 51 and 48 countries outside of the U.S., respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we earned royalties on ex-U.S. net sales of COTELLIC by Genentech of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also earned $0.1 million in royalties on the sale of MINNEBRO by Daiichi Sankyo for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Research and Development Services Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development services revenues include the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned under our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements increased in 2019, as compared to 2018, primarily as a result of reimbursements from Ipsen for their share of the increase in spending on the COSMIC-312 and COSMIC-021 studies.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues include royalties earned by GSK related to Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues, net of product supply costs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Sales of COTELLIC in the U.S. have declined following Genentech&#8217;s decision to scale back the personal promotion of COTELLIC commencing in January 2018.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, other collaboration revenues were reduced by $8.4 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GSK on the net sales by Ipsen of any product incorporating cabozantinib, as compared to $5.4 million in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As royalty generating sales of cabozantinib by Ipsen have increased as described above, our royalty payments to GSK have also increased. In addition, pursuant to a license agreement we entered into with Ligand, we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO; such amounts were either not significant or zero for the years ended December&#160;31, 2019 and 2018. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">2020 Expectations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our collaboration revenues to decrease in 2020 as a result of a decrease in milestones expected to be achieved during the year</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The cost of goods sold and our gross margins were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33,097</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">26,348</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">26</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty payable to GSK on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increase in cost of goods sold for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily the result of the increases in product sales volume described above. We expect the cost of goods sold and our gross margin to remain flat during 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">336,964</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">182,257</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">85</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial costs, personnel expenses, license and other collaboration costs, consulting and outside services, stock-based compensation and the allocation of general corporate costs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily related to increases in clinical trial costs, license and other collaboration costs, personnel expenses, consulting and outside services, the allocation of general corporate costs and stock-based compensation. Clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials, and comparator drug purchases, increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$70.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increase in clinical trial costs was primarily due to costs associated with the expanding clinical trial program for cabozantinib which includes COSMIC-311, COSMIC-312, COSMIC-313, COSMIC-021 and CheckMate 9ER. License and other collaboration costs increased $39.4 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily as a result of the collaboration agreements we entered into with&#160;Aurigene in July 2019 and Iconic in May 2019. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount to support our expanded discovery and development efforts. Consulting and outside services increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily in support of our expanded discovery and development efforts. Stock-based compensation increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to the increase in headcount, as well as the expense recognition for restricted stock units that were granted in September 2018 that either have vested or are expected to vest upon the achievement of specific performance targets (the 2018 PSUs). General corporate costs, which include our costs for facilities, information technology, human resources, financial planning and analysis and purchasing, are allocated to cost of goods sold, research and development and selling general and administrative expenses based on headcount. The allocation of general corporate costs to research and development expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the year ended December&#160;31, 2019, as compared to 2018, primarily due to increases in headcount to support our expanded discovery and development efforts. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened research and development expenses on a project-by-project basis.&#160;We group our research and development expenses into three categories: 1) development; 2) drug discovery; and 3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses by category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">136,763</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">66,434</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">61,433</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">48,114</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14,531</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,693</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,034</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,505</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">227,761</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">137,746</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License and other collaboration costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">47,691</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,245</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other drug discovery</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">25,610</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,699</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total drug discovery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">73,301</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21,944</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">35,902</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">22,567</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">336,964</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">182,257</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation and the allocation of general corporate costs to research and development. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, preliminary data from and final results of clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we expect our near-term research and development expenses to primarily relate to the continued clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">85</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. Notable studies of this program include: CheckMate 9ER and CheckMate&#160;040, each in collaboration with BMS; company-sponsored COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; company-sponsored COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; and company-sponsored COSMIC-311. In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we are conducting internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our research and development expenses to continue to increase in 2020 as a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the expected initiation and completion of numerous late-stage and other potentially label-enabling cabozantinib trials</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including our ability to expand the labeled indications of use for CABOMETYX and completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses were as follows (dollars in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">228,244</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation and marketing costs. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in selling, general and administrative expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily related to increases in personnel expenses, stock-based compensation, consulting and outside services and marketing costs, and were partially offset by a decrease in corporate giving. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to an increase in administrative headcount to support the company&#8217;s commercial and research and development organizations. Stock-based compensation increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to an increase in headcount as well as the expense recognition for certain of the 2018 PSUs. Consulting and outside services increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and marketing costs increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increased marketing activities in support of the launch of CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib and continued support of the product in an increasingly competitive RCC market. Corporate giving, consisting predominantly of donations to independent patient support foundations, decreased $6.5 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our selling, general and administrative expenses to continue to increase in 2020 in support of our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Income (Expenses), Net</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other income (expenses), net, was as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">27,959</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,840</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">118</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">680</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">397</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">71</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expenses), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28,639</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">116</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in interest income for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was the result of increase in our investment balance as well as an increase in the yield earned on those investments.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Tax Provision (Benefit)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income tax provision (benefit) was as follows (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">77,097</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(237,978</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19.4%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December&#160;31, 2018, we recorded a $244.1 million benefit related to the release of substantially all of our valuation allowance against our deferred tax assets. The decision to release the valuation allowance was made after we determined that it was more likely than not that these deferred tax assets, including net operating losses and tax credits, would be realized</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and was based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December 31, 2018 and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, as well as considering the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">utilization of net operating losses and tax credits prior to their expiration. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other than the benefit we recorded for the release of our valuation allowance, income taxes for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> primarily related to a provision for taxes in states for which we do not have net operating loss carryforwards due to a limited operating history. We expect that our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">effective tax rate will be between 20 percent and 22 percent in 2020. </span></div><div><a id="sBD34AD53609953CFA01C1B630ACF779A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect to continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flow activities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">526,956</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">415,720</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash used in investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(587,247</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(297,850</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,553</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,691</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factors that contributed to the increase in cash provided by operating activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were the increase in cash received on sales of our products and the changes in operating assets and liabilities described above, which were partially offset by an increase in cash paid for operating expenses.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily due to investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and purchases of property, equipment and other of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$608.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily due to investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$557.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and purchases of property and equipment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$33.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$293.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$22.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements.</span></div><div><a id="s65DBCC83EE3251BDB92EEC034C468E75"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contractual obligations as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Payments Due by Period</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Less&#160;than 1 Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">1-3 Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">3-5 Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">More than 5 Years</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leases </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">302,737</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,641</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">19,289</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,194</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">249,613</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchase obligations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33,344</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,335</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,913</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,096</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term obligations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,626</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,626</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total contractual cash obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">337,707</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33,976</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23,828</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">30,290</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">249,613</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">In addition to the amounts presented, we have committed to make payments for potential future milestones, research funding commitments and royalties to certain collaboration partners as part of our agreements with those parties. Because the amount and timing of those payments is uncertain they have not been included in the table above. For more information about these obligations, see &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">We entered into the build-to-suit lease agreement in October 2019, which is expected to commence in October 2021. The amounts presented include the estimated lease commitment payments at the estimated commencement of the lease, subject to adjustment dependent upon the actual total development costs of the premises but do not include the impact of a tenant improvement allowance of approximately </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$16.5 million</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">. For more information about our lease obligations, see &#8220;Note 11. Commitments&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Purchase obligations include firm purchase commitments related to manufacturing and maintenance of inventory, software services and other facilities and equipment.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div><a id="s59203DAB636C5FAFB16FB9171CCA6B93"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Policies and Estimates </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a complete description of our significant accounting policies, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> contained in Part II, Item 8 of this Annual Report on Form 10-K</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Net Product Revenues and Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration to which we are entitled to in exchange for those goods or services</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies, distributors and commercial payors; and (d) returns. Discounts and allowances are complex and require significant judgment by management. Management assesses estimates each period and updates them to reflect current information.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We initially record estimates for these deductions at the time we recognize the related gross product revenue. We base our estimates for the expected utilization on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. For a further description of our discounts and allowances, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We use key assumptions to determine the standalone selling price, which may include forecast revenues and costs, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. At the end of each subsequent reporting period, we re-evaluate the probability of earning of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. In addition, in recording revenues for our research and development services performance obligations, we use internal development projected cost estimates to determine the amount of revenue to record as we satisfy this performance obligation, known as the inputs method.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues and U.S. profits and losses under the collaboration agreement with Genentech based on estimates of the sales that occurred during the period. We base the relevant period estimates of sales on interim data provided by licensees and analysis of historical activity, adjusted for any changes in facts and circumstances, as appropriate. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We base our estimates on the best information available at the time provided to us by our collaboration partners. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases to be changes in estimates and they will be reflected in our Consolidated Statements of Operations in the period they become known.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inventory</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trial Accruals</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We execute all of our clinical trials with support from contract research organizations and other vendors and we accrue costs for clinical trial activities performed by these third parties based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock-based Compensation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock-based compensation expense requires us to estimate the fair value of stock options, including PSOs, and the estimate the number of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shares subject to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">PSUs that will ultimately vest. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value models require a number of complex and subjective assumptions including our stock price volatility, employee exercise patterns and risk-free interest rates. The most significant assumptions are our estimates of the expected volatility and the expected term of the stock option. The value of a stock option is derived from its potential for appreciation. The more volatile the stock, the more valuable the option becomes because of the greater possibility of significant changes in stock price. Because there is a market for options on our common stock, we consider implied volatilities as well as our historical volatilities when developing an estimate of expected volatility. The expected option term also has a significant effect on the value of the option. The longer the term, the more time the option holder has to allow the stock price to increase without a cash investment and thus, the more valuable the option. Further, lengthier option terms provide more opportunity to take advantage of market highs. However, empirical data show that employees typically do not wait until the end of the contractual term of a nontransferable option to exercise. Accordingly, we are required to estimate the expected term of the option for input to an option-pricing model. As required under generally accepted accounting principles, we review our valuation assumptions at each grant date and, as a result, from time to time we change the valuation assumptions we use to value stock options granted. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation could be materially different in the future. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize stock-based compensation for PSUs over the requisite service period only for awards which we estimate will ultimately vest, which requires judgment as to the probability and timing of the achievement of the underlying performance goals. Significant factors we consider in making those judgments include forecasts of our product revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and those of our collaboration partners, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">estimates regarding the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">operational progress </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of late-stage clinical development programs and discovery pipeline expansion performance targets. To the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For additional description of our stock-based compensation, see &#8220;Note&#160;8. Employee Benefit Plans&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We compute our income tax </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">provision or benefit </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">under the asset and liability method. Significant estimates are required in determining our income tax </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">provision or benefit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We base some of these estimates on interpretations of existing tax laws or regulations. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that we deem a reversal of any portion of our valuation allowance against our deferred tax assets to be appropriate, we recognize a tax benefit against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div><a id="s87FEDAF3557056BFA250D81B91DAA331"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to credit risk, changes in interest rates and foreign exchange rates. Our</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Credit Risk</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We manage credit risk </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">associated with our investment portfolio </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Interest Rate Risk</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative and short-term nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If market interest rates were to increase or decrease by one percentage point, the fair value of our investment portfolio would increase or decrease by an immaterial amount.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Foreign Exchange Rate Risk </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fluctuations in the exchange rates of the U.S. dollar and foreign currencies may have the effect of increasing or decreasing our revenues and expenses. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty revenues and sales-based milestones we receive from our collaboration agreements with Ipsen and Genentech are a percentage of the net sales made by those </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partners from sales made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the Euro. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses include clinical trial services performed by third-party contract research organizations and other vendors located outside the U.S. that may bill us in currencies where their services are provided, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">which is also predominantly the Euro. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the U.S. dollar strengthens against a foreign currency, then our royalty revenues will decrease for the same number of units sold in that foreign currency and the date </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we achieve certain </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales-based milestones may also be delayed. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Similarly, if the U.S. dollar weakens against a foreign currency, then our research and development expenses would increase. However, we believe that we are not subject to material risks arising from changes in foreign exchange rates and that a hypothetical 10% increase or decrease in foreign exchange rates would not have a material adverse impact on our financial condition, results of operations or cash flows.</span></div><div><a id="sC9EB9003094150519FFA3C18EBD86BBC"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 8. Financial Statements and Supplementary Data</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s531793F3053C594EB5A5DEF796CC0E1E"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s531793F3053C594EB5A5DEF796CC0E1E">73</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB16A297818515472AE6667263DEC7976"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB16A297818515472AE6667263DEC7976">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC1F425A4AAA7565086B2D5F2C8590B0E"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Income</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC1F425A4AAA7565086B2D5F2C8590B0E">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAE448B9BA1A955C8BD2C35D2C241D53C"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAE448B9BA1A955C8BD2C35D2C241D53C">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4A5A110BDFF8576EA8EF936120CA8669"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4A5A110BDFF8576EA8EF936120CA8669">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDFA0950FB8475D209E4B2B00EC3E212D"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDFA0950FB8475D209E4B2B00EC3E212D">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDB1B98EDF2245BB3B622C69BDE1902DF"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDB1B98EDF2245BB3B622C69BDE1902DF">79</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">72</span></div></div><hr style="page-break-after:always"></hr><div><a id="s531793F3053C594EB5A5DEF796CC0E1E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Exelixis, Inc. (the Company) as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three fiscal years in the period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, and the results of its operations and its cash flows for each of the three fiscal years in the period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Adoption of ASU No. 2014-09</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), effective December 30, 2017.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Critical Audit Matter </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective o</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:79%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Revenue recognition - Product sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Description of the Matter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">During the year ended January 3, 2020, the Company&#8217;s gross product revenues were $957.6 million. As discussed in Note 1 of the financial statements, the Company sells its products principally to specialty distributors and specialty pharmacy providers, or collectively, Customers. These Customers subsequently resell the products to health care providers and patients. Revenues from product sales are recognized when control is transferred to the Customer.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:79%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Auditing the Company&#8217;s product sales was challenging, specifically related to the effort required to audit Customer sales activity to assess whether incentives resulted in orders in excess of demand (i.e., channel stuffing) and whether any such transactions meet the criteria for revenue recognition. This involved judgmentally assessing factors including market demand, Customer ordering patterns, Customer inventory levels, contractual terms and incentives offered.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#24282d;font-style:italic;">How We Addressed the Matter in Our Audit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls designed to monitor and review inventory levels in the channel and sales under Customer incentive programs. This includes testing relevant controls over the information systems that are important to the initiation, recording and billing of revenue transactions as well as controls over the completeness and accuracy of the data used.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#212529;">Our audit procedures over the Company&#8217;s product sales included, among others, examination of inventory channel reports for unusual trends or transactions as well as performing analytical procedures to detect and investigate anomalies within the data. Procedures included those to detect sales of short dated product near year end as well as testing the completeness and accuracy of the underlying data. We also examined the terms and conditions of any new or amended contracts with Customers and its impact on the Company&#8217;s returns reserve. We also confirmed the terms and conditions of contracts directly with a selection of Customers, including whether there are side agreements and terms not formally included in the contract that may impact the Company&#8217;s returns reserve. In addition, we obtained written representations from members of the commercial function and the market access group regarding changes to Customer incentives and the completeness of the terms and conditions reported to the legal and accounting departments.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young LLP</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We have served as the Company&#8217;s auditor since 2002.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</span></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">74</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB16A297818515472AE6667263DEC7976"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e771-wk-Fact-01250ECF4ED255118BE21200D22D84B1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e790-wk-Fact-90F54B50CC015DC590E195EFBE556F53" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e805-wk-Fact-25D8C6D231DE5E4EBE828F04E2A91DC2" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">585,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e824-wk-Fact-109206491BEA59A7A137A9DE3633A65A" name="us-gaap:ShortTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">378,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e844-wk-Fact-0CFDCA9D00B35BF38DB2E73071480D32" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e863-wk-Fact-A518F3C77037591DA9B8BCE5358CF918" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e883-wk-Fact-334BC2A172925461BD731F96E60927B4" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e902-wk-Fact-108FD8E6E36C54A0B58796683CC80F1E" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e922-wk-Fact-510F4FE18E79538FB1C42FA04926BE85" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e941-wk-Fact-FA5DFF36154359B79C6A0E1424B822A2" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e961-wk-Fact-CB87FC3D5138514FA96027C5B7B3B236" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,011,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e980-wk-Fact-79D6BCD6C726582CBC7425DEF32FD9F4" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1000-wk-Fact-2A52DC58CBD257D5B4AD62E653907E4A" name="us-gaap:LongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">536,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1019-wk-Fact-32EE08F157D253FA9657E742AF864D58" name="us-gaap:LongTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">158,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1040-wk-Fact-81AA7FFF07FE5F84B6FB6B3F858272C1" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1059-wk-Fact-B2A50C77138252D19D547A4E7AE9A283" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1079-wk-Fact-2FF860101C2F58248419901027CE579C" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1098-wk-Fact-F106612E08BA5C8CBC932306BCB5D5E3" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1118-wk-Fact-D20A9256E89A55B1AAB7A81A7E0556A1" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1137-wk-Fact-9C433D52D4585D86B53313F8C4A8584F" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1157-wk-Fact-FC39DC5F2E6954EA8E1D74CDBA604FFA" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1176-wk-Fact-55FED27665D65F21866D1551CECA4ADD" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1201-wk-Fact-951C4162B17C53458B5D0C8149BDD5B9" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,885,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1220-wk-Fact-7C42804E861D57B494CABB0566AFE6A4" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1322-wk-Fact-7A193C3789EA51D480A960098535DD04" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1341-wk-Fact-E100ED8C05F753D5BD6D05F2ABABBA64" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1356-wk-Fact-081496F4471B57A99F5BAC9087E5A831" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1375-wk-Fact-DC5436BC981454D485E38C0CDB717ED6" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1395-wk-Fact-B17F52559774580BAD1E3BA255AE6439" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,777</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1414-wk-Fact-5138DB67F25A55D7818FBB404CDD98E4" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1434-wk-Fact-006926838AC45928809436DD978BDCC8" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1453-wk-Fact-07B0A54C0D295D54A810060C3AA909E4" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1474-wk-Fact-F5B01543BC295D12BA13BB62FA7FFABA" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1493-wk-Fact-A62B9423A4BF53B1B5727C0C670827F8" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1513-wk-Fact-9A1E01EE6D52548B95BF815C6C029A04" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1532-wk-Fact-F951A5C215585681B8CC3B8699EF0946" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1552-wk-Fact-4B704D7C65705578BEBEB04623EBA969" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1571-wk-Fact-00E5E1936CB459738CA1BB19D6DCFC0F" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1591-wk-Fact-6D180C9F98DF54B5924898A5BE2BD670" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1610-wk-Fact-17DF66A050485D2095DE5E8C1EAA48FE" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1630-wk-Fact-465D3B14C4885FD68234A459F458B06C" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1649-wk-Fact-C6DB8A3881AC5BEF860D21A9A7336011" name="exel:OperatingAndFinanceLeasesLiabilityTotal" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1669-wk-Fact-E2B42151F3A555E3A8710E010721E92D" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1688-wk-Fact-2132DCA810965FBA8E1F590B0E3A8668" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1708-wk-Fact-C7644F437DDA53F9B290D51B42C17092" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">199,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1727-wk-Fact-82A768A4ABB450EAA9E3BE60E0765CE6" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1747-wk-Fact-6D275C2E7B2A5764BA60766491BDC029" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1766-wk-Fact-7566DEA5372A5E19B6C3777BF3FAFFC2" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1827-wk-Fact-72E01B1AFA6F56749FFD1D6C5A9DEFDD" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1846-wk-Fact-A2943B4734D152F48E042512EBB2F100" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 304,831 and 299,876 at December 31, 2019 and 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1866-wk-Fact-7A3E443DAF2C5CF6802F0365DEA3F613" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1885-wk-Fact-A184E8A4B8B15D4FAEE52B30A6DCF549" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1906-wk-Fact-BCF8EE670B7C556B8F45E07D2C143C0E" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,241,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1925-wk-Fact-2916F02DE9565FF28646F5ECCBABBE3A" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e1945-wk-Fact-A319E229B7175905BAFBAC5C31F3E0AA" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21817206e1964-wk-Fact-241D68BA31155F718FB1378BF5680574" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21817206e1985-wk-Fact-4F200F92C2F659C7A60CECFFD35FA625" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">559,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21817206e2005-wk-Fact-07B61B2EAE6054D4A8D9556138695E15" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e2026-wk-Fact-7DEB41AA80AF5179814C8D33FE9E1430" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,685,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e2045-wk-Fact-FD5022E3207A55678B8FFBD54FCA8596" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e2070-wk-Fact-1FBCB4FF4897564B9E92BF6D4262D182" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,885,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817206e2089-wk-Fact-5ABC543424B65C55A32FCA11DB4DBE6C" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">75</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC1F425A4AAA7565086B2D5F2C8590B0E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e797-wk-Fact-4A7175F192395C85B0C7C6A02D7F643B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">759,950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e816-wk-Fact-2EA1F50A74FDA1A9B2E4C6FA4DF7260C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">619,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e835-wk-Fact-3D0827DEC1DB5BB5A4513DCDDE52D7D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">349,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e851-wk-Fact-9651ACAA83595E19B7AF718E8FD34546" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">207,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e870-wk-Fact-669337DF6374573799CCB10DBFE5ECD5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234,547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e889-wk-Fact-670E8F350E5A6011B6F27F72B0634FD9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e910-wk-Fact-C2F428FDC3B55296BD84486AB439D9DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">967,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e929-wk-Fact-D4F84C516D8153E6AABE4A9E657B33A0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">853,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e948-wk-Fact-A0BE00E5ACD05545886BD820391E213F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1031-wk-Fact-CBD0FE8A75215CF8B595352924B8DDD6" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1050-wk-Fact-2FA1D81521CB582987B405CF1AE32F58" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1069-wk-Fact-13F01A85ED895E64BFDC3C7BCFF12B65" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1090-wk-Fact-96E0525D08AF563CBC485E911D268984" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">336,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1109-wk-Fact-7ADC0F46CE22510BB6632DCF55BE6E88" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1128-wk-Fact-D40F27293FE65FC4DD4E808181651DA7" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1149-wk-Fact-784B2FE4B31B54D096D5C1D44FEFEEE9" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">228,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1168-wk-Fact-BAC1BB30082E5BB1B9C76994478F8138" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">206,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1187-wk-Fact-6697E4555C09B0013FDF8081811F263F" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1208-wk-Fact-2D64406621085CDC827DC2DA778583FB" name="us-gaap:OperatingExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">598,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1227-wk-Fact-7056E357290E57389071B3E743BA921A" name="us-gaap:OperatingExpenses" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">414,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1246-wk-Fact-9F984EA7A0B9A9E4989F8081817AD892" name="us-gaap:OperatingExpenses" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">286,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1268-wk-Fact-3F2B79B0CC1D5FA188BC6E33D50AB9AE" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">369,470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1287-wk-Fact-5B3D28F81C785A79A715D8E45C4FA39B" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">438,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1306-wk-Fact-D70EE074410197C7DAC980818151CC04" name="us-gaap:OperatingIncomeLoss" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">165,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expense), net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1389-wk-Fact-53A836BED72C528DB072B25D6E8889F2" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,959</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1408-wk-Fact-5BB32A3D90915F69AE2F2D6D7FDCD9A8" name="us-gaap:InterestIncomeOther" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1427-wk-Fact-13E74E2B2E9F192F5A4E80818101B9DE" name="us-gaap:InterestIncomeOther" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1448-wk-Fact-2ED9D14F2CD4D20D188D8081817FB99A" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1467-wk-Fact-5D8BB5BB5564F71E07247F5F58A7B15F" name="us-gaap:InterestExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21820265e1486-wk-Fact-41BBAA8DF3EC2A314B508081818C6EAA" name="us-gaap:InterestExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1508-wk-Fact-910A93B486C35DF6B02FD51EA29BD47D" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1527-wk-Fact-EE08081B886B5B84A65E566CD74C8ED7" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21820265e1546-wk-Fact-A0E7CA397EF3B3024623808180884D69" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1568-wk-Fact-4452EFB785385D50ABAF96807AD660CD" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1587-wk-Fact-A153FAD49F845CC9ABB1BF2FFE28AC74" name="us-gaap:NonoperatingIncomeExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21820265e1606-wk-Fact-91317C673617118CCBB980818175C997" name="us-gaap:NonoperatingIncomeExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1628-wk-Fact-616E253E4D8E54C3A09FE281797CD78A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">398,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1647-wk-Fact-BFE76473261F5B13990FFB3AB221F6D4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1666-wk-Fact-E1D2F2A315327807E3CD8081809F24D4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">158,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1687-wk-Fact-A6ED704EA7B65523846BE5FA5DBBDFF4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21820265e1706-wk-Fact-695D932D76AF546FABA1D6C1D58ED92B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">237,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1726-wk-Fact-CE414B47BA63BD330D71808181883018" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1752-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1771-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1790-wk-Fact-E80041C5117CF9436D1F808180B39357" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1873-wk-Fact-12C145AC98863A3F72ABC6FA4E0C3BE4" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1892-wk-Fact-EA9446E76D075BD783CEC9BEBC095B38" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1911-wk-Fact-84EB6CDF1C972769524580818133BECA" name="us-gaap:EarningsPerShareBasic" contextRef="D2017Q4FYYTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1933-wk-Fact-F5CBF3AE37B8593EBE8CE93947271519" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.02</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1952-wk-Fact-60A5C0148F765C9CA5BA78B57AD421FA" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e1971-wk-Fact-3B2E1870498EDA767BC880818115346E" name="us-gaap:EarningsPerShareDiluted" contextRef="D2017Q4FYYTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e2049-wk-Fact-7461894293B55C43BC5671A110CD9A60" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e2068-wk-Fact-137F5557559754A18B5EA37F1C0ACE01" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">297,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e2087-wk-Fact-028CF4F8A4C6E2035E538081813C15B1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2017Q4FYYTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">293,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e2108-wk-Fact-93632B71149D5780817A0E4932B6C1EF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315,009</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e2127-wk-Fact-C80150103651525CB70CC7179CB64C23" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21820265e2146-wk-Fact-300AAABA667196BEB2DA80818183D621" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2017Q4FYYTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div><a id="sAE448B9BA1A955C8BD2C35D2C241D53C"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e743-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e762-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e781-wk-Fact-E80041C5117CF9436D1F808180B39357" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e859-wk-Fact-AE2B77916A755C0F8F475B42CAC7F126" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21817750e878-wk-Fact-3701756D22D5546588A2CBACF00D4047" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e898-wk-Fact-242C8D48DCB59D59E79B7F5F589BC39D" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e924-wk-Fact-02A6ED58DDE65DB39CB4A4744E6A77DA" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">324,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e943-wk-Fact-3E5C84553FEE59D4B126EF148880DC79" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">689,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21817750e962-wk-Fact-471000BA413A976DAE817F5F58AAD187" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">76</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4A5A110BDFF8576EA8EF936120CA8669"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e854-wk-Fact-03964438CC5225AB7D7680828A5CF00D" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">289,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e873-wk-Fact-0FC0B4B36A2DB76BB96580828A447C48" name="us-gaap:StockholdersEquity" contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e892-wk-Fact-41ABFCB4D061CF669B9480828A7438EC" name="us-gaap:StockholdersEquity" contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,072,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e912-wk-Fact-98C15F9A28D1E1905F7B80828A53105D" name="us-gaap:StockholdersEquity" contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e932-wk-Fact-47DBD9900D367B043D0780828A8A3719" name="us-gaap:StockholdersEquity" contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,983,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e952-wk-Fact-5936E5F4FC1658AA92B893E629614859" name="us-gaap:StockholdersEquity" contextRef="I2016Q4Dec30" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">89,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Accounting Standards Update (ASU) No. 2016-09,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#160;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1003-wk-Fact-17D3E5EE2F71576AAD5D63C33D5A34CD" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e1042-wk-Fact-BD7AD95B938662DEDD2780828A494FD5" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1062-wk-Fact-573CC49EC51F513C83014C5FFBB4C2F2" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1155-wk-Fact-06EA5F1553B0B04026B380828A6AA388" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1174-wk-Fact-E80041C5117CF9436D1F808180B39357" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1248-wk-Fact-7C52942A664A5B6FBD34C0008D5BDCAE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1286-wk-Fact-6C35411F83FF6358364B80828A81D8F9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1307-wk-Fact-04346507133654A3B31ACB0E3B80F8DA" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1321-wk-Fact-CFF4DE354EEAE470B1AE80828A58FADD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1340-wk-Fact-44FF1D1106AD5A05ABAEF60ECCC131C5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1398-wk-Fact-6F0A70019E06E04E9BCD80828A6141D0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock on exercise of warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1419-wk-Fact-16EFADAA35BC307A392580828A861AEA" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1433-wk-Fact-7A3BCE09A572C3F2A6A980828A4EE00B" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e1452-wk-Fact-84B8AA23EECD5C5489E13A7674671B2D" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1511-wk-Fact-44234866B58D8E06605A80828A6FFB26" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1565-wk-Fact-52162D1982852C081D1080828A7C5D52" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1623-wk-Fact-A854E6005C0E50038B27025A5E5BF2A1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1644-wk-Fact-EF989C541345851259337F5F58F4EC3D" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">296,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1658-wk-Fact-B7CAC12A9065703931C97F5F58E497E3" name="us-gaap:StockholdersEquity" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1677-wk-Fact-893861F026D1137CFE627F5F5893CCA5" name="us-gaap:StockholdersEquity" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,114,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e1697-wk-Fact-5006B6727FD71A0B5ED57F5F5875CF7B" name="us-gaap:StockholdersEquity" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e1717-wk-Fact-AA9C531FA0FDDD895F4F7F5F58EEF297" name="us-gaap:StockholdersEquity" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,829,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1737-wk-Fact-67F4B655185867246EA47F5F58E256A0" name="us-gaap:StockholdersEquity" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">284,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of ASU No. 2014-09, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1832-wk-Fact-48EB05A77F1799D158477F5F58EA521F" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1851-wk-Fact-D68B5BBBF42D47004A657F5F589550DE" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of ASU No.&#160;2016-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1947-wk-Fact-3AC3C47FA2D13473E3A97F5F58B63ED6" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e1966-wk-Fact-1532FC0E326011CAA1C87F5F58BA39D8" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2059-wk-Fact-3FC748A8E2E6058DAD3780828A7896CE" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2078-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e2152-wk-Fact-1A9A06CB32BB84D1EED17F5F58BA4590" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e2191-wk-Fact-14CDE59B39E7963358847F5F58E5A6F6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2213-wk-Fact-B6DEC927BADC96169F777F5F58F24826" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2227-wk-Fact-1EFCAAC00989B5138F807F5F58B7E0BA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2246-wk-Fact-BFE00EF81AE572FF1C6E7F5F58E52096" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2304-wk-Fact-A4FC46B4EE4239162C3C7F5F58EED1A0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2358-wk-Fact-58A947585B69E87C58307F5F587361A5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2416-wk-Fact-02357CF1D3E6A8FEFB5B7F5F58B516BF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2437-wk-Fact-FEF261F5AAA25863A481C06F58D05F8B" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">299,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2451-wk-Fact-4F4652DC0E1955C7A59A68B7D9B3C5BA" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2470-wk-Fact-81F7FB2B55CB59F091B9EBFA35E749E0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e2490-wk-Fact-70C422CB6D6759DFA1FC990F6BB44C8B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e2510-wk-Fact-A2C437E660815E6CA08376EAAAE487E9" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2530-wk-Fact-FD5022E3207A55678B8FFBD54FCA8596" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2623-wk-Fact-4EEEDAA26C375371A01AFB0FE7DFDFC3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2642-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2716-wk-Fact-3D938B8F5779553889529902AB4B9EB1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2754-wk-Fact-7BFC0F4F95B4580D91C65F187EC3A99A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2775-wk-Fact-5ABF0BEF40985BBEBEA664D62E572174" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2789-wk-Fact-0CF20638F1CA5DEA91E20C023F9BB067" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2808-wk-Fact-00D770AD6F59576DBABF30BA8CF788A3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2866-wk-Fact-A8C0889326025B0AAD2E41B15F12EEC6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2920-wk-Fact-1654824D40F256FDB56858716E490E71" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2978-wk-Fact-D113E27F86445565B1AA898183E7A2B4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e2999-wk-Fact-A13C94919B1254E79909D3E99179218D" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">304,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e3018-wk-Fact-15B01E5198585F1F8DC01F06BB972F95" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e3037-wk-Fact-8A3B549EEB075710A215756241B12968" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,241,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e3057-wk-Fact-A3DC0D361B9D5F9CADFC940623E4DDA0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21830731e3076-wk-Fact-08CFCFFA7767595DAB5963F536AB29BC" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">559,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21830731e3096-wk-Fact-7DEB41AA80AF5179814C8D33FE9E1430" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,685,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">77</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDFA0950FB8475D209E4B2B00EC3E212D"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e738-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e757-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e776-wk-Fact-E80041C5117CF9436D1F808180B39357" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e854-wk-Fact-CBB93137BFF058C5B46ED927BB1365FC" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e873-wk-Fact-A045E3A875285182B2505762849AFC5D" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e892-wk-Fact-E102CD6D09C6B587B25D8082F0198EF3" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e913-wk-Fact-2F8E5FE3A2A35710B814FE73EBE1AEFA" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e932-wk-Fact-3EBD0795DD1F54CAABDBB14D5BB00CBF" name="us-gaap:ShareBasedCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e951-wk-Fact-6F72F8CB119ABAC245E98082F127EE30" name="us-gaap:ShareBasedCompensation" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-cash lease expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e972-wk-Fact-16463F703A255520816542DC7825E948" name="exel:NoncashLeaseExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,819</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e991-wk-Fact-38F9D40EBEC455D0B658B2407EA59153" name="exel:NoncashLeaseExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1010-wk-Fact-B92A5503F586535CB7F43381563A82C1" name="exel:NoncashLeaseExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1031-wk-Fact-03098947D4EA576D92AE93C28A14A970" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1050-wk-Fact-161E237592F35BFE8815313E58A93B30" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1070-wk-Fact-8B33D0A86CF1424587157F5F58C19E58" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1091-wk-Fact-A193A903FF6A537FAB9439BC1BF82E94" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1110-wk-Fact-52087E1851375624AAE23B330B0CF7CE" name="us-gaap:OtherNoncashIncomeExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1129-wk-Fact-0E9AD3A767FC5BE6DF828082F112FBA7" name="us-gaap:OtherNoncashIncomeExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1213-wk-Fact-0EE14D557F485D2A872B66281DAB3054" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1232-wk-Fact-94FAF0DE24BB526EB47576E5A1911A48" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1252-wk-Fact-87463119A27AFEA9211C8082F0EBBADA" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1275-wk-Fact-4E1E392ECAF152E08DCB7BD718D18F56" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1295-wk-Fact-2D43ACAD1E0654FFBEA0F4545E9706C5" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1315-wk-Fact-49CF06097E308FE04C4B8082F08F66A9" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1337-wk-Fact-00659E5350645D9BA259E0297B28AF70" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1357-wk-Fact-8A2179439CC750C5BED204F3B065E4AB" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1377-wk-Fact-8741950673279B92A529C772AB6A90B4" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1399-wk-Fact-0ED86C7C0CB15065B4292DC848C97010" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1419-wk-Fact-C26E4280D04D50DB8D43E3DBF1583A21" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1438-wk-Fact-5C3DA2E5B663A5F823768082F10D4EBC" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1459-wk-Fact-B054DACE0B4153C78B61AD95DB52DE25" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1478-wk-Fact-B76A2B1773BA5CB38E5D6DC191BAB998" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1497-wk-Fact-9E4454CE209170903CAB8082F0F93265" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1518-wk-Fact-01DC973052F050E29ADD745D3DC413E7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">526,956</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1537-wk-Fact-7E77D8F2B35E554B9D83EE2FB58B0F64" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">415,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1556-wk-Fact-6A66E5E1BDF1053E5A858082F12C5179" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">165,611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of property, equipment and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1639-wk-Fact-746DF29524615DD8A527C7FDC77A7FCB" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,834</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1659-wk-Fact-1D15AE718DB85967978BD9564F0ACFE0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1679-wk-Fact-69531239A5FCEB57284C8082F08A20F0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from sale of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1701-wk-Fact-97766E49C8565668ABCAA24A363A5566" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1720-wk-Fact-4E620B7D3F995AA1B24E8D836984F341" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1739-wk-Fact-4FA53B718E905F9E9D78C9749398ACB8" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1760-wk-Fact-9ABA46333B7C58D4B519918E2DDBE46A" name="us-gaap:PaymentsToAcquireInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,182,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1780-wk-Fact-AC8EC16F476F573AA5761251919DAFAD" name="us-gaap:PaymentsToAcquireInvestments" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">557,832</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1800-wk-Fact-553DD48C9B83960F92288082F0E64B33" name="us-gaap:PaymentsToAcquireInvestments" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">319,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from sales and maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1822-wk-Fact-705D3FA2055150408C807D496E75C58D" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">608,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1841-wk-Fact-0ECF7EC449E15469BFFA5C4B5BA5338E" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">292,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1860-wk-Fact-673257536762DA960C948082F07C5C42" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">376,864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1881-wk-Fact-879031053CDC5CB093B32EC31D225700" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">587,247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e1901-wk-Fact-2FF4BB9907975CF9A49D6FA05D3B615A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">297,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e1921-wk-Fact-004DD11577F034611E0B8082EFE67B0D" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2005-wk-Fact-1D6DADFF9F5D50248E52745239EC4737" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,499</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2024-wk-Fact-91934467BDE4572C9BA0790888377921" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2043-wk-Fact-95635F5DBD17B5146E458082F0F582CB" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2064-wk-Fact-F39ADB4C74E957D192E7B74892AA0D19" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2084-wk-Fact-04CBCA7DBD61547BBA922A289432C5D9" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2104-wk-Fact-391BC6D8F378AD478DC98082F108D463" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Principal repayments of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2126-wk-Fact-1D30D0B7F6BC664457D38082EECF1B90" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2145-wk-Fact-D1E8CA568C11F5D141F78082F11DFE9D" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2164-wk-Fact-7CED84AA12E87FAD9DA98082F123AC5F" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">185,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2186-wk-Fact-5B930ECCA0A052A3B650C2809BFCC84B" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2206-wk-Fact-D307B0080E9D5568B84BEFF6F107A2B0" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2226-wk-Fact-53E33624C7E15F7DB6C38CFD467E020F" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2247-wk-Fact-777CFA099F1251FA8DA4ADD0750C56CE" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2266-wk-Fact-233450AEDFCA587B96CEDB7FBFDE14C3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2285-wk-Fact-3ECCFFE6EFAB974FD7478082EE9AEBD1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">169,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net (decrease) increase in cash, cash equivalents and restricted cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21825214e2307-wk-Fact-A0EA2426ECEA50D58678C0EC15482FDE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">47,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2327-wk-Fact-920496F7986759B0A6A5E0DD8CC4B6B8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2346-wk-Fact-6D11D0DC88F57988836D8082EFB75E2C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2367-wk-Fact-BC0F0D36AF675667BF547125A5FB8F75" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2386-wk-Fact-319AEF2EF68A57B39FDD8082EF0DA57F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2405-wk-Fact-DA13427317AEC223B1F88082EED8C5C9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2016Q4Dec30" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">155,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2431-wk-Fact-AA9D8EEC2AAD55929D4FD5EAA16D1EA6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2450-wk-Fact-BC0F0D36AF675667BF547125A5FB8F75" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2469-wk-Fact-319AEF2EF68A57B39FDD8082EF0DA57F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplemental cash flow disclosure:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2552-wk-Fact-2BCB77589C3037632D027F5F587E2D06" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2571-wk-Fact-3EFFFE115B14D57DDC3A7F5F5878D200" name="us-gaap:InterestPaidNet" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2590-wk-Fact-CEF92979FF0B0801B2357F5F58B8F2BA" name="us-gaap:InterestPaidNet" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash paid for taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2612-wk-Fact-9F5917EC7027897EDFE07F5F58D2FAD0" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2631-wk-Fact-D061086177A2FCCB36F77F5F587B0201" name="us-gaap:IncomeTaxesPaidNet" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2650-wk-Fact-5886CEBBCD9E7CD4FD087F5F58CA3942" name="us-gaap:IncomeTaxesPaidNet" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-cash activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2733-wk-Fact-55729A4B2E95530FB3F11ADE765F241A" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2747-wk-Fact-5E9FCA99A77C51B79E5C2E92F4745F4F" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment deemed to have been acquired in build-to-suit lease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2792-wk-Fact-25C5F024E3720EC11B767F5F58C942D0" name="us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2811-wk-Fact-31D5D2038702FAF2EA617F5F58CE3DF0" name="us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2830-wk-Fact-6C96FF8455C00DFA78E27F5F58CC6679" name="us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred for purchases of property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2851-wk-Fact-7C027E41A7245F51BE9747CFA7033B8E" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2870-wk-Fact-47F23E04E5D357B7979B60CD5C07E869" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21825214e2889-wk-Fact-8CB558643F42B95B8A957F5F58D219F0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">78</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDB1B98EDF2245BB3B622C69BDE1902DF"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><a id="sCC4556CF051D579689DDBD6ED9BB548E"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-0-wk-Fact-6F7A6C2E08C0046EFF637F5F58DC6080" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-1" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-1" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e604-wk-Fact-E0ACB00ADB905ADF89A407B02438609E" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e608-wk-Fact-58798682438F5472937903F5F1B56A9A" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">Two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e615-wk-Fact-B2EF6F90299B53DD95D8BAE4906BFBC4" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-07E0EF91E1F6F571BBB47F5F59023DAB-0-wk-Fact-0DB20DFDA682512005277F5F58E7DC40" continuedAt="TextSelection-07E0EF91E1F6F571BBB47F5F59023DAB-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-07E0EF91E1F6F571BBB47F5F59023DAB-1">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:continuation> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have made&#160;reclassifications&#160;to our prior years&#8217; Consolidated Balance Sheet and Consolidated Statements of Cash Flows to conform to the current year&#8217;s presentation. These&#160;reclassifications&#160;had no effect on total current assets, total assets, total operating cash flows, total investing cash flows or total financing cash flows.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FiscalPeriod" id="TextSelection-F9F4C8E9E954A4739604C79DAE44FE0A-0-wk-Fact-70926E236FB88F3A25D1C79DBF40F761" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-B18F562178056E41C2AA7F5F59033AD9-0-wk-Fact-774EB9A196C24A8E7BF07F5F58D638F6" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e689-wk-Fact-095EA62E18C05DF3A2EF14C98D72AA72" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-9900F537435BDD40B2037F5F59024120-0-wk-Fact-826E4A5BAF87B026D86A7F5F58D4423C" continuedAt="TextSelection-9900F537435BDD40B2037F5F59024120-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-2" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-3"><ix:continuation id="TextSelection-9900F537435BDD40B2037F5F59024120-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:continuation><ix:continuation id="TextSelection-98C2C495CB88E772BE837F5F5904B661-0" continuedAt="TextSelection-98C2C495CB88E772BE837F5F5904B661-1"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the third quarter of 2019, we adopted ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 requires capitalized implementation costs to be expensed over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted ASU 2018-15 using the prospective transition method in the accompanying Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2019, we adopted ASU 2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income (loss) to accumulated deficit. In connection with the adoption of ASU 2018-02, we adopted the individual unit of account approach for releasing income tax effects from accumulated other comprehensive income (loss).</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-98C2C495CB88E772BE837F5F5904B661-1" continuedAt="TextSelection-98C2C495CB88E772BE837F5F5904B661-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2019, we also adopted ASU 2017-08, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-98C2C495CB88E772BE837F5F5904B661-2"> (ASU 2017-08). ASU 2017-08 shortens the amortization period for certain callable debt securities held at a premium. Specifically, ASU 2017-08 requires the premium to be amortized to the earliest call date. ASU 2017-08 does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </ix:continuation>The adoption of ASU 2017-08 did not have a material impact on our Consolidated Financial Statements. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="TextSelection-BDC562907B8AB4AA94D27F5F590321A8-0-wk-Fact-F61FD848C374A47BA0EB7F5F58D8FC2B" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:MarketableSecuritiesPolicy" id="TextSelection-56E800DFBF7DB55DE1627F5F5903FB1B-0-wk-Fact-06BAEFB6FEF6953078E87F5F58DE2ED9" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income (expense), net in the accompanying Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of restricted cash </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents as short-term or long-term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">dependent upon the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">longer of the remaining term to maturity of the investment or the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">remaining term of the related restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We subject all of our investments to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-E5BA175991FF8B4BBFA07F5F5904B98A-0-wk-Fact-F6958BFB22050CD1B2467F5F58D7A7C7" continuedAt="TextSelection-E5BA175991FF8B4BBFA07F5F5904B98A-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-3" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-4"><ix:continuation id="TextSelection-E5BA175991FF8B4BBFA07F5F5904B98A-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="TextSelection-AC8E6800E82600EF6A007F5F590357BF-0-wk-Fact-C13A2C65DE12F3FA71457F5F58E59711" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record trade accounts receivable net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">have been insignificant.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-C0075EB88549647F62AB7F5F5903A2BF-0-wk-Fact-C9D3B3B9FB70652FE04F7F5F58D7548F" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-4ED1BB439AB07F1F91E57F5F590316DC-0-wk-Fact-59752FE75C789826B85A7F5F58DD1506" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21838977e967-wk-Fact-C24A06EDEE5ADC6A9513C7B5F1493755" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">15</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="TextSelection-26360DFBC17FC0368B1A7F5F59027B6B-0-wk-Fact-40F54E63476169E027AE7F5F58EB2D2A" continuedAt="TextSelection-26360DFBC17FC0368B1A7F5F59027B6B-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-26360DFBC17FC0368B1A7F5F59027B6B-1" continuedAt="TextSelection-26360DFBC17FC0368B1A7F5F59027B6B-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We periodically review the carrying amount of goodwill for impairment (at least annually) and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. Historically, we assessed the recoverability of our goodwill on the last day of our third quarter. Beginning in 2019, we changed the date of our annual goodwill impairment assessment to the first day of our fourth quarter to allow for operational expediency. The change in goodwill impairment testing date does not represent a significant change to our accounting for goodwill</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value. We continue to operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1006-wk-Fact-095EA62E18C05DF3A2EF14C98D72AA72" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-26360DFBC17FC0368B1A7F5F59027B6B-2"> segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. </ix:continuation>We did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1015-wk-Fact-1A7B6F291FEB7E8D26447F5F58D43979" name="us-gaap:GoodwillImpairmentLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="TextSelection-5D8AC70AA6428D4B83C7C7A346A573DD-0-wk-Fact-2EC37FE16E359D35A0B3C7A35EE820E6" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We assess whether our collaboration agreements are subject to ASC 808:&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we assess whether the payments between us and our collaboration partner are subject to other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Topic 606. However, if we conclude that our collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, we present such payments as a reduction of research and development expense.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-939CDF545285764A60557F5F59045E02-0-wk-Fact-5C393154C2D8DFA8EFE07F5F58D31798" continuedAt="TextSelection-939CDF545285764A60557F5F59045E02-1" escape="true"><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-4" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-5"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Results for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while results for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have not been adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, ASC Topic 605: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 605). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: 1) identify the contract(s) with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations in the contract; and 5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1114-wk-Fact-4891D806CBB8EB6D64CDC7B9BC1311D8" name="exel:SalesRevenuePercentDiscountForPromptPayment" contextRef="FD2019Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1118-wk-Fact-060EE705DA5B08DD8083C7BA0F513859" name="exel:SalesRevenueDiscountExpectedtobeEarnedPercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty </span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-939CDF545285764A60557F5F59045E02-1" continuedAt="TextSelection-939CDF545285764A60557F5F59045E02-2"><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-5" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-6"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2018 and 2017, the</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1137-wk-Fact-E104C79D72AB1D4183B4CAE4EBA5E969" name="exel:MedicarePartDFundingMandate" contextRef="FD2018Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. This amount increased to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1141-wk-Fact-3DD21DEA0A363AB75C9DCAE4EB86F7E4" name="exel:MedicarePartDFundingMandate" contextRef="FD2019Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in 2019. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. Except for profit sharing arrangements, payments for product supply services </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and certain development cost reimbursements, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">each of these payment types were within the scope of Topic 606 during the years ended December 31, 2019 and 2018. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-6" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-7"><ix:continuation id="TextSelection-939CDF545285764A60557F5F59045E02-2" continuedAt="TextSelection-939CDF545285764A60557F5F59045E02-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When such services are provided to a customer, and they are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenue for these services as the performance obligations are satisfied over time. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We account for such arrangements in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the years ending December 31, 2019 and 2018 and accordingly, those profits are recognized as collaboration revenues in the accompanying Consolidated Statements of Income. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as selling, general and administrative expenses in the accompanying Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Royalty and Sales-based Milestone Payments:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenue at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1229-wk-Fact-6343E204966B553191B4C5CBC9BD292F" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-939CDF545285764A60557F5F59045E02-3">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018 and 2017 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory.</ix:continuation> There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21838977e1244-wk-Fact-9F9597670F9DA80231367F5F58D66C69" name="exel:InventoryManufacturedBeforeRegulatoryApproval" contextRef="FI2019Q4" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> amounts remaining related to previously expensed materials in our inventory balances as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or 2018.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-C1BECA0F02EC07FED0357F5F59033A00-0-wk-Fact-477C31C7DB46E3812A597F5F58D44C44" continuedAt="TextSelection-C1BECA0F02EC07FED0357F5F59033A00-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and primarily include: (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees, funded research and milestone payments incurred for our in-licensing arrangements with our collaboration partners; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-7" continuedAt="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-8"><ix:continuation id="TextSelection-C1BECA0F02EC07FED0357F5F59033A00-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">becomes more certain. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development, regulatory or commercial milestone payments to collaboration partners are recorded as research and development costs when we determine such payments become probable.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-6BC819E495CDBBB27AF07F5F59059CC4-0-wk-Fact-3C3A9AC0CD24CCFEB0927F5F58DF3637" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the weighted average discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not to apply the recognition requirements of Topic 842 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for short-term leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="TextSelection-CCCA6B320D9CD01972B8C7A880882650-0-wk-Fact-E9760719D41469817283C7A895E2C19B" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Advertising</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Advertising expenses were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21838977e1352-wk-Fact-3CA7547097CD0119CB72CAE9BDCDC8D0" name="us-gaap:AdvertisingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21838977e1356-wk-Fact-FD6934BDAEE6D20B7C4ACAE9BD383327" name="us-gaap:AdvertisingExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21838977e1360-wk-Fact-33FD815F991301881B59CAE9BDA10665" name="us-gaap:AdvertisingExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in sales, general and administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-5033F19587894EB70DC27F5F5903A1D0-0-wk-Fact-1D6CECD6690A173D3D287F5F58949454" continuedAt="TextSelection-5033F19587894EB70DC27F5F5903A1D0-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;awards, performance-based restricted&#160;stock&#160;awards (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Compensation-Stock&#160;Compensation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense relating to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-4B4FB77D323C835AA2F47F5F5904AA42-0-wk-Fact-158C6E35ABD25C4C72DF7F5F58D487D4" continuedAt="TextSelection-4B4FB77D323C835AA2F47F5F5904AA42-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><ix:continuation id="TextSelection-5033F19587894EB70DC27F5F5903A1D0-1"></ix:continuation>Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax provision or benefit is computed under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. Some of these estimates are based on interpretations of existing tax laws or regulations. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-8"><ix:continuation id="TextSelection-4B4FB77D323C835AA2F47F5F5904AA42-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the technical merits of the position</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-57E0CBE0C8658CE2476F7F5F59029429-0-wk-Fact-74669ACFBC60987A1FC77F5F58D923A9" continuedAt="TextSelection-57E0CBE0C8658CE2476F7F5F59029429-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-57E0CBE0C8658CE2476F7F5F59029429-1">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income (expense), net in the accompanying Consolidated Statements of Income. </ix:continuation>Net foreign currency translational gains and losses were not material for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-E0DE585E08050FE332897F5F5904CCC1-0-wk-Fact-3F7435EAEBD7C408C2D77F5F58D7817D" continuedAt="TextSelection-98C2C495CB88E772BE837F5F5904B661-0" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the FASB issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for us in the first quarter of 2020. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2016-13 on our Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">86</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF4C0C9E0F6FF5373A03511358E241A93"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-0-wk-Fact-B533D5DCF0424E53F07C7F5F58AAC1C5" continuedAt="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-1" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-1" continuedAt="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-CD0EBEFF4C381F8C80F77F5F5905030B-0-wk-Fact-97B9FF7E946B5598B02A7F5F58A773BE" continuedAt="TextSelection-D4909F99F09CA70FB6B16FC6AB537DB5-0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e800-wk-Fact-4F59989D3471533ABB86450C098F626A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">957,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e819-wk-Fact-23D22168B7BE5707BEA7CA7D12571BF6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">738,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e838-wk-Fact-A0A9B9575857587A3BAE7F5F58A0480A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">402,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e854-wk-Fact-ACA9732E8C6B5CBF91156F9C0044C1D9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">197,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e874-wk-Fact-C25957F6C9025DB5835AF81C01960D12" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">119,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e894-wk-Fact-6EB41DF1447FAE6BDC517F5F589C60F3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">53,561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e916-wk-Fact-4A7175F192395C85B0C7C6A02D7F643B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">759,950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e935-wk-Fact-2EA1F50A74FDA1A9B2E4C6FA4DF7260C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">619,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e954-wk-Fact-3D0827DEC1DB5BB5A4513DCDDE52D7D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">349,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1037-wk-Fact-FE956B8599155857A6114FF585369B41" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">161,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1056-wk-Fact-1109928D7F19534FADC09DAEAAC593F1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1075-wk-Fact-A2E4D50363363389FEFD7F5F58A166E7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">96,637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1096-wk-Fact-BCDD36CF09EB5462ABCAA904B540B5E2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1115-wk-Fact-479077F5A47A51B2B1A4B37E64FDF76D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1134-wk-Fact-23EE9A6866AF820721907F5F58993B70" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e1155-wk-Fact-3FA1DF303E885C6CA0B2AF029FEE6D95" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1175-wk-Fact-BFE8D4B9912D544BBD9122AF23417B36" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e1194-wk-Fact-4450FC3A2A5E49C3A6A17F5F58D3A027" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1216-wk-Fact-9651ACAA83595E19B7AF718E8FD34546" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">207,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1235-wk-Fact-669337DF6374573799CCB10DBFE5ECD5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234,547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1254-wk-Fact-670E8F350E5A6011B6F27F72B0634FD9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1281-wk-Fact-C2F428FDC3B55296BD84486AB439D9DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">967,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1300-wk-Fact-D4F84C516D8153E6AABE4A9E657B33A0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">853,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1319-wk-Fact-A0BE00E5ACD05545886BD820391E213F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, license revenues and research and development services revenues were recorded in accordance with Topic 606 during the years ended December&#160;31, 2019 and 2018 and Topic 605 during the year ended December&#160;31, 2017. During the periods presented in accordance with Topic 606, net product revenues and license revenues related to goods and intellectual property licenses transferred at a point in time and research and development services revenues related to services performed over time. License revenues includes the recognition of the portion of upfront payment milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues. Research and development services revenues includes the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned under our collaboration agreements. Other collaboration revenues were recorded in accordance with Topic 808 for all periods presented and includes product supply revenues, net of product supply costs and the royalties we paid to GSK on sales by Ipsen Pharma SAS (Ipsen) of products containing cabozantinib. Profits on the U.S. commercialization of COTELLIC for the years ended December 31, 2019 and 2018 were also included other collaboration revenues, and losses on the U.S. commercialization of COTELLIC for the year ended December&#160;31, 2017 were included in selling, general and administrative expenses</span></div><ix:continuation id="TextSelection-D4909F99F09CA70FB6B16FC6AB537DB5-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1492-wk-Fact-4F595FDEDF045109972560CF55C21E70" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">733,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1511-wk-Fact-CC8BDB7FD30E52DB90BC5A6891CF13E7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">599,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1530-wk-Fact-F96A73E68C9E5B3AAB641BA2B021470D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">324,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1546-wk-Fact-A3EABC3E14275F1389C68D9BEC5BD04E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1565-wk-Fact-64904BCCE13A5315994C6CB4B512D69A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1584-wk-Fact-E99F61A76994563A9205C3ACE2564980" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1610-wk-Fact-4A7175F192395C85B0C7C6A02D7F643B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">759,950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1629-wk-Fact-2EA1F50A74FDA1A9B2E4C6FA4DF7260C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">619,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1648-wk-Fact-3D0827DEC1DB5BB5A4513DCDDE52D7D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">349,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="TextSelection-D12CAA4D8B7E162983E56FC73A99DA62-0-wk-Fact-DEEBEFE7FA22B517E11B6FC7D83DCF6D" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1777-wk-Fact-A30FAEF91B6D5D84B2AAF2B3F72209A4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1792-wk-Fact-995CACD7123A5280826DC39D0ED58953" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1807-wk-Fact-E9A7938FC02344D0C9B87F5F588E11FD" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of CVS Health Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1823-wk-Fact-1D2C997A9DAF56C190980D27F702B41D" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1838-wk-Fact-2068532DED695216A6D5337CD94E0C53" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1853-wk-Fact-6643E40C77670A2E9E217F5F5896D2B8" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1869-wk-Fact-C7991F2AD61A5F5A8F46ED4B70091A37" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1884-wk-Fact-9EF84FFDE5745805B69022E2977E0545" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1899-wk-Fact-317162C5DF8A0FED1DA27F5F5874CD00" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1915-wk-Fact-23134C30B9F75D92928A09A3F22684B9" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1930-wk-Fact-14D6266B8F6B53FFA97F11C742A20379" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1945-wk-Fact-159E4AFE74019F2F9424CB038F6682CC" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1961-wk-Fact-16A935504876ED10B5207F729F65E4C1" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1976-wk-Fact-AE138ABB375951AA4C147F729FAFA363" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e1991-wk-Fact-081075E47AF5DD36E3C57F5F5875D1BC" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2007-wk-Fact-87F1F03A2CD1231354117F729FBD3505" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2022-wk-Fact-1BEC71EA48CE25782D697F729FCAFF19" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2037-wk-Fact-2F020BAF5B5243807AF77F5F589CF4A4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-2" continuedAt="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="TextSelection-79A2E25CFC00842C18256FC85E92B1ED-0-wk-Fact-A95EED715AA5B76DF5656FC8F3076C16" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2207-wk-Fact-CA4632403081540482E4F66C5F743F09" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">770,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2226-wk-Fact-3BAA3DFB9AEF579DA608BFA2B0D06546" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">632,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2245-wk-Fact-64BC7DE8C2245D41BEDBF002405C77E6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">367,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2261-wk-Fact-E5508A613E1858CDA446DD8F32F6A09C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2280-wk-Fact-1E036EA5BCBA50E0B0BC54D3E560094F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2299-wk-Fact-3DEC205E630C50BFA38B1C1D6480E9A2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69,792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2320-wk-Fact-26642089F58C5B71971ED9EA6E322BA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2339-wk-Fact-CAF547AE876059D69490D3BB999737A6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2358-wk-Fact-DFD2EA5C27EC563994F18FE9EA384529" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2384-wk-Fact-C2F428FDC3B55296BD84486AB439D9DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">967,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2403-wk-Fact-D4F84C516D8153E6AABE4A9E657B33A0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">853,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2422-wk-Fact-A0BE00E5ACD05545886BD820391E213F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic regions based on the ship-to location. Collaboration revenues are attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="TextSelection-D93F988C693E336C925C7F5F590525CB-0-wk-Fact-F470220664119BD5DC7D7F5F58A78DB0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2565-wk-Fact-750DD85EFB69ACB41C017F5F5873B6DD" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2584-wk-Fact-3EF2093CC92E1ECC21AA7F5F58EB0DBF" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2603-wk-Fact-B98EB675A5B0EBF0541F7F5F589D6087" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2623-wk-Fact-1E15F5A0F6B059B797B07F5F58F0A8B9" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,493</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2720-wk-Fact-658241FBD071E0E736277F5F58D9DF01" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">75,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2739-wk-Fact-DBE32CA89BE11D3087307F5F58E99183" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2758-wk-Fact-220F7AEA2C3F98C2D4637F5F58D8D15A" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2778-wk-Fact-B570CCDB8C3C88435F987F5F58EF0B21" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2798-wk-Fact-BE400B366C5749D087577F5F58D8F93C" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2818-wk-Fact-0A4BE49E6B9AC0CFAC517F5F58E8D2BA" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2837-wk-Fact-E02E4A0F5F97C561F6747F5F58F3BE31" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2858-wk-Fact-F7A5DF693D0922BAE70F7F5F58EC70A2" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2879-wk-Fact-30CDD321CCF5C7F8A9C67F5F58E7AEA1" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2899-wk-Fact-BEB1AA8B246338F774B37F5F58730D44" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2919-wk-Fact-CA85A5B49B2E1A00E84C7F5F58EEE78E" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e2940-wk-Fact-EFC74CFBED806FCE58AF7F5F58F299CA" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2961-wk-Fact-697FF98219825A60BB26107802BB886B" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2980-wk-Fact-C2B10D6DCAC357719F05BB404E98D91D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e2999-wk-Fact-7E1091581A485629B0ABDFFCDE4C13A4" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3019-wk-Fact-0B708B0F537C5EF3AB116FD0D1BD433B" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3121-wk-Fact-D0E89577CDEC5BE696C4BCFAE5C12167" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,936</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3140-wk-Fact-BFB0763293F45ECEA640E15A93FF51A1" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3159-wk-Fact-7DF4E4C39A7058E29807AF1C71406A10" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3179-wk-Fact-507425D706145BBE91E4B8A3911B45A2" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3199-wk-Fact-F49C152DC32D5013B6C552C7D90DD92A" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e3218-wk-Fact-9CE119EB6F125B939D8B2D0A6EFD3776" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3238-wk-Fact-D959472D5396572BB6A12F2A1E835E78" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3258-wk-Fact-292283948F755057A8FAC3E0394E2B6A" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e3278-wk-Fact-D6A3E249AC955F80B5196C8ED6B84F73" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e3298-wk-Fact-CCB2128B5558530FA84781728FAA3714" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e3318-wk-Fact-615475291AF35E1C8AFCE3A7645EC1DF" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21835141e3339-wk-Fact-10F8A44795A45B03A7AB6654ED370862" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3366-wk-Fact-8AB243A9FC8353D28F51CAE1C2610795" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3385-wk-Fact-38FC51A37B3C5FA7AA4A553F73109107" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3404-wk-Fact-B68DE1B538155026939D262EFD3261E4" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835141e3424-wk-Fact-0C7F65E60021552199E0219D42B6F6CD" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reserves for chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contract assets were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3446-wk-Fact-F8A7F2F885E9376154D312111C2A88D2" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3450-wk-Fact-6F27F5A2BF70AA9344F5121158428C9D" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, and are presented in p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">repaid expenses and other current assets in the accompanying Consolidated Balance Statements. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contract liabilities were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3480-wk-Fact-F65ECBBDAB778FACA3311210F76E83E2" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3484-wk-Fact-0D15153F1BDBEFC6BF6FCB2318716B54" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, and are presented in l</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ong-term portion of deferred revenue in the accompanying Consolidated Balance Sheets.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For those contracts that have multiple performance obligations, c</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ontract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Significant changes in contract assets during the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were a result of the determination that it is probable that we will earn a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3511-wk-Fact-9753642820A7A767B5BA12182CDBA12A" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone from Takeda Pharmaceutical Company Limited (Takeda) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the submission of a regulatory application in 2020 for cabozantinib as a treatment for patients with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">second-line </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in Japan</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. This contract asset was recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">repaid expenses and other current assets in the accompanying Consolidated Balance Sheets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, offset by the effect of reporting the Takeda contract asset and liability on a net basis.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3551-wk-Fact-AD733F880A3B57AD8AAD37EAA79EB552" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3555-wk-Fact-FBC32EB1738E5C36831A5448B9B83E99" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues that were included in the beginning deferred revenue balance for those years. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3577-wk-Fact-21FF19539B965A6C8B0A65F514C7AFB4" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">161.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3581-wk-Fact-7F6421F5657F54BFB591AD8AA7D108E6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">198.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835141e3597-wk-Fact-A3A5A4E1EB3B53E5736D121513D2685B" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our performance obligations had not been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; f</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or additional information about our performance obligations.</span></div></ix:continuation><div><a id="s3728D1F6891A528C8E5CE988032212DC"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-A2798372CF7157A0A0347F5F59063F34-0-wk-Fact-94D308E00A187DAD26EB7F5F58982394" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-1" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-1" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech and Daiichi Sankyo for other compounds and programs in our portfolio.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on the amount of collaboration revenues recognized during the years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Commercial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of 1) the expiration of patent claims related to cabozantinib, 2) the expiration of regulatory exclusivity covering cabozantinib or 3) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21836529e636-wk-Fact-CFFF046FBB11832FC18D7F5F587F823E" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the U.S. Food and Drug Administration (FDA) or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-2" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e646-wk-Fact-65347053A4D235C5C28A7F5F588593D8" name="exel:UpfrontPayments" contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from Ipsen in 2016. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have achieved aggregate milestones of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e654-wk-Fact-FE76AC45314CE7FD9C6E7F5F58CB4A0C" name="exel:MilestonePaymentsEarnedToDate" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">330.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to regulatory, development and sales-based progress by Ipsen since the inception of the collaboration agreement, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e658-wk-Fact-D6D4DFCC4638426599EF7F5F587A460E" name="exel:MilestonePaymentsEarned" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e662-wk-Fact-1182B31C1D2CBD7BF8B71238D7825F1C" name="exel:MilestonePaymentsEarned" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones achieved during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e682-wk-Fact-70645694FF8F34132B9C7F5F58E724C9" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e686-wk-Fact-57C4E1CB4EAD7F0D82177F5F58A961F8" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">470.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also receive royalties on the net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and going forward, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e696-wk-Fact-6278D9F7DE2A50C8EBC47F5F58C070BA" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e701-wk-Fact-59E97831331A889B57597F5F5891FFA6" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e705-wk-Fact-6278D9F7DE2A50C8EBC47F5F58C070BA" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e711-wk-Fact-463F8C04E7408A14D12B7F5F5894FE01" name="exel:RoyaltyTier" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="cad" decimals="INF" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of annual net sales and a tiered royalty thereafter to</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e717-wk-Fact-59E97831331A889B57597F5F5891FFA6" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these royalty tiers for Canada also reset each calendar year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e725-wk-Fact-6343E204966B553191B4C5CBC9BD292F" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e732-wk-Fact-8994898458BFB5314C657F5F588C664F" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding: CheckMate 9ER; CheckMate 040 (though Ipsen has opted not to co-fund the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); the dose escalation phase and first 20 expansion cohorts of COSMIC-021; and COSMIC-312.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e747-wk-Fact-6AC0EE1D1268505D98FAFD9785312A4D" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">152.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e751-wk-Fact-3EB5475A4EF3566B918CD7A6F2B57AEB" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e755-wk-Fact-836BDA639C855E7989CB093F2158FB5D" name="us-gaap:ContractWithCustomerLiability" contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e779-wk-Fact-B7E209CEFCBA53CF845F0E9EB97A9014" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#8220;&#8212;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;, below, for additional information related to the revenue recognition for this collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018 and May 2019, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of 1) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21836529e801-wk-Fact-1C4C75E67E86647956A67F5F587F623B" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after first generic entry with respect to such product in Japan or 2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21836529e805-wk-Fact-E42B2EE4D87E242DFD067F5F58D1DD57" name="exel:PeriodOfSpecificSalesVolumeThreshold" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-3" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-4"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e823-wk-Fact-03586B7E4D3FA71803ED7F5F5889FA2B" name="exel:UpfrontPayments" contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from Takeda in 2017. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have also achieved regulatory and development milestones in the aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e831-wk-Fact-1ABEC9DB6FD6A154BFDC159195ECCFDC" name="exel:MilestonePaymentsEarnedToDate" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> since the inception of the collaboration agreement, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e835-wk-Fact-621F2F6B53A0F3EEADBF159280568B93" name="exel:MilestonePaymentsEarned" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e839-wk-Fact-6617063334E844AD1D191592927B1E56" name="exel:MilestonePaymentsEarned" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones achieved during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had also determined that it was probable that we will earn a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e856-wk-Fact-9753642820A7A767B5BA12182CDBA12A" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone in the first quarter of 2020 for the anticipated January 2020 submission of a regulatory application </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to the Japanese MHLW for Manufacturing and Marketing Approval of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">cabozantinib as a treatment for patients in Japan with unresectable HCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">who progressed after prior systemic therapy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the collaboration agreement, as amended, as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are eligible to receive regulatory and development milestone payments from Takeda of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e873-wk-Fact-6E94C21E3DE8EE208D9C7F5F5894F73F" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to first-line RCC and second-line HCC, including the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e877-wk-Fact-9753642820A7A767B5BA12182CDBA12A" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we expect to earn for the submission of a regulatory application in the first quarter of 2020 described above</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are also eligible to receive additional regulatory and development milestone payments, without limit, for additional potential future indications. We are further eligible to receive sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e883-wk-Fact-C5C2770A4393F1612E687F5F587637E8" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">155.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also receive </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e890-wk-Fact-66F129214E0351C792197F5F58C667B1" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e894-wk-Fact-BF40CFCE028BD20AF2437F5F588F3E7B" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on the initial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e898-wk-Fact-42915333FFE989FC4D177F5F58C8D767" name="exel:RoyaltyTier" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and following this initial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e902-wk-Fact-42915333FFE989FC4D177F5F58C8D767" name="exel:RoyaltyTier" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e906-wk-Fact-BA6128898D3BC8DF2C357F5F588E70FA" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e910-wk-Fact-EC19BCAC1C56B171BCBB7F5F587A14C2" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales thereafter; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e915-wk-Fact-BA6128898D3BC8DF2C357F5F588E70FA" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e919-wk-Fact-EC19BCAC1C56B171BCBB7F5F587A14C2" name="exel:PercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e926-wk-Fact-6343E204966B553191B4C5CBC9BD292F" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e933-wk-Fact-B6C56800A5742D6AB1177F5F58D2B408" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e937-wk-Fact-9C1D874FB03B66D2DBA17F5F58F4BAB9" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate 9ER.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e954-wk-Fact-3A2A04BF19EF579BAE687254CBFAA5DB" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e958-wk-Fact-6FB226050367575193F09170E55B5BDB" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e962-wk-Fact-58653E467AE45EC195EA5D5E34747BE1" name="us-gaap:ContractWithCustomerLiability" contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e986-wk-Fact-F8E474B69BE35223ADA41496AB00DDDE" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified two performance obligations for both the Ipsen and Takeda collaboration agreements: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-4" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-5"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on our evaluation of the collaboration agreements as of the date adoption of Topic 606, we determined that for both agreements, the up-front, nonrefundable payments, the milestones and royalties achieved as of December 31, 2017, and our estimate for the reimbursements of our research and development services performance obligation over the term of each agreement constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. In addition, the transaction price for the Ipsen collaboration agreement included a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1009-wk-Fact-F901FAD4E4F4335153787F5F58E3DEBD" name="exel:MilestonePaymentsEarned" contextRef="FD2018Q1QTD_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we expected to achieve during the three months ended March 31, 2018. Other than the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1013-wk-Fact-F901FAD4E4F4335153787F5F58E3DEBD" name="exel:MilestonePaymentsEarned" contextRef="FD2018Q1QTD_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone, variable consideration for both agreements related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the transaction price increased as a result of the achievement of various milestones. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Bristol-Myers Squibb Company (BMS)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate 9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. Under the terms of the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and we are sponsoring the COSMIC-313 trial and BMS is sponsoring the CheckMate 9ER and CheckMate 040 trials. The responsibility for the payment of costs for any further trials will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-5" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-6"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal trials in advanced non-small cell lung cancer, metastatic castration-resistant prostate cancer and RCC. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond the initial three planned phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, we continue to be required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1079-wk-Fact-6343E204966B553191B4C5CBC9BD292F" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of other collaboration revenues for sales by our collaboration partners. Such royalties were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1083-wk-Fact-BC0B40F414D752F891BF347CD6C4AB2D" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1087-wk-Fact-FFBBF51A33005AADB9DAB56B72D41939" name="us-gaap:RoyaltyExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1091-wk-Fact-5D344630076DEC60462315A1C09BA20E" name="us-gaap:RoyaltyExpense" contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">93</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-6" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-7"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In-Licensing Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Aurigene Discovery Technologies Limited (Aurigene) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1131-wk-Fact-B72C70C2971951068435E6FC83B3F7FF" name="exel:CollaborationAgreementNumberOfPrograms" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1135-wk-Fact-4F091DDAB757F010068E15C8E8A0AB1C" name="exel:UpfrontPayments" contextRef="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1139-wk-Fact-B72C70C2971951068435E6FC83B3F7FF" name="exel:CollaborationAgreementNumberOfPrograms" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1143-wk-Fact-C012433EC13353888A814C4F6622C43E" name="exel:CollaborationAgreementNumberOfPreexistingPrograms" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> pre-existing programs. We are also responsible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1147-wk-Fact-05410DE1619B5961A4DF533F769E1ABC" name="exel:CollaborationAgreementResearchAndDevelopmentObligation" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in research funding for the discovery and preclinical development work on these programs. During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1156-wk-Fact-5A56AF01FD14523CAC03CCC1C560110F" name="exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in expense for the discovery and preclinical development funding commitment. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each option we decide to exercise, we will be required to pay an exercise fee of either </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1163-wk-Fact-B9939480F4EC5912B4B0072D964FE947" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1167-wk-Fact-434EDD594235577C88B2752ACC4759D5" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, depending on the program, and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1171-wk-Fact-8C53C71E420E5AE9B7DF58194B47B051" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential development and regulatory milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1175-wk-Fact-40F1E9553338555E9BD0B0A9F8AC309E" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential commercial milestone payments, as well as royalties on potential sales. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Iconic Therapeutics, Inc. (Iconic) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer, leveraging Iconic&#8217;s expertise in targeting tissue factor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology ADC program, in exchange for an upfront payment to Iconic of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1185-wk-Fact-75E374A2AA365745A7D9CABC8485BE8F" name="exel:CollaborationAgreementsUpfrontPayments" contextRef="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a commitment for preclinical development funding. During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1193-wk-Fact-1B649A4D43DF5E1987CED420B96C27FF" name="exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in expense for the preclinical development funding commitment. Both the upfront payment and the accrual for the preclinical development funding commitment were included in research and development expenses in the accompanying Consolidated Statements of Income. If we exercise the option, we will be required to make an option exercise fee payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1197-wk-Fact-6AA1588DF35F5184896E54095B8C93E2" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Iconic; we would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic would become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1201-wk-Fact-17E78EBC830F5371ADD2BE200ED49F43" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential development, regulatory and first-sale milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1206-wk-Fact-9B129F72CB2257DFA1F1A5649866AB65" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">262.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Invenra, Inc. (Invenra) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> technology platform, or with other platforms and formats at our option. As of December 31, 2019, we have initiated three additional discovery projects and two binder projects, and in total we incurred an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1221-wk-Fact-D11747DFA3ABB678D3D015A77BAA76CD" name="exel:ProjectInitiationFeePayment" contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1225-wk-Fact-3CC43403EC86C40B14F515A790618A8F" name="exel:ProjectInitiationFeePayment" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in expense during the years ended December 31, 2019 and 2018, respectively, in consideration of the upfront licensing and project initiation fees. Invenra is eligible to receive up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1229-wk-Fact-EBAF340041B1594499277F5F58CFB0FC" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1233-wk-Fact-68A551EA3FD54E71EE4C15A909D81257" name="exel:ProjectInitiationFeePayment" contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1238-wk-Fact-6FD8DD34B6EAE011E84A7F5F589894F2" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">325.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1242-wk-Fact-4FA3E6A89D8A253EF18E7F5F588FC768" name="exel:UpfrontAndMilestonePayments" contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;for each B-Body project and four additional binder projects subject to an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1246-wk-Fact-41C03249A1E2ADF5A1B015AABC5F2698" name="exel:UpfrontAndMilestonePayments" contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for each project, as well as additional milestone payments and royalties for any products that arise from these efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">StemSynergy Therapeutics, Inc. (StemSynergy) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">), a component of the Wnt</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> signaling pathway implicated in key oncogenic processes. Under the terms of the a</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">greement,&#160;we&#160;will partner with </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">94</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-7" continuedAt="TextSelection-A2798372CF7157A0A0347F5F59063F34-8"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We paid&#160;StemSynergy an upfront payment of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1273-wk-Fact-43BF3D9862F7C8E12B5A7F5F58B5418F" name="exel:UpfrontAndMilestonePayments" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in initial research and development funding during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December&#160;31, 2018 and provided </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1281-wk-Fact-5E8C0FE4C29F7AD864C115ABA1BD19FE" name="exel:AdditionalUpfrontAndMilestonePayments" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1285-wk-Fact-E70762C27558ABC072D97F5F58909D95" name="exel:AdditionalUpfrontAndMilestonePayments" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. StemSynergy is eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1298-wk-Fact-BEADB8D1CEE04276390B7F5F58969BD0" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding on an as needed basis. StemSynergy will also be eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1302-wk-Fact-253D971FB64C58C445CE7F5F58AB1DED" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2019Q4_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genentech</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-CCA2692739C69607C9047F5F590691A8-0-wk-Fact-A0F2D0BC7C1C4C9E7AB87F5F58EAB6C1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits and losses on U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21836529e1477-wk-Fact-064A053B627B570FB5E35B50068DB631" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21836529e1496-wk-Fact-603C8AFCB4E45946AF42B6524AF3662D" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21836529e1515-wk-Fact-B31F32DC6255558289F62AB533F4C05A" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21836529e1537-wk-Fact-F5DB727BE85853C9BCBE83EBF0863FD6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21836529e1556-wk-Fact-90E1454673BD551FB2BCFDBB3C2EE55B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21836529e1575-wk-Fact-D96AB6548EB458DCAD43F84FDA19DE88" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC for the years ended December 31, 2019 and 2018 were included collaboration revenues and losses on the U.S. commercialization of COTELLIC for the year ended December&#160;31, 2017 were included in selling, general and administrative expenses. The royalty revenues on ex-U.S. sales were included in Collaboration revenues for all periods presented. See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cobimetinib Profit Sharing and Royalty Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1594-wk-Fact-9B906584AE4D8A855C727F5F587BD672" name="exel:ProfitSharingAgreementPercentOfProfits" contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from the first </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1598-wk-Fact-D44E3012AF53D0B229F07F5F58D1FDEB" name="exel:ProfitSharingAgreementProfitThreshold" contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of U.S. actual sales, decreasing to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1602-wk-Fact-ED0D38FF6031CD78A0107F5F5875222F" name="exel:ProfitSharingAgreementPercentOfProfits" contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from U.S. actual sales in excess of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1606-wk-Fact-928A522E490DCE6F729A7F5F58A29FC1" name="exel:ProfitSharingAgreementProfitThreshold" contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">400.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Daiichi Sankyo</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">95</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-A2798372CF7157A0A0347F5F59063F34-8"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019, Daiichi Sankyo had its first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have achieved milestones of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1637-wk-Fact-24A3E73A3DA683B6927515BA2A6BEA59" name="exel:CollaborativeArrangementAchievedMilestoneAmount" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> each during the years ended December&#160;31, 2019 and 2018 for the approval and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are eligible to receive additional sales-based milestone payments of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1645-wk-Fact-94DB35B0B11B64A3BBFC7F5F5895DC80" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">90.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Such revenues were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1649-wk-Fact-66BAF7A88D92798F3DD815BCBCFDC3F4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_MINNEBROMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the year ended December 31, 2019. Daiichi Sankyo may terminate the agreement upon </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21836529e1653-wk-Fact-322ED2F4E1A5E1B9050515BEA11604EF" name="exel:CollaborationAgreementTerminationPeriod" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" format="ixt-sec:durday">90</ix:nonNumeric> days</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1660-wk-Fact-746121309A7B5DE39A8244A5BC2BF109" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1667-wk-Fact-A30BA7A1802B51CDAD99E89190D61F47" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21836529e1671-wk-Fact-ECF53CAD55D65D0AA7200F1BD4479549" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21836529e1675-wk-Fact-1143EDE6A4BBB8AAC1E216022BDAAA31" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Other Collaborations &#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have evaluated our collaborations agreements with Genentech and Daiichi Sankyo and have determined that those collaboration agreements each have one performance obligation: the delivery of intellectual property licenses to the collaboration partner. We have further determined that the licenses we provided represent functional intellectual property that was transferred at a point in time, when the agreements were executed</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> prior to the adoption of Topic 606. Potential variable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones and therefore, any additional consideration earned and received from these collaborations will be fully recognized when the milestone is no longer constrained. Any variable consideration related to royalties and other sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred, and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.</span></div></ix:continuation><div><a id="sBF77936F55155BF2A92D867871B84779"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-0-wk-Fact-E70C2E985D5FB35731687F5F58AC0859" continuedAt="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-1" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-1" continuedAt="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-1CCB5FB9967D7C1E71647F5F5906A268-0-wk-Fact-0E4C4A826EBF48AED4E87F5F589DDAA3" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-B0CEDD58CB249185170D7F5F59077BBA-0-wk-Fact-449089310A11B40663887F5F58B0CC44" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e750-wk-Fact-01250ECF4ED255118BE21200D22D84B1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e769-wk-Fact-90F54B50CC015DC590E195EFBE556F53" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e788-wk-Fact-D825E0EA324652CB91F045191D9C4FD7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">183,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e804-wk-Fact-E57CD94E0C7FF277B4C2CB2DDDA6D470" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e823-wk-Fact-59977E6F2EAB9F3D725CCB2DDDBCA944" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e842-wk-Fact-E931C304F3B15BB2B6C6AF751ECD67BC" name="us-gaap:RestrictedCashCurrent" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e863-wk-Fact-118B46408DE18045D05ECB2DDD7619D1" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e882-wk-Fact-E54453A03BD10F62625DCB2DDD912651" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e901-wk-Fact-933ED6E12A4D5C79B88F912CEDB84728" name="us-gaap:RestrictedCashNoncurrent" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e927-wk-Fact-AA9D8EEC2AAD55929D4FD5EAA16D1EA6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e946-wk-Fact-BC0F0D36AF675667BF547125A5FB8F75" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e965-wk-Fact-319AEF2EF68A57B39FDD8082EF0DA57F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit and, during prior periods, a purchasing card program. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of restricted cash </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">96</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-2" continuedAt="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents as short-term or long-term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">dependent upon the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">longer of the remaining term to maturity of the investment or the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">remaining term of the related restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-4EA1856D4D8BE1CD78F87F5F5907FD36-0-wk-Fact-A040848CBC1145C3F84A7F5F58953592" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investment securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1321-wk-Fact-BB4F0B3986245B6D904979D9E5FDC70F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1340-wk-Fact-2299077DCEE851E786067A29B64D2A31" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1359-wk-Fact-569881409AF756958C9E18277901749F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1379-wk-Fact-5D77D621171968404368CB2DC6839AC1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1394-wk-Fact-AE2F011D979B5BBCA81A32552D63459D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">752,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1413-wk-Fact-B752F2A35BDF503B9E5F21107C08FAFC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e1432-wk-Fact-CA931E9652175AAFB15483C0CCACBA75" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1453-wk-Fact-DB6AD50AC413417A13C9CB2DC6987611" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">756,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1473-wk-Fact-930874A5DD0A5074A22738C0C7DE2E41" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1492-wk-Fact-59456C8F9BE95E23868C7AA57E03EF76" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e1511-wk-Fact-50C9C2003AAE523C8EAB75840084749E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1532-wk-Fact-9CD3D6BE14302BDFAB50CB2DC6B14A28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1552-wk-Fact-AD7FA3DC56175F512CF77F5F58C1F596" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,308,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1571-wk-Fact-B1BC52DF674905BED38C7F5F58CEED46" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e1590-wk-Fact-C242D0227321C136E7DC7F5F5882161D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1611-wk-Fact-36E5FA1B0E3BE66D7B2E7F5F5881725A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1631-wk-Fact-0E717144563B5DB4B5025F5ACB74DC23" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1650-wk-Fact-928CEA822D015CA682C736F2E533F106" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1669-wk-Fact-316EE6D1D1A3521787B1B932A8A190AB" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1689-wk-Fact-F9E7CF1EE8CD56FF85CFA4309388BD5F" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1709-wk-Fact-1306DF3E7643589AAC5596B6A505649B" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1728-wk-Fact-7B488312060B535DA84AD55DE47D9F25" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1747-wk-Fact-E80E7A683A79518FBABC396FE21F3B25" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1767-wk-Fact-9430909CF80A03565F02CB32B02CC367" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1787-wk-Fact-09FB60A430C258CD989D85984BFCD1BB" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1806-wk-Fact-F59A062863DF5A8E918A13BB63A73F80" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1825-wk-Fact-E35DE72D6EDE5CD4BEFF8B7B3A2333CF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1845-wk-Fact-5E612728C23659A0A53B154AE03CDA6D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1870-wk-Fact-E66885B7A6870B7FD2C37F5F58BC5E38" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,384,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1889-wk-Fact-97117C4B721D441E5C117F5F58856F60" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e1908-wk-Fact-FB145834FD23F6C7D0677F5F58CC4C26" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e1929-wk-Fact-B8393E9F825BB019747E7F5F58BED339" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,388,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investment securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2233-wk-Fact-C7E368CA22C15D6F9B8C1934CE939A9F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2252-wk-Fact-E9C5823C927D5BFBB101782AAA511C49" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e2271-wk-Fact-25AE4171D913577582E03C697648D6C5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2292-wk-Fact-D0DCCC04591A650DFD457F5F589FC49B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2307-wk-Fact-77E7523C36B4521B9CFE87E2A4852604" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2326-wk-Fact-C8B6CA87A7755ED3A86386728DCFAAD2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e2345-wk-Fact-298C01908C4A566A957C2E53B7F3E5AA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2366-wk-Fact-B4A5D1F9E89CD36402787F5F58D5AF05" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2386-wk-Fact-75AE6221A89C5555A1D1B739F7B2687B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2405-wk-Fact-5CDFA679CF8A523ABA877E610AF9602B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e2424-wk-Fact-7A1717EBA39E538A96A0C6F0E6103B2D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2445-wk-Fact-CB58F5BCACF8A3594BD57F5F58E5CAA9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2465-wk-Fact-0E721FCC5178570FEFF27F5F58AD6931" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">781,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2484-wk-Fact-DEA770C815DD4C282D7E7F5F58D96CFD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e2503-wk-Fact-87095D78A55B3DF07B2E7F5F58DA9D88" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2524-wk-Fact-E9A20E83BD35513F999441AB81BC6B12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">780,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2544-wk-Fact-F72838C58632583F88B30B7447F02E2D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2563-wk-Fact-DA5C10CDC99C511A8DADE1923CA8DEE7" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2582-wk-Fact-285A408EAC5E57538C9A669DAE6D72FE" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2602-wk-Fact-D09AF6F51C0D5E4F8CFD1EA24E928AEC" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2622-wk-Fact-18DC9CB408B75AC2902C22AAA608B061" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2641-wk-Fact-1CA3CA6015B95B69B8CFEBA3A6EF85B2" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2660-wk-Fact-EB796814557450F1ABC2AE78DFA042D1" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2680-wk-Fact-4AF8F8BA02F171E080EFCB326B8D927B" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2700-wk-Fact-955D2B473EB65151A70C546DE6E365BF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2719-wk-Fact-D0773D566C8350C3B755A32A87AC763D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2738-wk-Fact-64DB5B806D895561A90A4F4AA9D00C84" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2758-wk-Fact-19186BD28A915895A0FFC8F60866CD65" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2783-wk-Fact-C1AC7E27D0D9815732927F5F587D99D5" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">852,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2802-wk-Fact-DEA770C815DD4C282D7E7F5F58D96CFD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e2821-wk-Fact-87095D78A55B3DF07B2E7F5F58DA9D88" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e2842-wk-Fact-C44D471DE0D0B37B84E07F5F58EA90A7" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">851,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investment securities available-for-sale were insignificant during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We manage credit risk </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">associated with our investment portfolio </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="TextSelection-B0126058EED41AF0C6167F5F5907321C-0-wk-Fact-8133FB726E97475703DB7F5F58ECF7D8" continuedAt="TextSelection-B0126058EED41AF0C6167F5F5907321C-1" escape="true">The fair value and gross unrealized losses on investment securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B0126058EED41AF0C6167F5F5907321C-1" continuedAt="TextSelection-B0126058EED41AF0C6167F5F5907321C-2"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3297-wk-Fact-B76F15F1DEB15BC7A6454BBF022F4F06" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e3316-wk-Fact-7228E4809A6C53E282B3B8FD6E0BB122" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3336-wk-Fact-7498DAC6C56A5172A1714715ADFFE83F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3356-wk-Fact-8F7764B2E4B45789A8A430CEC222B6C0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3375-wk-Fact-FE395F9D50375246A6F8913DCB0A601D" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e3395-wk-Fact-5CE8D32EF671535ABCD69EE46620E3D2" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3411-wk-Fact-AC8FB5EDD82253599D723C9D5CF84C59" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e3430-wk-Fact-C41314A5073B5BA0880B3E6508954BA5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3450-wk-Fact-311CC75F31995509BE49F7597B8036FA" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3470-wk-Fact-025B9C095B1F59A69E1F3E2A6BD38A12" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3489-wk-Fact-80FC4340A64E5704AD700B7870CD7FF5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e3508-wk-Fact-7501B3999D825175979D3BE70907B698" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3535-wk-Fact-914347B2F2605CD38E87687A7CD350A7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e3554-wk-Fact-6E2D8B705D655B7DA1D557E38D89F130" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3574-wk-Fact-473B0ED55E8F5F4487A3F122DF15BAAA" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3594-wk-Fact-0D5F260B033758F5A35EC8A68BA30FB2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e3613-wk-Fact-9235DD1B595C5180BC20B7D2B31BD059" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e3633-wk-Fact-BF135D59779451BE9657D26622D69C24" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">97</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-3"><ix:continuation id="TextSelection-B0126058EED41AF0C6167F5F5907321C-2"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4052-wk-Fact-E675C571551D531690BDCC703DAEC748" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4071-wk-Fact-7E4BF91689905C1889761DC0D4009F52" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4091-wk-Fact-2C311EED62E4573D8A8224CC8A793596" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4111-wk-Fact-9957F59ECC625A3A9B8F18EF84E0AFAC" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4131-wk-Fact-C45A98E6BBBA5BE18CED1D9F59F35ECA" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4151-wk-Fact-0C5A938C319A5185A60C3A75C2033255" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4167-wk-Fact-9CE9B85024085542B90D7C8FA6F1C8A7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4186-wk-Fact-8A52193D91B351C78A7C7876DB612B4B" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4206-wk-Fact-003F4ADDBA01572B93127EE75329E48F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4226-wk-Fact-AF98D79CE50658CB85A322C5035DEDE6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4246-wk-Fact-3D81DC18AD455F2A8AC56892C0D43363" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4265-wk-Fact-62FFB50DD0415E688987CEB2C75374EE" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4287-wk-Fact-2DC882EFF288551F9A0C595BCAF65FE8" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4306-wk-Fact-6892B147BCDE5BA992691CD2648F9523" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4326-wk-Fact-C50EC59E37AD5F48B423CAD8C002E94A" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4346-wk-Fact-83E593F0332759D78B48A2F139C5386C" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4365-wk-Fact-2D65CE44FAE054A2833B24FC1773C90C" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4384-wk-Fact-E29E863F56C15258853F1A17EF8F8B00" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4411-wk-Fact-5FE21F7E47115E889F729E767805A46F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4430-wk-Fact-5FE3CAA9E4DD58DEBF69961BB068D82E" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4450-wk-Fact-67510A3387B25E899D819D75E6164B15" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4470-wk-Fact-2BE05385B6DA512B877394E2261C7E5F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4490-wk-Fact-602DD02DAA025DA68CF92DC8DF6C536C" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21843681e4510-wk-Fact-4041E60F20E15F7F8F58922EDE933E72" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21843681e4524-wk-Fact-007B8E92DCC65121912494BE721C851B" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2019Q4" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21843681e4528-wk-Fact-4FEB689D28ED53FF951EE6405F75E46A" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2018Q4" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">199</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investment securities in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21843681e4557-wk-Fact-7A464EC152725353BBCB2C88F0154719" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="FD2019Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-E931793D62BDD9F51D757F5F5907C8DF-0-wk-Fact-BAA3C2A79559675CA7647F5F58D9EEBD" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investment securities available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4683-wk-Fact-37035C77481D5E8599DA4F9C3EFBA21F" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">789,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4702-wk-Fact-EE952B3080005DB389BC93B3CF6086B7" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">626,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4717-wk-Fact-5260F121163655FE9ACBD66D1091E2C1" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">522,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4736-wk-Fact-1F38BD12822E50418D004F90F003E225" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">153,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4761-wk-Fact-36E5FA1B0E3BE66D7B2E7F5F5881725A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21843681e4780-wk-Fact-E9A20E83BD35513F999441AB81BC6B12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">780,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s0C9578561F7B5D1C85E7E7E2C5249A09"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-0-wk-Fact-BB3F48E0AB9319D49FD27F5F58DFF840" continuedAt="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-1" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-1" continuedAt="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-DDF810CE9883527024F97F5F590A4B5B-0-wk-Fact-C61B2B7ADBF29BF377917F5F58E0333E" continuedAt="TextSelection-DDF810CE9883527024F97F5F590A4B5B-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e795-wk-Fact-CF50E76C73EB5E878547B3AEBA59E3D3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e814-wk-Fact-2016C08F6F955FD9AC31A888540547ED" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e833-wk-Fact-5D77D621171968404368CB2DC6839AC1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e849-wk-Fact-F6979BB7F6CA56C096C802FFA5C988DF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e868-wk-Fact-1427413FE4225A7188C71DC6DE546440" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">756,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e887-wk-Fact-DB6AD50AC413417A13C9CB2DC6987611" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">756,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e908-wk-Fact-01C504CBB28E5A06AF918D7590BCA433" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e927-wk-Fact-8BA94616AFF05C2EBE6881D6018DFB45" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e946-wk-Fact-9CD3D6BE14302BDFAB50CB2DC6B14A28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e967-wk-Fact-5D71AC0075916C3DE8207F5F58874E54" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e986-wk-Fact-6906E52BD2E1668831587F5F58864506" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1005-wk-Fact-36E5FA1B0E3BE66D7B2E7F5F5881725A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1026-wk-Fact-7309368F5B5D5B6CB225B2CE19D7E936" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1045-wk-Fact-082D3D7FA7B257408528F98B0D248ECD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1064-wk-Fact-BF61AE5FA7A54B7E0613124A466EB1C1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1085-wk-Fact-086B9EDA6E985B548D3F6E189BB546F2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1104-wk-Fact-F29DE0DE026C5811B6EBF8070A0E0698" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1123-wk-Fact-819EDD24097BEE330B4D7F5F58834B4A" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1149-wk-Fact-5F85E8E192CED043E8E87F5F58850068" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1168-wk-Fact-BC4DB0BCE9FB5E3AC64C7F5F588061F8" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,345,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1187-wk-Fact-8668F438A77C1B59DF6C7F5F587EAA3C" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,347,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">98</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-2" continuedAt="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-3"><ix:continuation id="TextSelection-DDF810CE9883527024F97F5F590A4B5B-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1351-wk-Fact-EC100B80B45D52939816209F2EC43ACB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1370-wk-Fact-FE4E676BF5775FDFAA5E0CE1699B945A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1389-wk-Fact-D0DCCC04591A650DFD457F5F589FC49B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1405-wk-Fact-C82CC303D4805F239E1E99A15F419034" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1424-wk-Fact-3C9D645DD5E551E091C0310D939E48AD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1443-wk-Fact-B4A5D1F9E89CD36402787F5F58D5AF05" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1464-wk-Fact-5BE968042E505E29B2EA0F8B323197DB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1483-wk-Fact-F3E33F4882EB55D682C32FB1ED12727D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1502-wk-Fact-CB58F5BCACF8A3594BD57F5F58E5CAA9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1523-wk-Fact-8302373CA370696E5C017F5F58C817CB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1542-wk-Fact-D27888236AB8F2C14E6C7F5F58C85F79" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">780,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1561-wk-Fact-E9A20E83BD35513F999441AB81BC6B12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">780,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1582-wk-Fact-91D92DB2ACB851A99A93882AD7E71336" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1601-wk-Fact-56316F63A4E55441BCC16776B2D8CCCB" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1620-wk-Fact-447EA43152DC3985D0B4124B3BD664C1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1641-wk-Fact-E4A806934808511DB125315A58919161" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1660-wk-Fact-8BC92E32B1CB967ED9467F5F58CA26BC" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1679-wk-Fact-EA6C43E418FFEDA4087E7F5F58C3ACD9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1705-wk-Fact-4DD371E359EC0CE2CE457F5F58C74A8C" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1724-wk-Fact-28887925614854B5535C7F5F58C94DAF" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">796,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21838470e1743-wk-Fact-B72282A1C40140FEC7D07F5F58CB0A48" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">844,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-3">The carrying amount of our remaining financial assets and liabilities, which include cash and restricted cash, receivables and payables approximate their fair values due to the short-term nature.</ix:continuation> </span></div><div><a id="sC15D228F09135CE5977760CEB2AA9FBC"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-0AC5522D30A7986BFA0D7F5F5907A001-0-wk-Fact-974FAAE84A64036A6A527F5F58A64662" continuedAt="TextSelection-0AC5522D30A7986BFA0D7F5F5907A001-1" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0AC5522D30A7986BFA0D7F5F5907A001-1"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-9FCAC0B8D881056203C87F5F5907C1DE-0-wk-Fact-A0E7EA10F884DF7C7DD97F5F58A4C2FF" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e700-wk-Fact-6513FAB3DE435353BE542BE61BCDB5D2" name="us-gaap:InventoryRawMaterials" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e719-wk-Fact-5DE34C30E3B95514B6DC1C5C107AF7F7" name="us-gaap:InventoryRawMaterials" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e734-wk-Fact-5890FB1496CE55CEAECA796008D68E53" name="us-gaap:InventoryWorkInProcess" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e753-wk-Fact-F49EA7AD98175FB4AC71CF653D2BA738" name="us-gaap:InventoryWorkInProcess" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e773-wk-Fact-9DAA7234749E512DA1887C2E02F772FD" name="us-gaap:InventoryFinishedGoods" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e792-wk-Fact-B1ACE76EDEBC54609F9E91329837A3F7" name="us-gaap:InventoryFinishedGoods" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e817-wk-Fact-D6AA89447B1158B9B4E3849410C94DAA" name="us-gaap:InventoryGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e836-wk-Fact-8FC38ECB8C14571CA231F840895AC296" name="us-gaap:InventoryGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e897-wk-Fact-5F1F3E41857E5EE8BD5CE69653AAA1EC" name="us-gaap:InventoryGross" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e916-wk-Fact-0B59B89E34D85FAFA403D36A252EC99F" name="us-gaap:InventoryGross" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e931-wk-Fact-C0272235C149502A87FC7CDB3CF3CEEE" name="us-gaap:InventoryGross" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e950-wk-Fact-9C10FA48F3315CC1AD68DC76D6468A54" name="us-gaap:InventoryGross" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e975-wk-Fact-D6AA89447B1158B9B4E3849410C94DAA" name="us-gaap:InventoryGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21835782e994-wk-Fact-8FC38ECB8C14571CA231F840895AC296" name="us-gaap:InventoryGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835782e1011-wk-Fact-B5989E9B49235FC594C8FE9C41EC6C62" name="us-gaap:InventoryWriteDown" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835782e1015-wk-Fact-FFD03F37A76858318E9AFECE17E452CB" name="us-gaap:InventoryWriteDown" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21835782e1019-wk-Fact-F1B3C64F7F03EF6276A97F5F58A84968" name="us-gaap:InventoryWriteDown" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div></ix:continuation><div><a id="s03E3DA14D974557E89DE476DA1409C01"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-3952F8884B3AAC5658AE7F5F59073FED-0-wk-Fact-ED74859EF9437D9FC9B87F5F589EE14F" continuedAt="TextSelection-3952F8884B3AAC5658AE7F5F59073FED-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-801F5631CC76E6E84B187F5F5907CC8D-0-wk-Fact-9EB62F5F86EB6870934A7F5F58F260AB" escape="true"><ix:continuation id="TextSelection-3952F8884B3AAC5658AE7F5F59073FED-1" continuedAt="TextSelection-3952F8884B3AAC5658AE7F5F59073FED-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:56%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Lives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">up to 15 years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e748-wk-Fact-65B4D59BBDC15802B7BE41FF3B66302B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e767-wk-Fact-EE8C40EAB0B35062B1B24C280399E5FB" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e792-wk-Fact-D4DBBF1903665A049742B5647EC24B59" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e811-wk-Fact-378D16834A1051BC91485312168313E8" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5 to 7 years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e841-wk-Fact-9B4E50F1C4895025B46B26F55F437DDF" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e860-wk-Fact-8F0F9BD108D15CB090BEAAE2F46C0B94" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e890-wk-Fact-43054D25AA84504ABF3E6FF42CA6F26B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e909-wk-Fact-F43AFBAB1A295AD4875730654AB1A045" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e939-wk-Fact-DA1B399F5FAE507EB0C8F47D4114DD10" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e958-wk-Fact-78FDB346E78A5775ACFB7DBC80C2046B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e988-wk-Fact-1AF178888729E1C0F04B7F5F58BFB2E9" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e1007-wk-Fact-EB97EA7FF280E170773B7F5F58B9C2E7" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21837602e1037-wk-Fact-307F1C8C980D596D9541BE6527E33259" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,560</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21837602e1057-wk-Fact-41C2754880D15B28AF8532074A70DA6A" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e1093-wk-Fact-81AA7FFF07FE5F84B6FB6B3F858272C1" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21837602e1112-wk-Fact-B2A50C77138252D19D547A4E7AE9A283" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">99</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-3952F8884B3AAC5658AE7F5F59073FED-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation and amortization expenses were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21837602e1124-wk-Fact-884E41D60721500B9B6DB0CBE2385DC4" name="us-gaap:Depreciation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21837602e1128-wk-Fact-51BE0A5789235E38BB6FC0F8D186DE27" name="us-gaap:Depreciation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21837602e1132-wk-Fact-2206CAEF825A7B415E661250FCE3CE74" name="us-gaap:Depreciation" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div></ix:continuation><div><a id="s0D830E536E25555FA74C3CE95B2C64C1"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-8A9FB83B077593F367807F5F59073C57-0-wk-Fact-8B148A8D869C7D19342E7F5F58D51E4C" continuedAt="TextSelection-8A9FB83B077593F367807F5F59073C57-1" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8A9FB83B077593F367807F5F59073C57-1" continuedAt="TextSelection-8A9FB83B077593F367807F5F59073C57-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Incentive Plans and ESPP</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-C32AD472B1B6EB97C5AA7F5F5908E68F-0-wk-Fact-D9C5D13D73CC137AA9237F5F58B96216" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e751-wk-Fact-551D2539E9F05DFE907BC1A0CF246AB8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e770-wk-Fact-EF4AC1DA5F4053C9A67936ABF34EEA3E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e789-wk-Fact-4F67CCD12AB2BED737CC7F5F5891F4E7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e805-wk-Fact-DABB26A333F95368805EE0A3F3D24A5A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e824-wk-Fact-D2B22307F45B56BCA8A61B11F3A016A4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,511</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e843-wk-Fact-0353527D2F78D4738D757F5F588D4ADD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e869-wk-Fact-B80B4F25440472E547D87F5F588B003D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e888-wk-Fact-C8B01EB4D4335D812B597F5F589067B7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e907-wk-Fact-423B5741F1E4AE4AE15B7F5F588F008D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we granted stock options and RSUs, including PSOs and PSUs, to employees and directors. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonFraction id="d21848482e925-wk-Fact-39447943AC765D2DBC2EA14F03AEC2EF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,258,319</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Board of Directors (the Board) delegated responsibility for administration of our equity incentive plans to the Compensation Committee of the Board, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seven</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year life from the date of grant. Stock options issued prior to May 2011 have a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year life from the date of grant. RSUs granted to our employees and directors generally have a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term and a one-year vesting term, respectively. PSUs and PSOs granted pursuant to our equity incentive plans vest upon the achievement of a performance target or market condition, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span><ix:nonFraction id="d21848482e956-wk-Fact-EF4074A87B29C34BE97F7F5F58BB0410" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the beginning of the offering period or</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span><ix:nonFraction id="d21848482e964-wk-Fact-37843334B29A92906FD67F5F58BBDDDC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the end of each</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">six</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">month purchase period. Compensation expense related to our ESPP was</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$<ix:nonFraction id="d21848482e981-wk-Fact-0C12880CF35091757AFF7F5F58BA43FB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$<ix:nonFraction id="d21848482e987-wk-Fact-30752E3720FFDEABB4FB7F5F58D47848" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$<ix:nonFraction id="d21848482e993-wk-Fact-E120DD6B530D91A086DB7F5F58B625B5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">for the years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. As of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, we had</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span><ix:nonFraction id="d21848482e1029-wk-Fact-E20D554F70E83C75C3167F5F58BF6190" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,238,999</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares available for issuance under our ESPP. Pursuant to the ESPP, we issued</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span><ix:nonFraction id="d21848482e1037-wk-Fact-D79C7D26EB55237FB9817F5F58B7CD97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">483,009</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span><ix:nonFraction id="d21848482e1044-wk-Fact-8FF4163546B0402B63637F5F58BB8448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">330,492</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span><ix:nonFraction id="d21848482e1052-wk-Fact-24EAB99F153DF603BDBA7F5F58BFBBF1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">434,523</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares of common stock at an average price per share of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$<ix:nonFraction id="d21848482e1060-wk-Fact-AF05FD446844134E6FDD7F5F58C50BCB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.60</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$<ix:nonFraction id="d21848482e1067-wk-Fact-C61265D34BE73E5EE35C7F5F58C005E5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.74</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$<ix:nonFraction id="d21848482e1075-wk-Fact-D0FF529CE26DA2914C047F5F58BBDD64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.20</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">during the years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Cash received</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from purchases under the ESPP for the years ended December 31, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e1138-wk-Fact-B074EA2F6EB6BFDA74787F5F58C1C01E" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e1142-wk-Fact-367CE01BD3993A8994497F5F58BE88F9" name="us-gaap:ProceedsFromStockPlans" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e1147-wk-Fact-A5673C7F390AC9D7C1597F5F58BA99CC" name="us-gaap:ProceedsFromStockPlans" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value PSOs that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="TextSelection-10F59E6DD3F790ACAAAE7F5F59086361-0-wk-Fact-CE0C39CB66D34BB4E8A27F5F58C0D3C9" continuedAt="TextSelection-10F59E6DD3F790ACAAAE7F5F59086361-1" escape="true">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-10F59E6DD3F790ACAAAE7F5F59086361-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1318-wk-Fact-DE2B41F3BD5B589AABDE106302E5D6E3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1337-wk-Fact-73C683F875185F9688CE442C4FA0E245" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1356-wk-Fact-3BEC6957EBF9DF82D4DF7F5F58E481C4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1377-wk-Fact-65502E67C56B5DD093EF72B78A039501" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1396-wk-Fact-CB8848AA60145180B4524A5196E7AEEC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1415-wk-Fact-5B7D72243E9081CD89327F5F58E48FC6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-8A9FB83B077593F367807F5F59073C57-2" continuedAt="TextSelection-8A9FB83B077593F367807F5F59073C57-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-16A08287764CF935FDDB7F5F59089E26-0-wk-Fact-6631E0CAC61F209B4B617F5F58BE5268" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="TextSelection-B55CF7A6CBDFEC67239B7F5F590824EE-0-wk-Fact-1AE978DED5986CE9EB8E7F5F58BD6215" continuedAt="TextSelection-B55CF7A6CBDFEC67239B7F5F590824EE-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1607-wk-Fact-661AAA8336FE5B87BE1E0A10EFCA0A51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1622-wk-Fact-C82FEFD63C6B5E1BAABF99550A28BA52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1637-wk-Fact-980DB72FAC3A54FBB90A2196370891B9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1653-wk-Fact-F51BC9F58F055E4DB4E243471A26B53E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1668-wk-Fact-5711B58A856258F3ACFCB754FF32C028" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1683-wk-Fact-4C4D5E373B415257917532BABECD8C2B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1699-wk-Fact-0AA75A94751B5027A5E151D20E1FE3EF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1714-wk-Fact-F74A89497BBE51B78BD7E242964ACE58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1729-wk-Fact-8694284C6E2156AC94AD2381CE57D91B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e1745-wk-Fact-298791AA4ACE542B9E92F763FD873510" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.3</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e1759-wk-Fact-44ACB1BB32425233B9ABD887265ECA66" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.4</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e1773-wk-Fact-6809D303C0795650BBF6E975E58BC437" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.5</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1834-wk-Fact-0ABB1F1DC3275316AB6C096AAE787053" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1849-wk-Fact-579ECA1B0AF85D8FA4456C0B323F970F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1864-wk-Fact-ABD8DE66A15F53B9966E171C9B294562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1880-wk-Fact-7151803598AC5835AFC7D3621C695C48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1895-wk-Fact-F961B5E793E25B30B48859BEDDC3CA52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1910-wk-Fact-D3653E6DFCAA5A8ABADD792F4A26D860" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1926-wk-Fact-C7902277EF0A54358AA053CBCB79D6F3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1941-wk-Fact-1D6CBDD50CAE534794F13D36EF461AE7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e1956-wk-Fact-B4E6B8CFE5FB59ACA7814DB3FF6DEA91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e1973-wk-Fact-3C506FBE178A5B83ADB04E3F3DC06C76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e1987-wk-Fact-3055E989CA985F9D80E6D7C2F4BC45ED" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e2001-wk-Fact-FCA8A8DD86685B258391923916271FD6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-B55CF7A6CBDFEC67239B7F5F590824EE-1"></ix:continuation>We considered both implied and historical volatilities in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs, including the PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-BF0048AA394D3390A5CE7F5F59083DB5-0-wk-Fact-DD36AFB03B032E3DDB327F5F58C403BB" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options, including PSOs, during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2188-wk-Fact-7A1A502FA8F159059CC5FFB4DE8AAF85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">22,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2207-wk-Fact-4E4A9AD22142521EBC92BA1DFB8F1D31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2253-wk-Fact-398E5E2A90955EC0AE0F3D4C604EDEFC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2272-wk-Fact-6CC94A7E506A5D3EA160EBAF9403E745" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">20.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21848482e2318-wk-Fact-1F0C748368D0548BAC6195FE49BC3303" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2338-wk-Fact-CC6CFDED08F65B0D990952D6B79E3530" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21848482e2384-wk-Fact-1FF32107DA755673AE4F5FC81DE64599" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2404-wk-Fact-78378185F3DE59B38E4BD962EE9257CC" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21848482e2450-wk-Fact-EC8C6A0791755D5FB3FEBC8AE5EE40A1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2470-wk-Fact-1BB496881C70515790F71B0350B4E678" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">22.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2516-wk-Fact-6ECC717655A63B60B75C7F5F58DB22CA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">20,443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2535-wk-Fact-056298AF5AE45F24AA7C08231FDDDC08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e2549-wk-Fact-75842EB164355896AE3C78AD31A3F64C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">3.2</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2565-wk-Fact-C582EE8384CA5326981D3322BFAC3CD3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options exercisable at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2580-wk-Fact-A845EF6A13A15A3AB10E34AA64B1CAE0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2019Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">16,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2599-wk-Fact-E14ACB471DD952668E5D6E827D8A3D74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e2613-wk-Fact-48FDDF47FFF150B79EC22D618FFC51BB" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">2.6</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2629-wk-Fact-01FC1CFF765B56A6B7DACB78C8E82304" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">167,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21848482e2653-wk-Fact-72F6A3F3E14B5EC6B338F54DA3088F8B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options, including PSOs. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonNumeric id="d21848482e2657-wk-Fact-12DE71E8177A5611BA1BBAC56D8EB223" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">2.2</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e2670-wk-Fact-0A2C8FC5EB0E765692E77F5F58B92990" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">308,365</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> PSOs to our President and Chief Executive Officer. In addition to the standard service conditions included in our other stock options, these PSOs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equal to or greater than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e2678-wk-Fact-D3602F6159FCE6BAF7067F5F58BDDA47" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">125</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the per share exercise price of the PSO over a period of at least 30 consecutive calendar days. The stock-based compensation expense for the PSO is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total intrinsic value of stock options exercised during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-8A9FB83B077593F367807F5F59073C57-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2708-wk-Fact-CE0761D7AD664B28D2F97F5F58C3A477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2712-wk-Fact-9769609A4DBC8C524FD67F5F58C4A256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2716-wk-Fact-95A0D8931DEE536821C57F5F58C3434D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Cash received from stock option exercises during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2733-wk-Fact-C4CB79FCF7EB7E835CA07F5F58C1D63B" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2737-wk-Fact-422DAA66E4FC9609AF757F5F58C402CE" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2742-wk-Fact-5570682C9B2C476A69EB7F5F58B70079" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The total estimated fair value of stock options vested and recorded as expense during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2758-wk-Fact-F4882B67D96E664717647F5F58C05964" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2762-wk-Fact-E40313A0C907BFF89DEA7F5F58C23166" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e2767-wk-Fact-7115DB1E0ADE542F9B207F5F58BDE119" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-0-wk-Fact-33B0A4C5BF4C31E801CE7F5F58BCFE85" continuedAt="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-1" escape="true">Activity for RSUs, including PSUs, during the </ix:nonNumeric></span><ix:continuation id="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-1" continuedAt="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></ix:continuation></div><ix:continuation id="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-2" continuedAt="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-3"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2934-wk-Fact-5CC94C211D9B5250BCE5D469A1A4534F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2953-wk-Fact-EA86FFCBB68453EB9C5E56ADF23AC77A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e2999-wk-Fact-CA91078372D358F083E2ECCE40102D94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e3018-wk-Fact-824DA26BF6FF598382A3B27806268686" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21848482e3064-wk-Fact-F288B4C02F8251A794C109269B62C93B" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e3084-wk-Fact-BAEBFC3F8AF85D03A79E9837D1E459EB" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21848482e3130-wk-Fact-C3DB61CDA63A5C1881114A7BCD854F72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e3150-wk-Fact-9704CC1506A9564A9AEDE155F4D5D736" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e3196-wk-Fact-430CCC12BA290DB1275C7F5F58DB6A9F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e3215-wk-Fact-A9AF98F2E3AB5488A582871BFE602921" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d21848482e3229-wk-Fact-D89EBE618C6F517C8256C2DD5BEE0525" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.2</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21848482e3245-wk-Fact-190FE96503185DB4899926942DB21ABB" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">149,701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-3"></ix:continuation>As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e3267-wk-Fact-815B6DF998275B9D8DA8F06C7067DF44" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">158.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including PSUs. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21848482e3271-wk-Fact-2B70D0264D7D52BF8B14839733496A3B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.7</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2019, in connection with our long-term incentive compensation program, we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3279-wk-Fact-DE982995CB285C13B919C3E90F543647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,926,605</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> PSUs (the target amount) that will vest upon the achievement of a performance target related to a product approval by the FDA (the 2019 PSUs); employees may earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3283-wk-Fact-4BD3A1D50D845626B7CBFE4C3D446F05" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">150</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount, or an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3287-wk-Fact-D5AB3B2FA3335FA09F31A03D09DC0221" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">963,136</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, if the performance target is achieved before December 31, 2020 and may earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3291-wk-Fact-8860E9102DEB5AD3AEDCD55B87333F03" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount, or up to an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3295-wk-Fact-4546C29D68D55B40882D0AC9E2D35159" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,926,605</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, if we receive a second product approval by December 31, 2021. During 2018 we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3300-wk-Fact-E970199132CE57A791A99A62E0ED2B9C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">693,131</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> PSUs that will vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we achieved two of the performance targets for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3315-wk-Fact-6DB0F4DE913D5852A2CB827772ADBF89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">281,238</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the 2018 PSUs and determined that it was probable that we would achieve one additional performance target for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3319-wk-Fact-CED935ECBA9120835C0A16A57C674CCC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">99,281</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional 2018 PSUs. As a result, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21848482e3323-wk-Fact-B7BFED721D59AAB1853216A5A448EC01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_exel_StatusAxis_exel_VestedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">141,004</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the 2018 PSUs have vested as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the remainder are expected to vest over various dates through November 2021. We recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e3332-wk-Fact-0E15AAA276A95244B6C2F887397F7A4A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense related to those 2018 PSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; the remaining unrecognized compensation expense for those 2018 PSUs was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e3344-wk-Fact-E90A357DAEAA54D29AA027BB888EAA73" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q4_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total unrecognized compensation expense for both the 2019 PSUs and the remaining 2018 PSUs for which we have not yet determined that attainment of the performance target is probable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21848482e3353-wk-Fact-AE7F17C54FA1524E80847C28F904F841" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q4_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sponsor the 401(k) Plan under which we historically made matching contributions to our employees&#8217; 401(k) accounts in the form of our common stock. We recorded compensation expense related to the stock match of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21848482e3367-wk-Fact-0374CAEC017D6DA0A3597F5F58C3D87D" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21848482e3371-wk-Fact-CE3DAA7AE5CBD512219B7F5F58B7BDA5" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21848482e3375-wk-Fact-4B15F1FFDA9F515E1B677F5F58BB73CB" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Beginning in 2020, we will make matching contributions to our employees&#8217; 401(k) accounts in cash</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">102</span></div></div><hr style="page-break-after:always"></hr><div><a id="s537C835B4FB95F15A1C161B50A9886D3"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-0-wk-Fact-9D050A9D693CD74DD3357F5F587D22D5" continuedAt="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-1" continuedAt="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-59641E987374C7ABDA837F5F59095BC9-0-wk-Fact-193BD6C5EBC0E1EC2D937F5F58826ACB" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income before income taxes is derived solely from within the U.S. Our income tax provision (benefit) was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e832-wk-Fact-58486DB9C8720E0197B07F5F58807B67" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e851-wk-Fact-A21ADC96319B9E3563D87F5F5884D02A" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e870-wk-Fact-628C417685AAC30D52C17F5F5883C10E" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e886-wk-Fact-B00F422A93DC2823B9C57F5F58851604" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e905-wk-Fact-4BE863877200771368877F5F58840253" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e924-wk-Fact-167EEE6C6A62D463CBB57F5F587E4447" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e945-wk-Fact-7537B1D5F01F982F4FB47F5F58940E7C" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e964-wk-Fact-DCF2D7C9848873490C587F5F58832E44" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e983-wk-Fact-B842FBACEAAC82165E7D7F5F588754A4" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1066-wk-Fact-5AC1150F644A12D99C8F7F5F58820C01" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,580</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1085-wk-Fact-7DF7B528048895388DC57F5F5886165B" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">238,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1105-wk-Fact-7040AFA094316756B9CA7F5F5887FE57" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1126-wk-Fact-15D2EB510168845911577F5F5888B44A" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1146-wk-Fact-1D4FD5B15684098A31927F5F5885878C" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1166-wk-Fact-6445B2DE4BA570CDB01F7F5F5882C2A3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1187-wk-Fact-FEDA12A54EF5FDEB37137F5F588633A6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1206-wk-Fact-9FC3F45CFA91E48E1C9A7F5F588018F2" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">244,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1226-wk-Fact-9A9B1E02395E1802143D7F5F5880ACFB" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1252-wk-Fact-A6ED704EA7B65523846BE5FA5DBBDFF4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1271-wk-Fact-695D932D76AF546FABA1D6C1D58ED92B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">237,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1291-wk-Fact-CE414B47BA63BD330D71808181883018" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income tax provision for the year ended December 31, 2019 primarily relates to the utilization of federal net operating loss and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. The income tax benefit for the year ended December 31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California. The income tax provision for the year ended December 31, 2017 primarily related to state taxes in jurisdictions outside of California. Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2019, 2018 and 2017. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-93930E4B44714E5B09487F5F5909814B-0-wk-Fact-5FDB57F956FDAC0BD8627F5F58E926FE" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of the U.S. federal income tax provision (benefit) at the statutory federal income tax rates of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21851538e1322-wk-Fact-C2733C856D063983155A7F5F58EB93BC" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21851538e1326-wk-Fact-6A33706AAB51CF6AE2957F5F588440FB" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21851538e1330-wk-Fact-550B6C8309D7D4231C997F5F58EBD795" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="D2017Q4FYYTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended December 31, 2019, 2018 and 2017, respectively, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to our income tax provision (benefit) was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax provision at statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1493-wk-Fact-09D834D9E708FFBF66287F5F5880239B" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83,603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1512-wk-Fact-262FEF28F05353690D4F7F5F587B66F2" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94,939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1531-wk-Fact-516850E3667907E66C647F5F58EC8600" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1547-wk-Fact-CDADAC66C65E684EBFD37F5F587864F7" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1566-wk-Fact-2DED2B57512D9F1C9C647F5F58EA51F6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1585-wk-Fact-E9355762A0C183E001BF7F5F587B9A33" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1606-wk-Fact-B6D3AD992E64943920697F5F58779F7D" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1625-wk-Fact-C79962EAC0A3705C9DF07F5F5878BD5F" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">315,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1645-wk-Fact-B0B8E7F70E515717C00F7F5F58EFC4E5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">34,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1667-wk-Fact-46DF011C03C840B79AF37F5F587AAB1E" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1687-wk-Fact-76FFBF4EC45C7149EB527F5F58F1943B" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1707-wk-Fact-38D7291C13708D20F5787F5F5879D8DF" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1728-wk-Fact-3528DAE6497B73E461697F5F587622BA" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1748-wk-Fact-CB0C651BA2EF5D2801E87F5F5879CFB9" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1768-wk-Fact-53CCD083586B16FCDA1B7F5F58EAA7EE" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible executive compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1790-wk-Fact-C0D43648E31E3A50D38D126CB9342930" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1809-wk-Fact-298112E8EDA11BB4997E126CB93CD05A" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1828-wk-Fact-2D7A4BB876A76A468803126CB9429156" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1849-wk-Fact-21D3CEF8BAEFA73293847F5F58ED154B" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1868-wk-Fact-37EA7DE2CF227ED09F047F5F58EAB169" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1887-wk-Fact-0D16FD67CF87440D545D7F5F58749069" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1908-wk-Fact-62BF67C1271DE4F141E57F5F587CF06B" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1927-wk-Fact-73BAF8E6EF4F6F81214C7F5F58EA73E5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">982</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1946-wk-Fact-0423BA3AE9A5C02CB1D27F5F58EBEA83" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e1973-wk-Fact-A6ED704EA7B65523846BE5FA5DBBDFF4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e1992-wk-Fact-695D932D76AF546FABA1D6C1D58ED92B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">237,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2012-wk-Fact-CE414B47BA63BD330D71808181883018" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">103</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-2" continuedAt="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-FD49BC879D982C7A1C987F5F59095407-0-wk-Fact-C45561BD1F5BAB86945B7F5F587EFA83" continuedAt="TextSelection-FD49BC879D982C7A1C987F5F59095407-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2195-wk-Fact-E869512143F9C469BFFB7F5F58CA1952" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2214-wk-Fact-E8C348F99F451E7B41F37F5F58C7FE62" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">146,701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2229-wk-Fact-586DA21031B56C8551C67F5F58C8BA1D" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">110,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2248-wk-Fact-B5FD02A73A80321BCEB87F5F58C77988" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2268-wk-Fact-9507393EAC0E60A6FD1F7F5F58C514C0" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2287-wk-Fact-8CA11E98BB0BC7E5FAA17F5F58C68C01" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2307-wk-Fact-67446559E2CA7C1E2B9F7F5F58CA2A83" name="exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2326-wk-Fact-783B9390D20F2EB66F527F5F58CBAE2F" name="exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2346-wk-Fact-42C0E4CF9842C9A16185126F75414250" name="exel:DeferredTaxAssetsLeasingArrangements" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2365-wk-Fact-429EB61DA05CD2758737126F753BAD24" name="exel:DeferredTaxAssetsLeasingArrangements" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2385-wk-Fact-112BC93CF9107E5423FF7F5F58C9DEE7" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2404-wk-Fact-AAE3ADFBF5D13A9FAD467F5F58C53785" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2424-wk-Fact-4B7DB09772570146DE437F5F58C9E319" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,547</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2443-wk-Fact-2BD3E4083290D21576137F5F58C45A25" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2463-wk-Fact-017EBA2F0018DAC9214A7F5F58C7BC95" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2482-wk-Fact-1F88C6118300C2CE495E7F5F58C470E6" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2503-wk-Fact-79A2AA68ED56B3CD14D87F5F58C6D5B2" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">243,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2522-wk-Fact-8A0ED1D3258BE2D888497F5F58C62363" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e2542-wk-Fact-0DFB6B0E13C7A42663117F5F58C2ABB5" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e2562-wk-Fact-E71B71CD4295F0F8AB2A7F5F58C86A21" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2583-wk-Fact-950E5444014A4DCBA3EB7F5F58C514B5" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2602-wk-Fact-A0D454A1CE05BA318EC07F5F58C6BA81" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">245,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e2663-wk-Fact-ADE411D7324545265EF07F5F58C2943F" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e2683-wk-Fact-6FF0BD2C26554F4820B47F5F58C57F9A" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e2704-wk-Fact-117A2CEC9C8CFE0C589F7F5F58C93975" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e2724-wk-Fact-9BD7B9031B633413C2D57F5F58CAB1EC" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2750-wk-Fact-DEA737C62C295C0FC0A87F5F58C81358" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e2769-wk-Fact-8D88942AE81178ECC56A7F5F58C70A0F" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-FD49BC879D982C7A1C987F5F59095407-1"></ix:continuation>ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2019, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December 31, 2019 and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, as well as considering the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">utilization of net operating losses and tax credits prior to their expiration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December 31, 2019 and 2018, we continue to carry a valuation allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e2802-wk-Fact-D251E48EB8D6FA6EDA8B69D2C5704475" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e2806-wk-Fact-4E79747C0BE3B539917F69D2A8E46EBF" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, against our California state deferred tax assets. Prior to December 31, 2018, because of our history of operating losses, management believed that recognition of the deferred tax assets was not more likely than not (as defined in Topic 740) to be realized and, accordingly, had provided a full valuation allowance. The valuation allowance increased by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e2811-wk-Fact-E5E27139E7C52E22DA661272567FCC65" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and decreased by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e2815-wk-Fact-48B1FD9F5E310D8783147F5F587FA163" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">360.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had federal net operating loss carryforwards of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21851538e2826-wk-Fact-895D1EA056CA914A7CB77F5F58E9E44B" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, of which approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e2830-wk-Fact-0EB60AE6788E0C9046AD127833CA91E8" name="exel:OperatingLossCarryforwardswithExpirationDates" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">203</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> will expire in the years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2035</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and federal business tax credits of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21851538e2843-wk-Fact-10181FBBB2551CB988D87F5F58E952CA" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which expire in the years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2039</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also had state net operating loss carryforwards of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21851538e2855-wk-Fact-8BD5578E882D736D55547F5F58EC1ABF" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">450</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which expire in the years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and California research and development tax credits of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d21851538e2868-wk-Fact-030AB2F3B473EB7EB7E17F5F587E0812" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which do not expire.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and concluded that an ownership change, as defined under Section 382, had not occurred. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">104</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-3" continuedAt="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="TextSelection-7FFC1384275813870F2C7F5F59092802-0-wk-Fact-75B1419605A862B037E57F5F587CCF2D" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3049-wk-Fact-F5544C2495B1C4D94A0C7F5F588D496E" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3068-wk-Fact-14E6CCD1D92F8A913B2D7F5F5887571D" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3087-wk-Fact-3A450DBF07790471F7907F5F5886D8C8" name="us-gaap:UnrecognizedTaxBenefits" contextRef="I2016Q4Dec30" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3103-wk-Fact-78E22ABC74FF2FE27D6C7F5F588AB808" name="exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">589</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e3122-wk-Fact-AB8E186F9B059F090C447F5F5889294B" name="exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" contextRef="D2018Q1Fiscal" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3142-wk-Fact-E1FB9C4259700CD26AC17F5F58899653" name="exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3163-wk-Fact-F7D4A924F4000F608B5B7F5F58815BFB" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3182-wk-Fact-522FFEEBB45EE51A3C767F5F58966AD8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="D2018Q1Fiscal" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3201-wk-Fact-A9EA098B2EA77739FA207F5F58884172" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3222-wk-Fact-ADA0671CEC94BDF82A197F5F58875ABA" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e3241-wk-Fact-DFCF5BC11C6E10EB93DC7F5F5888A111" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="D2018Q1Fiscal" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21851538e3261-wk-Fact-C5295E9FC9094045303F7F5F588CF13E" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3288-wk-Fact-A249E70389817BDAA9247F5F589500DC" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3307-wk-Fact-F5544C2495B1C4D94A0C7F5F588D496E" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21851538e3326-wk-Fact-14E6CCD1D92F8A913B2D7F5F5887571D" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not anticipate that the amount of unrecognized tax benefits existing as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> will significantly change over the next 12 months. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e3354-wk-Fact-9B0E710E587F92110B3B69DF915FCB7F" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in unrecognized tax benefits, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21851538e3358-wk-Fact-E3B8FD88A5575D55D8977F5F58E91954" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would reduce our income tax provision and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. </span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-4">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2019 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</ix:continuation> </span></div><div><a id="sD9B0E3612D4E52758C71D503610F0E9D"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-35FD2F01BEF267EBD4C77F5F59097B30-0-wk-Fact-6929CE1642C48A283D027F5F58DD7B2D" continuedAt="TextSelection-35FD2F01BEF267EBD4C77F5F59097B30-1" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="TextSelection-35FD2F01BEF267EBD4C77F5F59097B30-1" continuedAt="TextSelection-35FD2F01BEF267EBD4C77F5F59097B30-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-FB4256589003790A720C7F5F59090787-0-wk-Fact-18FA4842B4A9A832D8937F5F58E0DD89" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e825-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e844-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e863-wk-Fact-E80041C5117CF9436D1F808180B39357" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e879-wk-Fact-B2ECFB2EBB6B9E0268D27F5F58CF136F" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e898-wk-Fact-4F208D9BE9219D879E7A7F5F58CD007D" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21846478e917-wk-Fact-B53D45454B81ABC3F4CA7F5F58D0D048" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e939-wk-Fact-66D250028471C0C9E5447F5F58D13404" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e958-wk-Fact-BBE1AC9FE15C4E54033A7F5F58D1554F" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e977-wk-Fact-DB1F1519C9B6BA1382FB7F5F58D2CD34" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">153,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e998-wk-Fact-C44611D0958468DEEBA27F5F58CD36E9" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1017-wk-Fact-29286366CEFE526A49407F5F58CEFE5D" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1036-wk-Fact-D2150373D662D1E2DE3E7F5F58D03557" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1062-wk-Fact-8881CAEF75D722FB0FB87F5F58D2B3DD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1081-wk-Fact-E168B5B2CA2DE127F79E7F5F58CF383A" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1100-wk-Fact-DC7D199D097337A7A4DF7F5F58CF9D33" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">153,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1178-wk-Fact-7461894293B55C43BC5671A110CD9A60" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1197-wk-Fact-137F5557559754A18B5EA37F1C0ACE01" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">297,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1216-wk-Fact-028CF4F8A4C6E2035E538081813C15B1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2017Q4FYYTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">293,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive effect of employee stock plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1237-wk-Fact-56741C0E8BD15B50AD4C407042B8DAC6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1256-wk-Fact-0C364848F77C556193BAD5CC0B0017A1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">14,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1275-wk-Fact-293C296580625077B1356B82146EB75F" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D2017Q4FYYTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">18,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1297-wk-Fact-93632B71149D5780817A0E4932B6C1EF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315,009</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1316-wk-Fact-C80150103651525CB70CC7179CB64C23" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1335-wk-Fact-300AAABA667196BEB2DA80818183D621" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2017Q4FYYTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1361-wk-Fact-12C145AC98863A3F72ABC6FA4E0C3BE4" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1380-wk-Fact-EA9446E76D075BD783CEC9BEBC095B38" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1399-wk-Fact-84EB6CDF1C972769524580818133BECA" name="us-gaap:EarningsPerShareBasic" contextRef="D2017Q4FYYTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1420-wk-Fact-F5CBF3AE37B8593EBE8CE93947271519" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.02</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1439-wk-Fact-60A5C0148F765C9CA5BA78B57AD421FA" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1458-wk-Fact-3B2E1870498EDA767BC880818115346E" name="us-gaap:EarningsPerShareDiluted" contextRef="D2017Q4FYYTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Participating securities included warrants issued in January 2014 to purchase an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21846478e1472-wk-Fact-B680472F0F38F2D6DDB21288286C68BF" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock that were fully exercised in September 2017. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities included outstanding stock options, unvested RSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they are related to shares from PSOs and PSUs that were contingently issuable and the contingency had not been satisfied. See to &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-E27E78643ACCDA753D337F5F5909A480-0-wk-Fact-6E73BA3438EE58C126B47F5F58E0D490" continuedAt="TextSelection-E27E78643ACCDA753D337F5F5909A480-1" escape="true">These potential common shares were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="TextSelection-E27E78643ACCDA753D337F5F5909A480-1" continuedAt="TextSelection-E27E78643ACCDA753D337F5F5909A480-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></ix:continuation></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-E27E78643ACCDA753D337F5F5909A480-2"><ix:continuation id="TextSelection-35FD2F01BEF267EBD4C77F5F59097B30-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Anti-dilutive securities and contingently issuable shares excluded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1601-wk-Fact-BE641941195057939726085D94364558" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">9,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1615-wk-Fact-8EDBE0093CF659819F4C9E82653D1656" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21846478e1629-wk-Fact-900BD1579A09576B9D4CB17071F61808" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,645</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">105</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC0348C85FF4F57C49A5EB9955BCA5F7C"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-2E6ED98E8AEA2C735F107F5F590AD538-0-wk-Fact-26114C5025F2D8CD72267F5F58E23DD8" continuedAt="TextSelection-2E6ED98E8AEA2C735F107F5F590AD538-1" escape="true">COMMITMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2E6ED98E8AEA2C735F107F5F590AD538-1" continuedAt="TextSelection-2E6ED98E8AEA2C735F107F5F590AD538-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Headquarters Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019 and August 2019, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e592-wk-Fact-80E6BBC6039BE0291CEEB5FEC034CC02" name="us-gaap:AreaOfRealEstateProperty" contextRef="FI2019Q4_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">221,464</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space we have taken possession of as of December 31, 2019 (the Current Premises) under the amended Lease. We expect to take possession of the remainder of the space provided for under the August 2019 amendment on or prior to April 30, 2020, which will increase the space leased to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e596-wk-Fact-F887E34A9DD0F4FE3877B5FF1AF0DF7B" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2019Q3Aug30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">228,941</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The term of the Lease continues through October 31, 2031 (the Lease Term). We have </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e603-wk-Fact-83C129FA21BA511D815D00F66CE1E6AA" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" contextRef="FD2019Q4YTD_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember" unitRef="renewal_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have made certain tenant improvements on the Initial Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e610-wk-Fact-7001F633C4DA516C873EFE8FBA35295D" name="exel:TenantLeaseImprovementsAllowance" contextRef="I2019Q1_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. We were also provided an allowance of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e614-wk-Fact-48B94D0D2EC2552594FDE0032C8C7F86" name="exel:TenantLeaseImprovementsAllowance" contextRef="I2019Q2Apr30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the space we obtained under the April 2019 amendment which is expected to be received in 2020. </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="exel:AssetsAndLiabilitiesLesseeTableTextBlock" id="TextSelection-81B52285015ADDA628DF163D1A696AB9-0-wk-Fact-C826CEBE2EEBEDB726EC163D24C1CA89" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets included in other long-term assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e773-wk-Fact-6390399346ACBD72AE8D16341E1DA505" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e792-wk-Fact-DA13EBCD514B898816DC16341E1D2947" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e853-wk-Fact-2380053AE14C5DEC7CE01635AA15597B" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e872-wk-Fact-4BE4B7DA059B5367B8F6418F6BB9FD10" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e887-wk-Fact-465D3B14C4885FD68234A459F458B06C" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e906-wk-Fact-815F08E795B7532996AD93F122DA0FED" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e931-wk-Fact-1FE21175AF695E49A9041FADE714E438" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e950-wk-Fact-6988D7ACDCF55C3F8C9BA63256DC63AE" name="us-gaap:OperatingLeaseLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-8EE938BE8D9E5D7A13FE163D56DCEB0D-0-wk-Fact-B79A65E3E6A16930EA8A163D613D7F4C" continuedAt="TextSelection-8EE938BE8D9E5D7A13FE163D56DCEB0D-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017 </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1122-wk-Fact-F027B501B67A55BD896C1BA28A3B9A3E" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,844</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1141-wk-Fact-55769EECDF9655EBB1E3CE97D442F181" name="us-gaap:OperatingLeaseCost" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1160-wk-Fact-E6AAAF0E3F2EAAF2C0C41636B0435DCD" name="us-gaap:LeaseAndRentalExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1176-wk-Fact-036EE7163C5B5F0197A7496F857ED6B4" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1195-wk-Fact-91B574E245125033A83AB2A237E61708" name="us-gaap:VariableLeaseCost" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,661</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1214-wk-Fact-1BF176E64CAE5F8089C0E3510B81394D" name="exel:OperatingLeasesVariableLeaseExpense" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1235-wk-Fact-084EAD785B1A57A1A1732219DF65ED6D" name="us-gaap:SubleaseIncome" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1254-wk-Fact-8A5ED058A51C5C17BD84EC5B803A9E7F" name="us-gaap:SubleaseIncome" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21854044e1273-wk-Fact-56055C31BCA20EE9B0901636C5A2606D" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1300-wk-Fact-49BEDE3C5DD65250AEE7FDFCBF20C722" name="us-gaap:LeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1319-wk-Fact-499FFECFD8EF5BF2A1752D8EF3CC4AFD" name="us-gaap:LeaseCost" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1338-wk-Fact-CB89EE2700B75EF892235D634D72F572" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="D2017Q4FYYTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-8EE938BE8D9E5D7A13FE163D56DCEB0D-1" continuedAt="TextSelection-8EE938BE8D9E5D7A13FE163D56DCEB0D-2"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-8EE938BE8D9E5D7A13FE163D56DCEB0D-2"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The 2017 amounts have not been adjusted for the adoption of Topic 842 and continue to be reported in accordance with the previous lease guidance, ASC Topic 840: </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;">Leases</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">. </span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e1372-wk-Fact-3FB658FC0818543A8DBA614A01D66133" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">106</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><ix:continuation id="TextSelection-2E6ED98E8AEA2C735F107F5F590AD538-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-19C091CF8000E5E21CF8163D9373AF18-0-wk-Fact-65D1393F819E4AE90713163DA0988D7F" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ending December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1442-wk-Fact-AAA0106978B25A8782AE02D86F724D5E" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1462-wk-Fact-BE0AB2C43D9D5DD39D0FC75D9067E77A" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1487-wk-Fact-2F1A87F863DA516A9DE295E06B239B00" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1512-wk-Fact-4AC69BE8B9A65734A01164E09AE9BBB0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1537-wk-Fact-2E8E5170D0F85F6AABA6CC73950CFD6B" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1562-wk-Fact-E4AB2A256D9C5FAFAE7B99ED644416C0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1587-wk-Fact-9E01761AF144517BA1514481AC8FA661" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21854044e1638-wk-Fact-24C1BEEC6309590B876C45D475D802C8" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Future tenant improvement reimbursements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d21854044e1664-wk-Fact-3CD05B8CC19D586EA5D7B5465DFC1509" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21854044e1696-wk-Fact-1FE21175AF695E49A9041FADE714E438" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e1711-wk-Fact-7B3D28687B185F369022AA1CAA7168AD" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.9</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21854044e1715-wk-Fact-0919A0B178C7563CB91F4973FE652D5C" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">11.8</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Build-to-Suit Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e1725-wk-Fact-A4A1858A0DEE54A8B22B0DB7532976B7" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">220,000</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The term of the Build-to-Suit Lease is for a period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21854044e1732-wk-Fact-F8C1620F42135C9A861AD36EF86B35A6" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" format="ixt-sec:durmonth">242</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in October 2021 (the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e1736-wk-Fact-646420BBFC785902A8FAF2AEFBB95E6F" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to an annual increase of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e1740-wk-Fact-47165FCA74975506BCCB575AF8D5AD73" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21854044e1744-wk-Fact-61A9FF9AAC108EF6674B704F1A01663F" name="exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" format="ixt-sec:durwordsen">sixty days</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e1748-wk-Fact-D760A17576B2D7E5DD04A1D8E4E9A04D" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To the extent that the total development costs of the New Premises exceeds </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e1753-wk-Fact-45C519828AC1187D86D4164128BD8E47" name="exel:AreaOfRealEstatePropertyAvailableToLease" contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="USD_PER_sqft" decimals="INF" scale="0" format="ixt:numdotdecimal">525</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per square foot, we will also pay </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e1757-wk-Fact-CC82B77305D5615F8FED6FF86B31F849" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such excess costs prior to the commencement of the Term, and may be required to secure such amount and the cost of the tenant improvements in excess of the allowance by providing a letter of credit or depositing such amounts in an account with the lessor&#8217;s lender prior to the start of construction.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Build-to-Suit Lease includes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e1764-wk-Fact-339B9E2FFC15ED2CB4B0A1D56E95DDCE" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" unitRef="renewal_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d21854044e1768-wk-Fact-8E0F0E4AF2046DA652FEA1D5C4C10693" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember" format="ixt-sec:durmonth">180</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that, under the guidance provided in Topic 842, we do not have control of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">New Premises</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the construction period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Therefore, we will not record a right-of-use asset or lease liability for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Build-to-Suit Lease</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> until the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lease Commencement Date</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will evaluate the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">classification the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Letters of Credit</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e1860-wk-Fact-BFDDA8BC10EA85232427A1C6E2C93C7E" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d21854044e1864-wk-Fact-35F140FA4205D4641081A1C74C6476C9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d21854044e1876-wk-Fact-DABDCE6FDB030971470C7F5F58E8DBCB" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">None</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">107</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9CB2964B2A895B90B94BA964D26ABBB0"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-0-wk-Fact-046940B155AF1E740D747F5F58B53506" continuedAt="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-1" escape="true">QUARTERLY FINANCIAL DATA (UNAUDITED)</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="TextSelection-3135D368B7F3DD3680017F5F590A7FC3-0-wk-Fact-FA2427EFF2941B7B474C7F5F58B17F3B" escape="true"><ix:continuation id="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-1" continuedAt="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selected unaudited quarterly financial data was as follows (in thousands, except per share data):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal 2019 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">March&#160;31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e804-wk-Fact-C1E07B137388B9909C841652616595C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e823-wk-Fact-C2EFD4E6A78C3C4CEC5A7F5F588B1AC6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e842-wk-Fact-824CAC38F5DE2DC211EF7F5F589278E3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e862-wk-Fact-7967A8D5F17E5B17A2BA58633F788DD1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e884-wk-Fact-74018E785E58E84E188716525FEB5A39" name="us-gaap:GrossProfit" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e903-wk-Fact-C9C3E783C9B463C654C7165261390F92" name="us-gaap:GrossProfit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e922-wk-Fact-24A4DF6F7F7DA71223F8165261498C06" name="us-gaap:GrossProfit" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">184,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e942-wk-Fact-C32991CDC468E2BACB827F5F5886972D" name="us-gaap:GrossProfit" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">184,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e962-wk-Fact-C6F7372A9DD53E8F93BD1652613ED21F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e981-wk-Fact-E9722914CF69437CCFB07F5F5889248B" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1000-wk-Fact-DFC1999710D194C909BB7F5F58811093" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1020-wk-Fact-72D92CAA9A005123AF2072EE139444BA" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1040-wk-Fact-55593AD00B926DBF4848165261609C67" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">75,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1059-wk-Fact-BAFCD1021CC296BB43F57F5F58E4146D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1078-wk-Fact-2EAF231F62414193B3FD7F5F58E45197" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1098-wk-Fact-57E5FD7BF1505D4DBB0E410715DDE846" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1200-wk-Fact-730F9524DFC32083782D1652614E9C3F" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1219-wk-Fact-5068BC14018D8D0640997F5F5889F6F2" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1238-wk-Fact-B7413851170E9CE475957F5F58871685" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1258-wk-Fact-6D81F080457554B896D74D3E7A58F612" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1278-wk-Fact-270C35857391E0A3218816526122E231" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1297-wk-Fact-5E76DAAA147F38D45FD07F5F58E37835" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1316-wk-Fact-3D96054223FB28EA02A27F5F588ACEAD" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1336-wk-Fact-3EC10EA658C95F6E9DC7CE3C5302D172" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal 2018 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">March&#160;31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1554-wk-Fact-E16071141CD1766C20441652E71665BC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">213,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1573-wk-Fact-D8B2C133E615591E43F51652E8B80C17" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1592-wk-Fact-15ECBB824AC2020229B21652EA59724F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1612-wk-Fact-B120D46DCFB2B5584DA91652EBFDD4A8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">228,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1634-wk-Fact-4BFC2173FE8CD023E4DE1652ECF50B46" name="us-gaap:GrossProfit" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1653-wk-Fact-1D4867DCB0B0505CABDC1652EE96A029" name="us-gaap:GrossProfit" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1672-wk-Fact-783462EC6E31CEEAFB801652F036F937" name="us-gaap:GrossProfit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">155,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1692-wk-Fact-186E92B36848EE059A411652F1D873F1" name="us-gaap:GrossProfit" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">168,873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1712-wk-Fact-9229323C1999DE600D621652F2D1CD8F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">116,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1731-wk-Fact-1878E4101F4E4BE733F61652F47272C7" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1750-wk-Fact-B0A5B209F67050BD84751652F6139CD4" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1770-wk-Fact-35BDDE76E6FD6A4834641652F7B934E1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1792-wk-Fact-C3B74ACC2FAB0204CEEC1652F8EA30FA" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1811-wk-Fact-2A61712E2A00F8894F561652FA53B7EB" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1830-wk-Fact-FA8147605AF0415A359D1652FBEE5B9B" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1850-wk-Fact-DCD66E9A9071C72C66E71652FD8E858F" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">360,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1952-wk-Fact-462087F7B43982A5E9341653031AB314" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1971-wk-Fact-033B89D9FAA9EAF0F18716530533511B" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e1990-wk-Fact-38BEFA9EE3DFE5CE1FEA165306CE73BB" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e2010-wk-Fact-C2D7090D979BA66883381653087840B5" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e2030-wk-Fact-F30AC20834EDAA7A81C516530A2F8D64" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e2049-wk-Fact-4EAFB3B738D34D43872616530C09DE7B" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e2068-wk-Fact-E3B1401792EF5878CCCD16530DAAD2D0" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d21852399e2088-wk-Fact-C58C147223B79517F7C916530F4AB788" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Total revenues for the quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 included </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2108-wk-Fact-E30F5DA4F241F43044A516564D753F71" name="exel:MilestonePaymentsEarned" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2112-wk-Fact-29829017F12F3C280B8B16564C47694C" name="exel:MilestonePaymentsEarned" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2116-wk-Fact-69325998A593E7EBE07516564F635159" name="exel:MilestonePaymentsEarned" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2120-wk-Fact-588B28C8571EEEA7244116564C6596F9" name="exel:MilestonePaymentsEarned" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> in milestone revenue, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2124-wk-Fact-808839D2F9C47C5C9A5A16564F99B246" name="exel:MilestonePaymentsEarned" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2129-wk-Fact-D37730A0CF00FDBC508B16564F7B4189" name="exel:MilestonePaymentsEarned" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2133-wk-Fact-0C898E65A138C88ED44A16564F3E60ED" name="exel:MilestonePaymentsEarned" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2137-wk-Fact-2FFB07E841B99436B82016564CC4AADB" name="exel:MilestonePaymentsEarned" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> during the comparable periods in 2018. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as net product revenues less cost of goods sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Net income for the quarter ended December 31, 2018 included a </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$<ix:nonFraction id="d21852399e2155-wk-Fact-761F7CECD2611B26E9221658659CAA99" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets.</span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-2" continuedAt="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-3"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><ix:continuation id="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-3">The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.</ix:continuation> </span></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">108</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA41E8B4C5C2E50448F3A9AB9C85E1DC8"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s26B22B0521AB572D8679D12318C8B17C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9A. Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the Effectiveness of Controls.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S.&#160;generally accepted accounting principles.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of the end of our 2019 fiscal year, management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework established in the original </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Internal Control&#160;&#8211; Integrated Framework</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on this assessment, management has determined that our internal control over financial reporting as of January 3, 2020 was effective. There were no material weaknesses in internal control over financial reporting identified by management.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The independent registered public accounting firm Ernst&#160;&amp; Young LLP has issued an audit report on our internal control over financial reporting, which is included on the following page.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in Internal Control Over Financial Reporting.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">109</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Opinion on Internal Control Over Financial Reporting </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We have audited Exelixis, Inc.&#8217;s internal control over financial reporting as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">January 3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Exelixis, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">January 3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, based on the COSO criteria.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">January 3, 2020 and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 28, 2018 and, the related consolidated statements of income, comprehensive income, stockholders&#8216; equity and cash flows for each of the three fiscal years in the period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">January 3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, and the related notes and our report dated </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</span></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110</span></div></div><hr style="page-break-after:always"></hr><div><a id="s57A887B8024B5C17A96344A5BD991423"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9B. Other Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable</span></div><div><a id="s82D46CABF09B5926BFBCE1FE1C860E10"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART III</span></div><div><a id="s80FFD497F2D85865AB2F4C0F88CE5554"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 10.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our board of directors, is incorporated by reference to the section entitled &#8220;Proposal&#160;1&#160;&#8211; Election of Directors&#8221; appearing in our Proxy Statement for our 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we refer to as our 2020 Proxy Statement. The information required by this item regarding our executive officers is incorporated by reference to the section entitled &#8220;Information about our Executive Officers&#8221; appearing in our 2020 Proxy Statement. The information required by this item regarding compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the section entitled &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; appearing in our 2020 Proxy Statement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Code of Ethics</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Corporate Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. The Corporate Code of Conduct is posted on our website at www.exelixis.com under the caption &#8220;Investors &amp; Media&#8212;Corporate Governance&#8212;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Corporate Governance Documents</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span></div><div><a id="s34EC3EA7F54852A3A20A380592688726"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 11. Executive Compensation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the sections entitled &#8220;Compensation of Executive Officers,&#8221; &#8220;Compensation of Directors,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; appearing in our 2020 Proxy Statement.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">111</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0D686A2674325BEE918EDD6CBB721CBA"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item relating to security ownership of certain beneficial owners and management is incorporated by reference to the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in our 2020 Proxy Statement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Compensation Plan Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which consists of our 2000 Non-Employee Directors&#8217; Stock Option Plan (the Director Plan), our 2000 Employee Stock Purchase Plan (the ESPP), our 2011 Equity Incentive Plan (the 2011 Plan), our 2014 Equity Incentive Plan (the 2014 Plan), our 2016 Inducement Award Plan (the 2016 Plan) and our 2017 Equity Incentive Plan (the 2017 Plan):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Plan Category</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of&#160;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">securities to&#160;be issued upon exercise of outstanding&#160;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">options, warrants and rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted-average exercise&#160;price of outstanding&#160;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">options, warrants&#160;and&#160;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(c)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Equity compensation plans approved by stockholders</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,030,468</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6.86</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup>&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,497,315</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Equity compensation plans not approved by stockholders</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">213,014</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15.76</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup>&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,243,482</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6.93</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,497,315</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1 )</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Equity plans approved by our shareholders include the Director Plan, the 2011 Plan, the 2014 Plan, the 2017 Plan and the ESPP. As of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, a total of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">4,238,999</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 465,480 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding or and the weighted-average exercise&#160;price of such rights as of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, as those numbers are not known.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The weighted-average exercise price takes into account the shares subject to outstanding restricted stock units, including such awards with performance conditions (RSUs) which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $9.83.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents shares of our common stock issuable pursuant to the 2016 Plan. As of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, no shares of our common stock remained available for additional grants under the 2016 Plan. In November 2016, the Board adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 - that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Exelixis. An &#8220;Award&#8221; is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs, or any other stock award.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The weighted-average exercise price takes into account the shares subject to outstanding RSUs, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $19.41.</span></div></td></tr></table><div><a id="sA72B55362B8B5BE0A2ECF505489EFBED"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 &#8211; Election of Directors&#8221; appearing in our 2020 Proxy Statement.</span></div><div><a id="s22680314FC065C869068EEF38728EA37"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 14. Principal Accounting Fees and Services</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the section entitled &#8220;Proposal 2&#160;&#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; appearing in our 2020 Proxy Statement. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">112</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5C16DEA372FE579991D4BD78F836B0FD"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART IV</span></div><div><a id="sCF69B1826B725C41B7DC9565A4010D92"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 15. Exhibits, Financial Statement Schedules</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following documents are being filed as part of this report:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following financial statements and the Report of Independent Registered Public Accounting Firm are included in Part II, Item&#160;8:</span></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:72px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:84%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Page</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s531793F3053C594EB5A5DEF796CC0E1E"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s531793F3053C594EB5A5DEF796CC0E1E">73</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB16A297818515472AE6667263DEC7976"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB16A297818515472AE6667263DEC7976">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC1F425A4AAA7565086B2D5F2C8590B0E"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Income</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC1F425A4AAA7565086B2D5F2C8590B0E">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAE448B9BA1A955C8BD2C35D2C241D53C"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAE448B9BA1A955C8BD2C35D2C241D53C">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4A5A110BDFF8576EA8EF936120CA8669"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4A5A110BDFF8576EA8EF936120CA8669">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDFA0950FB8475D209E4B2B00EC3E212D"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDFA0950FB8475D209E4B2B00EC3E212D">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDB1B98EDF2245BB3B622C69BDE1902DF"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDB1B98EDF2245BB3B622C69BDE1902DF">79</a></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">All financial statement schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated Financial Statements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following Exhibits are filed as part of this report.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/25/2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/23/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000024/exhibit31amendedandres.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/20/2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specimen Common Stock Certificate.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">S-1,</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">as amended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">333-96335</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4/7/2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit42.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001409/0001012870-00-001409.txt"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Indemnity Agreement</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">S-1,<br/>as amended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">333-96335</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3/17/2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000009/exel20131231exhibit106.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/20/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">113</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511042330/dex107.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2011</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000170/def14a-20160413xproxy.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Employee Stock Purchase Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Schedule 14A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4/13/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000042/exel20181231exhibit108.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2011 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511210303/dex103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2011 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8/4/2011</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.7</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000042/exel20181231exhibit1010.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2014 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.10</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.8</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.9</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit104.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.10</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit105.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.11</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000042/exel20141014exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/16/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.12</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000042/exel20181231exhibit1015.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2016 Inducement Award Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.15</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.13</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the 2016 Inducement Award Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.14</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the 2016 Inducement Award Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1020.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.16</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit105.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.17</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1022.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.18</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit106.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.19</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1024.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.20</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-Employee Director Equity Compensation Policy</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.21</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904022709/a04-8650_1ex10d43.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated February 3, 2000, between Exelixis, Inc. and Michael Morrissey, Ph.D.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.43</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8/5/2004</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.22</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976715000102/exel20150930exhibit105.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated June 30, 2015, between Exelixis, Inc. and Christopher Senner</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/10/2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">114</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.23</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312506135893/dex101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated June&#160;20, 2006, between Exelixis, Inc. and Gisela M. Schwab,&#160;M.D.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6/26/2006</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000018/exel20140331exhibit104.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated February 10, 2014, between Exelixis, Inc. and Jeffrey J. Hessekiel.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.25</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000149/exel20151231exhibit1024.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated August 11, 2000, between Exelixis, Inc. and Peter Lamb.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/29/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.26</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1026.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated August 19, 2010, between Exelixis, Inc. and Patrick J. Haley</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.26</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.27</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510248047/dex101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Resignation Agreement dated July&#160;22, 2010, by and between Exelixis, Inc. and George A. Scangos</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/4/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.28</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/exel20180212exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Annual Cash Bonus Compensation Plan for Executives</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/16/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.29</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit1029.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash Compensation Information for Non-Employee Directors.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.30</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000069/exel20180331exhibit105.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/2/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit104.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Policy for Recoupment of Variable Compensation</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.32</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8/2/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.33</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1039.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated October 16, 2017, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.39</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.34</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated June 13, 2018, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8/1/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.35</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000090/exel20190401exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment dated April 1, 2019, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4/5/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.36</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Fourth Amendment dated August 30, 2019, to Lease Agreement dated May 2, 2017, between Hillwood Enterprises, L.P. (as successor in interest to Ascentris 105, LLC) and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.37</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit1037.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Fifth Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Waterfront EDP, LLC (as successor in interest to Hillwood Enterprises, L.P.) and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.38</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease Agreement dated October 25, 2019, between Ernst Development Partners, Inc. and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">115</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.39</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit1039.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Alameda BTS EDP, LLC (as successor in interest to Ernst Development Partners, Inc.) and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.40*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1045.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.45</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.41</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1046.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #1 dated April 16, 2013, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.46</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1047.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #2 dated July 18, 2016, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.47</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.43*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000042/exel20181231exhibit1040.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.44*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit103-ame.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9/30/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.45*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1049.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.49</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.46*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000183/exel20170930exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.47*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1046.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.46</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.48*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit104-ame.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9/30/2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.49*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1048.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.48</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.50**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.51*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000126/exel2017033110-qaexhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7/14/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.52*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8/1/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.53**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated May 17, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.54*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000069/exel20170331exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.55**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment No. 1 dated March 18, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.56**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment No. 2 dated August 15, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/30/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.57</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit1057.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment No. 3 dated November 22, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">117</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.58*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000069/exel20170331exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.59*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000218/exel20180930exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated July 6, 2018, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.60*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000218/exel20180930exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplement dated July 6, 2018, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Takeda Pharmaceutical Company Limited</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.61*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000218/exel20180930exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ono Territorial Supplemental Agreement dated July 6, 2018, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Ono Pharmaceutical Co., Ltd. and Bristol-Meyers Squibb Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.62**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit1062.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Joint Clinical Research Agreement dated December 18, 2019, by and between Exelixis, Inc. and F. Hoffmann-La Roche Ltd</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.63**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit1063.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplement dated December 18, 2019, to the Joint Clinical Research Agreement dated December 18, 2019, by and among Exelixis, Inc., F. Hoffmann-La Roche Ltd and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit211.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Subsidiaries of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit231.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consent of Independent Registered Public Accounting Firm</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">24.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD36375C21DEA5EECA0257D49077E197F"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Power of Attorney (contained on signature page)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit311.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit312.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">32.1&#8225;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit321.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">118</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Instance Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cover Page Interactive Data File</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Formatted as Inline XBRL and contained in Exhibit 101.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></span><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Management contract or compensatory plan.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Confidential treatment granted for certain portions of this exhibit.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8225;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">This certification accompanies this Annual Report on Form 10-K, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</span></div></td></tr></table></div></div><div><a id="s5E1E09DE6DA658BFA7AF47A662EFBB17"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;None provided.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">119</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD36375C21DEA5EECA0257D49077E197F"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">E</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, I</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">NC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">POWER OF ATTORNEY</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, that each person whose signature appears below constitutes and appoints </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MICHAEL M. MORRISSEY</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">CHRISTOPHER J. SENNER </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> JEFFREY J. HESSEKIEL </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Signatures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director, President and</span></div><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Chief&#160;Executive&#160;Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Executive&#160;Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and</span></div><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Chief&#160;Financial&#160;Officer </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Financial and</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accounting&#160;Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;S</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">TELIOS</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;P</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">APADOPOULOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Chairman of the Board</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Stelios Papadopoulos, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">HARLES</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">OHEN&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Charles Cohen, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ARL</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;B. F</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ELDBAUM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Carl B. Feldbaum, Esq.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ARIA</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;C. F</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">REIRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Maria C. Freire, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">120</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s87685C8EE92A570B9E53D6B24B688B3E"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Signatures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;A</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">LAN</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. G</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ARBER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Alan M. Garber, M.D., Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;V</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">INCENT</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;T. M</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ARCHESI&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Vincent T. Marchesi, M.D., Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;G</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">EORGE</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;P</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">OSTE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">George Poste, DVM, Ph.D., FRS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;G</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">EORGE</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;A. S</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">CANGOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">George A. Scangos, Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ULIE</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;A. S</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">MITH&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Julie A. Smith</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;L</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ANCE</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;W</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ILLSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Lance Willsey, M.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ACK</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;L. W</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">YSZOMIERSKI&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Jack L. Wyszomierski</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">121</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exel20191231exhibit42.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s01A8BC72B259E3BE7A2A6A07EB2A4EB3"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:32px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 4.2</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">DESCRIPTION OF THE COMMON STOCK OF EXELIXIS, INC.  <br>REGISTERED PURSUANT TO SECTION 12 OF THE <br>SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Description of Capital Stock</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The authorized capital stock of Exelixis, Inc. (Exelixis, we, our or us) consists of 400,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of preferred stock, $0.001 par value. A description of material terms and provisions of the common stock, and our amended and restated certificate of incorporation, as amended (certificate incorporation) and amended and restated bylaws (bylaws) affecting the rights of holders of our common stock is set forth below. The description is intended as a summary and is qualified in its entirety by reference to our certificate of incorporation and bylaws. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common stock </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Dividend rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Voting rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Our certificate of incorporation does not provide for the right of stockholders to cumulate votes for the election of directors. Our certificate of incorporation provides that all directors are elected at each annual meeting of our stockholders for one-year terms. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">No preemptive or similar rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of our preferred stock that we may designate and issue in the future. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Right to receive liquidation distributions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to holders of our common stock are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of our preferred stock. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any preferred stock that we may designate and issue in the future. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover effects of provisions of our certificate of incorporation and bylaws and Delaware law</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Certificate of incorporation and bylaws. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The holders of our common stock do not have cumulative voting rights in the election of directors. Because holders of our common stock do not have cumulative voting rights, stockholders holding a majority of the shares of common stock outstanding are able to elect all of the directors to be elected at each annual meeting of our stockholders. Our board of directors is able to elect a director to fill a vacancy created by the expansion of the board of directors or due to the resignation or departure of an existing board member. Our certificate of incorporation and bylaws also provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by a consent in writing, and our bylaws require the consent of stockholders holding at least 25% of our outstanding common stock in order for stockholders to call a special meeting of stockholders; otherwise, only the chairman of the board of directors, the president or the board of directors (pursuant to a resolution adopted by a majority of the total number of authorized directors) may call a special meeting of stockholders. In addition, our bylaws include a requirement for the advance notice of nominations for election to the board of directors or for proposing matters that can be acted upon at a stockholders&#8217; meeting. Our certificate of incorporation provides for the ability of the board of directors to issue, without stockholder approval, up to 10,000,000 shares of preferred stock with terms set by the board of directors, which rights could </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">be senior to those of our common stock. Our certificate of incorporation and bylaws also provides that approval of at least 66 2/3% of the shares entitled to vote at an election of directors will be required to adopt, amend or repeal our bylaws, or repeal the provisions of our certificate of incorporation regarding the election of directors and the inability of stockholders to take action by written consent in lieu of a meeting. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The foregoing provisions make it difficult for holders of our common stock to replace our board of directors. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Section 203 of the Delaware General Corporation Law </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. This section prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporation&#8217;s assets with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporation&#8217;s outstanding voting stock, unless:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Calibri,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:3%;"></td><td style="width:3%;"></td><td style="width:2%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the transaction is approved by the board of directors prior to the time that the interested stockholder became an interested stockholder;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">upon consummation of the transaction which resulted in the stockholder&#8217;s becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">at or subsequent to such time that the stockholder became an interested stockholder the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate or incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. We have not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Forum Selection Bylaw</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:22px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of Exelixis, (2) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of Exelixis to Exelixis or to our stockholders, (3) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, the certificate of incorporation or the bylaws or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of Exelixis is deemed to have notice of and consented to the forum selection provisions of the bylaws. This provision does not apply to actions arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or any claim for which the federal courts have exclusive jurisdiction.</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>3
<FILENAME>exel20191231exhibit1029.htm
<DESCRIPTION>EXHIBIT 10.29
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s87FBD713B46B5C0AA3A2B5705C07790A"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.29</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cash Compensation for Non-Employee Directors </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:55%;"></td><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$31,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">12</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Audit Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$12,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$13,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">13</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Compensation Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">13</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Nominating&#160;and Corporate Governance Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Research&#160;&amp; Development Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Risk Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  1</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meetings for which minutes are generated count toward the meeting threshold to determine when Meeting Fees are to be paid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  2</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of eight meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  3</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of seven meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  4</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of four meetings.</font></div></td></tr></table><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>4
<FILENAME>exel20191231exhibit1037.htm
<DESCRIPTION>EXHIBIT 10.37
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAF831CE104CC10FCC9F16A17D9BF39F9"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.37</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIFTH AMENDMENT TO LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">THIS FIFTH AMENDMENT TO LEASE AGREEMENT (this &#8220;Amendment&#8221;) is made and entered into on January 16, 2020 (the "Execution Date") by and between ALAMEDA WATERFRONT EDP, LLC, a California limited liability company (&#8220;Landlord&#8221;), and EXELIXIS, INC., a Delaware corporation (&#8220;Tenant&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A.&#160;&#160;&#160;&#160;Ascentris 105, LLC, a Colorado limited liability company (&#8220;Ascentris&#8221;), and Tenant entered into that certain Lease Agreement dated May&#160;2, 2017, as amended by that certain First Amendment to Lease Agreement dated October&#160;16, 2017, that certain Second Amendment to Lease Agreement dated June&#160;13, 2018, and that certain Third Amendment to Lease Agreement dated April 1, 2019 (the &#8220;Third Amendment&#8221;, and that lease, as amended through and including the Third Amendment, the &#8220;Original Lease&#8221;) with respect to premises in the multiple building project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California. Hillwood Enterprises, L.P. (&#8220;Hillwood&#8221;), a Texas limited partnership, and Tenant entered into that certain Fourth Amendment to Lease Agreement dated August 30, 2019 (the &#8220;Fourth Amendment&#8221;), which amended the Original Lease effective upon the Closing (as defined in the Fourth Amendment). Upon the Closing, Ascentris assigned the Original Lease to Landlord pursuant to an Assignment and Assumption of Leases dated as of October 31, 2019 and Hillwood assigned the Fourth Amendment to Landlord pursuant to an Assignment and Assumption of Fourth Amendment to Lease Agreement dated October 31, 2019. The Original Lease (as assigned to Landlord), as amended by the Fourth Amendment (as assigned to Landlord), is referred to herein as the &#8220;Lease&#8221;. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B.&#160;&#160;&#160;&#160;Landlord and Tenant desire to amend Tenant&#8217;s parking allocation on the terms and conditions of this Amendment. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">NOW THEREFORE, in consideration of good and valuable consideration and the mutual agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties do hereby agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Defined Terms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All capitalized terms used but not defined in this Amendment will have the meanings set forth for such terms in the Lease.  All terms that are defined in this Amendment and used in any provisions that are added to the Lease pursuant to this Amendment will have the meanings in the Lease set forth for such terms in this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Parking Allocation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 10 of the Third Amendment is hereby deleted. Section 10 of the Fourth Amendment is replaced in its entirety with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parking; Signage</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 19 of the Lease is hereby amended so that Tenant may utilize up to 396 unassigned parking spaces within the Project at no charge. Effective as of the 1601 Space Commencement Date, Section 19 of the Lease is hereby amended so that Tenant may utilize up to 509 unassigned parking spaces within the Project at no charge.  Effective as of the &#8220;Start Date&#8221; for Suite 100 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 12 additional unassigned parking spaces within the Project at no charge. Effective as of the &#8220;Start Date&#8221; for Suite 125 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 7 additional unassigned parking spaces within the Project at no charge. Effective as of the &#8220;Start Date&#8221; for Suite 150 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 3 additional unassigned parking spaces within the Project at no charge. Effective as of the &#8220;Start Date&#8221; for Suites 115 and 200 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 156 additional unassigned parking spaces within the Project at no charge. Accordingly, following the &#8220;Start Dates&#8221; for all 1701 Space and 1601 Space, Tenant may utilize up to 687 unassigned parking spaces within the Project at no charge. Notwithstanding anything in the Lease to the contrary, including but not limited to Section 1.3(g) of the Lease, Landlord may enter parking agreements with an affiliate of Landlord that owns property adjacent to the east of the Project commonly known as 1951 Harbor Bay Parkway, Alameda, California (the &#8220;BTS Site&#8221;) to permit a parking allocation for the buildings at the Project (other than the building located at 1750 North Loop Road) and the BTS Site of three (3) spaces per 1,000 square feet of building area (the &#8220;Targeted Parking Allocation&#8221;).  Notwithstanding the foregoing and anything to the contrary contained herein, the parking allocation for the building located at 1750 North Loop Road shall be two (2) </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">spaces per 1,000 square feet of building area. Section&#160;21.3 of the Lease is hereby amended so that Tenant may install exterior signs on the 1601 Building and, effective as of the first &#8220;Start Date&#8221; for the 1701 Space, the 1701 Building in accordance with the terms of Section 21.3 of the Lease. Such signage shall be substantially similar to the signage at the 1801 Building and the 1851 Building.&#8221;   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Landlord Obligations Regarding Parking</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant acknowledge that (i) because a prior landlord of the Project allocated parking spaces at the Project in excess of the Targeted Parking Allocation to certain existing tenants of the Project (the &#8220;Excess Parking Tenants&#8221;), the parking allocations for Tenant set forth in Section 10 of the Fourth Amendment (as amended by Section 2 of this Amendment) are not in accordance with the Targeted Parking Allocation and (ii) the number of parking spaces that have been allocated to Excess Parking Tenants in excess of the Targeted Parking Allocation is approximately 103 parking spaces.  Landlord agrees that (a) in connection with a lease extension for a lease with an Excess Parking Tenant pursuant to an Excess Parking Tenant&#8217;s right to extend under such lease, Landlord shall request that such Excess Parking Tenant amend any such lease so that such Excess Parking Tenant is allocated parking at the Project and BTS Site in accordance with the Targeted Parking Allocation, (b) in connection with any other lease extension for a lease with an Excess Parking Tenant or an expansion or contraction of the premises leased to an Excess Parking Tenant, Landlord shall amend any such leases so that such Excess Parking Tenant is allocated parking at the Project and BTS Site in accordance with the Targeted Parking Allocation, and (c) in connection with any other amendments to leases with Excess Parking Tenants, Landlord shall use commercially reasonable efforts to amend any such leases so that such Excess Parking Tenant is allocated parking at the Project and BTS Site in accordance with the Targeted Parking Allocation. Additionally, Landlord shall ensure that new leases for space at the Project reflect a parking allocation in accordance with the Targeted Parking Allocation. In each instance where Landlord reduces the parking allocated to an Excess Parking Tenant resulting in the Excess Parking Tenant&#8217;s parking allocation being in accordance with the Targeted Parking Allocation, or a lease with an Excess Parking Tenant terminates, such excess parking spaces shall be automatically added to Tenant&#8217;s parking rights under the Lease, and Landlord and Tenant shall amend the Lease to reflect an equivalent increase in Tenant&#8217;s allocated parking at the Project, until Tenant&#8217;s allocated parking at the Project is in accordance with the Targeted Parking Allocation. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;1601 Building Parking Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In connection with any agreement between Landlord and Tenant to demolish and reconstruct the 1601 Building, Landlord agrees to reasonably cooperate with Tenant to devise a parking plan for the 1601 Building, acceptable to Landlord in its reasonable discretion and the City of Alameda, that eliminates the need for the additional parking stackers at the BTS Site that are currently required to satisfy the City-approved parking plan at the BTS Site (the approved parking plan requires an estimated 12 parking stackers). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Brokers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant represent and warrant that no broker or agent negotiated or was instrumental in negotiating or consummating this Amendment.  Neither party knows of any real estate broker or agent who is or might be entitled to a commission or compensation in connection with this Amendment.  Tenant will indemnify and hold Landlord harmless from all damages paid or incurred by Landlord resulting from any claims asserted against Landlord by brokers or agents claiming through Tenant. Landlord will indemnify and hold Tenant harmless from all damages paid or incurred by Tenant resulting from any claims asserted against Tenant by brokers or agents claiming through Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Whole Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements with respect thereto.  Except as amended herein, or in a future writing signed by both parties, there shall be no other changes or modifications to the Lease between the parties and the Lease and the terms and provision contained therein shall remain in full force and effect. The terms of this Amendment will control over any conflicts between it and the terms of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Successors and Assigns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment shall be binding upon the parties hereto, their heirs, successors and assigns.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Ratification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as amended by this Amendment, the Lease has not been amended, and the parties ratify and confirm the Lease, as amended by this Amendment, as being in full force and effect.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Counterparts; Execution by Telecopy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment may be executed in counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one agreement.  Executed copies hereof may be delivered by telecopier or other electronic means, and upon receipt will be deemed originals and binding upon the parties hereto, regardless of whether originals are delivered thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signatures appear on next page]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;text-indent:336px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s41FE9CF86E85C5688CDB6A17D9DFCD2D"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Execution Date.</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LANDLORD:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ALAMEDA WATERFRONT EDP, LLC, <br>a Delaware limited liability company</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: Alameda Waterfront &amp; BTS EDP, LLC,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;a Delaware limited liability company,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;its sole member</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;By:  Waterfront &#8211; EXEL BTS Manager, LLC,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;a Delaware limited liability company,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;its managing member</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Joseph Ernst</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Name: &#160;&#160;&#160;&#160;Joseph Ernst</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Title: &#160;&#160;&#160;&#160;Manager</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TENANT:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC., <br>a Delaware corporation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Christopher J. Senner</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:&#160;&#160;&#160;&#160;Christopher J. Senner</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:&#160;&#160;&#160;&#160;EVP &amp; CFO</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:&#160;&#160;&#160;&#160;Michael M. Morrissey</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:&#160;&#160;&#160;&#160;President and CEO</font></div><div><br></div><div><div style="line-height:100%;text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">[Signature Page &#8211; Fifth Amendment to Lease]</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>5
<FILENAME>exel20191231exhibit1039.htm
<DESCRIPTION>EXHIBIT 10.39
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5EF40F9E8CA18DEC4FD66A23C5CEADED"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.39</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIRST AMENDMENT TO LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">THIS FIRST AMENDMENT TO LEASE AGREEMENT (this &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is made and entered into on January 16, 2020 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Execution Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between ALAMEDA BTS EDP, LLC, a California limited liability company (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and EXELIXIS, INC., a Delaware corporation (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A.&#160;&#160;&#160;&#160;Ernst Development Partners, Inc., a California corporation (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EDP</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and Tenant entered into that certain Lease Agreement (Commercial Single-Tenant Net Lease) dated October 25, 2019 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Lease</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), with respect to premises known as 1951 Harbor Bay Parkway, Alameda, California, as more particularly described in the Lease. EDP assigned the Lease to Landlord pursuant to that certain Assignment and Assumption of Lease Agreement dated as of October 31, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B.&#160;&#160;&#160;&#160;The City of Alameda approved a parking plan for the Project that requires construction of approximately 12 parking stackers (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parking Stackers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) at the Project to satisfy the required three (3) parking spaces per one thousand (1,000) rentable square feet of building area (the exact number of Parking Stackers will depend on the final design of the Building and the actual number of surface parking space constructed).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">C.&#160;&#160;&#160;&#160;Tenant has requested that Landlord defer construction of the Parking Stackers to provide Tenant time to obtain the City of Alameda&#8217;s approval of a Waterfront Parking Plan (as defined below).  Landlord and Tenant agree to defer construction of the Parking Stackers, and amend the Lease in certain other respects, on the terms and conditions of this Amendment. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">NOW THEREFORE, in consideration of good and valuable consideration and the mutual agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties do hereby agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Defined Terms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All capitalized terms used but not defined in this Amendment will have the meanings set forth for such terms in the Lease.  All terms that are defined in this Amendment and used in any provisions that are added to the Lease pursuant to this Amendment will have the meanings in the Lease set forth for such terms in this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Parking</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Landlord and Tenant agree that, although the Parking Stackers are part of Landlord&#8217;s Work, without constituting a Tenant Delay, Landlord shall defer construction of the Parking Stackers pending the City of Alameda&#8217;s approval of the to-be-devised Waterfront Parking Plan (as defined below), provided that, if (i) Waterfront Landlord or Tenant has not completed construction of parking spaces at the Adjacent Project in accordance with a Waterfront Parking Plan on or before January 1, 2024, (ii) the City of Alameda requires the installation of the Parking Stackers at the Project on or before January 1, 2024 to comply with applicable Laws or permit the occupancy of the Premises, as reasonably determined by Landlord, or (iii) Tenant ceases to diligently pursue a Waterfront Parking Plan (and construction of parking spaces related to such plan) for more than six (6) months and such failure continues for thirty (30) days after written notice thereof from Landlord at any time prior to January 1, 2024, as reasonably determined by Landlord (each of the events under clauses (i), (ii), and (iii), a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parking Stacker Trigger Event&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">), then Landlord shall, as soon as reasonably practical thereafter (but in no event longer than twelve (12) months after the Parking Stacker Trigger Event), cause the construction of the Parking Stackers at the Project in accordance with the City-approved parking plan for the Project, with the plans and specifications approved by Tenant (or deemed approved by Tenant) as provided below, and with this Section 2. Notwithstanding the foregoing, if Waterfront Landlord or Tenant has commenced construction of parking spaces at the Adjacent Project in accordance with a Waterfront Parking Plan on or before January 1, 2024, then all references to January 1, 2024 in the preceding sentence </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">are hereby revised to January 1, 2026. Landlord&#8217;s selection of a contractor to construct the Parking Stackers shall be based on at least two (2) competitive bids (which shall include timelines for the performance of the work and be shared with Tenant), and shall be subject to Tenant&#8217;s approval, which shall not be unreasonably withheld, conditioned, or delayed. If Landlord does not receive Tenant&#8217;s response within five (5) business days of Landlord&#8217;s request for approval of a contractor, Landlord&#8217;s selection of the contractor shall be deemed approved. Prior to commencing construction of the Parking Stackers, Landlord shall submit to Tenant for its approval, which approval shall not be unreasonably withheld, conditioned or delayed: (x) plans and specifications for the Parking Stackers and (y) a cost estimate for the construction of the Parking Stackers. If Tenant has not delivered an objection to such plans and specifications or cost estimate within five (5) business days after receipt of Landlord&#8217;s plans and specifications or cost estimate, as applicable, Tenant shall be deemed to have approved such plans and specifications or such cost estimate. Additionally, if such cost estimate estimates that the Parking Stacker Costs (as defined below) will be less than the amount of the Parking  Stacker Allowance, then Tenant shall be deemed to have approved such cost estimate. If Tenant timely disapproves of such plans and specifications or cost estimate, then Tenant shall specify a reasonable basis for such disapproval and Landlord and Tenant shall use good faith efforts to agree on revisions to such plans and specifications or cost estimate within five (5) business days after Landlord&#8217;s receipt of Tenant&#8217;s disapproval. Upon approval (or deemed approval) of such cost estimate by Tenant, Landlord shall enter into a guaranteed maximum price contract or lump sum contract with the approved general contractor (in the amount of such contractor&#8217;s bid approved by Tenant as described above) and any other lump sum contracts with other contractors for the construction of the Parking Stackers. Promptly after Landlord enters contracts for the construction of the Parking Stackers, Landlord shall deliver to Tenant a budget showing the portion of the Parking Stacker Costs that will be paid from the Parking Stacker Allowance (as defined below) and that portion that will be paid by Tenant.  Notwithstanding the foregoing, if the cost estimate delivered to Tenant pursuant to clause (y) immediately above estimates that the Parking Stacker Costs will exceed the Parking Stacker Allowance, then Tenant shall be permitted to value engineer the Parking Stackers to reduce costs; provided, however, (A) any cost associated with such value engineering by Tenant will be the responsibility of Tenant, subject to Landlord&#8217;s obligations with respect to the Parking Stacker Allowance pursuant to this Section, (B) any delays associated with the Tenant's efforts to value engineer the Parking Stackers will constitute an Excusable Delay to the extent such value engineering (or delays associated therewith) causes actual delays in the completion of the Parking Stackers, and (C) Tenant&#8217;s efforts to value engineer the Parking Stackers, including any delay caused thereby, shall not cause Landlord to violate Laws. After commencement of construction of the Parking Stackers, Landlord shall use commercially reasonable efforts to cause its contractors to diligently pursue completion of construction of the Parking Stackers in a good and workmanlike manner, in accordance with all laws and the plans and specifications approved by Landlord and Tenant pursuant to this Section, free of defects and using new materials and equipment of good quality and shall use commercially reasonable efforts to minimize interference with Tenant&#8217;s use of and access to the Premises and other parking spaces at the Project during the construction period. All Parking Stackers that may be installed or placed in or about the Project shall be and become the property of Landlord.  Provided that the warranties described in this sentence are available on commercially reasonable terms, Landlord shall obtain from the contractor for the Parking Stackers and each manufacturer of equipment installed as part of the Parking Stackers a standard construction or manufacturer&#8217;s warranty or guaranty, as applicable, in favor of Landlord and Tenant warranting that the Parking Stackers, in the case of the contractor, or the equipment provided, in the case of the manufacturers, shall be free from any defects of workmanship and materials for a period of not less than one (1) year from the date of substantial completion of the Parking Stackers. Substantial Completion and final completion of the Improvements shall be deemed to have occurred notwithstanding that the Parking Stackers have not been completed unless completion of the Parking Stackers is required by the City of Alameda for the legal occupancy of the Premises. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;In lieu of performing the work at its sole cost as provided in Section&#160;1.2 of Exhibit&#160;B to the Lease, Landlord shall pay towards the costs of construction of the Parking Stackers, including all pre-construction costs, permit fees, project management, costs of constructing the Parking Stackers, and the Parking Construction Fee (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parking Stacker Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), up to $300,000 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parking Stacker Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). In consideration for Landlord&#8217;s managing the construction of the Parking Stackers, Tenant shall pay to Landlord a management fee equal to five percent (5%) of hard and soft costs for the Parking Stackers (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parking Construction Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which fee shall be paid from the Parking Stacker Allowance on a monthly basis in lieu of the management fee set forth in Exhibit&#160;D to the Lease. Tenant shall be solely responsible for </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parking Stacker Costs in excess of the Parking Stacker Allowance.  Once Landlord has applied the full amount of the Parking Stacker Allowance toward the Parking Stacker Costs, then within thirty (30) days after Tenant&#8217;s receipt of a monthly invoice from Landlord for the portion of the Parking Stacker Costs in excess of the Parking Stacker Allowance that are due that month, Tenant shall pay to Landlord such portion of the Parking Stacker Costs, subject to the foregoing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Notwithstanding anything in the Lease to the contrary, including without limitation Section 3(a)(iii) of the Lease, upon a Parking Stacker Trigger Event (or, if earlier, Base Rent Commencement, provided that Tenant has not completed construction of the parking spaces at the Adjacent Project in accordance with the Waterfront Parking Plan), Total Development Costs shall include the full amount of the Parking Stacker Allowance (and no other Parking Stacker Costs shall be included in Total Development Costs) and Landlord shall re-calculate Initial Base Rent in accordance with Exhibit D-1 of the Lease. Any change to Initial Base Rent pursuant to this subsection shall be documented by notice from Landlord to Tenant, and any adjustments to Base Rent pursuant to this subsection shall be reflected in the Base Rent schedule in the Verification Memorandum. If Landlord increases Initial Base Rent pursuant to this subsection and the Parking Stacker Allowance exceeds the Parking Stacker Costs, then within thirty (30) days following construction of the Parking Stackers, Landlord shall pay to Tenant such excess Parking Stacker Allowance. Additionally, if a Parking Stacker Trigger Event has not occurred prior to Base Rent Commencement and if Tenant has not completed construction of the parking spaces at the Adjacent Project in accordance with the Waterfront Parking Plan prior to Base Rent Commencement, then within thirty (30) days after Base Rent Commencement, Landlord shall deposit an amount equal to the Parking Stacker Allowance in an escrow account with Commonwealth Land Title Insurance Company, as escrow agent, or another escrow agent to be agreed upon by Landlord and Tenant, and such amount shall be held by such escrow agent pursuant to an escrow agreement to be agreed on by Landlord, Tenant and the escrow agent in their reasonable discretion; provided that the escrow agreement shall (i) permit Landlord to draw on the escrow funds to construct the Parking Stackers if a Landlord is obligated to construct the Parking Stackers in accordance with Section 2(a) and (ii) permit the disbursement of the escrowed funds to Tenant if Tenant completes construction of the parking spaces at the Adjacent Project in accordance with the Waterfront Parking Plan prior to a Parking Stacker Trigger Event. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Tenant shall promptly notify Landlord of completion of construction of parking spaces at the Adjacent Project in accordance with the Waterfront Parking Plan and shall deliver to Landlord documentation reasonably requested by Landlord to evidence such completion. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Waterfront Parking Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean a to-be-devised parking plan with respect to Tenant&#8217;s premises located at the Adjacent Project, that (i) is approved by the City of Alameda in connection with the further development of the Adjacent Project, (ii) eliminates the need for Parking Stackers at the Project, and (iii) maintains a parking ratio of three parking spaces per 1,000 rentable square feet of building area at the Project and the Adjacent Project, other than the building at 1750 North Loop Road, as to which the ratio will only be two parking spaces for 1,000 square foot of such building. For the avoidance of doubt, no Waterfront Parking Plan has been devised or approved by Alameda Waterfront EDP, LLC (such entity or its successor, as landlord, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Waterfront Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), as the landlord under the lease between Waterfront Landlord and Tenant with respect to premises at the Adjacent Project (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Waterfront Lease</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and any approval by Waterfront Landlord shall be governed by the terms of the Waterfront Lease; provided, however, Landlord shall cooperate reasonably with Tenant in its efforts to devise and obtain the approval of the City of Alameda of the Waterfront Parking Plan and eliminate the need for the Parking Stackers. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Closing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant acknowledge that the Closing occurred December 20, 2019 and that, in connection with the Closing, Peet&#8217;s recorded a certificate of compliance (a copy of which is attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">), which consolidated the land acquired by Landlord pursuant to the Land Purchase Agreement into legal parcel, in the Official Records. Accordingly, Landlord has satisfied its obligations under the eleventh sentence of Section 26(u) of the Lease, neither Landlord nor Tenant shall have a right to terminate the Lease pursuant to the ninth sentence of Section 26(u) of the Lease, and Tenant shall have no right to terminate the Lease pursuant to Section 2.7(e) of the Work Letter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Brokers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant each represent and warrant that it has had no dealings with any real estate broker or agent in connection with this Amendment.  Neither party knows of any real estate broker or agent </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">who is or might be entitled to a commission or compensation in connection with this Amendment.  Tenant will indemnify and hold Landlord harmless from all damages paid or incurred by Landlord resulting from any claims asserted against Landlord by brokers or agents claiming through Tenant. Landlord will indemnify and hold Tenant harmless from all damages paid or incurred by Tenant resulting from any claims asserted against Tenant by brokers or agents claiming through Landlord. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Whole Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements with respect thereto.  Except as amended herein, or in a future writing signed by both parties, there shall be no other changes or modifications to the Lease between the parties and the Lease and the terms and provision contained therein shall remain in full force and effect. The terms of this Amendment will control over any conflicts between it and the terms of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Successors and Assigns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment shall be binding upon the parties hereto, their heirs, successors and assigns.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Ratification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as amended by this Amendment, the Lease has not been amended, and the parties ratify and confirm the Lease, as amended by this Amendment, as being in full force and effect.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Counterparts; Execution by Telecopy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment may be executed in counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one agreement.  Executed copies hereof may be delivered by telecopier or other electronic means, and upon receipt will be deemed originals and binding upon the parties hereto, regardless of whether originals are delivered thereafter.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signatures appear on next page]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s5D3965FED5A5570A0BEA6A23C5EFFA86"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Execution Date.</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LANDLORD:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ALAMEDA BTS EDP, LLC, <br>a Delaware limited liability company</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: Alameda Waterfront &amp; BTS EDP, LLC,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;a Delaware limited liability company,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;its sole member</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;By:  Waterfront &#8211; EXEL BTS Manager, LLC,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;a Delaware limited liability company,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;its managing member</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Joseph Ernst</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Name: &#160;&#160;&#160;&#160;Joseph Ernst</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Title: &#160;&#160;&#160;&#160;Manager</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TENANT:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC., <br>a Delaware corporation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Christopher J. Senner</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:&#160;&#160;&#160;&#160;Christopher J. Senner</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:&#160;&#160;&#160;&#160;EVP &amp; CFO</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:&#160;&#160;&#160;&#160;Michael M. Morrissey</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:&#160;&#160;&#160;&#160;President and CEO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">[Signature Page &#8211; First Amendment to Lease Agreement]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s1358ED41CC0119714BD96A23C6212170"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit A</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Copy of Certificate of Compliance</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[See Appendix A of the Attached Deed]</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.57
<SEQUENCE>6
<FILENAME>exel20191231exhibit1057.htm
<DESCRIPTION>EXHIBIT 10.57
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s668C730147FBEACD6E5B6A2E35E10EF5"></a></div><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.57</font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT  No. 3</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Amendment No. 3 (this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment No. 3&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) is entered into as of November 22, 2019 (the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Amendment No. 3 Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">), and is made and entered into by and between Exelixis, Inc., a Delaware corporation, located at 1851 Harbor Bay Parkway, Alameda, CA 94502 (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Exelixis&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">BMS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and BMS entered into that certain Clinical Trial Collaboration Agreement dated February 24, 2017, which was supplemented and amended by the Ono Territory Supplement Agreement having an effective date of July 6, 2018 and entered into by Exelixis, BMS and Ono Pharmaceutical Co. Ltd. (the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Ono Territory Supplemental Agreement&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) and amended by Amendment No. 1 to the Clinical Trial Collaboration Agreement having an effective date of March 8, 2019 (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment No. 1&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) and by Amendment No. 2 to the Clinical Trial Collaboration Agreement having an effective date of August 15, 2019 (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">No. 2&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) (such agreement, as amended by the Ono Territory Supplemental Agreement,  Amendment No. 1, and Amendment No. 2, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Agreement&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, beginning on February 1, 2019, Exelixis and BMS began joint discussions regarding potential filings with Regulatory Authorities relating to the Combined Therapy Clinical Trials; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and BMS want to amend the Agreement to ensure that all such exchanges are covered by the Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;NOW, THEREFORE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of the foregoing premises and the mutual promises and covenants contained herein, Exelixis and BMS agree as follows: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;The terms in this Amendment No. 3 with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth herein, or if not defined herein, as set forth in the Agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;The terms of this Amendment No. 3 are effective as of February 1, 2019, including without limitation the addition of the new paragraph below to the end of Section 9.1 of the Agreement, and apply to all discussions or other exchanges under the Agreement occurring on or after February 1, 2019, including those discussions or other exchanges relating to seeking approval of the use of the Exelixis Compound in combination with the BMS Compound(s) or vice versa for a Combined Therapy and to the preliminary meeting comments received by BMS from the FDA and provided to Exelixis after February 1, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;Section 9.1 of the Agreement is hereby amended by adding the following as a new paragraph at the end of Section 9.1:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;The Parties agree that Confidential Information includes information and materials a Party discloses to the other Party relating to seeking approval of the use of the Exelixis Compound in combination with the BMS Compound(s) or vice versa for a Combined Therapy, including the type of submission a Party intends to file with a Regulatory Authority, potential and actual questions submitted to a Regulatory Authority seeking guidance on administrative aspects, the technical format, and the proposed content of such submission, answers of a Regulatory Authority to such questions, and guidance provided by a Regulatory Authority with respect to such submission, such as preliminary meeting comments from the FDA. The Parties also agree that such Confidential Information may only be used for discussing the seeking of such approval and that the fact that the Parties are having discussions about the seeking of such approval is Confidential Information of each Party.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;Except as expressly set forth herein, all provisions of the Agreement shall remain unchanged and in full force and effect.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;This Amendment No. 3 shall be governed and construed in accordance with the internal laws of the State of New York, USA, excluding any choice of law rules that may direct the application of the laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;This Amendment No. 3 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument.  This Amendment No. 3 may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each party hereto as if they were original signatures. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signature page follows]</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE9888F41D83314BFE8A76A2E36013A32"></a></div><div><div style="line-height:130%;padding-bottom:10px;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and BMS, intending to be legally bound hereby, have caused this Amendment No. 3 to be executed by their duly authorized representatives as of the Amendment No. 3 Date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:    /s/ Gisela M. Schwab, M.D.      </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:    /s/ Nancy P. Forrest      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Gisela M. Schwab, M.D.      </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Nancy P. Forrest      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:    President, Product Development and    Medical Affairs and CMO</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date:   12/3/2019   </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  Vice President, Development and Commercial Alliances</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date:   12/3/2019   </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.62
<SEQUENCE>7
<FILENAME>exel20191231exhibit1062.htm
<DESCRIPTION>EXHIBIT 10.62
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF20F9B512C9CCB88B7F26A39248760C7"></a></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;<br>EXHIBIT 10.62</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">JOINT CLINICAL RESEARCH AGREEMENT</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">JOINT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL RESEARCH AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is made and entered into effective as December 18, 2019 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Delaware corporation having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502 (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">F. Hoffmann-La Roche Ltd</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a Swiss corporation having an address at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Exelixis and Roche may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis has developed a tyrosine kinase inhibitor known as Cabozantinib;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Roche has developed an anti-PD-L1 monoclonal antibody known as Atezolizumab;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties desire to collaborate with each other to sponsor one or more clinical trials of a combination therapy using Cabozantinib and Atezolizumab;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, certain rights related to Cabozantinib have been licensed by Exelixis to Ipsen Pharma SAS (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and Takeda Pharmaceutical Company Ltd. (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Takeda</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW THEREFORE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of the foregoing premises and the mutual promises and covenants contained herein, the Parties, intending to be legally bound, hereby agree as follows: </font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 1</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement have the meanings herein specified. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Study Protocol Summary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.9.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Affiliates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a particular Party, an entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such Party.  As used in this section, the term &#8220;control&#8221; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity. Notwithstanding the foregoing, unless expressly specified otherwise, for the purposes of this Agreement, [ * ].    </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Aggregate Safety Information</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Party&#8217;s Compound(s), the (a) safety and toxicity information for such Compound(s) that is Combined Therapy Study Data, plus (b) safety and toxicity information from other relevant clinical trials of such Compound(s), whether alone or in combination with another pharmaceutical agent, in each case including information related to serious adverse events, adverse drug reactions, adverse events, discontinuations due to adverse events and Grade 3 and Grade 4 laboratory abnormalities.  Aggregate Safety Information shall be provided by a Party to the other in the same format as is contained in the Investigators&#8217; Brochures prepared by such Party for its Compound(s) in each country where a Combined Therapy Trial will be conducted.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Applicable Law</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all applicable laws, rules, and regulations (whether federal, state, or local) that may be in effect from time to time and applicable to conduct under this Agreement, including current Good Clinical Practices (GCP), Good Laboratory Practices (GLP), and Good Manufacturing Practices (GMP).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.5&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Bioanalysis Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the bioanalysis plan for any Samples as may be contemplated by a Protocol or another subsequent written agreement between the Parties.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.6&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Business Day</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a day other than Saturday, Sunday, or any day on which commercial banks located in San Francisco, CA (USA), Welwyn (UK), Mississauga (Canada), Shanghai (China), Tokyo (Japan), or Basel (Switzerland) are authorized or obligated by Applicable Law to close. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.7&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Clinical Hold</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that (a) with respect to a clinical investigation in the U.S., the FDA has issued an order to a Party pursuant to 21 CFR &#167;312.42 to delay a proposed clinical investigation or to suspend an ongoing clinical investigation of the Combined Therapy or such Party&#8217;s Single Agent Compound(s), and (b) with respect to a clinical investigation outside the U.S., a Regulatory Authority has issued an order equivalent to the order specified in subsection (a).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.8&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a therapeutic treatment that consists of a combination of the Exelixis Compound and the Roche Compound, wherein each Compound of the combination treatment is used as an individual formulation, with or without another agent.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.9&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy IND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.3.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.10&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Invention(s)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all Inventions that are not Exelixis Study Inventions or Roche Study Inventions.  For the avoidance of doubt, Combination Therapy Inventions include any Invention comprising or claiming, whether generically or specifically, (a) the Roche Compound and/or any other molecule(s) that is/are designed to selectively bind to PD-1 or PD-L1 and (b) the Exelixis Compound and/or any other molecule(s) that is/are designed to selectively inhibit the activity of MET, VEGF receptors, AXL, and RET.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.11&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Patents that Cover a Combined Therapy Invention or Combined Therapy Study Data, excluding Roche Independent Patents and Exelixis Independent Patents. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.12&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 9.2.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.13&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.14&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Trial Regulatory Documentation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Regulatory Documentation to be submitted for the conduct of a Combined Therapy Trial, but excluding (a) any Exelixis Regulatory Documentation and (b) any Roche Regulatory Documentation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.15&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the level of effort and resources normally devoted by each Party to conduct a clinical trial for a biopharmaceutical product or compound that is owned by it or to which it has rights, which is of similar market potential, profit potential, or strategic value, and is at a similar stage in its development or product life based on conditions then prevailing. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.16&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Exelixis Compound or the Roche Compound, as the context dictates.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.17&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Conducting Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.2.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.18&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Conducting Party Compound(s)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means (a) in the case of Roche as the Conducting Party, the Roche Compound and (b), in the case of Exelixis as the Conducting Party, the Exelixis Compound.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.19&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Confidential Information</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all non-public information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement; provided that all Exelixis Study Inventions, Exelixis Technology and Exelixis Regulatory Documentation shall be Confidential Information of Exelixis, all Roche Study Inventions, Roche Technology, and Roche Regulatory Documentation shall be Confidential Information of Roche, and all joint owned Inventions shall be deemed both Parties&#8217; Confidential Information.  Confidential Information shall include: (a) the terms and conditions of this Agreement, and (b) Confidential Information disclosed by either Party pursuant to the Confidentiality Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.20&#160;&#160;&#160;&#160;&#8220;Confidentiality Agreement&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;means that certain confidentiality agreement between the Parties, dated [ * ]. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.21&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Controlled</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to any particular information, Patent, or other intellectual property rights, the legal authority or right (whether by ownership, license, or otherwise but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such information, Patent, or other intellectual property rights to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party, in each case without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.22&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cover</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a particular subject matter at issue and a relevant Patent, that, in the absence of ownership of or a license under such Patent, the manufacture, use, sale, offer for sale, or importation of such subject matter would infringe one or more claims of such Patent, or, as to a pending claim included in such Patent, the manufacture, use, sale, offer for sale, or importation of such subject matter would infringe such Patent if such pending claim were to issue in an issued patent.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.23&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CRO</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any Third Party contract research organization engaged in connection with the conduct of a Combined Therapy Trial, including laboratories and Third Parties used to maintain the safety database from a Combined Therapy Trial, but, for clarity, excluding clinical trial sites and any Third Parties who are individuals.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.24&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Executive Officers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means [ * ] of Exelixis, or his/her designee (such designee [ * ]), and [ * ] of Roche.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.25&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis&#8217; tyrosine kinase inhibitor known as Cabozantinib. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.26&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Indemnitees</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 12.1 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.27&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Independent Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Patents Controlled by Exelixis (or its Affiliates) as of the Effective Date or during the Term that Cover the use (whether alone or in combination with other agents), manufacture, formulation, or composition of matter of the Exelixis Compound, but excluding Exelixis Study Patents and Exelixis&#8217; interest in Combined Therapy Patents.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.28&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Regulatory Documentation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Regulatory Documentation related to the Exelixis Compound that exists as of the Effective Date or during the Term, but excluding all Combined Therapy Trial Regulatory Documentation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.29&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 9.2 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.30&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Study Invention</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Inventions that relate to (a) the composition of matter of the Exelixis Compound (and not any Roche Compound), (b) a method of manufacture or formulation of the Exelixis Compound (and not any Roche Compound) as a Single Agent, or (c) a method of use of the Exelixis Compound as a monotherapy or as used in combination with agents, antibodies, or compounds, in each case that are not the Roche Compound.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.31&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Study Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Patents that Cover an Exelixis Study Invention (and not a Roche Study Invention or Combined Therapy Invention) or any Exelixis Study Data, but excluding Exelixis Independent Patents and Exelixis Technology.  For the avoidance of doubt, any Patent that Covers both (a) an Exelixis Study Invention and (b) any other type of Invention shall be a Combined Therapy Patent.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.32&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Technology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all Technology that is (a) Controlled by Exelixis (or its Affiliates) as of the Effective Date or during the Term and (b) related to the Exelixis Compound or the Combined Therapy and necessary for the conduct of the Combined Therapy Trials, but excluding all Inventions, Study Data, and Combined Therapy Trial Regulatory Documentation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.33&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Territory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the U.S.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.34&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FDA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the United States Food and Drug Administration, or any successor agency having the same or similar authority. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.35&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Field</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the treatment of patients with indication(s) to be studied in a Combined Therapy Trial as set forth in the Protocol(s).</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.36&#160;&#160;&#160;&#160;&#8220;Full Time Equivalent&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;FTE&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;shall mean the equivalent of full-time work of an employee or appropriately qualified person otherwise engaged by a Party (&#8220;Personnel&#8221;) over a twelve-month period (excluding normal vacations, sick days and holidays). The portion of an FTE year devoted by Personnel for activities under the Agreement shall be determined by dividing the number of full days dedicated by such Personnel to the activities under this Agreement during any twelve-month period by the number of working days during such twelve-month period, such number of working days to accurately reflect actual working days for Personnel who were not employed or engaged by a Party for the entirety of such twelve-month period.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.37&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FTE Rate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the yearly rate [ * ].  &#160;The Parties may re-negotiate the FTE Rate in good faith, if either Party finds that the FTE Rate no longer represents a reasonable estimate of FTE cost.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.38&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GCP</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the current good clinical practice as set out in (a) ICH Harmonized Guidance on current Good Clinical Practice (CPMP/ICH/135/95), (b) U.S. 21 C.F.R. Parts 50, 54, 56, 58, 210, 211 and 312, as amended from time to time, and (c) the equivalent law or regulation in any other applicable jurisdiction in the Territory.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.39&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GLP</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S.), as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.40&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GMP</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the current minimum standards for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug as specified by applicable laws of the relevant countries at the time of manufacturing conducted in accordance with this Agreement, defined under (a) 21 C.F.R. Parts 210 and 211, (b) Directive 2003/94/EC, (c) Volume 4, Rules Governing Medicinal Products in the European Union Part I and II, and (d) equivalent law or regulations in any other applicable jurisdiction in the Territory, in each case (a) &#8211; (d), as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.41&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an application filed with a Regulatory Authority for authorization to commence clinical studies, including (a) an Investigational New Drug Application as defined in the United States Food, Drug and Cosmetic Act, (b) any equivalent of a United States IND in other countries or regulatory jurisdictions, (e.g., a Clinical Trial Application (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CTA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), and (c)&#160;all supplements, amendments, variations, extensions, and renewals thereof that may be filed with respect to the foregoing. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.42&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Independent Combined Therapy Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.9.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.43&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Independent Trial Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 8.2.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.44&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initial Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.45&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initiation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means dosing of the first patient in a Combined Therapy Trial. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.46&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Invention</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice in the course of performance of activities under this Agreement, together with all intellectual property rights therein, but excluding all Study Data.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.47&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">has the meaning set forth in the recitals of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.48&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen-Exelixis Agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means that certain Collaboration and License Agreement between Exelixis and Ipsen dated as February 29, 2016, as amended from time to time, and agreements between Exelixis and Ipsen and their Affiliates relating thereto that may be in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.49&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Territory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all the countries of the world other than those in the Exelixis Territory and the Takeda Territory (i.e., all countries other than the United States and Japan).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.50&#160;&#160;&#160;&#160; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Manufacture</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Manufacturing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means manufacturing, processing, formulating, packaging, labeling, holding (including storage), and quality control testing of a Single Agent Compound or the Combined Therapy, in each case so as to be suitable under Applicable Law for use in the Combined Therapy Trials.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.51&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Material Safety Issue</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Party&#8217;s good faith belief that there is an unacceptable risk for harm in humans based upon: (a) pre-clinical safety data, including data from animal toxicology studies; or (b) the observation of serious adverse effects in humans after the Exelixis Compound or the Roche Compound, either as </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Single Agent or in combination with another pharmaceutical agent (including as the Combined Therapy), has been administered to or taken by humans, such as during the Combined Therapy Trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.52&#160;&#160;&#160;&#160;&#8220;Non-Conducting Party&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;means, for any particular Combined Therapy Trial, the Party who is not the Conducting Party. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.53&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Conducting Party Compound(s)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means (a) in the case of Roche as the Non-Conducting Party, the Roche Compound and (b) in the case of Exelixis as the Non-Conducting Party, the Exelixis Compound.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.54&#160;&#160;&#160;&#160;&#8220;Operational Matters&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;has the meaning set forth in Section 3.6(c).   </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.55&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means (a)&#160;all patents, certificates of invention, applications for certificates of invention, priority patent filings, and patent applications, and (b)&#160;any renewals, divisions, continuations (in whole or in part), or requests for continued examination of any of such patents, certificates of invention and patent applications, and any and all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.56&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.57&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Proposing Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.9.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.58&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Protocol</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.59&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Quarter</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means each respective period of three (3) consecutive months ending on March&#160;31, June&#160;30, September&#160;30, and December&#160;31.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.60&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Regulatory Authority</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any applicable supra-national, federal, national, regional, state, provincial, or local governmental or regulatory authority, agency, department, bureau, commission, council, or other entities (e.g., the FDA, EMA, and PMDA) regulating or otherwise exercising authority with respect to activities contemplated in this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.61&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Regulatory Documentation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a product containing the Roche Compound as a monotherapy or the Exelixis Compound as a monotherapy, all submissions to Regulatory Authorities in connection with the development of such product, including all INDs, BLAs, and NDAs, drug master files, correspondence with regulatory agencies, safety update reports, adverse event files, complaint files, inspection reports, and manufacturing records, in each case together with all applicable supporting documents (including documents with respect to clinical data).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.62&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Responding Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 2.9.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.63&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Right of Reference</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the &#8220;right of reference or use&#8221; as defined in 21 C.F.R. &#167; 314.3(b) and any equivalent regulation outside the U.S., in each case as amended from time to time, to Regulatory Documentation (including the data contained or referenced therein) pertaining to a Party&#8217;s Compound (and, in the case of the Non-Conducting Party, an existing IND or the Combined Therapy IND) that is filed with a Regulatory Authority solely to the extent necessary for the conduct of a Combined Therapy Trial in such country, or as otherwise expressly permitted under this Agreement or required to enable a Party to exercise its rights or perform its obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.64&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Roche&#8217;s anti-PD-L1 monoclonal antibody known as Atezolizumab.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.65&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Indemnitees</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 12.2 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.66&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Independent Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Patents Controlled by Roche (or its Affiliates) as of the Effective Date or during the Term that Cover the use (whether alone or in combination with other agents), manufacture, formulation, or composition of matter of the Roche Compound, but excluding Roche Study Patents and Roche&#8217;s interest in Combined Therapy Patents.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.67&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Regulatory Documentation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Regulatory Documentation related to the Roche Compound that exists as of the Effective Date or during the Term, but excluding all Combined Therapy Trial Regulatory Documentation. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.68&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has the meaning set forth in Section 9.2 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.69&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Study Invention</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Inventions that relate to (a) the composition of matter of the Roche Compound (and not the Exelixis Compound), (b) a method of manufacture or formulation of the Roche Compound (and not the Exelixis Compound) as a Single Agent, or (c) a method of use of the Roche Compound as a monotherapy or as used in combination with agents, antibodies, or compounds, in each case that are not the Exelixis Compound.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.70&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Study Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all Patents that Cover a Roche Study Invention (and not an Exelixis Study Invention or Combined Therapy Invention) or any Roche Study Data, but excluding Roche Independent Patents and Roche Technology.  For the avoidance of doubt, any Patent that Covers both (a) a Roche Study Invention and (b) any other type of Invention shall be a Combined Therapy Patent.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.71&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Technology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all Technology that is (a) Controlled by Roche (or its Affiliates) as of the Effective Date or during the Term and (b) related to the Roche Compound or the Combined Therapy and necessary for the conduct of the Combined Therapy Trials, but excluding all Inventions, Study Data, and Combined Therapy Trial Regulatory Documentation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.72&#160;&#160;&#160;&#160;&#8220;Roche Territory&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;means worldwide.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.73&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Safety Database</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means the database documenting safety reports for the Combined Therapy, including pregnancy reports. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.74&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Samples</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means biological specimens collected from Combined Therapy Trial study subjects (including [ * ]).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.75&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Shared Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the costs incurred by a Party [ * ] directly attributable or reasonably allocable to the conduct of the Combined Therapy Trial, including [ * ].  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.76&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Single Agent Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, (a) with respect to Exelixis, the Exelixis Compound, and (b) with respect to Roche, the Roche Compound, in each case as a monotherapy.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.77&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Statistical Analysis Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a document that prespecifies statistical analyses, focusing on statistical methods for the primary and key secondary endpoints (efficacy and safety) to be prepared by the Conducting Party for each Combined Therapy Trial.  In consultation with the Non-Conducting Party, this document shall be finalized before the first formal efficacy analysis.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.78&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Takeda</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">has the meaning set forth in the recitals of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.79&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Takeda-Exelixis Agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means that certain Collaboration and License Agreement between Exelixis and Takeda dated as January 30, 2017, as amended from time to time, and agreements between Exelixis and Takeda and their Affiliates relating thereto that may be in effect from time to time.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.80&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Takeda Territory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Japan.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.81&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Technology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means information, inventions, discoveries, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results not generally known to the public (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and know-how, including study designs and protocols), in all cases, whether or not patentable, in written, electronic or any other form now known or hereafter developed, materials, data and results, including Regulatory Documentation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.82&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any Person or entity other than Exelixis and Roche and their respective Affiliates.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.83&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third Party License Payments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any and all payments due by a Party to a Third Party under a license agreement or other written agreement between such Party and Third Party, pursuant to which agreement such Party is granted rights under intellectual property owned or controlled by such Third Party that are necessary for (a) making, using, or importing such Party&#8217;s Compound for the conduct of a Combined Therapy Trial, or (b) the conduct of a Combined Therapy Trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.84&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">United States</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">U.S.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the United States of America, and its territories, districts, and possessions.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 2</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">COLLABORATION SCOPE</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Combined Therapy Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties shall, pursuant to this Agreement, conduct (i) the registrational clinical trials set forth in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initial Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and (ii) each other registrational clinical trial designed to evaluate a Combined Therapy as the Parties agree in writing (each Initial Trial and additional trial, a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Prior to commencing any Combined Therapy Trial, the Conducting Party, in consultation with the Non-Conducting Party, shall prepare a protocol for such Combined Therapy Trial (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Protocol</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) for review and approval by a JPT.  Any amendment to a Protocol shall be subject to review and approval by a JPT.  The Conducting Party shall, and shall ensure that, the Combined Therapy Trial is conducted in accordance with its Protocol.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;The Conducting Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Party primarily responsible for the conduct of a Combined Therapy Trial (such Party with respect to such Combined Therapy Trial, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Conducting Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) shall be agreed by the Parties (via the JSC) on a trial-by-trial basis.  The Conducting Party for each Initial Trial is identified in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the oversight of the JSC, as between the Parties, the Conducting Party shall have decision making authority with respect to all non-material operational issues in the conduct of the Combined Therapy Trial and shall be the regulatory lead and the sponsor of record with respect to such Combined Therapy Trial.  Such Conducting Party operational and decision-making authority is further described in at least Sections 3.6 and 3.7 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;Combined Therapy IND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Unless otherwise required by a Regulatory Authority, for each Combined Therapy Trial, the Conducting Party shall determine whether a combination IND (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy IND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is necessary.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;Right of Reference</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party (regardless of whether such Party is the Conducting Party or the Non-Conducting Party) shall have a Right of Reference to all Combined Therapy INDs (including Combined Therapy INDs for Independent Combined Therapy Trials) or such other IND upon which a Conducting Party is relying on for the conduct of a Combined Therapy Trial. Each Party hereby grants to the other Party a Right of Reference to any of such Party&#8217;s effective INDs for its Compound to the extent necessary for the conduct of a Combined Therapy Trial.  Neither Party shall grant any Third Party any Right of Reference with respect to any portion of the Combined Therapy IND relating to the other Party&#8217;s Compound for use either as a monotherapy or in combination with any other molecules without the prior written consent of such other Party, such consent not to be unreasonably withheld, conditioned, or delayed.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.5&#160;&#160;&#160;&#160;Investigator Brochure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall be responsible for (a) drafting and updating as necessary the investigator&#8217;s brochure for its Compound, and (b) filing all necessary Regulatory Documentation for its Compound with each applicable Regulatory Authority. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.6&#160;&#160;&#160;&#160;Information Exchange</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Party shall provide the other Party the following information with respect to its Compound promptly after the Effective Date: </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the most current investigator&#8217;s brochure; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">safety signals and safety issues impacting the Initial Trials; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">toxicology and efficacy signals relevant to the Initial Trials; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any information specified to be provided in the Pharmacovigilance Agreement.  </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Conducting Party shall provide the Non-Conducting Party the following relating to the Combined Therapy within [ * ] after the completion of each Initial Trial:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">safety analyses for each Combined Therapy Trial in accordance with the applicable Protocol and/or Statistical Analysis Plan;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">safety signals and safety issues relevant to the Combined Therapy Trials;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">toxicology and efficacy signals;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any other information and data relevant to the Combined Therapy Trials, including any information specified to be provided in the Pharmacovigilance Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Conducting Party shall provide the Non-Conducting Party, within [ * ] after the completion of each Combined Therapy Trial a copy of all of the Study Data generated for such Combined Therapy Trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Conducting Party shall provide the Non-Conducting Party a copy of all of the Clinical Study Reports (CSRs) generated for such Combined Therapy Trial, and as applicable, safety analyses for Non-Conducting Party Compound as a monotherapy in accordance with the applicable Protocol and/or Statistical Analysis Plan, within [ * ] of publication. For clarity, the Non-Conducting Party may use the safety information provided pursuant to this section for any purpose. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as provided in Section 2.6(c), each Party shall use the data and information exchanged pursuant to this Section 2.6 solely:  (i) to evaluate the safety and efficacy of the Combined Therapy in Combined Therapy Trials, (ii) to meet any regulatory requirements pertaining to its Compound and to the conduct of the Combined Therapy Trials, and (iii) as permitted elsewhere in this Agreement.  All such information and disclosures: (A) pertaining to the Combined Therapy shall be the Confidential Information of both Parties, (B) pertaining to the Exelixis Compound as a monotherapy (or used with agents other than the Roche Compound) shall be the Confidential Information of Exelixis, and (C) pertaining to the Roche Compound as a monotherapy (or used with agents other than the Exelixis Compound) shall be the Confidential Information of Roche. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.7&#160;&#160;&#160;&#160;Conditional Studies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If additional studies, including toxicity studies, are required or recommended by a Regulatory Authority as a prerequisite for conducting any Combined Therapy Trial, the Parties shall negotiate in good faith to agree upon a protocol for such studies, each of which shall be a Combined Therapy Trial under this Agreement.  If the Parties are unable to agree upon a protocol for any such additional study, or if the conduct of such study would cause a delay unacceptable to a Party, then the matter shall be referred to the JPT for resolution.  If the JPT is unable to reach a decision and the JSC is also unable to reach a resolution after such matter is escalated to them, then this Agreement shall automatically terminate solely as it relates to such individual Combined Therapy Trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.8&#160;&#160;&#160;&#160;Post-Marketing Commitments.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the case where both Parties have sought a labeled indication based on the Combined Therapy, if post-marketing commitments are required by a Regulatory Authority </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#222222;">(e.g.:  US post-marketing commitments and post marketing requirements, EU post approval commitments etc)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties shall negotiate in good faith.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.9&#160;&#160;&#160;&#160;Additional Studies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If a Party is interested in conducting an additional Combined Therapy study (in addition to the Initial Trials) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Proposing Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then the Proposing Party shall provide the other Party (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Responding Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with a written summary for such proposed Combined Therapy study (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Study Protocol Summary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) prior to initiating the protocol development for such study.  Within [ * ] after receipt of the Additional Study Protocol Summary, the JSC shall meet to review and discuss the Additional Study Protocol Summary.  If the JSC agrees to jointly conduct a study under this Agreement based on such Additional Study Protocol Summary, then such study shall be deemed a Combined Therapy Trial, the Parties will amend this Agreement to add such Combined Therapy Trial to Exhibit A, and the Parties shall commence Protocol development for such study in accordance with this Agreement.  If the JSC does not agree to jointly conduct such study under this Agreement, the Proposing Party may conduct up to [ * ] such studies per year independently (each an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Independent Combined Therapy Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), provided that [ * ] such Proposing Party shall conduct such Independent Combined Therapy Trial: (a) in accordance with all Applicable Laws; (b) under the oversight of the JSC; and (c) in a manner that would not have a material adverse effect on the Combined Therapy or on the Responding Party&#8217;s Compound. For clarity, decisions relating to whether a proposed study will have a material adverse effect on the Responding </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">8</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Party&#8217;s Compound shall be made in the sole reasonable judgment of the Responding Party.  Unless otherwise required by a Regulatory Authority, each Independent Combined Therapy Trial shall be conducted under either an existing IND or a Combined Therapy IND.  For clarity, the Proposing Party for an Independent Combined Therapy Trial shall be the Conducting Party with respect thereto, and shall have all operational responsibility therefor, but shall not be obliged to provide the Responding Party with any Study Data, other than safety data (and any other data required under the Pharmacovigilance Agreement), or any other information described in Sections 6.2(g), (h), (i), (j), (l), (o), (s), and (u) from such Independent Combined Therapy Trial unless the Responding Party reimburses the Proposing Party as set forth in Section 8.2.  For further clarity, the Responding Party shall only have the right to use data generated by the Proposing Party in an Independent Combined Therapy Trial to the extent reasonably necessary for the Responding Party to comply with its regulatory reporting and compliance obligations, including safety reporting obligations, and shall have the right to use such data to support its own development, but shall not have the right to use such data for regulatory approval, publications, or commercialization activities except pursuant to Section 8.2.  [ * ]</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.10&#160;&#160;&#160;&#160;Safety Data Exchange</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties shall comply with Applicable Law for safety reporting requirements.  Prior to First Patient In occurring in the first Combined Therapy Trial using the Combination, the Parties shall execute a separate pharmacovigilance agreement that defines the Parties&#8217; responsibilities and obligations with respect to the procedures and timeframes for compliance with Applicable Law pertaining to safety reporting for the Compounds and the Combination used in a Study (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Pharmacovigilance Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.11&#160;&#160;&#160;&#160;Amendments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any amendment to this Agreement, a Protocol, Bioanalysis Plan, Statistical Analysis Plan, Pharmacovigilance Agreement, or Quality Agreement shall require the written mutual agreement of the Parties (with neither Party having final say).  Amendments to this Agreement, the Pharmacogivilance Agreement, and Quality Agreement shall be executed in the form of a written amendment in accordance with Section 14.1.  Amendments to a Protocol, Bioanalysis Plan or Statistical Analysis Plan may be made in writing by approval of a JPT (without a formal amendment to this Agreement pursuant to Section 14.1).</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 3</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GOVERNANCE</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Joint Steering Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Promptly after the Effective Date, the Parties shall form a Joint Steering Committee (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">JSC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), composed of an equal number of [ * ] members of each Party, to oversee the collaboration of the Parties under this Agreement and the conduct of the Combined Therapy Trials.  The JSC shall act as a joint consultative body and in particular shall:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">establish one or more Joint Project Team(s) (as defined below) and other subcommittees and working groups as the JSC decides is necessary;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">oversee the activities of, and provide guidance to the JPTs and mediate any unresolvable Disputes arising at the JPT;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review the regulatory strategy for each Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review the status, progress, and results of each Combined Therapy Trial led by JPTs;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review and approve study summaries as well as the initial budget for each protocol;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">discuss any additional Combined Therapy Trials that either Party may be interested in conducting under this Agreement; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">discuss and provide guidance on commercial issues (e.g. post-approval issues).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">discuss any post-marketing commitments as contemplated in Section 2.8; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">establish a mechanism for the Non-Conducting Party to be informed and updated on a timely periodic basis regarding relevant Operational Matters. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;JSC Membership and Meetings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;JSC Members</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each JSC representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the JSC&#8217;s </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">responsibilities.  Each Party may replace its representatives on the JSC on written notice to the other Party.  Each Party shall appoint one of their respective representatives on the JSC to serve as a co-chair of the committee.  The co-chairpersons shall prepare and circulate agendas to JSC members at least [ * ] before each JSC meeting and shall direct the preparation of reasonably detailed minutes for each JSC meeting (such preparation to alternate between the Parties), which shall be approved by the co-chairpersons and circulated to the other JSC members within [ * ] after each such meeting.  The initial members of each of the JSC shall be determined by the Parties promptly following the Effective Date. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Meetings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The JSC shall hold meetings at such times as it elects to do so, but in no event less frequently than [ * ] during the Term.  The first JSC meeting shall be held within [ * ] after the Effective Date.  JSC meetings may be held in person, or by audio or video teleconference.  In-person meetings shall be held at locations alternately selected by the Parties.  Each Party shall be responsible for all of its own expenses of participating in any JSC meeting.  No action taken at any meeting of the JSC shall be effective unless at least one (1) representative of each Party is participating.  In addition, upon written notice to the other Party, either Party may request that a special </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">ad hoc</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;meeting of the JSC be convened for the purpose of resolving Disputes or for the purpose of reviewing or making decisions pertaining to material subject-matter, the review or resolution of which cannot be reasonably postponed until the following scheduled JSC meeting.  Such </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">ad hoc</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than [ * ] following the notification date of request that such meeting be held.    </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Non-Member Attendance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend JSC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#8217;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.  Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;Joint Project Team</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The JSC shall appoint one or more joint project teams (each a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">JPT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) for each Combined Therapy Trial, composed of any number of appropriate cross-functional members from each Party, with one (1) such member serving as the chair from each Party. The JPT(s) shall manage the conduct of the Combined Therapy Trial and in particular shall:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">oversee and monitor the status and progress of the Combined Therapy Trial and the activities of the Parties with respect to such Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">discuss any conditional studies required to be conducted prior to a Combined Therapy Trial (pursuant to Section 2.7);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">provide a forum for the Parties to discuss, monitor, and coordinate activities and communications for the Combined Therapy Trial, including recruitment status, results analysis (interim and final), and other information relevant to the conduct of the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review and approve each plan for medical monitoring, exchange information from site audits, and review the results of all such medical monitoring and site audits and agree on any actions in response to same;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review and approve the Protocol, Statistical Analysis Plan, Bioanalysis Plan, and any amendments to any of the foregoing (including associated budget amendments after initial approval by the JSC);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review, and approve the final clinical trial report (and/or final statistical analysis in accordance with the Statistical Analysis Plan) from the Combined Therapy Trial; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review, and approve communication strategies with Regulatory Authorities regarding the Combined Therapy Trial; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review, and approve all material Combined Therapy Trial Regulatory Documentation, or portions thereof, that relate to the Combined Therapy;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review and approve each Combined Therapy IND to be submitted to a Regulatory Authority, and any amendments thereto;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review, and approve any analysis of any Combined Therapy Study Data (other than any monotherapy data) proposed by a Party that is not included in the Statistical Analysis Plan; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review, and approve use of any Samples in accordance with Section 9.5 that are not described in the applicable Protocol and ICF for a Combined Therapy Trial so long as the JSC/JPT remains in force and effect (and if not in force and effect, by mutual written agreement of the Parties);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review and approve the template ICF form, the template case report form, and template clinical trial site agreement (or minimum language to be included therein) to be used in the Combined Therapy Trial;  the Conducting Party may authorize changes to such template or minimum language without review and approval of the JPT, provided that changes to information pertaining to the Non-Conducting Party&#8217;s Compound must be approved by the JPT;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">approve the countries in which the Combined Therapy Trial will be conducted, which shall be limited to those countries in which both the Roche Compound and the Exelixis Compound are then being commercialized or, if not then being commercialized by a Party, for which such Party plans to commercialize; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review each Party&#8217;s drug supply forecasts for the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">approve any immunogenicity analysis for the Combined Therapy Trial, including the protocol and the entity to do the analysis, to the extent not already included in the Protocol; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">endorse the selection of clinical trial sites, Recruitment Plans and Study Timelines and endorse material communications with trial sites or IRBs relating to patient safety or early termination/cessation of the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">select and approve any Third Party committees, reviewers, or other contractors; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">coordinate the transfer of materials and information between the Parties, including Study Data, Final Study Report, Tangible Materials (if any), Samples, and Sample Data; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">review quarterly budget reports; and </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">perform other activities requested by the JSC.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;JPT Membership and Meetings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;JPT Members</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each JPT representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the JPT&#8217;s responsibilities.  Each Party may replace its representatives on the JPT on written notice to the other Party.  Each Party shall appoint one of their respective representatives on the JPT to serve as a co-chair of the group; provided that where more than one Combined Therapy Trial is overseen by one JPT, additional co-chairs may serve with respect to those additional trials.  The co-chairpersons shall prepare and circulate agendas to JPT members at least [ * ] before each JPT meeting and shall direct the preparation of reasonably detailed minutes for each JPT meeting, which shall be approved by the co-chairpersons and circulated to the other JPT members within [ * ] after each such meeting.  The initial members of each of the JPT shall be determined by the Parties promptly following the Effective Date. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Meetings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The JPT shall hold meetings at such times as it elects to do so, or as requested by a Party&#8217;s chair, but in no event less frequently than [ * ] during the conduct of the applicable Combined Therapy Trial.  JPT meetings may be held in person, or by audio or video teleconference.  In-person meetings shall be held at locations alternately selected by the Parties.  Each Party shall be responsible for all of its own expenses of participating in any JSC meeting.  No action taken at any meeting of the JPT shall be effective unless at least one (1) representative of each Party is participating.  In addition, upon written notice to the other Party, either Party may request that a special </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">ad hoc</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;meeting of the JPT be convened for the purpose of resolving Disputes or for the purpose of reviewing or making decisions pertaining to material subject-matter, the review or resolution of which cannot be reasonably postponed until the following scheduled JPT meeting.  Such </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">ad hoc</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than [ * ] following the notification date of request that such meeting be held.   </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Non-Member Attendance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend JPT meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#8217;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.  Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Decision Making</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except for decisions expressly reserved to the JSC, the JPT(s) shall be responsible for the coordination and execution of all joint operations (e.g., clinical drug supply, response to regulatory agency questions, data exchange, pharmacovigilance, etc.).  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.5&#160;&#160;&#160;&#160;Data Monitoring and Coordination</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;iDMC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Conducting Party for a Combined Therapy Trial shall establish an independent data monitoring committee (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">iDMC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to monitor the safety of the Combined Therapy and the conduct of such Combined Therapy Trial and to review efficacy data at interim points during the conduct of the study (with such time points to be agreed by the Parties in advance of the Initiation of such study).  The members of the iDMC shall have appropriate levels of experience in the relevant disease area, statistical knowledge, and other relevant expertise, and shall be approved by a JPT.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;iDCC and DRB</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Conducting Party  shall establish (i) an independent Data Coordinating Center (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">iDCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to prepare then-current accurate and unblinded analyses for the iDMC to review and (ii) a Data Review Board (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">DRB</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), that updates and in good faith, considers input from the JPT, to review all Study Data from a Combined Therapy Trial to advise on key determinations, including whether to accept a recommendation from the iDMC to stop a Combined Therapy Trial.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.6&#160;&#160;&#160;&#160;Conducting Party Operational Authority</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Conducting Party for a Combined Therapy Trial shall, subject to the oversight and determinations of the JSC and JPT and the terms of the applicable Protocol and this Agreement, the Quality Agreement, the Pharmacovigilance Agreement, and the Supply Agreement:  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;manage and be primarily responsible for the conduct of such Combined Therapy Trial; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">be the sponsor and regulatory lead for such Combined Therapy Trial; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">as between the Parties, be the lead with respect to (i) the identification, selection, and management of clinical trial sites (including the negotiation and execution of clinical trial site agreements and related budgets, timelines, and contingency planning), (ii) the conduct of clinical study start-up activities, communications with, and obtaining approval from institutional review boards and/or ethics committees, as applicable, and draft the template informed consent form (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ICF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or other relevant documents for such Combined Therapy Trial, (iii) subject recruitment and retention activities, (iv) ongoing trial site monitoring and quality assurance audits, (v) management of safety reporting by CROs and clinical trial sites, (vi) ongoing medical monitoring, (vii) management, monitoring, and audits of CROs, (viii) inquiries from clinical study subjects, (ix) packaging, labeling, and distributing the Combined Therapy for use in such Combined Therapy Trial, and (x) management of health authority inspections at clinical trial sites ((i)-(x), collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Operational Matters</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  The Conducting Party shall use Commercially Reasonable Efforts to perform all Operational Matters; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in the event that the Conducting Party receives a telephonic communication from a Regulatory Authority requesting an immediate response regarding the Combined Therapy that the Conducting Party reasonably determines must be immediately given to protect patient safety or to prevent undue and significant disruption in the conduct of a Combined Therapy Trial, the Conducting Party shall provide such response as it reasonably deems advisable (and that is consistent with the terms of this Agreement); provided, that it immediately notifies the Non-Conducting Party via the JPT or JSC for approval; and provided further that in no event shall the Conducting Party make any response relating to the Non-Conducting Party Compound as a monotherapy without the Non-Conducting Party&#8217;s prior written consent; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">shall establish an External Study Steering Committee (&#8220;ESSC&#8221;) to provide scientific and medical advice and guidance of the Combined Therapy and the conduct of such Combined Therapy Trial during the conduct of the study.  The members of the ESSC shall have appropriate levels of experience in the relevant </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">12</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">disease area, scientific, medical, and clinical trial management experience, as well as shall function as investigative sites to evaluate and provide guidance on the design and conduct of the study. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.7&#160;&#160;&#160;&#160;Decision Making</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All decisions of the JSC and JPT shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote.  In the case of the JPTs, such one (1) vote shall rest with the designated chair for each Party.  If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before a committee, the representatives of the Parties cannot reach an agreement as to such matter within [ * ] after such matter was brought to such committee for resolution, then, if such disagreement arose within the JPT, it shall be referred to the JSC for resolution.  If the JSC cannot resolve such matter within [ * ], or if the disagreement first arose within the JSC, then either Party at any time may refer such issue to the Executive Officers for resolution.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Executive Officers are unable to reach a resolution within [ * ] of such referral, then: </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if such dispute is with respect to an amendment to a Protocol or protocol synopsis (including any immunogenicity analysis), Bioanalysis Plan, Statistical Analysis Plan, or Combined Therapy Trial budget, the status quo shall persist unless and until the Parties agree; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Conducting Party shall have final decision making authority with respect to the day-to-day management and operations (inclusive of trivial changes to the Protocol, Protocol synopsis, Sample Analysis Plan, and/or Statistical Analysis Plan) of the Combined Therapy Trial for which it is the Conducting Party; provided that the Conducting Party shall not have the right to make changes to day-to-day management and operations of the Combined Therapy Trial that will or are reasonably likely to have a material adverse effect on the Combined Therapy Trial or either Party&#8217;s rights under this Agreement; and provided further that if or to the extent that any such change results in an increase to the then-current budget, the terms of Section 8.4(b) shall govern the Parties&#8217; rights and obligations in respect of any such increased costs. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All other disputes under this Agreement which do not fall under Sections 3.7 (a) or (b) shall be resolved in accordance with Section 14.3.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.8&#160;&#160;&#160;&#160;Limitations on Authority</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The JSC and JPT shall have only such powers as are expressly assigned to such committee in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, neither the JSC nor the JPT will have the power to amend or interpret this Agreement, and no JSC or JPT decision may be in contravention of any term or condition of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.9&#160;&#160;&#160;&#160;Alliance Managers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Alliance Manager</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Term.  If not already a member of the JSC, each Alliance Manager shall be permitted to attend JSC meetings as appropriate as non-voting participants.  The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate communication between the Parties with respect to all such activities hereunder.  Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.  Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.  Each Party shall bear its own costs of its Alliance Manager. </font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LICENSE GRANTS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;Grant by Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms of this Agreement, Roche hereby grants, and shall cause its Affiliates to grant, to Exelixis a non-exclusive, worldwide, non-transferable, royalty-free license, with the right to sublicense in accordance with Section 4.3, under the Roche Independent Patents, Roche Technology, and Roche Regulatory Documentation to use the Roche Compound solely as necessary to perform Exelixis&#8217; obligations under this Agreement.  To the extent that a CRO or other Third Party assigns or licenses to Roche any right, title, or interest in any intellectual property rights to be owned by or licensed to Exelixis pursuant to the terms of this Agreement, </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Roche shall, where and to the extent expressly provided in this Agreement, assign or license same to Exelixis as provided in this Agreement and confirm such assignment or license in writing upon Exelixis&#8217; request.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Grant by Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms of this Agreement,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis hereby grants, and shall cause its Affiliates to grant, to Roche a non-exclusive, worldwide, non-transferable, royalty-free license, with the right to sublicense in accordance with Section 4.3, under the Exelixis Independent Patents, Exelixis Technology, and Exelixis Regulatory Documentation to use the Exelixis Compound, solely as necessary to perform its obligations under this Agreement, but excluding the Takeda Territory.  To the extent that a CRO or other Third Party assigns or licenses to Exelixis any right, title, or interest in any intellectual property rights to be owned by or licensed to Roche pursuant to the terms of this Agreement, Exelixis will, where and to the extent expressly provided in this Agreement, assign or license same to Roche as provided in this Agreement and confirm such assignment or license in writing upon Roche&#8217;s request.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;Sublicensing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Party shall have the right to grant sublicenses under the licenses granted to it under Section 4.1 or Section 4.2, as applicable, to Affiliates and Third Parties to perform its obligations with respect to the conduct of the Combined Therapy Trials, except that, (i) neither Roche nor any of its sublicensees shall have the right to grant Chugai (or any of Chugai&#8217;s Affiliates) any sublicense under the licenses granted to Roche in Section 4.2 without Exelixis&#8217; prior written consent, and (ii) neither Exelixis nor any of its sublicensees shall have the right to grant Ipsen, Takeda, or any of their respective Affiliates any sublicense under the licenses granted to Exelixis in Section 4.1 without Roche&#8217;s prior written consent. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Before allowing any subcontractor to begin performing any activity for a Combined Therapy Trial, the subcontracting Party shall enter into a written agreement with such subcontractor that obligates such subcontractor (and its personnel involved in the performance of such activity) to be bound by the terms and conditions of this Agreement applicable to the activity to be performed by such subcontractor in the same manner as such terms and conditions apply to such Party.  The subcontracting Party shall be responsible for the direction and coordination of the services of each subcontractor, and shall ensure the subcontractor&#8217;s compliance with the terms and conditions of this Agreement.  No contractual relationship shall be created between the non-subcontracting Party and the subcontracting Party&#8217;s subcontractors, other than the non-subcontracting Party&#8217;s position as a third-party beneficiary of the services of such subcontractors and to the written agreements between the subcontracting Party and its subcontractors.  Each Party shall provide written notice to the other of any sublicense granted by it.  The sublicensing Party shall remain liable for the actions of its sublicensees. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;No Implied Licenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as specifically set forth in this Agreement, neither Party shall acquire any license or other intellectual property right, by implication or otherwise, in any intellectual property of the other Party, including Confidential Information disclosed to it under this Agreement or under any Patents Controlled by the other Party or its Affiliates.</font></div><div style="line-height:120%;text-align:center;padding-left:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 5</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">MANUFACTURE AND SUPPLY</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Exelixis Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Manufacture, Supply, and Packaging</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis shall Manufacture or have Manufactured the Exelixis Compound in drug product and/or drug substance form (as necessary) in reasonable quantities and at the points in time as agreed by the JSC for each Combined Therapy Trial and each Independent Combined Therapy Trial.  If Exelixis is the Non-Conducting Party for a Combined Therapy Trial (or the Responding Party for an Independent Combined Therapy Trial), it shall supply such Exelixis Compound to Roche or its designee for use in such Combined Therapy Trial, and Roche shall package and label the Exelixis Compound for use in such Combined Therapy Trial.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Cost</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The cost of Manufacture and supply (including shipping, taxes and duty, if applicable) of Exelixis Compound for the Combined Therapy Trials shall be borne solely by Exelixis. Exelixis shall deliver the Exelixis Compound to Roche or its designee DAP (Roche site or its designated consignee site) Incoterms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;2010.  Exelixis shall be responsible for the payment of any Third Party License Payments that may be due as a result of the manufacture, supply, and use of the Exelixis Compound for use in the Combined Therapy Trials.  Reasonable out-of-pocket costs incurred by Roche in packaging and labeling the Exelixis Compound for use in the Combined Therapy Trials shall be included in the Shared Costs under the Agreement.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Quality</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Exelixis Compound shall be manufactured in accordance with Applicable Law (including GMP) and shall be of equivalent quality to the Exelixis Compound used by Exelixis for its other clinical trials of the Exelixis Compound.  Exelixis shall deliver certificates of analysis, and any other documents specified in the Quality Agreement for the Exelixis Compound provided under this Agreement.  Exelixis shall inform Roche as to the GMP Manufacturing and testing site of bulk drug substance for the Exelixis Compound, as well as the Exelixis Compound drug product GMP Manufacturing and testing site, prior to the start of the Combined Therapy Trials and provide [ * ] written notice if there is any change to any such site.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Use of Exelixis Compound by Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche shall use the quantities of Exelixis Compound supplied to it under this Agreement solely as necessary for, and in accordance with, this Agreement and the applicable Protocols, and for no other purpose.  Except as may be required under this Agreement, a Bioanalysis Plan, or a Protocol, Roche shall not perform, and shall not permit any Third Party to perform, any analytical testing of the Exelixis Compound supplied to it under this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Roche Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Manufacture, Supply, and Packaging</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche shall Manufacture or have Manufactured the Roche Compound in drug product and/or drug substance form (as necessary) in reasonable quantities and at the points in time as agreed by the JSC for each Combined Therapy Trial and each Independent Combined Therapy Trial.  If Roche is the Non-Conducting Party for a Combined Therapy Trial (or the Responding Party for an Independent Combined Therapy Trial), it shall supply such Roche Compound to Exelixis or its designee for use in such Combined Therapy Trial, and Exelixis shall package and label the Roche Compound for use in such Combined Therapy Trial.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Cost</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The cost of Manufacture and supply (including shipping, taxes and duty, if applicable) of Roche Compound for the Combined Therapy Trials shall be borne solely by Roche. Roche shall deliver the Roche Compound to Exelixis or its designee DAP (Exelixis site or its designated consignee site) Incoterms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;2010.  Roche shall be responsible for the payment of any Third Party License Payments that may be due as a result of the manufacture, supply, and use of the Roche Compound for use in the Combined Therapy Trials.  Reasonable out-of-pocket costs incurred by Exelixis in packaging and labeling the Roche Compound for use in the Combined Therapy Trials shall be included in the Shared Costs under the Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Quality</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Roche Compound shall be manufactured in accordance with Applicable Law (including GMP) and shall be of equivalent quality to the Roche Compound used by Roche for its other clinical trials of the Roche Compound.  Roche shall deliver to Exelixis certificates of analysis, and any other documents specified in the Quality Agreement for the Roche Compound provided under this Agreement.  Roche shall inform Exelixis as to the GMP Manufacturing and testing site of bulk drug substance for the Roche Compound, as well as the Roche Compound drug product GMP Manufacturing and testing site, prior to the start of the Combined Therapy Trials and provide [ * ] written notice if there is any change to any such site.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Use of Roche Compound by Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis shall use the quantities of Roche Compound supplied to it under this Agreement solely as necessary for, and in accordance with, this Agreement and the applicable Protocols, and for no other purpose.  Except as may be required under this Agreement, a Bioanalysis Plan, or a Protocol, Exelixis shall not perform, and shall not permit any Third Party to perform, any analytical testing of the Roche Compound supplied to it under this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.3&#160;&#160;&#160;&#160;Quality Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Within [ * ] after the Effective Date, and in no event later than the date on which the first shipment of bulk Exelixis Compound or bulk Roche Compound is supplied for use in the Combined Therapy Trials, the Parties shall enter into a quality agreement with respect to such supply (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Quality Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  The Quality Agreement shall detail the documentation required to enable regulatory submissions (CTAs), final Qualified Persons release, and import licenses for the Combined Therapy Trials.  The Quality Agreement shall also indicate whether any required transfer of analytical methods will be necessary to support identity testing of a Party&#8217;s Compound.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.4&#160;&#160;&#160;&#160;Supply Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Within [ * ] after the Effective Date (for the Initial Trials) or within [ * ] of finalizing a protocol for a Combined Therapy Trial, and in no event later than the date on which the first shipment of bulk Exelixis Compound or bulk Roche Compound is supplied for use in a Combined Therapy Trial, the Parties shall enter into a supply agreement with respect to such supply (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Supply Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), substantially in the form attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Supply Agreement shall set forth terms for forecasting, ordering, product acceptance </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">and rejection, and other customary provisions for the supply of the Compounds for use in the Combined Therapy Trials.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.5&#160;&#160;&#160;&#160;Customs Valuation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Conducting Party will provide the Non-Conducting Party in writing with a list of all countries participating in a Combined Therapy Trial prior to Initiation of such Combined Therapy Trial.  During the conduct of such Combined Therapy Trial, the Conducting Party will send in writing any changes to the list of participating countries to the Non-Conducting Party promptly after they become aware, and in any event, no later than [ * ] prior to the end of each [ * ].  If no changes are sent to the Non-Conducting Party by the Conducting Party for a particular [ * ], the prior [ * ] participating country list will be used as the basis for customs valuation for that [ * ].  The Non-Conducting Party will provide the Conducting Party with its Compound country-specific customs valuations prior to Initiation of the applicable Combined Therapy Trial and at the end of each [ * ] during the conduct of such Combined Therapy Trial.  The Conducting Party will use the Non-Conducting Party values for the import/export process and shall not make any change to such valuations without the Non-Conducting Party&#8217;s prior written consent.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 6</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RESPONSIBILITIES</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.1&#160;&#160;&#160;&#160;Specific Responsibilities of the Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms of this Agreement, each Party shall use Commercially Reasonable Efforts to (a) supply the quantities of its Compound as needed to conduct a Combined Therapy Trial on a timely basis; (b) conduct and complete each Combined Therapy Trial and any Statistical Analysis Plans and Bioanalysis Plans relating thereto on a timely basis in accordance with the Protocol, Bioanalysis Plans, Statistical Analysis Plans, and Third Party agreements relating thereto; (c) timely provide Rights of Reference where required by this Agreement; and (d) in the case of the Conducting Party, provide sufficient resources and personnel to conduct the Combined Therapy Trial for which it is the Conducting Party, and to adequately fund the Combined Therapy Trial, on a timely basis in accordance with the applicable Protocol and the terms of this Agreement.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.2&#160;&#160;&#160;&#160;Conducting Party&#8217;s Responsibilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to JPT direction and JSC oversight, and without limiting the other terms of this Agreement, a Party shall be responsible for the following activities in connection with each Combined Therapy Trial for which it is the Conducting Party:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">packaging and labeling the Combined Therapy for use in the Combined Therapy Trials;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the JPT with immediate notice of any Manufacturing and/or supply issues with respect to its Compound that may adversely impact the conduct or timelines of a Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing notice of any Regulatory Authority inspections, or any other events potentially impacting regulatory status of the Combined Therapy Trial and/or the Non-Conducting Party&#8217;s Compound promptly after the Conducting Party becomes aware of such;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">with the Non-Conducting Party&#8217;s cooperation, compiling, amending, and filing all necessary Combined Therapy Trial Regulatory Documentation with the applicable Regulatory Authorities;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">acting as the sponsor of record as provided in 21 CFR 312.50 (and applicable comparable ex-US laws), unless otherwise delegated in accordance with 21 CFR 312.52 (and applicable comparable ex-US laws), and making all required submissions to Regulatory Authorities related thereto on a timely basis;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">with the Non-Conducting Party&#8217;s cooperation, and subject to the provisions of Section 9.6, listing each Combined Therapy Trial required to be listed on a public database, including clinicaltrials.gov or other public registry in any country in which such Combined Therapy Trial is being conducted in accordance with Applicable Law and in accordance with each Party&#8217;s internal policies on clinical trial registration;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the Non-Conducting Party with reasonable advance notice of scheduled meetings or other material non-written communications with a Regulatory Authority and the opportunity to participate in each such meeting (to the extent permitted by Applicable Law and such Regulatory Authority) or other non-written communication, and providing such opportunity to participate in such meetings (to the extent permitted by Applicable Law and such Regulatory Authority) to those licensees of the Non-Conducting Party (for their respective territories), and, unless otherwise agreed by the JSC, approving all submissions and written </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">correspondence with a Regulatory Authority that relates to the conduct of the Combined Therapy Trial or the Non-Conducting Party Compound; except that (i) in no event shall the Conducting Party or any Affiliate of the Conducting Party communicate with any Regulatory Authority solely with respect to the Non-Conducting Party Compound without the prior written consent of the Non-Conducting Party; (ii) the Non-Conducting Party shall step out of any portions of any such Regulatory Authority meetings or other non-written communications that relate solely to the Conducting Party Compound; and (iii) the Conducting Party shall step out of any portions of such Regulatory Authority meetings or other non-written communications that relate solely to the Non-Conducting Party Compound; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">unless otherwise agreed by the JPT, providing to the Non-Conducting Party a written summary of meetings or other non-written communications with a Regulatory Authority within [ * ] after such meeting or communication, and copies of any official correspondence to or from a Regulatory Authority within [ * ] after a Party&#8217;s receipt or provision of such correspondence, and copies of all Combined Therapy Trial Regulatory Documentation within [ * ] after submission to Regulatory Authorities;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">drafting and providing to the Non-Conducting Party (through the JPT) for its review and approval each Protocol and investigator&#8217;s brochure for a Combined Therapy Trial, and the related template informed consent form, template clinical site agreement, Bioanalysis Plan, and Statistical Analysis Plan, and any amendments to each of the foregoing; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">coordinating with the Non-Conducting Party and providing to the JPT at least [ * ] in advance of submission drafts of (A) submissions to the Combined Therapy IND, (B) Combined Therapy Trial Regulatory Documentation, and (C) all other written correspondence with a Regulatory Authority relating to the Combined Therapy Trials; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">managing the operations of the Combined Therapy Trials in accordance with the applicable Protocol, including overseeing compliance by any CRO engaged by the Conducting Party for the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing to the Non-Conducting Party (via the JPT) a list of all proposed clinical trial sites and principal investigator(s) and recruitment plan for each Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">ensuring that all CRO agreements and clinical trial site agreements (i) are consistent with the relevant terms of this Agreement, including confidentiality and intellectual property provisions consistent with those set forth in this Agreement, and (ii) permit the Parties to audit trial sites for quality assurance and to inspect and copy all data, documentation and work products relating to the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">coordinating all iDMC, iDCC, and DRB activities;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the Non-Conducting Party with minutes from all external drug safety monitoring boards for the Combined Therapy Trials; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the Non-Conducting Party with updates on the status and details of the Combined Therapy Trials through the JPT and otherwise at the Non-Conducting Party&#8217;s reasonable request;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to Section 2.10 and the Pharmacovigilance Agreement, owning and being responsible for the maintenance of the Safety Database and safety reporting for the Combined Therapy, and providing the Non-Conducting Party the opportunity to participate in and comment on such pharmacovigilance activities;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the Non-Conducting Party with the most current Investigator&#8217;s Brochure for the Conducting Party&#8217;s Compound;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">analyzing the Study Data in a timely fashion and providing the Non-Conducting Party with access to the Study Data from the applicable Combined Therapy Trial as follows: </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a timetable determined by the JPT: (A) sharing with the Non-Conducting Party for review and comment drafts of interim and final clinical trial reports and statistical analysis conducted in accordance with the Statistical Analysis Plan from each Combined Therapy Trial and (B) providing the Non-Conducting Party the raw Study Data in electronic or other mutually agreed format;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">data set specifications (i.e., that define the structure, variables, and derivations for raw, SDTM, and ADAM data sets) upon finalization and amendment of such specifications during and throughout the conduct of the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">within [ * ] after either unblinding of a study, or following extracts for planned or unplanned analyses, a copy of the database (including, to the extent available, raw data (all study sources), Study Data Tabulation Model (SDTM) data sets, and&#160;the Analysis Data Model analysis data sets (e.g., ADAM) with associated specifications) in a form and by a method to be approved by the JPT at all analysis time points as specified in the Study Analysis Plan (SAP); </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">concurrent with the delivery to the Non-Conducting Party of each version of the final clinical trial report (e.g. interim, final, amendments), the Conducting Party shall also provide the SDTM data sets and the ADaM data sets used to generate such report or summary (to the extent not already provided), and other appropriate documentation including a Study Data Reviewers Guide, an Analysis Data Reviewers Guide that is provided to Health Authorities, a blank CRF, and an SDTM-annotated CRF; provided that (A) all data and information for cohorts that are&#160;not part of the Combined Therapy Trial will be redacted from the foregoing; and (B) prior to finalization of such  reports, the Conducting Party shall provide a redacted draft of the Study Data Tabulation Model (SDTM) and the Analysis Data Model (ADaM) data sets used to generate the report or summary (unless the Protocol for such Combined Therapy Trial provides otherwise or the JSC agrees otherwise);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">within [ * ] after either unblinding of a study, or following extracts for formal planned or unplanned analyses, access to safety databases that will be used for an interim review by an external consultant (or drug safety monitoring board, if required) to be agreed upon by the Parties;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">within [ * ] after database lock access to case report forms or patient profiles for all patients in each Combined Therapy Trial. Access to the aforementioned documents following extracts for formal planned or unplanned analyses will be subject to JPT discussion and approval.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">within [ * ] after the creation of a locked database for the Combined Therapy Trial, copies of the Form 1572s, financial disclosures, and other relevant documents required to meet regulatory requirements related to the Combined Therapy Trials (including any data or documents that may be required to provide Aggregate Safety Information to a Regulatory Authority with respect to the Non-Conducting Party Compound). Access to the aforementioned documents following extracts for formal planned or unplanned analyses will be subject to JPT discussion and approval; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">promptly providing the Non-Conducting Party with any programs or SAS codes to be used for the Statistical Analysis Plan for the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">obtaining supplies of co-medications required for use in a Combined Therapy Trial pursuant to the applicable Protocol, and promptly providing the Non-Conducting Party a copy of the information provided to the manufacturer of such co-medication; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the Non-Conducting Party with information on the pharmacokinetics, efficacy, and safety of the Conducting Party Compound in combination with the Non-Conducting Party Compound; provided however that such requests regarding the Non-Conducting party Compound alone shall be brought to JPT for discussion and approval to ensure proper input from the Non-Conducting Party on these analyses.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">collecting Samples; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the Non-Conducting Party, as provided in the Quality Agreement and based on the Non-Conducting Party sampling instructions, with samples of the Non-Conducting Party Compound (bulk and post packaging material) for analytical testing performed by the Non-Conducting Party; and </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">such other responsibilities as may be agreed to by the Parties or determined by the JPT or JSC.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Where the Conducting Party is to provide the Non-Conducting Party with the opportunity to review or comment on any document, the Conducting Party shall ensure the Non-Conducting Party has at least [ * ] from the date on which the Conducting Party provides the applicable document to the Non-Conducting Party to provide any comments.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.3&#160;&#160;&#160;&#160;Responsibilities of the Non-Conducting Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to JPT direction and JSC oversight, and without limiting the other terms of this Agreement, a Party shall be responsible for the following activities in connection with each Combined Therapy Trial for which it is the Non-Conducting Party:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the JPT or JSC with immediate notice of any Manufacturing and/or supply issues with respect to its Compound that may adversely impact the conduct or timelines of a Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">where and to the extent provided in the Quality Agreement, providing for the release by a Qualified Person (as such term is defined in the Quality Agreement), or providing the necessary documentation in support of such quality release, of the Non-Conducting Party Compound;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;performing analytical and biological testing of samples taken by the Conducting Party as necessary for the purpose of identification of the Non-Conducting Party Compound after receipt and packaging by the Conducting Party, and providing the results to the Conducting Party to permit a timely release of the Non-Conducting Party Compound for shipment to clinical trial sites;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">promptly reviewing each Protocol (including any immunogenicity analysis plan) and investigator&#8217;s brochure for the Combined Therapy, and the corresponding template informed consent form, Bioanalysis Plan, Statistical Analysis Plan, and any amendments to each of the foregoing; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">to the extent necessary for the conduct of such Combined Therapy Trial, providing a Right of Reference to the relevant Regulatory Documentation for the Non-Conducting Party Compound; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">assisting with the compilation, amendment, and filing of all necessary Combined Therapy Trial Regulatory Documentation with the applicable Regulatory Authorities, and providing the Conducting Party with copies of the Non-Conducting Party Regulatory Documentation necessary to obtain and maintain the Combined Therapy IND and prepare and file any other Combined Therapy Trial Regulatory Documentation in accordance with this Agreement, or otherwise comply with Applicable Law;  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">analyzing clinical pharmacokinetic Samples, or ADA, as required with the Non-Conducting Party Compound assay and providing copies of such data and data analysis to the Conducting Party or transferring the Non-Conducting Party Compound assays to the Conducting Party to perform the analysis;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing comment and input on the management of each Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reviewing and, if applicable, suggesting alternatives to the Conducting Party&#8217;s proposed list of principal investigators for each Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing and making available information and/or persons with knowledge on the Non-Conducting Party Compound as necessary to support the Combined Therapy Trial;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">providing the JPT with prompt notice of any interactions with Regulatory Authorities relating to the Non-Conducting Party Compound that might reasonably be expected to materially impact such Combined Therapy Trial; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">such other responsibilities as may be agreed to by the Parties or determined by the JPT.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.4&#160;&#160;&#160;&#160;Other Clinical Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  For clarity, except for the Combined Therapy Trials, each clinical trial of a Party&#8217;s Compound, alone or in combination with other pharmaceutical agents, shall not be subject to this Agreement (subject to each Party&#8217;s obligation to share relevant safety information as provided in this Agreement, the Quality Agreement, and the Pharmacovigilance Agreement).  Nothing in this Agreement shall preclude a Party from conducting a clinical trial of its Compound outside this Agreement so long as it does not use or rely on the Confidential Information of the other Party in doing so.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.5&#160;&#160;&#160;&#160;Additional Combined Therapy Trials.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If the Parties agree in writing to conduct any additional Combined Therapy Trial beyond the Initial Trials, the Pharmacovigilance Agreement and the Quality Agreement shall be amended to provide for such additional Combined Therapy Trial(s).</font></div><div style="line-height:120%;text-align:center;padding-left:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 7  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INTELLECTUAL PROPERTY</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.1&#160;&#160;&#160;&#160;Inventions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All ownership and rights in and to Inventions shall be allocated as follows:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Exelixis Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All Exelixis Study Inventions shall be owned solely by Exelixis, and Exelixis will have the full right to exploit such Exelixis Study Inventions without the consent of, or any obligation to account to, Roche.  Roche shall assign and hereby does assign (and shall cause its Affiliates and contractors to assign) all right, title, and interest in and to all Exelixis Study Inventions to Exelixis.  Roche shall execute such further documents and provide such other assistance as may be reasonably requested by Exelixis to perfect Exelixis&#8217; rights in such Exelixis Study Inventions, at Exelixis&#8217; expense.  Exelixis shall have the sole right, but not the obligation, to prepare, file, prosecute, and maintain all Exelixis Study Patents at its own expense.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Roche Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All Roche Study Inventions shall be owned solely by Roche, and Roche will have the full right to exploit such Roche Study Inventions without the consent of, or any obligation to account to, Exelixis.  Exelixis shall assign and hereby does assign (and shall cause its Affiliates and contractors to assign) all right, title, and interest in and to all Roche Study Inventions to Roche.  Exelixis shall execute such further documents and provide such other assistance as may be reasonably requested by Roche to perfect Roche&#8217;s rights in such Roche Study Inventions, at Roche&#8217;s expense.  Roche shall have the sole right, but not the obligation, to prepare, file, prosecute, and maintain all Roche Study Patents at its own expense.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Combined Therapy Inventions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All Combined Therapy Inventions shall be jointly and equally owned by the Parties.  Each Party shall be entitled to practice and exploit the Combined Therapy Inventions and Combined Therapy Patents without the duty of accounting or seeking consent from the other Party (except as expressly set forth in Section 7.1(d) and Section 7.3(d) with regard to the filing, prosecution, maintenance, and enforcement of Combined Therapy Patents).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Prosecution and Maintenance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  &#8220;Prosecution and Maintenance&#8221; with regard to a given Patent, means the preparation, filing, prosecution and maintenance of such Patent, as well as any ex parte and inter partes proceedings, including reexaminations, reissues, applications for patent term extensions, interferences, derivation proceedings, post grant review proceedings, oppositions, litigations, arbitrations and other similar proceedings with respect to such Patent. The Parties shall agree as to which of Roche or Exelixis shall be responsible for Prosecution and Maintenance of the Combined Therapy Patents, and such Party shall use outside counsel acceptable to the other Party. Each Party shall cooperate with and assist the other Party in the Prosecution and Maintenance of any Combined Therapy Patent, including consulting with the other Party after receiving any substantial action, communication or development in the Prosecution and Maintenance of such Patent and&#160;making its relevant scientists and scientific records reasonably available.  In addition, each Party shall sign and deliver, or use commercially reasonable efforts to have signed and delivered, at no charge to the other Party, all documents necessary in connection with such Prosecution and Maintenance. With respect to any Combined Therapy Patent, the outside counsel (if any) shall be instructed to (a)&#160;keep the Parties informed regarding the Prosecution and Maintenance thereof; (b)&#160;promptly furnish to each Party a copy of such Patent and copies of documents relevant to such Prosecution and Maintenance, including copies of correspondence with any patent office, foreign associates and outside counsel; and (c)&#160;act on the Parties&#8217; instructions relating to such Prosecution and Maintenance, provided that if there is a conflict in the instructions given by the Parties, outside counsel shall inform the Parties and allow for their resolution of this conflict. Notwithstanding the foregoing, the Prosecuting Party shall not take any position in a submission to a Patent office that interprets the scope of a Patent or Patent application of the Non-Prosecuting Party without the prior written consent of such Non-Prosecuting Party. The Non-Prosecuting Party shall reimburse the Prosecuting Party for [ * ] costs incurred by the Prosecuting Party in the prosecution and maintenance of the Combined Therapy Patents.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Abandonment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If a Party elects to not file or maintain a Combined Therapy Patent in a given country (or elects to not reimburse the other Party for [ * ] costs of prosecution and maintenance of such Combined Therapy Patent in such country), the other Party shall have the right to file or maintain such Patent in such country in its own name and at its own expense.  In such event, the Party who decides not to file and maintain (or not to reimburse the other Party) a joint Patent for a given country shall promptly assign its rights to the joint invention in said country to the Party who wishes to file or maintain said Patent. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Dispute</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If the Parties cannot agree with respect to the decision to file or maintain a Combined Therapy Patent within [ * ] after the initiation of the Parties&#8217; good faith efforts to resolve any disagreement, then either Party shall have the right to file or maintain a patent application for the Combined </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">20</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Therapy Patent in the names of both Parties, provided that: (A) any resulting Patent shall be deemed to be a Combined Therapy Patent jointly owned by the Parties and subject to this Section 7.1(c). </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Separation of Patent Rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  To more efficiently enable the prosecution and maintenance of the Roche Study Patents, Exelixis Study Patents, and Combined Therapy Patents, the Parties shall use commercially reasonable efforts to separate Roche Study Patents, Exelixis Study Patents, Combined Therapy Patents, Roche Independent Patents, and Exelixis Independent Patents into separate patent filings to the extent possible and without adversely impacting such prosecution and maintenance.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.2&#160;&#160;&#160;&#160;Disclosure and Assignment of Inventions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall disclose promptly to the other Party in writing and on a confidential basis all Inventions, prior to any public disclosure or filing of Patent applications and allowing sufficient time for comment by the other Party.  In addition, each Party shall assign, and hereby does assign, and shall cause its Affiliates and contractors to so assign, to the other Party, without additional compensation, such right, title, and interest in and to any Inventions as is necessary to effect the sole ownership provided for in Sections 7.1(a) and 7.1(b) and the joint ownership provided for in Section 7.1(c), as applicable.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.3&#160;&#160;&#160;&#160;Infringement of Patent Rights by Third Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall promptly notify the other Party in writing of any alleged or threatened (in writing) infringement, or misappropriation by a Third Party, of any Combined Therapy Patent of which it becomes aware (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Infringement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Infringement of Exelixis Study Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis shall have the exclusive right to prosecute any and all Infringement of any Exelixis Study Patents as it may determine in its discretion, at its own expense.  Roche shall reasonably cooperate with Exelixis in any such action (to the extent Roche has relevant information arising out of this Agreement), at Exelixis&#8217; request and expense. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Infringement of Roche Study Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche shall have the exclusive right to prosecute any and all Infringement of any Roche Study Patents as it may determine in its discretion, at its own expense.  Exelixis shall reasonably cooperate with Roche in any such action (to the extent Exelixis has relevant information arising out of this Agreement), at Roche&#8217;s request and expense.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Infringement of Combined Therapy Patents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  With respect to Infringement of any Combined Therapy Patents, the Parties shall mutually agree whether to bring an enforcement action and, if so, which Party shall bring such action.  The non-prosecuting Party shall reasonably cooperate in any such action, including, if required, by joining such action.  If the Parties mutually agree to bring an enforcement action, each Party shall be responsible for [ * ] costs incurred in connection with such action.  Any damages recovered from a Third Party in an Infringement action shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">pro rata</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;if insufficient to cover the totality of such expenses), and any remaining amounts shall be [ * ], unless the Parties agree in writing to a different allocation.  In connection with any proceeding under this Section 7.3(d), neither Party shall enter into any settlement without the prior written consent of the other Party.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.4&#160;&#160;&#160;&#160;Infringement of Third Party Rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If the performance of a Combined Therapy Trial becomes the subject of a claim of infringement of a patent, copyright, or other proprietary right by a Third Party, the Party first having notice of the claim shall promptly notify the other Party and, without regard to which Party is charged with said infringement and the venue of such claim, the Parties shall promptly confer to discuss the claim and the appropriate course of action and may, if appropriate, agree on and enter into a &#8220;common interest agreement&#8221; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Defense</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If an infringement claim described in Section 7.4(a) is brought against one or both Parties, the Parties shall defend such claim jointly, unless they agree otherwise in writing.  If the Parties jointly defend the claim, the Parties shall [ * ].  If only one Party is charged with infringement, such Party will have the first right, but not the obligation, to defend such claim.  If the charged Party does not commence actions to defend such claim within [ * ] after being so charged, then the other Party shall have the right, but not the obligation, to defend such claim.  The non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim and shall have the right to participate with separate counsel at its own expense, and the defending Party shall consider in good faith the non-defending Party&#8217;s comments and suggestions on strategy for defending such </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">21</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">action.  The Party defending the claim shall [ * ].  No Party shall enter into any settlement concerning activities under this Agreement or the Combined Therapy that affects the other Party&#8217;s rights under this Agreement or imposes any obligations on the other Party, including any admissions of wrongdoing on behalf of the other Party, without such other Party&#8217;s prior written consent, such consent not to be unreasonably withheld or delayed.  Notwithstanding the foregoing, if a claim relates solely to one Party&#8217;s Compound, such Party shall have the sole right, but not the obligation, to defend and settle the disposition of such claim, at its sole expense, so long as the other Party&#8217;s rights under this Agreement are not materially adversely impacted. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.5&#160;&#160;&#160;&#160;Combined Therapy Trial Regulatory Documentation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties shall jointly and equally own all right, title, and interest in and to the Combined Therapy Trial Regulatory Documentation.  For clarity, Roche shall retain sole and exclusive ownership of the Roche Regulatory Documentation that is submitted with or referenced in the Combined Therapy Trial Regulatory Documentation, and Exelixis shall retain sole and exclusive ownership of the Exelixis Regulatory Documentation that is submitted with or referenced in the Combined Therapy Trial Regulatory Documentation.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.6&#160;&#160;&#160;&#160;Joint Research Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties acknowledge and agree that this Agreement is a &#8220;Joint Research Agreement&#8221; as defined in 35 USC &#167; 100 (h).</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FINANCIAL TERMS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.1&#160;&#160;&#160;&#160;Combined Therapy Trial Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche shall be responsible for fifty percent (50%), and Exelixis shall be responsible for fifty percent (50%), of the Shared Costs for each Combined Therapy Trial.  Shared Costs shall be incurred consistent with the JSC-approved budget for such Combined Therapy Trial.  The Parties must approve, under the JSC, a final budget prior to [ * ] for a given Combined Therapy Trial.  A JPT will review the budget on a [ * ] basis, and re-calibration of study forecast will be conducted by the Conducting Party if the applicable JPT determines it is necessary.  Each Party shall calculate Shared Costs in accordance with US GAAP (Generally Accepted Accounting Principles) or International Financial Reporting Standards.  For clarity, expenses incurred as described in Article 5 (regarding manufacturing and supply) and Article 7 (regarding intellectual property) shall not be considered &#8220;Shared Costs&#8221;, and shall be borne or shared by the Parties as provided in such Articles.&#160; In addition, each Party shall bear its own Third Party License Payments as set forth in Section 5.1(b).&#160; For the avoidance of doubt, nothing in this Agreement shall establish an employment relationship between one Party and the employees of the other Party regardless of the reimbursement to such other Party for work performed by its employees under this Agreement.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.2&#160;&#160;&#160;&#160;Independent Combined Therapy Trial Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Party conducting an Independent Combined Therapy Trial shall be solely responsible for the costs incurred in the performance of such Independent Combined Therapy Trial, subject to Section 5.1(a) and 5.2(a), as applicable (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Independent Trial Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  [ * ]  If the Responding Party desires to submit any portion of the data resulting from an Independent Combined Therapy Trial to support a regulatory approval, or use the data for its own development, regulatory or commercial purposes, then the Responding Party shall notify the Proposing Party in writing at any time following the completion of such Independent Combined Therapy Trial.  Within [ * ] after its receipt of such notice, the Proposing Party shall submit to the Responding Party a [ * ] invoice setting forth [ * ], and the Responding Party shall pay the amount invoiced [ * ].  Once payment is made, data transfer to the Responding Party shall occur as provided in this Agreement for a Combined Therapy Trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.3&#160;&#160;&#160;&#160;Background Data Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If either Party wishes to include any data from the other Party&#8217;s clinical trials of the Combined Therapy conducted prior to or outside of this Agreement (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Background Combined Therapy Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) in an application for regulatory approval or marketing approval of the Combined Therapy, or wishes to use such data for their own development, regulatory or commercial activities, then the conducting Party shall deliver a copy of the database and data generated in such Background Combined Therapy Trial, on a cohort-by-cohort basis, at a cost equal to [ * ] the costs incurred in connection with the relevant cohort within such Background Combined Therapy Trial, to the requesting Party.  Prior to the delivery of such data, the conducting Party shall submit a reasonably detailed invoice [ * ] for [ * ] such costs and the requesting Party shall pay the amount invoiced within [ * ] after its receipt of such invoice; provided however that the requesting Party shall have a right to request supporting documentation for such invoice and any dispute over the accuracy of such invoice shall be resolved by the applicable JPT.  The conducting Party shall provide the requested data to the requesting Party within [ * ] of receipt of such payment.  The method for calculating such costs on a cohort-by-cohort basis shall be [ * ].  For </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">clarity, the foregoing payment shall not apply to safety data required by a Regulatory Authority, and each Party shall provide all such safety data to such Regulatory Authority at no additional cost to the other Party.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.4&#160;&#160;&#160;&#160;Shared Costs Invoicing; Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. &#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Reporting and Invoicing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.&#160; Within [ * ] after the end of each Quarter, each Party shall provide to the other Party a reasonably detailed report setting forth the Shared Costs incurred by such Party during such Quarter (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Quarterly Report</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).&#160; The Parties shall cooperate to promptly resolve any questions or Disputes related to such reports within [ * ] following the end of each Quarter.&#160; Using the Quarterly Reports, the Parties&#8217; respective finance teams shall determine the amount, if any, owed by one Party to the other Party for such Quarter within [ * ] the end of each Quarter.  The Party owing the other Party shall make a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">True-Up Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; to such other Party within [ * ] after end of each Quarter.  Disputes that cannot be resolved by the Parties&#8217; respective finance teams shall be escalated to the JSC for resolution.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Budget Overruns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.&#160; Any amounts incurred by a Party that exceed [ * ] amounts approved by the JSC in the applicable budget (i.e., more than [ * ] over the budgeted amount) shall require approval of the JSC to be deemed a Shared Cost.  To the extent that such overruns can be [ * ] by the Conducting Party, the JSC shall approve such increases to the applicable budget. If the JSC so agrees, the Parties shall bear the cost of any such budget overrun equally; except that if the reason for the overrun [ * ], then the amount of any overrun that [ * ] shall be [ * ].&#160; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.5&#160;&#160;&#160;&#160;Audit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.&#160;&#160;Each Party shall keep, and shall require its Affiliates to keep, complete and accurate records pertaining to the performance of its activities under this Agreement.  Each Party shall keep such books and records for [ * ] following the calendar year to which they pertain, or such longer period of time as may be required by Applicable Laws.&#160; Upon reasonable prior notice and during regular business hours at such place or places where such records are customarily kept, a Party&#8217;s records may be inspected on the other Party&#8217;s behalf by an independent certified public accountant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Auditor</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying the accuracy of the Quarterly Reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, to a Party pursuant to this Agreement.  Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.  Such audits shall be limited to results in  and further limited to the [ * ] prior to audit notification. Such audits shall not be performed more frequently than [ * ] each calendar year and once with respect to records covering any specific period of time.  Such auditor shall not disclose a Party&#8217;s Confidential Information to the other Party, and shall only verify the accuracy or inaccuracy of the Quarterly reports furnished by a Party or the amount of payments to or by a Party under this Agreement, and, in the case of any inaccuracy, the amount of such inaccuracy.  In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within [ * ] after the Auditor&#8217;s report.  The auditing Party shall bear the full cost of such audit unless such audit reveals an underpayment of more than [ * ] by the audited Party, in which case the audited Party shall reimburse the auditing Party for the reasonable costs of such audit.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 9</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECORDS AND STUDY DATA</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.1&#160;&#160;&#160;&#160;Records</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall maintain complete and accurate records of all work conducted with respect to the Combined Therapy Trials and of all results, information, data, data analyses, reports, records, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences and developments made by or provided to either Party, or by the Parties together, in the course of such Party&#8217;s efforts with respect to the Combined Therapy Trials (including the Statistical Analysis Plan and Bioanalysis Plan to be conducted pursuant to this Agreement) (all of the foregoing, the &#8220;Study Data&#8221;).  Such records shall fully and properly reflect all work done and results achieved in the performance of the Combined Therapy Trials in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.2&#160;&#160;&#160;&#160;Ownership of Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche shall own the Study Data that relates exclusively to the Roche Compound (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), Exelixis shall own the Study Data that relates exclusively to the Exelixis Compound (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and the Parties shall jointly and equally own all other Study Data (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combined Therapy Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Each Party shall assign, and hereby does assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title, and interest in and to all Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.  </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">23</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.3&#160;&#160;&#160;&#160;Use of Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Use of a Party&#8217;s Own Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche may use and analyze the Roche Study Data for any purpose without obligation or accounting to Exelixis.  Exelixis may use and analyze the Exelixis Study Data for any purpose without obligation or accounting to Roche. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Use of Combined Therapy Study Data by Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche and its Affiliates and (sub)licensees of the Roche Compound shall have the right to use and analyze the Combined Therapy Study Data for any and all purposes without the consent of, or any obligation to account to, Exelixis, including (i) in connection with their independent development, commercialization or other exploitation of the Roche Compound (alone or in combination with the Exelixis Compound and/or other pharmaceutical agents) and for inclusion in the safety database for the Roche Compound, and (ii) to conduct studies with Samples pursuant to Section 9.5.  Subject to Section 9.5, the results of all such uses or analyses shall be owned by Roche, including any intellectual property rights therein, unless the Parties otherwise agree in writing.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Use in Regulatory Filings by Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In addition, Roche and its Affiliates and (sub)licensees of the Roche Compound shall have the right to use the Combined Therapy Study Data during and following the term of this Agreement to (i) submit regulatory filings and seek approvals for the Roche Compound as part of the Combined Therapy and (ii) following the applicable approval of the Combined Therapy, to promote indications based on, and to disseminate, the Combined Therapy Study Data for the benefit of the Roche Compound as part of the Combined Therapy, where permitted by and in accordance with Applicable Law.  If Roche submits Combined Therapy Study Data to a Regulatory Authority in a filing for approval for the use of the Roche Compound in combination with the Exelixis Compound, then Roche shall be granted a Right of Reference to the relevant Regulatory Documentation Controlled by Exelixis for the Exelixis Compound and the Combined Therapy solely to the extent required for the purpose of such approval (which right shall survive any expiration or termination of this Agreement).  In such case, Exelixis shall reasonably cooperate with Roche and make written authorizations and other filings with the applicable Regulatory Authority reasonably required to effect such Right of Reference.  Such grant to Roche of a Right of Reference shall not include a Right of Reference for use in the Takeda Territory, without Exelixis&#8217; prior written consent; provided, however, that Exelixis shall use all reasonable efforts to obtain rights for Roche in Japan, subject to their agreement with Takeda in Japan.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Use of Combined Therapy Study Data by Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and its Affiliates and (sub)licensees of the Exelixis Compound shall have the right to use and analyze the Combined Therapy Study Data for any and all purposes without the consent of, or any obligation to account to, Roche, including (i) in connection with their independent development, commercialization or other exploitation of the Exelixis Compound (alone or in combination with the Roche Compound and/or other pharmaceutical agents) and for inclusion in the safety database for the Exelixis Compound, and (ii) to conduct studies with Samples pursuant to Section 9.5.  Subject to Section 9.5, the results of all such uses or analyses shall be owned by Exelixis, including any intellectual property rights therein, unless the Parties otherwise agree in writing.   </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Use in Regulatory Filings by Exelixis.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In addition, Exelixis and its Affiliates and (sub)licensees of the Exelixis Compound shall have the right to use the Combined Therapy Study Data during and following the term of this Agreement to (i) submit regulatory filings and seek approvals for the Exelixis Compound as part of the Combined Therapy and (ii) following the applicable approval of the Combined Therapy, to promote indications based on, and to disseminate, the Combined Therapy Study Data for the benefit of the Exelixis Compound as part of the Combined Therapy, where permitted by and in accordance with Applicable Law.  If Exelixis submits Combined Therapy Study Data to a Regulatory Authority in a filing for approval for the use of the Exelixis Compound in combination with the Roche Compound, then Exelixis shall be granted a Right of Reference to the relevant Regulatory Documentation Controlled by Roche for the Roche Compound and the Combined Therapy solely to the extent required for the purpose of such approval (which right shall survive any expiration or termination of this Agreement).  In such case, Roche shall reasonably cooperate with Exelixis and make written authorizations and other filings with the applicable Regulatory Authority reasonably required to effect such Right of Reference.  Such grant to Exelixis of a Right of Reference shall not include a Right of Reference for use in Japan, without Roche&#8217;s prior written consent; provided, however, that Roche shall use all reasonable efforts to obtain rights for Exelixis in Japan, subject to any agreement Roche may have with a local Affiliate.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Biomarker Development</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party may use and disclose to a Third Party the Combined Therapy Study Data and its Compound&#8217;s Study Data, under obligations of confidentiality consistent with this Agreement, to develop and commercialize a biomarker or diagnostic test for use with its Compound and/or the Combined Therapy, and, unless otherwise mutually agreed by the Parties in writing, will own any intellectual </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">24</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">property arising out of the work funded or conducted by it with or through such Third Party.  The Parties will discuss in good faith any opportunities to jointly participate in the development of any such biomarker or diagnostic test for use with the Combined Therapy.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;[ * ]</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;No Other Uses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly set forth in this Agreement, neither Party may use Study Data for any other purpose without the consent of the other Party during and after the Term of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.4&#160;&#160;&#160;&#160;Access to Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the Pharmacovigilance Agreement, each Party shall have access to all Study Data (including, but not limited to, de-identified patient records) as soon as reasonably practicable after Study Data is available to or generated by the Party responsible for generating or collecting such Study Data.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.5&#160;&#160;&#160;&#160;Samples</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Samples collected in the course of activities conducted under this Agreement shall be jointly and equally owned by the Parties (to the extent not owned by the patient and/or the clinical trial site).  Any such Samples shall be collected in accordance with the applicable Protocol and ICFs.  Except as set forth in a Bioanalysis Plan, no Party shall be permitted to use such Samples for any purpose without the approval of the JPT.  All data and intellectual property arising out of such Sample use shall be owned by the Party conducting such study; provided that to the extent that any such data or intellectual property relates to the Combined Therapy (or biomarkers solely for use with the Combined Therapy), such data and intellectual property shall be considered Combined Therapy Study Data or Combined Therapy Inventions, and Combined Therapy Patents, as applicable.  The Parties shall agree on which Party shall store the Samples for PK and ADA analysis for future use; provided that [ * ].  If neither Party has any further use for the Samples, then the remaining Samples shall be destroyed pursuant to the respective Party&#8217;s standard operating procedures for sample destruction, subject to the terms of and permission(s) granted in the ICFs signed by the subjects contributing such Samples in the Combined Therapy Trials.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.6&#160;&#160;&#160;&#160;Existing Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If a Combined Therapy Trial is added to a pre-existing clinical trial of one of the Parties, none of the cohorts of such pre-existing clinical trial shall be deemed part of the Combined Therapy Trial and none of the results, information, data, data analyses, reports, records, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, and developments from such cohorts will be Study Data unless the Protocol expressly provides otherwise.  Where a cohort of a Combined Therapy Trial is a monotherapy cohort with just the Exelixis Compound or with just the Roche Compound, then the Study Data from such cohort will be Exelixis Study Data in the case where such cohort is a monotherapy cohort with just the Exelixis Compound and Roche Study Data in the case where such cohort is a monotherapy cohort with just the Roche Compound.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONFIDENTIALITY</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.1&#160;&#160;&#160;&#160;Confidential Information</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [ * ] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to the remainder of this Article 10, shall not publish or otherwise disclose the terms of this Agreement.  Each Party may use the other Party&#8217;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.  Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the other Party&#8217;s Confidential Information.  Each Party will promptly notify the other upon discovery of any loss or unauthorized use or disclosure of the other Party&#8217;s Confidential Information.  For clarity, Combined Therapy Study Data shall be treated as Confidential Information of both Parties and shall not be disclosed to Third Parties unless it falls within the exceptions set forth in Section 10.2 below or is reasonably necessary to be disclosed in order for a Party to exercise its rights under Section 9.3.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.2&#160;&#160;&#160;&#160;Exceptions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The obligations of confidentiality and restriction on use under Section 10.1 will not apply to any information that the receiving Party can prove by competent written evidence:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">is independently discovered or developed by the receiving Party without the use of the disclosing Party&#8217;s Confidential Information. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.3&#160;&#160;&#160;&#160;Authorized Disclosure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding any other provision of this Agreement, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">prosecuting or defending litigation as permitted by this Agreement; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">complying with Applicable Law (including regulations promulgated by any securities exchange); </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">disclosure, in connection with the performance of this Agreement, to Affiliates, permitted sublicensees, contractors, manufacturers, ethics committees and IRBs, academic institutions, consultants, agents, investigators, and employees engaged in connection with the performance of a Combined Therapy Trial, each of whom prior to disclosure must be bound by similar terms of confidentiality and non-use at least equivalent in scope to those set forth in this Article 10; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">disclosure of the Combined Therapy Study Data, Combined Therapy Inventions, and Combined Therapy Patents to Regulatory Authorities in connection with the development of the Combined Therapy, the Exelixis Compound, or the Roche Compound; and</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">disclosure of relevant safety information contained within the Combined Therapy Study Data to investigators, IRBs, and/or ethics committees and Regulatory Authorities that are involved in other clinical trials of the Exelixis Compound with respect to Exelixis, and the Roche Compound with respect to Roche, and (in the event of a Material Safety Issue) to Third Parties that are collaborating with Exelixis or Roche, respectively in the conduct of such other clinical trials of the Exelixis Compound or the Roche Compound, in each case solely to the extent necessary for the conduct of such clinical trials and/or to comply with Applicable Law and regulatory requirements. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;10.3(a) or (b), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as such Party would use to protect its own confidential information of a similar nature, but in no event less than reasonable efforts.  In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information.  Any information disclosed pursuant to any of Sections 10.3(a)-(e) shall remain Confidential Information and subject to the restrictions set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.4&#160;&#160;&#160;&#160;Disclosure to Ipsen and Takeda</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding any other provision of this Agreement, Roche hereby expressly authorizes Exelixis to disclose to Ipsen and Takeda (a) this Agreement, the Protocols, Combined Therapy Inventions, and Combined Therapy Patents, and (b) any other Roche Confidential Information necessary for Exelixis to fulfill its obligations to Ipsen and Takeda under the Ipsen-Exelixis Agreements and the Takeda-Exelixis Agreements; provided that Ipsen and Takeda are each under confidentiality obligations at least as restrictive as set forth herein.  Exelixis shall be free to disclose the Exelixis Study Data and the Combined Therapy Study Data to Ipsen and Takeda as Exelixis may determine as provided in Section 10.3(c) or 10.3(d) and otherwise to fulfill its obligations under each of the Ipsen-Exelixis Agreements and the Takeda-Exelixis Agreements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.5&#160;&#160;&#160;&#160;Press Releases and Publications</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Parties shall jointly agree to the content and timing of all external communications with respect to this Agreement, including an initial press release by Exelixis, the content of which shall be as </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">26</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, subsequent press releases, media Q&amp;As, and the content and wording of any listing of a Combined Therapy Trial on a public database or public registry (such as clinicaltrials.gov).  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis and Roche agree to collaborate to publicly disclose, publish, or present (with the Conducting Party to lead) (i) top-line results from each Combined Therapy Trial, limited if possible to avoid jeopardizing the future publication of the Study Data at a scientific conference or in a scientific journal, solely for the purpose of disclosing, as soon as reasonably practicable, the safety or efficacy results and conclusions that are material to any Party under applicable securities laws, and (ii) the conclusions and outcomes (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Results</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) of each Combined Therapy Trial at a scientific conference as soon as reasonably practicable following the completion of such Combined Therapy Trial, subject to the following terms and conditions.  The Party proposing to disclose, publish, or present the Results shall deliver to the other Party a copy of the proposed disclosure, publication, or presentation:  (a) for abstracts, slide presentations or posters, at least [ * ] prior to submission (in the case of abstracts) or first public presentation (in the case of slide presentations and posters); and (b) at least [ * ] in advance of first submission and each subsequent submission in the case of manuscripts; or (c) within such other timeframe as the Parties may agree.  The reviewing Party shall determine whether any of its Confidential Information that may be contained in such disclosure, publication, or presentation should be modified or deleted, whether to file a patent application on any Exelixis Study Invention (solely with respect to Exelixis) or Roche Study Invention (solely with respect to Roche) or Combined Therapy Invention disclosed therein.  The disclosure, publication, or presentation shall be delayed for an additional [ * ] if a reviewing Party reasonably requests such extension to allow time for the preparation and filing of relevant patent applications.  If a reviewing Party reasonably requests modifications to the disclosure, publication, or presentation to prevent the disclosure of such Party&#8217;s Confidential Information, the publishing Party shall remove such information prior to submission of the disclosure, publication, or presentation.  In the event of a disagreement as to content, timing, and/or venue or forum for any disclosure, publication, or presentation of the Results, such dispute (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Publication Dispute</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) shall be referred to the Executive Officers (or their respective designees) for resolution; provided that, in the absence of agreement after such good faith discussions, and upon expiration of an additional [ * ], (A) academic collaborators engaged by the Conducting Party in connection with the performance of the Combined Therapy Trials may publish Combined Therapy Study Data obtained by such academic collaborator solely to the extent that such ability to publish such Combined Therapy Study Data is set forth in an agreement between the Conducting Party and such academic collaborator relating to the conduct of Combined Therapy Trials and (B) the publishing Party may proceed with the disclosure, publication, or presentation provided that such disclosure, publication, or presentation is consistent with its internal publication guidelines and customary industry practices for the publication of similar data and does not contain any Confidential Information of the non-publishing Party.  Authorship of any publication shall be determined based on the accepted standards used in peer-reviewed academic journals at the time of the proposed disclosure, publication, or presentation.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, nothing herein shall prevent or restrict Chugai, Ipsen, or Takeda from making any disclosures of published Study Data disclosed to it by Roche pursuant to Section 10.4 or Exelixis pursuant to Section 10.5 of the existence of this Agreement, in each case in order for Chugai, Ipsen, or Takeda to comply with requirements of Applicable Law, the rules or regulations of any securities exchange or listing entity on which its stock may be traded, or pursuant to an order of a court or governmental entity to publicly disclose the existence of the Agreement and the Study Data.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.6&#160;&#160;&#160;&#160;Compliance with Sunshine Laws</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For purposes of compliance with reporting obligations under Sunshine Laws, as between the Parties, the Conducting Party will report payments or other transfers of value (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">POTV</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) made by the Conducting Party or the CRO related to the conduct of the Combined Therapy Trials and any applicable associated contractor engagements as required under the Sunshine Laws for each Combined Therapy Trial.  Interpretation of the Sunshine Laws for purposes of reporting any POTV by a Party shall be in such Party&#8217;s sole discretion so long as the interpretation complies with Applicable Law.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Conducting Party (i) will provide (to the extent in the possession of the Conducting Party), or will utilize Commercially Reasonable Efforts to obligate and ensure that each CRO and other applicable Third Party contractors for a Combined Therapy Trial provides, the Non-Conducting Party with any information requested by the Non-Conducting Party as the Non-Conducting Party may reasonably determine for the Non-Conducting Party to comply with its reporting obligations under Sunshine Laws (with such amounts paid to, or at the direction of, each recipient to be reported to the Non-Conducting Party within a reasonable time period specified by the Non-Conducting Party) and (ii) will reasonably cooperate with, and will use Commercially </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">27</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reasonable Efforts to obligate and ensure that each CRO and other applicable Third Party contractors for a Combined Therapy Trial reasonably cooperates with, the Non-Conducting Party in connection with its compliance with such Sunshine Laws. The form in which the Conducting Party provides any such information shall be mutually agreed, but in any case sufficient to enable the Non-Conducting Party to comply with its reporting obligations and the Non-Conducting Party may disclose any information that it reasonably believes is necessary to comply with Sunshine Laws.  Without limiting the foregoing, the Non-Conducting Party shall have the right to allocate payments or other transfers of value in connection with this Agreement in any required reporting under Sunshine Laws in accordance with its normal business practices. These obligations shall survive the expiration and termination of the agreement to the extent necessary for the Non-Conducting Party to comply with Sunshine Laws.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For purposes of this Section 10.6, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Sunshine Laws</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Applicable Laws requiring collection, reporting and disclosure of POTVs to certain healthcare providers, entities and individuals.  These Applicable Laws may include, without limitation, relevant provisions of the Patient Protection and Affordable Health Care Act of 2010 and implementing regulations thereunder.  &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Recipients</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means healthcare providers, teaching hospitals and/or any other persons for whom transfers of value or payments must be reported under Sunshine Laws.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.7&#160;&#160;&#160;&#160;Destruction of Confidential Information</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Upon expiration or termination of the Agreement, the receiving Party shall, upon request by the other Party, immediately destroy all of the other Party&#8217;s Confidential Information relating solely to its Compound(s) as monotherapy (but not to the Combined Therapy or the Combined Therapy Study Data) in its possession; provided, however, that the receiving Party shall be entitled to retain one (1) copy of Confidential Information solely for record-keeping purposes and shall not be required to destroy any off-site computer files created during routine and automatic system back up which are subsequently stored securely by the receiving Party. </font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 11</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.1&#160;&#160;&#160;&#160;Authority and Binding Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Exelixis and Roche each represents and warrants to the other that, as of the Effective Date, (a) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (b) it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and (c) the Agreement has been duly executed and delivered on behalf of each Party and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.2&#160;&#160;&#160;&#160;No Conflicts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that, to the best of its knowledge, as of the Effective Date it has not entered, and shall not enter, into any agreement with any Third Party that is in conflict with the rights granted to any other Party under this Agreement, and has not taken any action that would in any way prevent it from granting the rights granted to any other Party under this Agreement, or that would otherwise materially conflict with or adversely affect the rights granted to any other Party under this Agreement.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.3&#160;&#160;&#160;&#160;Litigation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that, to the best of its knowledge, as of the Effective Date it is not aware of any pending or threatened litigation (and has not received any communication) that alleges that its activities related to this Agreement have violated, or that by conducting the activities as contemplated in this Agreement it would violate, any of the intellectual property rights of any other Person (after giving effect to the license grants in this Agreement).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.4&#160;&#160;&#160;&#160;No Adverse Proceedings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that, to the best of its knowledge, as of the Effective Date there is no pending or threatened, in writing, claim, suit, action, or governmental proceeding against such Party that would, if adversely determined, materially impair the ability of such Party to perform its obligations under this Agreement.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.5&#160;&#160;&#160;&#160;Consents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that, to the best of its knowledge, as of the Effective Date all necessary consents, approvals, and authorizations of all regulatory and governmental authorities and other Persons (a) required to be obtained by such Party in connection with the execution and delivery of this Agreement have been obtained and (b) required to be obtained by such Party in connection with the performance of its obligations under this Agreement have been obtained or will be obtained prior to such performance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">28</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.6&#160;&#160;&#160;&#160;No Debarment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Product.  In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.7&#160;&#160;&#160;&#160;Compliance with Applicable Law</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that it shall comply, and shall cause its and its Affiliates&#8217; employees and contractors to comply, with all Applicable Laws of the country or other jurisdiction, or any court or agency thereof, applicable to the performance of its activities hereunder or any obligation or transaction hereunder.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.8&#160;&#160;&#160;&#160;Affiliates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that, to the extent the intellectual property, Regulatory Documentation, or Technology licensed by it hereunder are Controlled by its Affiliates or a Third Party, it has the right to use, and has the right to grant (sub)licenses to the other Party to use, such intellectual property, Regulatory Documentation, or Technology in accordance with the terms of this Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.9&#160;&#160;&#160;&#160;Ethical Business Practices</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis and Roche each represents and warrants that neither it nor its Affiliates will make any payment, either directly or indirectly, of money or other assets, including the compensation such Party derives from this Agreement (collectively a &#8220;Payment&#8221;), to government or political party officials, officials of International Public Organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing (collectively &#8220;Officials&#8221;) where such Payment would constitute violation of any law, including the Foreign Corrupt Practices Act of 1977, 15 U.S.C. &#167;&#167; 78dd-1, et seq.  In addition, regardless of legality, neither it nor its Affiliates will make any Payment either directly or indirectly to Officials if such Payment is for the purpose of improperly influencing decisions or actions with respect to the subject matter of this Agreement.  All activities will be conducted in compliance with the U.S. False Claims Act and the U.S. Anti-Kickback Statute.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.10&#160;&#160;&#160;&#160;Single Agent Compound Safety Issues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party represents and warrants that, to the best of its knowledge, as of the Effective Date it is not aware of any material safety or toxicity issue with respect to its Single Agent Compound that is not reflected in the investigator&#8217;s brochure(s) for its Single Agent Compound existing as of the Effective Date.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.11&#160;&#160;&#160;&#160;Accounting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party represents and warrants that all transactions under the Agreement shall be properly and accurately recorded in all material respects on its books and records and that each document upon which entries in such books and records are based is complete and accurate in all material respects.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.12&#160;&#160;&#160;&#160;Compliance with Ipsen-Exelixis Agreements and Takeda-Exelixis Agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis will use Commercially Reasonable Efforts to comply with its obligations under the Ipsen-Exelixis Agreements and the Takeda-Exelixis Agreements (and not to voluntarily terminate same) to the extent necessary for each Combined Therapy Trial to be completed in accordance with the terms of this Agreement and for Roche to receive the rights and benefits provided to it under this Agreement.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.13&#160;&#160;&#160;&#160;DISCLAIMER OF WARRANTY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE, OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 12</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEMNIFICATION</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.1&#160;&#160;&#160;&#160;Roche Indemnification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Roche hereby agrees to defend, indemnify, and hold harmless Exelixis, its Affiliates, and their respective directors, officers, employees, and agents (each, an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Indemnitee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) from and against any and all liabilities, expenses, and losses, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Losses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), to which any Exelixis Indemnitee may become subject as a result of any claim, demand, action, or other proceeding (each, a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Claim</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by any Third Party to the extent such Losses arise out of:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">29</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the negligence or intentional misconduct of Roche, any Roche Indemnitee, or any (sub)licensee of Roche conducting activities on behalf of Roche under this Agreement; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any breach by Roche of any provision of this Agreement; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any injury to a subject in a Combined Therapy Trial caused solely by the development, use, or manufacture of the Roche Compound;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the use by Roche, its Affiliates, contractors, or (sub)licensees of any Combined Therapy Study Data, Roche Study Data, Roche Study Inventions, Roche Study Patents, Combined Therapy Inventions, and Combined Therapy Patents outside the scope of this Agreement (other than with respect to Third Party Claims that are covered under Section 7.4); but excluding, in each case ((a) through (e)), any such Losses to the extent Exelixis is obligated to Indemnify the Roche Indemnitees pursuant to Section 12.2.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.2&#160;&#160;&#160;&#160;Exelixis Indemnification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby agrees to defend, indemnify, and hold harmless Roche, its Affiliates, and their respective directors, officers, employees, and agents (each, a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche Indemnitee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) from and against any and all Losses to which any Roche Indemnitee may become subject as a result of any Claim by any Third Party to the extent such Losses arise out of: </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the negligence or intentional misconduct of Exelixis, any Exelixis Indemnitee, or any (sub)licensee of Exelixis conducting activities on behalf of Exelixis under this Agreement; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any breach by Exelixis of any provision of this Agreement; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any injury to a subject in a Combined Therapy Trial caused solely by the development, use, or manufacture of the Exelixis Compound; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the use by Exelixis, its Affiliates, contractors, or (sub)licensees of Combined Therapy Study Data, Exelixis Study Data, Exelixis Study Inventions, Exelixis Study Patents, Combined Therapy Inventions and Combined Therapy Patents outside the scope of this Agreement (other than with respect to Third Party Claims that are covered under Section 7.4), but excluding, in each case ((a) through (e)), any such Losses to the extent Roche is obligated to Indemnify the Exelixis Indemnitees pursuant to Section 12.1.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.3&#160;&#160;&#160;&#160;Indemnification Procedure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  A Party that intends to claim indemnification under this Article 12 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indemnitee&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) shall promptly notify the indemnifying Party (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indemnitor</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) in writing of any Claim in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement of such Claim.  The Indemnitee may participate at its expense in the Indemnitor&#8217;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#8217;s own choice.  The indemnity arrangement in this Article 12 shall not apply to amounts paid in settlement of any action with respect to a Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.  The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 12 if and to the extent the Indemnitor is actually prejudiced thereby.  The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.4&#160;&#160;&#160;&#160;Separate Defense of Claims</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. In the event that the Parties cannot agree as to the application of Sections 12.1 and/or 12.2 to any particular Loss, the Parties may conduct separate defenses of such Loss.  Each Party further reserves the right to claim indemnity from the other in accordance with Sections 12.1 and/or 12.2 upon resolution of the underlying claim, notwithstanding the provisions of Section 12.3.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.5&#160;&#160;&#160;&#160;Insurance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall maintain commercially reasonable levels of insurance or other adequate and commercially reasonable forms of protection or self-insurance in light of its obligations under this Agreement.  Each Party shall provide the other Party with written notice at least [ * ] prior to the cancellation, non-renewal, or material change in such insurance or self-insurance which would materially adversely affect the rights of the other Party hereunder.  The maintenance of any insurance shall not constitute any limit or restriction on damages available to a Party under this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.6&#160;&#160;&#160;&#160;LIMITATION OF LIABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  EXCEPT FOR DAMAGES THAT (A) ARISE IN CONNECTION WITH A PARTY&#8217;S (I) WILLFUL MISCONDUCT OR FRAUD OR (II) BREACH OF ITS OBLIGATIONS UNDER ARTICLE 10, OR (B) ARE SUBJECT TO INDEMNIFICATION UNDER SECTION 12.1 OR 12.2, NEITHER PARTY SHALL BE LIABLE IN CONTRACT, </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">30</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, OR OTHERWISE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY (OR ITS AFFILIATES OR (SUB)LICENSEES), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 13</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TERM AND TERMINATION</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.1&#160;&#160;&#160;&#160;Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Agreement shall be effective as of the Effective Date and, unless earlier terminated as provided in this Agreement, shall continue in effect until completion by all centers or institutions participating in the Combined Therapy Trials for such Combined Therapy combination, the delivery of all Study Data, including all completed case report forms, all final analyses, and all final clinical study reports for the Combined Therapy Trials to both Parties, and the completion of any then agreed upon Statistical Analysis and Bioanalysis Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.2&#160;&#160;&#160;&#160;Termination for Material Breach</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within [ * ] after notice of such breach from the non-breaching Party.  If cure of such breach (other than non-payment) cannot reasonably be effected within such [ * ] period, the breaching Party shall deliver to the non-breaching Party a plan reasonably calculated to cure such breach within a reasonable timeframe, but in any event within [ * ].  So long as the breaching Party is diligently carrying out such plan, the non-breaching Party shall not have the right to terminate this Agreement.  If the breaching Party fails to diligently carry out such plan and cure such breach as provided above, then the non-breaching Party may terminate this Agreement upon written notice to the breaching Party.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.3&#160;&#160;&#160;&#160;Termination for Bankruptcy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee, or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation, or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within [ * ] after the commencement thereof.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.4&#160;&#160;&#160;&#160;Termination due to Material Safety Issue; Clinical Hold</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Roche or Exelixis shall each have the independent right to immediately suspend the treatment of subjects in the Combined Therapy Trial and terminate this Agreement upon written notice if it deems it necessary to protect the safety, health, or welfare of subjects enrolled in any Combined Therapy Trial due to the existence of a Material Safety Issue.  In the event of a termination due to a Material Safety Issue, prior to the terminating Party providing written notice, each Party&#8217;s safety committee shall, to the extent practicable, meet and discuss in good faith the safety concerns raised by the terminating Party and consider in good faith the input, questions and advice of the non-terminating Party, but should any dispute arise in such discussion, the dispute resolution processes set forth herein shall not apply to such dispute and the terminating Party shall have the right to issue such notice and such suspension shall take effect without the Parties first following the dispute resolution procedures set forth herein and the Agreement shall subsequently terminate once the Combined Therapy Trial has been wound down pursuant to Section 13.5. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Clinical Hold with respect to either the Roche Compound(s) or the Exelixis Compound should arise at any time after the Effective Date, the Parties will meet and discuss the basis for the Clinical Hold, how long the Clinical Hold is expected to last, and how they might address the issue that caused the Clinical Hold.  If, after [ * ] of discussions following the Clinical Hold, a Party reasonably concludes that the issue is not solvable or that unacceptable and material additional costs/delays have been and/or will continue to be incurred in the conduct of the Combined Therapy Trial, then such Party may immediately terminate this Agreement upon written notice to the other Party.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.5&#160;&#160;&#160;&#160;Effect of Termination</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Upon expiration or termination of this Agreement:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Licenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The licenses granted to each Party under this Agreement shall terminate upon completion of any ongoing activities under this Agreement; and</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">31</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Wind Down</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties shall use reasonable efforts to wind down activities under this Agreement in a reasonable manner and avoid incurring any additional expenditures or non-cancellable obligations; provided that, in the case of termination, the Conducting Party may continue to dose subjects enrolled in any then ongoing Combined Therapy Trial through completion of the applicable Protocol if dosing is required by the applicable Regulatory Authority(ies) and/or Applicable Law(s).  Any such wind-down activities will include the return to a Party, or destruction, of all of such Party&#8217;s Compound provided to the other Party and not used in the Combined Therapy Trials.  If applicable, upon termination of this Agreement, the Parties shall remain responsible pursuant to the terms of this Agreement for any expenses incurred that are associated with terminating any ongoing clinical trial work and/or result from such ongoing activities under this Agreement solely to the extent such activities are deemed necessary by the Conducting Party (after agreement by the JSC) based on reasonable medical judgment to protect the health of subjects participating in any Combined Therapy Trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.6&#160;&#160;&#160;&#160;Survival.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">following Articles and Sections of this Agreement and all definitions relating thereto shall survive any expiration or termination of this Agreement for any reason:  Section 2.4, Section 2.6(b), Section 2.10, Article 7, Sections 8.1, 8.2, 8.3, and 8.5, Article 9, Article 10, Article 11, Article 12, Sections 13.5 and 13.6, and Sections 14.1, 14.2, 14.3, 14.5, 14.6, 14.7, 14.9, 14.10, 14.11, 14.12, 14.14, and 14.15</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 14</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.1&#160;&#160;&#160;&#160;Entire Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. The Parties acknowledge that this Agreement shall govern all activities of the Parties with respect to the Combined Therapy Trials from the Effective Date forward.  This Agreement, including the Exhibits hereto and together with the Protocol, Quality Agreement, and Pharmacovigilance Agreement, sets forth the complete, final, and exclusive agreement between the Parties concerning the subject matter hereof and supersedes all prior agreements and understandings between the Parties with respect to such subject matter.  There are no covenants, promises, agreements, warranties, representations, conditions, or understandings, either oral or written, between the Parties with respect to such subject matter other than as are set forth in this Agreement.  All Exhibits attached hereto are incorporated herein as part of this Agreement.  This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.2&#160;&#160;&#160;&#160;Governing Law</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Agreement shall be governed and construed in accordance with the internal laws of the State of California, USA, excluding any choice of law rules that may direct the application of the laws of another jurisdiction.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.3&#160;&#160;&#160;&#160;Dispute Resolution</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;General</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as provided in Sections 3.7 and 8.5, any dispute between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Dispute</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) shall be resolved pursuant to this Section 14.3.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Executive Officers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any Dispute shall first be referred to the Executive Officers of the Parties, who shall confer in good faith on the resolution of the issue.  Any final decision mutually agreed to by the Executive Officers shall be conclusive and binding on the Parties.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Arbitration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If the Executive Officers are not able to agree on the resolution of a Dispute within [ * ] (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then, if a Party wishes to pursue further resolution of such Dispute, such Dispute shall be finally resolved by binding arbitration in accordance with this Section 14.3(c).  Such Dispute shall be referred to and finally resolved by arbitration JAMS pursuant to its Streamlined Arbitration Rules then in effect (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Rules</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), as then in effect, by a tribunal of three (3) arbitrators.  The seat and legal place of the arbitration shall be San Francisco, California.  Each Party shall nominate one arbitrator and the third arbitrator shall be nominated by the two Party-nominated arbitrators within [ * ] after the second arbitrator&#8217;s appointment.  If a Party does not nominate its arbitrator within [ * ] following the expiry of the allotted period, then such arbitrator shall be appointed by the ICC in accordance with its rules.  Any arbitrator appointed by JAMS shall have at least ten (10) years&#8217; experience in the pharmaceutical industry.  The arbitration shall be conducted, and all documents submitted to the arbitrators shall be, in English.  Each Party shall bear its own legal costs for its counsel and other expenses, and the Parties shall equally share the costs of the arbitration; provided that the arbitral tribunal shall have the discretion to provide that the losing party is responsible for all or a portion of such arbitration and legal costs, in such case the arbitral award will so provide.  The arbitrators shall have no power to award damages prohibited pursuant to Section 12.6.  In no event shall the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">32</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">arbitrators assign a value to any issue greater than the greatest value for such issue claimed by either Party or less than the smallest value for such issue for such item claimed by either Party.  The award shall be final and binding upon the Parties and the Parties undertake to carry out any award without delay.  Judgment on the award may be entered in any court of competent jurisdiction.  Except to the extent necessary to confirm, enforce, or challenge an award of the arbitration, to protect or pursue a legal right, or as otherwise required by Applicable Law or regulation or securities exchange, neither Party nor any arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties.  Notwithstanding anything to the contrary in the foregoing, in no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy, or claim would be barred by the applicable statute of limitations.  Any Disputes concerning the propriety of the commencement of the arbitration shall be finally settled by the arbitral tribunal.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Subject Matter Exclusions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the provisions of Section 14.3(c), any Dispute not resolved internally by the Parties pursuant to Section 14.3(c) that involves the validity, enforceability, or infringement of a Patent relevant to this Agreement (a) that is issued in the United States shall be subject to actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants resides; and (b) that is issued in any other country shall be brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Interim Relief</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything herein to the contrary, nothing in this Section 14.3 shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction, or other interim equitable relief concerning a Dispute in any court of competent jurisdiction before or after the initiation of an arbitration as set forth in Section 14.3(c), if necessary to protect the interests of such Party.  This Section shall be specifically enforceable.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.4&#160;&#160;&#160;&#160;Force Majeure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties shall be excused from the performance of their obligations under this Agreement (other than the payment of monies owed to the other Party) to the extent that such performance is prevented by force majeure and the non-performing Party promptly provides notice of the prevention to each other Party.  Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure means acts of God, strikes or other concerted acts of workers, civil disturbances, fires, earthquakes, acts of terrorism, floods, explosions, riots, war, rebellion, sabotage or failure or default of public utilities or common carriers or similar conditions beyond the control of the Parties. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.5&#160;&#160;&#160;&#160;Notices</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if such notice is timely and is: (a) mailed by first class certified or registered mail, postage prepaid, return receipt requested, (b) sent by express delivery service, or (c) personally delivered.  Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:228px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For Exelixis:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1851 Harbor Bay Parkway </font></div><div style="line-height:120%;text-align:left;padding-left:180px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Alameda, CA 94502</font></div><div style="line-height:120%;text-align:left;padding-left:180px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attn: EVP and General Counsel</font></div><div style="line-height:120%;text-align:left;padding-left:180px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:228px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">With invoices to: </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:228px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For Roche:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">F. Hoffmann-La Roche Ltd</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Grenzacherstrasse 124</font></div><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CH-4070 Basel, </font></div><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Switzerland</font></div><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attention: Group Legal Department</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:228px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">With invoices to: </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Genentech, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1 DNA Way</font></div><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">South San Francisco, California 94080</font></div><div style="line-height:120%;text-align:left;padding-left:180px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attention: Customer Finance</font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any such communication shall be deemed to have been received when delivered.  It is understood and agreed that this Section 14.5 is not intended to govern the day-to-day business communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.6&#160;&#160;&#160;&#160;Waiver</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The waiver by either Party of any right under this Agreement or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.  Any waiver by a Party of a particular term or condition will be effective only if set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.7&#160;&#160;&#160;&#160;No Strict Construction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Agreement has been prepared jointly and shall not be strictly construed against either Party. No presumption as to construction of this Agreement shall apply against either Party with respect to any ambiguity in the wording of any provision(s) of this Agreement irrespective of which Party may be deemed to have authored the ambiguous provision(s).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.8&#160;&#160;&#160;&#160;Independent Contractor</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors.  This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties.  Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.9&#160;&#160;&#160;&#160;Assignment; Licensees.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Assignment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned, or delayed); provided, however, that either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent: </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in connection with the transfer or sale of all or substantially all of the business or assets of such Party relating to this Agreement to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or otherwise; provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the acquiring Party by operation of law (e.g., in the context of a reverse triangular merger)), the intellectual property rights of the acquiring Party to such transaction (if other than one of the Parties to this Agreement) shall not be included in the technology for which rights have been granted under this Agreement, and notice is provided to the other Party; or </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">to an Affiliate, provided that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, the Agreement shall be automatically assigned back to the assigning Party or its successor.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Section 14.9.  Any assignment not in accordance with this Section 14.9 shall be null and void and of no legal effect. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Licensees</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If a Party grants a Third Party a license (other than a license solely to make a Product for a Party and other than any license rights granted Ipsen for the Ipsen Territory and Takeda for the Takeda Territory) to develop and commercialize its Single Agent Compound on a worldwide basis or in any geographic region and/or for all purposes or a limited field, such Party will obtain such Third Party licensee&#8217;s agreement to abide by the relevant terms of this Agreement in the same manner as the licensor Party.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.10&#160;&#160;&#160;&#160;Headings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The captions to the several Sections and Articles hereof are not a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.11&#160;&#160;&#160;&#160;Counterparts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument.  This Agreement may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.12&#160;&#160;&#160;&#160;Severability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.  The Parties will in such an instance use their best efforts to replace the invalid, unenforceable, or illegal provision(s) with valid, enforceable, and legal provision(s) that best implement the original intent of the Parties and purposes of this Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.13&#160;&#160;&#160;&#160;Further Assurance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in order to perfect any license, assignment or other transfer or any properties or rights under, or pursuant, to this Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.14&#160;&#160;&#160;&#160;No Benefit to Third Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The representations, warranties, and agreements set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other parties. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.15&#160;&#160;&#160;&#160;Interpretation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.  All references in this Agreement to the singular shall include the plural where applicable.  Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.  The word &#8220;including&#8221; and similar words means including without limitation.  The word &#8220;or&#8221; means &#8220;and/or&#8221; unless the context dictates otherwise because the subjects of the conjunction are, or are intended to be, mutually exclusive.  The words &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.  All references to days in this Agreement mean calendar days, unless otherwise specified.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  This Agreement has been prepared in the English language and the English language shall control its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[Signature page follows]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">35</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sD33AFF838DC76EF5A6A36A39266BB6C5"></a></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties hereto, intending to be legally bound hereby, have caused this Clinical Trial Collaboration Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President and CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">18 December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">F. Hoffmann-La Roche Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Laurence Lehuu</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Louis DuPasquier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Laurence Lehuu</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Louis DuPasquier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Operation Program Leader</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Legal Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">18 December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[Signature Page]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[Signature Page]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><a name="s6B50F8B37C7000E182E16A392679162A"></a></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit A</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit A-1</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><a name="s30C24F26927B878C8AD76A3926986437"></a></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:282px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit B</font></div><div style="line-height:120%;text-align:left;padding-left:48px;"><img src="exhibit1062jcraroche2_image1.gif" alt="exhibit1062jcraroche2_image1.gif" style="height:296px;width:624px;"></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS ENTERS INTO A CLINICAL COLLABORATION FOR THREE PHASE 3 COMBINATION TRIALS </font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FOR PATIENTS WITH ADVANCED SOLID TUMORS</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">New pivotal trials will evaluate the combination of cabozantinib and atezolizumab</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">renal cell carcinoma</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#8211;</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration based on data from phase 1b COSMIC-021 trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#8211;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ALAMEDA, Calif. &#8211; December 19, 2019 &#8211;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis, Inc. (NASDAQ: EXEL) today announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX&#174;), Exelixis&#8217; small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ&#174;), Roche&#8217;s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. The clinical program, which will be co-funded by the companies, is expected to include three phase 3 pivotal trials in advanced non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and renal cell carcinoma (RCC).</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Encouraging phase 1 data suggests this combination of cabozantinib and atezolizumab may improve outcomes for patients with prostate, lung and kidney cancers, and we look forward to collaborating with Roche to learn more in these pivotal trials,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. &#8220;This clinical collaboration is an important further step in our committed efforts to maximize the value of the cabozantinib franchise through these cost-sharing clinical collaborations in additional high-impact indications, while building value with new compounds from internal and external sources in 2020 and beyond.&#8221; </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The clinical development collaboration builds on encouraging activity observed in the phase 1b COSMIC-021 trial. The trial is currently enrolling 24 expansion cohorts in 12 tumor types including RCC, NSCLC and CRPC.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">TECENTRIQ&#174; (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">About CABOMETYX</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;(cabozantinib)</font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit B-1</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced RCC and for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">About Exelixis&#8217; Collaboration with Ipsen</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">On February 29, 2016, Exelixis and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib indications outside of the United States, Canada and Japan. On December 21, 2016, this agreement was amended to include commercialization rights for Ipsen in Canada. Under the parties&#8217; collaboration agreement, if Ipsen opts to participate in funding these phase 3 trials, or future studies, Ipsen will have access to the respective study results to support potential future regulatory submissions in their territory.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">About Exelixis&#8217; Collaboration with Takeda</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">On January 30, 2017, Exelixis and Takeda jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib indications in Japan. Under the parties&#8217; collaboration agreement, if Takeda opts to participate in funding these phase 3 trials, or future studies, Takeda will have access to the respective study results to support potential future regulatory submissions in their territory.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the United States.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">About</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(cabozantinib), COMETRIQ</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(cabozantinib), COTELLIC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(cobimetinib) and MINNEBRO</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;our existing therapeutic assets with targeted business development activities and internal drug discovery &#8212; all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard &amp; Poor&#8217;s (S&amp;P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#233dfd;text-decoration:underline;">,</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis&#8217; expectation that the clinical program co-funded by Exelixis and Roche will include three phase 3 pivotal trials evaluating the combination of cabozantinib and atezolizumab in NSCLC, CRPC and RCC; the potential for the combination of cabozantinib and atezolizumab to improve outcomes for patients with prostate, lung and kidney cancers; Exelixis&#8217; belief that it can maximize the value of the cabozantinib franchise through these cost-sharing clinical collaborations in additional high-impact indications, while building value with new compounds from internal and external sources in 2020 and beyond; and Exelixis&#8217; plans to reinvest in its business to maximize the potential of the company&#8217;s pipeline, including through targeted business development activities and internal drug discovery. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which </font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit B-2</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">include, without limitation: risks and uncertainties related to regulatory review and approval processes and Exelixis&#8217; compliance with applicable legal and regulatory requirements; the potential failure of the combination of cabozantinib and atezolizumab to demonstrate safety and/or efficacy in COSMIC-021 or in future phase 3 pivotal trials; uncertainties inherent in the product development process; the costs of conducting clinical trials, including the ability or willingness of Exelixis&#8217; collaboration partners to invest in the resources necessary to complete the trials; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of cabozantinib; Exelixis&#8217; ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; changes in economic and business conditions; and other factors affecting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">and its development programs discussed under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; Quarterly Report on Form 10-Q filed with the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Securities and Exchange Commission</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">(</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">SEC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">) on</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">October 30, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">, and in Exelixis&#8217; future filings with the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">SEC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">. All forward-looking statements in this press release are based on information available to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">as of the date of this press release, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">undertakes no obligation to update or revise any forward-looking statements contained herein.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a Japanese trademark.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;"># #  #</font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit B-3</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sE5542B6362A33A58EDC26A3926DA2E55"></a></div><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit C</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:center;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL SUPPLY AGREEMENT SUPPLEMENT TEMPLATE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">{insert consecutive numbers 1, 2, 3, etc}</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;text-indent:36px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Clinical Supply Agreement Supplement (each, a &#8220;CSA Supplement&#8221;) is entered into as of {DATE} (the &#8220;Effective Date&#8221;), by and between </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;a Delaware corporation having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502  (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">F. Hoffmann-La Roche Ltd</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a Swiss corporation having  an address at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).   Exelixis and Roche may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Roche and Exelixis are parties to that Joint Clinical Research Agreement, effective as of December 18, 2019 (the &#8220;Agreement&#8221;);</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, pursuant to the terms of the Agreement, {Exelixis/Roche} desires to conduct a clinical trial entitled {INSERT STUDY TITLE} (the &#8220;Study&#8221;); and</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, {Exelixis/Roche} agrees, consistent with the terms of the Agreement and this CSA Supplement, to provide the {Exelixis/Roche} COMPOUND for the Study.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of the premises and of the following mutual promises, covenants and conditions and any sums to be paid, the Parties hereto agree as follows:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">SUPPLY OF CLINICAL TRIAL MATERIAL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shipment of the {Exelixis/Roche} Compound will require a  lead time of approximately [ * ] after the provision of an IND number (for shipments to the US) and a lead time of approximately [ * ] for shipments to the EU/ROW and an import license (depending on import requirements) from the time of {Exelixis/Roche} request. {Exelixis/Roche} will provide {Exelixis/Roche} with a [ * ] demand forecast over the course of the trial. Individual supply orders must be placed by {Exelixis/Roche} with a lead time of [ * ] after receipt of a complete {Form} for Drug Supply by {Exelixis/Roche} and an Import License (depending on Import License). Individual order quantities may be adjusted as per mutual agreement between the supply teams, by up to [ * ] from the most recent demand forecast, provided this does not adversely affect conduct of the {Exelixis/Roche} Study and is available at {Exelixis/Roche}. If greater than [ * ] adjustment is required, both parties will discuss as applicable. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;padding-left:24px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">{Exelixis/Roche} will provide {Exelixis/Roche} with the following {Exelixis/Roche} Compound:</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;padding-left:60px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">{compound name}</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;padding-left:60px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">{describe packaging[ * ]} </font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;padding-left:60px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">{describe product[ * ]}</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The total estimated demand of {units} and the estimated timeline for the Compound will be documented and communicated in the form set forth in ATTACHMENT 1. These estimated supply and delivery details will be updated [ * ] and would be documented in the [ * ] forecast {Exelixis/Roche} will provide to {Exelixis/Roche}:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;Shipment Delivery: &#8220;Sender&#8221; shall make delivery of Product to &#8220;Recipient&#8221; in accordance with Section 5.1b or 5.2b of the Agreement, as applicable.  [ * ].</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product Documents: {Exelixis/Roche} shall provide all relevant documents such as, but not limited to product value and appropriate supporting documents required by local regulatory authority for &#8220;Import License Application&#8221; during the conduct of the trial in accordance to terms set forth in section (a) and (b).</font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit C-1</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;text-indent:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inspection and Acceptance of Product: In order to reject delivery of any portion of such delivered shipment in accordance to terms set forth in section (a), (b) and (c); &#8220;Recipient&#8221; must provide written notice to &#8220;Sender&#8221; of such rejection specifying [ * ] the reasons for such rejection within [ * ]. If no such notice of rejection is received within such [ * ], &#8220;Recipient&#8221; will be deemed to have accepted compound provided by &#8220;Sender&#8221;. Following any notice of rejection given by &#8220;Recipient&#8221; in accordance with this Section, &#8220;Sender&#8221; shall have the right to inspect &#8220;Sender&#8221; Compound in question and &#8220;Recipient&#8221; shall cooperate with &#8220;Sender&#8221; inspection, including, upon &#8220;Sender&#8221; request, providing &#8220;Sender&#8221; with samples of the &#8220;Sender&#8221; Compound in question for testing.  If &#8220;Sender&#8221; agrees with such notice of nonconformity, &#8220;Sender&#8221; shall replace such &#8220;Sender&#8221; Compound as soon as reasonably practicable after receipt of notification of such nonconformity.</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;padding-left:60px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product is to be delivered to:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">TERM</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This CSA Supplement shall continue until the Study is completed and all information-sharing obligations under the Agreement are completed, or until terminated as provided in the Agreement.</font></div><div style="line-height:138%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">INCORPORATION BY REFERENCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The CSA Supplement is governed by the terms and conditions of the Agreement and forms an integral part of the Agreement.  All defined terms within the Agreement shall have the same meaning when used in this CSA Supplement unless specifically defined in this CSA Supplement.  If the event of a conflict between a term or terms in this CSA Supplement and a term or terms of the Agreement, the term(s) of the Agreement shall prevail.</font></div><div style="line-height:138%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In addition to the recipients of notice listed in the Agreement, notices applicable to this CSA Supplement directed to Roche shall be sent to the attention of {____________________}.  Notices applicable to this CSA Supplement directed to Exelixis shall be sent to the attention of {__________________________}.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the respective representatives of the parties have executed this CSA Supplement as of the day and year shown on the first page hereof.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.3061224489796%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">F. HOFFMANN-LA ROCHE LTD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Signature</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">_____________________________________________</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">_____________________________________________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Signature</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">_____________________________________________</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">_____________________________________________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ATTACHMENT 1: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&lt;Study Number&gt;,&lt;Enter Study Protocol Description&gt;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;* </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">]</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit C-2</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.63
<SEQUENCE>8
<FILENAME>exel20191231exhibit1063.htm
<DESCRIPTION>EXHIBIT 10.63
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE7D8437DCFB973AB75666A4773341931"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;<br>EXHIBIT 10.63</font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SUPPLEMENT TO THE</font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">JOINT CLINICAL RESEARCH AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SUPPLEMENT TO THE JOINT CLINICAL RESEARCH AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Supplement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is made and entered into effective as of December 18, 2019 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and among Exelixis, Inc. a Delaware corporation, located at 1851 Harbor Bay Parkway, Alameda, CA 94501, (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), F. Hoffmann-La Roche Ltd, a Swiss corporation having an address at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and Ipsen Pharma SAS, a French Corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ipsen</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  The terms in this Supplement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth herein, or if not defined herein, as set forth in the Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and Roche have entered into a certain Joint Clinical Research Agreement dated December 18, 2019 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to collaborate with each other to sponsor one or more clinical trials of a combination therapy using Exelixis&#8217; tyrosine kinase inhibitor known as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Cabozantinib&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, certain rights to which are licensed by Exelixis to, and shared by Exelixis with  Ipsen Pharma SAS (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Ipsen&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and Takeda Pharmaceutical Company Ltd. (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Takeda&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">), and Roche&#8217;s human monoclonal antibody that binds PD-L1 known as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Atezolizumab&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and Ipsen entered into a Collaboration and License Agreement dated February 29, 2016 (such agreement, as amended from time to time, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ipsen-Exelixis Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">wherein Exelixis and Ipsen formed a collaboration for the continued development of and commercialization of Cabozantinib and wherein Exelixis granted to Ipsen certain exclusive rights to develop and commercialize Cabozantinib worldwide, with the exception of the United States and Japan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ipsen Territory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;);</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis, under the Agreement, shall grant to Roche, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">inter alia</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, certain patent rights, access to Regulatory Documentation, and Right of Reference as contemplated therein;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Roche further requires from Ipsen certain additional patent rights, access to Regulatory Documentation, and Right of Reference under Ipsen&#8217;s control in the Ipsen Territory as contemplated in the Agreement; </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of Ipsen granting to Roche certain patent rights, access to Regulatory Documentation, and Right of Reference under Ipsen&#8217;s control in the Ipsen Territory, Ipsen requires from Roche and Exelixis certain additional patent rights, access to Regulatory Documentation and Right of Reference under Roche&#8217;s control, which shall be obtained from Roche for the sole purpose of submitting any portion of the Combined Therapy Study Data to support certain of Ipsen&#8217;s regulatory filings and approval in the Ipsen Territory for a Combination Therapy under the Ipsen-Exelixis Agreement; and</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, under the Agreement, Ipsen as Exelixis&#8217; collaboration partner and exclusive licensee in the Ipsen Territory will contribute to the fulfillment of the clinical trials contemplated in the Agreement, and will be provided data from Roche and Exelixis as well as Exelixis&#8217; interest in certain patent rights, Regulatory Documentation and Right of Reference under Exelixis&#8217; control arising from such clinical trials and the Agreement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;NOW, THEREFORE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of the foregoing premises and the mutual promises and covenants contained herein, Exelixis, Roche and Ipsen agree as follows: </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;COLLABORATION SCOPE; BACKGROUND</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;Scope of Collaboration between Exelixis and Roche.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis and Roche intend, pursuant to the Agreement, to collaborate to conduct (i) the clinical trials identified in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of the Agreement (referred to as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Initial Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and (ii) such other clinical trials evaluating a Combined Therapy of the Roche Compound with the Exelixis Compound as Exelixis and Roche may agree to conduct pursuant to the terms of the Agreement (any such trial in (i) or (ii), a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Combined Therapy Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2&#160;&#160;&#160;&#160;Protocol review and conduct of Combined Therapy Trials.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The final Protocol for each Combined Therapy Trial shall be subject to review and approval of the Exelixis-Roche JPT under the Agreement and review of the Exelixis-Ipsen Joint Steering Committee (as described in the Ipsen-Exelixis Agreements) before such Combined Therapy Trial can be initiated.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Either Exelixis or Roche shall be primarily responsible for the conduct of each Combined Therapy Trial (either Exelixis or Roche, with respect to such Combined Therapy Trial, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Conducting Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;, and the other of Exelixis or Roche, with respect to the same Combined Therapy Clinical trial, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Conducting Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  In each Combined Therapy Trial the Conducting Party will be the sponsor of record. Unless otherwise required by a Regulatory Authority, for each Combined Therapy Trial, the Conducting Party shall determine whether a combination IND (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Combined Therapy IND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is necessary.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen acknowledges and agrees to Article 6 of the Agreement, which sets forth the Responsibilities of the Conducting Party and the Non-Conducting Party in fulfillment of the Combined Therapy Trials. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;Certain Definitions.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following terms when used in connection with Ipsen in this Supplement shall have the meaning set forth in the Agreement except that any reference in such terms to &#8220;a Party&#8221; or &#8220;Such Party&#8221; or &#8220;the applicable Party&#8221; shall be replaced with reference to &#8220;Ipsen&#8221; and any reference to &#8220;the other Party&#8221; shall be replaced with reference to &#8220;Roche&#8221; or &#8220;Exelixis&#8221; as the context requires: &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Controlled</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">When granted by Ipsen in this Supplement &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Right of Reference</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean, with regard to Roche as the Conducting Party, allowing the applicable Regulatory Authority in a country to have access to relevant information (by cross-reference, incorporation by reference or otherwise) contained in Regulatory Documentation (and any data contained therein) filed with such Regulatory Authority with respect to Exelixis Compound (and, in the case of Roche as the Non-Conducting Party, the Right of Reference to the IND or the Combined Therapy IND), only to the extent necessary for the conduct of a Combined Therapy Trial in such country or as otherwise expressly permitted or required under the Agreement and/or this Supplement to enable Roche to exercise its rights or perform its obligations under the Agreement and/or this Supplement, and, except as to information contained in the IND or Combined Therapy IND relating to the Combined Therapy, without the disclosure of such information to Roche. </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;APPROVALS BY IPSEN AND EXELIXIS</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Combined Therapy Trial Approvals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Ipsen and Exelixis have agreed to the division of responsibilities for the Initial Trials, including but not limited to Roche&#8217;s right to be the Conducting Party and holder of the IND, or Combined Therapy IND as necessary, as identified in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Agreement.  Ipsen and Exelixis have agreed to amend the Global Development Plan (as that term is defined in the Ipsen-Exelixis Agreements) to include the Combined Therapy Trials as described in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of the Agreement and the Protocols for such trials.  Consistent with its agreement to </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">said </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen agrees to consider, in good faith, Protocol(s) for such additional Combined Therapy Trials as may be approved by the Exelixis-Roche JPT, and if acceptable and approved by the Exelixis-Ipsen Joint Steering Committee under the Ipsen-Exelixis Agreement, those Combined Therapy Trials will be added to the Ipsen-Exelixis Global Development Plan under the Ipsen-Exelixis Agreement in due course.  If a Combined Therapy Trial is not approved by the Exelixis-Ipson Joint Steering Committee, Exelixis shall act to effectuate its obligations under the Agreement independent of Ipsen. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;Approved Protocols.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">With respect to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Combined Therapy Trials for which the Protocols are: (a) reviewed and approved by the Exelixis-Roche JPT under the Agreement; and (b) approved by the Exelixis-Ipsen Joint Steering Committee and added to the Global Development Plan under the Ipsen-Exelixis Agreements; the rights and obligations of Exelixis, Roche, and Ipsen under such Protocol, this Supplement and the Agreement will prevail over any conflicting terms in the Ipsen-Exelixis Agreements (and for any amendments to the Agreement, provided that Ipsen will have reviewed any such amendments in full).&#160; </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;Ipsen&#8217;s</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">participation in the Exelixis-Roche JPT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If a Combination Therapy is approved by the Exelixis-Ipsen Joint Steering Committee as set forth in Section 2.1 above, Ipsen&#8217;s representatives having expertise in development activities and regulatory affairs will have the right to participate in and contribute to the Exelixis-Roche JPT for the relevant Combination Therapy as a non-voting attendee, as approved by the JPT pursuant to Section 3.4(c) of the Agreement.  Exelixis shall ensure to inform Ipsen of the date of such Exelixis-Roche JPT meeting and invite Ipsen&#8217;s identified representatives who will participate in the Exelixis-Roche JPT as soon as Exelixis and Roche would have agreed to convene such JPT meeting.  Exelixis shall also ensure that relevant agendas of the Exelixis-Roche JPT for the above-mentioned meetings are circulated to such Ipsen&#8217;s identified representative at least [ * ] prior to such meetings. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;GRANTS, REPRESENTATIONS, AND WARRANTIES BY IPSEN</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;License Grant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Ipsen hereby grants, and shall cause its Affiliates to grant, to Roche a non-exclusive, worldwide, non-transferable, free of charge and royalty-free license (and for the avoidance of doubt, free and clear of any payment by Roche to Ipsen and/or Exelixis) under Ipsen&#8217;s interest in the Exelixis Independent Patent rights, Exelixis Technology, and Exelixis Regulatory Documentation and under the Licensee Technology (as the term is defined in the Ipsen-Exelixis Agreement) in the Ipsen Territory to use the Exelixis Compound, solely to the extent necessary to discharge Roche&#8217;s obligations under the Agreement with respect to the conduct of the Combined Therapy Trials.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;Sublicenses.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Roche shall further have the right to grant sublicenses, under the licenses granted to it under Section 3.1 above, to Affiliates and to Third Parties, solely to the extent required for a an Affiliate or Third Party to perform its duties with respect to the conduct of the Combined Therapy Trials, solely as necessary to assist Roche in carrying out its responsibilities with respect to the Combined Therapy Trials, and otherwise in accordance with the Agreement.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;Right of Reference.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Ipsen hereby grants, and shall cause its Affiliates to grant, to Roche a Right of Reference to the relevant Regulatory Documentation Controlled by Ipsen and its Affiliates for the Exelixis Compound and the Combined Therapy (i) for the conduct of any Combined Therapy Trial, and (ii) with respect to regulatory filings and approvals, solely to the extent required to submit regulatory filings and seek approvals for the Roche Compound as part of a Combined Therapy or if required by the relevant Regulatory Authority (which right shall survive any expiration or termination of this Supplement and the Agreement).  In such case, Ipsen shall reasonably cooperate with Exelixis and Roche and make written authorizations and other filings with the applicable Regulatory Authority required to effect such Right of Reference.  </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;No Implied Licenses.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as specifically set forth in this Supplement, no right or license or other intellectual property interest, shall be granted to Roche by Ipsen by implication or otherwise in any intellectual property of Ipsen, including any Patent Rights controlled by Ipsen or its Affiliates not specifically licensed herein.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.5&#160;&#160;&#160;&#160;Representations and Warranties.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen represents and warrants that: (a) it has the corporate power and authority and the legal right to enter into this Supplement and perform its obligations hereunder; (b) it has the corporate power and authority and the legal right to assist in the performance of the obligations under the Agreement that are agreed to by Exelixis, but require further licenses, rights, and/or assistance from Ipsen; (c) it has reviewed the Agreement in full, and to the extent not otherwise provided for under this Supplement, it shall grant all licenses and rights that are necessary and desirable, and provide such assistance as is reasonably necessary, for Exelixis and Roche to exercise their rights and to fulfill their obligations under the Agreement and/or this Supplement.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;GRANTS, REPRESENTATIONS, AND WARRANTIES BY EXELIXIS</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;License Grant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to the terms and conditions of the Agreement, Exelixis hereby grants to Ipsen a non-exclusive, non-transferable, free of charge and royalty-free sublicense (and for the avoidance of doubt, free and clear of any payment by Ipsen to Roche) under the Roche Independent Patents, Roche Technology, and Roche Regulatory Documentation, solely to the extent that Exelixis has been granted license rights to the Roche Independent Patent rights, Roche Technology, Roche Regulatory Documentation, and Right of Reference to Roche Regulatory Documentation under the Agreement.  Such sublicense rights are limited to use of any portion of the Combined Therapy Study Data and Right of Reference reasonably needed to support regulatory filing and approval of a Combined Therapy, or if required by relevant Regulatory Authority, in the Ipsen Territory in accordance with and under the Ipsen-Exelixis Agreement (which right shall survive any expiration or termination of this Supplement and the Agreement).  In such case, Roche and Exelixis shall reasonably cooperate with Ipsen to make written authorizations and other filings with the applicable Regulatory Authority reasonably required to effect such Right of Reference.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to the terms and conditions of the Agreement, Exelixis hereby grants, and shall cause its Affiliates to grant, to Ipsen an exclusive, non-transferable, royalty-free sublicense under (i) Exelixis&#8217; interest in the Combined Therapy Patents and Combined Therapy Inventions, (ii) Exelixis Technology, (iii) Exelixis Independent Patents, (iv) Exelixis Study Inventions, (v) Exelixis Study Patents and (vi) Exelixis Regulatory Documentation, in the Ipsen Territory for purposes of using any portion of the Combined Therapy Study Data to support Ipsen&#8217;s regulatory approval of a Combined Therapy in the Ipsen Territory, or if required by the relevant Regulatory Authority, and performing Ipsen&#8217;s obligations under the Ipsen-Exelixis Agreement, including conducting development, regulatory, and commercialization activities in accordance with the Ipsen-Exelixis Agreement.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Sublicenses.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Ipsen shall further have the right to grant sublicenses, under the licenses granted to it under Section 4.1 above, to Affiliates and to Third Parties, solely to the extent required for an Affiliate or Third Party to perform its duties, solely as necessary to assist Ipsen in carrying out its responsibilities with respect to using any portion of the Combined Therapy Study Data to support Ipsen&#8217;s regulatory filing and approval for a Combined Therapy in the Ipsen Territory, or if required by the relevant Regulatory Authority. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;No Implied Licenses.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as specifically set forth in this Supplement, no right or license or other intellectual property interest, shall be granted by Exelixis to Ipsen by implication or otherwise in any intellectual property of Roche, including any Patent Rights controlled by Roche or its Affiliates not specifically licensed herein.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;Additional Combined Therapy Trials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event Exelixis and Roche decide to conduct further Combined Therapy Trials beyond the Initial Trials as set forth in Section 6.5 of the Agreement, Exelixis shall ensure that Ipsen is </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">granted access to any data arising from such additional Combined Therapy Trials, subject to Ipsen agreeing to amend the Global Development Plan of the Ipsen-Exelixis Agreement to include such additional Combined Therapy Trials and the Protocol for such Trials. </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.5&#160;&#160;&#160;&#160;Representations and Warranties.  </font></div><div style="line-height:138%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis represents and warrants that: (a) it has the corporate power and authority and the legal right to enter into this Supplement and perform its obligations hereunder; (b) it has the corporate power and authority and the legal right to assist in the performance the obligations under the Agreement that are agreed to with Roche, but require further licenses, rights, and/or assistance from Roche; (c) to the extent not otherwise provided for under this Supplement, it shall grant all licenses and rights that are necessary and desirable, and provide such assistance as is reasonably necessary, for Ipsen to exercise its rights and to fulfill its obligations under this Supplement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Roche represents and warrants that: (a) it has the corporate power and authority and the legal right to enter into this Supplement and perform its obligations hereunder; (b) it has the corporate power and authority and the legal right to assist in the performance the obligations under the Agreement that are agreed to with Exelixis, but require further licenses, rights, and/or assistance from Exelixis; (c) to the extent not otherwise provided for under this Supplement, it shall grant all licenses and rights that are necessary and desirable, and provide such assistance as is reasonably necessary, for Ipsen to exercise its rights and to fulfill its obligations under this Supplement.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;CONDUCT AND COOPERATION</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Conduct.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each of Exelixis, Roche, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen shall use Commercially Reasonable Efforts to perform and fulfill its respective activities under this Supplement, and shall do so in accordance with Applicable Law. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Cooperation. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event that Roche, Exelixis, or Ipsen receives questions or requests from Regulatory Authorities in relation to obtaining or maintaining regulatory approvals for the Combination Therapy, Roche, Exelixis, and Ipsen shall cooperate with each other in the applicable Party&#8217;s effort to obtain and maintain such regulatory approvals.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.1&#160;&#160;&#160;&#160;Confidential Information</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except to the extent expressly authorized by the Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [ * ] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as expressly provided for in the Agreement, any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to the remainder of this Article 6 shall not publish or otherwise disclose the terms of this Agreement.  Each Party may use the other Party&#8217;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.  Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the other Party&#8217;s Confidential Information.  Each Party will promptly notify the other upon discovery of any loss or unauthorized use or disclosure of the other Party&#8217;s Confidential Information.  For clarity, Combined Therapy Study Data shall be treated as Confidential Information of both Parties and shall not be disclosed to Third Parties unless it falls within the exceptions set forth in Section 6.2 below or is reasonably necessary to be disclosed in order for a Party to exercise its rights under Section Article 6.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.2&#160;&#160;&#160;&#160;Exceptions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The obligations of confidentiality and restriction on use under Section 6.1 will not apply to any information that the receiving Party can prove by competent written evidence:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">is independently discovered or developed by the receiving Party without the use of the disclosing Party&#8217;s Confidential Information. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.3&#160;&#160;&#160;&#160;Authorized Disclosure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding any other provision of this Agreement, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">prosecuting or defending litigation as permitted by this Agreement; </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">complying with Applicable Law (including regulations promulgated by any securities exchange); </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">disclosure, in connection with the performance of this Agreement, to Affiliates, permitted sublicensees, contractors, manufacturers, ethics committees and IRBs, academic institutions, consultants, agents, investigators, and employees engaged in connection with the performance of a Combined Therapy Trial, each of whom prior to disclosure must be bound by similar terms of confidentiality and non-use at least equivalent in scope to those set forth in this Article 6; </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">disclosure of the Combined Therapy Study Data, Combined Therapy Inventions, and Combined Therapy Patents to Regulatory Authorities in connection with the development of the Combined Therapy, the Exelixis Compound, or the Roche Compound; and</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">disclosure of relevant safety information contained within the Combined Therapy Study Data to investigators, IRBs, and/or ethics committees and Regulatory Authorities that are involved in other clinical trials of the Exelixis Compound with respect to Exelixis, and the Roche Compound with respect to Roche, and (in the event of a Material Safety Issue) to Third Parties that are collaborating with Exelixis or Roche, respectively in the conduct of such other clinical trials of the Exelixis Compound or the Roche Compound, in each case solely to the extent necessary for the conduct of such clinical trials and/or to comply with Applicable Law and regulatory requirements. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;6.3(a) or (b), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as such Party would use to protect its own confidential information of a similar nature, but in no event less than reasonable efforts.  In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information.  Any information disclosed pursuant to any of Sections 10.3(a)-(e) shall remain Confidential Information and subject to the restrictions set forth in this Agreement.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;MISCELLANEOUS</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.1&#160;&#160;&#160;&#160;Full Force and Effect.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;This Supplement is deemed incorporated into, and governed by all other terms of, the Agreement.  The provisions of the Agreement remain in full force and effect.  </font></div><div style="line-height:138%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.2&#160;&#160;&#160;&#160;Term; Survival.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;This Supplement shall be effective as of the Effective Date and expire or terminate upon expiration or termination of the Agreement. The following Sections of this Supplement, all definitions relating thereto, </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">and any other provisions of this Supplement that by their nature are intended to survive expiration or termination of this Supplement shall survive any expiration or termination of this Supplement for any reason: Sections 1.3, 2.2, 3.3, 4.1, 4.2, 4.3, 4.5, 5.2, 6.1-6.4, 6.2, 6.3, 7.5 through 7.12, 7.14, and 7.16.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.3&#160;&#160;&#160;&#160;Governing Law. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Supplement shall be governed and construed in accordance with the internal laws of the State of California, USA, excluding any choice of law rules that may direct the application of the laws of another jurisdiction.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.4&#160;&#160;&#160;&#160;Force Majeure. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The parties shall be excused from the performance of their obligations under this Supplement to the extent such performance is prevented by force majeure and the non-performing party promptly provides notice of the prevention to each other party. Such excuse shall be continued so long as the condition constituting force majeure continues and the non-performing party takes reasonable efforts to remove the condition. For purpose of this Supplement, force majeure means acts of God, strikes or other concerted acts of workers, civil disturbances, fires, earthquakes, acts of terrorism, floods, explosions, riots, war, rebellion, sabotage, or failure or default of public utilities or common carriers or similar conditions beyond the control of the parties.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.5&#160;&#160;&#160;&#160;No Waiver; Modifications. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">It is agreed that no waiver by a party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default. No amendment, modification, release or discharge shall be binding upon the parties unless in writing and duly executed by authorized representatives of all parties.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.6&#160;&#160;&#160;&#160;No Strict Construction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;This Supplement has been prepared jointly and shall not be strictly construed against any party. No presumption as to construction of this Supplement shall apply against any party with respect to any ambiguity in the wording of any provision(s) of this Supplement irrespective of which party may be deemed to have authored the ambiguous provision(s).</font></div><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.7&#160;&#160;&#160;&#160;Independent Contractor.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;The parties are independent contractors of each other, and the relationship between the parties shall not constitute a partnership, joint venture, or agency. No party shall be the agent of another party or have any authority to act for, or on behalf of, another party in any manner.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.8&#160;&#160;&#160;&#160;Assignment. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No party may assign or transfer this Supplement or any rights or obligations hereunder without prior written consent of each other party, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">except</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a party may make such assignment without each other party&#8217;s consent (a) to an Affiliate, (b) to a Third Party that merges with, consolidates with, or acquires substantially all of the assets or voting control of the assigning party or (c) to a Third Party that acquires all the rights to Exelixis Compound, in the case of Exelixis or the case of Ipsen, or the Roche Compound, in the case of Roche. Any assignment or attempted assignment by any party in violation of the terms of this Section shall be null and void and of no legal effect.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.9&#160;&#160;&#160;&#160;Headings. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The captions to the several Sections and Articles hereof are not a part of this Supplement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.10&#160;&#160;&#160;&#160;Counterparts.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;This Supplement may be executed in three (3) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. This Agreement may be executed by electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures, provided that ink originals will be promptly exchanged.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.11&#160;&#160;&#160;&#160;Severability. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any provision of this Supplement is held to be illegal, invalid, or unenforceable under any present or future law, and if the rights or obligations of a party under this Supplement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Supplement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof, (c) the remaining </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">provisions of this Supplement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a part of this Supplement a legal, valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the parties.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.12&#160;&#160;&#160;&#160;No Benefit to Third Parties.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;The representations, warranties, and agreements set forth in this Supplement are for the sole benefit of the parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other parties.</font></div><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.13&#160;&#160;&#160;&#160;The Agreement. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Roche and Exelixis shall execute the Agreement concurrently with the execution of this Supplement by Roche, Exelixis, and Ipsen, and if the Agreement is not so executed concurrently with this Supplement, this Supplement shall be null and void and of no force or effect.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.14&#160;&#160;&#160;&#160;Construction. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise explicitly specified to the contrary, (a) references to a Section, Article, or Exhibit means a Section or Article of, or Exhibit to, this Supplement and all subsections thereof, unless another agreement is specified; (b) references to a particular statute or regulation include all rules and regulations promulgated thereunder and any successor statutes, rules, or regulations then in effect, in each case including the then-current amendments thereto; (c) words in the singular or plural form include the plural and singular form, respectively; (d) the terms &#8220;including,&#8221; &#8220;include(s),&#8221; &#8220;such as,&#8221; and &#8220;for example&#8221; used in this Supplement mean including the generality of any description preceding such term and will be deemed to be followed by &#8220;without limitation&#8221;; and (e) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereunder,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Supplement. No presumption as to construction of this Supplement shall apply against any party with respect to any ambiguity in the wording of any provision(s) of this Supplement irrespective of which party may be deemed to have authored the ambiguous provision(s).</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.15&#160;&#160;&#160;&#160;Further Assurance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Each of Roche, Exelixis, and Ipsen duly execute and deliver or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as another party may reasonably request in order to perfect any license, assignment, or other transfer or any properties or rights under, or pursuant, to this Supplement. </font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.16&#160;&#160;&#160;&#160;Entire Agreement. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Roche, Exelixis, and Ipsen agree that this Supplement sets forth the complete, final and exclusive agreement between Roche, Exelixis, and Ipsen collectively concerning the subject matter hereof and supersedes all prior agreements and understandings by and between Roche, Exelixis, and Ipsen collectively with respect to such subject matter. For the avoidance of doubt, this Supplement does not supersede the Agreement or the Ipsen-Exelixis Agreement. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between Roche, Exelixis, and Ipsen collectively with respect to such subject matter other than as are set forth in this Supplement.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.17&#160;&#160;&#160;&#160;Dispute Resolution.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;The terms and conditions of Section 14.3 of the Agreement shall be binding upon Ipsen with respect to any dispute, controversy, or claim between Ipsen and Roche and arising out of, relating to, or in connection with this Supplement to the same extent such terms and conditions are binding upon the parties to the Agreement. In the application of Section 14.3 to Ipsen with respect to such dispute, controversy, or claim, the &#8220;Alliance Manager&#8221; of Ipsen shall be interpreted to mean the representative of Ipsen acting as Alliance Manager, and the &#8220;Executive Officer&#8221; of Ipsen shall be interpreted to mean the [ * ] of Ipsen (or his or her designee).</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Signature page follows</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Roche, Exelixis, and Ipsen, intending to be legally bound hereby, have caused this Supplement to the Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Pharma, SAS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Fran&#231;ois Garnier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Fran&#231;ois Garnier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President and CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">EVP, General Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">18 December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">18 December 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">F. Hoffmann-La Roche Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Laurence Lehuu</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Louis DuPasquier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Laurence Lehuu</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Louis DuPasquier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Operation Program Leader</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Legal Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">18 December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (I) not material and (II) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>exel20191231exhibit211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s24EC48A62F7256CB8A58B631A08AEF76"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARIES OF EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:548px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:277px;"></td><td style="width:270px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Name of Subsidiary</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">State or Other Jurisdiction of Incorporation or Organization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis International (Bermuda) Ltd.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Patent Company, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Plant Sciences, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis U.S., LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>exel20191231exhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAAA4AE4CEF0253F2817AC2A7A459F779"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-226493, 333-223225, 333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement&#160; (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>exel20191231exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5810A6CA84E554AFAB1D0944B657F5A4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-K of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>exel20191231exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDEF7DA49A4315498819CE30831A52E0D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-K of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>exel20191231exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1DAC1BA5C54854FAA72191B50112C6BA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">25th</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>exel-20200103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20200103" xmlns:exel="http://www.exelixis.com/20200103" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200103_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200103_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2104100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsGrossUnrealizedLossesDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails">
        <link:definition>2404404 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2404405 - Disclosure - Cash and Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2404402 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsSummaryByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails">
        <link:definition>2404406 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsSummaryBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails">
        <link:definition>2404403 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2304301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInvenraCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherCollaborationsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails">
        <link:definition>2403409 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.exelixis.com/role/Commitments">
        <link:definition>2111100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails">
        <link:definition>2411403 - Disclosure - Commitments (Balance Sheet Classification of Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsComponentsOfLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails">
        <link:definition>2411404 - Disclosure - Commitments (Components of Lease Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>2411405 - Disclosure - Commitments (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2">
        <link:definition>2411405 - Disclosure - Commitments (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails">
        <link:definition>2411402 - Disclosure - Commitments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://www.exelixis.com/role/CommitmentsTables">
        <link:definition>2311301 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical">
        <link:definition>1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans">
        <link:definition>2108100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>2408403 - Disclosure - Employee Benefit Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2408402 - Disclosure - Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails">
        <link:definition>2408405 - Disclosure - Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails">
        <link:definition>2408407 - Disclosure - Employee Benefit Plans (Summary of All RSU Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails">
        <link:definition>2408406 - Disclosure - Employee Benefit Plans (Summary of All Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables">
        <link:definition>2308301 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
        <link:definition>2408404 - Disclosure - Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2405402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2109100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>2409402 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2409405 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails">
        <link:definition>2409404 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails">
        <link:definition>2409403 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>2409406 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exelixis.com/role/IncomeTaxesTables">
        <link:definition>2309301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2106100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2406402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsCalc2" roleURI="http://www.exelixis.com/role/InventoryDetailsCalc2">
        <link:definition>2406402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2306301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2110100 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails">
        <link:definition>2410402 - Disclosure - Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareNarrativeDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails">
        <link:definition>2410404 - Disclosure - Net Income Per Share (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails">
        <link:definition>2410403 - Disclosure - Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2310301 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2107100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2407403 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2307301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2112100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2412402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2312301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2102100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails">
        <link:definition>2402406 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedByProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails">
        <link:definition>2402403 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails">
        <link:definition>2402402 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesContractAssetsAndLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails">
        <link:definition>2402407 - Disclosure - Revenues Revenues (Contract Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails">
        <link:definition>2402405 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails">
        <link:definition>2402404 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2302301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AchievedMember" name="AchievedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" name="AdditionalDevelopmentAndRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AdditionalUpfrontAndMilestonePayments" name="AdditionalUpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesOfAmerisourceBergenCorporationMember" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofCVSHealthCorporationMember" name="AffiliatesofCVSHealthCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForProductRebatesMember" name="AllowanceForProductRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AreaOfRealEstatePropertyAvailableToLease" name="AreaOfRealEstatePropertyAvailableToLease" nillable="true" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_BuiltToSuitLeaseMember" name="BuiltToSuitLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ChargebacksAndDiscountsForPromptPaymentMember" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementNumberOfPreexistingPrograms" name="CollaborationAgreementNumberOfPreexistingPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementNumberOfPrograms" name="CollaborationAgreementNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" name="CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" name="CollaborationAgreementResearchAndDevelopmentExpenseAccrued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementResearchAndDevelopmentObligation" name="CollaborationAgreementResearchAndDevelopmentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementTerminationPeriod" name="CollaborationAgreementTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" name="CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" name="CollaborationAgreementWithIconicTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementsUpfrontPayments" name="CollaborationAgreementsUpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementwithDaiichiSankyoMember" name="CollaborationAgreementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationLicenseMember" name="CollaborationLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationMember" name="CollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationOtherMember" name="CollaborationOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationResearchAndDevelopmentServiceMember" name="CollaborationResearchAndDevelopmentServiceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementAchievedMilestoneAmount" name="CollaborativeArrangementAchievedMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementWithInvenraMember" name="CollaborativeArrangementWithInvenraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementWithStemSynergyMember" name="CollaborativeArrangementWithStemSynergyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithDaiichiSankyoMember" name="CollaborativeArrangementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CotellicMember" name="CotellicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" name="DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DeferredTaxAssetsLeasingArrangements" name="DeferredTaxAssetsLeasingArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_DevelopmentAndRegulatoryMilestoneMember" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiplomatSpecialtyPharmacyMember" name="DiplomatSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiscoveryProjectMember" name="DiscoveryProjectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EMAFilingAcceptanceHCCMember" name="EMAFilingAcceptanceHCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" name="EarningsPerShareBasicDilutedOtherDisclosuresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_FinalTierMember" name="FinalTierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FirstProductToReachMarketMember" name="FirstProductToReachMarketMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlobalMember" name="GlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_HeadquartersLeaseMember" name="HeadquartersLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InitialMember" name="InitialMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_InventoryManufacturedBeforeRegulatoryApproval" name="InventoryManufacturedBeforeRegulatoryApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LeaseArrangementsAxis" name="LeaseArrangementsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LeaseArrangementsDomain" name="LeaseArrangementsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" name="LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MINNEBROMember" name="MINNEBROMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_MedicarePartDFundingMandate" name="MedicarePartDFundingMandate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveAxis" name="MilestoneObjectiveAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveDomain" name="MilestoneObjectiveDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MilestonePaymentsEarned" name="MilestonePaymentsEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_MilestonePaymentsEarnedToDate" name="MilestonePaymentsEarnedToDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_NotProbableMember" name="NotProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiabilityTotal" name="OperatingAndFinanceLeasesLiabilityTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OperatingLeaseAssetsAbstract" name="OperatingLeaseAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesAbstract" name="OperatingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingLeasesVariableLeaseExpense" name="OperatingLeasesVariableLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingLossCarryforwardswithExpirationDates" name="OperatingLossCarryforwardswithExpirationDates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PercentOfRoyaltyOnNetSale" name="PercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceShareOptionsPSOMember" name="PerformanceShareOptionsPSOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceSharesAchievedBeforeDecember312020Member" name="PerformanceSharesAchievedBeforeDecember312020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceSharesSecondProductApprovalMember" name="PerformanceSharesSecondProductApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PeriodOfSpecificSalesVolumeThreshold" name="PeriodOfSpecificSalesVolumeThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProbableMember" name="ProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductCommercializationMember" name="ProductCommercializationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductGrossMember" name="ProductGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductSalesDiscountsAndAllowancesMember" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedFromCabozantinibMember" name="ProductsDerivedFromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedFromOtherCompoundsMember" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementPercentOfProfits" name="ProfitSharingAgreementPercentOfProfits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementProfitThreshold" name="ProfitSharingAgreementProfitThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierOneMember" name="ProfitSharingTierOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierThreeMember" name="ProfitSharingTierThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierTwoMember" name="ProfitSharingTierTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersAxis" name="ProfitSharingTiersAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersDomain" name="ProfitSharingTiersDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProjectInitiationFeePayment" name="ProjectInitiationFeePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ResultingFromDiscoveryEffortsMember" name="ResultingFromDiscoveryEffortsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_RoyaltyTier" name="RoyaltyTier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltyTierAxis" name="RoyaltyTierAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierDomain" name="RoyaltytierDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenuePercentDiscountForPromptPayment" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusAxis" name="StatusAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusDomain" name="StatusDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_TenantLeaseImprovementsAllowance" name="TenantLeaseImprovementsAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontAndMilestonePayments" name="UpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontPayments" name="UpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_VestedMember" name="VestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" name="WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>exel-20200103_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20200103.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20200103.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20200103.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20200103.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20200103.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20200103.xsd#CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:href="exel-20200103.xsd#CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20200103.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:href="exel-20200103.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20200103.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20200103.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20200103.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20200103.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20200103.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:href="exel-20200103.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20200103.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20200103.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20200103.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20200103.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20200103.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20200103.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20200103.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20200103.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20200103.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetailsCalc2" xlink:href="exel-20200103.xsd#InventoryDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20200103.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20200103.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20200103.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails" xlink:href="exel-20200103.xsd#NetIncomePerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20200103.xsd#NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20200103.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20200103.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20200103.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20200103.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20200103.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20200103.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20200103.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20200103.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20200103.xsd#RevenuesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_167ec6f2-cd00-1650-5a57-e231dd2cfd76" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_167ec6f2-cd00-1650-5a57-e231dd2cfd76" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_384A7F6E47AF56369CF6D0E8B9A2494D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_384A7F6E47AF56369CF6D0E8B9A2494D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_B1B5C59954ACD7227CEBD0F6D5060929" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_384A7F6E47AF56369CF6D0E8B9A2494D" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_B1B5C59954ACD7227CEBD0F6D5060929" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="arc" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6FD99A3B0CC89428D36E704564C72A4D" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6FD99A3B0CC89428D36E704564C72A4D" xlink:type="arc" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6FD99A3B0CC89428D36E704564C72A4D" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_B1B5C59954ACD7227CEBD0F6D5060929" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4E074AF6956734733DC5D0F957AA4316" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6FD99A3B0CC89428D36E704564C72A4D" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4E074AF6956734733DC5D0F957AA4316" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6FD99A3B0CC89428D36E704564C72A4D" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_167ec6f2-cd00-1650-5a57-e231dd2cfd76" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A58B8844B69BDDC0A96D0EA2FC3037F" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A58B8844B69BDDC0A96D0EA2FC3037F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A58B8844B69BDDC0A96D0EA2FC3037F" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4E074AF6956734733DC5D0F957AA4316" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_8dd289f8-9bc4-5eca-8aa4-41500fe587c8" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_SubleaseIncome_8dd289f8-9bc4-5eca-8aa4-41500fe587c8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_8cbd5c71-3137-5b03-cd70-20248e389340" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_4ff4f2d7-6662-e810-4740-ec43000ee89c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_8cbd5c71-3137-5b03-cd70-20248e389340" xlink:to="loc_us-gaap_LeaseAndRentalExpense_4ff4f2d7-6662-e810-4740-ec43000ee89c" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeasesVariableLeaseExpense" xlink:label="loc_exel_OperatingLeasesVariableLeaseExpense_B59F237A81CB6A9A22E66FEEB5F8214E" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_8cbd5c71-3137-5b03-cd70-20248e389340" xlink:to="loc_exel_OperatingLeasesVariableLeaseExpense_B59F237A81CB6A9A22E66FEEB5F8214E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_a2d0afa6-5872-ff13-eeda-3f09e5edddc0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_8cbd5c71-3137-5b03-cd70-20248e389340" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_a2d0afa6-5872-ff13-eeda-3f09e5edddc0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_CDC45F3FD4659466CB456FF179F76F08_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_CDC45F3FD4659466CB456FF179F76F08_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_CDC45F3FD4659466CB456FF179F76F08_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_CDC45F3FD4659466CB456FF179F76F08_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CDC45F3FD4659466CB456FF179F76F08_6e6d1773-a9c9-8650-0b6d-e231dc044f26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_CDC45F3FD4659466CB456FF179F76F08_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CDC45F3FD4659466CB456FF179F76F08_6e6d1773-a9c9-8650-0b6d-e231dc044f26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_CDC45F3FD4659466CB456FF179F76F08_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_CDC45F3FD4659466CB456FF179F76F08_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_CDC45F3FD4659466CB456FF179F76F08_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f46016be-a090-7f0b-44f7-8ddf156c8efc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f46016be-a090-7f0b-44f7-8ddf156c8efc" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8181aa43-5e6e-efd7-8594-e231dc44bff4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_8181aa43-5e6e-efd7-8594-e231dc44bff4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_ed5805c5-9fe5-ff84-0411-6c376b91c188" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_ed5805c5-9fe5-ff84-0411-6c376b91c188" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_070c23c0-5d18-82af-08b1-e231dbcc5321" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_070c23c0-5d18-82af-08b1-e231dbcc5321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_EEB79B0E5C7CCBD40ACC44568A5E2655" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_EEB79B0E5C7CCBD40ACC44568A5E2655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3b304564-1a0d-03c8-a331-770e72d1f6fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3b304564-1a0d-03c8-a331-770e72d1f6fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_93f5c047-4b64-266d-dad0-d21441a97f7a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_93f5c047-4b64-266d-dad0-d21441a97f7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d3769ff7-3f7d-8a64-ea69-f16e64d6f178" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d3769ff7-3f7d-8a64-ea69-f16e64d6f178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_NoncashLeaseExpense" xlink:label="loc_exel_NoncashLeaseExpense_61EE44208E449E015DF8C77B2FAB19F3" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_NoncashLeaseExpense_61EE44208E449E015DF8C77B2FAB19F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_fcba1b70-9744-b5e7-d3f6-0354ac274304" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestIncomeOther_fcba1b70-9744-b5e7-d3f6-0354ac274304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9fd2e560-0aac-aea4-6be8-8b4e4e77d184" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9fd2e560-0aac-aea4-6be8-8b4e4e77d184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_06fdd8fa-20aa-c385-b288-61c16515fae0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_06fdd8fa-20aa-c385-b288-61c16515fae0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_a4d13b31-0abc-061c-626d-7f5f6ef35d64" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_a4d13b31-0abc-061c-626d-7f5f6ef35d64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_80b07582-c513-7f5b-387a-d22f4a77e72b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_80b07582-c513-7f5b-387a-d22f4a77e72b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DeferredTaxAssetsLeasingArrangements" xlink:label="loc_exel_DeferredTaxAssetsLeasingArrangements_CC4387307FA96F3CD6046FBDA877E04F" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_exel_DeferredTaxAssetsLeasingArrangements_CC4387307FA96F3CD6046FBDA877E04F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:to="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4c5a1085-469a-cd6c-e26f-53287b62aa26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4c5a1085-469a-cd6c-e26f-53287b62aa26" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_49a08e86-47b2-01fa-94cc-0320e102ec63" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_49a08e86-47b2-01fa-94cc-0320e102ec63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_8aacea24-b78b-d0a4-5334-45b52d9eb0b2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_8aacea24-b78b-d0a4-5334-45b52d9eb0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3c49146a-876e-0398-a795-05386dec675e" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3c49146a-876e-0398-a795-05386dec675e" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_2A1300DFC525BAC7EF05126C899FA895" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_2A1300DFC525BAC7EF05126C899FA895" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_fc662cb4-22a7-eaf1-57df-aa538af7744b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:to="loc_us-gaap_InventoryRawMaterials_fc662cb4-22a7-eaf1-57df-aa538af7744b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_02c38264-930d-9c2f-e0a7-6a0838599d0b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:to="loc_us-gaap_InventoryWorkInProcess_02c38264-930d-9c2f-e0a7-6a0838599d0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_4b469d73-0d86-8f9c-e98a-661ef709c068" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:to="loc_us-gaap_InventoryFinishedGoods_4b469d73-0d86-8f9c-e98a-661ef709c068" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetailsCalc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90e25e8e-b555-9209-062f-62d312826e2f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90e25e8e-b555-9209-062f-62d312826e2f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_3a8c0eb1-6ef9-655a-02de-5dccbd1ce86b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_3a8c0eb1-6ef9-655a-02de-5dccbd1ce86b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_69de72ae-c4fb-f728-a0ba-9de4da86f14d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90e25e8e-b555-9209-062f-62d312826e2f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_69de72ae-c4fb-f728-a0ba-9de4da86f14d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>exel-20200103_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20200103.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20200103.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20200103.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20200103.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20200103.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20200103.xsd#CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:href="exel-20200103.xsd#CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20200103.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20200103.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20200103.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20200103.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20200103.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20200103.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:href="exel-20200103.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20200103.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20200103.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20200103.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20200103.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20200103.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20200103.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20200103.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20200103.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20200103.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20200103.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20200103.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20200103.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails" xlink:href="exel-20200103.xsd#NetIncomePerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20200103.xsd#NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20200103.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20200103.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20200103.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20200103.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20200103.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20200103.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20200103.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20200103.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20200103.xsd#RevenuesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1F4B21E5700BBAA47988123BC6C02A6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1F4B21E5700BBAA47988123BC6C02A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7F2FC4E54F60C7403EE5123BC6C002AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7F2FC4E54F60C7403EE5123BC6C002AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2AD99F83BDCB70512ADB1240DF60B488" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:to="loc_us-gaap_CommercialPaperMember_2AD99F83BDCB70512ADB1240DF60B488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6F61F218690EDE52C4B8703C4838F67B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CommercialPaperMember_6F61F218690EDE52C4B8703C4838F67B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6AD787988E3DBF12020B703C4838321B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6AD787988E3DBF12020B703C4838321B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_BE85E4372805617CD02C703C48381DBC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_BE85E4372805617CD02C703C48381DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2F6D6B4B0041ECC83259703C4838C151" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2F6D6B4B0041ECC83259703C4838C151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7C0F8D9B8B3560EBCA14703C483947CA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7C0F8D9B8B3560EBCA14703C483947CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:to="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:to="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:to="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CDDEFE7B41402D2FE08015C6E946D32E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:to="loc_srt_MinimumMember_CDDEFE7B41402D2FE08015C6E946D32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C1711A2AFD4C4DAFC15515C6E95412C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:to="loc_srt_MaximumMember_C1711A2AFD4C4DAFC15515C6E95412C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_CDA24A65AD0340BCD3F615C837A51F6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_UpfrontPayments_CDA24A65AD0340BCD3F615C837A51F6D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_B9828CABBF79B7D1543015C6E8EE1788" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_B9828CABBF79B7D1543015C6E8EE1788" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:to="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:to="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:to="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860" xlink:to="loc_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:to="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:to="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:to="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6EAD83F089DF971583321597728D30BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6EAD83F089DF971583321597728D30BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_7D30A75587FA16C500101597728DE353" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_exel_UpfrontAndMilestonePayments_7D30A75587FA16C500101597728DE353" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_DE55BD37270FB355CA926FAE6E76EFC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_DE55BD37270FB355CA926FAE6E76EFC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:to="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:to="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_869C54264CACDE5E84986FAE6E7607CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:to="loc_srt_MinimumMember_869C54264CACDE5E84986FAE6E7607CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A95F3801AFC7002AFC5A6FAE6E77C3F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:to="loc_srt_MaximumMember_A95F3801AFC7002AFC5A6FAE6E77C3F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:to="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:to="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_CA487A002A6DDEFEF64E6FAE6E77563F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:to="loc_exel_FinalTierMember_CA487A002A6DDEFEF64E6FAE6E77563F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_5D4491F9DDA6433A78F06FAE6E78814D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:to="loc_exel_InitialMember_5D4491F9DDA6433A78F06FAE6E78814D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:to="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:to="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_445D6D864EEEEFD0EAB66FAE6E786FB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55" xlink:to="loc_exel_GlaxoSmithKlineMember_445D6D864EEEEFD0EAB66FAE6E786FB2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_E99DDDE7087F9F2C1CEC6FAE6E7939B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_E99DDDE7087F9F2C1CEC6FAE6E7939B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_D40071723E51897787006FAE6E79BB71" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_UpfrontPayments_D40071723E51897787006FAE6E79BB71" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarnedToDate" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_DAF1C6768650778CB1BC702F654C0E72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_DAF1C6768650778CB1BC702F654C0E72" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_6749F9D087E3C7D62FC66FAE6E792E3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_MilestonePaymentsEarned_6749F9D087E3C7D62FC66FAE6E792E3D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_51E1B0A3D4A2E7837EC66FAE6E79E58B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_51E1B0A3D4A2E7837EC66FAE6E79E58B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_6CDE0BDFC1F13DDE6AF76FAE6E7ACBA5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_6CDE0BDFC1F13DDE6AF76FAE6E7ACBA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_B1069E27EAB97307CF8D6FAE6E7ADFF2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_B1069E27EAB97307CF8D6FAE6E7ADFF2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_51154324B246E1E2D0F56FAE6E7A567B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_RoyaltyTier_51154324B246E1E2D0F56FAE6E7A567B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_16B15CA3DAC4CE611B286FAE6E7AF445" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_16B15CA3DAC4CE611B286FAE6E7AF445" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_5334043CD6BAAB865D486FAE6E7AF491" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_5334043CD6BAAB865D486FAE6E7AF491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1F2FA557768C04FD66BE6FAE6E7BE20C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1F2FA557768C04FD66BE6FAE6E7BE20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_A1F0AE8AA9634D97CA206FAE6E7B7EA7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_A1F0AE8AA9634D97CA206FAE6E7B7EA7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:to="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:to="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MINNEBROMember" xlink:label="loc_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0" xlink:to="loc_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:to="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:to="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="loc_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="loc_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="loc_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_6C04B069026AD40E92366FAE6DFE321C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_6C04B069026AD40E92366FAE6DFE321C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:to="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:to="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1ECA49F5C66527C8512E6FAE6DFFB1BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:to="loc_srt_MaximumMember_1ECA49F5C66527C8512E6FAE6DFFB1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_988244FAED54C0EC96BD6FAE6DFFB2D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:to="loc_srt_MinimumMember_988244FAED54C0EC96BD6FAE6DFFB2D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_880D66371B464D4CB5CD6FAE6E00CD06" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_880D66371B464D4CB5CD6FAE6E00CD06" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementTerminationPeriod" xlink:label="loc_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_49850F4891BFA8A7ED9B6FAE6E01ADA9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_49850F4891BFA8A7ED9B6FAE6E01ADA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:to="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:to="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:to="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_6F425D02D4D3EA846B8215976B3405F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38" xlink:to="loc_exel_GlaxoSmithKlineMember_6F425D02D4D3EA846B8215976B3405F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_95DD9E3740693825E3A715A60D540501" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_95DD9E3740693825E3A715A60D540501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:to="loc_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:to="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:to="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:to="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077" xlink:to="loc_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AdditionalUpfrontAndMilestonePayments" xlink:label="loc_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ACE5141A8D24EAD9B2AC1597729C7349" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ACE5141A8D24EAD9B2AC1597729C7349" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:to="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:to="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:to="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:to="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D03A6B169DB5EF2D01D36FAE6E635138" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:to="loc_srt_MinimumMember_D03A6B169DB5EF2D01D36FAE6E635138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_30A131A2A4778E53D2BC6FAE6E644AB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:to="loc_srt_MaximumMember_30A131A2A4778E53D2BC6FAE6E644AB1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:to="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:to="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:to="loc_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:to="loc_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:to="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:to="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:to="loc_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:to="loc_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarnedToDate" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsAxis" xlink:label="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:to="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:to="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:to="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_HeadquartersLeaseMember" xlink:label="loc_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:to="loc_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_BuiltToSuitLeaseMember" xlink:label="loc_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:to="loc_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:to="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:to="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:to="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AreaOfRealEstatePropertyAvailableToLease" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:to="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:to="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:to="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:to="loc_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:to="loc_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99F5A633ABCE802712A17CB6706F57B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99F5A633ABCE802712A17CB6706F57B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:to="loc_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:label="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:to="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_6C148F104A02753B7F5C6FAE6F16ABAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_6C148F104A02753B7F5C6FAE6F16ABAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:to="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:to="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:to="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:to="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:to="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_VestedMember" xlink:label="loc_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:to="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BA9430A16A10D86F9016703C47DE6FB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BA9430A16A10D86F9016703C47DE6FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B6BF9BD49877C6021051703C47DF18A2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_EmployeeStockMember_B6BF9BD49877C6021051703C47DF18A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceSharesSecondProductApprovalMember" xlink:label="loc_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:to="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B12DC4A363CA5E5B00793EEED7DCFBFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B12DC4A363CA5E5B00793EEED7DCFBFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_941E665BA3322BD2857C3EEED7DCA891" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:to="loc_us-gaap_EmployeeStockMember_941E665BA3322BD2857C3EEED7DCA891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:to="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7AD5A90A839B7DBEE1626FAE6C6414F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7AD5A90A839B7DBEE1626FAE6C6414F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:to="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:to="loc_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:to="loc_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLossCarryforwardswithExpirationDates" xlink:label="loc_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:to="loc_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:to="loc_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:to="loc_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20200103.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:type="locator" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:to="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:to="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductsDerivedFromOtherCompoundsMember" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:to="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:to="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:to="loc_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:to="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:to="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:to="loc_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:to="loc_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MedicarePartDFundingMandate" xlink:label="loc_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_InventoryManufacturedBeforeRegulatoryApproval" xlink:label="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:to="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:to="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:to="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_982AF8055FF50B4026C315B343625864" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:to="loc_srt_MinimumMember_982AF8055FF50B4026C315B343625864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4A5FF6B07D7B929B17E815B34362EA2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:to="loc_srt_MaximumMember_4A5FF6B07D7B929B17E815B34362EA2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8324F60917B5F53D037415B34364350B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8324F60917B5F53D037415B34364350B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="loc_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_A490CD364EC6DB83691D3EF7318F551D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_A490CD364EC6DB83691D3EF7318F551D" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:to="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:to="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:to="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:to="loc_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:to="loc_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:to="loc_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_A490CD364EC6DB83691D3EF7318F551D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9F22CC0EDB71F3ED59CB703C48C99264" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9F22CC0EDB71F3ED59CB703C48C99264" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:to="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:to="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:to="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductSalesDiscountsAndAllowancesMember" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_01304C239004DAD78756703C48C8A708" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_us-gaap_ProductMember_01304C239004DAD78756703C48C8A708" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationLicenseMember" xlink:label="loc_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationResearchAndDevelopmentServiceMember" xlink:label="loc_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationOtherMember" xlink:label="loc_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_544A061017739943349F703C48C9D4A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9F22CC0EDB71F3ED59CB703C48C99264" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_544A061017739943349F703C48C9D4A7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_B56E14831B4DD3D8DD706FCBBBDF8E88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_B56E14831B4DD3D8DD706FCBBBDF8E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3984636CEFD28409AAE36FCBBBBAEC10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3984636CEFD28409AAE36FCBBBBAEC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:to="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:to="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:to="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:to="loc_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:to="loc_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_0A4B0CC1471D364F85C93EF731B7B0DB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:to="loc_country_JP_0A4B0CC1471D364F85C93EF731B7B0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B86DB6FD3C60DA86413EF731B808FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B86DB6FD3C60DA86413EF731B808FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:to="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:to="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesofCVSHealthCorporationMember" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3541EFB4465EC49623B46FAE6EA9A011" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3541EFB4465EC49623B46FAE6EA9A011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>exel-20200103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:type="arc" />
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:to="lab_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:to="lab_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:to="lab_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:to="lab_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:to="lab_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="lab_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:type="arc" />
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived From Other Compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductsDerivedFromOtherCompoundsMember" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:to="lab_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:to="lab_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:to="lab_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:to="lab_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2_label_en-US" xlink:label="lab_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:to="lab_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88_terseLabel_en-US" xlink:label="lab_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88_label_en-US" xlink:label="lab_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:to="lab_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8_label_en-US" xlink:label="lab_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:to="lab_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD_label_en-US" xlink:label="lab_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:to="lab_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:to="lab_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:to="lab_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent discount for prompt payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:type="arc" />
    <link:label id="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D_terseLabel_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D_label_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D_documentation_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MedicarePartDFundingMandate" xlink:label="loc_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:to="lab_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8_verboseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold is related to product</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:type="arc" />
    <link:label id="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283_terseLabel_en-US" xlink:label="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Materials in inventory balances</link:label>
    <link:label id="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283_label_en-US" xlink:label="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Manufactured Before Regulatory Approval</link:label>
    <link:label id="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283_documentation_en-US" xlink:label="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Manufactured Before Regulatory Approval</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_InventoryManufacturedBeforeRegulatoryApproval" xlink:label="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:to="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:to="lab_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:type="arc" />
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets amortization of deferred stock compensation - non-qualified.</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:to="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:type="arc" />
    <link:label id="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_DeferredTaxAssetsLeasingArrangements" xlink:label="loc_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:to="lab_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:to="lab_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:to="lab_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:to="lab_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:to="lab_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:to="lab_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total investment securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31,</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5_negatedTerseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:to="lab_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:to="lab_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89_verboseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments Due to the Adoption of Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843_label_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:to="lab_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Objective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A_label_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Objective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for MilestoneObjective [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:to="lab_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:type="arc" />
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC_terseLabel_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC</link:label>
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC_label_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC [Member]</link:label>
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC_documentation_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:to="lab_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A_label_en-US" xlink:label="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A_documentation_en-US" xlink:label="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:to="lab_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D_label_en-US" xlink:label="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:to="lab_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:type="arc" />
    <link:label id="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3_terseLabel_en-US" xlink:label="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial</link:label>
    <link:label id="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3_label_en-US" xlink:label="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3_documentation_en-US" xlink:label="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:to="lab_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final tier</link:label>
    <link:label id="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B_label_en-US" xlink:label="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B_documentation_en-US" xlink:label="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:to="lab_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:to="lab_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:to="lab_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:type="arc" />
    <link:label id="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560_terseLabel_en-US" xlink:label="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global</link:label>
    <link:label id="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560_label_en-US" xlink:label="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560_documentation_en-US" xlink:label="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:to="lab_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:type="arc" />
    <link:label id="lab_country_JP_4ED36B76146D68388B866FAE6E65719D_terseLabel_en-US" xlink:label="lab_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_4ED36B76146D68388B866FAE6E65719D_label_en-US" xlink:label="lab_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:to="lab_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:type="arc" />
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C_terseLabel_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales volume period</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C_label_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C_documentation_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:to="lab_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053_terseLabel_en-US" xlink:label="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053_label_en-US" xlink:label="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053_documentation_en-US" xlink:label="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:to="lab_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:type="arc" />
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments earned to date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarnedToDate" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:to="lab_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:type="arc" />
    <link:label id="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:to="lab_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:type="arc" />
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3_label_en-US" xlink:label="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3_documentation_en-US" xlink:label="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:to="lab_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement percent of royalty on net sale</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:to="lab_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:type="arc" />
    <link:label id="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67_terseLabel_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Product To Reach Market</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67_label_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67_documentation_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:to="lab_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:to="lab_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4_terseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4_label_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4_documentation_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments.</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:to="lab_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:type="arc" />
    <link:label id="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036_terseLabel_en-US" xlink:label="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional upfront and milestone payments</link:label>
    <link:label id="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036_label_en-US" xlink:label="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Upfront And Milestone Payments</link:label>
    <link:label id="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036_documentation_en-US" xlink:label="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Upfront And Milestone Payments</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AdditionalUpfrontAndMilestonePayments" xlink:label="loc_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:to="lab_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:type="arc" />
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161_terseLabel_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change relating to prior year provision</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161_label_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161_documentation_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:to="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change relating to current year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions based on the lapse of the applicable statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847" xlink:type="arc" />
    <link:label id="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB_terseLabel_en-US" xlink:label="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB_label_en-US" xlink:label="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB_documentation_en-US" xlink:label="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:to="lab_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:type="arc" />
    <link:label id="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5_terseLabel_en-US" xlink:label="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5_label_en-US" xlink:label="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5_documentation_en-US" xlink:label="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="lab_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:type="arc" />
    <link:label id="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6_terseLabel_en-US" xlink:label="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6_label_en-US" xlink:label="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6_documentation_en-US" xlink:label="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:to="lab_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:type="arc" />
    <link:label id="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091_terseLabel_en-US" xlink:label="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091_label_en-US" xlink:label="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested [Member]</link:label>
    <link:label id="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091_documentation_en-US" xlink:label="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vested [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_VestedMember" xlink:label="loc_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:to="lab_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:type="arc" />
    <link:label id="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1_terseLabel_en-US" xlink:label="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1_label_en-US" xlink:label="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1_documentation_en-US" xlink:label="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:to="lab_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:type="arc" />
    <link:label id="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC_terseLabel_en-US" xlink:label="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Probable</link:label>
    <link:label id="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC_label_en-US" xlink:label="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC_documentation_en-US" xlink:label="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:to="lab_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:to="lab_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E_terseLabel_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO)</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E_label_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E_documentation_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:to="lab_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA_label_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA_documentation_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:to="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares, Second Product Approval</link:label>
    <link:label id="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434_label_en-US" xlink:label="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares, Second Product Approval [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434_documentation_en-US" xlink:label="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Shares, Second Product Approval [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceSharesSecondProductApprovalMember" xlink:label="loc_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:to="lab_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life of stock options granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate from market value on purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate from market value on offering date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:to="lab_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise threshold, percentage of per share exercise price of the PSO</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from option exercises and purchases under the ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees percentage</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares to be earned (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses relating to stock match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739" xlink:to="lab_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7_label_en-US" xlink:label="lab_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="lab_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7_terseLabel_en-US" xlink:label="lab_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7_label_en-US" xlink:label="lab_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:to="lab_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:to="lab_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:to="lab_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:to="lab_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC_label_en-US" xlink:label="lab_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:to="lab_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB_label_en-US" xlink:label="lab_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:to="lab_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:to="lab_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:to="lab_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:to="lab_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:to="lab_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:to="lab_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:to="lab_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A_label_en-US" xlink:label="lab_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:to="lab_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:to="lab_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8_label_en-US" xlink:label="lab_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:to="lab_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04_label_en-US" xlink:label="lab_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:to="lab_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18_label_en-US" xlink:label="lab_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:to="lab_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:to="lab_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:to="lab_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:to="lab_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:to="lab_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:to="lab_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:to="lab_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA_label_en-US" xlink:label="lab_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:to="lab_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77_label_en-US" xlink:label="lab_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:to="lab_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55_label_en-US" xlink:label="lab_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:to="lab_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:to="lab_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:to="lab_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:to="lab_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:to="lab_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investment securities available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:type="arc" />
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1_terseLabel_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1_label_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1_documentation_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:to="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E_label_en-US" xlink:label="lab_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:to="lab_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:to="lab_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:to="lab_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4_label_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeaseAssetsAbstract" xlink:label="loc_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:to="lab_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B" xlink:to="lab_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal income tax provision at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:type="arc" />
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2_negatedTerseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Awards outstanding at end of the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Awards outstanding at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:to="lab_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:type="arc" />
    <link:label id="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73_terseLabel_en-US" xlink:label="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73_label_en-US" xlink:label="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73_documentation_en-US" xlink:label="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:to="lab_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Ipsen</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:to="lab_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE_label_en-US" xlink:label="lab_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:to="lab_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="lab_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:to="lab_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:to="lab_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:to="lab_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:to="lab_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards Update (ASU) No. 2016-09, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:to="lab_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A" xlink:to="lab_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB" xlink:to="lab_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment to net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:to="lab_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:to="lab_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:type="arc" />
    <link:label id="lab_country_US_CA593247E5E9292417CE3EF731B754DD_terseLabel_en-US" xlink:label="lab_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_CA593247E5E9292417CE3EF731B754DD_label_en-US" xlink:label="lab_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:to="lab_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB_label_en-US" xlink:label="lab_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:to="lab_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E_label_en-US" xlink:label="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E_documentation_en-US" xlink:label="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:to="lab_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesofCVSHealthCorporationMember" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:to="lab_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:type="arc" />
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32_terseLabel_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32_label_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32_documentation_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:to="lab_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:type="arc" />
    <link:label id="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6_terseLabel_en-US" xlink:label="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery Project</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6_label_en-US" xlink:label="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6_documentation_en-US" xlink:label="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:to="lab_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:type="arc" />
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714_terseLabel_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714_label_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714_documentation_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:to="lab_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:type="arc" />
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436_terseLabel_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436_label_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436_documentation_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:to="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:type="arc" />
    <link:label id="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D_terseLabel_en-US" xlink:label="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Commercialization</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D_label_en-US" xlink:label="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D_documentation_en-US" xlink:label="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:to="lab_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Invenra</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Invenra [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement With Invenra [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:to="lab_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:type="arc" />
    <link:label id="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969_terseLabel_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project initiation fee</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969_label_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969_documentation_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:to="lab_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489_label_en-US" xlink:label="lab_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:to="lab_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:type="arc" />
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127_label_en-US" xlink:label="lab_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:to="lab_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:to="lab_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71_terseLabel_en-US" xlink:label="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards with expiration dates</link:label>
    <link:label id="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71_label_en-US" xlink:label="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards with Expiration Dates</link:label>
    <link:label id="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71_documentation_en-US" xlink:label="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards with Expiration Dates</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLossCarryforwardswithExpirationDates" xlink:label="loc_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:to="lab_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:to="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc.</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:to="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:to="lab_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement pre-existing programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Preexisting Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Preexisting Programs</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:to="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical development work on these programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F_label_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Obligation</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Obligation</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:to="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense for the discovery and preclinical development funding commitment</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F_label_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Expense Accrued</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Expense Accrued</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:to="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement option exercise fee payment, upon exercising option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B_label_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:to="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272_label_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:to="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003_label_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:to="lab_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB" xlink:to="lab_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550_label_en-US" xlink:label="lab_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:to="lab_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C_terseLabel_en-US" xlink:label="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C_label_en-US" xlink:label="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C_documentation_en-US" xlink:label="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:to="lab_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:to="lab_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="lab_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:to="lab_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:to="lab_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:to="lab_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B_label_en-US" xlink:label="lab_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:to="lab_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:to="lab_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:to="lab_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:to="lab_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:to="lab_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D_label_en-US" xlink:label="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Basic Diluted Other Disclosures [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D_documentation_en-US" xlink:label="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share Basic Diluted Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:label="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:to="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:to="lab_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:to="lab_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:to="lab_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:type="arc" />
    <link:label id="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_NoncashLeaseExpense" xlink:label="loc_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:to="lab_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:to="lab_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment deemed to have been acquired in build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:to="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="lab_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="lab_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:to="lab_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:to="lab_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B_label_en-US" xlink:label="lab_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:to="lab_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:to="lab_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:to="lab_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE_label_en-US" xlink:label="lab_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:to="lab_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642_label_en-US" xlink:label="lab_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:to="lab_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:to="lab_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:to="lab_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583_terseLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Total</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Total</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:to="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157_label_en-US" xlink:label="lab_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:to="lab_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:to="lab_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="lab_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:to="lab_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 304,831 and 299,876 at December 31, 2019 and 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:to="lab_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:to="lab_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0" xlink:to="lab_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues Disaggregated by Significant Customer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:type="arc" />
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:to="lab_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:to="lab_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:to="lab_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="lab_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:to="lab_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:to="lab_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:to="lab_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607_label_en-US" xlink:label="lab_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:to="lab_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:to="lab_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:to="lab_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:to="lab_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:to="lab_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB_terseLabel_en-US" xlink:label="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB_label_en-US" xlink:label="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Variable Lease Expense</link:label>
    <link:label id="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB_documentation_en-US" xlink:label="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Variable Lease Expense</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeasesVariableLeaseExpense" xlink:label="loc_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:to="lab_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:to="lab_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9_label_en-US" xlink:label="lab_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:to="lab_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD_label_en-US" xlink:label="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD_documentation_en-US" xlink:label="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:to="lab_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26_label_en-US" xlink:label="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26_documentation_en-US" xlink:label="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:to="lab_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:to="lab_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:to="lab_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:to="lab_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:type="arc" />
    <link:label id="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E_terseLabel_en-US" xlink:label="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MINNEBRO</link:label>
    <link:label id="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E_label_en-US" xlink:label="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MINNEBRO [Member]</link:label>
    <link:label id="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E_documentation_en-US" xlink:label="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MINNEBRO [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_MINNEBROMember" xlink:label="loc_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:to="lab_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4_label_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:to="lab_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A_label_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="lab_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE_label_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:to="lab_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904_label_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:to="lab_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D_label_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:to="lab_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:to="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB_label_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:to="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:to="lab_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:to="lab_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achieved milestone amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achieved Milestone Amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achieved Milestone Amount</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:to="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D_label_en-US" xlink:label="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Termination Period</link:label>
    <link:label id="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Termination Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementTerminationPeriod" xlink:label="loc_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:to="lab_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:to="lab_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash equivalents included in long-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817_label_en-US" xlink:label="lab_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:to="lab_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B" xlink:to="lab_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436" xlink:to="lab_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81" xlink:to="lab_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction price allocated to our performance obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:to="lab_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at ending of the year (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at ending of the year (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options outstanding at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding at end of the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains or losses on available-for-sale securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:type="arc" />
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0_terseLabel_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Warrants</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0_label_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0_documentation_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:to="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:type="arc" />
    <link:label id="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsAxis" xlink:label="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:to="lab_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:type="arc" />
    <link:label id="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Lease Arrangements [Axis]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:to="lab_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:type="arc" />
    <link:label id="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Headquarters Lease</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974_label_en-US" xlink:label="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974_documentation_en-US" xlink:label="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_HeadquartersLeaseMember" xlink:label="loc_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:to="lab_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:type="arc" />
    <link:label id="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Built-To-Suit Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_BuiltToSuitLeaseMember" xlink:label="loc_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:to="lab_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:to="lab_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:to="lab_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of leased property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to extend the lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant lease improvements allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:to="lab_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Build-to-suit lease period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently estimated amount</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment commencement period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:type="arc" />
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6_terseLabel_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of property available for lease (in squire feet)</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6_label_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6_documentation_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_AreaOfRealEstatePropertyAvailableToLease" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:to="lab_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of excess costs</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Line of credit borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:type="arc" />
    <link:label id="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85_label_en-US" xlink:label="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85_documentation_en-US" xlink:label="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:to="lab_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:type="arc" />
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductSalesDiscountsAndAllowancesMember" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72_terseLabel_en-US" xlink:label="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72_label_en-US" xlink:label="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration, License [Member]</link:label>
    <link:label id="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72_documentation_en-US" xlink:label="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration, License [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationLicenseMember" xlink:label="loc_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:to="lab_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C_terseLabel_en-US" xlink:label="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development service revenues</link:label>
    <link:label id="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C_label_en-US" xlink:label="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration, Research And Development Service [Member]</link:label>
    <link:label id="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C_documentation_en-US" xlink:label="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration, Research And Development Service [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationResearchAndDevelopmentServiceMember" xlink:label="loc_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:to="lab_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335_terseLabel_en-US" xlink:label="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335_label_en-US" xlink:label="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration, Other [Member]</link:label>
    <link:label id="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335_documentation_en-US" xlink:label="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationOtherMember" xlink:label="loc_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:to="lab_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:to="lab_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>exel-20200103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20200103.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20200103.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20200103.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20200103.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20200103.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20200103.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20200103.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20200103.xsd#CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:href="exel-20200103.xsd#CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20200103.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20200103.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20200103.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20200103.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20200103.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20200103.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20200103.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:href="exel-20200103.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20200103.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20200103.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20200103.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20200103.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20200103.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20200103.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20200103.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20200103.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20200103.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20200103.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20200103.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20200103.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20200103.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20200103.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails" xlink:href="exel-20200103.xsd#NetIncomePerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20200103.xsd#NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20200103.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20200103.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20200103.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20200103.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20200103.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20200103.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20200103.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20200103.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20200103.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20200103.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20200103.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20200103.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BBB36B411255D716E1976FAE6DD1246A" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_19BB9093DE9B6CB192586FFE712B6B47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40D90B375750843996A5123BC6BE7565" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40D90B375750843996A5123BC6BE7565" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D923DF9B9C001163CA20123BC6BF9FC1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1F4B21E5700BBAA47988123BC6C02A6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1F4B21E5700BBAA47988123BC6C02A6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7F2FC4E54F60C7403EE5123BC6C002AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7F2FC4E54F60C7403EE5123BC6C002AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2AD99F83BDCB70512ADB1240DF60B488" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A6F73289F800B0F98948123BC6BF1D3F" xlink:to="loc_us-gaap_CommercialPaperMember_2AD99F83BDCB70512ADB1240DF60B488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_DFD7820AF3AE9303D45A123BC6BF9658" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_D5D0101C10EC95452563123BC6C13301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3B6BE197DD1C885760D7123BC6C1F2E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_C94DB2F049B1CF7A42E4123BC6C12D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94BB617C75F0CB3F4315123BC6C049DF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_801E6B78DEEDE62104B4123BC6C19B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4C34F1D842090CD02093123BC6C29717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_06BE6C8D4DA95F47E820123BC6C142C0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9980D192F016A809344D123BC6C208B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F9F114C159C362F41FF3CB2B19FD7EFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F9F114C159C362F41FF3CB2B19FD7EFB" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_366191F5289F47425B42CB4348490636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F9F114C159C362F41FF3CB2B19FD7EFB" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9B89C812629042350DB6CB4348498AFB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D981E95D567455A5360E15B340D367A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D981E95D567455A5360E15B340D367A4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41AF2D76BB3BB936AC4D15B340D4AADC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D981E95D567455A5360E15B340D367A4" xlink:to="loc_us-gaap_RestrictedCashCurrent_0BEF654166B4F4AE834615B340D4806A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D981E95D567455A5360E15B340D367A4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_D4B327C8B0586C7C100B15B340D49362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D981E95D567455A5360E15B340D367A4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9BA628AF0F184E262FA15B340D5DF5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7BAB2F10AFA738737BDADCED69DE2E0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7BAB2F10AFA738737BDADCED69DE2E0F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8347269D22E077E5F026DCED69DEBD07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7BAB2F10AFA738737BDADCED69DE2E0F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_B34B83F6051EF6966711DCED69DF53B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7BAB2F10AFA738737BDADCED69DE2E0F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A188C6B9E2F6105A7FCCDCED69DFDF80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6A97DF84B3BE01FC6462703C48372870" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6A97DF84B3BE01FC6462703C48372870" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A213057F97976E47D8F5703C4837ACBF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6F61F218690EDE52C4B8703C4838F67B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CommercialPaperMember_6F61F218690EDE52C4B8703C4838F67B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6AD787988E3DBF12020B703C4838321B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6AD787988E3DBF12020B703C4838321B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_BE85E4372805617CD02C703C48381DBC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_BE85E4372805617CD02C703C48381DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CashMember_3D003E8C8E33AD21041F703C4838B489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2F6D6B4B0041ECC83259703C4838C151" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2F6D6B4B0041ECC83259703C4838C151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7C0F8D9B8B3560EBCA14703C483947CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4BDCEAEA386BAC19154703C4837F0A1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7C0F8D9B8B3560EBCA14703C483947CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5897ACEC09606E195274703C48379548" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8858E91D801C1554890F703C483966F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1AF0C4E92C3108C67FBF703C483ACAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5B23C0701A7BB324E6EF703C483A5F9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_56C98F76946D964B08D5703C483996C2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B53439C14881AF1F554D703C483AD74A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_C81B76AF78073AB31D1570457CB11AD8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_CCDB64611F4E19DB03A3703C483BE06C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_6632717030CD40FD1564703C483BABAD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0D4A0B928671B9DDE754703C483AD5E4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_E34879D735AB51F2471F703C483BB8C0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_22748EE98AC98F9E2D1F703C483BF527" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1607123FDCC47FC479FC703C483B675D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9AAD9341A7245177756C703C483CE0B1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F2241E368E8328BE2C2D703C4839D95E" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9CE99921BD4EB0426985703C483CE151" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E74CBCD24080E112FBAC7F5FB299940B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E74CBCD24080E112FBAC7F5FB299940B" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_61CE652F705C76FB04F67F5FB299918E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E74CBCD24080E112FBAC7F5FB299940B" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_64EE924BD4738668D5397F5FB2994BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E74CBCD24080E112FBAC7F5FB299940B" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_283F9C47A9166D7066AE7F5FB299E89F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E74CBCD24080E112FBAC7F5FB299940B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_23F3EEC06648E7810F8F7F5FB2993FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E74CBCD24080E112FBAC7F5FB299940B" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_BD7142053FB480885F857F5FB29AC044" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7B13D69F1DF6074686293EED7B980FF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7B13D69F1DF6074686293EED7B980FF8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C176CC3E3E124038C2883EED7B980E39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_453C599B98D6D5D1822415C6E4DADBFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_453C599B98D6D5D1822415C6E4DADBFD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:to="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_EEF40F3BD90CEA4BB5C315C6E917E623" xlink:to="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_CDDEFE7B41402D2FE08015C6E946D32E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:to="loc_srt_MinimumMember_CDDEFE7B41402D2FE08015C6E946D32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C1711A2AFD4C4DAFC15515C6E95412C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DE3D292A1D4969A6D40C15C6E9194326" xlink:to="loc_srt_MaximumMember_C1711A2AFD4C4DAFC15515C6E95412C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27A9E10904A3586B525F15C6E89E5230" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_CE663EB7777A3A2500E615C6E937415B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7DE38B15422F61855E9E15C6E89FCFE4" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_038E93A513530AE328F015C6E963BD89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_660E08E5381389C53A5C15C6E89DE882" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_A2EC113678D1AD41D8BB15C6E8B4694A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_CDA24A65AD0340BCD3F615C837A51F6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_UpfrontPayments_CDA24A65AD0340BCD3F615C837A51F6D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_9D2C46FC9B8355B0DDC615C6E8BF7B83" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_A2D2D6B954C841CB2BF815C6E8C9BA4F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_EF3B640C0FC7B356DAC315C6E8D44D3F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_1A638A11D933CDE52C3A15C6E8DFB94B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_B9828CABBF79B7D1543015C6E8EE1788" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_B9828CABBF79B7D1543015C6E8EE1788" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_168A389A2289E175B8AD15C6E8F9B272" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CA1B163E76564728665615C6E8A317F1" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_39A849E30D13C971E94A15C6E905C003" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D532B136561B27CCBCA615977138A8C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D532B136561B27CCBCA615977138A8C7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70CC6C9C064AB952C58E159771393CBE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9263D3F6C9ADE5AB458215977139E625" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_35592EC689122F8949041597713AC92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:to="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B4645060AF0F10CF02431597713AC204" xlink:to="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_840A501E06D3316D42161597713AA860" xlink:to="loc_exel_CotellicMember_266C626782994B5EB0901597713AAF73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_182CD677DEBB9F968CC715977139885A" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_42F0AD3E19D5C30489DA1597713B4E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_DFDDB8C86E600CCA7ACC1597713B9A79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C6FCDEBBB9BC2DD67ED31597713BB900" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56CFE7BEF8936450106D1597728943C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56CFE7BEF8936450106D1597728943C9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:to="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_84D0072E7B770A0F40101597728A55B0" xlink:to="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_DiscoveryProjectMember_28533EB0C367DCABAE6A1597728B4AE6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_DA76E76625E8862D85061597728B5714" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_9BFC5A2C8FE9F648250E1597728B2436" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_CC20FC938557C46B11C61597728B2052" xlink:to="loc_exel_ProductCommercializationMember_DBE6DFC1834D7FD357261597728CB68D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7B024D40D305FAD452081597728C099C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40612752269ECDC6B6D31597728C2712" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_51AE3BA5936826C6EF7E1597728C2416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3C3B87D6175FC8EE987C1597728A758C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_exel_ProjectInitiationFeePayment_307ED5A66824968F9F8F1597728DA969" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6EAD83F089DF971583321597728D30BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6EAD83F089DF971583321597728D30BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_7D30A75587FA16C500101597728DE353" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_808A0DFCDD419B2268781597728CDEA4" xlink:to="loc_exel_UpfrontAndMilestonePayments_7D30A75587FA16C500101597728DE353" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3F29BD0D34BC417A64BB6FAE6E748EC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3F29BD0D34BC417A64BB6FAE6E748EC1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9F05A22E3C9EAF461BCB6FAE6E75E6BC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_45EAF1EFB3DD7B19378A6FAE6E763B6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_DE55BD37270FB355CA926FAE6E76EFC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B89A4B1A003E26F96B216FAE6E75E6FE" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_DE55BD37270FB355CA926FAE6E76EFC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_79119C9D73B151F394FF6FAE6E7659E8" xlink:to="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_869C54264CACDE5E84986FAE6E7607CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:to="loc_srt_MinimumMember_869C54264CACDE5E84986FAE6E7607CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A95F3801AFC7002AFC5A6FAE6E77C3F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_04C255B574DADA5AE6096FAE6E76D37A" xlink:to="loc_srt_MaximumMember_A95F3801AFC7002AFC5A6FAE6E77C3F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_99C53690BC1610CC2D4F6FAE6E776F0A" xlink:to="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_CA487A002A6DDEFEF64E6FAE6E77563F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:to="loc_exel_FinalTierMember_CA487A002A6DDEFEF64E6FAE6E77563F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_5D4491F9DDA6433A78F06FAE6E78814D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_8B8DFC1D5923F816EFD96FAE6E77DF91" xlink:to="loc_exel_InitialMember_5D4491F9DDA6433A78F06FAE6E78814D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9426516578E0B51D1F016FAE6E782AB2" xlink:to="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_445D6D864EEEEFD0EAB66FAE6E786FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_642B599033BF895C39DE6FAE6E782A55" xlink:to="loc_exel_GlaxoSmithKlineMember_445D6D864EEEEFD0EAB66FAE6E786FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A6CAD660DE4FA0A36D456FAE6E7459AD" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_E99DDDE7087F9F2C1CEC6FAE6E7939B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_E99DDDE7087F9F2C1CEC6FAE6E7939B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_D40071723E51897787006FAE6E79BB71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_UpfrontPayments_D40071723E51897787006FAE6E79BB71" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarnedToDate" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_DAF1C6768650778CB1BC702F654C0E72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_DAF1C6768650778CB1BC702F654C0E72" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_6749F9D087E3C7D62FC66FAE6E792E3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_MilestonePaymentsEarned_6749F9D087E3C7D62FC66FAE6E792E3D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_51E1B0A3D4A2E7837EC66FAE6E79E58B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_51E1B0A3D4A2E7837EC66FAE6E79E58B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_6CDE0BDFC1F13DDE6AF76FAE6E7ACBA5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_6CDE0BDFC1F13DDE6AF76FAE6E7ACBA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_B1069E27EAB97307CF8D6FAE6E7ADFF2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_B1069E27EAB97307CF8D6FAE6E7ADFF2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_51154324B246E1E2D0F56FAE6E7A567B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_RoyaltyTier_51154324B246E1E2D0F56FAE6E7A567B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_16B15CA3DAC4CE611B286FAE6E7AF445" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_16B15CA3DAC4CE611B286FAE6E7AF445" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_5334043CD6BAAB865D486FAE6E7AF491" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_5334043CD6BAAB865D486FAE6E7AF491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1F2FA557768C04FD66BE6FAE6E7BE20C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1F2FA557768C04FD66BE6FAE6E7BE20C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_A1F0AE8AA9634D97CA206FAE6E7B7EA7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C3B3149FF278DFE15D896FAE6E7951A8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_A1F0AE8AA9634D97CA206FAE6E7B7EA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5140562BEB677E82D13B6FAE6DFC6044" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5140562BEB677E82D13B6FAE6DFC6044" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_D64F07BF26572AA1F636700598AAAF03" xlink:to="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MINNEBROMember" xlink:label="loc_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_26E5771B55FFE8DF08CE700598AA52E0" xlink:to="loc_exel_MINNEBROMember_23AFAF2A0909475574137005F7842D5E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersAxis_67865EDAC1A1A002D3E16FAE6DFC9DD4" xlink:to="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="loc_exel_ProfitSharingTierOneMember_ED00ED832436E24EF9C46FAE6DFD83DE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="loc_exel_ProfitSharingTierTwoMember_401ECFADF5A1583959596FAE6DFD9904" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_9A274C4EFD4A9E0929546FAE6DFD3A2A" xlink:to="loc_exel_ProfitSharingTierThreeMember_78EC398EC32CEA9293886FAE6DFDAE8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E12FF530AD9DE8304586FAE6DFD0B74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_6C04B069026AD40E92366FAE6DFE321C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_6C04B069026AD40E92366FAE6DFE321C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_981F32AF36E408DECD2F6FAE6DFECDC5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E85B6EEE779BD90873D36FAE6DFEBCAD" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_7769180BCE7276F3A33C6FAE6DFE09EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9A8798DAB8906F73A05E6FAE6DFF16A5" xlink:to="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1ECA49F5C66527C8512E6FAE6DFFB1BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:to="loc_srt_MaximumMember_1ECA49F5C66527C8512E6FAE6DFFB1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_988244FAED54C0EC96BD6FAE6DFFB2D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5CE8C0D9334361CFB8646FAE6DFFC69F" xlink:to="loc_srt_MinimumMember_988244FAED54C0EC96BD6FAE6DFFB2D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_98BCABD1741309DA2A166FAE6DFC834B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_F721C2708C3A2B4CE4446FAE6E00148A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_8065FD09D0257C74C99B6FAE6E00CBBA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_EBAC78BFC504FB4BD5A06FAE6E00F7C8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_880D66371B464D4CB5CD6FAE6E00CD06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_880D66371B464D4CB5CD6FAE6E00CD06" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementTerminationPeriod" xlink:label="loc_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborationAgreementTerminationPeriod_B4AA2F1F9060B824FE3A6FAE6E00B47D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_49850F4891BFA8A7ED9B6FAE6E01ADA9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_49850F4891BFA8A7ED9B6FAE6E01ADA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D4E53CBDCD6922B64426FAE6DFFD7AA" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047537AC6BE77902C02E6FAE6E01AECF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CB179B89E1A781C0A00B15976B2DCDEE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CB179B89E1A781C0A00B15976B2DCDEE" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:to="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7D84AD1721F4A2F8CE9815976B342FDF" xlink:to="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_6F425D02D4D3EA846B8215976B3405F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2F7A7955AEFCFDAC817E15976B34FC38" xlink:to="loc_exel_GlaxoSmithKlineMember_6F425D02D4D3EA846B8215976B3405F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29DF6622C02BAF5F67BB15976B34A387" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46ECF1682038348A882615976B356323" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E8149EA629241AF9BF2E15976B35EEF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3502C3C7B375EA440BB515976B335E9F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_95DD9E3740693825E3A715A60D540501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_95DD9E3740693825E3A715A60D540501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B4F94AD4DCD24339621B15976B351839" xlink:to="loc_us-gaap_RoyaltyExpense_134C9F3026AFBB69D64C15976B369D8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_068A3E001699FE0619BA1597729863AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_068A3E001699FE0619BA1597729863AD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:to="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_293C9131888C0C2ABB031597729AB4AC" xlink:to="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_30B6C3EF190CB30FB12A1597729A2077" xlink:to="loc_exel_FirstProductToReachMarketMember_10FA21DFEB519C5642C81597729A2D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F674CDDC99F1351D6A6E1597729B3FD6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A2B341F5117CD5272401597729B9DD9" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_17E405A7B2B77BAF98201597729B59AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ABD180B3B1F2CEECC65159772998671" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_exel_UpfrontAndMilestonePayments_B9E60EB56D3FB9954FEE1597729C0CB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AdditionalUpfrontAndMilestonePayments" xlink:label="loc_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_exel_AdditionalUpfrontAndMilestonePayments_547A0BE07B8EA3980B891597729C6036" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ACE5141A8D24EAD9B2AC1597729C7349" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_60D120683C471CC671721597729B53AF" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ACE5141A8D24EAD9B2AC1597729C7349" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FB6C13602F9097518B407F5FB4AEB763" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FB6C13602F9097518B407F5FB4AEB763" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_782849BF3AD92BE3315A7F5FB4AE2DBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81D1F77297B9316A80BA6FAE6E5FF9C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81D1F77297B9316A80BA6FAE6E5FF9C1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_590919ABB037868230426FAE6E606C63" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2A4FD78AE59DCD9CAAE46FAE6E609EC6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_18D1C9671D71F02D34106FAE6E60E8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AE0C885E7F6B901CABC06FAE6E61BA89" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8A40C85475E28620497A6FAE6E6172E7" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8BB15F92E167D0C70C7E6FAE6E610F89" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_25B77FC1CB8231DAB75D6FAE6E62F843" xlink:to="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_684DE873673003813D1C6FAE6E62B48A" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_960B10023452EB8FDA196FAE6E6210FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_178D1AB3C4E76DA918816FAE6E62AFC1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953C9C74C26C43EBCC456FAE6E62A7F7" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_4E7307E130C67E7220DC6FAE6E630B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DDD35A949DADB5BB7EDE6FAE6E6349C1" xlink:to="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D03A6B169DB5EF2D01D36FAE6E635138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:to="loc_srt_MinimumMember_D03A6B169DB5EF2D01D36FAE6E635138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_30A131A2A4778E53D2BC6FAE6E644AB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56452D8B2ED3B262CBAD6FAE6E63571D" xlink:to="loc_srt_MaximumMember_30A131A2A4778E53D2BC6FAE6E644AB1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_172FE6F05B49543C254E6FAE6E64278A" xlink:to="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:to="loc_exel_InitialMember_3546E4580ED22A7ECEA06FAE6E64D0A3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_DF99732D8485E8B9527C6FAE6E64480D" xlink:to="loc_exel_FinalTierMember_C35E7524F5E9C60523096FAE6E656F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_85AABE7787F9354258AE6FAE6E658C38" xlink:to="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:to="loc_exel_GlobalMember_A38CB993A4F34E4D66CE6FAE6E657560" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_79737C9EE5E671F253356FAE6E65EFEC" xlink:to="loc_country_JP_4ED36B76146D68388B866FAE6E65719D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53E681A43476C996528F6FAE6E60A58C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_1AE946BE92B957978A7E6FAE6E66CC52" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_9884AC154010DEE334A66FAE6E66CC3C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_UpfrontPayments_3EFD20239057E29495066FAE6E662053" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarnedToDate" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_CC27815E47179665E53B702B373C589A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_MilestonePaymentsEarned_09AA97E390316554BB2C6FAE6E66C984" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_AB136CE90F8F665FFA096FAE6E662E0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E7E0014947F40EDC36716FAE6E67ACB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_B8491F90FA63C38E39296FAE6E67C4EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_09C9724F81F5305A19DA6FAE6E6706CE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_RoyaltyTier_7E51A25E4464A5F429516FAE6E67F9A3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_AFBFE110200999CCA7516FAE6E6764B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7DA4EE91B8BA23A093D66FAE6E67DB0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_E55CB2AA740EDFDCA19A6FAE6E68CF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BC0F659A6F718798D0EC6FAE6E6657A2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1FAE990A91C04030A7566FAE6E68C058" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0402FD4B426427C41DC3694B225BA099" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0402FD4B426427C41DC3694B225BA099" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD830AC2699EF6015D0E694B225BB136" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C295239DB91DA3E03776FAE6BB78CE7" xlink:type="locator" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeaseAssetsAbstract" xlink:label="loc_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C295239DB91DA3E03776FAE6BB78CE7" xlink:to="loc_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_2968C1D91A9CBCBE34646FAE6BB7E4B4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_07B86F05DAC62701D56F6FAE6BB70DD8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C295239DB91DA3E03776FAE6BB78CE7" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_12AD362AD2B88A4095E56FAE6BB7D166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C760B70FEC57197282886FAE6BB827D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C6F9DED2F4C33D7B93386FAE6BB7D2BC" xlink:to="loc_us-gaap_OperatingLeaseLiability_5F11C1B0601E7561AF6B6FAE6BB8328B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_OperatingLeaseCost_C9E9A38138E283CD0AD96FAE6BB24126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_LeaseAndRentalExpense_83EC35790EB066592C946FECFE6C98BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_VariableLeaseCost_7B242AB1B699855546EA6FAE6BB3D1F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLeasesVariableLeaseExpense" xlink:label="loc_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_exel_OperatingLeasesVariableLeaseExpense_32047ADFAAAD73A7BEF46FEEBE6E43AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_SubleaseIncome_275C436E883E60DB77A16FAE6BB37883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_0DBE9B68F6DE8515334D6FED61D11893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_LeaseCost_9F6FAC9B9AFFAB42271E6FAE6BB37CC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91F944AB0C0808EDEADD6FAE6BB201C6" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_BA9C0F73B562E273DC7C6FED95198E0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0775205AB97AE36E0E236FF0698A8B85" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_66C1A5E6B48B08518F396FF0698A3A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F7C33A0BB14DEB983EE26FF0698B5AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9FDC2F3065A0AE7F71C36FF0698B06DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0A1AEC716BF4B20964C06FF0698B8518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D20203BA14C3DF3CBDF26FF0698B0FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_450DBBA3EC5F743858CB6FF0698B7E20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A79733E96ADCC1B380C76FF0698B0F11" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84789FA4DAAF94F4A83A6FF0698CEBAA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_A70B2099271762CAAC716FF0698C2265" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8E32A2846BCED884AC8A6FF0698CAEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9AC0D2FAA85CB85B0A796FF0698AB320" xlink:to="loc_us-gaap_OperatingLeaseLiability_3F99C773A19ABA1DDB4F6FF0698CF766" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2DFB16B1D193F9F44AE0703C47638512" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2DFB16B1D193F9F44AE0703C47638512" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsAxis" xlink:label="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:to="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_652371260E0E50B70172703C4764E09F" xlink:to="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_HeadquartersLeaseMember" xlink:label="loc_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:to="loc_exel_HeadquartersLeaseMember_8B584E7105A3D479CDB7703C47646974" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_BuiltToSuitLeaseMember" xlink:label="loc_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_F12D3FDFA468A36DBCEC703C47649D5B" xlink:to="loc_exel_BuiltToSuitLeaseMember_6078EC47922965486A56703C47650713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:to="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3ED2EB453C6B2BD10D15703C4765C5BB" xlink:to="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2FA3A745DBAB771FAF00703C47652EA0" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_3A3FC4FD6A5D0084443A703C4765C0B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1E2685C276CF2E20FB83703C4763832C" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_B5B2DB4065434D73ABE5703C4766A15A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_227B21D8DB05B6B7D326703C47667B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E946A89E9B57BB45F8E1704C99A6F561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5FEC3258D4C4C065FC5C703C47661AE1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_6856F214479376EE35F7703C47664D5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_0DB6476A7BFFA0432C53703C4766D866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_OperatingLeasePayments_A27BD19AE5893379F7F1703C47674A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D23227AD438F4F64A9E9703C4767ECEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_19661B0423CAA97B17FD703C476767D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_A0F9372812CDDB23E6A4703C4767BF16" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_089FC54F0FD30CF03A9E703C47676C2D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_C179657FE32ED81F7A2C704F18739E36" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AreaOfRealEstatePropertyAvailableToLease" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_9AC20CFD9133D83F2DD3703C4767E7F6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7AE07AE12F6EAB2C45E3703C47682128" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_1F170AA2036962B7F479703C4768B78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_612217B45D039249D4F9703C476896C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6EAE4C432CA6EC7D9146703C476537FE" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_F6B71BB9CEC1D138E4F5703C4768E394" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDB8665FA878E38DB6A26FAE6BC8ADA1" xlink:type="locator" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDB8665FA878E38DB6A26FAE6BC8ADA1" xlink:to="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_47A361F9AC5776BC4B316FAE6BC9C2B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDB8665FA878E38DB6A26FAE6BC8ADA1" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_8CE230EF6FE17AEE11776FAE6BC9803F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDB8665FA878E38DB6A26FAE6BC8ADA1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D62DC26EF6F496D0B0B6FAE6BC90820" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_781EA5A7BC67B8476B8D6FAE6F4C3282" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_781EA5A7BC67B8476B8D6FAE6F4C3282" xlink:to="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_717D159970E835C6456B6FAE6F4D423D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="loc_us-gaap_ShortTermInvestments_158F1E39440CED8765066FAE6F4D8EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="loc_us-gaap_ReceivablesNetCurrent_FC8860B871BD47D686556FAE6F4EC815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="loc_us-gaap_InventoryNet_319A3FC1BAF5D9C3C24B6FAE6F4EB89B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ED87D5F07E23CC2D7A816FAE6F4E595B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DAA2FBAAD7BE822DC5436FAE6F4DFE53" xlink:to="loc_us-gaap_AssetsCurrent_B9652B2BEFC2B513F7D96FAE6F4E45E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_LongTermInvestments_E97B0273BA20AFA2C9FE6FAE6F4E2280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_169071A0C40AEEAAC3C76FAE6F4E79EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_09331ED500F1C1F9292F6FAE6F4EEAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_Goodwill_6DACBDD4775E370D098A6FAE6F4FF0DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75A28AF83C8BB5C5BFBE6FAE6F4F22DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FC2A3B01AE1CE5D104FB6FAE6F4C9BFB" xlink:to="loc_us-gaap_Assets_398610D52F2C013489906FAE6F4FA642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_781EA5A7BC67B8476B8D6FAE6F4C3282" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_us-gaap_AccountsPayableCurrent_0D61D0CBE28549D3E16B6FAE6F505D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3A0AA0BEFD46BA25887A6FAE6F50ED06" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_C11B66509F14D1012F6F6FAE6F509EB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_71E5D80976F590D63B346FAE6F502C77" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_03AE9D0EB3A6AE2D2D576FAE6F50AD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_A99E2A5E3E7351FA5FDF6FAE6F51FE1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF369221DD44FD2881276FAE6F4FA65F" xlink:to="loc_us-gaap_LiabilitiesCurrent_AEDF01079E02C04D08B26FAE6F51A346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_AE84E5D763156148BE9B6FAE6F5165C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_743B253C1691FBCFF06E6FAE6F513FC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_743B253C1691FBCFF06E6FAE6F513FC5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_4CC5DB8A08A4EF68694C701F76BD6583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_B66725A08CE496A2C8156FAE6F514A4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_us-gaap_Liabilities_0FD7578EF6D5F88CF7526FAE6F515157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A039A113F929E22602336FAE6F4F3C8C" xlink:to="loc_us-gaap_CommitmentsAndContingencies_870D7FA820F3C89ECC1D6FAE6F52E6F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_781EA5A7BC67B8476B8D6FAE6F4C3282" xlink:to="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="loc_us-gaap_PreferredStockValue_4EDDC47C819C27882F4C6FAE6F52C397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="loc_us-gaap_CommonStockValue_B85F985FA80D8EF8C08F6FAE6F522505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9981827EDD2C6DA6B5956FAE6F52C1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E2F04DEF037A551EED766FAE6F526D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F7F1D7A7C475DA0C64D76FAE6F530B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C5E9D5301717D87E2BB46FAE6F52D50A" xlink:to="loc_us-gaap_StockholdersEquity_E14090E845DDDB23CF546FB7494583D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_781EA5A7BC67B8476B8D6FAE6F4C3282" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2FCDEABD75E0709521296FAE6F53BE12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F6DDCAA7E44FF393E43C6E21F192D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3285EC4A50A3C44B28E3C6E21F19C40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_322056D887DD99E239E3C6F53DD43D30" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6F966B8D00704DCFBFD2C6E21F197DC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31285126C60395C9A51FC6E21F1881DE" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_C2D3DE352545E16CA4C7C6E21F19046B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_08724A72BDA7EC5E09EBC6E21F19C9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:to="loc_us-gaap_CommonStockSharesIssued_295AE971A30CE139AF33C6E21F1AC21F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_68E9BD2EBB86C84ED5E9C6F50F7CCA4F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_736204DB9A92C52D47CFC6E21F1AC412" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7E748E200FDBE7DF364D6FAE6F0684B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:to="loc_us-gaap_NetIncomeLoss_7E748E200FDBE7DF364D6FAE6F0684B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_CBC94BF421AE5B0CCAFF6FAE6F06B53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="loc_us-gaap_ShareBasedCompensation_4D26091516842EBA38D16FAE6F078FB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_NoncashLeaseExpense" xlink:label="loc_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="loc_exel_NoncashLeaseExpense_7D1A6B97B4F5C81ACF2F6FAE6F07C9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_546013219762818D18766FAE6F078ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_62915E39086E498867516FAE6F0727CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F413BE58895D72F2B5456FAE6F0667AE" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2D8F16F6235C98E5BFD06FAE6F07804D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0FB6A98968D967946FA26FAE6F080478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E13019BB5CEA69E5DA26FAE6F08B821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_BEC0A70C650F7BAEB8496FAE6F081690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_75ACBC0827FDE43C11F96FAE6F07C2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_78FFA5A6023A8B9924576FAE6F086944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B922713BEABA3AE879026FAE6F057E21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E9CC64782F03B9C99DE96FAE6F084E3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D10D2D9E4B0660D29C1B6FAE6F098C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_83C3E42B4458082C03756FAE6F09D252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_F53CBEFEF1A10A203B5E6FAE6F0906D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_B5912D1356437E44B5476FAE6F0923F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_930BD23D6E936DA9EFD86FAE6F084875" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48043C3B17AA364CFD706FAE6F0A55C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E5514EA4A9294DE9D9566FAE6F0ACE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A5A64D988EBE2D6363796FAE6F0AA675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7B509653E73EBEE8E0946FAE6F0A4A3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_211A22FBE33D823CBE246FAE6F0AF3A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_462B638296966ABF9E086FAE6F0A7939" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88A9D0775D1DB1129A386FAE6F0BE7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A2173352DAA57343AAE76FAE6F0B0B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A8FF25BEE4D28B97C6136FAE6F0B2C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FC165B8C90EAE00ACF8E6FAE6F0B10AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:to="loc_us-gaap_InterestPaidNet_B99223590D95338590556FAE6F0B67A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4BE4D50F0E67148131F56FAE6F0B6C7D" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3F88037B6EEDAB563E4B6FAE6F0CE9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C2B6BC7789B4F2AFF8026FAE6F05B095" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_D61DE31627B82B5CFD196FAE6F0C12C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_B717BD075C1CC080B4F16FAE6F0C1632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2E6F1F993CEB88D2D7226FAE6F0C3E67" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0F40F891B3344870D70F6FAE6F0D7774" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:to="loc_us-gaap_NetIncomeLoss_3C153BC8E1718721C8A36FAE6F22F7C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8B00E417796AEB60926C6FAE6F22A36F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91504389067BDAC21FF36FBA7EE8A414" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9D60D557ED15D88F82BA6FAE6F227CF9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_D20589E33893F9144E6E6FAE6F22285E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AE4D6BEB8C90FC0746CEC6E21ED4DC9D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AE4D6BEB8C90FC0746CEC6E21ED4DC9D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_B7EBD316CB1370436030C753A6C436DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BE33FB5A87D8F8A41CAC7CB6706D6EFB" xlink:to="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:to="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1AB86F3DF73A343FA2E37CB6706D4D67" xlink:to="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:to="loc_us-gaap_ProductMember_F8C54BC9E8A912F72B3F7CB6706E8550" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3B1D9A0ACEF0D2F675F57CB6706DB771" xlink:to="loc_exel_CollaborationMember_7B7687ED393960D3B76F7CB6706EAC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A5C52CD7B1BADDD8E3B87CB6706D0990" xlink:to="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99F5A633ABCE802712A17CB6706F57B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3605A486AB1AAC81611D7CB6706F1173" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99F5A633ABCE802712A17CB6706F57B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_EFD491923C2BDF1128597CB670705791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9A210F381CFC8B2BED187CB67070F922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C061BBD4358A57E05CE7CB67070C5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D5C2684433C03754565E7CB6706FA47C" xlink:to="loc_us-gaap_OperatingExpenses_997EE053CB270ED3F6717CB6707121DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_OperatingIncomeLoss_E3393B65EB5CEE2D343D7CB670713A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_InterestIncomeOther_5673544B7A43391AD0EF7CB67071D902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_InterestExpense_AF8AE953DD690BBB82327CB67071AD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_FB57CA57AE7511A40F097CB67072EC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6BFC4EF8F7378436B7BF7CB67071CC41" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_E5D99232F2215036DD417CB67072CA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_FCF04C239835660C006A7CB67072177F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5BE825ECC65421452B357CB67072BD9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_NetIncomeLoss_44B64D2D9573149634E77CB67073EA7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:to="loc_us-gaap_EarningsPerShareBasic_BF3C37DC56481E508BBE7CB670730D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1E80B8B0EA563BC663187CB670739538" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5BEF50137313264276397CB67073087D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:label="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71A8AE7CAF1F371D31567CB6706F1603" xlink:to="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_420D45C7EF037D1406B97CB670743FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_48CD3033793AD0E69C4E7CB670745A1D" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1F0B4DE03E0508FBF5C77CB670746730" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_BEF38A6F367753DF1FEC6FAE6F15208F" xlink:to="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F697A3C58470079D1C7A6FAE6F153A6B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_BEB95552FE7EECC2E6D46FAE6F162114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_6C148F104A02753B7F5C6FAE6F16ABAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_6C148F104A02753B7F5C6FAE6F16ABAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A8D4EFE0CACE5476BCC86FAE6F15A0AD" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_2A4E96734E6C6A72932F6FAE6F16D05E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_712236AFC5755114249F6FAE6F168981" xlink:to="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_CommonStockMember_40E8C002E35852C545256FAE6F174978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_D39EF78830208C5B2BFB6FAE6F17265B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BF41BE352D88063A82376FAE6F17B15E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CDF4C4BA370D39B72316FAE6F163592" xlink:to="loc_us-gaap_RetainedEarningsMember_E5BE6868780DF4A90E1B6FAE6F171AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_891AFB7EEE29007E4C436FAE6F15CFEE" xlink:to="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F9AF81A74C55456CA9BA6FAE6F1880CA" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockholdersEquity_B298B51DBD431BEC920A6FB80B0E5FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4B1976C36C264CEA9E926FAE6F185F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9E09DD7D76689F2CFE766FAE6F190D87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_NetIncomeLoss_F3A55689A56521209C346FAE6F197DDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F4D754D7C60258F1693F6FAE6F190981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A6CC2395F2AA7F44EF296FAE6F19FC1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2C9AAC57D46C2622C5A36FAE6F194363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_476334252FAB1FB728656FAE6F1A57B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_842DC22E88E88506201C6FAE6F1AF558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8E37AF87D1352C34CBF06FAE6F1A6B77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_C55DA107251EE6CDA5E86FAE6F1A04EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A73051D898289178AB846FAE6F18EBCC" xlink:to="loc_us-gaap_StockholdersEquity_22359522B8375C9EA2E76FB8EA3E7F3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentType_55C405D03DAB4FB43BED6FAE6F5E2CA7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentAnnualReport_390C4942342CB2F954206FAE6F5E284F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentPeriodEndDate_B86BC4FD0DFC181D4DB96FAE6F5EC871" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentTransitionReport_ACC1DDB2635E40D98FF76FAE6F5E25D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityFileNumber_2B88C3364741BD7890D76FAE6F5F58EC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityRegistrantName_B926FD8352FED2E0313F6FAE6F5F9DAB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_B95AD6CD0491B5BBD5006FAE6F5F3108" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityTaxIdentificationNumber_65E4E73FD0F4354932116FAE6F5F1086" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityAddressAddressLine1_0777DE4E655CFA574CF06FAE6F5FF69C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityAddressCityOrTown_8565C3479FB719A40D226FAE6F5F977B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityAddressStateOrProvince_135218D5140072AE938B6FAE6F5F1DCA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityAddressPostalZipCode_BAAD5CCC201670A7F22C6FAE6F60E0EB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_CityAreaCode_92CB14A75A16166988246FAE6F60B50A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_LocalPhoneNumber_9B72C78C50E9FE34C8F36FAE6F60EA18" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_Security12bTitle_1B28776E7ED256742CF76FAE6F60CBA8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_TradingSymbol_6AC7D1C62BEAE9F51F016FAE6F608F04" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_SecurityExchangeName_91784B1CBAEA8E6188066FAE6F611D18" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5AD738CA51137FD5DD436FAE6F61C5C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityVoluntaryFilers_82E99CD5C812682C6A6E6FAE6F61BAEC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityCurrentReportingStatus_B345D0A1FD6B27F121556FAE6F61B51E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityInteractiveDataCurrent_4365A93224F73F448D846FAE6F6145A1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityFilerCategory_D336BCAF1B0A6E5FB5FB6FAE6F619A58" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntitySmallBusiness_DBCF36D9B8F5E4F927606FAE6F615382" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityEmergingGrowthCompany_7BB71AED4D424B53222E6FAE6F623BEA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityShellCompany_8837A915F4AD7619C2586FAE6F6211AA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityPublicFloat_AE32625CE1ED92AE13FC6FAE6F623C77" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_43ED6F9762B0114471416FAE6F623FFD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5EA62FF88A52F2143A486FAE6F627DDD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_AmendmentFlag_C2BFB42F59CD455C449C6FAE6F5D8C55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentFiscalYearFocus_107901FDB4F49A599A676FAE6F5D4E7E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_FAFCD8F9A33508A4FD066FAE6F5DD060" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_EntityCentralIndexKey_7BB58F52CAF5BEA56D566FAE6F5E848C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0BC9982C002D0726B3026FAE6F5D6AF7" xlink:to="loc_dei_CurrentFiscalYearEndDate_593FEC46EA9C00B8717F6FAE6F5E0024" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5D1F7D57E32D5A28E3576FAE6CFFA249" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5D1F7D57E32D5A28E3576FAE6CFFA249" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DEA9BB154A1459BA67F56FAE6CFF0C9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EDF5EAAFBDF759D1AE01703C47DC508F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EDF5EAAFBDF759D1AE01703C47DC508F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:to="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_5F8745ACEC1A2977BD34703C47DC23FB" xlink:to="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_AchievedMember_F18AA76F62C5CAE44BC1703C47DD4AF6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_VestedMember" xlink:label="loc_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_VestedMember_E2062DB9EF84DFCB254F703C47DD6091" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_ProbableMember_D33EC8EE0F24FEF3EC88703C47DD92D1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_75638CA7251C178238E9703C47DDB0E5" xlink:to="loc_exel_NotProbableMember_572F60CEEF73BB1AAC53703C47DE22DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:to="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9EB9C2E272190D9C29D0703C47DE37B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BA9430A16A10D86F9016703C47DE6FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BA9430A16A10D86F9016703C47DE6FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_PerformanceSharesMember_F1E12C66253299687D0A703C47DF8468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_10BAA11EB3E52A0C498F703C47DFB050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B6BF9BD49877C6021051703C47DF18A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_us-gaap_EmployeeStockMember_B6BF9BD49877C6021051703C47DF18A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_14A71212EFBB0D187774703C47DF996E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_F45FBF5A2FAA4F6E7670703C47DF13EA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_PerformanceSharesSecondProductApprovalMember" xlink:label="loc_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F3548BFB75E9CE88BE10703C47DEA857" xlink:to="loc_exel_PerformanceSharesSecondProductApprovalMember_D0E51BEBF1B89D70C705703C47DFB434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2E397C16787E4559B431703C47DCCFE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7CC77A1043FDC746B58A703C47E044E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0873A94C782EB1E3FDD6703C47E082C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_FF9CA7C7C7595804B84D703C47E0200C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_AEE8DC91B48D74B7C6AB703C47E08C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B60DA2D817AB679A5F57703C47E0F8BB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_1ABE88002EFFAFC4A9BE703C47E1FFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7569CAAA2C109A07ED8E703C47E15FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_DCF652C3E6FAEABEB7B1703C47E1E1C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_3F6AF629C8D6D8442F37703C47E15FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ProceedsFromStockPlans_C40DE16490E2A0FBD97F703C47E1BE73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C5676AEA96C1669A99E3703C47E1A9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1DE57511192E0EDAC0AA703C47E28117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_743F2266F82DB0BA72B3703C47E2749D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5ECC4D98F8BAC194052A703C47E2AF54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E83A2545F6E5FC0523E8703C47E21E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_D9A630C6EAFB39A2DF59703C47E2ABF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_38292AEFC810F00A4531703C47E2C1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E88B07F4615B18C3BB7B703C47E3EDD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_35B2BD249AD3127E588A703C47E38129" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_9410F4264F6E49996699703C47E32B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C10DC68B9CAEE28E30FE703C47E3FCF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8457F22F92C2066BBDC1703C47E0D932" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_EB94C1EAE903699DBA39703C47E31C0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B6A8EF2E32E6F6A42AC66FAE6CB53A70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B6A8EF2E32E6F6A42AC66FAE6CB53A70" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_572F6C7B934306610BB96FAE6CB57419" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0EE013E09EF360979D866FAE6CB6768F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C39ADBC0C5967CD67686FAE6CB5F225" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4255884D61E19FA4CA686FAE6CB6357E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_54D754AD40EB25D5879E6FAE6CB53EFD" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2043E8B385FE44FE96AA6FAE6CB767B3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_90DB2ABB4CADB57DE6DD6FAE6CB75BCC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6A9ABC393DE25007C61D3EEED7DB507C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6A9ABC393DE25007C61D3EEED7DB507C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:to="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1DE08A9382091F01BA3E3EEED7DCC1DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B12DC4A363CA5E5B00793EEED7DCFBFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B12DC4A363CA5E5B00793EEED7DCFBFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_941E665BA3322BD2857C3EEED7DCA891" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08AFB193FAFE82FBFE3F3EEED7DC54B5" xlink:to="loc_us-gaap_EmployeeStockMember_941E665BA3322BD2857C3EEED7DCA891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13B596FEAD59ED0C75883EEED7DBEF82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E7C8EE2376480C13AE1B3EEED7DDA7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_06B9D8B7177253B3EED93EEED7DF5D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ECBD03A556093405E92A3EEED7DFBF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B5DC4AEBFF4A6BFE52683EEED7DD2031" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8332BD26DF1C9099109A3EEED7DF046A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77C6E0580A076A661AC86FAE6C63B806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77C6E0580A076A661AC86FAE6C63B806" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:to="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9701CEC3920D24B01C3E6FAE6C645CB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7AD5A90A839B7DBEE1626FAE6C6414F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CAE69B5E931EE18FE0336FAE6C64C65A" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7AD5A90A839B7DBEE1626FAE6C6414F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7EB1B9AAEC44CC63EE956FAE6C636ED6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1D7174E71839FB6122D26FAE6C657320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D810E533CD8F96B589C76FAE6C668B3A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_F2F3F42C48A0349D33066FAE6C66B4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1894803C0768F99EDA9A6FAE6C662CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11E32C73C1948F4509A46FAE6C65EA04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E2487752CCCE71B857076FAE6C665F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6092A86E9177C92FDC926FAE6C676FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0FDAD6258CA0FD5B8AD36FAE6C676CBD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_D820B0EE35522145BC5C6FAE6C6CCD84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6A6D196209A6E08C65C06FAE6C6DF754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_41FCC14E5F2A8A868D916FAE6C66EC0E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7F6E26680BF5EAFB457D6FAE6C6D4254" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_F2487558639620EBF57B6FAE6C6D5A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6B23FE276D6CAD4AB4596FAE6C65C33B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9596D549F6FA6CDA08C46FAE6C6D1968" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A9EAB7F6E5C3ADB9642B6FAE6C8112A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EA873E4BEA8C7ABDA72B6FAE6C81C465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5C33122C03BD08FDBED96FAE6C814685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4E46122CC5C2DA28FA9C6FAE6C826C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_EDEC106F9BC4D1CABF286FAE6C82CBCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4BCFD14F2DE7F73862F96FAE6C815384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1FF4EDF0EB81A863D94A6FAE6C82A603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_171BDFBDC7AB40C4F9C46FAE6C820A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D319A25E8E269CF64DC6FAE6C820538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_76B3581096CD62DB79AE6FAE6C83655E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60C58DB23B2EE90528B36FAE6C834DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_880546A66F60EB5E46F46FAE6C8323EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_094E74D3D797EB1B19456FAE6C834C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_CF5BEB8AEF651E86FCD16FAE6C821EFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CAD1A44CAAB8220930086FAE6C83F61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_88D8D0DEAF97AA3675296FAE6C83AED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2BF8E071BC6CA5D193A86FAE6C843E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8998E3AA56043A25BFB36FAE6C840AF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20913985C2AA8B799E926FAE6C8425FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F600886FBEB941F96C316FAE6C80EF6A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5C915C90705407D61D546FAE6C845AA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E1242453BD34E61E12BB3EEEDC060AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C791041B35D4FE10D6CA3EEEDC074733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5E320D2D7141976D2AA93EEEDC071E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_C27C7CF1AE9EBAF14ED63EEEDC078359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_588A9C749FA28B4888C53EEEDC07218C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A380FF76C784C6E66FA3EEEDC065D9C" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_A8C998416C20C734448A3EEEDC0713D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53D3B9D37F68AFD7D1CA3EEEDC1353BC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:to="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C56DFBDEA9B4A9111CBE3EEEDC14B0A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BE0643A526FDC630667B3EEEDC145060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F95117245EC61C73FB903EEEDC1444D8" xlink:to="loc_us-gaap_EmployeeStockMember_B0BD33C41513C998EEF53EEEDC151FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ACF1C94F526FED5515A3EEEDC130398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5E0EE327242A16AACCD53EEEDC152184" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A6A5F96BA3F8324BD9EF3EEEDC15C63C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_111A228D3CFF2926B51C3EED64A18938" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_111A228D3CFF2926B51C3EED64A18938" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3ABA733DB7343424CFB53EED64A399BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7B7E70A75F8C473E52DA6FAE6D5BDACC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D45CEB3FB1E06B1074CC6FAE6D5B2C73" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_CommercialPaperMember_64C0EE325BDF67BC65E96FAE6D5CB878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_EBEF96BDF0A79D52331A6FAE6D5CADF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_12964C415DE9BA1415716FAE6D5CDB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_CC68018487909DA791E16FAE6D5D44F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_EFE20DE5C0BFB5D5262F6FAE6D5C6D8F" xlink:to="loc_us-gaap_CertificatesOfDepositMember_64B5EFE60CFBD33AB6366FAE6D5D6406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1BAFBF6B7FDB087FD59E6FAE6D5E8549" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3676E6CFCE1A9A7A46B26FAE6D5E9B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_389B296CB4476383332D6FAE6D5EDC6D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_553C82B7E9B81C384C196FAE6D5E451C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69A6538E2B89F466AF4C6FAE6D5BF6AE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BB12E621AF358ACB2BA36FAE6D5F86B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9EA44D47210A92D774026FCE12623461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33D333368EF7822AF0D56FAE6D5E7E4B" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_EBE1D1828779C6A74EA96FAE6D641E7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8344F815D77E01F571B57F5FB46B12C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8344F815D77E01F571B57F5FB46B12C3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2FB34A6B5310AD90632B7F5FB46B07C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EB0B06CF4CFEE3C7A43F3EED73DA5003" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EB0B06CF4CFEE3C7A43F3EED73DA5003" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_07E39D6A6B0530F354913EED73DAFF8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4F1187EC4CE1C5E44AF0448C574E34F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4F1187EC4CE1C5E44AF0448C574E34F4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_886B23A68460BE69672A448C574E0E0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5ED41EEA79A5D60EB874448C574EDC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_A620364345FA9B31F924448C574E9F27" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_978E6C9A707F7EC75F1F448C574E1C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4F1187EC4CE1C5E44AF0448C574E34F4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_633C00AD530333C8E1C0448C574F7D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_81B5BF775B603CA9AD44448C574F074C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_C1D5ECCBFA9721FEF05B448C574F5D61" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3209DD947CCB8A2AB361448C574FD4C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4F1187EC4CE1C5E44AF0448C574E34F4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E34D19E6B3BA7F4316CE448C574F9866" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A7C585CE530B53ABB8AA77274B775C15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A7C585CE530B53ABB8AA77274B775C15" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3A0F381FBD67DED8A49C77274B77CDAD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_39F6171B1F10C828A14977274B787ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2CE02BF2A3D70A1A992277274B781210" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5F7C8D37D3EF8232CDDD77274B784721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8A2DA359309A8D64C01877274B788651" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_63C7E45372ACC2CC273B77274B7911D5" xlink:to="loc_us-gaap_ResearchMember_BF6DFA7E05120EE804C277274B79E127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_18F76121DD5238F5D12C77274B776845" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9B8747C1B453B7E9D23A77274B799A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_696971A95CD5995678DB77274B79C21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7FCBED2AD97B2C7DF48177274B7AA9AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OperatingLossCarryforwardswithExpirationDates" xlink:label="loc_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_exel_OperatingLossCarryforwardswithExpirationDates_36D32323BB8C9BB6004A77274B7A2E71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9C2AC5663CD38530B65A77274B7ADEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_F3AAD97557AD3713DAA777274B7A1560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AE0E132D1DFD514E75B977274B79BC0C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_F450FDA1AD11D51FE16377274B7A3B18" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7E3D68C5B9DF871B47746FAE6C157D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00C48D1D1203512A57016FAE6C163E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_02C3B2AA998C845E9F666FAE6C16122F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_C0BD7D8BB4CF4A8E8C826FAE6C1B0823" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DeferredTaxAssetsLeasingArrangements" xlink:label="loc_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_exel_DeferredTaxAssetsLeasingArrangements_07E2AD94B078C29BDD8F6FBDBEC34A23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_C471CF2EBB5772244B6B6FAE6C1BC87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_CD305797390D97F3C2566FAE6C1CC137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3AAB8C2B8B47EE1D7EF96FAE6C1C824C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_C83AC85D6E0A86E40DAA6FAE6C1C1F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E6C3FDD43ECB15B4BE376FAE6C1C35E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_E1488FA6B5DFFCDA287B6FAE6C15E6D1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_C530117AF754AE53BC526FAE6C1CAC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_9D914C47C7FF244BD86A6FAE6C1D5481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_A094EB75792BFEDF125D6FAE6C1CD83B" xlink:to="loc_us-gaap_DeferredTaxLiabilities_A150E167E8EDBD5109786FAE6C1D5360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711FD7009873EAA6081F6FAE6C15A68B" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_E7A237696E9D135CE7266FAE6C1D8190" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1D5C438F9EA2DFEB93497C6766AC8A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E46CC8FE0DC9E52BD3CA7C6766ACF7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_611AF241DE6586AD72987C6766AC3528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F31C5F3F5497995174F87C6766AC03E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3F919B4E64DFEDA2C1947C6766AC2883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_B7CF00DF3434E784BB8D7C6766AD3E8E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_AD975B0A9B8CB00F7FEE7C6766AD1860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_EBE0F0FB446F9FDCD7957C6766AD16E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_D00035495C4F3F9E188F7C6766AD3B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CE1B56826FAB954084C37C6766ADA76A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78EC7DFE3F74EFF9CD7A7C6766AC7F89" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CE1B56826FAB954084C37C6766ADA76A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A51B23017CD5AC9C415C7F5FB2F481F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A51B23017CD5AC9C415C7F5FB2F481F5" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_691B09151AC28D71A9C07F5FB2F470CA" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:to="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_1C88CCBAFF3A3C7682A47F5FB2F5B161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_569F52F643474DB539107F5FB2F51A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_742E9E215783C0F3D6EA7F5FB2F52FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6639B313E64187BD63717F5FB2F4C223" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_EF23B3D785397D53C16C7F5FB2F57847" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDB2FE638D6CE206E287F5FB1B2C112" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDB2FE638D6CE206E287F5FB1B2C112" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_77DB8DBE59B76FC742E67F5FB1B27235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDB2FE638D6CE206E287F5FB1B2C112" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622571182FD6168CF0CD7F5FB1B24188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDB2FE638D6CE206E287F5FB1B2C112" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4803A3336276FA45EEA57F5FB1B2617E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0FDB2FE638D6CE206E287F5FB1B2C112" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_67790BBDE4D3134A4EE47F5FB1B23704" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_141C8546AD6C166E2CE73EED6DCE301E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_141C8546AD6C166E2CE73EED6DCE301E" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1EA198D8C73F7ADCC9433EED6DCE3AA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_600696282359740D4DFD6FAE6D39B18D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_600696282359740D4DFD6FAE6D39B18D" xlink:to="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB562AD18A5F9D0079276FAE6D3A2CB0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:to="loc_us-gaap_InventoriesMember_7EE14837E49135ED30F66FAE6D3A6AAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A71795B26A5359D64FB6FAE6D3A8B25" xlink:to="loc_exel_OtherLongtermAssetsMember_6F1708209D0D145C19346FAE6D3B09FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_BACA2BC687A3491955386FAE6D39F006" xlink:to="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryRawMaterials_A1FB012D772C11E26AD76FAE6D3BE97D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryWorkInProcess_AE4B807AF43D91C3BBE56FAE6D3B10E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryFinishedGoods_C0F07B46FA9A465B482A6FAE6D3B61CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryGross_DF4A5E8EE148CAE227506FAE6D3CE607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C93E801C0D53A047D7C56FAE6D3BE5D8" xlink:to="loc_us-gaap_InventoryWriteDown_53F6214443305EC53F306FAE6D3CC498" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21FBAFC1778CA3CB043E7F5FB45108E0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5C51EB1FE96007EDAC3D7F5FB4526E80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BA9C6E755C61B256579D6FAE6BE1B739" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_34B9265FC173EF4E23C36FAE6BE10C2D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A9E79935F8EFF63DED9169802AD0070C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A9E79935F8EFF63DED9169802AD0070C" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:to="loc_us-gaap_NetIncomeLoss_924F48DCFF0AB605053D69802AD132CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_33F8FBB0A34CE04EFE7569802AD2122F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_57EA51B57BD9871AD9D069802AD371FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_909CB0F9C97A0CE1BB9E69802AD32BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_899E96E6A4624F10038769802AD0AF08" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9C3F4B9F549C2BEA235069802AD36762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A9E79935F8EFF63DED9169802AD0070C" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AFD8F8C7DCD3B8056BDB69802AD49C0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E0D1C248672687BEAFB969802AD49F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3CD0409EF8E29B55C02569802AD44952" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:to="loc_us-gaap_EarningsPerShareBasic_69AB3CDC6C26F31790E069802AD5DEDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DC5849374A711B0B1CBF69802AD4BBD6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_070CA63FB8974C6DB60369802AD5BF05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5A6A1D45FAEF86F04AE26FAE6BCE941C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5A6A1D45FAEF86F04AE26FAE6BCE941C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_389F06491874C3D024DF6FAE6BCF3775" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_618CB2ADB0C9F434A5CA6FAE6BCF6974" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_340C9303BE3E56EC917A6FAE6BCFCCD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_58687199766380A840CD6FAE6BCE5C6B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11E5BFE69DAD4D8AFE626FAE6BD049B8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98BAD4FC12265A88300D6FAE6BD003AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CB3081E9D540FE016773698025EF49B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB3081E9D540FE016773698025EF49B0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_075BB01490A2CC7B799E698025F0C7F1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1568BA56088F45B3397D698025F0DE7F" xlink:to="loc_us-gaap_StockCompensationPlanMember_5EEECD35BE82EC31DB78698025F01C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0E20BCC6A1AD14A49635698025EF1C15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_257DDFF9FA2892809F26698025F11FDF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3BE0E0C1F90DA9A06824698025F1610F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0598B81AC14F4D23B47769802ADC3FA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0598B81AC14F4D23B47769802ADC3FA4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63515D66C9393065467269802ADC3176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0598B81AC14F4D23B47769802ADC3FA4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A33C7B3821B95B2F00E69802ADDF7F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62740A67087BC7733B7D3EED682F676B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62740A67087BC7733B7D3EED682F676B" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86F7B2356F5222A7BDCF3EED682F3FCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492" xlink:type="locator" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AEB98862021C464C233C6FAE6EE7B492" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1D545B1776B02FC5D79D6FAE6EE7557C" xlink:to="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_82C41D1372FA1D79AB096FAE6EE8A927" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_FF45EDD9B84A37FD9EA66FAE6EE848F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductsDerivedFromOtherCompoundsMember" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A286931FCBD76A8C6B736FAE6EE818CD" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_DE036FD745ED2A92D7686FAE6EE83B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E9A324F522AC3C483E586FAE6EE85AF3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1BC4A348FA6A705966076FAE6EE9A0EB" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_FC61BFB948BA3C07EEBA6FAE6EE97824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6808787BF1B2DCBF33006FAE6EE971CE" xlink:to="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_EE031F443D8CCE1FDDF46FAE6EE96106" xlink:to="loc_exel_GlaxoSmithKlineMember_2B4D87489843A37F697E6FAE6EEADBFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8BEAC34A1D01CC1738AE6FAE6EEB86C2" xlink:to="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:to="loc_srt_MinimumMember_605A2FF5E64876F4717F6FAE6EEB6FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CE86D7D1B363D1DA67C26FAE6EEBCA88" xlink:to="loc_srt_MaximumMember_203F2ABBEB05532D23D66FAE6EEB8DDD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_082BC5FC5B4D2B654B556FAE6EE79C0E" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_NumberofProductsinCommercialMarket_645205B3ED4812D89AB86FAE6EECCF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8FB1DE342BFEB0A716326FAE6EEC402B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48C40239DF437F1034C86FAE6EEC31E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_BBFCCF6D78B9547836F06FAE6EEC1FC2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_D039977BB7DBA587F0D26FAE6EEDFC2D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_D81F28CF5DD5DA33CCD96FAE6EEDC729" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MedicarePartDFundingMandate" xlink:label="loc_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_MedicarePartDFundingMandate_6879A1E87CB39118EE3F6FAE6EED092D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_F5077D8C974B04ABF9106FAE6EED42C8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_InventoryManufacturedBeforeRegulatoryApproval" xlink:label="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_4E147061CB3F7DA5FB046FAE6EED8283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ED658DEFF7FBEA9E8F666FAE6EEB6531" xlink:to="loc_us-gaap_AdvertisingExpense_B317C36CC783732A3FB86FAE6EEDB330" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7E04264CF861A98E4BCF6FAE6EF4DB46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_FiscalPeriod_99504473CEC4AE49CCCF6FAE6EF40EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_00696211B51BD9CC2ECD6FAE6EF49B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_UseOfEstimates_7AA42BD01DA7CD5338696FAE6EF42134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4CE9A702087765DB1CAB6FAE6EF571F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_E7E5747EEC3AC68BD6616FAE6EF5C609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_FD523278FF953EAC13286FAE6EF5D599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_38DA49BDB75A19A1DCEE6FAE6EF5FDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_833AA710A928551E6E4B6FAE6EF59A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_A44EBE3DDECB30680ABD6FAE6EF577AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_A010C4502F4A984458496FAE6EF652F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6F84958AFE3D71D8A94E6FAE6EF628F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_62B47F97D5F1D013A50F6FAE6EF694C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2E7D1E131BFB53B952186FAE6EF6960C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BD885226888F7D24C5F16FAE6EF63DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_52F0795CC9FCDD3669206FAE6EF60964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_6C93224CAAE403080D086FAE6EF75CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E99E0F21204A6966049F6FAE6EF788DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_15A3260C241249F7ADFD6FAE6EF7C9DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C28D0481285FE39735E6FAE6EF4652A" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C07CB0F0B8765EE7E2C16FAE6EF7255F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A105F38FF87A0E13080A3EF2CE02A7E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A105F38FF87A0E13080A3EF2CE02A7E6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9207057D1B706B8BFAF13EF2CE05770B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5A1BA85CD71102D83B071256B4B51DBD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5A1BA85CD71102D83B071256B4B51DBD" xlink:to="loc_us-gaap_Depreciation_D4FD1DB718371CF3452E1256B4B8786E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_703524ECDD507A29F60615B343619FDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_703524ECDD507A29F60615B343619FDC" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:to="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_C8DDEBF4B79D526F25B415B343616787" xlink:to="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_982AF8055FF50B4026C315B343625864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:to="loc_srt_MinimumMember_982AF8055FF50B4026C315B343625864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4A5FF6B07D7B929B17E815B34362EA2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BEB87E039D21FBD0B75E15B343620D8A" xlink:to="loc_srt_MaximumMember_4A5FF6B07D7B929B17E815B34362EA2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C6F5DDFD13FB5F50446A15B343627D8A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_45BD9A4110A95C40AB3C15B343630618" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_4703AF4C7C9E193F91AB15B34363880A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_99522154291873FD4DB515B3436373C0" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_exel_LaboratoryEquipmentMember_F20571CCADD69DD189E515B343630433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_391D85BD9E39FF92BBAB15B343623BC6" xlink:to="loc_us-gaap_ConstructionInProgressMember_FFF7193302FF81350E8915B34364C130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74D9F4BB753BA5AECE3E15B343612287" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8324F60917B5F53D037415B34364350B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8324F60917B5F53D037415B34364350B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8082BA13C7B566D648F115B343647D7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CA128047AC91DF49CEE615B3436428CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B81F7FE37BF0837C581315B3436447D8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3BC9A77E73C58FB6C42115B34365494D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53543075A92ABF8633BE7F5FB454DF69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22635880F440BD6B2E737F5FB454F022" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_BF62F618CBAE4BB56C0D3EED81F52081" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D68B27B6671E46EB4B6B3EED81F52A52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0467696A41F1D552A96C7013D13265DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0467696A41F1D552A96C7013D13265DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_GrossProfit_8B37C385C18F538C3D626FAE6B961817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_OperatingIncomeLoss_82C0B4B2A7122355B4C16FAE6B96886B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DE3EB6109BCBA58D198F6FAE6B96D78A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_NetIncomeLoss_DE3EB6109BCBA58D198F6FAE6B96D78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_EarningsPerShareBasic_5BD3C4A7F8A34FC777DC6FAE6B967436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9568F1E97C5BE1E0CE736FAE6B96BF81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_AAF726D14087838D0F6D6FAE6B96967B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_046D1B538A24E71C401B6FAE6B950DE6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4AC025CE3B058E345E3E6FAE6B94FB67" xlink:to="loc_exel_MilestonePaymentsEarned_046D1B538A24E71C401B6FAE6B950DE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_739FFF9D1DC6BED529047F5FB342DA16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_739FFF9D1DC6BED529047F5FB342DA16" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_84D660F56516255F9AB67F5FB3422065" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2ABF25A0A0708867438B3EED6AD8DF36" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2ABF25A0A0708867438B3EED6AD8DF36" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_78C0770E84DA8857BA4C3EED6AD821D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C5CD8639C409B618F8107CB66F72C84A" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_F141932CE044D427874B7CB66F73A6EB" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_532795737F21C8688DC27CB66F74B4E1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_F2AA0FFE11B2D9C4BCDE7CB66F746C08" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7291DA80F6B5CF70E1FA7CB66F73E582" xlink:to="loc_exel_AllowanceForProductRebatesMember_A0E85D3333FF8DFB2FE57CB66F7415A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_064926AA7EB376A5483C7CB66F72E504" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_917E70C6F41F22BEBDED7CB66F74A7D1" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_951C6393240614F5DF9A7CB66F75893F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_250B9471E6E00B83B47F7CB66F76D32D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_00D1ED130B476183812C7CB66F758FC2" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_03455F245DA2AD6B36AB7CB66F76B452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_864CDC71D9751D8E44A87CB66F76E911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CFDFE8B6F5177091CB487CB66F754F42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_C6F683CD4160FCFBB3977CB66F76D90F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_174889D6B4EF1C05DBEE3EF7318EA682" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_174889D6B4EF1C05DBEE3EF7318EA682" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:to="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7209C3EDDD6A13D4BF193EF7318E4F98" xlink:to="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:to="loc_exel_CabometyxMember_1EB91FC67C91EAE6AA733F33348EC3AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:to="loc_exel_CometriqMember_3491725B7A9F1F83C60B3F3334B51F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A67A4F392EC570AD1B523EF7318EC017" xlink:to="loc_us-gaap_ProductMember_DF56A4260911672F57353EF7318FB7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_A490CD364EC6DB83691D3EF7318F551D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1850CE99D83D08FDFF8C3EF7318E31E2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_A490CD364EC6DB83691D3EF7318F551D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_A490CD364EC6DB83691D3EF7318F551D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8146197FA8D8812E07ED3EF7318FB6FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81AF03F84E552C64C3A0703C48C62FBD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81AF03F84E552C64C3A0703C48C62FBD" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:to="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28FFB1EEE10AF6DA1951703C48C76B62" xlink:to="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_ProductGrossMember_46D5D0840AD91743C759703C48C7AC85" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ProductSalesDiscountsAndAllowancesMember" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_9C6532F411C9E090A516703C48C8DFFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_01304C239004DAD78756703C48C8A708" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_us-gaap_ProductMember_01304C239004DAD78756703C48C8A708" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationLicenseMember" xlink:label="loc_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationLicenseMember_91F585A9E6CCF40ACEC4703C48C8AF72" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationResearchAndDevelopmentServiceMember" xlink:label="loc_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationResearchAndDevelopmentServiceMember_56B64D6A10CF4FF40EEF703C48C85F1C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationOtherMember" xlink:label="loc_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationOtherMember_B5AEDAC6EA84CCC55664703C48C85335" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_944594DB256AF7D964BD703C48C7271E" xlink:to="loc_exel_CollaborationMember_D214423FC49D9889D1B3703C48C91DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9F22CC0EDB71F3ED59CB703C48C99264" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_B657D25D8061863EAFEA703C48C73A15" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9F22CC0EDB71F3ED59CB703C48C99264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_544A061017739943349F703C48C9D4A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9F22CC0EDB71F3ED59CB703C48C99264" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_544A061017739943349F703C48C9D4A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C782560896B1DBD35AB76FAE6E8D43A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C782560896B1DBD35AB76FAE6E8D43A3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A6FFC0D1EC703337CB4F6FCBBBC95717" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_B56E14831B4DD3D8DD706FCBBBDF8E88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45FE1ECCE7B2CBA07D306FCBBBC902D2" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_B56E14831B4DD3D8DD706FCBBBDF8E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47EC9248825EC497CE586FCBBAF1C60D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_99621B5E58D42AB4834A6FAE6E8D31CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_976F1F4083583CB2F7B56FAE6E8D410A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3984636CEFD28409AAE36FCBBBBAEC10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3984636CEFD28409AAE36FCBBBBAEC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8C72296B706AF46CF6B06FAE6E8D7408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_E78198C14D0AF9229BC36FAE6E8D14B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6845BF8029107EED7B406FCBBB017B04" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_B03A3D02F5C561FB22777008B536ED06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EA66A33038CEE6B031143EF731B190CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EA66A33038CEE6B031143EF731B190CB" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:to="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_F398C78B4E31DCEB7E163EF731B123FC" xlink:to="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:to="loc_country_US_CA593247E5E9292417CE3EF731B754DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:to="loc_srt_EuropeMember_B5B8ADACEE82533C18E03EF731B70ECB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_0A4B0CC1471D364F85C93EF731B7B0DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_C9E746320530A3D336303EF731B1F078" xlink:to="loc_country_JP_0A4B0CC1471D364F85C93EF731B7B0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8C0447FA2E117B800CA3EF731B1797E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B86DB6FD3C60DA86413EF731B808FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_65F65D78F5405987C5163EF731B8C835" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B86DB6FD3C60DA86413EF731B808FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D14E794054954742F9366FAE6EA5DFDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D14E794054954742F9366FAE6EA5DFDF" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_AF92A18014C4ED12ADA36FAE6EA5C243" xlink:to="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_IpsenMember_F8266EAE0DE83B89FB166FAE6EA6EC6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesofCVSHealthCorporationMember" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_40ADE64A457BD99987AA6FAE6EA6E106" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_FACC426AF6C70F223C916FAE6EA60655" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_4ECFD17681F8F41DC90B6FAE6EA7A7D9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_AccredoHealthIncorporatedMember_56AE1935E9B7C982AC456FAE6EA7B7EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB7BB9C7990FCFC93FBB6FAE6EA6B725" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_662ADA64E988FDDB1CF46FAE6EA72B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_BFBD5DB1EB4C2330810D6FAE6EA72CE7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6CB29ACE971E3657E64A6FAE6EA7EB1A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_59369315E2E7120200036FAE6EA76565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_DC4B06FE19BF613636356FAE6EA826C7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4F9E2CA1650AB15A63C76FAE6EA808DD" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_A55390A62351D583C24C6FAE6EA87E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_FD1DFC90ECB3B23F28766FAE6EA5D61A" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3541EFB4465EC49623B46FAE6EA9A011" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3541EFB4465EC49623B46FAE6EA9A011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_259FF94FEEE9FD5576AB6FAE6EA8965F" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_C786B70AB9A4C4EE3B036FAE6EA99246" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F92C4BF333BBBDC4BB816FAE6EBA39C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F92C4BF333BBBDC4BB816FAE6EBA39C2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2832C8DC39F26425B0646FAE6EBAD260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F92C4BF333BBBDC4BB816FAE6EBA39C2" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_B669AEE93AB98757CC586FC7D8349709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F92C4BF333BBBDC4BB816FAE6EBA39C2" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_822CAFC9F1F3B37F5EC86FC8F2FCE5E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200103.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F92C4BF333BBBDC4BB816FAE6EBA39C2" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_A511B76F0824979649556FAE6EBB9168" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exellogo19q4.jpg
<TEXT>
begin 644 exellogo19q4.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
M**** /G7_@H]^PKI_P"VQ\&)+>V6"U\::"KW&A7SC +D9:VD/_/.3 &?X6"M
MS@JWX8^)_#.H>"_$=]I&K6<^GZGIL[VUU;3+MD@E0E65AZ@@U_2Q7Y^_\%E_
M^"=H^*7ARY^+'@NPW>)='@W:]9PI\VJ6J#_7J!UEB4<]VC'JBAM*<K:,B4>I
M^3GS>U'S>U'S>U'S>U;F0?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM2
MQ2M!*KHS(Z,&5E.&4CH0?6D^;VH^;VH _9__ (),?\%#(_VJ_ATOA'Q1>K_P
ML'PS;@.\K_/K5JN +@>LB\"0>I#?Q$+]C5_-U\*?BEKGP4^(FD^*O#=])INM
M:+<"XMID]1P58?Q*RDJRGAE8@]:_>?\ 8G_:]T/]L_X(V/BC2_+M=2BQ;:QI
MN_<^G70 ++ZE&^\C=U/9@P&$XVU1M&5SUZBBBLR@HHHH **** "N+_:!^/'A
M[]FKX2ZOXR\3W7V;2])BW;%(\VZD/"0Q@_>D=L #IW. "1UFJ:I;Z'IMQ>WE
MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
M!0__ (6'HEK\(O&5]NU[2X2OAV\G?YM0MT4DVS$]9(E!*^L:XZIEORF^;VJW
MX>\07WA+7K+5-,NI['4M-G2ZM;F!RDEO*C!D=2.0P8 @^HJ91NK%1E9G]+5%
M?-__  37_;QL?VU_@^K7LD%KXX\/HD.MVBX42DC"W4:_\\Y,'('W&RO3:3[M
M\1/B%H_PG\#:KXD\07T.FZ-HMNUU=W$A^6-%_F3P !R20!DD5SVL[&QY_P#M
MH_M;Z'^QI\$[[Q5JQCN;YLV^DZ=OVR:C=$':@[A1]YF[*#U) /X+_%_XM:]\
M=?B5K'BSQ-?/J&M:W<&XN)3]U>RH@_A15 55' 50.U>D?MX_MG:Q^VO\;KG7
M[SSK30=/W6NA::6^6RMMWWF'3S9,!G;G)PN=JJ!XI\WM6\(VU,92N'S>U'S>
MU'S>U'S>U62'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[5]J
M_P#!(7_@GB?VE?'B^//%UCN\!^&[C]S!,F5UN\7!$>#UA3@N>C'"<Y?:G*VH
M+4^A_P#@C)_P3O/PWT2V^+GC2PV^(-4A)\/64Z?-IULZX^TL#TDE4D+W6,GN
MY"_H30JA%P. .@]**YI2;=V;I6"BBBD,**** "BBB@ HHHH **** "OS?_X.
M(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z_-1_] MZJ.Y,MC\NOF]J
M/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK],_P#@
MW3Z?&+_N"_\ N0K\S/F]J_3/_@W3Z?&+_N"_^Y"HJ?"5'<_3*BBBN<V"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M%_:@_P"3:?B)_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4
M^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8
MK"IN:T]@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE
M_P""Q7_*./XC?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F
M]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*
M_P#)8_"7_89L_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444
M %%%% !1110 4444 %?-_P#P4Q_9$'[4'P*DN=+MA)XN\*A[W2]H^>Z3 \VV
M_P"!A05_VT49 +5](45YN<95A\RP=3 XI7A-6?EV:\T]5YH]GA[/L7DN94<T
MP3M4I2379]T_*2NFNJ;/YY71HW*LI5E."".0:;7V!_P5P_9!_P"%*?%@>.-%
MM?+\,^,IV:=47"6-^06=/99 #(ON)!@ "OC^OX=S[)<1E./J8#$_%![]&NC7
MDUJ?Z>\*<383/\JHYM@W[M17MUC+:47YQ=UY[K1A1117CGT04444 %%%% !7
MZH?\$A?VO_\ A;GPQ;X?ZY=>9XB\(P#[$\C9>\L 0J_5HB50_P"R8^O-?E?7
M5_!+XOZQ\!/BGHOBS0Y?+U'1[@3*I.$G0\/$W^RZ%E/L:^OX(XHJ9%FD,6OX
M;]V:[Q>_S6Z]+;-GY[XF\#4N*LCJ8!V56/O4Y=IK9>DOA?D[[I'[XT5RGP3^
M+VD?'KX6Z+XMT.7S-/UJW$RJ2"T#]'B;'\2,&4^X-=77]KT*].M3C6I.\9)-
M-;-/5/YG^:.*PM7#5IX>O%QG!N,D]TT[-/S3"BBBMCG"BBB@ HHHH 9)(L,;
M.[*JJ,LQ. !ZFOR@_P""H'[>C?M%^,7\'>%[MO\ A!]"G/F31M\NLW"\>83W
MB0Y"#H>7Y^7;[#_P5G_;[_L>UO/A3X-O?]+G4Q^([Z%O]0A_Y<T/]YA_K".@
M.SDEPOYR5_.'BQQ][64LCR^7NK2I)=7_ ")]E]KN].CO_9'@#X4>PC#BC-X>
M_)7HQ:V3_P"7C7=_8[+WMVK%%%%?@1_6 4444 %%%% '9?L_?!;4_P!H?XQ:
M#X/TD;;K6;D1O+C*VT0^:65O9$#-[XQU-?N=\-_A]I?PI\!:1X;T6W6VTO1+
M5+2W0==JC&3ZLQR2>Y)/>OD/_@C=^RK_ ,*W^&=S\1M8MMFL>+H_)TT./FM[
M ,#N]O-<!O\ =1"/O&OMBOZQ\(^%?[-RWZ_77[VO9^:A]E?/XG\NQ_ _T@>/
M/[9SK^RL+*]#"MK3:53[3_[=^%>:DUHPHHHK];/Y_"BBB@ HHHH **** "BB
MB@ KYE_X+%?\HX_B-_W#?_3G:5]-5\R_\%BO^4<?Q&_[AO\ Z<[2JCN@/PT^
M;VH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@
MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
M3G:5]-5\R_\ !8K_ )1Q_$;_ +AO_ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^
M;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O\ R6/PE_V&;/\ ]'I7
M,?-[5T_P5_Y+'X2_[#-G_P"CTI ?T?4445RG0%%%% !1110 4444 %?F3_P7
M(_89D%Q_PNCPS:;D<1VOB>"-?ND82&\QZ8VQOZ8C..6(_3:JFN:)9^)M%N]-
MU"UAO;"_A>WN;>9 \<\;@JR,#P002"#ZU496=Q-7/YI?F]J/F]J^JO\ @II_
MP3BU/]C?QW+K>AV]Q??#C69S]@NLF1M,D;G[+,>V.=C'[RCJ6#5\J_-[5T)W
MV,-@^;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4
M?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4
M?-[4 'S>U'S>U'S>U'S>U !\WM7HGP-_:T^)'[-M\LW@OQAK&BQJVYK1)?-L
MY#U^:!]T3'W*YYKSOYO:CYO:EN!^E_[-7_!?UU:WT[XK>%U9>$.LZ$,$=!F2
MV<_B61Q[)VK[^^!_[2'@;]I#PTNJ^"?$VF:_:[09$@DVW%MGM+"V)(S[.HK^
M=+YO:M?P)X_USX8>*+76_#NK:AHFK63;H+NRG:&:/U^92#@]".A'!S6<J:Z%
MJ;/Z3J*_,']C/_@NW=64EKH/QEL_M4/$:>)-.@"R)SUN;=1AA_M1 $ ?<8DD
M?I1X&\>:+\3?"EGKGA[5+'6='U"/S+>[M)A+%*OL1W'0@\@@@@$5G*+6YHI)
MFM1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y^?^"@?_ ">Y\5?^
MQFOO_1K5Y!\WM7K_ /P4#_Y/<^*O_8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4
M?-[4P#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO
M:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO
M:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^
M;VK]I_\ @A["T?[!FFLRLJR:Q?,I(^\-X&1Z\@C\*_%CYO:OWT_X)M_"6;X*
M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
MB'3_ .JQ?^6I_P#=E?IE11SR#E1^9O\ Q#I_]5B_\M3_ .[*/^(=/_JL7_EJ
M?_=E?IE11SR#E1^9O_$.G_U6+_RU/_NRGVG_  ;K1)<+Y_Q>DDB_B6/PN$8_
M0F[./R-?I?11SR#E1\;?!7_@AW\&?AA?0WFN+KGCB[C8,(]4N!%:*P.0?*A"
M[AZAV=3Z5]=>&?"^F^"]!M=*T?3[+2=+L4\NWM+.!8((%Z[510 HZ]!WJ_12
M<F]RK6"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YY_\
M%G/^"B/_  K[1;KX0^"[[;KFJ0A?$5[ _P UA;N,_95(/$DBGYO[J-CJ_P O
MO?\ P4J_;PLOV*?@ZS6,EO<>./$"/#HEHX#"(CAKJ1?[D>1@'[S$#IN(_#;7
M]?OO%6N7FJ:E=7%]J.HSO<W5S.YDEN)78L[LQY+%B22>I-:4XWU9$I="I\WM
M1\WM1\WM1\WM6YD'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 ?
M1_\ P38_;NOOV*?C&KWLEQ<^"/$#I!K=FN6\H9PMU&O_ #TCR>!]Y<KUVD?N
M5X>U^Q\6:#8ZIIEU;WVFZE EU:W,#AX[B)U#(ZD<%2I!!]#7\TWS>U?H3_P1
MB_X*'_\ "NM;M?A%XROMN@ZI/M\.WDS?+I]R[9-LQ[1RL<K_ '9&QT?*Y5(]
M32,NC/U<HHHK$T"BBB@ HHHH **** "BBB@ HHHH **** "OS?\ ^#B'_D3/
MA;_U^:C_ .@6]?I!7YO_ /!Q#_R)GPM_Z_-1_P#0+>JCN3+8_+KYO:CYO:CY
MO:CYO:NDQ#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J^F?^"=/_  3I
M_P"&_?\ A,?^*R_X1/\ X1/[%_S"?M_VK[1]H_Z;1;-OD?[6=_;'/S-\WM7Z
M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** */B3PQIOC'1+
MC3=8T^QU73;I=D]K>0+/!,OHR,"K#ZBOAO\ :X_X(9^"_B9;W.K?#&X7P3KI
M!?\ LZ9GFTN[;.<#.7@//5=R#  0=:^\J*:DUL%KG\XOQI^!_BK]GGQ_=^&?
M&&CW6BZQ9\F*5<K,A) DC<?+)&<'#*2#@]P<<I\WM7] O[:7[&OAG]M'X27'
MA_6H8K;5K=6ET?5ECS-IEQC@CNT;8 =,X8>C!6'X+_%#X:ZQ\'?B'K/A?7[4
MV>L:#=O9W474!U.,@]U(P0>A!!K>,KF,HV,+YO:CYO:CYO:CYO:K)#YO:CYO
M:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J_4W_ (-Y/&C7GPW^)7ATR'9INI6>
MHHA/&;B*2-B/_ 9<_A7Y9?-[5^B/_!O+J#Q_%;XD6H*^7-I-I*1W)29P/_0S
M^8J*GPE1W/U4HHHKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _GY_X*!_\GN?%7_L
M9K[_ -&M7D'S>U>O_P#!0/\ Y/<^*O\ V,U]_P"C6KR#YO:NJ.QSA\WM1\WM
M1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#^@7_@G[_P F0_"K
M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**^,/^"N/_!0[_AEWP#_ ,(7X3O OC[Q+;G=-&WS:+:-E3-[2O@B/TP7XPH9
MI7=@V/GK_@M!_P %$/\ A-]9NO@_X,OC_8VFRA?$E["_%[<*<BT4CK'&P!?^
M\X X"'=^=WS>U*[M,[,S%F8Y))R2:3YO:NF,;*Q@W</F]J/F]J/F]J/F]J8@
M^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:O1_P!E+]F3Q!^UQ\:=+\&^
M'HRLMT?.O;MEW1:=:J1YD[^RY  R-S,JCEA7#^$_"FI>.O$^GZ-H]E<:EJNJ
M7"6MI:P+NDGE<A551ZDD5^ZG_!.K]AS3OV)O@M'8R+;W7C#7 EQKU^G(>0 [
M8$/_ #RCW$#^\2S<;L")RLBHQN>H? +X%^'_ -F[X3Z/X.\,VHMM+TB'8&('
MF7,AY>:0C[SNV23[X&  !V5%%<YL?D+_ ,%BO^"=Q^!'BZ;XF>#[';X-UZX_
MXF=K"ORZ->.WW@!]V&4GCLKDKP&05\*?-[5_2CXV\%Z7\1?"6I:#K=E#J.D:
MQ;O:7=M,,I-&XPP/Y]1R#R,5^$W_  4&_8CU7]B7XUS:2WGWGA;5R]SH.HN/
M]?#GF)ST\V/(##N"K8 8 ;4Y=&9RCU/!_F]J/F]J/F]J/F]JU,P^;VH^;VH^
M;VH^;VH /F]J/F]J/F]J/F]J #YO:O6_V*_VN]=_8S^-MCXITDR7.GR8MM7T
M[?MCU&U)RRGL'7[R-V8#J"P/DGS>U'S>U+<#^D/X3_%30_C=\.M'\5>&[V/4
M-%URW6YMIEX.#P58?PNK JRGE64@\BNBK\7?^"3'_!0I_P!E/XC?\(EXHO"/
MA]XFN )))&^71;IL*+D>D; !9!Z!6_A(;]H(I5GC62-E=' 964Y# ]"#7/*-
MF;1E<=1114E!1110 4444 %%%% !1110 5^;_P#P<0_\B9\+?^OS4?\ T"WK
M](*_-_\ X.(?^1,^%O\ U^:C_P"@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S>
MU'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_  ;I]/C%_P!P7_W(5^9G
MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
MQ)^'>K?"3Q]JWAO7+9K35M%N6M;F/G&Y>C*>ZL,,I[J0>]8=?I?_ ,%D?V0?
M^$Q\*Q?%+0;7=JFAQ"WUR.-.;BT'W)SCJT1.">?D8<@1U^:%?Q+QEPS5R/,Y
MX*>L=X/O%[?-;/S3Z'^FGASQK0XHR2EF5.RG\-2*^S-;KT>DH^376X4445\J
M?=!1110 4444 %?=G_!&_P#; _X0_P 5R?"W7KK;IFMR&?0Y)&XM[L\O!ST6
M4#*C^^",$R5\)U8TO5+G0]3M[VSGFM;RSE6>":)BKPR*0RLI'(((!![$5[W#
M.?U\FS&GCZ'V7JOYHO=/U6W9V?0^5XUX3PO$F3ULIQ6TU[LNL9KX9+T>_=76
MS/Z%**\4_8-_:KM_VL_@-8ZS(\2>(M-Q8ZU N!LN% _> =DD&&'8'<O.TU[7
M7]PY;F%#'86&,PSO":33\G^JV:Z,_P P\XRG%97CJN78V/+4IR<9+S7;NGNG
MU5F%%%%=IYH4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X+%?\HX_B
M-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[
M4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_ &&;/_T>
ME(#^CZBBBN4Z HHHH **** "L3XC_$/1_A+X$U;Q)X@OHM.T71;9[J[N).D:
M*.PZECP HY)( R2!6W7Y'?\ !:3]OG_A</CA_A7X5O=WA?PW<;M8N(7^74[Y
M"1Y>1UCA.1Z-)DX.Q#51C=BE*R/FC]MK]K?6/VS/CMJ'BO4?-M=-3_1='T]F
MRNGVBDE$XX+MDLY[LQ[!0/(OF]J/F]J/F]JZ%H8!\WM1\WM1\WM1\WM3 /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#7\#_ ! UWX9^(8=6\.ZSJFA:I;_Z
MN[L+I[>9/8,A!P?3O7V/\ ?^"[/Q2^&R0V?C'3])\?:?'@&64?8;_'_76-2A
M_P"!1$GUKXA^;VH^;VI<J>XTVC]H_@W_ ,%N_@I\2HXH=:N]8\$WS\,FJ6;2
MVY;_ &98=XQ[N$Z=J^F/AS\<_!?Q>MUD\*^+/#GB)6&[&G:C%<,H]U5B5/L0
M"*_G$^;VI8)WMIHY(W:.2-@RLIPRD<@@^M9^S1?M&?TR45_/'X*_;*^+/P["
M+HOQ(\;6,,?W8!K$[0#H?]6S%.WI_6O2_#O_  5Z_:&\.A57X@37D2]4N]*L
MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
MKYE_X+%?\HX_B-_W#?\ TYVE?35?,O\ P6*_Y1Q_$;_N&_\ ISM*J.Z _#3Y
MO:CYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:O:_^
M"<?PTF^*_P"W!\-=,CC:2.VUJ'5)_ERHBM3]I?=VP1%M]]P'4BO%/F]J_4O_
M ((-_LCS>%_#>K?%S6K5HY]<B;2]!61>?LP<&><#_;D144\'$;]0PJ92LBHZ
ML_1JBBBN8V"BBB@ HHHH ***^<?^"FO[57_#-'[/5S#IMRT/BCQ9OT[2RC;7
MMUP/.N!W&Q& !'1W0]C7FYOFE#+<%4QV)=H4TV_T2\V[)>;/8X?R/%9SF5'*
M\&KU*LE%>7=ORBKM^29\&_\ !4[]JK_AHC]H*;2=,N/,\+^#"]A9[&RES/D>
M?/[Y90B\D;8P1C<:^8Z**_AG.LVKYGCJF/Q+]Z;OZ=DO)*R7DC_43AO(,+DF
M64<JP:M"E%)>;ZR?G)W;\VPHHHKRSW KHOA3\+=;^-/Q!TOPSX=LVOM6U:80
MPQCA5[EV/\**,LS'@ $UAV%A/JE]#;6T,UQ=7$BQ111(7DE=CA551R220 !R
M37Z]?\$W?V%(/V4_A]_;.N012^//$$*F];AO[,A.&%JC>O0N1P6  )"J3]KP
M/P=7X@QZHJZI1LYR[+LO[SZ?-]#\U\3_ !$PW"65/$RM*O.ZIP[OJWUY8[OO
MHKIL]*_9&_99T3]DOX1VOAW2U2XOI,3ZIJ&S$FH7&,%CW"#HJ] /<L3ZE117
M]FX' T,'0AA<-%1A!))+HE_7SW/\W\SS+%9ABJF.QDW.I4;E*3W;?]:+9+1:
M!11174<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YC_\ !8W]
MD+_A!O&D?Q0T*UVZ3XBE$.LI&O%M>8^68^BR@<G^^I)Y<5\-U^_GQ3^&FD_&
M+X=ZOX7UVW^U:3K5LUM<)T8 \AE/9E8!E/8J#7X>_M&? 36OV:?B]JWA+7(W
M\ZPD+6UP4*QW]N2?+G3_ &6 ]3@AE/*D5_*WBYP?_9^._M3#1_=5GK;:,^OR
MENO._D?W=]'WQ#6;Y9_8>-E^_P .ERWWG3V7SA\+\N7=W.%HHHK\</Z*"BBB
M@ HHHH *Z#X7?$O5O@Y\0M'\4:'<?9=5T6Y6YMWZJ2."K#NK*2K#N&([US]%
M:4:TZ4U5INTHM--;IK5-&.(P].O2E1K14HR333U33T::[-'[R?L[?'/2?VD/
M@]HWB[1SMM]4A!F@+;GLYUXDA8\<JP(S@9&"."*[BOR9_P""3G[7W_"A_C!_
MPB.M77E^%?&4RQAI'Q'8WW"QR\\!7XC8_P"X20$K]9J_M7@3BJ&>Y7'$O^)'
MW9KM)=?26Z^:Z'^:OBEP)4X5SR>#BG[&?O4GW@WLWWB_=??1]4%%%%?9GYN%
M%%% !7S+_P %BO\ E''\1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_].=I5
M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
M&:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\ PX<^-W_/WX%_\&DO
M_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I_P##ASXW?\_?@7_P
M:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!
M?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\ PX<^-W_/
MWX%_\&DO_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I_P##ASXW
M?\_?@7_P:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM7VG_ ,.'
M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
MPX<^-W_/WX%_\&DO_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I
M_P##ASXW?\_?@7_P:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM
M7VG_ ,.'/C=_S]^!?_!I+_\ &:FL/^""/QJO)]DFJ?#^U7&=\NIW!7Z?+;L?
MTI<R#E9\3?-[5>\+^%M2\;>(;32='L+S5-4U"00VUI:Q-+-.YZ*JKDDU^B_P
MJ_X-ZM2ENX9?&_Q"LK>!2#+:Z'9M*\@[A9IMH7ZF)OI7W%^S!^PO\-/V1-/V
M^#O#\<6IR1^7<:O>-]HU"Y'<&4_<4X&4C"(2 =N:3J);#4&>!_\ !*[_ ()?
M?\,LVJ>.O'$4%QX_OH2EM: K)'H,3C# -T:=AD,P.%!*C.6)^VJ**Q;N[FNP
M4444@"BBL;X@76N6?@C5)/#5K8WWB!;=_P"SX;V8PVSSXPGF,H)" X)P"2!Q
M0!\A_P#!7C_@H:/V:? 3>!?"=]M\>>)+8^=/"WSZ):-P9,_PS.,A.ZC+\83/
MXWLVXY/)/))[U]W?$G_@C%^T1\7?'FJ^)O$6M>"]3UK6KAKF[N9-5EW2.>P'
MDX"@8"J,!5  P !6)_PX<^-W_/WX%_\ !I+_ /&:WBXI&4KL^+/F]J/F]J^T
M_P#APY\;O^?OP+_X-)?_ (S1_P .'/C=_P _?@7_ ,&DO_QFJYD+E9\6?-[4
M?-[5]I_\.'/C=_S]^!?_  :2_P#QFC_APY\;O^?OP+_X-)?_ (S1S(.5GQ9\
MWM1\WM7VG_PX<^-W_/WX%_\ !I+_ /&:/^'#GQN_Y^_ O_@TE_\ C-',@Y6?
M%GS>U:7@WP=JGQ"\5Z?H>B6-QJ6K:M<):VEK NZ2>1CA5'X]SP.^*^P?^'#G
MQN_Y^_ O_@TE_P#C-?7O_!+_ /X)92?LB:I?^+O&\FE:IXVDW6NG"T=IK?2[
M<C#.K,JDRR9()Q\JC /S-2=1) HL]9_X)Z_L/Z7^Q+\%H=,_T>\\6:P$N=>U
M%!GS9L<0QDC/DQY(7.,DLV 6P/?***Y]S8**** "BBB@ HHHH **** "BBB@
M HHHH **** "J'B?PQI_C3PY?:/JUG!J&EZG ]K=6TZ[HYXG!5E8>A!(J_10
M!^.?_!0S_@D)XA_9WU"^\5?#VUOO$G@0DS2VR9FOM%'4AP/FDB'.) "5 ^?I
MO;XF^;VK^F6OF_\ ::_X)4_!_P#:<O)]1O-$D\,^()R6?4]"9;629O62,J8I
M"3U8IO/]X5K&IW,Y0['X5?-[4?-[5^BOQ$_X-Z/$UG<2-X3^(>@ZA$>8TU>R
MELV7KP6B\W/;G:/IVK@]0_X((?&JRE58]6^'UX&&2T6IW( ]OGMU/Z5?.B>5
MGQ-\WM1\WM7VG_PX<^-W_/WX%_\ !I+_ /&:/^'#GQN_Y^_ O_@TE_\ C-/F
M0<K/BSYO:CYO:OM/_APY\;O^?OP+_P"#27_XS1_PX<^-W_/WX%_\&DO_ ,9H
MYD'*SXL^;VKZ]_X)/?\ !0>3]DKXE_\ ",^);IO^%?>*)U%RSG(T>Y.%6Z'^
MP1A9!_= ;DIAM;_APY\;O^?OP+_X-)?_ (S1_P .'/C=_P _?@7_ ,&DO_QF
MDY1:L"31^QUO<1WD$<T,B2PRJ'1T;<KJ>001U!J2OG7_ ()R?";XM_ +X0MX
M+^)TVA:E::+M30[VQOWN)DM^0;>0-&ORI@;#D_*=O 5<_15<YL%%%% !7YO_
M /!Q#_R)GPM_Z_-1_P#0+>OT@KY"_P""LW[#GC3]M?P]X)M?!TNB12>'[B[E
MNO[1NG@!$JQ!=NU&S]PYZ=JJ.Y,MC\5_F]J/F]J^T_\ APY\;O\ G[\"_P#@
MTE_^,T?\.'/C=_S]^!?_  :2_P#QFM^9&?*SXL^;VH^;VK[3_P"'#GQN_P"?
MOP+_ .#27_XS1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/F]J/F]J^T_\ APY\
M;O\ G[\"_P#@TE_^,T?\.'/C=_S]^!?_  :2_P#QFCF0<K/BSYO:CYO:OM/_
M (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\ \9HYD'*SXL^;VH^;
MVK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/
MF]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\.'/C=_S]^!?_  :2_P#QFCF0
M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
M!+S]@EOVAO%R>-/%5F?^$(T.<>3!*ORZU<J<[,=X4.-YZ,<)S\^WV,AR/%9O
MC88'"*\I?<EU;[)?\!:M'S_%/$V!X?RVIFF82M""VZR?2,5U;>WWNR39[)_P
M29_8'_X1ZTL_BIXQLO\ 3[E/,\/6,R_\>\9'_'VX/\;#/E@]%.[J5(^_*9'&
ML"*B*JJHPJ@8  ["GU_:G#/#N%R7 1P.%6VK?64NK?Z=E9=#_-/C7C''<39K
M4S3'/5Z1CTA%;17IU?5W;W"BBBOH#Y,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\;_;)_8R\._MA_#_ /L_4MNGZ[8!FTK5DCW2V;GJ
MK#(WQ-QN3/N,$ U[)17'F&7X?'8>6$Q<%*$E9I_UH^J:U3U1Z64YMC,LQE/'
MX"HZ=6#O&2W7Z-/9IZ-:-6/PD_:&_9C\9?LO^,6T?Q;I4EKN)^RWD>9+.^4?
MQ128PW8E3AER-P'2O/J_H"\>_#[0_B?X8N-%\1:58ZUI=V/WMK=PB2-CV.#T
M8=01@@\@BOD'XT_\$2O _BZZFN_!NO:IX1FD;<+2=/[0LU]EW,LB_4NWTK^;
M^)/!;'4:CJY/)5(=(R:4EY7=HOUNGY']D<&?24RO$THT.(H.C46\XIR@_.RO
M*+\K27GT/R[HK[,\1_\ !$/XHZ=<?\2[7O!>I0YP&:YN()/J5,)'IT8_UK,_
MX<K_ !A_Y^?!O_@QE_\ C-? 3\/^(HOE>$G\E?\ %:'ZU3\6N#IQYHYA3^;L
M_N:3/D:BOKG_ (<K_&'_ )^?!O\ X,9?_C-'_#E?XP_\_/@W_P &,O\ \9J/
M]0>(?^@.I_X":?\ $5N$/^AC2_\  CY&HKZY_P"'*_QA_P"?GP;_ .#&7_XS
M1_PY7^,/_/SX-_\ !C+_ /&:/]0>(?\ H#J?^ A_Q%;A#_H8TO\ P(^2 =IR
M/E*]#7[ ?\$P/VO?^&E_@@NF:Q=>=XO\(HEI?EV^>\AQB&YYY)(&US_?4DXW
M+7QM_P .5_C#_P _/@W_ ,&,O_QFO2?V3?\ @G'\<OV6_CCH_BRQNO!\D%N_
MD:C:C4Y0+RT? DC_ -5UQAESP&53SBONO#_+>(\BS2-6>$J>RG[LUR].DO6+
MU]+KJ?E_BUG'!O%.1SP]/,*7UBG>=)\R^*VL;]IK3M?E;V/T:HHHK^I#^%PH
MHHH *^9?^"Q7_*./XC?]PW_TYVE?35>-?\% ?@-KG[3?[(OB[P/X;:QCUK6_
ML?V=KR4Q0#RKV"=MS!6(^2-L<'G'UIQW _G_ /F]J/F]J^T_^'#GQN_Y^_ O
M_@TE_P#C-'_#ASXW?\_?@7_P:2__ !FNCF1CRL^+/F]J/F]J^T_^'#GQN_Y^
M_ O_ (-)?_C-'_#ASXW?\_?@7_P:2_\ QFCF0<K/BSYO:CYO:OO?PG_P;Z?$
MN^NU&N>,_ ^FV[$;FLC=7DBCO\K11#(_WOQKZF_9K_X(F_"GX)7MOJ7B0W?Q
M"UB [E_M.-8M/5AW%LI(;OQ*\@]N,TG42#E9\+_\$Y?^"77B']KGQ!9>)/$=
MO=:'\-[68/+<R*8YM:"GF*V[[3C:TO1>0-S @?M#X8\,:?X+\.6.CZ39P:?I
M>F0):VMM NV.") %55'H  *MVMK'8VT<,,<<,,*A(XT4*J*!@  <  =A4E8R
MDV:1C8****DH**** "BBB@ HHHH **** "H[JUCOK:2&:..:&92DD;J&5U(P
M00>"".QJ2B@#X_\ VGO^"+?PH^.[7.H>'89?AYKTQ+^=I<8>QD8_W[4D*![1
M&/WS7Y^_M$?\$@?C/\!7GN;;0AXUT:/)%[H&ZYD"]MUO@3 ^NU648/S=Z_<*
MBJ4VB7%,_F?OK"?2[R2WN89K>XA8I)%*A1XV'4$'D&HOF]J_HE^,W[*OPY_:
M%@9?&?@W0=>E*[1<SVP6Z08QA9UQ*HQZ,.@]!7R3\8/^" OPY\5R2W'@WQ/X
MA\(S29*P7"KJ5HGH%#%)?SD;_'55%U)]FS\D/F]J/F]J^U?BC_P0C^,G@UY)
M/#]QX9\86X_U:VU[]CN&^JSA4!^DAKY]^(/[#WQ@^%K-_;GPW\86L:G!GBTV
M2XMP?^NL09/U[5?,B+,\L^;VH^;VI]S:R65PT4T<D,L9PR.I5E/H0:9\WM3$
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M26=G-J-TD-O#)/-(<)'&I9F/L!R:]:^''[ ?QH^++0_V+\-?%<D5QCRY[NS-
MC;N#W$L^Q,>^[%*]@/(?F]J/F]J^[_A!_P $"/B5XK>.;QAXB\.>$;5C\T4!
M;4KQ?7Y5VQ?E*?IZ_77P)_X(H_!?X1-#=:S8ZCX[U./#&36)L6H;_9MX]JE?
M]F0R=?RGVB*46?D;\$_V;/'G[1VN_P!G^"?"^K>()E8++);PXM[<GG][,V(X
M_P#@;#-?H=^R;_P06T[1GM=8^+NL#5)U(D_L#29&CMAWVS7'#OZ%8PF".'85
M^B7AKPOIG@S1H--T?3K'2=.M5VPVMG;I!#$/144!0/H*O5FZC9HH)&3X*\#:
M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\N_;"_:-L_V6?@)K7BNX:-[Z-/
MLNEV[G_CZO) 1&N.X&"[8YV(QKU&OR1_X*S?M5_\+V^/+>&=+N/,\->"&>T0
MHV4NKP\3R^X4@1KU'R,0</7P_B!Q0LCRF=>#_>S]V'^)]?\ MU:^MEU/T[PE
MX'EQ/Q!3PM1?N*?OU7_=3^'UF[1[VNUL?+NO:[>>)]<O-2U"XEO+_4)WN;F>
M0Y>:1V+,Q/J22?QJG117\6RDY/FEJS_2B,8QBHQ5DMD@K[:_X)2_L#?\+:UV
MW^)'B^RW>%]+GSI-G,ORZK<(?]8P/WH8V'3H[C!R%93Y+_P3]_8GOOVO?BA_
MIBSVO@W0W235[M?E\W/*VT9_YZ/W/\"Y/4J#^Q_A[P]8^$]"L]+TRU@L=/T^
M%;>VMX4VQPQJ %51V  Q7[5X4\ _7ZJSC'Q_<Q?N)_;DNK_NQ?WO39-/^:?'
MCQ7_ +*H2X=RF?\ M%1?O)+>G%K9/I.2^<8Z[M-7:***_J _A\**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CFF6WA:
M21E1$4L[,<*H'4DT >"?\%&_VIQ^RY^SO?7%C<>5XG\1;M-T<*<-$[#]Y./^
MN2'(/]\Q@]:_&1W:1RS$LS'))/)->[?\%$/VI6_:E_:(U"^LYVD\,Z'G3=&7
M/RO$K?//CIF5\MGKMV _=KP>OXU\2N*O[:S:7LG>C2O&'9]Y?]O/;R2/]&_!
M?@3_ %:X?A[>-L17M.IW5U[L/^W4]?[SD%=]^S7^SMKW[4/Q8T_PKX?C_>W!
M\R[NF7,6GVX(WS/[#(P,@LQ51R:Y7P5X+U3XB^+=/T+1+*;4=6U6=;:UMX1E
MI78X ] .Y)P  22 ":_9O]AG]CK2_P!C_P"%$>GKY-WXEU0)/K6H ?ZZ4 XB
M0]?+CR0OJ<L<%L"?#_@FKG^-_>75"&LWW_NKS?X+7>R=^+7B91X3RW]RU+%5
M4U3CV[SDOY8]%]IZ;7:[SX$_!'0?V=OA?I?A/PY;^1I^FQX:1L&:[E/WYI#_
M !.QY/8<  * !V-%%?V-A\/3H4HT:,5&,4DDMDELD?YTXS%UL57GB<3)RG-M
MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit1062jcraroche2_image1.gif
<TEXT>
begin 644 exhibit1062jcraroche2_image1.gif
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M;WSAPQ[O,@B]#GKP@R ,H0A'2,(2FO"$*$RA"E<XE*4!@ 0#*4[6&D*S?10
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MB<VIPW("0 +M7(<W SB&"X/CBQLFK8G4$7!R$C'@(=Y0K-<)#X&U Q\20(?
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MY3N>!7TO_ A2?R 0Y-_T&'M!_M%/?^'?O?X;(KS^^___ !B  CB !%B !GB
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M, 4XL -/H&T#X0YL,*\+D $?*Q#&\ :D?V[SZOP9X ;/2A"ZL >*X B*  G
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M"Y_COPKD+763P!2Q% NSOTTROT!Q++AH*?U;I:3K)*]H**_PN7:SP!;D+3Y
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6QX;LR);LR:;LRK;LR\;LS![+@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>fiveyearchart2019.jpg
<TEXT>
begin 644 fiveyearchart2019.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,P-@  DI(
M @    ,P-@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( AP$ P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\
MQ-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KC
MP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA_
M_P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q
M-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?
M_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0
MF^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5
MP?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_
M  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T
M)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %
M<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)1
M0!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/
M!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_
M /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\
MQ-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KC
MP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA_
M_P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q
M-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?
M_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0
MF^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5
MP?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_
M  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T
M)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %
M<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)1
M0!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/
M!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_
M /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\
MQ-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KC
MP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA_
M_P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q
M-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?
M_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0
MF^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5
MP?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_
M  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T
M)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %
M<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)1
M0!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/
M!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_
M /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\
MQ-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KC
MP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA_
M_P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q
M-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?
M_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0
MF^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5
MP?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_
M  KCP1_T)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T
M)OA__P %<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %
M<'_Q-=)10!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)1
M0!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!S?_"N/
M!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!\0_&^WAT3XR:YI
M^C11Z?90_9_*MK11%&F;>-CA5P!DDGZDT5)^T'_R7;Q#_P!NW_I-%10!];?#
MC_DEGA3_ + MG_Z(2NDKF_AQ_P DL\*?]@6S_P#1"5TE !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ7H7VG[5_9]NL'G^7L\S Z[<G'TR:V*TE;F=MB(WY5<****DH**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **C2XADFDACE1I8L>8BL"R9Z9';-
M24#::W"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS<!4J*?))Z/OW\OU/M.+J.!=&-2FOWBM\-K<O3F\OY7^AV5%%%>V?F@4444
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M%GIPO(UM""(XE;/[@KSG;SD[CS@GV"^\/6FH^(M-UB[>:273%D^S0;AY2NX
M,A&,EPH*@YP S<9.:U:&D_Q^[3_+\0O;3^NO^9XI%HOC#PYX;\"^)=2TJ\U7
M4-!>YBOM/MI/.N5M9LJH7G]XR*$&._X$B]%I.I_%#Q)K&M7FBZAX?TW^PIM'
MLH]5A$-Q))+R\ACR2JC@#U_,#UVBB7O7OY_CH_S?WB5U:WE^#O\ UY:'A=QJ
M7BGQ+\.K7X;/X+UNQU5XHK"]U&Y@ L8XHR \BS9(?*KP!U)X)QS[A!"MO;QP
MQ_=C0(OT Q4E%-MN[>[$DEHMD%96K>%?#VO7"3ZYH.F:E-&NQ)+RSCF95SG
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M/^@=:?\ ?A?\*/[&TS_H'6G_ 'X7_"KM% %+^QM,_P"@=:?]^%_PH_L;3/\
MH'6G_?A?\*NT4 4O[&TS_H'6G_?A?\*/[&TS_H'6G_?A?\*NT4 4O[&TS_H'
M6G_?A?\ "C^QM,_Z!UI_WX7_  J[10!2_L;3/^@=:?\ ?A?\*/[&TS_H'6G_
M 'X7_"KM% %+^QM,_P"@=:?]^%_PH_L;3/\ H'6G_?A?\*NT4 4O[&TS_H'6
MG_?A?\*/[&TS_H'6G_?A?\*NT4 4O[&TS_H'6G_?A?\ "C^QM,_Z!UI_WX7_
M  J[10!2_L;3/^@=:?\ ?A?\*/[&TS_H'6G_ 'X7_"KM% %+^QM,_P"@=:?]
M^%_PH_L;3/\ H'6G_?A?\*NT4 4O[&TS_H'6G_?A?\*/[&TS_H'6G_?A?\*N
MT4 4O[&TS_H'6G_?A?\ "C^QM,_Z!UI_WX7_  J[10!2_L;3/^@=:?\ ?A?\
M*/[&TS_H'6G_ 'X7_"KM% %+^QM,_P"@=:?]^%_PH_L;3/\ H'6G_?A?\*NT
M4 4O[&TS_H'6G_?A?\*/[&TS_H'6G_?A?\*NT4 4O[&TS_H'6G_?A?\ "C^Q
MM,_Z!UI_WX7_  J[10!2_L;3/^@=:?\ ?A?\*/[&TS_H'6G_ 'X7_"KM% %+
M^QM,_P"@=:?]^%_PH_L;3/\ H'6G_?A?\*NT4 4O[&TS_H'6G_?A?\*/[&TS
M_H'6G_?A?\*NT4 4O[&TS_H'6G_?A?\ "C^QM,_Z!UI_WX7_  J[10!2_L;3
M/^@=:?\ ?A?\*/[&TS_H'6G_ 'X7_"KM% %+^QM,_P"@=:?]^%_PH_L;3/\
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M  JXK*Z!D8,K#((.012UV'G%+^QM,_Z!UI_WX7_"C^QM,_Z!UI_WX7_"KM%
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M_D'8[JBO*%^-&HQVUMKM_P"![ZT\'W4ZQQZT]Y&7",=J2M;XW*I..<]"",Y
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M !RCRM3_ .?RT_\  1O_ (Y5VB@"EY6I_P#/Y:?^ C?_ !RCRM3_ .?RT_\
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M !RCRM3_ .?RT_\  1O_ (Y5VB@"EY6I_P#/Y:?^ C?_ !RCRM3_ .?RT_\
M 1O_ (Y5VB@"EY6I_P#/Y:?^ C?_ !RCRM3_ .?RT_\  1O_ (Y5VB@"EY6I
M_P#/Y:?^ C?_ !RN8U6\U;7M4E\.Z7>0^6JXO[R& KY(/\ )<Y8],?\ U\:'
MB+6;I[Q-!T @ZG<+F27^&TC[N??T'_ULZFB:-:Z%IB6=F"0/FDD;[TCGJQ/J
M:XYMUY.G'X5N_P!%^O;UV]&E%86"K37O/X5_[<_T77?;>+3]+NM+L(K.QGLX
MH(EVJHM&_/\ UG)]ZL>5J?\ S^6G_@(W_P <J[176DHJR//E)R;E)W;*7E:G
M_P _EI_X"-_\<H\K4_\ G\M/_ 1O_CE7:*8BEY6I_P#/Y:?^ C?_ !RCRM3_
M .?RT_\  1O_ (Y5VB@"EY6I_P#/Y:?^ C?_ !RCRM3_ .?RT_\  1O_ (Y5
MVB@"EY6I_P#/Y:?^ C?_ !RCRM3_ .?RT_\  1O_ (Y5VB@#F=8\+WFHW4=_
M;W\%GJ4/^KN8+9E9O]EOG(*_4'^E0Z5X@U2743I6M/:Z?J2_<1K=F2=?[R-O
M&?I_]?'65GZQHEEKME]GOX]V#NCD4X>-O[RGL:Y9TI1E[2EOU71_Y/S^\[J>
M(C."I5]8]'UC_FO+[K#_ "M3_P"?RT_\!&_^.4>5J?\ S^6G_@(W_P <K MM
M9O\ PS<1V'BAS/9N=EOJH'!]%E]#[_\ US75JP=0RD,I&00>"*TI58U/)K==
M48U\/*BTWJGLUL_Z[;HI^5J?_/Y:?^ C?_'*/*U/_G\M/_ 1O_CE7:*V.<I>
M5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3
M_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>
M5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3
M_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>
M5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3
M_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>
M5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3
M_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>
M5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3
M_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>
M5J?_ #^6G_@(W_QRCRM3_P"?RT_\!&_^.5=HH I>5J?_ #^6G_@(W_QRCRM3
M_P"?RT_\!&_^.5=HH **** "BBB@ HHHH **** /B7]H/_DNWB'_ +=O_2:*
MBC]H/_DNWB'_ +=O_2:*B@#ZV^''_)+/"G_8%L__ $0E=)7-_#C_ ))9X4_[
M MG_ .B$KI* "BBB@ HHHH **** "BBB@#F_"_\ R,7C/_L-1_\ IOLZZ2N;
M\+_\C%XS_P"PU'_Z;[.NDH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO$FO/IJQ6.F
M1BYU:\^6VA_N^KMZ*/Z?6K'B#78M"L!(4,]S,WEVULGWIG/0#V]357PYH4UD
MTNIZNXGU>\YF?M$O:-?0#]:Y:LY3E[*GOU?9?YOI]YW4*<*</;UEIT7\S_R7
M7[O2QX=T%-#LW\R0W%]<-YEU<M]Z5_\  =A6O116\(1IQ48[(Y:M2=6;G-W;
M"BBBK,PHHHH **** "BBB@ HHHH **** ([FVAO+:2WNHEEAD&UT<9#"N2,&
MH>"&,EH)=0T'.6@SNEM!ZK_>7V[?F3V-%85:*G[R=I+9_P!;KR.FAB'23@U>
M+W7];/S_ $*]A?VNIV<=W83+/!(,JZG]/8^U6*Y:_P##]WI%Y)JOA/:CN=US
MI['$5Q[C^ZWO_DZNA^(+378&,&Z&YB.V>UE&)(6]"/ZU-.L^;V=16E^#]/\
M+<NKAUR^UHN\?Q7K_GL_70U****Z3C"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^)?V@_^2[>(?^W;_P!)HJ*/V@_^2[>(?^W;_P!)HJ*
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M<"QM%)# X/((^H(KJ/[9TS_H(VG_ '_7_&LCPO\ \C%XS_[#4?\ Z;[.NDH
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M?]!&T_[_ *_XT?VSIG_01M/^_P"O^-7:* *7]LZ9_P!!&T_[_K_C1_;.F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !39)$BC:25@B("S,QP !W-.KCKR:7QKJCZ;9.R:):OB\
MN$./M+C_ )9J?3U/_P!;.-:K[-62NWLOZZ=SIP]#VK;D[16[[?\ !?1"0H_C
MG4UN9U9?#]I)^YC88^V2#^(C^Z/\]\=D!@8' ID,,=O D,"+'%&H5$48"@=
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MO_OB'_XBC[#<?]!2[_[XA_\ B* +M%4OL-Q_T%+O_OB'_P"(H^PW'_04N_\
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M4444 <WX7_Y&+QG_ -AJ/_TWV==)7-^%_P#D8O&?_8:C_P#3?9UTE !1110
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M;_XF@"[15+^U;?\ YYW?_@'-_P#$T?VK;_\ /.[_ / .;_XF@"[15+^U;?\
MYYW?_@'-_P#$T?VK;_\ /.[_ / .;_XF@"[15+^U;?\ YYW?_@'-_P#$T?VK
M;_\ /.[_ / .;_XF@"[15+^U;?\ YYW?_@'-_P#$T?VK;_\ /.[_ / .;_XF
M@"[15+^U;?\ YYW?_@'-_P#$T?VK;_\ /.[_ / .;_XF@"[15+^U;?\ YYW?
M_@'-_P#$T?VK;_\ /.[_ / .;_XF@"[15+^U;?\ YYW?_@'-_P#$T?VK;_\
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M=_\ @'-_\31_:MO_ ,\[O_P#F_\ B: +M%4O[5M_^>=W_P" <W_Q-']JV_\
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M?VK;_P#/.[_\ YO_ (F@"[15+^U;?_GG=_\ @'-_\31_:MO_ ,\[O_P#F_\
MB: +M%4O[5M_^>=W_P" <W_Q-']JV_\ SSN__ .;_P")H NT52_M6W_YYW?_
M (!S?_$T?VK;_P#/.[_\ YO_ (F@".[\/Z/?9^UZ9:2D_P 30KN_/K66W@+1
M48MI_P!KTYSSNM+IT.?7DD5L?VK;_P#/.[_\ YO_ (FC^U;?_GG=_P#@'-_\
M36$L/1F[RBON.F&+Q%-6C-I>NGW&-_PCFNVO_(-\57)4=$O(%FS]6X-'F>-+
M/[\&E:B@Z>6[Q.?KGBMG^U;?_GG=_P#@'-_\31_:MO\ \\[O_P  YO\ XFH^
MK17PR:^;_6Z-/KLW\<8R_P"W4OQ5G^)C?\)5J-K_ ,A3POJ47J;4K< ?BN*?
M%X]\/O)Y<]V]I+WCN87C(_$C'ZUK?VK;_P#/.[_\ YO_ (FH;RYT_4+22UO+
M:ZEAE4HZFSFY!&#SMR/J*/9UX_#._JO\K#57"R?OTVO\+_1W_,\O^)_Q4B^S
MRZ'X7N%D,J[;F\C.0%(Y1#Z^I[=!ST3X6?% ,L'A[Q', P CL[MSU["-SZ]@
M?P/OQ/C[P+)X8OFN=.2YETB1ODDE@=#"3_ Q8#/L>]-\!^!I?%%^MQ?I<PZ3
M$W[R:*!W,A'\"E0>?4]J\OVN)^L^?;I8_2OJ&2_V+?F]S?F^US?Y].7_ (<^
MG**S+.YL-/L;>SM(+N.WMXEBB3[),=JJ, 9*Y/ [U-_:MO\ \\[O_P  YO\
MXFO>/RAVOIL7:*I?VK;_ //.[_\  .;_ .)H_M6W_P">=W_X!S?_ !- B[15
M+^U;?_GG=_\ @'-_\31_:MO_ ,\[O_P#F_\ B: +M%4O[5M_^>=W_P" <W_Q
M-']JV_\ SSN__ .;_P")H NT444 %%%% !1110 4444 ?$O[0?\ R7;Q#_V[
M?^DT5%'[0?\ R7;Q#_V[?^DT5% 'UM\./^26>%/^P+9_^B$KE/B%X:^)'B;5
MK>/19/"T>DV%_!?V?VMKD3L\7.)-H*[=V>F#C'(KJ_AQ_P DL\*?]@6S_P#1
M"5TE'5,?2QPVH^(_%6D0>%--O(M(G\0ZMJ/E7D=JLI@6V4,TLD>XA@579RV1
MD].165>>#_'VA:]K4GP_U30TTS6YS=RQZK'+YMG.PP[1;,ALXW?-QGC'4GT@
MV5JU\EZUM";M(S$LYC'F*A()4-U ) ..G J:C1_C^FGX"\OZ]?QL>:7?PMO=
M*\+>&HO!FIP1:YX;E>6"XOXSY5V90?.60+R Y.>,D8Q[BSH?@/6M2U;5=;^(
M]UI]SJ%_I[:7';:4KBWM[9N7VF3YBS$\YZ8[]O0J*'K>_7]=PVM;^NOYGD$?
MPY\?7VAVG@SQ!KFBR^$K9D1[BWBE%_<P1ME(V!^1<X4$@D@#OSGUY55$"H J
MJ, #L*6BG=O<5@HHHI#.;\+_ /(Q>,_^PU'_ .F^SKI*YOPO_P C%XS_ .PU
M'_Z;[.NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *AN[N"PLYKN\E6&"%"\DC'A5 R33KBXBM+66XN'"10H7=S_"H&2?RKYU^)
M'Q(G\6W36&FL\.CQ-PO1K@C^)O;T'XGGIS8C$1H1N]^A[>3Y/6S2OR1TBOB?
M;_@]CZ&MK^UN].CO[:X1[22/S5F!PI7&<^U<K$K^.=3%Q*&7P_:2?NHR,?;9
M!_$1_<'Z_GCP[PKXNFTY(]&U6[N/[ FG5KF*+EE'?;W /<#T]>OTSIDMI/I-
MI-IFW[')"CV^U2H\L@%< \C@CBN6G4^N.ST2W7=_Y?G^?=F>63R23MJY7Y9=
ME_\ )?ENO*T    , = ****],^6"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O?V%MJFGSV-_$)K:X0Q
MRQDD;E/N.1]1R*-/L+72]/@L=/A6"VMT"1QK_"![GD_4\FK%%*RO<OVD^3DO
MIO;I?N%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** /B7]H/_ )+M
MXA_[=O\ TFBHH_:#_P"2[>(?^W;_ -)HJ* /K;X<?\DL\*?]@6S_ /1"5TE<
MW\./^26>%/\ L"V?_HA*Z2@ HHKS_P 1>*?&-WXXG\,^ ;/11-86D=U>76M/
M+L;S"0J1K'S_  DDGCMQCE=;!TN>@45YG'\4M13X:#5KC1HW\0G43HT5A#*?
M*N+P/LRCG^#(+<GC!&>]2:-XP\::3XXT[P]\1;'10NLQ2&PO-&:78LD8+-'(
M).<E>01@?7/#W_KRO^0/1?UZ'I%%>0S_ !$^(&HZ3J'BWPOHFB2^%;&60QQ7
M4DHO;V&)L/)&5^10<-@,,C'1N,^H:)JUOKV@6&K66?L]];I<1ANH5E! /OS0
MM5<'H[?UIN7J*** .;\+_P#(Q>,_^PU'_P"F^SKI*YOPO_R,7C/_ +#4?_IO
MLZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN:U#Q
M3+<7CZ9X6MUU"]7B28G]Q;^[-W/L/_K5E4JQIJ\O^"_0WHT*E9V@MMWT7J^A
MKZMK-CHEG]HU&<1J>$7JTA]%'<UX?XX\ ZA?07OBO3=)73K3_6R61;]YMZM+
MMZ+ZE?K7K^D>%DM;S^TM7N&U/5#_ ,MY1\L7LB]%'^>*WZY9T)XE?O=%T77Y
MO]%][/7P.9_V35Y\-[SZMW2:[)?J]>R1XK\*_A@MPD'B+Q%$&B8"2SM6&0XZ
MB1AZ=P._4^_M5%%=-&C&C#EB<F9YG7S*NZU9^BZ)=OZW"BBBMCS HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*7?_ 'Q#_P#$5=HH I?8;C_H*7?_ 'Q#_P#$4?8;C_H*7?\ WQ#_ /$5=HH
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M7V&X_P"@I=_]\0__ !%'V&X_Z"EW_P!\0_\ Q%7:* *7V&X_Z"EW_P!\0_\
MQ%'V&X_Z"EW_ -\0_P#Q%7:* *7V&X_Z"EW_ -\0_P#Q%'V&X_Z"EW_WQ#_\
M15VB@"E]AN/^@I=_]\0__$4?8;C_ *"EW_WQ#_\ $5=HH I?8;C_ *"EW_WQ
M#_\ $4?8;C_H*7?_ 'Q#_P#$5=HH I?8;C_H*7?_ 'Q#_P#$4?8;C_H*7?\
MWQ#_ /$5=HH I?8;C_H*7?\ WQ#_ /$4?8;C_H*7?_?$/_Q%7:* *7V&X_Z"
MEW_WQ#_\11]AN/\ H*7?_?$/_P 15VB@"E]AN/\ H*7?_?$/_P 11]AN/^@I
M=_\ ?$/_ ,15VB@"E]AN/^@I=_\ ?$/_ ,11]AN/^@I=_P#?$/\ \15VB@"E
M]AN/^@I=_P#?$/\ \11]AN/^@I=_]\0__$5=HH I?8;C_H*7?_?$/_Q%'V&X
M_P"@I=_]\0__ !%7:* *7V&X_P"@I=_]\0__ !%'V&X_Z"EW_P!\0_\ Q%7:
M* *7V&X_Z"EW_P!\0_\ Q%'V&X_Z"EW_ -\0_P#Q%7:* *7V&X_Z"EW_ -\0
M_P#Q%'V&X_Z"EW_WQ#_\15VB@"E]AN/^@I=_]\0__$4?8;C_ *"EW_WQ#_\
M$5=HH I?8;C_ *"EW_WQ#_\ $4?8;C_H*7?_ 'Q#_P#$5=HH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?$O[0?_)=O$/_ &[?^DT5%'[0?_)=O$/_
M &[?^DT5% 'UM\./^26>%/\ L"V?_HA*Z2N;^''_ "2SPI_V!;/_ -$)724
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M"[O_ +[A_P#BZ/MUQ_T"[O\ [[A_^+J[10!2^W7'_0+N_P#ON'_XNC[=<?\
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MA_\ BZ/MUQ_T"[O_ +[A_P#BZNT4 4OMUQ_T"[O_ +[A_P#BZ/MUQ_T"[O\
M[[A_^+J[10!2^W7'_0+N_P#ON'_XNC[=<?\ 0+N_^^X?_BZNT4 4OMUQ_P!
MN[_[[A_^+H^W7'_0+N_^^X?_ (NKM% %+[=<?] N[_[[A_\ BZ/MUQ_T"[O_
M +[A_P#BZNT4 4OMUQ_T"[O_ +[A_P#BZ/MUQ_T"[O\ [[A_^+J[10!2^W7'
M_0+N_P#ON'_XNC[=<?\ 0+N_^^X?_BZNT4 4OMUQ_P! N[_[[A_^+H^W7'_0
M+N_^^X?_ (NKM% %+[=<?] N[_[[A_\ BZ/MUQ_T"[O_ +[A_P#BZNT4 4OM
MUQ_T"[O_ +[A_P#BZ/MUQ_T"[O\ [[A_^+J[10!2^W7'_0+N_P#ON'_XNC[=
M<?\ 0+N_^^X?_BZNT4 4OMUQ_P! N[_[[A_^+H^W7'_0+N_^^X?_ (NKM% %
M+[=<?] N[_[[A_\ BZ/MUQ_T"[O_ +[A_P#BZNT4 4OMUQ_T"[O_ +[A_P#B
MZ/MUQ_T"[O\ [[A_^+J[10!2^W7'_0+N_P#ON'_XNC[=<?\ 0+N_^^X?_BZN
MT4 4OMUQ_P! N[_[[A_^+H^W7'_0+N_^^X?_ (NKM% %+[=<?] N[_[[A_\
MBZ/MUQ_T"[O_ +[A_P#BZNT4 4OMUQ_T"[O_ +[A_P#BZ/MUQ_T"[O\ [[A_
M^+J[10!2^W7'_0+N_P#ON'_XNC[=<?\ 0+N_^^X?_BZNT4 4OMUQ_P! N[_[
M[A_^+H^W7'_0+N_^^X?_ (NKM% %+[=<?] N[_[[A_\ BZ/MUQ_T"[O_ +[A
M_P#BZNT4 4OMUQ_T"[O_ +[A_P#BZ/MUQ_T"[O\ [[A_^+J[10!2^W7'_0+N
M_P#ON'_XNC[=<?\ 0+N_^^X?_BZNT4 4OMUQ_P! N[_[[A_^+H^W7'_0+N_^
M^X?_ (NKM% %+[=<?] N[_[[A_\ BZ/MUQ_T"[O_ +[A_P#BZNT4 4OMUQ_T
M"[O_ +[A_P#BZ/MUQ_T"[O\ [[A_^+J[10!2^W7'_0+N_P#ON'_XNC[=<?\
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M?^DT5% 'UM\./^26>%/^P+9_^B$KI*YOX<?\DL\*?]@6S_\ 1"5TE !1110
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M?V5;_P#/2[_\#)O_ (J@"[15+^RK?_GI=_\ @9-_\51_95O_ ,]+O_P,F_\
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M*M_^>EW_ .!DW_Q5 %VBJ7]E6_\ STN__ R;_P"*H_LJW_YZ7?\ X&3?_%4
M7:*I?V5;_P#/2[_\#)O_ (JC^RK?_GI=_P#@9-_\50!=HJE_95O_ ,]+O_P,
MF_\ BJ/[*M_^>EW_ .!DW_Q5 %VBJ7]E6_\ STN__ R;_P"*H_LJW_YZ7?\
MX&3?_%4 7:*I?V5;_P#/2[_\#)O_ (JC^RK?_GI=_P#@9-_\50!=HJE_95O_
M ,]+O_P,F_\ BJ/[*M_^>EW_ .!DW_Q5 %VBJ7]E6_\ STN__ R;_P"*H_LJ
MW_YZ7?\ X&3?_%4 7:*I?V5;_P#/2[_\#)O_ (JC^RK?_GI=_P#@9-_\50!=
MHJE_95O_ ,]+O_P,F_\ BJ/[*M_^>EW_ .!DW_Q5 %VBJ7]E6_\ STN__ R;
M_P"*H_LJW_YZ7?\ X&3?_%4 7:*I?V5;_P#/2[_\#)O_ (JC^RK?_GI=_P#@
M9-_\50!=HJE_95O_ ,]+O_P,F_\ BJ/[*M_^>EW_ .!DW_Q5 %VBJ7]E6_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"<#)X%
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M+O;S?5_ET"BBBN@\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /B7]H/_DNWB'_MV_\ 2:*BC]H/_DNWB'_MV_\ 2:*B@#ZV^''_ "2S
MPI_V!;/_ -$)725S?PX_Y)9X4_[ MG_Z(2NDH *X[Q3\2;'PQJ9T]-$U_6[J
M.,2W":/IS3BV4_=+L2%&[#8P3]TYQ78USOC#Q;%X9LHH;:%K_6K\F+3--B_U
MES+C_P =1>K.<!1WZ IWZ#6Y"?B-X:_X5]_PFGV[.C>7O$FP[RV[;LV]=V[Y
M<>OMS5+PO\4=+\3:^=$ETG6]"U)H?/@MM:LOL[7"#.YDY.<8YZ>V<''&ZUX7
M;P?X,\ :3J$ZW#+XHMYK^50 CS2-(YZ_P[VP/H.];_Q"7/Q0^'OV8*;T7-X5
MX^81_9SN_#./:FVE=^=OP3_7[D3TMY7_ !?^7XC]5^-GAW2]3O(/[,UV\L-/
MN/LU[J]GIYDL[:0$!@\F<_+D9P#[9KT&WN(KNVBN+:1989D#QNIR&4C((]B*
M\I\ _8_^&8Y/M6SR_P"S[[[5YF/O;I=V[WS^-=A\+UF7X4>&%N 1(-,@R"#P
M-@QU]L4[6NGTM^-_\AO=6ZW_  M_GJ=51165JUQXAAN$&AZ7IEY"5R[WFI26
MS!L] JP2 C&.<CZ4@*'A?_D8O&?_ &&H_P#TWV==)7%>#I]:;6/%S7FGV$5P
M=83S8XKYW13]AM,88PJ3Q@_=')(YQD]1YNI_\^=I_P"!;?\ QN@"[15+S=3_
M .?.T_\  MO_ (W1YNI_\^=I_P"!;?\ QN@"[15+S=3_ .?.T_\  MO_ (W1
MYNI_\^=I_P"!;?\ QN@"[15+S=3_ .?.T_\  MO_ (W1YNI_\^=I_P"!;?\
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M )\[3_P+;_XW1YNI_P#/G:?^!;?_ !N@"[15+S=3_P"?.T_\"V_^-T>;J?\
MSYVG_@6W_P ;H NT52\W4_\ GSM/_ MO_C='FZG_ ,^=I_X%M_\ &Z +M%4O
M-U/_ )\[3_P+;_XW1YNI_P#/G:?^!;?_ !N@"[15+S=3_P"?.T_\"V_^-T>;
MJ?\ SYVG_@6W_P ;H NT52\W4_\ GSM/_ MO_C='FZG_ ,^=I_X%M_\ &Z +
MM%4O-U/_ )\[3_P+;_XW1YNI_P#/G:?^!;?_ !N@"[15+S=3_P"?.T_\"V_^
M-T>;J?\ SYVG_@6W_P ;H NT52\W4_\ GSM/_ MO_C='FZG_ ,^=I_X%M_\
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M=3_Y\[3_ ,"V_P#C=>0>X7:*I>;J?_/G:?\ @6W_ ,;H\W4_^?.T_P# MO\
MXW0!=HJEYNI_\^=I_P"!;?\ QNCS=3_Y\[3_ ,"V_P#C= %VBJ7FZG_SYVG_
M (%M_P#&Z/-U/_GSM/\ P+;_ .-T 7:*** "BBB@ HHHH **** /B7]H/_DN
MWB'_ +=O_2:*BC]H/_DNWB'_ +=O_2:*B@#ZV^''_)+/"G_8%L__ $0E=)7-
M_#C_ ))9X4_[ MG_ .B$KI* "N!\1_"33_$7C"7Q*OB/Q)I&H26ZVQ;2K]8
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M_A+M7_Z%2^_-O_B*/^$NU?\ Z%2^_-O_ (BG[2/])A[:'])G645R?_"7:O\
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M(N7\,P@>IN''_M.HV^)VNJI+>';< =S=-_\ $4_<_GC_ .!+_,7UNGY_<_\
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MU.,?WFM#BC_A,M._YX7W_@*U<?UG#=OQ_P" >Q^\_P"?B^[_ ()G?\+)LO\
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MINH>%M5LK75+%Y[FRFBC4W2#+,A &2>.350JX;F6G_DR_P B9^WY'::^Y_\
MR1\Z?\)AXF_Z&+5O_ Z3_P"*KO\ X8_$)[%=33Q-J&I7[.8C;*1)<,/O[L=<
M?P_E7*6OAV2VT^ZM;X1BXD.,I(L@7'3#*2#SZ&N^^$%F?#$>KOKES96HNA 8
M@;R)BVW?GA6./O#K7HU<=A*L*D%;W6ENM?-?C_3/"PE+$1K0;;UOO?31[G5?
M\+)L7_X]=#\076?N^3IS'=],D4?\)[>2_P#'KX,\1-GIYUL(OSR>*W?^$ET3
M_H*6O_?T5'_PEFA?]!.#\S7E^WPZZ+[SW^6IUJ?@C&_X2[Q-+_QZ^!;QL]/.
MO8HN??/2C^W?'4W^K\'6UOG@>=JB/CW^45K'QCH"G!U*/\%8_P!*8WC?P\IP
M=1'X1.?Y+2^M4%TC][_S%ROK5?\ Y+_D9GVOXBS?ZO3-!M\\?OIY'Q[_ "]J
M/(^(\O\ K+SPY;YX_<Q3-CW^;O6C_P )OH)_U5U)+Z[()./TH_X3323_ *O[
M5(?1+9_\*/KE+IRA[./6;^__ ",[^QO'DO\ K/%=E;YX_<Z<K8]_F/6C_A%/
M%<O_ !\^/+ANQ\G3HH^/P/7WK1_X3*P/"6NH.W95M6R:/^$OM_X=+U9CV M#
MS^M'UU=&ON7^0>RI=9/_ ,"?^9G?\(+J,G_'SXUUUNW[J58^/P'7WH_X5O;/
M_P ?/B/Q)<]OWNI$\>G '%:/_"6?]0#7/_ /_P"O1_PD]Q_T+VJ_]^A_C1]=
M?27X?\ /8T.WYF=_PJWPX_\ Q\B^N?\ KK>R'CTX(J2+X6^#(ONZ(AYS\\\K
M?S:KO_"1Z@>5\.7^.V2H/Y4?V]J[<Q^&KDC_ &IT4_E2^NS_ )G^(>QP_P#(
MON$C\ ^%(ONZ!8G_ 'H@W\ZN1^%O#\.?*T+3(\]=MG&/Z54_MK7F_P!5X8<^
MN^]C7^E']J^)'X7PVD?N]^A_D*EXJ3W;^YFBA26T?P_X!KQZ;8PY\JSMTSUV
MQ*,_I5FN?_M#Q.W T2V0^K78('Y"C[7XJ/ TRP'N;@X%0ZR?1_<RU)+9?@>=
M_$?X;:IJ7B+4O$4=[8Q63K&Q65W$@VHJ8P%())''/>L_PC\*=8_M72-<2^TY
M[.*YBN"!(^_:C@D8V8W<$=>O>NE\:ZUJS[=*U);6/&)7%LS'/7 .?SQ]*N?#
M?6-DTVDS-Q)^]ASZC[P_+G\#6D<XK>T5%?#:VQY;P>'E7YFG=N_S/0Z***#V
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^)?V@_^2[>(?\ MV_])HJ*
M/V@_^2[>(?\ MV_])HJ* /K;X<?\DL\*?]@6S_\ 1"5TE<W\./\ DEGA3_L"
MV?\ Z(2NDH **** "BBB@ HHHH **** .;\+_P#(Q>,_^PU'_P"F^SKI*YOP
MO_R,7C/_ +#4?_IOLZZ2@ HHHH **** "BBB@#F_&?ARX\26EI%:_9E:WF,N
M^8D$?*5P, \')S]!7!VG@K6KO6+VP-MY M-N;F8%89MPR/+;!W>_''0X->P4
M5S5<-"K)2D3[.F[N2NW^!C>$M$;P[X8M=+D9&: R$E"2OS2,W&0/[U;-%%=.
MO4(Q48J*V04444%!1110 4444 %%%% !1110 4444 %%%% #94\V%XP[)N4K
MN0X9<]Q[UYR?A7> _)KUN%[#^SSP/^_M>D45,H1E\2N9SI1J?$<CX5\$3>'-
M6DOI]2AO"T!A54M#$5RRG.2[?W>E==113225D.$(P5HA1113+"BBB@ HHHH
M*C^SP_\ /*/_ +Y%244 0&PLR<FU@)_ZYBHVTK3V;+6%J3ZF%?\ "K=%+E78
M5D46T/27.7TNS8^IMT/]*C;P[HS]=*L_P@4?R%:5%3R1[!RKL93>&-$9<'2[
M;\(P/Y4P^$M"((.F0_AD?UK8HI>SA_*A<L>QA_\ "&^'_P#H&I_WVW^->?\
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M;(B%M J@+#& .@""I%54&$4*/0#%+156&%%%% !1110 4444 %%%% !1110
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MD\#J35FBA:*R#<*RM6\*^'M>N$GUS0=,U*:-=B27EG',RKG. 6!(&2>*U:*
M/._#O@#P?-KWBM)_">B21P:M'' KZ;"1&GV&U8JH*\#<S' [DGN:Z#_A7'@C
M_H3?#_\ X*X/_B:Z2B@#F_\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@
MK@_^)KI** .;_P"%<>"/^A-\/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XFNDHH
M YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B:Z2B@#F_\ A7'@
MC_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)KI** .;_P"%<>"/^A-\/_\
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MNDHH YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B:Z2B@#F_\
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M^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\
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M /X*X/\ XFC_ (5QX(_Z$WP__P""N#_XFNDHH YO_A7'@C_H3?#_ /X*X/\
MXFC_ (5QX(_Z$WP__P""N#_XFNDHH YO_A7'@C_H3?#_ /X*X/\ XFC_ (5Q
MX(_Z$WP__P""N#_XFNDHH Y?X>6T5EX3DM;:%+>"'5M3CBAC0*L:"_G"JH'
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MXN7,=M9:;:M//.P&2%4<<*"QR1P#]*WJHZUK6G>'M'N-5UJ[CM+*V7=+-)T
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M"OQ&@\6:I]DMO#/B;3X6B,L5]J.F&&VF7C&U\GJ#D9 R/RKL:\OL[KQOX/\
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M>$=*\%Z)_9FC)*4:0S3SSR&26XE;&Z1V[L<#T'H!6Y10M%9 ]0HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$KI*YOX<?\DL\*?]@6S_ /1"5TE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <QXY\&_\ "8Z=9+;:E)I6HZ;=
MI>V-XD*S"*500"T;<,,$\<<X^AR-#^'>L)XIL=>\:^,)O$EUI8D&GHNGQ6:0
M&1=LA8)G>2,8Y&,'KV[ZBA:; ]0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XE_:#_P"2
M[>(?^W;_ -)HJ*/V@_\ DNWB'_MV_P#2:*B@#ZV^''_)+/"G_8%L_P#T0E=)
M7-_#C_DEGA3_ + MG_Z(2NDH **** ,"\\::/9:E<V#KJ=Q<6CJDXL](N[E8
MV**X4O%$RYVNIQG.&%1?\)YI'_/GX@_\)S4/_C%'A?\ Y&+QG_V&H_\ TWV=
M=)0!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=
M)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD
M?\^?B#_PG-0_^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_
M^,4?\)YI'_/GX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,4?\)YI'_/G
MX@_\)S4/_C%=)10!S?\ PGFD?\^?B#_PG-0_^,5:TOQ;I6KZF-/MA?PW1A:=
M8[W3+FUWHI56*F6-0V"Z9QG&X5M5S=]_R5/0O^P+J7_H^QH Z2BBB@#XE_:#
M_P"2[>(?^W;_ -)HJ*/V@_\ DNWB'_MV_P#2:*B@#ZV^''_)+/"G_8%L_P#T
M0E=)7-_#C_DEGA3_ + MG_Z(2NDH **** .;\+_\C%XS_P"PU'_Z;[.NDKF_
M"_\ R,7C/_L-1_\ IOLZZ2@ HHHH **** "BBB@ HK.UC1_[7CB3^T;^Q\LD
MYLI_++Y]3@YK*_X0K_J9?$7_ ('_ /V-83G54K1A=>IU4Z=&4;SJ6?:S9L:S
MK-CH&E3:CJDPAMXAR>['LH'<GTK@_!GQ>M/$>NS:;J<*6#2R?Z"V[AQV1B?X
MO3L>G7JWQQ\+KG6-$+:=K6IWMY;Y>*"_N?,1_4#@;6]#^!]1Y7X-\ ZIXIUY
M[0QR6<%J^+N9U(,1!^[@_P 7M7#6Q&)C5BE&WEW/L,KRO**V7U:M:K[RZ[<O
M:RZW_'9:GU!17+IX("1J@\3>(B%&!F__ /L:>O@S8X8>)?$)P<X-]D'_ ,=K
ML]I6_P"??XH^3='#=*O_ )*RG\5];U/P[\,]4U/0KK['?PF$13^6LFS=,BGY
M6!!X8]13?#'AOQMIFKI=>(_'_P#;MEY; V?]BPVV6(X;>A)X].]4/CMY?_"E
M]<\[_5_Z/O\ I]HCS6'\+;_X-VOB26W^&\NS5;FV82 B\^:-2&/,WRC& ?6N
MF/7^NAPR^%?UV_JQWG_">^&O^$9EU_\ M(#3HIS;2.89!(LP?9Y9BV[]^[C;
MMSWZ52\2?%7P5X1U./3O$.NQVEY(@?R?)DD9 >F[8IV?1L5Y;=RP?\)XWQ+6
MS:3P2NKHDJ DJTJH8O[2"=-H<[<\DXW=<5F:IJ=WX1\;^*H]5^(;^$X]5OVN
MH1)X:6_COX'4;&6;!R%4[2O0=NII7V_KMI^-_3I>]FUJ_P"N_P"5K=-?E?UW
MQ?K$C:UX%ETC4&-GJ&K89[:8^7<Q&WE89*G#*< ]QP#5F#Q-::1+XJO]9\1-
M>V.EW*"6%-.8'35,:G9E%)E&&#%L' //0UP^G:=_97AWX4V@ENI535W96N[7
M[-)M:&=AF+<VS@\#/3'3I6OI>M:;X?U'XG:GK>TV,&HQ^:A7=YN;6(! .Y8D
M*!WS3?N\R[7_ /;"5JX^=O\ VX[74/$^DPS6=@NIJEYJEO)-9&*)ILHJ[C+\
MH("@$'+8!Z5BV_CS0O#?P[TK6_%/BF.\M[F-=FIM9M"UV3R&6!06''8#C&37
MGGP\T^X\#:\]AXLMC#<:[I).CS22%_LD:[G:PR>C*&#>^,=A3!JGA[2?A+\/
MKO7M7U+P[>06#/IVM6EJ9XH)3'M,<B;6#!@<[2O(0_,O<>E_E^<OQT_X=6&M
M6OG^2_#7Y>MSV?P]XCTGQ7HL6K>'[U+VQF)"2H"O(.""I (/L0#6F>AKSCP3
MX\BC^'>H^)?%;P6^G6]ZR)JL%A) NH1914N?)P6!<G!QD9'H*]&R&3(Z$9%$
MU9:?UH*/F>=>"_B-:P_#G2=7\=ZU#;SW]Y<VR7,Z"-&9)9 H)4!5^1.IQG'J
M:W_"?Q'\)^.+BX@\+ZS'?36RAI(O*DB8*3C(#J"1GN,@9'J*\AT>RMM1\ ?#
M2UO[>.YMY/%-P'BE0,KCS+@X(/!'%>AZK$B?M":!)&BI))H5VKN!@L!)'@$]
MP,G'UI]?FU]T;CEHW;^O>:-"]^+?@73_ !1_PCUWXA@34_.$!B6.1E60G&TR
M!2@.>#D\'KBNRKP[P#XX\,>%/#*^!_%5I./$JW\D=QI?]GO*UY*\VY9 =NU@
M05()(X7CC&?5=)\66.L^)];T*UBN4NM$:);AY8P(W,B[EV'.3P.<@4+;O_2_
MS!Z2:_K^F;E%%%( HHHH **** "BBJNIV/\ :6FS68NKFS\U<>?:R;)$Y_A;
M!P::WU$[I:%JL?Q9KX\+^%[O6#;?:OLVS]SOV;MSJO7!Q][/2L;_ (5W_P!3
MAXK_ /!G_P#8U@>-_ %S#X-OI+#6_$VK3KY>RRFNS.LO[Q<Y0+DX&3[8SVKJ
MI4Z3J13EU[''6JUU3DU#6SZHS/\ A?O_ %+7_D__ /:Z]7TC4!JVB6.HB/RA
M=V\<XCW9V;U#8SWQFOE[_A#_ !-_T+NK?^ ,G_Q->V:#\/97\.::UQXF\46<
MK6D1>V2_,:PML&4"E?E /&.V*[<9A\-"*Y';\3S\#B<74DU45_N7Z'H-87CC
M4;K1_ .NZEITODW=I8330R;0VQU0D'!!!Y'<5E_\*[_ZG#Q7_P"#/_[&IOB#
M#]F^$7B& RR3&/1YT\R4Y=\1$98]R>]>/748P;C*Y[E"4Y32G&WXG,^ _'&M
MZEX&UFU\1SH?$FDV?VGSUC51/%)%YD,P4#;[$ 8ROO6SH_C[3])^$VA>)?'&
MKQ6QN[.%Y9W3#2R,H)VH@R3U.%' R>@KC/&NG7.D_#OP]XXT:!I;BPT5++4H
MXQS/92P@-GU\ML./QS534?$=UX=^#OP\DANK?1[>6VC$VOS::;TZ81!\I1,'
M#/DID]F/UJIZ.?DTOS_-6^8J>L8^:;_+\M?D>H:'\1_"/B/0[W6-(URWFL+#
M)NI7#1>2,9RRN 0/0XP<''2E\)?$3PKXY:Y7PMJZ7SVH!F3RI(F4'H<.H)''
M4<5X?H.I:?J=YXZN_%FM:EXDTBZTNR\W5;7238R-'YC*)DC&"5C()+X/W&X(
M&#U_@SQ1>^+-0UW2] UD>*+!=)F%KKTFFM:7%M*QPEL[E563C#;@J\@DU+V;
M\G^%_P#+_@E+UZ_G;_/_ (!;^(7QA\)2^$O$FDZ!XJCCUR"TD$)@:2,^8,<1
MRX"EO3:Q/I73:K\3_"7@RPTR'Q7KL=K=W-JD@CV232$;1\S!%8@$]"<9P<9P
M:\DO_&_A9_V?)O!46FW1U^QTSR[K3/[-?=:3)_K)W)4*H#98MG.6'<UK>*_&
M=[H_BR+3W\40^!XO[-M/L]ZGA\W\VJY4Y4M@X6,D@ =W/X&S:6NWS^+;^F&]
MF]-_EMN>R)XJT*3PJ/$B:I;?V,8?.^V%\)M_'H<\8ZYXQGBL+0_B[X%\1WEM
M::-X@AN;FZG\B&#R94D9]I;[K*"%P#\Q^7/&<\5Y1I=M=S?LZ6LUQ9W-_;Z?
MXC-UJ5I]E"O+;QW1,JM#T&.I3H,'L*W=6\=^&/''Q*\!R^%EFO1;ZE(CZC]A
M>*-/W+?N=[J#NZ-M'&.::UDO-K[G;7\;?+Y">D6^U_POI^%_G\STCQ]XK?P=
MX2FU&UMA>7TDB6UE;$X$T\C;47Z9.3[ USUEX=^*D-W;:C=^.M-N6,JO<:0=
M)5+<*3\Z+,#YAV@G:2,D@9ZFK_Q8TG4]2\'PW>A6S7E]H^H6^IQVB?>N/);)
M0=>2,X&#DC%9]A\=?!FJ3VMC82ZC/K%Q(L7]E)I\OVB-R<,&R-@V<EOFX"GK
M2C^-_P -/UN.6WE;^OPL:>O?%_P'X:UMM(UGQ%#!?)@21)%)*(R3C#,BE5/J
M"01WK8U?QGX<T+3[&_U;6+6VLM0<):W1?,4I*%P=XRH!4$@DX/XBO)_"?CSP
MMX$\+ZCX1\;6L\'B W5S]JL38R3-JK2,2KJ0I#B12JC<>V.G--'AN:R\$_"O
M1?$UDK$ZYNDL[A=XC1EF=(V!Z[05!!]*%JEZK7U_R_X>P2]UORO^']?\.=Y;
M?&KX=W>DW6I0^*+86UHRK+YD<B29/3;&RAW[_=!Z'TK4M_B+X3N_"B^);?68
M7TAIE@-R$?Y)&8*%9<;E.2.H& 0>G-<Y<Z;92?M+V5S):0/,GAIY%D:,$JXN
M H8'L=K$9ZX)%<#XN$-OX9^)"FU\Z!?%5F[6T<8;S,F L O0EN?J30G>WG_\
MDH_\'_,&K7\O_D6SUK0OBGX*\3>('T30_$%O=Z@F[$05U$FWKL9@%?N?E)X!
M/3FE\4_%'P9X+OX['Q+KD5I=2+O$*Q23.H]6$:MMSGC.,]JX74O%OA_Q_P"+
M/!^C^"8)Y+[1M42ZN\V#P#3((T*O&^Y1MR<+M&1E<>F5TSQKX?\ AGXU\76_
MCTR:9>ZGJ1N[6^:UEE6]MBH$:JR*Q^3!&#@ GCO@_P"#\[6V^]]]G\C_ ('R
MWW^Y?>COM2^(_A'2?"UMXCOM=METF[(6"XCW2>:?0*H+$C!R,9&#G&*IMXPT
MSQ GAK4O#GBM(+"_OVA5$LC+]N(1B826&82-I.2 >/>O*H'T;PYX=M]5\0SZ
MOX)%YJ]]J'AZZBLC(M@CJJB*6+:P^<9<)MZ*<,O?8TK7K[Q&?!=]?PP,I\52
MI;ZA!9M:KJ40M9,7/EMR"W.>V1Q32N_FOE=K1^:OY>C5Q2T7W_A?7TT_X.QT
M'A?XW>']?\?ZGX??48-IN8X-(\NUG#W)V?O-Q(P,,"!G;QZ]:Z+Q-\4_!?@[
M54TWQ%KL5I>,H;R1%)*5!Z;MBG;GKSCCFN:T/Q%IOAWXZ^*]%UB62VO==ELY
M=-4P.RW"B JV& (&"I!)P.*X#5]0OO!OCOQ9!K/Q!E\(#4]0>YB27PT+Y+Z%
ME&TK+@DA1\A4\ Y]34WTCZ?CIIZ]]_0JVK_KOKZ?=ZGT;;74%[:175G-'<6\
MR"2*6)@RNI&0P(X(([UQ/A;QC*+/QKJ'B>^_T'1-9N(4D\D?N;>-$;&$7+8R
M?4U>^%VG?V5\,]&M!+=2JD3,K7=K]FDVL[,,Q;FV<'@9Z8Z=*\_;_DF7QA_[
M"FH?^B8Z)^XY6Z)_G$(>\HWZM?DSN['XN> ]3\1PZ%8>)+6>_G(6)$5RCDC(
M42;=A/.,;LYXZ\5-XB^*'@SPGK46D^(->@L[Z4*1$4=]@/0N54A.N?F(XYZ5
MR'C;3;*Q^#WA2.RM(($M]0TMX1'&%\MFD3<PQT)W')ZG)]:JZ=XOT'P!XY\9
M6'C.&XBU+6-2$]D1823-J-NT:K'$A53NP=RX.!EL>N*DK2<>S?SM;_/SV)B[
MQ3[I?*]_\OQ.A^&GBB'_ (5K?:[K^L>9:0ZC>L;VYN"ZB(3,$PQ)R,8  ]@*
MUO#OQ2\&^*TO3X>UI;UK&$SSQ+;RK*$'5EC90S_\!!Y('4BO'_[+OM0_9ZC?
M2+>XLHK'Q++=3V\=DL\D$*7#Y'D9VML)4E.F$/:M#P;KUIK?Q"L=<N_B5-XH
MCT6TN99Y5\-_88K6(ISYLWRX!QD##9*]NM);:]$O_24[_P!?>-[_ #?YM6_K
M[CV >-O#S:5I.HQZDLEKK,B16#11N[3NW0!0"PQ@YR!MP<XK>KP+P@B^'_'F
MF^+M7L&M?#?B*XN4T:.4G&E23,"K%3PGGA2>.%W =S7OM/I?^EY>O^>PNMOZ
M?GZ!1112&%%%% !1110 445BW7AO[5=23_VUJ\/F,6\N&ZVHOL!C@5,FULKB
M;?0VJR]>UZWT"UBFN07\V4(%!YQW;\!_2J?_  B?_4?US_P,_P#K5Y[XA@O)
M=7EAB?4KRW@8I&]T6D/N0<=,BN6O7G3A>VIC4J2BMCV%'61%="&5AD$'@BEK
MS_PCIL^JV$D=WJ>M6DMN0JI'<%$V8XP"/8_I70?\(G_U']<_\#/_ *U:0JRG
M%24?Q+C-R5TCH*\@/Q!\0:5\;-2LM4NDE\*+>6^FA3$@-I--"'C?<!DJS!E.
MXD#<*]0TO2_[,61?M][>>80<W<WF%<>G Q7G-AX>L_%?BWXIZ)J2YM[R2SC+
M8R4;[/\ *X]U."/<5M%N]VMEM\U^AHM59Z7_ ."=)I&OW]Q\5O$^D75T#IVG
MV5I-!$44"-G#[SNQDYVCJ>,5'IWQ@\!:OXC30M.\26\^H22F*-!'($D<=ED*
M[&SVPQSQC.:X#X8ZOKDOBKQR=8L6GUW2M+MK2>%@3]JEA64*P[D2 *??=Q7#
MW7BV\U_3]"A_X3);LP:G8O-X;L_#7V:'2OWJ@)YY&55"0@Y))('O5Q5Y*/\
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MY]E=QB6&78R[U/0X8 C\17A^A>,O#GA7P3KO@OQ-87<OB62YO6N-.737FDU
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MF*A4$8RI*D]<=":SO'GC6[\&?%KQ$+/5-"TZ2_L[6&7^W+2ZG,JB,_/$8(V
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M_P!"]X?_ /!]/_\ (= '245S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\
M\'T__P AT =)17-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'0
M!TE%<W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (= '245S?V[Q
MO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AT =)35C1"Q1%4N=S$#&X
M],G\A7._;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'0!TE%<W]N
M\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (= '245S?V[QO_T+WA__
M ,'T_P#\AT?;O&__ $+WA_\ \'T__P AT =)17-_;O&__0O>'_\ P?3_ /R'
M1]N\;_\ 0O>'_P#P?3__ "'0!TE%<W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"
M]X?_ /!]/_\ (= '245S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T_
M_P AT 3^*?#*^*8;"TN[GR]/@O$N;JW$>[[4$^9(R<_*N_:QX.=N.,UNUS?V
M[QO_ -"]X?\ _!]/_P#(='V[QO\ ]"]X?_\ !]/_ /(='D!TE%<W]N\;_P#0
MO>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?
M3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]
MN\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O
M>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3
M_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!T
ME%<W]N\;_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;
M_P#0O>'_ /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_
M /P?3_\ R'1]N\;_ /0O>'__  ?3_P#R'0!TE%<W]N\;_P#0O>'_ /P?3_\
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M?_\ !]/_ /(='V[QO_T+WA__ ,'T_P#\AT =)17-_;O&_P#T+WA__P 'T_\
M\AT?;O&__0O>'_\ P?3_ /R'0!TE%<W]N\;_ /0O>'__  ?3_P#R'1]N\;_]
M"]X?_P#!]/\ _(= '245S?V[QO\ ]"]X?_\ !]/_ /(='V[QO_T+WA__ ,'T
M_P#\AT =)17-_;O&_P#T+WA__P 'T_\ \AT?;O&__0O>'_\ P?3_ /R'0!TE
M%<W]N\;_ /0O>'__  ?3_P#R'1]N\;_]"]X?_P#!]/\ _(= '245S?V[QO\
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MIXJU/6?!?CB3P\-69);R"32X;S?(J[059R"HV@?+SSGUP-_[=XW_ .A>\/\
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MO_T+WA__ ,'T_P#\AT =)17-_;O&_P#T+WA__P 'T_\ \AT?;O&__0O>'_\
MP?3_ /R'0!TE%<W]N\;_ /0O>'__  ?3_P#R'1]N\;_]"]X?_P#!]/\ _(=
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M\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\
M_@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//
M_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'
MJ/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\
MAJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQ
MO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"
MO#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__
M (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S
M_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#Q
MZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#Z
MVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY
M)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:
MK\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_
M /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*
M\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\
M_@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//
M_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'
MJ/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\
MAJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQ
MO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"
MO#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__
M (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S
M_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#Q
MZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#Z
MVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY
M)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:
MK\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_
M /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*
M\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\
M_@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//
M_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'
MJ/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\
MAJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQ
MO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"
MO#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__
M (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S
M_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#Q
MZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#Z
MVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY
M)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:
MK\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_
M /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*
M\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\
M_@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//
M_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'
MJ/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\
MAJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQ
MO_T"O#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"
MO#__ (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__
M (#S_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S
M_P#QZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#Q
MZ@#ZVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#Z
MVHKY)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY
M)_X:K\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#ZVHKY)_X:
MK\;_ /0*\/\ _@//_P#'J/\ AJOQO_T"O#__ (#S_P#QZ@#F_P!H/_DNWB'_
L +=O_2:*BN:\6>([OQUXHN_$>KQPPWE[L\Q+52L8V(J# 8D]$'?KFB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825116960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPrograms', window );">Collaboration agreement, number of programs | program</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPreexistingPrograms', window );">Collaboration agreement pre-existing programs | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentObligation', window );">Preclinical development work on these programs</a></td>
<td class="nump">$ 32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued', window );">Expense for the discovery and preclinical development funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">148.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member', window );">Collaboration Agreement With Iconic Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued', window );">Expense for the discovery and preclinical development funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPreexistingPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Preexisting Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPreexistingPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Expense Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6833534928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Other Collaborations, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 240,310,000<span></span>
</td>
<td class="nump">$ 271,703,000<span></span>
</td>
<td class="nump">$ 240,275,000<span></span>
</td>
<td class="nump">$ 215,487,000<span></span>
</td>
<td class="nump">$ 228,602,000<span></span>
</td>
<td class="nump">$ 225,397,000<span></span>
</td>
<td class="nump">$ 186,108,000<span></span>
</td>
<td class="nump">$ 213,719,000<span></span>
</td>
<td class="nump">$ 967,775,000<span></span>
</td>
<td class="nump">$ 853,826,000<span></span>
</td>
<td class="nump">$ 452,477,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Collaborative Arrangement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievedMilestoneAmount', window );">Achieved milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember', window );">Profit Sharing Tier One | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember', window );">Profit Sharing Tier Two | Collaborative Arrangement with Genentech | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember', window );">Profit Sharing Tier Three | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember', window );">Profit Sharing Tier Three | Collaborative Arrangement with Genentech | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_MINNEBROMember', window );">MINNEBRO | Collaborative Arrangement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievedMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achieved Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievedMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementPercentOfProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Percent of Profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementPercentOfProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementProfitThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Profit Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementProfitThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_MINNEBROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_MINNEBROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843640592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 68,743<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 75,775<span></span>
</td>
<td class="nump">$ 360,089<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 115,857<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income allocable to common stock - basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,012<span></span>
</td>
<td class="nump">690,070<span></span>
</td>
<td class="nump">153,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Adjustment to net income allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income allocable to common stock - diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 153,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,584<span></span>
</td>
<td class="nump">297,892<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,425<span></span>
</td>
<td class="nump">14,911<span></span>
</td>
<td class="nump">18,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,009<span></span>
</td>
<td class="nump">312,803<span></span>
</td>
<td class="nump">312,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830708256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax provision at statutory rate</a></td>
<td class="nump">$ 83,603<span></span>
</td>
<td class="nump">$ 94,939<span></span>
</td>
<td class="nump">$ 53,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax expense</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">8,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">3,208<span></span>
</td>
<td class="num">(315,394)<span></span>
</td>
<td class="num">(34,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(8,299)<span></span>
</td>
<td class="num">(18,308)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(9,177)<span></span>
</td>
<td class="num">(5,998)<span></span>
</td>
<td class="num">(20,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation', window );">Non-deductible executive compensation</a></td>
<td class="nump">4,228<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="num">(5,640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 77,097<span></span>
</td>
<td class="num">$ (237,978)<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6749276128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.77%<span></span>
</td>
<td class="nump">2.81%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.16%<span></span>
</td>
<td class="nump">1.93%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6823105344">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 258,505,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">258,505,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (252,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819877344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>290</ContextCount>
  <ElementCount>463</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Commitments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues (Revenues by Disaggregated Category) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails</Role>
      <ShortName>Revenues (Net Product Revenues Disaggregated by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails</Role>
      <ShortName>Revenues (Revenues Disaggregated by Significant Customer) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails</Role>
      <ShortName>Revenues (Revenues Disaggregated by Geographic Region) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Revenues Revenues (Contract Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>Revenues Revenues (Contract Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails</Role>
      <ShortName>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2403409 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Other Collaborations, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments (Summary by Security Type) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails</Role>
      <ShortName>Cash and Investments (Gross Unrealized Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Cash and Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments (Summary by Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Employee Benefit Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails</Role>
      <ShortName>Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails</Role>
      <ShortName>Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Employee Benefit Plans (Summary of All Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails</Role>
      <ShortName>Employee Benefit Plans (Summary of All Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2408407 - Disclosure - Employee Benefit Plans (Summary of All RSU Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails</Role>
      <ShortName>Employee Benefit Plans (Summary of All RSU Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails</Role>
      <ShortName>Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Net Income Per Share (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails</Role>
      <ShortName>Net Income Per Share (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsNarrativeDetails</Role>
      <ShortName>Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Commitments (Balance Sheet Classification of Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments (Balance Sheet Classification of Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Commitments (Components of Lease Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Commitments (Components of Lease Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Commitments (Maturities of Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments (Maturities of Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="exel2019123110-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - exel2019123110-k.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - exel2019123110-k.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="exel2019123110-k.htm">exel2019123110-k.htm</File>
    <File>exel-20200103.xsd</File>
    <File>exel-20200103_cal.xml</File>
    <File>exel-20200103_def.xml</File>
    <File>exel-20200103_lab.xml</File>
    <File>exel-20200103_pre.xml</File>
    <File>exel20191231exhibit1029.htm</File>
    <File>exel20191231exhibit1037.htm</File>
    <File>exel20191231exhibit1039.htm</File>
    <File>exel20191231exhibit1057.htm</File>
    <File>exel20191231exhibit1062.htm</File>
    <File>exel20191231exhibit1063.htm</File>
    <File>exel20191231exhibit211.htm</File>
    <File>exel20191231exhibit231.htm</File>
    <File>exel20191231exhibit311.htm</File>
    <File>exel20191231exhibit312.htm</File>
    <File>exel20191231exhibit321.htm</File>
    <File>exel20191231exhibit42.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exellogo19q4.jpg</File>
    <File>fiveyearchart2019.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825720896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>957,621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>738,529</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>402,569</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(197,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(119,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(53,561</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>759,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>619,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>349,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>161,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>192,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>96,637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,905</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>207,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>234,547</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>103,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>967,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>853,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>452,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>733,421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>599,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>324,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>759,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>619,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>349,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenues Disaggregated by Significant Customer</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of CVS Health Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>770,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>632,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>367,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182,879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>69,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>967,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>853,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>452,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,493</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>75,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>119,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(403</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(153</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(350</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(74,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24,741</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,322</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,038</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,916</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,276</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>129,936</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,791</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(128,733</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(15,035</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(44,946</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(188,714</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819921392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">NET INCOME PER SHARE<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>690,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>154,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(367</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>690,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>690,070</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>302,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>297,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>293,588</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive effect of employee stock plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,415</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.06</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Participating securities included warrants issued in January 2014 to purchase an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock that were fully exercised in September 2017. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities included outstanding stock options, unvested RSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they are related to shares from PSOs and PSUs that were contingently issuable and the contingency had not been satisfied. See to &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. These potential common shares were as follows (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Anti-dilutive securities and contingently issuable shares excluded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,645</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843516400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">8,348<span></span>
</td>
<td class="nump">4,915<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">56,602<span></span>
</td>
<td class="nump">40,626<span></span>
</td>
<td class="nump">23,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">71,002<span></span>
</td>
<td class="num">(244,111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="num">(6,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="nump">43,716<span></span>
</td>
<td class="num">(85,471)<span></span>
</td>
<td class="num">(43,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(5,731)<span></span>
</td>
<td class="num">(3,181)<span></span>
</td>
<td class="num">(3,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(5,723)<span></span>
</td>
<td class="num">(8,525)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(9,301)<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">13,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">44,124<span></span>
</td>
<td class="nump">17,143<span></span>
</td>
<td class="nump">26,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">526,956<span></span>
</td>
<td class="nump">415,720<span></span>
</td>
<td class="nump">165,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(12,834)<span></span>
</td>
<td class="num">(33,297)<span></span>
</td>
<td class="num">(21,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,182,682)<span></span>
</td>
<td class="num">(557,832)<span></span>
</td>
<td class="num">(319,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">608,269<span></span>
</td>
<td class="nump">292,971<span></span>
</td>
<td class="nump">376,864<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(587,247)<span></span>
</td>
<td class="num">(297,850)<span></span>
</td>
<td class="nump">36,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">22,499<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
<td class="nump">22,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(9,904)<span></span>
</td>
<td class="num">(7,574)<span></span>
</td>
<td class="num">(6,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(185,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">12,553<span></span>
</td>
<td class="nump">9,691<span></span>
</td>
<td class="num">(169,928)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="num">(47,738)<span></span>
</td>
<td class="nump">127,561<span></span>
</td>
<td class="nump">32,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
<td class="nump">155,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">268,137<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">7,873<span></span>
</td>
<td class="nump">10,677<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">29,562<span></span>
</td>
<td class="nump">17,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Property and equipment deemed to have been acquired in build-to-suit lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>exel2019123110-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:exel="http://www.exelixis.com/20200103"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20200103.xsd" xlink:type="simple"/>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="I2020Q4feb18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="D2017Q4FYYTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2016Q4Dec30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2016-12-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-30</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2018Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2017Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:ProductCommercializationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-02</startDate>
            <endDate>2016-12-30</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAFilingAcceptanceHCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_MINNEBROMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:MINNEBROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:AdditionalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:FirstProductToReachMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesSecondProductApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_exel_StatusAxis_exel_VestedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:VestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2010Q4Jan02-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-02</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Fiscal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-03-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-31</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="I2019Q3Aug30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q4_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="I2019Q1_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="I2019Q2Apr30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-09-28</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-09-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-29</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="program">
        <measure>exel:program</measure>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="renewal_option">
        <measure>exel:renewal_option</measure>
    </unit>
    <unit id="USD_PER_sqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utreg:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q4YTD"
      id="Fact-3E0DE728E16A9835DC307F5F58881B11-wk-Fact-3E0DE728E16A9835DC307F5F58881B11">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q4YTD"
      id="Fact-772E0FB5EED22B7A48097F5F58899E96-wk-Fact-772E0FB5EED22B7A48097F5F58899E96">--01-03</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q4YTD"
      id="Fact-590004BBBC8151568AA6B1BFC5E60A6E-wk-Fact-590004BBBC8151568AA6B1BFC5E60A6E">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q4YTD"
      id="Fact-C18039D1514D550D81F4A4A79C72A647-wk-Fact-C18039D1514D550D81F4A4A79C72A647">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q4YTD"
      id="Fact-7CDF3EA17DADF3C127F17F5F58871AE7-wk-Fact-7CDF3EA17DADF3C127F17F5F58871AE7">0000939767</dei:EntityCentralIndexKey>
    <exel:CollaborativeArrangementAchievedMilestoneAmount
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember"
      decimals="-5"
      id="Fact-E6DECAC2D7A91EB87DE015BA6907B36C-wk-Fact-E6DECAC2D7A91EB87DE015BA6907B36C"
      unitRef="usd">20000000</exel:CollaborativeArrangementAchievedMilestoneAmount>
    <exel:InventoryManufacturedBeforeRegulatoryApproval
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-2E98D7A638AE54319B51C7BD70F4AF10-wk-Fact-2E98D7A638AE54319B51C7BD70F4AF10"
      unitRef="usd">0</exel:InventoryManufacturedBeforeRegulatoryApproval>
    <exel:MedicarePartDFundingMandate
      contextRef="FD2017Q1YTD"
      decimals="2"
      id="Fact-A377A412DB6A11A0A1BC649AF7319F76-wk-Fact-A377A412DB6A11A0A1BC649AF7319F76"
      unitRef="number">0.50</exel:MedicarePartDFundingMandate>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="Fact-E0F0D75714C198CF36B9DD2CB6A9FB27-wk-Fact-E0F0D75714C198CF36B9DD2CB6A9FB27">P6M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-48C0C2D323AC546C9E0D7675C1D85853-wk-Fact-48C0C2D323AC546C9E0D7675C1D85853"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0931248BC90E584D87ECEE5C77E9F5F1-wk-Fact-0931248BC90E584D87ECEE5C77E9F5F1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-E02155D2139E5CC2947BA59B216F4A51-wk-Fact-E02155D2139E5CC2947BA59B216F4A51"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-C90D9143603D53C99C1C5F927C170EAB-wk-Fact-C90D9143603D53C99C1C5F927C170EAB"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="-3"
      id="Fact-5BA1BB968A9A524F8A0C020D2AEC35D5-wk-Fact-5BA1BB968A9A524F8A0C020D2AEC35D5"
      unitRef="shares">299876000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-CD42DA9BAFC254CEAD51295F80503451-wk-Fact-CD42DA9BAFC254CEAD51295F80503451"
      unitRef="shares">304831000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="Fact-C7DD8DC68CF25A699E5794F8B3C09B00-wk-Fact-C7DD8DC68CF25A699E5794F8B3C09B00"
      unitRef="shares">299876000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-5640D752D09C5E98BBF57450E6989067-wk-Fact-5640D752D09C5E98BBF57450E6989067"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q4_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      id="Fact-6CE0FCE5C266BE2D59E470505A81F3C0-wk-Fact-6CE0FCE5C266BE2D59E470505A81F3C0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q4_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember"
      id="Fact-7D947BE1EC78C1C3F83B704C99E9BD1F-wk-Fact-7D947BE1EC78C1C3F83B704C99E9BD1F">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="Fact-9F06C2B7C23632DAECF4C754417C14D6-wk-Fact-9F06C2B7C23632DAECF4C754417C14D6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="Fact-CCDF6C015C347E142B5DC7544179CBA8-wk-Fact-CCDF6C015C347E142B5DC7544179CBA8"
      unitRef="usd">-156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="Fact-913C1AF8854955839A99B9E5063CD579-wk-Fact-913C1AF8854955839A99B9E5063CD579"
      unitRef="usd">1049000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="Fact-5D33F43624FB0D5C31E07F5F58926AC7-wk-Fact-5D33F43624FB0D5C31E07F5F58926AC7"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="Fact-E48D6712496480715A727F5F58DFB6D0-wk-Fact-E48D6712496480715A727F5F58DFB6D0"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-CE2044CCF8405CFA8A83A89588D712F6-wk-Fact-CE2044CCF8405CFA8A83A89588D712F6"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-1FF457A008955FBFB8C24E73D2BC50FC-wk-Fact-1FF457A008955FBFB8C24E73D2BC50FC"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-EF960E95643A512E9C1F47E2F51D4E39-wk-Fact-EF960E95643A512E9C1F47E2F51D4E39"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-938BEFB6D1B8595C9B03636833CBE85C-wk-Fact-938BEFB6D1B8595C9B03636833CBE85C"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-AA61665A7D8F5B258AE1766E2557517F-wk-Fact-AA61665A7D8F5B258AE1766E2557517F"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-A6327BDDDC1F5EE6B1204EE4B3F2E950-wk-Fact-A6327BDDDC1F5EE6B1204EE4B3F2E950"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      id="Fact-295A53780EBAC7DDA118125838E9B588-wk-Fact-295A53780EBAC7DDA118125838E9B588">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      id="Fact-CE6B9ECAD44394412B84125838AEB4A5-wk-Fact-CE6B9ECAD44394412B84125838AEB4A5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-7DABC88CC728E3D5959612583915F158-wk-Fact-7DABC88CC728E3D5959612583915F158">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      id="Fact-B4A8BFFF1FB3025574E07F5F58C2586E-wk-Fact-B4A8BFFF1FB3025574E07F5F58C2586E">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-246047967E0F105CD9E4125838CD9F75-wk-Fact-246047967E0F105CD9E4125838CD9F75">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="D2010Q4Jan02-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-07143095F83750495D89A84F45F2B52A-wk-Fact-07143095F83750495D89A84F45F2B52A">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-2539F3C03FD9A5D5B0B0A84EA270C9BF-wk-Fact-2539F3C03FD9A5D5B0B0A84EA270C9BF">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact-D162C5A3C48A883EC907A84FEA89ACC0-wk-Fact-D162C5A3C48A883EC907A84FEA89ACC0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-9B56F2ABD4F151A9AFA2A84ECDB8F3D5-wk-Fact-9B56F2ABD4F151A9AFA2A84ECDB8F3D5">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:DocumentType
      contextRef="FD2019Q4YTD"
      id="d21809722e594-wk-Fact-334E1EB9C0A03C0912D480153F31FC1B">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="FD2019Q4YTD"
      id="d21809722e597-wk-Fact-9C37EE5ABBD184F149F785DD3F26E085">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q4YTD"
      id="d21809722e607-wk-Fact-CD72CF5A1602EDBAAAFA80158BAFD5D0">2020-01-03</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q4YTD"
      id="d21809722e613-wk-Fact-F6C98F8C5F0A2CCFCCB485DE2C30FE9A">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q4YTD"
      id="d21809722e623-wk-Fact-B10BE84969D35B5B81C8B6C7AB139976">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q4YTD"
      id="d21809722e644-wk-Fact-45472465F2265347A9FAB2F03814D0BD">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q4YTD"
      id="d21809722e664-wk-Fact-6768AACFEFB655EAA9B01700DF1BDC4C">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q4YTD"
      id="d21809722e669-wk-Fact-92F714AE241352969A54530EB430CA78">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q4YTD"
      id="d21809722e684-wk-Fact-D0DB7D9C6F1B56FDA6B9837538B59FBD">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q4YTD"
      id="d21809722e690-wk-Fact-AF229F23A7145D5A8B242638F0E7B29C">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q4YTD"
      id="d21809722e695-wk-Fact-452C5D454C415C75A72B70F2ABF7E8F0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q4YTD"
      id="d21809722e700-wk-Fact-AD7E79C0C42058799D5323E488704C8E">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q4YTD"
      id="d21809722e708-wk-Fact-8F56829B12BD5730A1ABB662433C42E7">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q4YTD"
      id="d21809722e713-wk-Fact-B2A470547A4F5F29B3C7DC4542C2C63B">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD"
      id="d21809722e753-wk-Fact-49A629C1E38BCE0BFCD18016B29A039F">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD"
      id="d21809722e758-wk-Fact-D8358DCC00834A5E7ADB8016B34029A9">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD"
      id="d21809722e763-wk-Fact-93BC9FEDBBF93708F6568016B3F2D990">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2019Q4YTD"
      id="d21809722e774-wk-Fact-279776635351ED02FDAF80176ECA9987">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="FD2019Q4YTD"
      id="d21809722e794-wk-Fact-5A16BE4B83D07955FC1680178B2DE859">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q4YTD"
      id="d21809722e804-wk-Fact-1200FC4AADB4FA21D03B8017C48C9340">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q4YTD"
      id="d21809722e821-wk-Fact-5B367E39302947E872108017E259329E">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q4YTD"
      id="d21809722e853-wk-Fact-2C128E49E7CEC8C5BBE180180D1AF64A">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q4YTD"
      id="d21809722e904-wk-Fact-A2B823EB5BF5CC388A06801830D406F2">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q4YTD"
      id="d21809722e934-wk-Fact-C49BA09681A919C246AC700E176109AE">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q4YTD"
      id="d21809722e949-wk-Fact-BF9EF909BA31256CDCF48019426621DD">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="FI2019Q2"
      decimals="0"
      id="d21809722e961-wk-Fact-BF3ED92059334E0694147F5F588D8D17"
      unitRef="usd">5731439777</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q4feb18"
      decimals="INF"
      id="d21809722e972-wk-Fact-7AC819A676D755CF992E403B349646BA"
      unitRef="shares">305393240</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D8A4E2CE2E75F1A4FA437F8790007DF6-0-wk-Fact-C5E2B66FF15BA3C16E5B7F89598D643D">Certain portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than May 4, 2020, in connection with the registrant&#x2019;s 2020 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e771-wk-Fact-01250ECF4ED255118BE21200D22D84B1"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e790-wk-Fact-90F54B50CC015DC590E195EFBE556F53"
      unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e805-wk-Fact-25D8C6D231DE5E4EBE828F04E2A91DC2"
      unitRef="usd">585742000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e824-wk-Fact-109206491BEA59A7A137A9DE3633A65A"
      unitRef="usd">378559000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e844-wk-Fact-0CFDCA9D00B35BF38DB2E73071480D32"
      unitRef="usd">119073000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e863-wk-Fact-A518F3C77037591DA9B8BCE5358CF918"
      unitRef="usd">162771000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e883-wk-Fact-334BC2A172925461BD731F96E60927B4"
      unitRef="usd">12886000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e902-wk-Fact-108FD8E6E36C54A0B58796683CC80F1E"
      unitRef="usd">9838000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e922-wk-Fact-510F4FE18E79538FB1C42FA04926BE85"
      unitRef="usd">26988000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e941-wk-Fact-FA5DFF36154359B79C6A0E1424B822A2"
      unitRef="usd">31073000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e961-wk-Fact-CB87FC3D5138514FA96027C5B7B3B236"
      unitRef="usd">1011190000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e980-wk-Fact-79D6BCD6C726582CBC7425DEF32FD9F4"
      unitRef="usd">897016000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1000-wk-Fact-2A52DC58CBD257D5B4AD62E653907E4A"
      unitRef="usd">536385000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1019-wk-Fact-32EE08F157D253FA9657E742AF864D58"
      unitRef="usd">158287000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1040-wk-Fact-81AA7FFF07FE5F84B6FB6B3F858272C1"
      unitRef="usd">48892000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1059-wk-Fact-B2A50C77138252D19D547A4E7AE9A283"
      unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1079-wk-Fact-2FF860101C2F58248419901027CE579C"
      unitRef="usd">172374000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1098-wk-Fact-F106612E08BA5C8CBC932306BCB5D5E3"
      unitRef="usd">244111000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1118-wk-Fact-D20A9256E89A55B1AAB7A81A7E0556A1"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1137-wk-Fact-9C433D52D4585D86B53313F8C4A8584F"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1157-wk-Fact-FC39DC5F2E6954EA8E1D74CDBA604FFA"
      unitRef="usd">53145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1176-wk-Fact-55FED27665D65F21866D1551CECA4ADD"
      unitRef="usd">8291000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1201-wk-Fact-951C4162B17C53458B5D0C8149BDD5B9"
      unitRef="usd">1885670000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1220-wk-Fact-7C42804E861D57B494CABB0566AFE6A4"
      unitRef="usd">1422286000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1322-wk-Fact-7A193C3789EA51D480A960098535DD04"
      unitRef="usd">11581000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1341-wk-Fact-E100ED8C05F753D5BD6D05F2ABABBA64"
      unitRef="usd">10901000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1356-wk-Fact-081496F4471B57A99F5BAC9087E5A831"
      unitRef="usd">37364000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1375-wk-Fact-DC5436BC981454D485E38C0CDB717ED6"
      unitRef="usd">32142000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1395-wk-Fact-B17F52559774580BAD1E3BA255AE6439"
      unitRef="usd">38777000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1414-wk-Fact-5138DB67F25A55D7818FBB404CDD98E4"
      unitRef="usd">18231000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1434-wk-Fact-006926838AC45928809436DD978BDCC8"
      unitRef="usd">18719000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1453-wk-Fact-07B0A54C0D295D54A810060C3AA909E4"
      unitRef="usd">14954000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1474-wk-Fact-F5B01543BC295D12BA13BB62FA7FFABA"
      unitRef="usd">11856000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1493-wk-Fact-A62B9423A4BF53B1B5727C0C670827F8"
      unitRef="usd">7419000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1513-wk-Fact-9A1E01EE6D52548B95BF815C6C029A04"
      unitRef="usd">24449000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1532-wk-Fact-F951A5C215585681B8CC3B8699EF0946"
      unitRef="usd">21825000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1552-wk-Fact-4B704D7C65705578BEBEB04623EBA969"
      unitRef="usd">142746000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1571-wk-Fact-00E5E1936CB459738CA1BB19D6DCFC0F"
      unitRef="usd">105472000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1591-wk-Fact-6D180C9F98DF54B5924898A5BE2BD670"
      unitRef="usd">6596000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1610-wk-Fact-17DF66A050485D2095DE5E8C1EAA48FE"
      unitRef="usd">15897000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1630-wk-Fact-465D3B14C4885FD68234A459F458B06C"
      unitRef="usd">48011000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <exel:OperatingAndFinanceLeasesLiabilityTotal
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1649-wk-Fact-C6DB8A3881AC5BEF860D21A9A7336011"
      unitRef="usd">12178000</exel:OperatingAndFinanceLeasesLiabilityTotal>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1669-wk-Fact-E2B42151F3A555E3A8710E010721E92D"
      unitRef="usd">2347000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1688-wk-Fact-2132DCA810965FBA8E1F590B0E3A8668"
      unitRef="usd">1286000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1708-wk-Fact-C7644F437DDA53F9B290D51B42C17092"
      unitRef="usd">199700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1727-wk-Fact-82A768A4ABB450EAA9E3BE60E0765CE6"
      unitRef="usd">134833000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d21817206e1747-wk-Fact-6D275C2E7B2A5764BA60766491BDC029"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d21817206e1766-wk-Fact-7566DEA5372A5E19B6C3777BF3FAFFC2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1827-wk-Fact-72E01B1AFA6F56749FFD1D6C5A9DEFDD"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1846-wk-Fact-A2943B4734D152F48E042512EBB2F100"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1866-wk-Fact-7A3E443DAF2C5CF6802F0365DEA3F613"
      unitRef="usd">305000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1885-wk-Fact-A184E8A4B8B15D4FAEE52B30A6DCF549"
      unitRef="usd">300000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1906-wk-Fact-BCF8EE670B7C556B8F45E07D2C143C0E"
      unitRef="usd">2241947000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1925-wk-Fact-2916F02DE9565FF28646F5ECCBABBE3A"
      unitRef="usd">2168217000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1945-wk-Fact-A319E229B7175905BAFBAC5C31F3E0AA"
      unitRef="usd">3069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e1964-wk-Fact-241D68BA31155F718FB1378BF5680574"
      unitRef="usd">-701000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e1985-wk-Fact-4F200F92C2F659C7A60CECFFD35FA625"
      unitRef="usd">-559351000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e2005-wk-Fact-07B61B2EAE6054D4A8D9556138695E15"
      unitRef="usd">-880363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e2026-wk-Fact-7DEB41AA80AF5179814C8D33FE9E1430"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e2045-wk-Fact-FD5022E3207A55678B8FFBD54FCA8596"
      unitRef="usd">1287453000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21817206e2070-wk-Fact-1FBCB4FF4897564B9E92BF6D4262D182"
      unitRef="usd">1885670000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21817206e2089-wk-Fact-5ABC543424B65C55A32FCA11DB4DBE6C"
      unitRef="usd">1422286000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21820265e797-wk-Fact-4A7175F192395C85B0C7C6A02D7F643B"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21820265e816-wk-Fact-2EA1F50A74FDA1A9B2E4C6FA4DF7260C"
      unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21820265e835-wk-Fact-3D0827DEC1DB5BB5A4513DCDDE52D7D0"
      unitRef="usd">349008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d21820265e851-wk-Fact-9651ACAA83595E19B7AF718E8FD34546"
      unitRef="usd">207825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d21820265e870-wk-Fact-669337DF6374573799CCB10DBFE5ECD5"
      unitRef="usd">234547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d21820265e889-wk-Fact-670E8F350E5A6011B6F27F72B0634FD9"
      unitRef="usd">103469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e910-wk-Fact-C2F428FDC3B55296BD84486AB439D9DE"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e929-wk-Fact-D4F84C516D8153E6AABE4A9E657B33A0"
      unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e948-wk-Fact-A0BE00E5ACD05545886BD820391E213F"
      unitRef="usd">452477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1031-wk-Fact-CBD0FE8A75215CF8B595352924B8DDD6"
      unitRef="usd">33097000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1050-wk-Fact-2FA1D81521CB582987B405CF1AE32F58"
      unitRef="usd">26348000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1069-wk-Fact-13F01A85ED895E64BFDC3C7BCFF12B65"
      unitRef="usd">15066000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1090-wk-Fact-96E0525D08AF563CBC485E911D268984"
      unitRef="usd">336964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1109-wk-Fact-7ADC0F46CE22510BB6632DCF55BE6E88"
      unitRef="usd">182257000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1128-wk-Fact-D40F27293FE65FC4DD4E808181651DA7"
      unitRef="usd">112171000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1149-wk-Fact-784B2FE4B31B54D096D5C1D44FEFEEE9"
      unitRef="usd">228244000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1168-wk-Fact-BAC1BB30082E5BB1B9C76994478F8138"
      unitRef="usd">206366000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1187-wk-Fact-6697E4555C09B0013FDF8081811F263F"
      unitRef="usd">159330000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1208-wk-Fact-2D64406621085CDC827DC2DA778583FB"
      unitRef="usd">598305000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1227-wk-Fact-7056E357290E57389071B3E743BA921A"
      unitRef="usd">414971000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1246-wk-Fact-9F984EA7A0B9A9E4989F8081817AD892"
      unitRef="usd">286567000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1268-wk-Fact-3F2B79B0CC1D5FA188BC6E33D50AB9AE"
      unitRef="usd">369470000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1287-wk-Fact-5B3D28F81C785A79A715D8E45C4FA39B"
      unitRef="usd">438855000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1306-wk-Fact-D70EE074410197C7DAC980818151CC04"
      unitRef="usd">165910000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1389-wk-Fact-53A836BED72C528DB072B25D6E8889F2"
      unitRef="usd">27959000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1408-wk-Fact-5BB32A3D90915F69AE2F2D6D7FDCD9A8"
      unitRef="usd">12840000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1427-wk-Fact-13E74E2B2E9F192F5A4E80818101B9DE"
      unitRef="usd">4883000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1448-wk-Fact-2ED9D14F2CD4D20D188D8081817FB99A"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1467-wk-Fact-5D8BB5BB5564F71E07247F5F58A7B15F"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1486-wk-Fact-41BBAA8DF3EC2A314B508081818C6EAA"
      unitRef="usd">8679000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1508-wk-Fact-910A93B486C35DF6B02FD51EA29BD47D"
      unitRef="usd">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1527-wk-Fact-EE08081B886B5B84A65E566CD74C8ED7"
      unitRef="usd">397000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1546-wk-Fact-A0E7CA397EF3B3024623808180884D69"
      unitRef="usd">-3537000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1568-wk-Fact-4452EFB785385D50ABAF96807AD660CD"
      unitRef="usd">28639000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1587-wk-Fact-A153FAD49F845CC9ABB1BF2FFE28AC74"
      unitRef="usd">13237000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1606-wk-Fact-91317C673617118CCBB980818175C997"
      unitRef="usd">-7333000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1628-wk-Fact-616E253E4D8E54C3A09FE281797CD78A"
      unitRef="usd">398109000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1647-wk-Fact-BFE76473261F5B13990FFB3AB221F6D4"
      unitRef="usd">452092000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1666-wk-Fact-E1D2F2A315327807E3CD8081809F24D4"
      unitRef="usd">158577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1687-wk-Fact-A6ED704EA7B65523846BE5FA5DBBDFF4"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1706-wk-Fact-695D932D76AF546FABA1D6C1D58ED92B"
      unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1726-wk-Fact-CE414B47BA63BD330D71808181883018"
      unitRef="usd">4350000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e1752-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e1771-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e1790-wk-Fact-E80041C5117CF9436D1F808180B39357"
      unitRef="usd">154227000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21820265e1873-wk-Fact-12C145AC98863A3F72ABC6FA4E0C3BE4"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="2"
      id="d21820265e1892-wk-Fact-EA9446E76D075BD783CEC9BEBC095B38"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2017Q4FYYTD"
      decimals="2"
      id="d21820265e1911-wk-Fact-84EB6CDF1C972769524580818133BECA"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21820265e1933-wk-Fact-F5CBF3AE37B8593EBE8CE93947271519"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="2"
      id="d21820265e1952-wk-Fact-60A5C0148F765C9CA5BA78B57AD421FA"
      unitRef="usdPerShare">2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2017Q4FYYTD"
      decimals="2"
      id="d21820265e1971-wk-Fact-3B2E1870498EDA767BC880818115346E"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e2049-wk-Fact-7461894293B55C43BC5671A110CD9A60"
      unitRef="shares">302584000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e2068-wk-Fact-137F5557559754A18B5EA37F1C0ACE01"
      unitRef="shares">297892000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e2087-wk-Fact-028CF4F8A4C6E2035E538081813C15B1"
      unitRef="shares">293588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21820265e2108-wk-Fact-93632B71149D5780817A0E4932B6C1EF"
      unitRef="shares">315009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21820265e2127-wk-Fact-C80150103651525CB70CC7179CB64C23"
      unitRef="shares">312803000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21820265e2146-wk-Fact-300AAABA667196BEB2DA80818183D621"
      unitRef="shares">312003000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21817750e743-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21817750e762-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21817750e781-wk-Fact-E80041C5117CF9436D1F808180B39357"
      unitRef="usd">154227000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21817750e859-wk-Fact-AE2B77916A755C0F8F475B42CAC7F126"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21817750e878-wk-Fact-3701756D22D5546588A2CBACF00D4047"
      unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21817750e898-wk-Fact-242C8D48DCB59D59E79B7F5F589BC39D"
      unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21817750e924-wk-Fact-02A6ED58DDE65DB39CB4A4744E6A77DA"
      unitRef="usd">324782000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21817750e943-wk-Fact-3E5C84553FEE59D4B126EF148880DC79"
      unitRef="usd">689716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21817750e962-wk-Fact-471000BA413A976DAE817F5F58AAD187"
      unitRef="usd">154296000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e854-wk-Fact-03964438CC5225AB7D7680828A5CF00D"
      unitRef="shares">289924000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e873-wk-Fact-0FC0B4B36A2DB76BB96580828A447C48"
      unitRef="usd">290000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e892-wk-Fact-41ABFCB4D061CF669B9480828A7438EC"
      unitRef="usd">2072591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e912-wk-Fact-98C15F9A28D1E1905F7B80828A53105D"
      unitRef="usd">-416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e932-wk-Fact-47DBD9900D367B043D0780828A8A3719"
      unitRef="usd">-1983147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2016Q4Dec30"
      decimals="-3"
      id="d21830731e952-wk-Fact-5936E5F4FC1658AA92B893E629614859"
      unitRef="usd">89318000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e1003-wk-Fact-17D3E5EE2F71576AAD5D63C33D5A34CD"
      unitRef="usd">252000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e1042-wk-Fact-BD7AD95B938662DEDD2780828A494FD5"
      unitRef="usd">-252000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member"
      decimals="-3"
      id="d21830731e1062-wk-Fact-573CC49EC51F513C83014C5FFBB4C2F2"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:NetIncomeLoss
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e1155-wk-Fact-06EA5F1553B0B04026B380828A6AA388"
      unitRef="usd">154227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21830731e1174-wk-Fact-E80041C5117CF9436D1F808180B39357"
      unitRef="usd">154227000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e1248-wk-Fact-7C52942A664A5B6FBD34C0008D5BDCAE"
      unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21830731e1286-wk-Fact-6C35411F83FF6358364B80828A81D8F9"
      unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e1307-wk-Fact-04346507133654A3B31ACB0E3B80F8DA"
      unitRef="shares">5408000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e1321-wk-Fact-CFF4DE354EEAE470B1AE80828A58FADD"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e1340-wk-Fact-44FF1D1106AD5A05ABAEF60ECCC131C5"
      unitRef="usd">17404000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21830731e1398-wk-Fact-6F0A70019E06E04E9BCD80828A6141D0"
      unitRef="usd">17409000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e1419-wk-Fact-16EFADAA35BC307A392580828A861AEA"
      unitRef="shares">877000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e1433-wk-Fact-7A3BCE09A572C3F2A6A980828A4EE00B"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e1452-wk-Fact-84B8AA23EECD5C5489E13A7674671B2D"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21830731e1511-wk-Fact-44234866B58D8E06605A80828A6FFB26"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e1565-wk-Fact-52162D1982852C081D1080828A7C5D52"
      unitRef="usd">23938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21830731e1623-wk-Fact-A854E6005C0E50038B27025A5E5BF2A1"
      unitRef="usd">23938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e1644-wk-Fact-EF989C541345851259337F5F58F4EC3D"
      unitRef="shares">296209000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e1658-wk-Fact-B7CAC12A9065703931C97F5F58E497E3"
      unitRef="usd">296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e1677-wk-Fact-893861F026D1137CFE627F5F5893CCA5"
      unitRef="usd">2114184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e1697-wk-Fact-5006B6727FD71A0B5ED57F5F5875CF7B"
      unitRef="usd">-347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e1717-wk-Fact-AA9C531FA0FDDD895F4F7F5F58EEF297"
      unitRef="usd">-1829172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21830731e1737-wk-Fact-67F4B655185867246EA47F5F58E256A0"
      unitRef="usd">284961000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e1832-wk-Fact-48EB05A77F1799D158477F5F58EA521F"
      unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d21830731e1851-wk-Fact-D68B5BBBF42D47004A657F5F589550DE"
      unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e1947-wk-Fact-3AC3C47FA2D13473E3A97F5F58B63ED6"
      unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d21830731e1966-wk-Fact-1532FC0E326011CAA1C87F5F58BA39D8"
      unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e2059-wk-Fact-3FC748A8E2E6058DAD3780828A7896CE"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21830731e2078-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e2152-wk-Fact-1A9A06CB32BB84D1EED17F5F58BA4590"
      unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21830731e2191-wk-Fact-14CDE59B39E7963358847F5F58E5A6F6"
      unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2213-wk-Fact-B6DEC927BADC96169F777F5F58F24826"
      unitRef="shares">3667000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2227-wk-Fact-1EFCAAC00989B5138F807F5F58B7E0BA"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e2246-wk-Fact-BFE00EF81AE572FF1C6E7F5F58E52096"
      unitRef="usd">13407000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21830731e2304-wk-Fact-A4FC46B4EE4239162C3C7F5F58EED1A0"
      unitRef="usd">13411000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e2358-wk-Fact-58A947585B69E87C58307F5F587361A5"
      unitRef="usd">40626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21830731e2416-wk-Fact-02357CF1D3E6A8FEFB5B7F5F58B516BF"
      unitRef="usd">40626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2437-wk-Fact-FEF261F5AAA25863A481C06F58D05F8B"
      unitRef="shares">299876000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2451-wk-Fact-4F4652DC0E1955C7A59A68B7D9B3C5BA"
      unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e2470-wk-Fact-81F7FB2B55CB59F091B9EBFA35E749E0"
      unitRef="usd">2168217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e2490-wk-Fact-70C422CB6D6759DFA1FC990F6BB44C8B"
      unitRef="usd">-701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e2510-wk-Fact-A2C437E660815E6CA08376EAAAE487E9"
      unitRef="usd">-880363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21830731e2530-wk-Fact-FD5022E3207A55678B8FFBD54FCA8596"
      unitRef="usd">1287453000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e2623-wk-Fact-4EEEDAA26C375371A01AFB0FE7DFDFC3"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21830731e2642-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e2716-wk-Fact-3D938B8F5779553889529902AB4B9EB1"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21830731e2754-wk-Fact-7BFC0F4F95B4580D91C65F187EC3A99A"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2775-wk-Fact-5ABF0BEF40985BBEBEA664D62E572174"
      unitRef="shares">4955000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2789-wk-Fact-0CF20638F1CA5DEA91E20C023F9BB067"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e2808-wk-Fact-00D770AD6F59576DBABF30BA8CF788A3"
      unitRef="usd">17128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21830731e2866-wk-Fact-A8C0889326025B0AAD2E41B15F12EEC6"
      unitRef="usd">17133000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e2920-wk-Fact-1654824D40F256FDB56858716E490E71"
      unitRef="usd">56602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21830731e2978-wk-Fact-D113E27F86445565B1AA898183E7A2B4"
      unitRef="usd">56602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e2999-wk-Fact-A13C94919B1254E79909D3E99179218D"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d21830731e3018-wk-Fact-15B01E5198585F1F8DC01F06BB972F95"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d21830731e3037-wk-Fact-8A3B549EEB075710A215756241B12968"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d21830731e3057-wk-Fact-A3DC0D361B9D5F9CADFC940623E4DDA0"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d21830731e3076-wk-Fact-08CFCFFA7767595DAB5963F536AB29BC"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21830731e3096-wk-Fact-7DEB41AA80AF5179814C8D33FE9E1430"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e738-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e757-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e776-wk-Fact-E80041C5117CF9436D1F808180B39357"
      unitRef="usd">154227000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e854-wk-Fact-CBB93137BFF058C5B46ED927BB1365FC"
      unitRef="usd">8348000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e873-wk-Fact-A045E3A875285182B2505762849AFC5D"
      unitRef="usd">4915000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e892-wk-Fact-E102CD6D09C6B587B25D8082F0198EF3"
      unitRef="usd">1187000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e913-wk-Fact-2F8E5FE3A2A35710B814FE73EBE1AEFA"
      unitRef="usd">56602000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e932-wk-Fact-3EBD0795DD1F54CAABDBB14D5BB00CBF"
      unitRef="usd">40626000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e951-wk-Fact-6F72F8CB119ABAC245E98082F127EE30"
      unitRef="usd">23938000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e972-wk-Fact-16463F703A255520816542DC7825E948"
      unitRef="usd">2819000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e991-wk-Fact-38F9D40EBEC455D0B658B2407EA59153"
      unitRef="usd">2854000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1010-wk-Fact-B92A5503F586535CB7F43381563A82C1"
      unitRef="usd">0</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1031-wk-Fact-03098947D4EA576D92AE93C28A14A970"
      unitRef="usd">-71002000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1050-wk-Fact-161E237592F35BFE8815313E58A93B30"
      unitRef="usd">244111000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1070-wk-Fact-8B33D0A86CF1424587157F5F58C19E58"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1091-wk-Fact-A193A903FF6A537FAB9439BC1BF82E94"
      unitRef="usd">-88000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1110-wk-Fact-52087E1851375624AAE23B330B0CF7CE"
      unitRef="usd">-1129000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1129-wk-Fact-0E9AD3A767FC5BE6DF828082F112FBA7"
      unitRef="usd">6795000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1213-wk-Fact-0EE14D557F485D2A872B66281DAB3054"
      unitRef="usd">-43716000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1232-wk-Fact-94FAF0DE24BB526EB47576E5A1911A48"
      unitRef="usd">85471000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1252-wk-Fact-87463119A27AFEA9211C8082F0EBBADA"
      unitRef="usd">43299000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1275-wk-Fact-4E1E392ECAF152E08DCB7BD718D18F56"
      unitRef="usd">5731000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1295-wk-Fact-2D43ACAD1E0654FFBEA0F4545E9706C5"
      unitRef="usd">3181000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1315-wk-Fact-49CF06097E308FE04C4B8082F08F66A9"
      unitRef="usd">3319000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1337-wk-Fact-00659E5350645D9BA259E0297B28AF70"
      unitRef="usd">5723000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1357-wk-Fact-8A2179439CC750C5BED204F3B065E4AB"
      unitRef="usd">8525000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1377-wk-Fact-8741950673279B92A529C772AB6A90B4"
      unitRef="usd">378000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1399-wk-Fact-0ED86C7C0CB15065B4292DC848C97010"
      unitRef="usd">-9301000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1419-wk-Fact-C26E4280D04D50DB8D43E3DBF1583A21"
      unitRef="usd">271000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1438-wk-Fact-5C3DA2E5B663A5F823768082F10D4EBC"
      unitRef="usd">13745000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1459-wk-Fact-B054DACE0B4153C78B61AD95DB52DE25"
      unitRef="usd">44124000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1478-wk-Fact-B76A2B1773BA5CB38E5D6DC191BAB998"
      unitRef="usd">17143000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1497-wk-Fact-9E4454CE209170903CAB8082F0F93265"
      unitRef="usd">26305000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1518-wk-Fact-01DC973052F050E29ADD745D3DC413E7"
      unitRef="usd">526956000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1537-wk-Fact-7E77D8F2B35E554B9D83EE2FB58B0F64"
      unitRef="usd">415720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1556-wk-Fact-6A66E5E1BDF1053E5A858082F12C5179"
      unitRef="usd">165611000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1639-wk-Fact-746DF29524615DD8A527C7FDC77A7FCB"
      unitRef="usd">12834000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1659-wk-Fact-1D15AE718DB85967978BD9564F0ACFE0"
      unitRef="usd">33297000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1679-wk-Fact-69531239A5FCEB57284C8082F08A20F0"
      unitRef="usd">21143000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1701-wk-Fact-97766E49C8565668ABCAA24A363A5566"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1720-wk-Fact-4E620B7D3F995AA1B24E8D836984F341"
      unitRef="usd">308000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1739-wk-Fact-4FA53B718E905F9E9D78C9749398ACB8"
      unitRef="usd">164000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1760-wk-Fact-9ABA46333B7C58D4B519918E2DDBE46A"
      unitRef="usd">1182682000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1780-wk-Fact-AC8EC16F476F573AA5761251919DAFAD"
      unitRef="usd">557832000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1800-wk-Fact-553DD48C9B83960F92288082F0E64B33"
      unitRef="usd">319090000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1822-wk-Fact-705D3FA2055150408C807D496E75C58D"
      unitRef="usd">608269000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1841-wk-Fact-0ECF7EC449E15469BFFA5C4B5BA5338E"
      unitRef="usd">292971000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1860-wk-Fact-673257536762DA960C948082F07C5C42"
      unitRef="usd">376864000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e1881-wk-Fact-879031053CDC5CB093B32EC31D225700"
      unitRef="usd">-587247000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e1901-wk-Fact-2FF4BB9907975CF9A49D6FA05D3B615A"
      unitRef="usd">-297850000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e1921-wk-Fact-004DD11577F034611E0B8082EFE67B0D"
      unitRef="usd">36795000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2005-wk-Fact-1D6DADFF9F5D50248E52745239EC4737"
      unitRef="usd">22499000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2024-wk-Fact-91934467BDE4572C9BA0790888377921"
      unitRef="usd">17278000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2043-wk-Fact-95635F5DBD17B5146E458082F0F582CB"
      unitRef="usd">22423000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2064-wk-Fact-F39ADB4C74E957D192E7B74892AA0D19"
      unitRef="usd">9904000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2084-wk-Fact-04CBCA7DBD61547BBA922A289432C5D9"
      unitRef="usd">7574000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2104-wk-Fact-391BC6D8F378AD478DC98082F108D463"
      unitRef="usd">6563000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2126-wk-Fact-1D30D0B7F6BC664457D38082EECF1B90"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2145-wk-Fact-D1E8CA568C11F5D141F78082F11DFE9D"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2164-wk-Fact-7CED84AA12E87FAD9DA98082F123AC5F"
      unitRef="usd">185788000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2186-wk-Fact-5B930ECCA0A052A3B650C2809BFCC84B"
      unitRef="usd">-42000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2206-wk-Fact-D307B0080E9D5568B84BEFF6F107A2B0"
      unitRef="usd">-13000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2226-wk-Fact-53E33624C7E15F7DB6C38CFD467E020F"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2247-wk-Fact-777CFA099F1251FA8DA4ADD0750C56CE"
      unitRef="usd">12553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2266-wk-Fact-233450AEDFCA587B96CEDB7FBFDE14C3"
      unitRef="usd">9691000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2285-wk-Fact-3ECCFFE6EFAB974FD7478082EE9AEBD1"
      unitRef="usd">-169928000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2307-wk-Fact-A0EA2426ECEA50D58678C0EC15482FDE"
      unitRef="usd">-47738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2327-wk-Fact-920496F7986759B0A6A5E0DD8CC4B6B8"
      unitRef="usd">127561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2346-wk-Fact-6D11D0DC88F57988836D8082EFB75E2C"
      unitRef="usd">32478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21825214e2367-wk-Fact-BC0F0D36AF675667BF547125A5FB8F75"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21825214e2386-wk-Fact-319AEF2EF68A57B39FDD8082EF0DA57F"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2016Q4Dec30"
      decimals="-3"
      id="d21825214e2405-wk-Fact-DA13427317AEC223B1F88082EED8C5C9"
      unitRef="usd">155836000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21825214e2431-wk-Fact-AA9D8EEC2AAD55929D4FD5EAA16D1EA6"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21825214e2450-wk-Fact-BC0F0D36AF675667BF547125A5FB8F75"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21825214e2469-wk-Fact-319AEF2EF68A57B39FDD8082EF0DA57F"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2552-wk-Fact-2BCB77589C3037632D027F5F587E2D06"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2571-wk-Fact-3EFFFE115B14D57DDC3A7F5F5878D200"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2590-wk-Fact-CEF92979FF0B0801B2357F5F58B8F2BA"
      unitRef="usd">20460000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2612-wk-Fact-9F5917EC7027897EDFE07F5F58D2FAD0"
      unitRef="usd">7873000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2631-wk-Fact-D061086177A2FCCB36F77F5F587B0201"
      unitRef="usd">10677000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2650-wk-Fact-5886CEBBCD9E7CD4FD087F5F58CA3942"
      unitRef="usd">538000</us-gaap:IncomeTaxesPaidNet>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2733-wk-Fact-55729A4B2E95530FB3F11ADE765F241A"
      unitRef="usd">29562000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2747-wk-Fact-5E9FCA99A77C51B79E5C2E92F4745F4F"
      unitRef="usd">17180000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2792-wk-Fact-25C5F024E3720EC11B767F5F58C942D0"
      unitRef="usd">0</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
    <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2811-wk-Fact-31D5D2038702FAF2EA617F5F58CE3DF0"
      unitRef="usd">0</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
    <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2830-wk-Fact-6C96FF8455C00DFA78E27F5F58CC6679"
      unitRef="usd">14530000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21825214e2851-wk-Fact-7C027E41A7245F51BE9747CFA7033B8E"
      unitRef="usd">26000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21825214e2870-wk-Fact-47F23E04E5D357B7979B60CD5C07E869"
      unitRef="usd">802000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21825214e2889-wk-Fact-8CB558643F42B95B8A957F5F58D219F0"
      unitRef="usd">524000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EFEA375BD5DC3078D77A7F5F59035312-0-wk-Fact-6F7A6C2E08C0046EFF637F5F58DC6080">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Since we were founded in 1994, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;Two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The other &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have made&#160;reclassifications&#160;to our prior years&#x2019; Consolidated Balance Sheet and Consolidated Statements of Cash Flows to conform to the current year&#x2019;s presentation. These&#160;reclassifications&#160;had no effect on total current assets, total assets, total operating cash flows, total investing cash flows or total financing cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the third quarter of 2019, we adopted ASU No.&#160;2018-15,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15 requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 requires capitalized implementation costs to be expensed over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted ASU 2018-15 using the prospective transition method in the accompanying Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the first quarter of 2019, we adopted ASU 2018-02, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income (loss) to accumulated deficit. In connection with the adoption of ASU 2018-02, we adopted the individual unit of account approach for releasing income tax effects from accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the first quarter of 2019, we also adopted ASU 2017-08, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Receivables&#x2014;Nonrefundable Fees and Other Costs (Subtopic 310-20)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-08). ASU 2017-08 shortens the amortization period for certain callable debt securities held at a premium. Specifically, ASU 2017-08 requires the premium to be amortized to the earliest call date. ASU 2017-08 does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The adoption of ASU 2017-08 did not have a material impact on our Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income (expense), net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of restricted cash &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;equivalents as short-term or long-term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;dependent upon the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;longer of the remaining term to maturity of the investment or the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;remaining term of the related restriction&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We subject all of our investments to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record trade accounts receivable net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;have been insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We periodically review the carrying amount of goodwill for impairment (at least annually) and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. Historically, we assessed the recoverability of our goodwill on the last day of our third quarter. Beginning in 2019, we changed the date of our annual goodwill impairment assessment to the first day of our fourth quarter to allow for operational expediency. The change in goodwill impairment testing date does not represent a significant change to our accounting for goodwill&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#x2019;s goodwill exceeds its fair value. We continue to operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We assess whether our collaboration agreements are subject to ASC 808:&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we assess whether the payments between us and our collaboration partner are subject to other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Topic 606. However, if we conclude that our collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, we present such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Results for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 606, while results for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; have not been adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, ASC Topic 605: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 605). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: 1) identify the contract(s) with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations in the contract; and 5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Customers in the U.S. receive a discount of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect our Customers will earn &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2018 and 2017, the&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. This amount increased to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in 2019. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. Except for profit sharing arrangements, payments for product supply services &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and certain development cost reimbursements, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;each of these payment types were within the scope of Topic 606 during the years ended December 31, 2019 and 2018. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When such services are provided to a customer, and they are &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenue for these services as the performance obligations are satisfied over time. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit Sharing Arrangements: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We account for such arrangements in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the years ending December 31, 2019 and 2018 and accordingly, those profits are recognized as collaboration revenues in the accompanying Consolidated Statements of Income. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as selling, general and administrative expenses in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenue at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cost of goods sold is related to our product revenues and consists primarily of a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018 and 2017 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. There were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; amounts remaining related to previously expensed materials in our inventory balances as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred and primarily include: (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees, funded research and milestone payments incurred for our in-licensing arrangements with our collaboration partners; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;becomes more certain. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Development, regulatory or commercial milestone payments to collaboration partners are recorded as research and development costs when we determine such payments become probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the weighted average discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;not to apply the recognition requirements of Topic 842 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Advertising expenses were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$17.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in sales, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;awards, performance-based restricted&#160;stock&#160;awards (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense relating to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income tax provision or benefit is computed under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. Some of these estimates are based on interpretations of existing tax laws or regulations. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#x201c;Note 9. Income Taxes&#x201d;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;based on the technical merits of the position&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income (expense), net in the accompanying Consolidated Statements of Income. Net foreign currency translational gains and losses were not material for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the FASB issued ASU No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for us in the first quarter of 2020. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2016-13 on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember"
      decimals="INF"
      id="d21838977e604-wk-Fact-E0ACB00ADB905ADF89A407B02438609E"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember"
      decimals="INF"
      id="d21838977e608-wk-Fact-58798682438F5472937903F5F1B56A9A"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember"
      decimals="INF"
      id="d21838977e615-wk-Fact-B2EF6F90299B53DD95D8BAE4906BFBC4"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-07E0EF91E1F6F571BBB47F5F59023DAB-0-wk-Fact-0DB20DFDA682512005277F5F58E7DC40">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="FD2019Q4YTD"
      id="TextSelection-F9F4C8E9E954A4739604C79DAE44FE0A-0-wk-Fact-70926E236FB88F3A25D1C79DBF40F761">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively. &lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B18F562178056E41C2AA7F5F59033AD9-0-wk-Fact-774EB9A196C24A8E7BF07F5F58D638F6">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d21838977e689-wk-Fact-095EA62E18C05DF3A2EF14C98D72AA72"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q4YTD"
      id="TextSelection-9900F537435BDD40B2037F5F59024120-0-wk-Fact-826E4A5BAF87B026D86A7F5F58D4423C">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BDC562907B8AB4AA94D27F5F590321A8-0-wk-Fact-F61FD848C374A47BA0EB7F5F58D8FC2B">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-56E800DFBF7DB55DE1627F5F5903FB1B-0-wk-Fact-06BAEFB6FEF6953078E87F5F58DE2ED9">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income (expense), net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of restricted cash &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;equivalents as short-term or long-term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;dependent upon the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;longer of the remaining term to maturity of the investment or the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;remaining term of the related restriction&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We subject all of our investments to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-E5BA175991FF8B4BBFA07F5F5904B98A-0-wk-Fact-F6958BFB22050CD1B2467F5F58D7A7C7">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-AC8E6800E82600EF6A007F5F590357BF-0-wk-Fact-C13A2C65DE12F3FA71457F5F58E59711">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record trade accounts receivable net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;have been insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C0075EB88549647F62AB7F5F5903A2BF-0-wk-Fact-C9D3B3B9FB70652FE04F7F5F58D7548F">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4ED1BB439AB07F1F91E57F5F590316DC-0-wk-Fact-59752FE75C789826B85A7F5F58DD1506">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d21838977e967-wk-Fact-C24A06EDEE5ADC6A9513C7B5F1493755">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-26360DFBC17FC0368B1A7F5F59027B6B-0-wk-Fact-40F54E63476169E027AE7F5F58EB2D2A">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We periodically review the carrying amount of goodwill for impairment (at least annually) and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. Historically, we assessed the recoverability of our goodwill on the last day of our third quarter. Beginning in 2019, we changed the date of our annual goodwill impairment assessment to the first day of our fourth quarter to allow for operational expediency. The change in goodwill impairment testing date does not represent a significant change to our accounting for goodwill&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#x2019;s goodwill exceeds its fair value. We continue to operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt; segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. </us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d21838977e1006-wk-Fact-095EA62E18C05DF3A2EF14C98D72AA72"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d21838977e1015-wk-Fact-1A7B6F291FEB7E8D26447F5F58D43979"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-5D8AC70AA6428D4B83C7C7A346A573DD-0-wk-Fact-2EC37FE16E359D35A0B3C7A35EE820E6">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We assess whether our collaboration agreements are subject to ASC 808:&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we assess whether the payments between us and our collaboration partner are subject to other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Topic 606. However, if we conclude that our collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, we present such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-939CDF545285764A60557F5F59045E02-0-wk-Fact-5C393154C2D8DFA8EFE07F5F58D31798">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Results for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 606, while results for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; have not been adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, ASC Topic 605: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 605). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: 1) identify the contract(s) with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations in the contract; and 5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Customers in the U.S. receive a discount of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect our Customers will earn &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2018 and 2017, the&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. This amount increased to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in 2019. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. Except for profit sharing arrangements, payments for product supply services &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and certain development cost reimbursements, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;each of these payment types were within the scope of Topic 606 during the years ended December 31, 2019 and 2018. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When such services are provided to a customer, and they are &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenue for these services as the performance obligations are satisfied over time. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit Sharing Arrangements: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We account for such arrangements in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the years ending December 31, 2019 and 2018 and accordingly, those profits are recognized as collaboration revenues in the accompanying Consolidated Statements of Income. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as selling, general and administrative expenses in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenue at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cost of goods sold is related to our product revenues and consists primarily of a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.&lt;/span&gt;&lt;/div&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018 and 2017 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <exel:SalesRevenuePercentDiscountForPromptPayment
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21838977e1114-wk-Fact-4891D806CBB8EB6D64CDC7B9BC1311D8"
      unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
    <exel:SalesRevenueDiscountExpectedtobeEarnedPercent
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d21838977e1118-wk-Fact-060EE705DA5B08DD8083C7BA0F513859"
      unitRef="number">1</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
    <exel:MedicarePartDFundingMandate
      contextRef="FD2018Q1YTD"
      decimals="2"
      id="d21838977e1137-wk-Fact-E104C79D72AB1D4183B4CAE4EBA5E969"
      unitRef="number">0.50</exel:MedicarePartDFundingMandate>
    <exel:MedicarePartDFundingMandate
      contextRef="FD2019Q1YTD"
      decimals="2"
      id="d21838977e1141-wk-Fact-3DD21DEA0A363AB75C9DCAE4EB86F7E4"
      unitRef="number">0.70</exel:MedicarePartDFundingMandate>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember"
      decimals="2"
      id="d21838977e1229-wk-Fact-6343E204966B553191B4C5CBC9BD292F"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <exel:InventoryManufacturedBeforeRegulatoryApproval
      contextRef="FI2019Q4"
      decimals="INF"
      id="d21838977e1244-wk-Fact-9F9597670F9DA80231367F5F58D66C69"
      unitRef="usd">0</exel:InventoryManufacturedBeforeRegulatoryApproval>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-C1BECA0F02EC07FED0357F5F59033A00-0-wk-Fact-477C31C7DB46E3812A597F5F58D44C44">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred and primarily include: (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees, funded research and milestone payments incurred for our in-licensing arrangements with our collaboration partners; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;becomes more certain. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Development, regulatory or commercial milestone payments to collaboration partners are recorded as research and development costs when we determine such payments become probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6BC819E495CDBBB27AF07F5F59059CC4-0-wk-Fact-3C3A9AC0CD24CCFEB0927F5F58DF3637">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the weighted average discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;not to apply the recognition requirements of Topic 842 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for short-term leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CCCA6B320D9CD01972B8C7A880882650-0-wk-Fact-E9760719D41469817283C7A895E2C19B">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Advertising expenses were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$17.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in sales, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21838977e1352-wk-Fact-3CA7547097CD0119CB72CAE9BDCDC8D0"
      unitRef="usd">17900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-5"
      id="d21838977e1356-wk-Fact-FD6934BDAEE6D20B7C4ACAE9BD383327"
      unitRef="usd">14800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="D2017Q4FYYTD"
      decimals="-5"
      id="d21838977e1360-wk-Fact-33FD815F991301881B59CAE9BDA10665"
      unitRef="usd">8600000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-5033F19587894EB70DC27F5F5903A1D0-0-wk-Fact-1D6CECD6690A173D3D287F5F58949454">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;awards, performance-based restricted&#160;stock&#160;awards (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense relating to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. &lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4B4FB77D323C835AA2F47F5F5904AA42-0-wk-Fact-158C6E35ABD25C4C72DF7F5F58D487D4">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income tax provision or benefit is computed under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. Some of these estimates are based on interpretations of existing tax laws or regulations. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#x201c;Note 9. Income Taxes&#x201d;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;based on the technical merits of the position&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-57E0CBE0C8658CE2476F7F5F59029429-0-wk-Fact-74669ACFBC60987A1FC77F5F58D923A9">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Remeasurement&lt;/span&gt;&lt;/div&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income (expense), net in the accompanying Consolidated Statements of Income. </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E0DE585E08050FE332897F5F5904CCC1-0-wk-Fact-3F7435EAEBD7C408C2D77F5F58D7817D">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the FASB issued ASU No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for us in the first quarter of 2020. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2016-13 on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the third quarter of 2019, we adopted ASU No.&#160;2018-15,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15 requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 requires capitalized implementation costs to be expensed over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted ASU 2018-15 using the prospective transition method in the accompanying Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the first quarter of 2019, we adopted ASU 2018-02, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income (loss) to accumulated deficit. In connection with the adoption of ASU 2018-02, we adopted the individual unit of account approach for releasing income tax effects from accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the first quarter of 2019, we also adopted ASU 2017-08, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Receivables&#x2014;Nonrefundable Fees and Other Costs (Subtopic 310-20)&lt;/span&gt; (ASU 2017-08). ASU 2017-08 shortens the amortization period for certain callable debt securities held at a premium. Specifically, ASU 2017-08 requires the premium to be amortized to the earliest call date. ASU 2017-08 does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8A2B31F9F6B36D2406997F5F59054F1F-0-wk-Fact-B533D5DCF0424E53F07C7F5F58AAC1C5">REVENUES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;957,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;738,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;402,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(197,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(119,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(53,561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759,950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;619,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;349,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;161,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;192,188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development service revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,737&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234,547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;103,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;967,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;853,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;452,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, license revenues and research and development services revenues were recorded in accordance with Topic 606 during the years ended December&#160;31, 2019 and 2018 and Topic 605 during the year ended December&#160;31, 2017. During the periods presented in accordance with Topic 606, net product revenues and license revenues related to goods and intellectual property licenses transferred at a point in time and research and development services revenues related to services performed over time. License revenues includes the recognition of the portion of upfront payment milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues. Research and development services revenues includes the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned under our collaboration agreements. Other collaboration revenues were recorded in accordance with Topic 808 for all periods presented and includes product supply revenues, net of product supply costs and the royalties we paid to GSK on sales by Ipsen Pharma SAS (Ipsen) of products containing cabozantinib. Profits on the U.S. commercialization of COTELLIC for the years ended December 31, 2019 and 2018 were also included other collaboration revenues, and losses on the U.S. commercialization of COTELLIC for the year ended December&#160;31, 2017 were included in selling, general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;733,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;599,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;324,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759,950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;619,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;349,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;770,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;632,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;367,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,771&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69,792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;967,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;853,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;452,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic regions based on the ship-to location. Collaboration revenues are attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,493&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(74,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11,980&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(111,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;129,936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(128,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(15,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(44,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(188,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reserves for chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Contract assets were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, and are presented in p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;repaid expenses and other current assets in the accompanying Consolidated Balance Statements. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Contract liabilities were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$15.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, and are presented in l&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ong-term portion of deferred revenue in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For those contracts that have multiple performance obligations, c&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ontract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Significant changes in contract assets during the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, were a result of the determination that it is probable that we will earn a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;milestone from Takeda Pharmaceutical Company Limited (Takeda) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for the submission of a regulatory application in 2020 for cabozantinib as a treatment for patients with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;second-line &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in Japan&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. This contract asset was recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;repaid expenses and other current assets in the accompanying Consolidated Balance Sheets&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, offset by the effect of reporting the Takeda contract asset and liability on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;years ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues that were included in the beginning deferred revenue balance for those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;years ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$161.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$198.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Daiichi Sankyo&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$63.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our performance obligations had not been satisfied. See &#x201c;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; f&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;or additional information about our performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CD0EBEFF4C381F8C80F77F5F5905030B-0-wk-Fact-97B9FF7E946B5598B02A7F5F58A773BE">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;957,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;738,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;402,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(197,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(119,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(53,561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759,950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;619,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;349,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;161,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;192,188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development service revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,737&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234,547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;103,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;967,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;853,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;452,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;733,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;599,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;324,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759,950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;619,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;349,008&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d21835141e800-wk-Fact-4F59989D3471533ABB86450C098F626A"
      unitRef="usd">957621000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d21835141e819-wk-Fact-23D22168B7BE5707BEA7CA7D12571BF6"
      unitRef="usd">738529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d21835141e838-wk-Fact-A0A9B9575857587A3BAE7F5F58A0480A"
      unitRef="usd">402569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d21835141e854-wk-Fact-ACA9732E8C6B5CBF91156F9C0044C1D9"
      unitRef="usd">-197671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d21835141e874-wk-Fact-C25957F6C9025DB5835AF81C01960D12"
      unitRef="usd">-119250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d21835141e894-wk-Fact-6EB41DF1447FAE6BDC517F5F589C60F3"
      unitRef="usd">-53561000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21835141e916-wk-Fact-4A7175F192395C85B0C7C6A02D7F643B"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21835141e935-wk-Fact-2EA1F50A74FDA1A9B2E4C6FA4DF7260C"
      unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21835141e954-wk-Fact-3D0827DEC1DB5BB5A4513DCDDE52D7D0"
      unitRef="usd">349008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember"
      decimals="-3"
      id="d21835141e1037-wk-Fact-FE956B8599155857A6114FF585369B41"
      unitRef="usd">161299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember"
      decimals="-3"
      id="d21835141e1056-wk-Fact-1109928D7F19534FADC09DAEAAC593F1"
      unitRef="usd">192188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationLicenseMember"
      decimals="-3"
      id="d21835141e1075-wk-Fact-A2E4D50363363389FEFD7F5F58A166E7"
      unitRef="usd">96637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember"
      decimals="-3"
      id="d21835141e1096-wk-Fact-BCDD36CF09EB5462ABCAA904B540B5E2"
      unitRef="usd">49965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember"
      decimals="-3"
      id="d21835141e1115-wk-Fact-479077F5A47A51B2B1A4B37E64FDF76D"
      unitRef="usd">39501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationResearchAndDevelopmentServiceMember"
      decimals="-3"
      id="d21835141e1134-wk-Fact-23EE9A6866AF820721907F5F58993B70"
      unitRef="usd">8737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember"
      decimals="-3"
      id="d21835141e1155-wk-Fact-3FA1DF303E885C6CA0B2AF029FEE6D95"
      unitRef="usd">-3439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationOtherMember"
      decimals="-3"
      id="d21835141e1175-wk-Fact-BFE8D4B9912D544BBD9122AF23417B36"
      unitRef="usd">2858000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationOtherMember"
      decimals="-3"
      id="d21835141e1194-wk-Fact-4450FC3A2A5E49C3A6A17F5F58D3A027"
      unitRef="usd">-1905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d21835141e1216-wk-Fact-9651ACAA83595E19B7AF718E8FD34546"
      unitRef="usd">207825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d21835141e1235-wk-Fact-669337DF6374573799CCB10DBFE5ECD5"
      unitRef="usd">234547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d21835141e1254-wk-Fact-670E8F350E5A6011B6F27F72B0634FD9"
      unitRef="usd">103469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21835141e1281-wk-Fact-C2F428FDC3B55296BD84486AB439D9DE"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21835141e1300-wk-Fact-D4F84C516D8153E6AABE4A9E657B33A0"
      unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21835141e1319-wk-Fact-A0BE00E5ACD05545886BD820391E213F"
      unitRef="usd">452477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d21835141e1492-wk-Fact-4F595FDEDF045109972560CF55C21E70"
      unitRef="usd">733421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d21835141e1511-wk-Fact-CC8BDB7FD30E52DB90BC5A6891CF13E7"
      unitRef="usd">599946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d21835141e1530-wk-Fact-F96A73E68C9E5B3AAB641BA2B021470D"
      unitRef="usd">324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d21835141e1546-wk-Fact-A3EABC3E14275F1389C68D9BEC5BD04E"
      unitRef="usd">26529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d21835141e1565-wk-Fact-64904BCCE13A5315994C6CB4B512D69A"
      unitRef="usd">19333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d21835141e1584-wk-Fact-E99F61A76994563A9205C3ACE2564980"
      unitRef="usd">25008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21835141e1610-wk-Fact-4A7175F192395C85B0C7C6A02D7F643B"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21835141e1629-wk-Fact-2EA1F50A74FDA1A9B2E4C6FA4DF7260C"
      unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d21835141e1648-wk-Fact-3D0827DEC1DB5BB5A4513DCDDE52D7D0"
      unitRef="usd">349008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D12CAA4D8B7E162983E56FC73A99DA62-0-wk-Fact-DEEBEFE7FA22B517E11B6FC7D83DCF6D">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1777-wk-Fact-A30FAEF91B6D5D84B2AAF2B3F72209A4"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1792-wk-Fact-995CACD7123A5280826DC39D0ED58953"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1807-wk-Fact-E9A7938FC02344D0C9B87F5F588E11FD"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1823-wk-Fact-1D2C997A9DAF56C190980D27F702B41D"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1838-wk-Fact-2068532DED695216A6D5337CD94E0C53"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1853-wk-Fact-6643E40C77670A2E9E217F5F5896D2B8"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1869-wk-Fact-C7991F2AD61A5F5A8F46ED4B70091A37"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1884-wk-Fact-9EF84FFDE5745805B69022E2977E0545"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1899-wk-Fact-317162C5DF8A0FED1DA27F5F5874CD00"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1915-wk-Fact-23134C30B9F75D92928A09A3F22684B9"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1930-wk-Fact-14D6266B8F6B53FFA97F11C742A20379"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1945-wk-Fact-159E4AFE74019F2F9424CB038F6682CC"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1961-wk-Fact-16A935504876ED10B5207F729F65E4C1"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1976-wk-Fact-AE138ABB375951AA4C147F729FAFA363"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e1991-wk-Fact-081075E47AF5DD36E3C57F5F5875D1BC"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e2007-wk-Fact-87F1F03A2CD1231354117F729FBD3505"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e2022-wk-Fact-1BEC71EA48CE25782D697F729FCAFF19"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d21835141e2037-wk-Fact-2F020BAF5B5243807AF77F5F589CF4A4"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-79A2E25CFC00842C18256FC85E92B1ED-0-wk-Fact-A95EED715AA5B76DF5656FC8F3076C16">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;770,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;632,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;367,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,771&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69,792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;967,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;853,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;452,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d21835141e2207-wk-Fact-CA4632403081540482E4F66C5F743F09"
      unitRef="usd">770244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d21835141e2226-wk-Fact-3BAA3DFB9AEF579DA608BFA2B0D06546"
      unitRef="usd">632927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d21835141e2245-wk-Fact-64BC7DE8C2245D41BEDBF002405C77E6"
      unitRef="usd">367906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d21835141e2261-wk-Fact-E5508A613E1858CDA446DD8F32F6A09C"
      unitRef="usd">152771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d21835141e2280-wk-Fact-1E036EA5BCBA50E0B0BC54D3E560094F"
      unitRef="usd">182879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d21835141e2299-wk-Fact-3DEC205E630C50BFA38B1C1D6480E9A2"
      unitRef="usd">69792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d21835141e2320-wk-Fact-26642089F58C5B71971ED9EA6E322BA3"
      unitRef="usd">44760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d21835141e2339-wk-Fact-CAF547AE876059D69490D3BB999737A6"
      unitRef="usd">38020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d21835141e2358-wk-Fact-DFD2EA5C27EC563994F18FE9EA384529"
      unitRef="usd">14779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21835141e2384-wk-Fact-C2F428FDC3B55296BD84486AB439D9DE"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21835141e2403-wk-Fact-D4F84C516D8153E6AABE4A9E657B33A0"
      unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21835141e2422-wk-Fact-A0BE00E5ACD05545886BD820391E213F"
      unitRef="usd">452477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D93F988C693E336C925C7F5F590525CB-0-wk-Fact-F470220664119BD5DC7D7F5F58A78DB0">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,493&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(74,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11,980&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(111,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;129,936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(128,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(15,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(44,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(188,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e2565-wk-Fact-750DD85EFB69ACB41C017F5F5873B6DD"
      unitRef="usd">1928000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e2584-wk-Fact-3EF2093CC92E1ECC21AA7F5F58EB0DBF"
      unitRef="usd">1795000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e2603-wk-Fact-B98EB675A5B0EBF0541F7F5F589D6087"
      unitRef="usd">5770000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21835141e2623-wk-Fact-1E15F5A0F6B059B797B07F5F58F0A8B9"
      unitRef="usd">9493000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e2720-wk-Fact-658241FBD071E0E736277F5F58D9DF01"
      unitRef="usd">75543000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e2739-wk-Fact-DBE32CA89BE11D3087307F5F58E99183"
      unitRef="usd">13017000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e2758-wk-Fact-220F7AEA2C3F98C2D4637F5F58D8D15A"
      unitRef="usd">31040000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21835141e2778-wk-Fact-B570CCDB8C3C88435F987F5F58EF0B21"
      unitRef="usd">119600000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e2798-wk-Fact-BE400B366C5749D087577F5F58D8F93C"
      unitRef="usd">-403000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e2818-wk-Fact-0A4BE49E6B9AC0CFAC517F5F58E8D2BA"
      unitRef="usd">206000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e2837-wk-Fact-E02E4A0F5F97C561F6747F5F58F3BE31"
      unitRef="usd">-153000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21835141e2858-wk-Fact-F7A5DF693D0922BAE70F7F5F58EC70A2"
      unitRef="usd">-350000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e2879-wk-Fact-30CDD321CCF5C7F8A9C67F5F58E7AEA1"
      unitRef="usd">74746000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e2899-wk-Fact-BEB1AA8B246338F774B37F5F58730D44"
      unitRef="usd">11980000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e2919-wk-Fact-CA85A5B49B2E1A00E84C7F5F58EEE78E"
      unitRef="usd">24741000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21835141e2940-wk-Fact-EFC74CFBED806FCE58AF7F5F58F299CA"
      unitRef="usd">111467000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e2961-wk-Fact-697FF98219825A60BB26107802BB886B"
      unitRef="usd">2322000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e2980-wk-Fact-C2B10D6DCAC357719F05BB404E98D91D"
      unitRef="usd">3038000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e2999-wk-Fact-7E1091581A485629B0ABDFFCDE4C13A4"
      unitRef="usd">11916000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21835141e3019-wk-Fact-0B708B0F537C5EF3AB116FD0D1BD433B"
      unitRef="usd">17276000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e3121-wk-Fact-D0E89577CDEC5BE696C4BCFAE5C12167"
      unitRef="usd">129936000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e3140-wk-Fact-BFB0763293F45ECEA640E15A93FF51A1"
      unitRef="usd">15605000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e3159-wk-Fact-7DF4E4C39A7058E29807AF1C71406A10"
      unitRef="usd">48250000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21835141e3179-wk-Fact-507425D706145BBE91E4B8A3911B45A2"
      unitRef="usd">193791000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e3199-wk-Fact-F49C152DC32D5013B6C552C7D90DD92A"
      unitRef="usd">3989000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e3218-wk-Fact-9CE119EB6F125B939D8B2D0A6EFD3776"
      unitRef="usd">-111000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e3238-wk-Fact-D959472D5396572BB6A12F2A1E835E78"
      unitRef="usd">2000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21835141e3258-wk-Fact-292283948F755057A8FAC3E0394E2B6A"
      unitRef="usd">3880000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e3278-wk-Fact-D6A3E249AC955F80B5196C8ED6B84F73"
      unitRef="usd">128733000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e3298-wk-Fact-CCB2128B5558530FA84781728FAA3714"
      unitRef="usd">15035000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e3318-wk-Fact-615475291AF35E1C8AFCE3A7645EC1DF"
      unitRef="usd">44946000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21835141e3339-wk-Fact-10F8A44795A45B03A7AB6654ED370862"
      unitRef="usd">188714000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d21835141e3366-wk-Fact-8AB243A9FC8353D28F51CAE1C2610795"
      unitRef="usd">7514000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d21835141e3385-wk-Fact-38FC51A37B3C5FA7AA4A553F73109107"
      unitRef="usd">3497000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d21835141e3404-wk-Fact-B68DE1B538155026939D262EFD3261E4"
      unitRef="usd">15222000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21835141e3424-wk-Fact-0C7F65E60021552199E0219D42B6F6CD"
      unitRef="usd">26233000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d21835141e3446-wk-Fact-F8A7F2F885E9376154D312111C2A88D2"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2018Q4"
      decimals="0"
      id="d21835141e3450-wk-Fact-6F27F5A2BF70AA9344F5121158428C9D"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d21835141e3480-wk-Fact-F65ECBBDAB778FACA3311210F76E83E2"
      unitRef="usd">6600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d21835141e3484-wk-Fact-0D15153F1BDBEFC6BF6FCB2318716B54"
      unitRef="usd">15900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21835141e3511-wk-Fact-9753642820A7A767B5BA12182CDBA12A"
      unitRef="usd">10000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21835141e3551-wk-Fact-AD733F880A3B57AD8AAD37EAA79EB552"
      unitRef="usd">6500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d21835141e3555-wk-Fact-FBC32EB1738E5C36831A5448B9B83E99"
      unitRef="usd">8700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21835141e3577-wk-Fact-21FF19539B965A6C8B0A65F514C7AFB4"
      unitRef="usd">161200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d21835141e3581-wk-Fact-7F6421F5657F54BFB591AD8AA7D108E6"
      unitRef="usd">198100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4"
      decimals="-5"
      id="d21835141e3597-wk-Fact-A3A5A4E1EB3B53E5736D121513D2685B"
      unitRef="usd">63100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A2798372CF7157A0A0347F5F59063F34-0-wk-Fact-94D308E00A187DAD26EB7F5F58982394">COLLABORATION AGREEMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech and Daiichi Sankyo for other compounds and programs in our portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit sharing payments. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 2. Revenues&#x201d; for information on the amount of collaboration revenues recognized during the years ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Commercial &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of 1) the expiration of patent claims related to cabozantinib, 2) the expiration of regulatory exclusivity covering cabozantinib or 3) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the U.S. Food and Drug Administration (FDA) or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#x2019;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Consideration under the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$210.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; from Ipsen in 2016. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have achieved aggregate milestones of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$330.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; related to regulatory, development and sales-based progress by Ipsen since the inception of the collaboration agreement, including &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$140.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones achieved during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$79.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$470.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We also receive royalties on the net sales of cabozantinib by Ipsen outside of the U.S. and Japan. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and going forward, we are entitled to receive a tiered royalty of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;on the first CAD&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of annual net sales and a tiered royalty thereafter to&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on annual net sales; these royalty tiers for Canada also reset each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are required to pay a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding: CheckMate 9ER; CheckMate 040 (though Ipsen has opted not to co-fund the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); the dose escalation phase and first 20 expansion cohorts of COSMIC-021; and COSMIC-312.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Revenues from the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$152.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$182.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$69.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#x201c;&#x2014;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x201d;, below, for additional information related to the revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018 and May 2019, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of 1) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after first generic entry with respect to such product in Japan or 2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#x2019;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;agree to terminate the collaboration agreement if Japan&#x2019;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#x2019; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Consideration under the Collaboration&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; from Takeda in 2017. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have also achieved regulatory and development milestones in the aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$26.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; since the inception of the collaboration agreement, including &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones achieved during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we had also determined that it was probable that we will earn a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone in the first quarter of 2020 for the anticipated January 2020 submission of a regulatory application &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to the Japanese MHLW for Manufacturing and Marketing Approval of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;cabozantinib as a treatment for patients in Japan with unresectable HCC &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;who progressed after prior systemic therapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the collaboration agreement, as amended, as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we are eligible to receive regulatory and development milestone payments from Takeda of up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; related to first-line RCC and second-line HCC, including the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone we expect to earn for the submission of a regulatory application in the first quarter of 2020 described above&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We are also eligible to receive additional regulatory and development milestone payments, without limit, for additional potential future indications. We are further eligible to receive sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$155.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We also receive &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;24%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;on the initial &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, and following this initial &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, we are then entitled to receive a tiered royalty of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;on annual net sales thereafter; these &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty tiers reset each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are required to pay a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Takeda is responsible for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the costs associated with the cabozantinib development plan&#x2019;s current and future trials, provided Takeda opts into such trials, and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate 9ER.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#x2019;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Revenues from the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$24.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$18.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$18.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We identified two performance obligations for both the Ipsen and Takeda collaboration agreements: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Based on our evaluation of the collaboration agreements as of the date adoption of Topic 606, we determined that for both agreements, the up-front, nonrefundable payments, the milestones and royalties achieved as of December 31, 2017, and our estimate for the reimbursements of our research and development services performance obligation over the term of each agreement constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. In addition, the transaction price for the Ipsen collaboration agreement included a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone we expected to achieve during the three months ended March 31, 2018. Other than the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone, variable consideration for both agreements related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the transaction price increased as a result of the achievement of various milestones. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib Development Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#x2019;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate 9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. Under the terms of the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#x2019;s compounds in the conduct of each clinical trial. The parties&#x2019; efforts are governed through a joint development committee established to guide and oversee the collaboration&#x2019;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and we are sponsoring the COSMIC-313 trial and BMS is sponsoring the CheckMate 9ER and CheckMate 040 trials. The responsibility for the payment of costs for any further trials will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;F. Hoffmann-La Roche Ltd. (Roche) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#x2019;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#x2019;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal trials in advanced non-small cell lung cancer, metastatic castration-resistant prostate cancer and RCC. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond the initial three planned phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#x2019;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#x2019; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, we continue to be required to pay a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of other collaboration revenues for sales by our collaboration partners. Such royalties were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$31.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$24.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In-Licensing Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Aurigene Discovery Technologies Limited (Aurigene) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$17.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for exclusive options to license up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; programs, including &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; pre-existing programs. We are also responsible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$32.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in research funding for the discovery and preclinical development work on these programs. During the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we incurred &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in expense for the discovery and preclinical development funding commitment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For each option we decide to exercise, we will be required to pay an exercise fee of either &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, depending on the program, and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$148.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program in potential development and regulatory milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$280.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program in potential commercial milestone payments, as well as royalties on potential sales. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Iconic Therapeutics, Inc. (Iconic) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer, leveraging Iconic&#x2019;s expertise in targeting tissue factor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#x2019;s lead oncology ADC program, in exchange for an upfront payment to Iconic of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and a commitment for preclinical development funding. During the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we incurred &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$9.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in expense for the preclinical development funding commitment. Both the upfront payment and the accrual for the preclinical development funding commitment were included in research and development expenses in the accompanying Consolidated Statements of Income. If we exercise the option, we will be required to make an option exercise fee payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Iconic; we would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic would become eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$190.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in potential development, regulatory and first-sale milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$262.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Invenra, Inc. (Invenra) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#x2019;s B-Body&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;TM&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; technology platform, or with other platforms and formats at our option. As of December 31, 2019, we have initiated three additional discovery projects and two binder projects, and in total we incurred an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in expense during the years ended December 31, 2019 and 2018, respectively, in consideration of the upfront licensing and project initiation fees. Invenra is eligible to receive up to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$131.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$43.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$325.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;for each B-Body project and four additional binder projects subject to an upfront payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for each project, as well as additional milestone payments and royalties for any products that arise from these efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;StemSynergy Therapeutics, Inc. (StemSynergy) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x3b1;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;), a component of the Wnt&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; signaling pathway implicated in key oncogenic processes. Under the terms of the a&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;greement,&#160;we&#160;will partner with &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x3b1;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We paid&#160;StemSynergy an upfront payment of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;in initial research and development funding during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; December&#160;31, 2018 and provided &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in additional research and development funding during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. StemSynergy is eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in additional research and development funding on an as needed basis. StemSynergy will also be eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$56.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Genentech&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Profits and losses on U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits and losses on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,615&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Profits on the U.S. commercialization of COTELLIC for the years ended December 31, 2019 and 2018 were included collaboration revenues and losses on the U.S. commercialization of COTELLIC for the year ended December&#160;31, 2017 were included in selling, general and administrative expenses. The royalty revenues on ex-U.S. sales were included in Collaboration revenues for all periods presented. See &#x201c;&#x2014;Performance Obligations and Transaction Prices for our Other Collaborations&#x201d;, below, for additional information related to revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Cobimetinib Profit Sharing and Royalty Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#x2019;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of profits and losses from the first &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of U.S. actual sales, decreasing to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of profits and losses from U.S. actual sales in excess of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$400.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Daiichi Sankyo&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In&#160;January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019, Daiichi Sankyo had its first commercial sale of MINNEBRO&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have achieved milestones of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; each during the years ended December&#160;31, 2019 and 2018 for the approval and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;first commercial sale of MINNEBRO&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We are eligible to receive additional sales-based milestone payments of up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$90.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Such revenues were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the year ended December 31, 2019. Daiichi Sankyo may terminate the agreement upon &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2019; written notice, in which case Daiichi Sankyo&#x2019;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;0.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Ligand on net sales of MINNEBRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;&#x2014;Performance Obligations and Transaction Prices for our Other Collaborations&#x201d;, below, for additional information related to revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Performance Obligations and Transaction Prices for our Other Collaborations &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have evaluated our collaborations agreements with Genentech and Daiichi Sankyo and have determined that those collaboration agreements each have one performance obligation: the delivery of intellectual property licenses to the collaboration partner. We have further determined that the licenses we provided represent functional intellectual property that was transferred at a point in time, when the agreements were executed&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; prior to the adoption of Topic 606. Potential variable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones and therefore, any additional consideration earned and received from these collaborations will be fully recognized when the milestone is no longer constrained. Any variable consideration related to royalties and other sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred, and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      id="d21836529e636-wk-Fact-CFFF046FBB11832FC18D7F5F587F823E">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:UpfrontPayments
      contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e646-wk-Fact-65347053A4D235C5C28A7F5F588593D8"
      unitRef="usd">210000000.0</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e654-wk-Fact-FE76AC45314CE7FD9C6E7F5F58CB4A0C"
      unitRef="usd">330000000.0</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e658-wk-Fact-D6D4DFCC4638426599EF7F5F587A460E"
      unitRef="usd">55000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e662-wk-Fact-1182B31C1D2CBD7BF8B71238D7825F1C"
      unitRef="usd">140000000.0</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e682-wk-Fact-70645694FF8F34132B9C7F5F58E724C9"
      unitRef="usd">79000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e686-wk-Fact-57C4E1CB4EAD7F0D82177F5F58A961F8"
      unitRef="usd">470400000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="INF"
      id="d21836529e696-wk-Fact-6278D9F7DE2A50C8EBC47F5F58C070BA"
      unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="INF"
      id="d21836529e701-wk-Fact-59E97831331A889B57597F5F5891FFA6"
      unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="INF"
      id="d21836529e705-wk-Fact-6278D9F7DE2A50C8EBC47F5F58C070BA"
      unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
    <exel:RoyaltyTier
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="INF"
      id="d21836529e711-wk-Fact-463F8C04E7408A14D12B7F5F5894FE01"
      unitRef="cad">30000000.0</exel:RoyaltyTier>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="INF"
      id="d21836529e717-wk-Fact-59E97831331A889B57597F5F5891FFA6"
      unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember"
      decimals="2"
      id="d21836529e725-wk-Fact-6343E204966B553191B4C5CBC9BD292F"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="2"
      id="d21836529e732-wk-Fact-8994898458BFB5314C657F5F588C664F"
      unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e747-wk-Fact-6AC0EE1D1268505D98FAFD9785312A4D"
      unitRef="usd">152800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e751-wk-Fact-3EB5475A4EF3566B918CD7A6F2B57AEB"
      unitRef="usd">182900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e755-wk-Fact-836BDA639C855E7989CB093F2158FB5D"
      unitRef="usd">69800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d21836529e779-wk-Fact-B7E209CEFCBA53CF845F0E9EB97A9014"
      unitRef="usd">45000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      id="d21836529e801-wk-Fact-1C4C75E67E86647956A67F5F587F623B">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:PeriodOfSpecificSalesVolumeThreshold
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      id="d21836529e805-wk-Fact-E42B2EE4D87E242DFD067F5F58D1DD57">P6Y</exel:PeriodOfSpecificSalesVolumeThreshold>
    <exel:UpfrontPayments
      contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e823-wk-Fact-03586B7E4D3FA71803ED7F5F5889FA2B"
      unitRef="usd">50000000.0</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e831-wk-Fact-1ABEC9DB6FD6A154BFDC159195ECCFDC"
      unitRef="usd">26000000.0</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e835-wk-Fact-621F2F6B53A0F3EEADBF159280568B93"
      unitRef="usd">16000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e839-wk-Fact-6617063334E844AD1D191592927B1E56"
      unitRef="usd">10000000.0</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e856-wk-Fact-9753642820A7A767B5BA12182CDBA12A"
      unitRef="usd">10000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e873-wk-Fact-6E94C21E3DE8EE208D9C7F5F5894F73F"
      unitRef="usd">20000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e877-wk-Fact-9753642820A7A767B5BA12182CDBA12A"
      unitRef="usd">10000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e883-wk-Fact-C5C2770A4393F1612E687F5F587637E8"
      unitRef="usd">155000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e890-wk-Fact-66F129214E0351C792197F5F58C667B1"
      unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e894-wk-Fact-BF40CFCE028BD20AF2437F5F588F3E7B"
      unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
    <exel:RoyaltyTier
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e898-wk-Fact-42915333FFE989FC4D177F5F58C8D767"
      unitRef="usd">300000000.0</exel:RoyaltyTier>
    <exel:RoyaltyTier
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e902-wk-Fact-42915333FFE989FC4D177F5F58C8D767"
      unitRef="usd">300000000.0</exel:RoyaltyTier>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e906-wk-Fact-BA6128898D3BC8DF2C357F5F588E70FA"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e910-wk-Fact-EC19BCAC1C56B171BCBB7F5F587A14C2"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e915-wk-Fact-BA6128898D3BC8DF2C357F5F588E70FA"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e919-wk-Fact-EC19BCAC1C56B171BCBB7F5F587A14C2"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember"
      decimals="2"
      id="d21836529e926-wk-Fact-6343E204966B553191B4C5CBC9BD292F"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="2"
      id="d21836529e933-wk-Fact-B6C56800A5742D6AB1177F5F58D2B408"
      unitRef="number">0.20</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="INF"
      id="d21836529e937-wk-Fact-9C1D874FB03B66D2DBA17F5F58F4BAB9"
      unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e954-wk-Fact-3A2A04BF19EF579BAE687254CBFAA5DB"
      unitRef="usd">24600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e958-wk-Fact-6FB226050367575193F09170E55B5BDB"
      unitRef="usd">18000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e962-wk-Fact-58653E467AE45EC195EA5D5E34747BE1"
      unitRef="usd">14800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e986-wk-Fact-F8E474B69BE35223ADA41496AB00DDDE"
      unitRef="usd">18100000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:MilestonePaymentsEarned
      contextRef="FD2018Q1QTD_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e1009-wk-Fact-F901FAD4E4F4335153787F5F58E3DEBD"
      unitRef="usd">10000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2018Q1QTD_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d21836529e1013-wk-Fact-F901FAD4E4F4335153787F5F58E3DEBD"
      unitRef="usd">10000000.0</exel:MilestonePaymentsEarned>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember"
      decimals="2"
      id="d21836529e1079-wk-Fact-6343E204966B553191B4C5CBC9BD292F"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d21836529e1083-wk-Fact-BC0B40F414D752F891BF347CD6C4AB2D"
      unitRef="usd">31300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d21836529e1087-wk-Fact-FFBBF51A33005AADB9DAB56B72D41939"
      unitRef="usd">24000000.0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d21836529e1091-wk-Fact-5D344630076DEC60462315A1C09BA20E"
      unitRef="usd">12400000</us-gaap:RoyaltyExpense>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d21836529e1131-wk-Fact-B72C70C2971951068435E6FC83B3F7FF"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:UpfrontPayments
      contextRef="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1135-wk-Fact-4F091DDAB757F010068E15C8E8A0AB1C"
      unitRef="usd">17500000</exel:UpfrontPayments>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d21836529e1139-wk-Fact-B72C70C2971951068435E6FC83B3F7FF"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:CollaborationAgreementNumberOfPreexistingPrograms
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d21836529e1143-wk-Fact-C012433EC13353888A814C4F6622C43E"
      unitRef="program">3</exel:CollaborationAgreementNumberOfPreexistingPrograms>
    <exel:CollaborationAgreementResearchAndDevelopmentObligation
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1147-wk-Fact-05410DE1619B5961A4DF533F769E1ABC"
      unitRef="usd">32600000</exel:CollaborationAgreementResearchAndDevelopmentObligation>
    <exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1156-wk-Fact-5A56AF01FD14523CAC03CCC1C560110F"
      unitRef="usd">4000000.0</exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1163-wk-Fact-B9939480F4EC5912B4B0072D964FE947"
      unitRef="usd">10000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1167-wk-Fact-434EDD594235577C88B2752ACC4759D5"
      unitRef="usd">12000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1171-wk-Fact-8C53C71E420E5AE9B7DF58194B47B051"
      unitRef="usd">148800000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d21836529e1175-wk-Fact-40F1E9553338555E9BD0B0A9F8AC309E"
      unitRef="usd">280000000.0</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborationAgreementsUpfrontPayments
      contextRef="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d21836529e1185-wk-Fact-75E374A2AA365745A7D9CABC8485BE8F"
      unitRef="usd">7500000</exel:CollaborationAgreementsUpfrontPayments>
    <exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d21836529e1193-wk-Fact-1B649A4D43DF5E1987CED420B96C27FF"
      unitRef="usd">9800000</exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d21836529e1197-wk-Fact-6AA1588DF35F5184896E54095B8C93E2"
      unitRef="usd">20000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d21836529e1201-wk-Fact-17E78EBC830F5371ADD2BE200ED49F43"
      unitRef="usd">190600000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d21836529e1206-wk-Fact-9B129F72CB2257DFA1F1A5649866AB65"
      unitRef="usd">262500000</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:ProjectInitiationFeePayment
      contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1221-wk-Fact-D11747DFA3ABB678D3D015A77BAA76CD"
      unitRef="usd">7000000.0</exel:ProjectInitiationFeePayment>
    <exel:ProjectInitiationFeePayment
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1225-wk-Fact-3CC43403EC86C40B14F515A790618A8F"
      unitRef="usd">4000000.0</exel:ProjectInitiationFeePayment>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1229-wk-Fact-EBAF340041B1594499277F5F58CFB0FC"
      unitRef="usd">131500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:ProjectInitiationFeePayment
      contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1233-wk-Fact-68A551EA3FD54E71EE4C15A909D81257"
      unitRef="usd">43400000</exel:ProjectInitiationFeePayment>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1238-wk-Fact-6FD8DD34B6EAE011E84A7F5F589894F2"
      unitRef="usd">325000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:UpfrontAndMilestonePayments
      contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1242-wk-Fact-4FA3E6A89D8A253EF18E7F5F588FC768"
      unitRef="usd">2000000.0</exel:UpfrontAndMilestonePayments>
    <exel:UpfrontAndMilestonePayments
      contextRef="FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember"
      decimals="-5"
      id="d21836529e1246-wk-Fact-41C03249A1E2ADF5A1B015AABC5F2698"
      unitRef="usd">1500000</exel:UpfrontAndMilestonePayments>
    <exel:UpfrontAndMilestonePayments
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember"
      decimals="-5"
      id="d21836529e1273-wk-Fact-43BF3D9862F7C8E12B5A7F5F58B5418F"
      unitRef="usd">3000000.0</exel:UpfrontAndMilestonePayments>
    <exel:AdditionalUpfrontAndMilestonePayments
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember"
      decimals="-5"
      id="d21836529e1281-wk-Fact-5E8C0FE4C29F7AD864C115ABA1BD19FE"
      unitRef="usd">1900000</exel:AdditionalUpfrontAndMilestonePayments>
    <exel:AdditionalUpfrontAndMilestonePayments
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember"
      decimals="-5"
      id="d21836529e1285-wk-Fact-E70762C27558ABC072D97F5F58909D95"
      unitRef="usd">1200000</exel:AdditionalUpfrontAndMilestonePayments>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember"
      decimals="-5"
      id="d21836529e1298-wk-Fact-BEADB8D1CEE04276390B7F5F58969BD0"
      unitRef="usd">500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2019Q4_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember"
      decimals="-5"
      id="d21836529e1302-wk-Fact-253D971FB64C58C445CE7F5F58AB1DED"
      unitRef="usd">56500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CCA2692739C69607C9047F5F590691A8-0-wk-Fact-A0F2D0BC7C1C4C9E7AB87F5F58EAB6C1">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Profits and losses on U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits and losses on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,615&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d21836529e1477-wk-Fact-064A053B627B570FB5E35B50068DB631"
      unitRef="usd">4615000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d21836529e1496-wk-Fact-603C8AFCB4E45946AF42B6524AF3662D"
      unitRef="usd">8084000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d21836529e1515-wk-Fact-B31F32DC6255558289F62AB533F4C05A"
      unitRef="usd">-2140000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d21836529e1537-wk-Fact-F5DB727BE85853C9BCBE83EBF0863FD6"
      unitRef="usd">5679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d21836529e1556-wk-Fact-90E1454673BD551FB2BCFDBB3C2EE55B"
      unitRef="usd">5564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d21836529e1575-wk-Fact-D96AB6548EB458DCAD43F84FDA19DE88"
      unitRef="usd">6398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ProfitSharingAgreementPercentOfProfits
      contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="2"
      id="d21836529e1594-wk-Fact-9B906584AE4D8A855C727F5F587BD672"
      unitRef="number">0.50</exel:ProfitSharingAgreementPercentOfProfits>
    <exel:ProfitSharingAgreementProfitThreshold
      contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="INF"
      id="d21836529e1598-wk-Fact-D44E3012AF53D0B229F07F5F58D1FDEB"
      unitRef="usd">200000000.0</exel:ProfitSharingAgreementProfitThreshold>
    <exel:ProfitSharingAgreementPercentOfProfits
      contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="2"
      id="d21836529e1602-wk-Fact-ED0D38FF6031CD78A0107F5F5875222F"
      unitRef="number">0.30</exel:ProfitSharingAgreementPercentOfProfits>
    <exel:ProfitSharingAgreementProfitThreshold
      contextRef="FD2019Q4YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="INF"
      id="d21836529e1606-wk-Fact-928A522E490DCE6F729A7F5F58A29FC1"
      unitRef="usd">400000000.0</exel:ProfitSharingAgreementProfitThreshold>
    <exel:CollaborativeArrangementAchievedMilestoneAmount
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember"
      decimals="-5"
      id="d21836529e1637-wk-Fact-24A3E73A3DA683B6927515BA2A6BEA59"
      unitRef="usd">20000000.0</exel:CollaborativeArrangementAchievedMilestoneAmount>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember"
      decimals="INF"
      id="d21836529e1645-wk-Fact-94DB35B0B11B64A3BBFC7F5F5895DC80"
      unitRef="usd">90000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_exel_MINNEBROMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember"
      decimals="-5"
      id="d21836529e1649-wk-Fact-66BAF7A88D92798F3DD815BCBCFDC3F4"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementTerminationPeriod
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember"
      id="d21836529e1653-wk-Fact-322ED2F4E1A5E1B9050515BEA11604EF">P90D</exel:CollaborationAgreementTerminationPeriod>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="3"
      id="d21836529e1660-wk-Fact-746121309A7B5DE39A8244A5BC2BF109"
      unitRef="number">0.005</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-5"
      id="d21836529e1667-wk-Fact-A30BA7A1802B51CDAD99E89190D61F47"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-5"
      id="d21836529e1671-wk-Fact-ECF53CAD55D65D0AA7200F1BD4479549"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-5"
      id="d21836529e1675-wk-Fact-1143EDE6A4BBB8AAC1E216022BDAAA31"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2AC3BA55F6B5587F651E7F5F5906AD81-0-wk-Fact-E70C2E985D5FB35731687F5F58AC0859">CASH AND INVESTMENTS&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Short-term restricted cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit and, during prior periods, a purchasing card program. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of restricted cash &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;equivalents as short-term or long-term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;dependent upon the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;longer of the remaining term to maturity of the investment or the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;remaining term of the related restriction&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investment securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;752,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,308,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,384,510&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,388,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investment securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;781,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;852,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investment securities available-for-sale were insignificant during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We manage credit risk &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;associated with our investment portfolio &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on investment securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investment securities in an unrealized loss position as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;years ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investment securities available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;789,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;626,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;522,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1CCB5FB9967D7C1E71647F5F5906A268-0-wk-Fact-0E4C4A826EBF48AED4E87F5F589DDAA3">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Short-term restricted cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B0CEDD58CB249185170D7F5F59077BBA-0-wk-Fact-449089310A11B40663887F5F58B0CC44">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Short-term restricted cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e750-wk-Fact-01250ECF4ED255118BE21200D22D84B1"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e769-wk-Fact-90F54B50CC015DC590E195EFBE556F53"
      unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21843681e788-wk-Fact-D825E0EA324652CB91F045191D9C4FD7"
      unitRef="usd">183164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e804-wk-Fact-E57CD94E0C7FF277B4C2CB2DDDA6D470"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e823-wk-Fact-59977E6F2EAB9F3D725CCB2DDDBCA944"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21843681e842-wk-Fact-E931C304F3B15BB2B6C6AF751ECD67BC"
      unitRef="usd">504000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e863-wk-Fact-118B46408DE18045D05ECB2DDD7619D1"
      unitRef="usd">1636000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e882-wk-Fact-E54453A03BD10F62625DCB2DDD912651"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21843681e901-wk-Fact-933ED6E12A4D5C79B88F912CEDB84728"
      unitRef="usd">4646000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e927-wk-Fact-AA9D8EEC2AAD55929D4FD5EAA16D1EA6"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e946-wk-Fact-BC0F0D36AF675667BF547125A5FB8F75"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d21843681e965-wk-Fact-319AEF2EF68A57B39FDD8082EF0DA57F"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4EA1856D4D8BE1CD78F87F5F5907FD36-0-wk-Fact-A040848CBC1145C3F84A7F5F58953592">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investment securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;752,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,308,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,384,510&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,388,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investment securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;781,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;852,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e1321-wk-Fact-BB4F0B3986245B6D904979D9E5FDC70F"
      unitRef="usd">389573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e1340-wk-Fact-2299077DCEE851E786067A29B64D2A31"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e1359-wk-Fact-569881409AF756958C9E18277901749F"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e1379-wk-Fact-5D77D621171968404368CB2DC6839AC1"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e1394-wk-Fact-AE2F011D979B5BBCA81A32552D63459D"
      unitRef="usd">752295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e1413-wk-Fact-B752F2A35BDF503B9E5F21107C08FAFC"
      unitRef="usd">3934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e1432-wk-Fact-CA931E9652175AAFB15483C0CCACBA75"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e1453-wk-Fact-DB6AD50AC413417A13C9CB2DC6987611"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e1473-wk-Fact-930874A5DD0A5074A22738C0C7DE2E41"
      unitRef="usd">166483000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e1492-wk-Fact-59456C8F9BE95E23868C7AA57E03EF76"
      unitRef="usd">187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e1511-wk-Fact-50C9C2003AAE523C8EAB75840084749E"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e1532-wk-Fact-9CD3D6BE14302BDFAB50CB2DC6B14A28"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1552-wk-Fact-AD7FA3DC56175F512CF77F5F58C1F596"
      unitRef="usd">1308351000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1571-wk-Fact-B1BC52DF674905BED38C7F5F58CEED46"
      unitRef="usd">4121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1590-wk-Fact-C242D0227321C136E7DC7F5F5882161D"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1611-wk-Fact-36E5FA1B0E3BE66D7B2E7F5F5881725A"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e1631-wk-Fact-0E717144563B5DB4B5025F5ACB74DC23"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e1650-wk-Fact-928CEA822D015CA682C736F2E533F106"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e1669-wk-Fact-316EE6D1D1A3521787B1B932A8A190AB"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e1689-wk-Fact-F9E7CF1EE8CD56FF85CFA4309388BD5F"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e1709-wk-Fact-1306DF3E7643589AAC5596B6A505649B"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e1728-wk-Fact-7B488312060B535DA84AD55DE47D9F25"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e1747-wk-Fact-E80E7A683A79518FBABC396FE21F3B25"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e1767-wk-Fact-9430909CF80A03565F02CB32B02CC367"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e1787-wk-Fact-09FB60A430C258CD989D85984BFCD1BB"
      unitRef="usd">32728000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e1806-wk-Fact-F59A062863DF5A8E918A13BB63A73F80"
      unitRef="usd">5000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e1825-wk-Fact-E35DE72D6EDE5CD4BEFF8B7B3A2333CF"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e1845-wk-Fact-5E612728C23659A0A53B154AE03CDA6D"
      unitRef="usd">32733000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1870-wk-Fact-E66885B7A6870B7FD2C37F5F58BC5E38"
      unitRef="usd">1384510000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1889-wk-Fact-97117C4B721D441E5C117F5F58856F60"
      unitRef="usd">4126000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1908-wk-Fact-FB145834FD23F6C7D0677F5F58CC4C26"
      unitRef="usd">8000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e1929-wk-Fact-B8393E9F825BB019747E7F5F58BED339"
      unitRef="usd">1388628000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e2233-wk-Fact-C7E368CA22C15D6F9B8C1934CE939A9F"
      unitRef="usd">381134000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e2252-wk-Fact-E9C5823C927D5BFBB101782AAA511C49"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e2271-wk-Fact-25AE4171D913577582E03C697648D6C5"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e2292-wk-Fact-D0DCCC04591A650DFD457F5F589FC49B"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e2307-wk-Fact-77E7523C36B4521B9CFE87E2A4852604"
      unitRef="usd">344741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e2326-wk-Fact-C8B6CA87A7755ED3A86386728DCFAAD2"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e2345-wk-Fact-298C01908C4A566A957C2E53B7F3E5AA"
      unitRef="usd">857000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e2366-wk-Fact-B4A5D1F9E89CD36402787F5F58D5AF05"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e2386-wk-Fact-75AE6221A89C5555A1D1B739F7B2687B"
      unitRef="usd">55224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e2405-wk-Fact-5CDFA679CF8A523ABA877E610AF9602B"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e2424-wk-Fact-7A1717EBA39E538A96A0C6F0E6103B2D"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e2445-wk-Fact-CB58F5BCACF8A3594BD57F5F58E5CAA9"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2465-wk-Fact-0E721FCC5178570FEFF27F5F58AD6931"
      unitRef="usd">781099000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2484-wk-Fact-DEA770C815DD4C282D7E7F5F58D96CFD"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2503-wk-Fact-87095D78A55B3DF07B2E7F5F58DA9D88"
      unitRef="usd">883000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2524-wk-Fact-E9A20E83BD35513F999441AB81BC6B12"
      unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e2544-wk-Fact-F72838C58632583F88B30B7447F02E2D"
      unitRef="usd">6883000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e2563-wk-Fact-DA5C10CDC99C511A8DADE1923CA8DEE7"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e2582-wk-Fact-285A408EAC5E57538C9A669DAE6D72FE"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d21843681e2602-wk-Fact-D09AF6F51C0D5E4F8CFD1EA24E928AEC"
      unitRef="usd">6883000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e2622-wk-Fact-18DC9CB408B75AC2902C22AAA608B061"
      unitRef="usd">47744000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e2641-wk-Fact-1CA3CA6015B95B69B8CFEBA3A6EF85B2"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e2660-wk-Fact-EB796814557450F1ABC2AE78DFA042D1"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21843681e2680-wk-Fact-4AF8F8BA02F171E080EFCB326B8D927B"
      unitRef="usd">47744000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e2700-wk-Fact-955D2B473EB65151A70C546DE6E365BF"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e2719-wk-Fact-D0773D566C8350C3B755A32A87AC763D"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e2738-wk-Fact-64DB5B806D895561A90A4F4AA9D00C84"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21843681e2758-wk-Fact-19186BD28A915895A0FFC8F60866CD65"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2783-wk-Fact-C1AC7E27D0D9815732927F5F587D99D5"
      unitRef="usd">852322000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2802-wk-Fact-DEA770C815DD4C282D7E7F5F58D96CFD"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2821-wk-Fact-87095D78A55B3DF07B2E7F5F58DA9D88"
      unitRef="usd">883000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e2842-wk-Fact-C44D471DE0D0B37B84E07F5F58EA90A7"
      unitRef="usd">851621000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B0126058EED41AF0C6167F5F5907321C-0-wk-Fact-8133FB726E97475703DB7F5F58ECF7D8">The fair value and gross unrealized losses on investment securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e3297-wk-Fact-B76F15F1DEB15BC7A6454BBF022F4F06"
      unitRef="usd">14529000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e3316-wk-Fact-7228E4809A6C53E282B3B8FD6E0BB122"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e3336-wk-Fact-7498DAC6C56A5172A1714715ADFFE83F"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e3356-wk-Fact-8F7764B2E4B45789A8A430CEC222B6C0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e3375-wk-Fact-FE395F9D50375246A6F8913DCB0A601D"
      unitRef="usd">14529000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e3395-wk-Fact-5CE8D32EF671535ABCD69EE46620E3D2"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e3411-wk-Fact-AC8FB5EDD82253599D723C9D5CF84C59"
      unitRef="usd">2848000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e3430-wk-Fact-C41314A5073B5BA0880B3E6508954BA5"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e3450-wk-Fact-311CC75F31995509BE49F7597B8036FA"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e3470-wk-Fact-025B9C095B1F59A69E1F3E2A6BD38A12"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e3489-wk-Fact-80FC4340A64E5704AD700B7870CD7FF5"
      unitRef="usd">2848000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e3508-wk-Fact-7501B3999D825175979D3BE70907B698"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e3535-wk-Fact-914347B2F2605CD38E87687A7CD350A7"
      unitRef="usd">17377000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e3554-wk-Fact-6E2D8B705D655B7DA1D557E38D89F130"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e3574-wk-Fact-473B0ED55E8F5F4487A3F122DF15BAAA"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e3594-wk-Fact-0D5F260B033758F5A35EC8A68BA30FB2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e3613-wk-Fact-9235DD1B595C5180BC20B7D2B31BD059"
      unitRef="usd">17377000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e3633-wk-Fact-BF135D59779451BE9657D26622D69C24"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e4052-wk-Fact-E675C571551D531690BDCC703DAEC748"
      unitRef="usd">236162000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e4071-wk-Fact-7E4BF91689905C1889761DC0D4009F52"
      unitRef="usd">606000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e4091-wk-Fact-2C311EED62E4573D8A8224CC8A793596"
      unitRef="usd">39627000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e4111-wk-Fact-9957F59ECC625A3A9B8F18EF84E0AFAC"
      unitRef="usd">251000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e4131-wk-Fact-C45A98E6BBBA5BE18CED1D9F59F35ECA"
      unitRef="usd">275789000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21843681e4151-wk-Fact-0C5A938C319A5185A60C3A75C2033255"
      unitRef="usd">857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e4167-wk-Fact-9CE9B85024085542B90D7C8FA6F1C8A7"
      unitRef="usd">28105000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e4186-wk-Fact-8A52193D91B351C78A7C7876DB612B4B"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e4206-wk-Fact-003F4ADDBA01572B93127EE75329E48F"
      unitRef="usd">9182000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e4226-wk-Fact-AF98D79CE50658CB85A322C5035DEDE6"
      unitRef="usd">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e4246-wk-Fact-3D81DC18AD455F2A8AC56892C0D43363"
      unitRef="usd">37287000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21843681e4265-wk-Fact-62FFB50DD0415E688987CEB2C75374EE"
      unitRef="usd">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e4287-wk-Fact-2DC882EFF288551F9A0C595BCAF65FE8"
      unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e4306-wk-Fact-6892B147BCDE5BA992691CD2648F9523"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e4326-wk-Fact-C50EC59E37AD5F48B423CAD8C002E94A"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e4346-wk-Fact-83E593F0332759D78B48A2F139C5386C"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e4365-wk-Fact-2D65CE44FAE054A2833B24FC1773C90C"
      unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21843681e4384-wk-Fact-E29E863F56C15258853F1A17EF8F8B00"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4411-wk-Fact-5FE21F7E47115E889F729E767805A46F"
      unitRef="usd">271358000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4430-wk-Fact-5FE3CAA9E4DD58DEBF69961BB068D82E"
      unitRef="usd">623000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4450-wk-Fact-67510A3387B25E899D819D75E6164B15"
      unitRef="usd">48809000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4470-wk-Fact-2BE05385B6DA512B877394E2261C7E5F"
      unitRef="usd">260000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4490-wk-Fact-602DD02DAA025DA68CF92DC8DF6C536C"
      unitRef="usd">320167000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4510-wk-Fact-4041E60F20E15F7F8F58922EDE933E72"
      unitRef="usd">883000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2019Q4"
      decimals="INF"
      id="d21843681e4524-wk-Fact-007B8E92DCC65121912494BE721C851B"
      unitRef="investment">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2018Q4"
      decimals="INF"
      id="d21843681e4528-wk-Fact-4FEB689D28ED53FF951EE6405F75E46A"
      unitRef="investment">199</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d21843681e4557-wk-Fact-7A464EC152725353BBCB2C88F0154719"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E931793D62BDD9F51D757F5F5907C8DF-0-wk-Fact-BAA3C2A79559675CA7647F5F58D9EEBD">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investment securities available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;789,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;626,711&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;522,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e4683-wk-Fact-37035C77481D5E8599DA4F9C3EFBA21F"
      unitRef="usd">789913000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4702-wk-Fact-EE952B3080005DB389BC93B3CF6086B7"
      unitRef="usd">626711000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e4717-wk-Fact-5260F121163655FE9ACBD66D1091E2C1"
      unitRef="usd">522551000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4736-wk-Fact-1F38BD12822E50418D004F90F003E225"
      unitRef="usd">153687000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21843681e4761-wk-Fact-36E5FA1B0E3BE66D7B2E7F5F5881725A"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21843681e4780-wk-Fact-E9A20E83BD35513F999441AB81BC6B12"
      unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-12FED09EAF0FEE30D7087F5F590AB861-0-wk-Fact-BB3F48E0AB9319D49FD27F5F58DFF840">FAIR VALUE MEASUREMENTS &lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,345,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,347,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;796,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;844,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;The carrying amount of our remaining financial assets and liabilities, which include cash and restricted cash, receivables and payables approximate their fair values due to the short-term nature.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-DDF810CE9883527024F97F5F590A4B5B-0-wk-Fact-C61B2B7ADBF29BF377917F5F58E0333E">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,345,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,347,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investment securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;796,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;844,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21838470e795-wk-Fact-CF50E76C73EB5E878547B3AEBA59E3D3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21838470e814-wk-Fact-2016C08F6F955FD9AC31A888540547ED"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21838470e833-wk-Fact-5D77D621171968404368CB2DC6839AC1"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21838470e849-wk-Fact-F6979BB7F6CA56C096C802FFA5C988DF"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21838470e868-wk-Fact-1427413FE4225A7188C71DC6DE546440"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21838470e887-wk-Fact-DB6AD50AC413417A13C9CB2DC6987611"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21838470e908-wk-Fact-01C504CBB28E5A06AF918D7590BCA433"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21838470e927-wk-Fact-8BA94616AFF05C2EBE6881D6018DFB45"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21838470e946-wk-Fact-9CD3D6BE14302BDFAB50CB2DC6B14A28"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="d21838470e967-wk-Fact-5D71AC0075916C3DE8207F5F58874E54"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d21838470e986-wk-Fact-6906E52BD2E1668831587F5F58864506"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21838470e1005-wk-Fact-36E5FA1B0E3BE66D7B2E7F5F5881725A"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21838470e1026-wk-Fact-7309368F5B5D5B6CB225B2CE19D7E936"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21838470e1045-wk-Fact-082D3D7FA7B257408528F98B0D248ECD"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21838470e1064-wk-Fact-BF61AE5FA7A54B7E0613124A466EB1C1"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21838470e1085-wk-Fact-086B9EDA6E985B548D3F6E189BB546F2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21838470e1104-wk-Fact-F29DE0DE026C5811B6EBF8070A0E0698"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21838470e1123-wk-Fact-819EDD24097BEE330B4D7F5F58834B4A"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="d21838470e1149-wk-Fact-5F85E8E192CED043E8E87F5F58850068"
      unitRef="usd">2467000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d21838470e1168-wk-Fact-BC4DB0BCE9FB5E3AC64C7F5F588061F8"
      unitRef="usd">1345197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21838470e1187-wk-Fact-8668F438A77C1B59DF6C7F5F587EAA3C"
      unitRef="usd">1347664000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21838470e1351-wk-Fact-EC100B80B45D52939816209F2EC43ACB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21838470e1370-wk-Fact-FE4E676BF5775FDFAA5E0CE1699B945A"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d21838470e1389-wk-Fact-D0DCCC04591A650DFD457F5F589FC49B"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21838470e1405-wk-Fact-C82CC303D4805F239E1E99A15F419034"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21838470e1424-wk-Fact-3C9D645DD5E551E091C0310D939E48AD"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d21838470e1443-wk-Fact-B4A5D1F9E89CD36402787F5F58D5AF05"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21838470e1464-wk-Fact-5BE968042E505E29B2EA0F8B323197DB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21838470e1483-wk-Fact-F3E33F4882EB55D682C32FB1ED12727D"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d21838470e1502-wk-Fact-CB58F5BCACF8A3594BD57F5F58E5CAA9"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="d21838470e1523-wk-Fact-8302373CA370696E5C017F5F58C817CB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d21838470e1542-wk-Fact-D27888236AB8F2C14E6C7F5F58C85F79"
      unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21838470e1561-wk-Fact-E9A20E83BD35513F999441AB81BC6B12"
      unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21838470e1582-wk-Fact-91D92DB2ACB851A99A93882AD7E71336"
      unitRef="usd">47744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21838470e1601-wk-Fact-56316F63A4E55441BCC16776B2D8CCCB"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d21838470e1620-wk-Fact-447EA43152DC3985D0B4124B3BD664C1"
      unitRef="usd">47744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21838470e1641-wk-Fact-E4A806934808511DB125315A58919161"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21838470e1660-wk-Fact-8BC92E32B1CB967ED9467F5F58CA26BC"
      unitRef="usd">16596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d21838470e1679-wk-Fact-EA6C43E418FFEDA4087E7F5F58C3ACD9"
      unitRef="usd">16596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="d21838470e1705-wk-Fact-4DD371E359EC0CE2CE457F5F58C74A8C"
      unitRef="usd">47744000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d21838470e1724-wk-Fact-28887925614854B5535C7F5F58C94DAF"
      unitRef="usd">796994000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21838470e1743-wk-Fact-B72282A1C40140FEC7D07F5F58CB0A48"
      unitRef="usd">844738000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0AC5522D30A7986BFA0D7F5F5907A001-0-wk-Fact-974FAAE84A64036A6A527F5F58A64662">INVENTORY&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,886&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Write-downs related to excess and expiring inventory were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-9FCAC0B8D881056203C87F5F5907C1DE-0-wk-Fact-A0E7EA10F884DF7C7DD97F5F58A4C2FF">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,886&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21835782e700-wk-Fact-6513FAB3DE435353BE542BE61BCDB5D2"
      unitRef="usd">2709000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21835782e719-wk-Fact-5DE34C30E3B95514B6DC1C5C107AF7F7"
      unitRef="usd">1922000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21835782e734-wk-Fact-5890FB1496CE55CEAECA796008D68E53"
      unitRef="usd">9447000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21835782e753-wk-Fact-F49EA7AD98175FB4AC71CF653D2BA738"
      unitRef="usd">6170000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21835782e773-wk-Fact-9DAA7234749E512DA1887C2E02F772FD"
      unitRef="usd">4367000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21835782e792-wk-Fact-B1ACE76EDEBC54609F9E91329837A3F7"
      unitRef="usd">3836000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21835782e817-wk-Fact-D6AA89447B1158B9B4E3849410C94DAA"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21835782e836-wk-Fact-8FC38ECB8C14571CA231F840895AC296"
      unitRef="usd">11928000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d21835782e897-wk-Fact-5F1F3E41857E5EE8BD5CE69653AAA1EC"
      unitRef="usd">12886000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d21835782e916-wk-Fact-0B59B89E34D85FAFA403D36A252EC99F"
      unitRef="usd">9838000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d21835782e931-wk-Fact-C0272235C149502A87FC7CDB3CF3CEEE"
      unitRef="usd">3637000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d21835782e950-wk-Fact-9C10FA48F3315CC1AD68DC76D6468A54"
      unitRef="usd">2090000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21835782e975-wk-Fact-D6AA89447B1158B9B4E3849410C94DAA"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21835782e994-wk-Fact-8FC38ECB8C14571CA231F840895AC296"
      unitRef="usd">11928000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21835782e1011-wk-Fact-B5989E9B49235FC594C8FE9C41EC6C62"
      unitRef="usd">1300000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-5"
      id="d21835782e1015-wk-Fact-FFD03F37A76858318E9AFECE17E452CB"
      unitRef="usd">1100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D2017Q4FYYTD"
      decimals="-5"
      id="d21835782e1019-wk-Fact-F1B3C64F7F03EF6276A97F5F58A84968"
      unitRef="usd">1200000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3952F8884B3AAC5658AE7F5F59073FED-0-wk-Fact-ED74859EF9437D9FC9B87F5F589EE14F">PROPERTY AND EQUIPMENT&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;74,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Depreciation and amortization expenses were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$8.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-801F5631CC76E6E84B187F5F5907CC8D-0-wk-Fact-9EB62F5F86EB6870934A7F5F58F260AB">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;74,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d21837602e748-wk-Fact-65B4D59BBDC15802B7BE41FF3B66302B"
      unitRef="usd">33904000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d21837602e767-wk-Fact-EE8C40EAB0B35062B1B24C280399E5FB"
      unitRef="usd">33941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="d21837602e792-wk-Fact-D4DBBF1903665A049742B5647EC24B59"
      unitRef="usd">17338000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="d21837602e811-wk-Fact-378D16834A1051BC91485312168313E8"
      unitRef="usd">15022000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d21837602e841-wk-Fact-9B4E50F1C4895025B46B26F55F437DDF"
      unitRef="usd">13053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d21837602e860-wk-Fact-8F0F9BD108D15CB090BEAAE2F46C0B94"
      unitRef="usd">12709000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      decimals="-3"
      id="d21837602e890-wk-Fact-43054D25AA84504ABF3E6FF42CA6F26B"
      unitRef="usd">8904000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      decimals="-3"
      id="d21837602e909-wk-Fact-F43AFBAB1A295AD4875730654AB1A045"
      unitRef="usd">5668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d21837602e939-wk-Fact-DA1B399F5FAE507EB0C8F47D4114DD10"
      unitRef="usd">1253000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d21837602e958-wk-Fact-78FDB346E78A5775ACFB7DBC80C2046B"
      unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21837602e988-wk-Fact-1AF178888729E1C0F04B7F5F58BFB2E9"
      unitRef="usd">74452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21837602e1007-wk-Fact-EB97EA7FF280E170773B7F5F58B9C2E7"
      unitRef="usd">68206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21837602e1037-wk-Fact-307F1C8C980D596D9541BE6527E33259"
      unitRef="usd">25560000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21837602e1057-wk-Fact-41C2754880D15B28AF8532074A70DA6A"
      unitRef="usd">17309000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21837602e1093-wk-Fact-81AA7FFF07FE5F84B6FB6B3F858272C1"
      unitRef="usd">48892000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21837602e1112-wk-Fact-B2A50C77138252D19D547A4E7AE9A283"
      unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21837602e1124-wk-Fact-884E41D60721500B9B6DB0CBE2385DC4"
      unitRef="usd">8300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-5"
      id="d21837602e1128-wk-Fact-51BE0A5789235E38BB6FC0F8D186DE27"
      unitRef="usd">4900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D2017Q4FYYTD"
      decimals="-5"
      id="d21837602e1132-wk-Fact-2206CAEF825A7B415E661250FCE3CE74"
      unitRef="usd">1200000</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8A9FB83B077593F367807F5F59073C57-0-wk-Fact-8B148A8D869C7D19342E7F5F58D51E4C">EMPLOYEE BENEFIT PLANS&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Equity Incentive Plans and ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,511&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,369&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,626&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have several equity incentive plans under which we granted stock options and RSUs, including PSOs and PSUs, to employees and directors. At &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;6,258,319&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under our equity incentive plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Board of Directors (the Board) delegated responsibility for administration of our equity incentive plans to the Compensation Committee of the Board, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;seven&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year life from the date of grant. Stock options issued prior to May 2011 have a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ten&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year life from the date of grant. RSUs granted to our employees and directors generally have a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year vesting term and a one-year vesting term, respectively. PSUs and PSOs granted pursuant to our equity incentive plans vest upon the achievement of a performance target or market condition, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#x2019;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;of the closing price at the beginning of the offering period or&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;of the closing price at the end of each&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;six&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;month purchase period. Compensation expense related to our ESPP was&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, and&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;for the years ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively. As of&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, we had&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;4,238,999&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares available for issuance under our ESPP. Pursuant to the ESPP, we issued&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;483,009&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;330,492&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;434,523&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares of common stock at an average price per share of&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;$12.60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;$15.74&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;&lt;span&gt;$11.20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;during the years ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;Cash received&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;from purchases under the ESPP for the years ended December 31, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$5.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We used a Monte Carlo simulation pricing model to value PSOs that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options, including PSOs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options, including PSOs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We considered both implied and historical volatilities in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#x2019; current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of RSUs, including the PSUs, was based on the closing price of the underlying common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options, including PSOs, during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3,274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,443&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.6 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;167,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$33.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested stock options, including PSOs. The compensation expense for the unvested stock options will be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;2.2 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;308,365&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; PSOs to our President and Chief Executive Officer. In addition to the standard service conditions included in our other stock options, these PSOs &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;equal to or greater than &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;125%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the per share exercise price of the PSO over a period of at least 30 consecutive calendar days. The stock-based compensation expense for the PSO is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The total intrinsic value of stock options exercised during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$54.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$39.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$85.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. Cash received from stock option exercises during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$17.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. The total estimated fair value of stock options vested and recorded as expense during the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$23.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$18.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$13.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Activity for RSUs, including PSUs, during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;149,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$158.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested RSUs, including PSUs. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2.7 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During 2019, in connection with our long-term incentive compensation program, we awarded &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1,926,605&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; PSUs (the target amount) that will vest upon the achievement of a performance target related to a product approval by the FDA (the 2019 PSUs); employees may earn &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;150%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the target amount, or an additional &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;963,136&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares relative to the target amount, if the performance target is achieved before December 31, 2020 and may earn &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the target amount, or up to an additional &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1,926,605&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares relative to the target amount, if we receive a second product approval by December 31, 2021. During 2018 we awarded &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;693,131&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; PSUs that will vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we achieved two of the performance targets for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;281,238&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the 2018 PSUs and determined that it was probable that we would achieve one additional performance target for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;99,281&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; additional 2018 PSUs. As a result, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;141,004&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the 2018 PSUs have vested as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and the remainder are expected to vest over various dates through November 2021. We recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$4.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in compensation expense related to those 2018 PSUs during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;; the remaining unrecognized compensation expense for those 2018 PSUs was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The total unrecognized compensation expense for both the 2019 PSUs and the remaining 2018 PSUs for which we have not yet determined that attainment of the performance target is probable was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$80.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exelixis, Inc. 401(k) Plan (the 401(k) Plan)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sponsor the 401(k) Plan under which we historically made matching contributions to our employees&#x2019; 401(k) accounts in the form of our common stock. We recorded compensation expense related to the stock match of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$3.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. Beginning in 2020, we will make matching contributions to our employees&#x2019; 401(k) accounts in cash&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C32AD472B1B6EB97C5AA7F5F5908E68F-0-wk-Fact-D9C5D13D73CC137AA9237F5F58B96216">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,511&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,369&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,626&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d21848482e751-wk-Fact-551D2539E9F05DFE907BC1A0CF246AB8"
      unitRef="usd">19374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d21848482e770-wk-Fact-EF4AC1DA5F4053C9A67936ABF34EEA3E"
      unitRef="usd">13115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d21848482e789-wk-Fact-4F67CCD12AB2BED737CC7F5F5891F4E7"
      unitRef="usd">7569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d21848482e805-wk-Fact-DABB26A333F95368805EE0A3F3D24A5A"
      unitRef="usd">37228000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d21848482e824-wk-Fact-D2B22307F45B56BCA8A61B11F3A016A4"
      unitRef="usd">27511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d21848482e843-wk-Fact-0353527D2F78D4738D757F5F588D4ADD"
      unitRef="usd">16369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21848482e869-wk-Fact-B80B4F25440472E547D87F5F588B003D"
      unitRef="usd">56602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21848482e888-wk-Fact-C8B01EB4D4335D812B597F5F589067B7"
      unitRef="usd">40626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21848482e907-wk-Fact-423B5741F1E4AE4AE15B7F5F588F008D"
      unitRef="usd">23938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4"
      decimals="INF"
      id="d21848482e925-wk-Fact-39447943AC765D2DBC2EA14F03AEC2EF"
      unitRef="shares">6258319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e956-wk-Fact-EF4074A87B29C34BE97F7F5F58BB0410"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e964-wk-Fact-37843334B29A92906FD67F5F58BBDDDC"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d21848482e981-wk-Fact-0C12880CF35091757AFF7F5F58BA43FB"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d21848482e987-wk-Fact-30752E3720FFDEABB4FB7F5F58D47848"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d21848482e993-wk-Fact-E120DD6B530D91A086DB7F5F58B625B5"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e1029-wk-Fact-E20D554F70E83C75C3167F5F58BF6190"
      unitRef="shares">4238999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e1037-wk-Fact-D79C7D26EB55237FB9817F5F58B7CD97"
      unitRef="shares">483009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e1044-wk-Fact-8FF4163546B0402B63637F5F58BB8448"
      unitRef="shares">330492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e1052-wk-Fact-24EAB99F153DF603BDBA7F5F58BFBBF1"
      unitRef="shares">434523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1060-wk-Fact-AF05FD446844134E6FDD7F5F58C50BCB"
      unitRef="usdPerShare">12.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1067-wk-Fact-C61265D34BE73E5EE35C7F5F58C005E5"
      unitRef="usdPerShare">15.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1075-wk-Fact-D0FF529CE26DA2914C047F5F58BBDD64"
      unitRef="usdPerShare">11.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d21848482e1138-wk-Fact-B074EA2F6EB6BFDA74787F5F58C1C01E"
      unitRef="usd">6100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d21848482e1142-wk-Fact-367CE01BD3993A8994497F5F58BE88F9"
      unitRef="usd">5200000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d21848482e1147-wk-Fact-A5673C7F390AC9D7C1597F5F58BA99CC"
      unitRef="usd">4900000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-10F59E6DD3F790ACAAAE7F5F59086361-0-wk-Fact-CE0C39CB66D34BB4E8A27F5F58C0D3C9">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options, including PSOs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1318-wk-Fact-DE2B41F3BD5B589AABDE106302E5D6E3"
      unitRef="usdPerShare">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1337-wk-Fact-73C683F875185F9688CE442C4FA0E245"
      unitRef="usdPerShare">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1356-wk-Fact-3BEC6957EBF9DF82D4DF7F5F58E481C4"
      unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1377-wk-Fact-65502E67C56B5DD093EF72B78A039501"
      unitRef="usdPerShare">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1396-wk-Fact-CB8848AA60145180B4524A5196E7AEEC"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1415-wk-Fact-5B7D72243E9081CD89327F5F58E48FC6"
      unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-16A08287764CF935FDDB7F5F59089E26-0-wk-Fact-6631E0CAC61F209B4B617F5F58BE5268">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options, including PSOs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B55CF7A6CBDFEC67239B7F5F590824EE-0-wk-Fact-1AE978DED5986CE9EB8E7F5F58BD6215">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options, including PSOs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d21848482e1607-wk-Fact-661AAA8336FE5B87BE1E0A10EFCA0A51"
      unitRef="number">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d21848482e1622-wk-Fact-C82FEFD63C6B5E1BAABF99550A28BA52"
      unitRef="number">0.0281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d21848482e1637-wk-Fact-980DB72FAC3A54FBB90A2196370891B9"
      unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1653-wk-Fact-F51BC9F58F055E4DB4E243471A26B53E"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1668-wk-Fact-5711B58A856258F3ACFCB754FF32C028"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d21848482e1683-wk-Fact-4C4D5E373B415257917532BABECD8C2B"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1699-wk-Fact-0AA75A94751B5027A5E151D20E1FE3EF"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1714-wk-Fact-F74A89497BBE51B78BD7E242964ACE58"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d21848482e1729-wk-Fact-8694284C6E2156AC94AD2381CE57D91B"
      unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d21848482e1745-wk-Fact-298791AA4ACE542B9E92F763FD873510">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d21848482e1759-wk-Fact-44ACB1BB32425233B9ABD887265ECA66">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d21848482e1773-wk-Fact-6809D303C0795650BBF6E975E58BC437">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d21848482e1834-wk-Fact-0ABB1F1DC3275316AB6C096AAE787053"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d21848482e1849-wk-Fact-579ECA1B0AF85D8FA4456C0B323F970F"
      unitRef="number">0.0193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d21848482e1864-wk-Fact-ABD8DE66A15F53B9966E171C9B294562"
      unitRef="number">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1880-wk-Fact-7151803598AC5835AFC7D3621C695C48"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1895-wk-Fact-F961B5E793E25B30B48859BEDDC3CA52"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d21848482e1910-wk-Fact-D3653E6DFCAA5A8ABADD792F4A26D860"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1926-wk-Fact-C7902277EF0A54358AA053CBCB79D6F3"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1941-wk-Fact-1D6CBDD50CAE534794F13D36EF461AE7"
      unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d21848482e1956-wk-Fact-B4E6B8CFE5FB59ACA7814DB3FF6DEA91"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d21848482e1973-wk-Fact-3C506FBE178A5B83ADB04E3F3DC06C76">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d21848482e1987-wk-Fact-3055E989CA985F9D80E6D7C2F4BC45ED">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d21848482e2001-wk-Fact-FCA8A8DD86685B258391923916271FD6">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BF0048AA394D3390A5CE7F5F59083DB5-0-wk-Fact-DD36AFB03B032E3DDB327F5F58C403BB">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options, including PSOs, during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3,274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,443&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.6 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;167,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21848482e2188-wk-Fact-7A1A502FA8F159059CC5FFB4DE8AAF85"
      unitRef="shares">22674000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d21848482e2207-wk-Fact-4E4A9AD22142521EBC92BA1DFB8F1D31"
      unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21848482e2253-wk-Fact-398E5E2A90955EC0AE0F3D4C604EDEFC"
      unitRef="shares">1311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21848482e2272-wk-Fact-6CC94A7E506A5D3EA160EBAF9403E745"
      unitRef="usdPerShare">20.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21848482e2318-wk-Fact-1F0C748368D0548BAC6195FE49BC3303"
      unitRef="shares">3274000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21848482e2338-wk-Fact-CC6CFDED08F65B0D990952D6B79E3530"
      unitRef="usdPerShare">5.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21848482e2384-wk-Fact-1FF32107DA755673AE4F5FC81DE64599"
      unitRef="shares">217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21848482e2404-wk-Fact-78378185F3DE59B38E4BD962EE9257CC"
      unitRef="usdPerShare">16.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21848482e2450-wk-Fact-EC8C6A0791755D5FB3FEBC8AE5EE40A1"
      unitRef="shares">51000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21848482e2470-wk-Fact-1BB496881C70515790F71B0350B4E678"
      unitRef="usdPerShare">22.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21848482e2516-wk-Fact-6ECC717655A63B60B75C7F5F58DB22CA"
      unitRef="shares">20443000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d21848482e2535-wk-Fact-056298AF5AE45F24AA7C08231FDDDC08"
      unitRef="usdPerShare">9.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD"
      id="d21848482e2549-wk-Fact-75842EB164355896AE3C78AD31A3F64C">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21848482e2565-wk-Fact-C582EE8384CA5326981D3322BFAC3CD3"
      unitRef="usd">169299000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21848482e2580-wk-Fact-A845EF6A13A15A3AB10E34AA64B1CAE0"
      unitRef="shares">16216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d21848482e2599-wk-Fact-E14ACB471DD952668E5D6E827D8A3D74"
      unitRef="usdPerShare">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD"
      id="d21848482e2613-wk-Fact-48FDDF47FFF150B79EC22D618FFC51BB">P2Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21848482e2629-wk-Fact-01FC1CFF765B56A6B7DACB78C8E82304"
      unitRef="usd">167449000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2653-wk-Fact-72F6A3F3E14B5EC6B338F54DA3088F8B"
      unitRef="usd">33700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d21848482e2657-wk-Fact-12DE71E8177A5611BA1BBAC56D8EB223">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember"
      decimals="INF"
      id="d21848482e2670-wk-Fact-0A2C8FC5EB0E765692E77F5F58B92990"
      unitRef="shares">308365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember"
      decimals="2"
      id="d21848482e2678-wk-Fact-D3602F6159FCE6BAF7067F5F58BDDA47"
      unitRef="number">1.25</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2708-wk-Fact-CE0761D7AD664B28D2F97F5F58C3A477"
      unitRef="usd">54100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2712-wk-Fact-9769609A4DBC8C524FD67F5F58C4A256"
      unitRef="usd">39100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2716-wk-Fact-95A0D8931DEE536821C57F5F58C3434D"
      unitRef="usd">85200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2733-wk-Fact-C4CB79FCF7EB7E835CA07F5F58C1D63B"
      unitRef="usd">16400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2737-wk-Fact-422DAA66E4FC9609AF757F5F58C402CE"
      unitRef="usd">12100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2742-wk-Fact-5570682C9B2C476A69EB7F5F58B70079"
      unitRef="usd">17600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2758-wk-Fact-F4882B67D96E664717647F5F58C05964"
      unitRef="usd">23400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2762-wk-Fact-E40313A0C907BFF89DEA7F5F58C23166"
      unitRef="usd">18900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d21848482e2767-wk-Fact-7115DB1E0ADE542F9B207F5F58BDE119"
      unitRef="usd">13100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-69B1CF6C5A75CE4735DB7F5F5908FF21-0-wk-Fact-33B0A4C5BF4C31E801CE7F5F58BCFE85">Activity for RSUs, including PSUs, during the &lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(357&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;149,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d21848482e2934-wk-Fact-5CC94C211D9B5250BCE5D469A1A4534F"
      unitRef="shares">4857000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d21848482e2953-wk-Fact-EA86FFCBB68453EB9C5E56ADF23AC77A"
      unitRef="usdPerShare">18.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d21848482e2999-wk-Fact-CA91078372D358F083E2ECCE40102D94"
      unitRef="shares">5842000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d21848482e3018-wk-Fact-824DA26BF6FF598382A3B27806268686"
      unitRef="usdPerShare">19.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d21848482e3064-wk-Fact-F288B4C02F8251A794C109269B62C93B"
      unitRef="shares">1541000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d21848482e3084-wk-Fact-BAEBFC3F8AF85D03A79E9837D1E459EB"
      unitRef="usdPerShare">17.23</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d21848482e3130-wk-Fact-C3DB61CDA63A5C1881114A7BCD854F72"
      unitRef="shares">357000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d21848482e3150-wk-Fact-9704CC1506A9564A9AEDE155F4D5D736"
      unitRef="usdPerShare">18.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d21848482e3196-wk-Fact-430CCC12BA290DB1275C7F5F58DB6A9F"
      unitRef="shares">8801000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d21848482e3215-wk-Fact-A9AF98F2E3AB5488A582871BFE602921"
      unitRef="usdPerShare">19.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d21848482e3229-wk-Fact-D89EBE618C6F517C8256C2DD5BEE0525">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d21848482e3245-wk-Fact-190FE96503185DB4899926942DB21ABB"
      unitRef="usd">149701000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d21848482e3267-wk-Fact-815B6DF998275B9D8DA8F06C7067DF44"
      unitRef="usd">158000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d21848482e3271-wk-Fact-2B70D0264D7D52BF8B14839733496A3B">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d21848482e3279-wk-Fact-DE982995CB285C13B919C3E90F543647"
      unitRef="shares">1926605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member"
      decimals="2"
      id="d21848482e3283-wk-Fact-4BD3A1D50D845626B7CBFE4C3D446F05"
      unitRef="number">1.50</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member"
      decimals="INF"
      id="d21848482e3287-wk-Fact-D5AB3B2FA3335FA09F31A03D09DC0221"
      unitRef="shares">963136</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember"
      decimals="2"
      id="d21848482e3291-wk-Fact-8860E9102DEB5AD3AEDCD55B87333F03"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember"
      decimals="INF"
      id="d21848482e3295-wk-Fact-4546C29D68D55B40882D0AC9E2D35159"
      unitRef="shares">1926605</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d21848482e3300-wk-Fact-E970199132CE57A791A99A62E0ED2B9C"
      unitRef="shares">693131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d21848482e3315-wk-Fact-6DB0F4DE913D5852A2CB827772ADBF89"
      unitRef="shares">281238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d21848482e3319-wk-Fact-CED935ECBA9120835C0A16A57C674CCC"
      unitRef="shares">99281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_exel_StatusAxis_exel_VestedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d21848482e3323-wk-Fact-B7BFED721D59AAB1853216A5A448EC01"
      unitRef="shares">141004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d21848482e3332-wk-Fact-0E15AAA276A95244B6C2F887397F7A4A"
      unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q4_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d21848482e3344-wk-Fact-E90A357DAEAA54D29AA027BB888EAA73"
      unitRef="usd">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q4_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d21848482e3353-wk-Fact-AE7F17C54FA1524E80847C28F904F841"
      unitRef="usd">80200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21848482e3367-wk-Fact-0374CAEC017D6DA0A3597F5F58C3D87D"
      unitRef="usd">4600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-5"
      id="d21848482e3371-wk-Fact-CE3DAA7AE5CBD512219B7F5F58B7BDA5"
      unitRef="usd">3600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="D2017Q4FYYTD"
      decimals="-5"
      id="d21848482e3375-wk-Fact-4B15F1FFDA9F515E1B677F5F58BB73CB"
      unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0C5B40B4E351EEA01FF17F5F590992D6-0-wk-Fact-9D050A9D693CD74DD3357F5F587D22D5">INCOME TAXES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income before income taxes is derived solely from within the U.S. Our income tax provision (benefit) was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total current tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71,580&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(238,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(244,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(237,978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The income tax provision for the year ended December 31, 2019 primarily relates to the utilization of federal net operating loss and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. The income tax benefit for the year ended December 31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California. The income tax provision for the year ended December 31, 2017 primarily related to state taxes in jurisdictions outside of California. Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2019, 2018 and 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reconciliation of the U.S. federal income tax provision (benefit) at the statutory federal income tax rates of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;34%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2019, 2018 and 2017, respectively, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to our income tax provision (benefit) was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83,603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(315,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(34,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(18,308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(237,978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;146,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;110,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,474&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;303,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(61,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;245,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;172,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;244,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2019, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as of&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; December 31, 2019 and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;forecasts of future operating results, as well as considering the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;utilization of net operating losses and tax credits prior to their expiration&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December 31, 2019 and 2018, we continue to carry a valuation allowance of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$61.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$58.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, against our California state deferred tax assets. Prior to December 31, 2018, because of our history of operating losses, management believed that recognition of the deferred tax assets was not more likely than not (as defined in Topic 740) to be realized and, accordingly, had provided a full valuation allowance. The valuation allowance increased by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and decreased by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$360.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended December 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we had federal net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, of which approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$203 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; will expire in the years &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2035&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2036&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and federal business tax credits of approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which expire in the years &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2039&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We also had state net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$450 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which expire in the years &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2036&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and California research and development tax credits of approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$38 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and concluded that an ownership change, as defined under Section 382, had not occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;589&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to current year provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,429&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We do not anticipate that the amount of unrecognized tax benefits existing as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; will significantly change over the next 12 months. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$79.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in unrecognized tax benefits, of which &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$48.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; would reduce our income tax provision and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. &lt;/span&gt;&lt;/div&gt;We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2019 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-59641E987374C7ABDA837F5F59095BC9-0-wk-Fact-193BD6C5EBC0E1EC2D937F5F58826ACB">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income before income taxes is derived solely from within the U.S. Our income tax provision (benefit) was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total current tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,095&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71,580&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(238,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(244,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(237,978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e832-wk-Fact-58486DB9C8720E0197B07F5F58807B67"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e851-wk-Fact-A21ADC96319B9E3563D87F5F5884D02A"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e870-wk-Fact-628C417685AAC30D52C17F5F5883C10E"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e886-wk-Fact-B00F422A93DC2823B9C57F5F58851604"
      unitRef="usd">6095000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e905-wk-Fact-4BE863877200771368877F5F58840253"
      unitRef="usd">6133000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e924-wk-Fact-167EEE6C6A62D463CBB57F5F587E4447"
      unitRef="usd">4350000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e945-wk-Fact-7537B1D5F01F982F4FB47F5F58940E7C"
      unitRef="usd">6095000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e964-wk-Fact-DCF2D7C9848873490C587F5F58832E44"
      unitRef="usd">6133000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e983-wk-Fact-B842FBACEAAC82165E7D7F5F588754A4"
      unitRef="usd">4350000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1066-wk-Fact-5AC1150F644A12D99C8F7F5F58820C01"
      unitRef="usd">71580000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1085-wk-Fact-7DF7B528048895388DC57F5F5886165B"
      unitRef="usd">-238675000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1105-wk-Fact-7040AFA094316756B9CA7F5F5887FE57"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1126-wk-Fact-15D2EB510168845911577F5F5888B44A"
      unitRef="usd">-578000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1146-wk-Fact-1D4FD5B15684098A31927F5F5885878C"
      unitRef="usd">-5436000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1166-wk-Fact-6445B2DE4BA570CDB01F7F5F5882C2A3"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1187-wk-Fact-FEDA12A54EF5FDEB37137F5F588633A6"
      unitRef="usd">71002000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1206-wk-Fact-9FC3F45CFA91E48E1C9A7F5F588018F2"
      unitRef="usd">-244111000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1226-wk-Fact-9A9B1E02395E1802143D7F5F5880ACFB"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1252-wk-Fact-A6ED704EA7B65523846BE5FA5DBBDFF4"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1271-wk-Fact-695D932D76AF546FABA1D6C1D58ED92B"
      unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1291-wk-Fact-CE414B47BA63BD330D71808181883018"
      unitRef="usd">4350000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-93930E4B44714E5B09487F5F5909814B-0-wk-Fact-5FDB57F956FDAC0BD8627F5F58E926FE">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reconciliation of the U.S. federal income tax provision (benefit) at the statutory federal income tax rates of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;34%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2019, 2018 and 2017, respectively, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to our income tax provision (benefit) was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83,603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(315,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(34,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(18,308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(237,978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d21851538e1322-wk-Fact-C2733C856D063983155A7F5F58EB93BC"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="INF"
      id="d21851538e1326-wk-Fact-6A33706AAB51CF6AE2957F5F588440FB"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D2017Q4FYYTD"
      decimals="INF"
      id="d21851538e1330-wk-Fact-550B6C8309D7D4231C997F5F58EBD795"
      unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1493-wk-Fact-09D834D9E708FFBF66287F5F5880239B"
      unitRef="usd">83603000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1512-wk-Fact-262FEF28F05353690D4F7F5F587B66F2"
      unitRef="usd">94939000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1531-wk-Fact-516850E3667907E66C647F5F58EC8600"
      unitRef="usd">53916000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1547-wk-Fact-CDADAC66C65E684EBFD37F5F587864F7"
      unitRef="usd">1148000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1566-wk-Fact-2DED2B57512D9F1C9C647F5F58EA51F6"
      unitRef="usd">4690000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1585-wk-Fact-E9355762A0C183E001BF7F5F587B9A33"
      unitRef="usd">8282000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1606-wk-Fact-B6D3AD992E64943920697F5F58779F7D"
      unitRef="usd">3208000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1625-wk-Fact-C79962EAC0A3705C9DF07F5F5878BD5F"
      unitRef="usd">-315394000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1645-wk-Fact-B0B8E7F70E515717C00F7F5F58EFC4E5"
      unitRef="usd">-34266000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1667-wk-Fact-46DF011C03C840B79AF37F5F587AAB1E"
      unitRef="usd">8299000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1687-wk-Fact-76FFBF4EC45C7149EB527F5F58F1943B"
      unitRef="usd">18308000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1707-wk-Fact-38D7291C13708D20F5787F5F5879D8DF"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1728-wk-Fact-3528DAE6497B73E461697F5F587622BA"
      unitRef="usd">-9177000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1748-wk-Fact-CB0C651BA2EF5D2801E87F5F5879CFB9"
      unitRef="usd">-5998000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1768-wk-Fact-53CCD083586B16FCDA1B7F5F58EAA7EE"
      unitRef="usd">-20548000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1790-wk-Fact-C0D43648E31E3A50D38D126CB9342930"
      unitRef="usd">4228000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1809-wk-Fact-298112E8EDA11BB4997E126CB93CD05A"
      unitRef="usd">1111000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1828-wk-Fact-2D7A4BB876A76A468803126CB9429156"
      unitRef="usd">1239000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1849-wk-Fact-21D3CEF8BAEFA73293847F5F58ED154B"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1868-wk-Fact-37EA7DE2CF227ED09F047F5F58EAB169"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1887-wk-Fact-0D16FD67CF87440D545D7F5F58749069"
      unitRef="usd">1367000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1908-wk-Fact-62BF67C1271DE4F141E57F5F587CF06B"
      unitRef="usd">2386000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1927-wk-Fact-73BAF8E6EF4F6F81214C7F5F58EA73E5"
      unitRef="usd">982000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e1946-wk-Fact-0423BA3AE9A5C02CB1D27F5F58EBEA83"
      unitRef="usd">-5640000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e1973-wk-Fact-A6ED704EA7B65523846BE5FA5DBBDFF4"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21851538e1992-wk-Fact-695D932D76AF546FABA1D6C1D58ED92B"
      unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21851538e2012-wk-Fact-CE414B47BA63BD330D71808181883018"
      unitRef="usd">4350000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FD49BC879D982C7A1C987F5F59095407-0-wk-Fact-C45561BD1F5BAB86945B7F5F587EFA83">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;146,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;110,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,547&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,474&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;303,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(61,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;245,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;172,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;244,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2195-wk-Fact-E869512143F9C469BFFB7F5F58CA1952"
      unitRef="usd">65131000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2214-wk-Fact-E8C348F99F451E7B41F37F5F58C7FE62"
      unitRef="usd">146701000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2229-wk-Fact-586DA21031B56C8551C67F5F58C8BA1D"
      unitRef="usd">110037000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2248-wk-Fact-B5FD02A73A80321BCEB87F5F58C77988"
      unitRef="usd">98467000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2268-wk-Fact-9507393EAC0E60A6FD1F7F5F58C514C0"
      unitRef="usd">26792000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2287-wk-Fact-8CA11E98BB0BC7E5FAA17F5F58C68C01"
      unitRef="usd">29929000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2307-wk-Fact-67446559E2CA7C1E2B9F7F5F58CA2A83"
      unitRef="usd">14966000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
    <exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2326-wk-Fact-783B9390D20F2EB66F527F5F58CBAE2F"
      unitRef="usd">11366000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
    <exel:DeferredTaxAssetsLeasingArrangements
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2346-wk-Fact-42C0E4CF9842C9A16185126F75414250"
      unitRef="usd">11211000</exel:DeferredTaxAssetsLeasingArrangements>
    <exel:DeferredTaxAssetsLeasingArrangements
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2365-wk-Fact-429EB61DA05CD2758737126F753BAD24"
      unitRef="usd">3265000</exel:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2385-wk-Fact-112BC93CF9107E5423FF7F5F58C9DEE7"
      unitRef="usd">8248000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2404-wk-Fact-AAE3ADFBF5D13A9FAD467F5F58C53785"
      unitRef="usd">7160000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2424-wk-Fact-4B7DB09772570146DE437F5F58C9E319"
      unitRef="usd">6547000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2443-wk-Fact-2BD3E4083290D21576137F5F58C45A25"
      unitRef="usd">5474000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2463-wk-Fact-017EBA2F0018DAC9214A7F5F58C7BC95"
      unitRef="usd">345000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2482-wk-Fact-1F88C6118300C2CE495E7F5F58C470E6"
      unitRef="usd">1140000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2503-wk-Fact-79A2AA68ED56B3CD14D87F5F58C6D5B2"
      unitRef="usd">243277000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2522-wk-Fact-8A0ED1D3258BE2D888497F5F58C62363"
      unitRef="usd">303502000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2542-wk-Fact-0DFB6B0E13C7A42663117F5F58C2ABB5"
      unitRef="usd">61659000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2562-wk-Fact-E71B71CD4295F0F8AB2A7F5F58C86A21"
      unitRef="usd">58112000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2583-wk-Fact-950E5444014A4DCBA3EB7F5F58C514B5"
      unitRef="usd">181618000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2602-wk-Fact-A0D454A1CE05BA318EC07F5F58C6BA81"
      unitRef="usd">245390000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2663-wk-Fact-ADE411D7324545265EF07F5F58C2943F"
      unitRef="usd">9244000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2683-wk-Fact-6FF0BD2C26554F4820B47F5F58C57F9A"
      unitRef="usd">1279000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2704-wk-Fact-117A2CEC9C8CFE0C589F7F5F58C93975"
      unitRef="usd">9244000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2724-wk-Fact-9BD7B9031B633413C2D57F5F58CAB1EC"
      unitRef="usd">1279000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e2750-wk-Fact-DEA737C62C295C0FC0A87F5F58C81358"
      unitRef="usd">172374000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e2769-wk-Fact-8D88942AE81178ECC56A7F5F58C70A0F"
      unitRef="usd">244111000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d21851538e2802-wk-Fact-D251E48EB8D6FA6EDA8B69D2C5704475"
      unitRef="usd">61700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d21851538e2806-wk-Fact-4E79747C0BE3B539917F69D2A8E46EBF"
      unitRef="usd">58100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21851538e2811-wk-Fact-E5E27139E7C52E22DA661272567FCC65"
      unitRef="usd">3500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-5"
      id="d21851538e2815-wk-Fact-48B1FD9F5E310D8783147F5F587FA163"
      unitRef="usd">-360800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-6"
      id="d21851538e2826-wk-Fact-895D1EA056CA914A7CB77F5F58E9E44B"
      unitRef="usd">225000000</us-gaap:OperatingLossCarryforwards>
    <exel:OperatingLossCarryforwardswithExpirationDates
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-6"
      id="d21851538e2830-wk-Fact-0EB60AE6788E0C9046AD127833CA91E8"
      unitRef="usd">203000000</exel:OperatingLossCarryforwardswithExpirationDates>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-6"
      id="d21851538e2843-wk-Fact-10181FBBB2551CB988D87F5F58E952CA"
      unitRef="usd">112000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-6"
      id="d21851538e2855-wk-Fact-8BD5578E882D736D55547F5F58EC1ABF"
      unitRef="usd">450000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      decimals="-6"
      id="d21851538e2868-wk-Fact-030AB2F3B473EB7EB7E17F5F587E0812"
      unitRef="usd">38000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7FFC1384275813870F2C7F5F59092802-0-wk-Fact-75B1419605A862B037E57F5F587CCF2D">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;589&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to current year provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,429&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e3049-wk-Fact-F5544C2495B1C4D94A0C7F5F588D496E"
      unitRef="usd">76060000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d21851538e3068-wk-Fact-14E6CCD1D92F8A913B2D7F5F5887571D"
      unitRef="usd">79342000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I2016Q4Dec30"
      decimals="-3"
      id="d21851538e3087-wk-Fact-3A450DBF07790471F7907F5F5886D8C8"
      unitRef="usd">61809000</us-gaap:UnrecognizedTaxBenefits>
    <exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e3103-wk-Fact-78E22ABC74FF2FE27D6C7F5F588AB808"
      unitRef="usd">589000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
    <exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions
      contextRef="D2018Q1Fiscal"
      decimals="-3"
      id="d21851538e3122-wk-Fact-AB8E186F9B059F090C447F5F5889294B"
      unitRef="usd">-4254000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
    <exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d21851538e3142-wk-Fact-E1FB9C4259700CD26AC17F5F58899653"
      unitRef="usd">247000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e3163-wk-Fact-F7D4A924F4000F608B5B7F5F58815BFB"
      unitRef="usd">2429000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="D2018Q1Fiscal"
      decimals="-3"
      id="d21851538e3182-wk-Fact-522FFEEBB45EE51A3C767F5F58966AD8"
      unitRef="usd">1083000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d21851538e3201-wk-Fact-A9EA098B2EA77739FA207F5F58884172"
      unitRef="usd">17378000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21851538e3222-wk-Fact-ADA0671CEC94BDF82A197F5F58875ABA"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="D2018Q1Fiscal"
      decimals="-3"
      id="d21851538e3241-wk-Fact-DFCF5BC11C6E10EB93DC7F5F5888A111"
      unitRef="usd">111000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d21851538e3261-wk-Fact-C5295E9FC9094045303F7F5F588CF13E"
      unitRef="usd">92000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21851538e3288-wk-Fact-A249E70389817BDAA9247F5F589500DC"
      unitRef="usd">79078000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21851538e3307-wk-Fact-F5544C2495B1C4D94A0C7F5F588D496E"
      unitRef="usd">76060000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d21851538e3326-wk-Fact-14E6CCD1D92F8A913B2D7F5F5887571D"
      unitRef="usd">79342000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-5"
      id="d21851538e3354-wk-Fact-9B0E710E587F92110B3B69DF915FCB7F"
      unitRef="usd">79100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="FI2019Q4"
      decimals="-5"
      id="d21851538e3358-wk-Fact-E3B8FD88A5575D55D8977F5F58E91954"
      unitRef="usd">48100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-35FD2F01BEF267EBD4C77F5F59097B30-0-wk-Fact-6929CE1642C48A283D027F5F58DD7B2D">NET INCOME PER SHARE&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321,012&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;690,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;154,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321,012&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;690,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321,012&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;690,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;302,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;297,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;293,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive effect of employee stock plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,009&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Participating securities included warrants issued in January 2014 to purchase an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of our common stock that were fully exercised in September 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Dilutive securities included outstanding stock options, unvested RSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they are related to shares from PSOs and PSUs that were contingently issuable and the contingency had not been satisfied. See to &#x201c;Note 8. Employee Benefit Plans&#x201d; for a further description of our equity awards. These potential common shares were as follows (in thousands):&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FB4256589003790A720C7F5F59090787-0-wk-Fact-18FA4842B4A9A832D8937F5F58E0DD89">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321,012&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;690,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;154,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321,012&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;690,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321,012&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;690,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;302,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;297,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;293,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive effect of employee stock plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,009&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e825-wk-Fact-1F5C000628DB5810ABB8D6C031E71CAF"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e844-wk-Fact-966DE8BCBCF155018FC0AB2ECBAB06AF"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e863-wk-Fact-E80041C5117CF9436D1F808180B39357"
      unitRef="usd">154227000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e879-wk-Fact-B2ECFB2EBB6B9E0268D27F5F58CF136F"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e898-wk-Fact-4F208D9BE9219D879E7A7F5F58CD007D"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e917-wk-Fact-B53D45454B81ABC3F4CA7F5F58D0D048"
      unitRef="usd">367000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e939-wk-Fact-66D250028471C0C9E5447F5F58D13404"
      unitRef="usd">321012000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e958-wk-Fact-BBE1AC9FE15C4E54033A7F5F58D1554F"
      unitRef="usd">690070000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e977-wk-Fact-DB1F1519C9B6BA1382FB7F5F58D2CD34"
      unitRef="usd">153860000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e998-wk-Fact-C44611D0958468DEEBA27F5F58CD36E9"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e1017-wk-Fact-29286366CEFE526A49407F5F58CEFE5D"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e1036-wk-Fact-D2150373D662D1E2DE3E7F5F58D03557"
      unitRef="usd">-22000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e1062-wk-Fact-8881CAEF75D722FB0FB87F5F58D2B3DD"
      unitRef="usd">321012000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e1081-wk-Fact-E168B5B2CA2DE127F79E7F5F58CF383A"
      unitRef="usd">690070000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e1100-wk-Fact-DC7D199D097337A7A4DF7F5F58CF9D33"
      unitRef="usd">153882000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e1178-wk-Fact-7461894293B55C43BC5671A110CD9A60"
      unitRef="shares">302584000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e1197-wk-Fact-137F5557559754A18B5EA37F1C0ACE01"
      unitRef="shares">297892000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e1216-wk-Fact-028CF4F8A4C6E2035E538081813C15B1"
      unitRef="shares">293588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e1237-wk-Fact-56741C0E8BD15B50AD4C407042B8DAC6"
      unitRef="shares">12425000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e1256-wk-Fact-0C364848F77C556193BAD5CC0B0017A1"
      unitRef="shares">14911000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e1275-wk-Fact-293C296580625077B1356B82146EB75F"
      unitRef="shares">18415000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21846478e1297-wk-Fact-93632B71149D5780817A0E4932B6C1EF"
      unitRef="shares">315009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21846478e1316-wk-Fact-C80150103651525CB70CC7179CB64C23"
      unitRef="shares">312803000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21846478e1335-wk-Fact-300AAABA667196BEB2DA80818183D621"
      unitRef="shares">312003000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21846478e1361-wk-Fact-12C145AC98863A3F72ABC6FA4E0C3BE4"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="2"
      id="d21846478e1380-wk-Fact-EA9446E76D075BD783CEC9BEBC095B38"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2017Q4FYYTD"
      decimals="2"
      id="d21846478e1399-wk-Fact-84EB6CDF1C972769524580818133BECA"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d21846478e1420-wk-Fact-F5CBF3AE37B8593EBE8CE93947271519"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="2"
      id="d21846478e1439-wk-Fact-60A5C0148F765C9CA5BA78B57AD421FA"
      unitRef="usdPerShare">2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2017Q4FYYTD"
      decimals="2"
      id="d21846478e1458-wk-Fact-3B2E1870498EDA767BC880818115346E"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember"
      decimals="-5"
      id="d21846478e1472-wk-Fact-B680472F0F38F2D6DDB21288286C68BF"
      unitRef="shares">1000000.0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E27E78643ACCDA753D337F5F5909A480-0-wk-Fact-6E73BA3438EE58C126B47F5F58E0D490">These potential common shares were as follows (in thousands):&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d21846478e1601-wk-Fact-BE641941195057939726085D94364558"
      unitRef="shares">9111000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d21846478e1615-wk-Fact-8EDBE0093CF659819F4C9E82653D1656"
      unitRef="shares">3968000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d21846478e1629-wk-Fact-900BD1579A09576B9D4CB17071F61808"
      unitRef="shares">1645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2E6ED98E8AEA2C735F107F5F590AD538-0-wk-Fact-26114C5025F2D8CD72267F5F58E23DD8">COMMITMENTS&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019 and August 2019, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;221,464&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of space we have taken possession of as of December 31, 2019 (the Current Premises) under the amended Lease. We expect to take possession of the remainder of the space provided for under the August 2019 amendment on or prior to April 30, 2020, which will increase the space leased to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;228,941&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The term of the Lease continues through October 31, 2031 (the Lease Term). We have &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have made certain tenant improvements on the Initial Premises, for which we received &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in reimbursements in January 2019. We were also provided an allowance of up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for tenant improvements to the space we obtained under the April 2019 amendment which is expected to be received in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,844&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Sublease income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;The 2017 amounts have not been adjusted for the adoption of Topic 842 and continue to be reported in accordance with the previous lease guidance, ASC Topic 840: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,538&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the weighted average discount rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and the weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;11.8 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Build-to-Suit Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;220,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The term of the Build-to-Suit Lease is for a period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;242&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in October 2021 (the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, subject to an annual increase of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;sixty days&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. To the extent that the total development costs of the New Premises exceeds &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$525&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per square foot, we will also pay &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of such excess costs prior to the commencement of the Term, and may be required to secure such amount and the cost of the tenant improvements in excess of the allowance by providing a letter of credit or depositing such amounts in an account with the lessor&#x2019;s lender prior to the start of construction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Build-to-Suit Lease includes &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that, under the guidance provided in Topic 842, we do not have control of the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;New Premises&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the construction period&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Therefore, we will not record a right-of-use asset or lease liability for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Build-to-Suit Lease&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; until the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lease Commencement Date&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We will evaluate the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;classification the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;None&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="FI2019Q4_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember"
      decimals="0"
      id="d21854044e592-wk-Fact-80E6BBC6039BE0291CEEB5FEC034CC02"
      unitRef="sqft">221464</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2019Q3Aug30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember"
      decimals="0"
      id="d21854044e596-wk-Fact-F887E34A9DD0F4FE3877B5FF1AF0DF7B"
      unitRef="sqft">228941</us-gaap:AreaOfRealEstateProperty>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="FD2019Q4YTD_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember"
      decimals="INF"
      id="d21854044e603-wk-Fact-83C129FA21BA511D815D00F66CE1E6AA"
      unitRef="renewal_option">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="I2019Q1_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember"
      decimals="-5"
      id="d21854044e610-wk-Fact-7001F633C4DA516C873EFE8FBA35295D"
      unitRef="usd">8200000</exel:TenantLeaseImprovementsAllowance>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="I2019Q2Apr30_exel_LeaseArrangementsAxis_exel_HeadquartersLeaseMember"
      decimals="-5"
      id="d21854044e614-wk-Fact-48B94D0D2EC2552594FDE0032C8C7F86"
      unitRef="usd">1700000</exel:TenantLeaseImprovementsAllowance>
    <exel:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-81B52285015ADDA628DF163D1A696AB9-0-wk-Fact-C826CEBE2EEBEDB726EC163D24C1CA89">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e773-wk-Fact-6390399346ACBD72AE8D16341E1DA505"
      unitRef="usd">41835000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21854044e792-wk-Fact-DA13EBCD514B898816DC16341E1D2947"
      unitRef="usd">5867000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e853-wk-Fact-2380053AE14C5DEC7CE01635AA15597B"
      unitRef="usd">2728000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21854044e872-wk-Fact-4BE4B7DA059B5367B8F6418F6BB9FD10"
      unitRef="usd">2738000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e887-wk-Fact-465D3B14C4885FD68234A459F458B06C"
      unitRef="usd">48011000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21854044e906-wk-Fact-815F08E795B7532996AD93F122DA0FED"
      unitRef="usd">12099000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e931-wk-Fact-1FE21175AF695E49A9041FADE714E438"
      unitRef="usd">50739000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d21854044e950-wk-Fact-6988D7ACDCF55C3F8C9BA63256DC63AE"
      unitRef="usd">14837000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8EE938BE8D9E5D7A13FE163D56DCEB0D-0-wk-Fact-B79A65E3E6A16930EA8A163D613D7F4C">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,844&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Sublease income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;The 2017 amounts have not been adjusted for the adoption of Topic 842 and continue to be reported in accordance with the previous lease guidance, ASC Topic 840: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21854044e1122-wk-Fact-F027B501B67A55BD896C1BA28A3B9A3E"
      unitRef="usd">2844000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21854044e1141-wk-Fact-55769EECDF9655EBB1E3CE97D442F181"
      unitRef="usd">4189000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseAndRentalExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21854044e1160-wk-Fact-E6AAAF0E3F2EAAF2C0C41636B0435DCD"
      unitRef="usd">3944000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21854044e1176-wk-Fact-036EE7163C5B5F0197A7496F857ED6B4"
      unitRef="usd">1024000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21854044e1195-wk-Fact-91B574E245125033A83AB2A237E61708"
      unitRef="usd">1661000</us-gaap:VariableLeaseCost>
    <exel:OperatingLeasesVariableLeaseExpense
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21854044e1214-wk-Fact-1BF176E64CAE5F8089C0E3510B81394D"
      unitRef="usd">2216000</exel:OperatingLeasesVariableLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21854044e1235-wk-Fact-084EAD785B1A57A1A1732219DF65ED6D"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21854044e1254-wk-Fact-8A5ED058A51C5C17BD84EC5B803A9E7F"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21854044e1273-wk-Fact-56055C31BCA20EE9B0901636C5A2606D"
      unitRef="usd">1225000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:LeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d21854044e1300-wk-Fact-49BEDE3C5DD65250AEE7FDFCBF20C722"
      unitRef="usd">3868000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818"
      decimals="-3"
      id="d21854044e1319-wk-Fact-499FFECFD8EF5BF2A1752D8EF3CC4AFD"
      unitRef="usd">5850000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="D2017Q4FYYTD"
      decimals="-3"
      id="d21854044e1338-wk-Fact-CB89EE2700B75EF892235D634D72F572"
      unitRef="usd">4935000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d21854044e1372-wk-Fact-3FB658FC0818543A8DBA614A01D66133"
      unitRef="usd">2900000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-19C091CF8000E5E21CF8163D9373AF18-0-wk-Fact-65D1393F819E4AE90713163DA0988D7F">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,538&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41,585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1442-wk-Fact-AAA0106978B25A8782AE02D86F724D5E"
      unitRef="usd">4538000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1462-wk-Fact-BE0AB2C43D9D5DD39D0FC75D9067E77A"
      unitRef="usd">4669000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1487-wk-Fact-2F1A87F863DA516A9DE295E06B239B00"
      unitRef="usd">4820000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1512-wk-Fact-4AC69BE8B9A65734A01164E09AE9BBB0"
      unitRef="usd">5147000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1537-wk-Fact-2E8E5170D0F85F6AABA6CC73950CFD6B"
      unitRef="usd">5407000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1562-wk-Fact-E4AB2A256D9C5FAFAE7B99ED644416C0"
      unitRef="usd">41585000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1587-wk-Fact-9E01761AF144517BA1514481AC8FA661"
      unitRef="usd">66166000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1638-wk-Fact-24C1BEEC6309590B876C45D475D802C8"
      unitRef="usd">13685000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1664-wk-Fact-3CD05B8CC19D586EA5D7B5465DFC1509"
      unitRef="usd">1742000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d21854044e1696-wk-Fact-1FE21175AF695E49A9041FADE714E438"
      unitRef="usd">50739000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q4"
      decimals="3"
      id="d21854044e1711-wk-Fact-7B3D28687B185F369022AA1CAA7168AD"
      unitRef="number">0.039</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q4"
      id="d21854044e1715-wk-Fact-0919A0B178C7563CB91F4973FE652D5C">P11Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="-3"
      id="d21854044e1725-wk-Fact-A4A1858A0DEE54A8B22B0DB7532976B7"
      unitRef="sqft">220000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      id="d21854044e1732-wk-Fact-F8C1620F42135C9A861AD36EF86B35A6">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="-5"
      id="d21854044e1736-wk-Fact-646420BBFC785902A8FAF2AEFBB95E6F"
      unitRef="usd">700000</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage
      contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="INF"
      id="d21854044e1740-wk-Fact-47165FCA74975506BCCB575AF8D5AD73"
      unitRef="number">0.03</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage>
    <exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod
      contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      id="d21854044e1744-wk-Fact-61A9FF9AAC108EF6674B704F1A01663F">P60D</exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="-5"
      id="d21854044e1748-wk-Fact-D760A17576B2D7E5DD04A1D8E4E9A04D"
      unitRef="usd">16500000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <exel:AreaOfRealEstatePropertyAvailableToLease
      contextRef="I2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="INF"
      id="d21854044e1753-wk-Fact-45C519828AC1187D86D4164128BD8E47"
      unitRef="USD_PER_sqft">525</exel:AreaOfRealEstatePropertyAvailableToLease>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts
      contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="2"
      id="d21854044e1757-wk-Fact-CC82B77305D5615F8FED6FF86B31F849"
      unitRef="number">0.50</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      decimals="INF"
      id="d21854044e1764-wk-Fact-339B9E2FFC15ED2CB4B0A1D56E95DDCE"
      unitRef="renewal_option">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="D2019Q4Oct31_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember"
      id="d21854044e1768-wk-Fact-8E0F0E4AF2046DA652FEA1D5C4C10693">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember"
      decimals="INF"
      id="d21854044e1860-wk-Fact-BFDDA8BC10EA85232427A1C6E2C93C7E"
      unitRef="usd">1600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember"
      decimals="INF"
      id="d21854044e1864-wk-Fact-35F140FA4205D4641081A1C74C6476C9"
      unitRef="usd">1100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember"
      decimals="INF"
      id="d21854044e1876-wk-Fact-DABDCE6FDB030971470C7F5F58E8DBCB"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A538C5202A04FFDB57C77F5F590ADD03-0-wk-Fact-046940B155AF1E740D747F5F58B53506">QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Selected unaudited quarterly financial data was as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fiscal 2019 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;172,080&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;184,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;184,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;84,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fiscal 2018 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;213,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;228,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128,633&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;155,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;168,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;116,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;85,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;111,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126,630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;360,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Total revenues for the quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 included &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$20.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$50.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$15.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; in milestone revenue, respectively, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$66.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$25.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$42.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$29.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; during the comparable periods in 2018. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross profit is computed as net product revenues less cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Net income for the quarter ended December 31, 2018 included a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$244.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(4)&lt;/span&gt;&lt;/div&gt;The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3135D368B7F3DD3680017F5F590A7FC3-0-wk-Fact-FA2427EFF2941B7B474C7F5F58B17F3B">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Selected unaudited quarterly financial data was as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fiscal 2019 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;172,080&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;184,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;184,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;84,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fiscal 2018 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;213,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;228,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128,633&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;155,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;168,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;116,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;85,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;111,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126,630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;360,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Total revenues for the quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 included &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$20.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$50.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$15.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; in milestone revenue, respectively, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$66.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$25.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$42.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$29.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; during the comparable periods in 2018. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross profit is computed as net product revenues less cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Net income for the quarter ended December 31, 2018 included a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;$244.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d21852399e804-wk-Fact-C1E07B137388B9909C841652616595C8"
      unitRef="usd">215487000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d21852399e823-wk-Fact-C2EFD4E6A78C3C4CEC5A7F5F588B1AC6"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d21852399e842-wk-Fact-824CAC38F5DE2DC211EF7F5F589278E3"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d21852399e862-wk-Fact-7967A8D5F17E5B17A2BA58633F788DD1"
      unitRef="usd">240310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d21852399e884-wk-Fact-74018E785E58E84E188716525FEB5A39"
      unitRef="usd">172080000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d21852399e903-wk-Fact-C9C3E783C9B463C654C7165261390F92"
      unitRef="usd">186136000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d21852399e922-wk-Fact-24A4DF6F7F7DA71223F8165261498C06"
      unitRef="usd">184231000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d21852399e942-wk-Fact-C32991CDC468E2BACB827F5F5886972D"
      unitRef="usd">184406000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d21852399e962-wk-Fact-C6F7372A9DD53E8F93BD1652613ED21F"
      unitRef="usd">84559000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d21852399e981-wk-Fact-E9722914CF69437CCFB07F5F5889248B"
      unitRef="usd">91989000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d21852399e1000-wk-Fact-DFC1999710D194C909BB7F5F58811093"
      unitRef="usd">115606000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d21852399e1020-wk-Fact-72D92CAA9A005123AF2072EE139444BA"
      unitRef="usd">77316000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d21852399e1040-wk-Fact-55593AD00B926DBF4848165261609C67"
      unitRef="usd">75775000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d21852399e1059-wk-Fact-BAFCD1021CC296BB43F57F5F58E4146D"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d21852399e1078-wk-Fact-2EAF231F62414193B3FD7F5F58E45197"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4QTD"
      decimals="-3"
      id="d21852399e1098-wk-Fact-57E5FD7BF1505D4DBB0E410715DDE846"
      unitRef="usd">68743000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1YTD"
      decimals="2"
      id="d21852399e1200-wk-Fact-730F9524DFC32083782D1652614E9C3F"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d21852399e1219-wk-Fact-5068BC14018D8D0640997F5F5889F6F2"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d21852399e1238-wk-Fact-B7413851170E9CE475957F5F58871685"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4QTD"
      decimals="2"
      id="d21852399e1258-wk-Fact-6D81F080457554B896D74D3E7A58F612"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1YTD"
      decimals="2"
      id="d21852399e1278-wk-Fact-270C35857391E0A3218816526122E231"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d21852399e1297-wk-Fact-5E76DAAA147F38D45FD07F5F58E37835"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d21852399e1316-wk-Fact-3D96054223FB28EA02A27F5F588ACEAD"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4QTD"
      decimals="2"
      id="d21852399e1336-wk-Fact-3EC10EA658C95F6E9DC7CE3C5302D172"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d21852399e1554-wk-Fact-E16071141CD1766C20441652E71665BC"
      unitRef="usd">213719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d21852399e1573-wk-Fact-D8B2C133E615591E43F51652E8B80C17"
      unitRef="usd">186108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d21852399e1592-wk-Fact-15ECBB824AC2020229B21652EA59724F"
      unitRef="usd">225397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d21852399e1612-wk-Fact-B120D46DCFB2B5584DA91652EBFDD4A8"
      unitRef="usd">228602000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d21852399e1634-wk-Fact-4BFC2173FE8CD023E4DE1652ECF50B46"
      unitRef="usd">128633000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d21852399e1653-wk-Fact-1D4867DCB0B0505CABDC1652EE96A029"
      unitRef="usd">139839000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d21852399e1672-wk-Fact-783462EC6E31CEEAFB801652F036F937"
      unitRef="usd">155586000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d21852399e1692-wk-Fact-186E92B36848EE059A411652F1D873F1"
      unitRef="usd">168873000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d21852399e1712-wk-Fact-9229323C1999DE600D621652F2D1CD8F"
      unitRef="usd">116307000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d21852399e1731-wk-Fact-1878E4101F4E4BE733F61652F47272C7"
      unitRef="usd">85770000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d21852399e1750-wk-Fact-B0A5B209F67050BD84751652F6139CD4"
      unitRef="usd">125176000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d21852399e1770-wk-Fact-35BDDE76E6FD6A4834641652F7B934E1"
      unitRef="usd">111602000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d21852399e1792-wk-Fact-C3B74ACC2FAB0204CEEC1652F8EA30FA"
      unitRef="usd">115857000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d21852399e1811-wk-Fact-2A61712E2A00F8894F561652FA53B7EB"
      unitRef="usd">87494000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d21852399e1830-wk-Fact-FA8147605AF0415A359D1652FBEE5B9B"
      unitRef="usd">126630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d21852399e1850-wk-Fact-DCD66E9A9071C72C66E71652FD8E858F"
      unitRef="usd">360089000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q1YTD"
      decimals="2"
      id="d21852399e1952-wk-Fact-462087F7B43982A5E9341653031AB314"
      unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d21852399e1971-wk-Fact-033B89D9FAA9EAF0F18716530533511B"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d21852399e1990-wk-Fact-38BEFA9EE3DFE5CE1FEA165306CE73BB"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d21852399e2010-wk-Fact-C2D7090D979BA66883381653087840B5"
      unitRef="usdPerShare">1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q1YTD"
      decimals="2"
      id="d21852399e2030-wk-Fact-F30AC20834EDAA7A81C516530A2F8D64"
      unitRef="usdPerShare">0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d21852399e2049-wk-Fact-4EAFB3B738D34D43872616530C09DE7B"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d21852399e2068-wk-Fact-E3B1401792EF5878CCCD16530DAAD2D0"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d21852399e2088-wk-Fact-C58C147223B79517F7C916530F4AB788"
      unitRef="usdPerShare">1.15</us-gaap:EarningsPerShareDiluted>
    <exel:MilestonePaymentsEarned
      contextRef="FD2019Q1YTD"
      decimals="-5"
      id="d21852399e2108-wk-Fact-E30F5DA4F241F43044A516564D753F71"
      unitRef="usd">10000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d21852399e2112-wk-Fact-29829017F12F3C280B8B16564C47694C"
      unitRef="usd">20400000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d21852399e2116-wk-Fact-69325998A593E7EBE07516564F635159"
      unitRef="usd">50600000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2019Q4QTD"
      decimals="-5"
      id="d21852399e2120-wk-Fact-588B28C8571EEEA7244116564C6596F9"
      unitRef="usd">15100000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2018Q1YTD"
      decimals="-5"
      id="d21852399e2124-wk-Fact-808839D2F9C47C5C9A5A16564F99B246"
      unitRef="usd">66500000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d21852399e2129-wk-Fact-D37730A0CF00FDBC508B16564F7B4189"
      unitRef="usd">25800000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d21852399e2133-wk-Fact-0C898E65A138C88ED44A16564F3E60ED"
      unitRef="usd">42600000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d21852399e2137-wk-Fact-2FFB07E841B99436B82016564CC4AADB"
      unitRef="usd">29600000</exel:MilestonePaymentsEarned>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2018Q4QTD"
      decimals="-5"
      id="d21852399e2155-wk-Fact-761F7CECD2611B26E9221658659CAA99"
      unitRef="usd">244100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830398768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830469840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">REVENUES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>957,621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>738,529</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>402,569</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(197,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(119,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(53,561</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>759,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>619,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>349,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>161,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>192,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>96,637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,905</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>207,825</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>234,547</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>103,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>967,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>853,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>452,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, license revenues and research and development services revenues were recorded in accordance with Topic 606 during the years ended December&#160;31, 2019 and 2018 and Topic 605 during the year ended December&#160;31, 2017. During the periods presented in accordance with Topic 606, net product revenues and license revenues related to goods and intellectual property licenses transferred at a point in time and research and development services revenues related to services performed over time. License revenues includes the recognition of the portion of upfront payment milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues. Research and development services revenues includes the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned under our collaboration agreements. Other collaboration revenues were recorded in accordance with Topic 808 for all periods presented and includes product supply revenues, net of product supply costs and the royalties we paid to GSK on sales by Ipsen Pharma SAS (Ipsen) of products containing cabozantinib. Profits on the U.S. commercialization of COTELLIC for the years ended December 31, 2019 and 2018 were also included other collaboration revenues, and losses on the U.S. commercialization of COTELLIC for the year ended December&#160;31, 2017 were included in selling, general and administrative expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>733,421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>599,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>324,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>759,950</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>619,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>349,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of CVS Health Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>770,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>632,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>367,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182,879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>69,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>967,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>853,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>452,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic regions based on the ship-to location. Collaboration revenues are attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,493</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>75,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>119,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(403</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(153</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(350</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(74,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24,741</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,322</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,038</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,916</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,276</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>129,936</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,791</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(128,733</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(15,035</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(44,946</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(188,714</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reserves for chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contract assets were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, and are presented in p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">repaid expenses and other current assets in the accompanying Consolidated Balance Statements. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contract liabilities were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$15.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, and are presented in l</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ong-term portion of deferred revenue in the accompanying Consolidated Balance Sheets.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For those contracts that have multiple performance obligations, c</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ontract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Significant changes in contract assets during the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were a result of the determination that it is probable that we will earn a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone from Takeda Pharmaceutical Company Limited (Takeda) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the submission of a regulatory application in 2020 for cabozantinib as a treatment for patients with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">second-line </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in Japan</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. This contract asset was recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">repaid expenses and other current assets in the accompanying Consolidated Balance Sheets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, offset by the effect of reporting the Takeda contract asset and liability on a net basis.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues that were included in the beginning deferred revenue balance for those years. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$161.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$198.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$63.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our performance obligations had not been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; f</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or additional information about our performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842698080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">33,097<span></span>
</td>
<td class="nump">26,348<span></span>
</td>
<td class="nump">15,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">336,964<span></span>
</td>
<td class="nump">182,257<span></span>
</td>
<td class="nump">112,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">228,244<span></span>
</td>
<td class="nump">206,366<span></span>
</td>
<td class="nump">159,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">598,305<span></span>
</td>
<td class="nump">414,971<span></span>
</td>
<td class="nump">286,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">369,470<span></span>
</td>
<td class="nump">438,855<span></span>
</td>
<td class="nump">165,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">27,959<span></span>
</td>
<td class="nump">12,840<span></span>
</td>
<td class="nump">4,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="num">(3,537)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">28,639<span></span>
</td>
<td class="nump">13,237<span></span>
</td>
<td class="num">(7,333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">398,109<span></span>
</td>
<td class="nump">452,092<span></span>
</td>
<td class="nump">158,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">77,097<span></span>
</td>
<td class="num">(237,978)<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">302,584<span></span>
</td>
<td class="nump">297,892<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">315,009<span></span>
</td>
<td class="nump">312,803<span></span>
</td>
<td class="nump">312,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 759,950<span></span>
</td>
<td class="nump">$ 619,279<span></span>
</td>
<td class="nump">$ 349,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 207,825<span></span>
</td>
<td class="nump">$ 234,547<span></span>
</td>
<td class="nump">$ 103,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Basic Diluted Other Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6833731248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge on goodwill | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Percent discount for prompt payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Discount expected to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MedicarePartDFundingMandate', window );">Medicare Part D Funding Mandate</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InventoryManufacturedBeforeRegulatoryApproval', window );">Materials in inventory balances | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Cost of goods sold is related to product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting From Discovery Efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products Derived from Cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products Derived From Other Compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InventoryManufacturedBeforeRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Manufactured Before Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InventoryManufacturedBeforeRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MedicarePartDFundingMandate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare Part D Funding Mandate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MedicarePartDFundingMandate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842950640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues Disaggregated by Geographic Region) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,244<span></span>
</td>
<td class="nump">632,927<span></span>
</td>
<td class="nump">367,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,771<span></span>
</td>
<td class="nump">182,879<span></span>
</td>
<td class="nump">69,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,760<span></span>
</td>
<td class="nump">$ 38,020<span></span>
</td>
<td class="nump">$ 14,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MX7<5=L'8O?W'QA?!OH-?=]%_ 5!+ P04    " "N@5E0F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( *Z!65"Q*LA<?P,  "\1   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULC9AK;YLP%(;_"N('#'PAERJ)U#2:-FF3JD[;/M/$25 !9T"2
M[M_/&$J)S^MJ7P(X[SG']NO'7!977;W41Z6:X+7(RWH9'IOF=!=%]?:HBK3^
MI$^J-/_L=56DC;FL#E%]JE2ZLT%%'O$XGD1%FI7A:F';'JO50I^;/"O58Q74
MYZ)(J[]KE>OK,F3A6\-3=C@V;4.T6IS2@_JAFI^GQ\I<14.675:HLLYT&51J
MOPSOV=U&3-H J_B5J6L].@_:H3QK_=)>?-TMP[CMD<K5MFE3I.9P40\JS]M,
MIA]_^J3A4+,-')^_9?]L!V\&\YS6ZD'GO[-=<UR&LS#8J7UZSILG??VB^@$E
M8="/_INZJ-S(VYZ8&EN=U_8WV)[K1A=]%M.5(GWMCEEIC]?N'RG[,!S ^P ^
M!,SB#P-$'R"& /9Q!=D'R/> Q,Y6-Q0[-YNT25>+2E^#JK/WE+:KB-U),_O;
MMM%.MOW/3$]M6B^K>!%=VC2]8MTI^$C!!D5D<@\%."JPYB2<WQ9XH IQJ]A0
MA<1=$'",PH:+47B"PR4,ES9<CL(GSA11Q1072&"!A(3/G )4,<<%)K# A(0S
MUV4@\=@\A26F--[Q>0TD I>8P1(S&B^=$D#BL7H.2\QIO.LUD'C,9C$F+J89
M7+^1QN,X\W#-2 9.R 8:C^D,PGW/.,W@VHXT'M\9YI<)FL%U'FD\UC.,.:,4
M<]=\I/&YCUEG%&5.W <:G_L8>$9Q%L1]H/&YCYEGE&A!W <:G_L8>T:A%L1]
MH/&YC\EGE&M!W <:C_L<L\\IU\)U'VD\[G/,/J=<2]=]I/'=US'[G'(M7?>1
MQN,^Q^QSRK5TW4<:WU@P^YQR+1.W"M#XJF#V.>5:NFL,:7QK#+//*=>2K#%P
MN_?Y@MGGE&LY=ZO\_QV?8_8YY3HA*QG<]'U5,/N<<IVPVRJ;7I-83=EIIH))
M,9]./?X(O <(RG?B/A+WFLFHFH@3,1=\!/)M,;P5"(IYXCQ=KY'&]WR-MP)!
M,4]<?(#&9Y/P/,93S!,7'Z3QV8.W D$Q3UQ\D,:S10N\%0B*^<1=V$CCV7 $
MW@H$Q7SB;M%(X_H2C=XF"U4=[)MZ'6SUN;2?"4:MP]> >V[?1M_EW:>$[VEU
MR,HZ>-:->:>U;YY[K1MENA)_,@,^JG0W7.1JW[2G4W->=:_PW46C3_WGB6CX
M1K+Z!U!+ P04    " "N@5E0MBD7D84$  "3%0  &    'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;(68W6[C-A"%7\7P_:XT0_$O< Q47BQ:H 6"+;:]5F(F
M-E:R7$F)MV]?2E8,>V:8WL22<H8\0Y$?1UR=VNY'OPMA6/QLZD-_O]P-P_$N
MR_JG76BJ_G-[#(?XG^>V:ZHAWG8O67_L0K6=@IHZPSPW65/M#\OU:GKVT*U7
M[>M0[P_AH5OTKTU3=?^6H6Y/]TM8OC_XMG_9#>.#;+TZ5B_ASS!\/SYT\2Z[
MM++=-^'0[]O#H@O/]\M?X&ZCS!@P*?[:AU-_=;T84WELVQ_CS6_;^V4^.@IU
M>!K&)JKX\Q8VH:['EJ*/?^9&EY<^Q\#KZ_?6OT[)QV0>JSYLVOKO_7;8W2_=
M<K$-S]5K/7QK3[^&.2&]7,S9_Q[>0AWEHY/8QU-;]]/?Q=-K/[3-W$JTTE0_
MS[_[P_1[FMM_#Y,#< [ 2P 4'P:H.4"1@.SL;$KU2S54ZU77GA;=^6T=JW%2
MP)V*@_DT/IS&;OI?S+:/3]_6IEAE;V,[LZ0\2_!*@K>*#5<8?9%DL?^+"11-
MX!2OKN.-'*_$>#7%%]?QEB1QENA)<C@G88S.@63"90H*:Q/9%**;@KMQQ,U9
M8JZZT4[;@HXKERGKM/:R&RVZT=R-)VXTZP; YU81-X+,H+4@NS&B&\/<V)RX
M,;P;=,X0,USEG7*R%2M:L=P*F0VE99V@\8Z\S U7*;@>O1LO3O3BN!<R%TK'
MAR6'\3T1-USGO,TAL9Z\:,=S.V0RE)[/8&64T\0-EX%VZ*SL!G*943GWPR"5
MLYX*YSPC%9?I/ Y0PD^"F<#]:.H'>.86%?6]$718%/'%)AS)  7DC@QUA*PG
MHXQCAOY/=NM'!C)P(EM*Y%ES.X6@H#-(D#GTJ>&1B0P<R98B&3ALP3EM*)\V
MDK! 1)=88B!S&33;]&P"[""S%#A,'84I"#2-*Y!N>Y(L]WEJE&6@ B<J[:@$
M 996T9)C(\D0KO;'6S\R5(%3U5&J L>E<I;.U8T@ X<J-3XR58%CU5&L@@!,
M9\%3/X*L\#JQ2%'&*G*L4AJ4R'D)$%<%\2/(; &)Z8PR59%3E6XG)8JT+.CP
M2++XOE(U::(HY4RE54B)')9QEMJ"C8^@RW5A$Q,:9:HBIZJC5$6.2Z,]\\-5
MD0JI;1!EJB*G*JV-2N2P+%P.E#^"###WJ0DD$Q5YJ<MJ-12*6 2;*!Q1!B\*
MX*4U-7*BHBHH5P05)#<2E+&+'+NT*"R1\Q1\+ OIWB;I5.%4HIA%&;S(P>OI
M1B!I:+'VL>;6B8Q<]&R3]8E<E Q)Q2'I*205IQ\=V \EMSYD.BI.1T_IJ#CV
M5$[K*5&4\B*347$R4L*4BA,/,6X); E(0C N+LJ$I\01 &>C9V< G'HJIU_#
M&T'UR:9*(26C47$T>HI&Q9GW*7[;*\W.) 2A<WG\W$IXDO&H.!X]I9:2OO&=
M]JP(EH3QLZ[0*4\R214G*5 HE;/H^E!&KLPEH5B99U>G8^-QY1]5][(_](O'
M=AC:9CH.>V[;(<1&\\^QN5VHMI>;.CP/XZ6-U]WYF/!\,[3'^0@TNYS#KO\#
M4$L#!!0    ( *Z!65 $<([^,@(  'X'   8    >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&ULC97M;ILP%(9O!7$!L?DF$4%:,U6;M$E1IVV_G>0DH!I,;2=T
M=S_;4!3 ;<F/^.L]KY_C@^RL9?Q9% #2>:UH+;9N(66S04@<"ZB(6+$&:K5R
M9KPB4@WY!8F& SF9H(HB'^,85:2LW3PS<WN>9^PJ:5G#GCOB6E6$_WL RMJM
MZ[EO$T_EI9!Z N590R[P"^3O9L_5" TNI[*"6I2L=CB<M^X7;[/SL XPBC\E
MM.*N[^A4#HP]Z\'WT];%F@@H'*6V(*JYP0XHU4Z*XZ4W=8<]=>!]_\W]T22O
MDCD0 3M&_Y8G66S=U'5.<"97*I]8^PWZA"+7Z;/_ 3>@2JY)U!Y'1H7Y=XY7
M(5G5NRB4BKQV;5F;MNU6HJ0/LP?X?8 _!'CAAP%!'Q!, E!'9E+]2B3),\Y:
MAW?5:HC^*+Q-H [SJ"?-V9DUE:U0L[?<PUZ&;MJHUSQT&O].XX\5N[DBC@8)
M4@ #A6^E\$U\,*+P[0:!U2 P!N'(()BDT6D2HZF-!J_P--G=9ZH13&B%"2TP
MX02FT\1WVWBX^TUX%@A'2)$5*;(@11.D:+;3E.4CQ0@BMD+$EBK'=H/$:I L
MJ'*RJ,J?J48PJ14F75#E='9@(;:7>8ER!+6V0JT7U'D]VRK 81IX<ZBYTE^O
MTR1^%TI=Z-9+!ENPDNDM@Q=S6:3O@:&[BU"_3#\)OY2U< Y,JCO5W'QGQB0H
M6[Q2WW>A'L-A0.$L=3=1?=Z]"-U LJ9_[=#PY.;_ 5!+ P04    " "N@5E0
MG<E)GFD$  #C$P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(V8W6[C
M-A"%7T70?2QR^!\X!F(;10NT0+!%VVO%9F)C)<N5E'C[]J5DQ:L,A]O>V)+\
M<7B&(N?07%Z:]FMW\+[/OM75J7O(#WU_OB^*;G?P==DMFK,_A5]>FK8N^W#;
MOA;=N?7E?FQ45P4PIHNZ/)[RU7)\]M2NELU;7QU/_JG-NK>Z+MM_UKYJ+@\Y
MSS\>?#F^'OKA0;%:GLM7_[OO_S@_M>&NN$79'VM_ZH[-*6O]RT/^R.^W@@T-
M1N+/H[]TL^ML2.6Y:;X.-[_L'W(V*/*5W_5#B#)\O?N-KZHA4M#Q]Q0TO_4Y
M-)Q??T3_:4P^)/-<=G[35'\=]_WA(;=YMO<OY5O5?VDN/_LI(95G4_:_^G=?
M!7Q0$OK8-54W?F:[MZYOZBE*D%*7WZ[?Q]/X?9GB?S2C&\#4 &X-N/YA S$U
M$-\;R!\VD%,#B1H4UU3&L=F6?;E:MLTE:Z^O]UP.LXC?RS#ZN^'A.-CC;V%X
MNO#T?<6971;O0Z")65\9F#,WH@C1;UT U<4:HN;PN8--3&CU&=G&"&>.5B'(
M1,480,P#<$8'D&0 .0:0GP)P-%)71HW,:62<-L:@9#8Q9I6PH%'.,2852&-H
MU8I4K8BT@0Z@R0":2%N@M*^,G@D5@CF#LHXIT$*BR;:-*:Z8UK1D0THVA&2)
M)!M"LG8:89L8XQ9 H=2V!,:!F\0RL:1J2ZA&$V=MXR$$"Q*K)C"FA<;S*\:X
M<N'-T:H=J=H1JE$_:Q?UHYP5#*^*&)-<.H/6V#;&P&JE$ZN",[KL,4*WP76/
MQ9-$.VD8$DYP4EBK< TC.*Z52Y4AGJC8G%C2-A&"K,B/'(CL'<X>XH$V3CF<
M?(QQL)+AW&-,6BL2LND2SD4L&QB6+:*.HO?UG\B60.ZL-@G'X;1C<,(R %O&
M!,U[TC92'$,"U]<M =T))5(+@_8+K@C-@#4K:@V*:&K$&!<@(MTQ=F>$2,T-
MVJ8XX5. ?8H31N7L?",Q"8^YX+S, 59.F955*8?FM%UQPJ\ ^Q6/+<:8V&,)
M["Z,N#/89@E0"I6J1+1C<<*R %O6!,UW,0(XXW@/2'#:,8:+[9;@N)( J3&G
M;8N[N(A"8I,!M(4 82& +62"[%SM@B&#W! 4+ 2>;03%%BJQF0/:/( 3HO%^
M?X*0Z&C3'E.PP.5M2U!L(1-U%&B[ B!>5BH$;1U 6(? U@%QT1<,E,7;*X*#
ML,*B\D!R0MF$60/M(D"XB, N H1!A'US5-E(#BP36#K),98HRD";"1!F(E(3
MEJ[KH/___S:@ZRM0_P>B 31163'*.86=F. T=V <'L"8$S+4L]2[IRLL$!4V
M98Q 5SH@*EUJ  5=Z02U6<8#.$'SA($9B_U@0W%"*HEW!03'F9 :K_MB=M)1
M^_9U/$7JLEWS=NJ' X/9T]M)U2,,)R7H^9K?;Z_G3=_#7(^_?BO;U^.IRYZ;
MOF_J\;3DI6EZ'V2& IQG!U_N;S>5?^F'2Q.NV^NQT_6F;\[3D5IQ.]=;_0M0
M2P,$%     @ KH%94"\/.L ^ @  B08  !@   !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q]5=N.FS 4_!7$>]=@;DE$D#:)JE9JI6BKML\..0EH#::VDVS_
MOK8A+#'NOH!]F!G/V'#(;XR_B@I >F\-;<7:KZ3L5@B)LH*&B"?60:N>G!AO
MB%13?D:BXT".AM10A(,@10VI6[_(36W/BYQ=)*U;V'-/7)J&\+\;H.RV]D/_
M7GBISY74!53D'3G##Y _NSU7,S2J'.L&6E&SUN-P6OO/X6J7:;P!_*KA)B9C
M3R<Y,/:J)U^/:S_0AH!"*;4"4;<K;(%2+:1L_!DT_7%)39R.[^J?37:5Y4 $
M;!G]71]EM?87OG>$$[E0^<)N7V#(D_C>$/X;7($JN':BUB@9%>;JE1<A63.H
M*"L->>OO=6ONMT'_3G,3\$# (R%,/R1$ R%Z)\0?$N*!$%L$U$<Q>[,CDA0Y
M9S>/]Z?;$?T2A:M8[7ZIBV:SS3.U/4)5KT48Q3FZ:J$!L^DQ>(H9$4BICTM@
MUQ(;/*/CQP6V<T2:/$)V<T@8+-TN(F?0R A$#T$3MT#L%(B-0#P5P);+38])
M#*8UF B'06CGG</291!D@95Y#@N3&./,[3IQNDX<L5.W0.H42.>QH\R*W6/2
M:>S,3K.=@SY%B?6J[>:@]#^GG#G=9@ZW"\MMYCBD.%O8AS2'I8ME%J:6XSE,
M']+2WF,T^2 ;X&?3[(17LDLK]7L]J8[]]!GK#]JJ;U2?[=OBNTS?I+\3?JY;
MX1V85.W"?-0GQB0HE\&3,EBI_\(XH7"2>IBI,>^[8S^1K!L:/QK_/L4_4$L#
M!!0    ( *Z!65#^4ZSN[P$  -L$   8    >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL?53;CILP$/T5Q'O77--N!$B;1%4KM5*TU;;/#@P7K8VI;<+V[VL;
MAR6 ]@5[QN><N>!Q,C#^*FH Z;Q1THK4K:7L]@B)O :*Q0/KH%4G)>,42V7R
M"HF. RX,B1(4>-X.4=RT;I88WYEG">LE:5HX<T?TE&+^[P"$#:GKNS?'<U/5
M4CM0EG2X@E\@7[HS5Q::5(J&0BL:UCH<RM1]\O>G2.,-X'<#@YCM'5W)A;%7
M;7PO4M?3"0&!7&H%K)8K'($0+:32^&LUW2FD)L[W-_6OIG95RP4+.#+RIRED
MG;I?7*> $O=$/K/A&]AZ8M>QQ?^ *Q %UYFH&#DCPGR=O!>24:NB4J'X;5R;
MUJR#U;_1M@F!)003P=]]2 @M(7PG1!\2(DN(%@0TEF)Z<\(29PEG@\/'O]MA
M?8G\?:2ZGVNG:;8Y4^T1RGO-_/ Q05<M9#&'$1/,,1,"*?4I1+ 5XA"LZ,%]
M@.,:L8OO(:<UQ/<>M[,(-PL-C4!X5VB\+1!M"D1&()H+1-ZB4R,F-IC68#[Y
M7K3HYW&-\N/=HMXUQELDBV:_F *OS/@()V=]*W6G9MYI0I\"?446_H.:W''0
MWF7&L?^)>=6TPKDPJ2Z@N28E8Q)4@MZ#RJU6+\UD$"BEWGY6>S[.VVA(UMFG
M!$WO6?8?4$L#!!0    ( *Z!65!^T,>T/00  %,4   8    >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&ULE9AAC^(V$(;_"N([%\_8<>P5('594"NUTNI.;3]G
MP;N@2PA-LLOUWS<)60Z/)T"_0!+>F7G'=IZ83(]%^;W:.E>/?N39OIJ-MW5]
M>(BB:KUU>5I]*0YNW_SR6I1Y6C>GY5M4'4J7;KJ@/(M0"!WEZ6X_GD^[:\_E
M?%J\U]EN[Y[+4?6>YVGY[Z/+BN-L#.//"U]W;]NZO1#-IX?TS7US]9^'Y[(Y
MB\Y9-KO<[:M=L1^5[G4V_@4>5FC;@$[QU\X=JXOC4=O*2U%\;T]^V\S&HG7D
M,K>NVQ1I\_7A%B[+VDR-CW_ZI.-SS3;P\O@S^ZIKOFGF):W<HLC^WFWJ[6QL
MQJ.->TW?L_IK<?S5]0W%XU'?_>_NPV6-O'72U%@76=5]CM;O55WD?9;&2I[^
M.'WO]MWWL<__&<8'8!^ YP# JP&R#Y _ ^35 -4'J', )E<#XCX@/@<H?35
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M<DR XC+,,H$!LP-P!\:LHF8AO-&EE8:ZN27S#?'@!8:\<4R'!L-*5J,8N$6
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MI#DN3Z^Y3B=U<>A?X47G]XCS_P!02P,$%     @ KH%94$4/4]QE!0  [AH
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MWYO79AOEHY/8QEV[[:>_B[N7?FAW<RW1RJ[^=OC=[*??M[G^]V*X ,\%^%B
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M!>9P,[3/\]>EU?$3U\W_4$L#!!0    ( *Z!65#L*(^-L0$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL?5-A;YLP$/TKEG] G1#:;1$@-:VJ
M3=JDJ-.ZSPX<8-7V,=N$[M_/-H2R#.T+OCONO7MW/F<#FE?; CCRIJ2V.6V=
MZ_:,V;(%Q>T-=J#]GQJ-XLZ[IF&V,\"K"%*2)9O-'5-<:%ID,78T18:]DT+#
MT1#;*\7-[P-(''*ZI9? LVA:%P*LR#K>P'=P/[JC\1Z;62JA0%N!FABH<WJ_
MW1_2D!\37@0,=F&3T,D)\34X7ZJ<;H(@D%"ZP,#]<88'D#(0>1F_)DXZEPS
MI7UA?XJ]^UY.W,(#RI^B<FU./U)20<U[Z9YQ^ Q3/[>43,U_A3-(GQZ4^!HE
M2AN_I.RM0S6Q>"F*OXVGT/$<)OX+;!V03(#D"L#&0E'Y(W>\R P.Q(RS[WBX
MXNT^\;,I0S".(O[SXJV/GHOMIS1CYT TY1S&G&29,V<PSSZ72-9*'))_X,DZ
M?+>J<!?AN[\4WJX3I*L$:21(_]OB6L[=51&VF*D"T\1MLJ3$7L=-7D3GA;U/
MXIV\IX_;_HV;1FA+3NC\S<;YUX@.O)3-C5^AUC^PV9%0NV!^\+89UVQT'';3
M"V+S,R[^ %!+ P04    " "N@5E07 _H^K4!  #2 P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q]4V%OVR 0_2N('U 2QVO2R+;4=)HV:9.B3ML^
M$_MLHP+G H[;?U_ KN=MUKX =]Q[]^XXL@'-DVT!''E14MN<MLYU1\9LV8+B
M]@8[T/ZF1J.X\Z9IF.T,\"J"E&3)9G/+%!>:%EGTG4V18>^DT' VQ/9*<?-Z
M HE#3K?TW?$HFM8%!RNRCC?P'=R/[FR\Q6:62BC05J F!NJ<WF^/IS3$QX"?
M @:[.)-0R07Q*1A?JIQN@B"04+K P/UVA0>0,A!Y&<\3)YU3!N#R_,[^*=;N
M:[EP"P\H?XG*M3D]4%)!S7OI'G'X#%,]'RB9BO\*5Y ^/"CQ.4J4-JZD[*U#
M-;%X*8J_C+O0<1_&FW0_P=8!R01(9L AYF%CHJC\(W>\R P.Q(R][WAXXNTQ
M\;TI@S.V(MYY\=9[K\7V;I^Q:R":8DYC3+*,F2.89Y]3)&LI3LD_\&0=OEM5
MN(OPW1\*#^L$Z2I!&@G2_Y:X%G/W5Q*VZ*D"T\1ILJ3$7L=)7GCG@;U/XIO\
M#A^G_1LWC="67-#YEXW]KQ$=>"F;&S]"K?]@LR&A=N&X]V<SCMEH..RF'\3F
M;UR\ 5!+ P04    " "N@5E0GV(64+ !  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q]4]MNG# 0_17+'Q#O>C=MN@*D;*JJE1)IE:KMLQ<&
ML.(+M<V2_'W'AJ4H17W!,\,Y9RX>9X-U+[X%".15*^-SVH;0'1CS90M:^!O;
M@<$_M75:!'1=PWSG0%2)I!7CF\T'IH4TM,A2[.2*S/9!20,G1WROM7!O1U!V
MR.F67@//LFE##+ BZT0#WR'\Z$X./3:K5%*#\=(:XJ#.Z?WV<-Q'? +\E##X
MA4UB)V=K7Z+SK<KI)A8$"LH0%00>%W@ I:(0EO%[TJ1SRDA<VE?U+ZEW[.4L
M/#Q8]4M6H<WI'245U*)7X=D.7V'JYY:2J?E'N(!">*P$<Y16^?0E9>^#U9,*
MEJ+%ZWA*D\YATK_2U@E\(O!W!#8F2I5_%D$4F;,#<>/L.Q&O>'O@.)LR!M,H
MTC\LWF/T4N"%9NP2A2;,<<3P!68[(QBJSRGX6HHC_X?.U^F[U0IWB;Y;9O]T
MNRZP7Q78)X']?UM<P[QODBUFJL$U:9L\*6UOTB8OHO/"WO-T)W_AX[8_"==(
MX\G9!KS9-/_:V@!8RN8&5ZC%!S8["NH0S8]HNW'-1B?8;GI!;'[&Q1]02P,$
M%     @ KH%94)I  R2T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL?5-A;]P@#/TKB!]0$B[=JE,2J==JVJ1-.G7:]IE+G 05X@S(I?OW
M Y)FV1;U"V#C]_QL3#ZA>;8=@",O6O6VH)USPY$Q6W6@A;W! 7I_TZ#1PGG3
MM,P.!D0=05HQGB3OF!:RIV4>?6=3YC@Z)7LX&V)'K87Y=0*%4T%3^NIXDFWG
M@H.5^2!:^ KNVW VWF(K2RTU]%9B3PPT!;U/CZ<LQ,> [Q(FNSF34,D%\3D8
MG^J")D$0**A<8!!^N\(#*!6(O(R?"R==4P;@]OS*_B'6[FNY" L/J'[(VG4%
MO:.DAD:,RCWA]!&6>FXI68K_#%=0/CPH\3DJ5#:NI!JM0[VP>"E:O,R[[.,^
MS3>WZ0+;!_ %P%? 7<S#YD11^:-PHLP-3L3,O1]$>.+TR'UOJN",K8AW7KSU
MWFO)$YZS:R!:8DYS#-_$I&L$\^QK"KZ7XL3_@_-]^&%7X2'"#W\I/.P39+L$
M623(WBQQ+R;[)PG;]%2#:>,T65+AV,=)WGC7@;WG\4W^A,_3_D685O:67-#Y
MEXW];Q =>"G)C1^ASG^PU5#0N'!\[\]F'K/9<#@L/XBMW[C\#5!+ P04
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M@ZV&A,:%XWM_-O.8S8;#8?E!;/W&Y6]02P,$%     @ KH%94!X?9S&U 0
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MJ'TXWN'93F,V&=[T\P]BRS<N?@-02P,$%     @ KH%94.]/"$^S 0  T@,
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M?S;3F$V&PW[^06SYQL4?4$L#!!0    ( *Z!65"P'E<OM $  - #   9
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M:A^.G_!LIS&;#&_Z^0>QY1L7?P!02P,$%     @ KH%94.R5_0D> P  CPT
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M#D+Z$4 ^ 604=(%=_SW]DP#_08\$['WWA-[>!PCN),0#+JY:- +U%!'!#8>
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M&#(/&$9>8QZQ< S,TX?6+#X.>&E#()3X#%$\4VBK0(>A\A!7B'"%J%6(AC$
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MT"TO+P-QG=?'W?J&LT-SE+?:_R>,_P-02P,$%     @ KH%94&+B\X$S P
MP0P  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULE5?;<ILP%/P5A@\H
MNH $&=LSN<>7SF32:?M,;-EF L@%V4[_OA+(!$MR0E\,DG>7/4='XC Z\NJM
MWC(FO/<B+^NQOQ5B=Q4$]7++BK3^QG>LE/^L>56D0@ZK35#O*I:N&E*1!P@
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M(?X8WB$&=PIK,K#NVOH!G('#&7B3@7<S4&-_%BU&-)BLY2F(7_\9[6 #A1\
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M%UUCZA:*-WW/14/CS_\"4$L#!!0    ( *Z!65"Q8,)%\P(  +@+   9
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MT<Z2[4+Q4S<G1_VPOOP'4$L#!!0    ( *Z!65!H6\!\; (  #0(   9
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M>3?'NHUDC9W17O^AD/T#4$L#!!0    ( *Z!65 ;*T4G*0(  &<&   9
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MFH&YLF?&)*@:U;X[J%!=?UA0.$L]7:HY[WI?MY"LZ=LZ'OXMV1]02P,$%
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M8EM6E[ZZSIO#@^:FE(?V8,2YG,[,_P-02P,$%     @ KH%94$,P8YPY @
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M,'/9'[A]H$4[W"5@O-#6?P%02P,$%     @ KH%94"[">5*"!   'A@  !D
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ME&:9XKK8SLFW+I@X$A&'53$GB="I:X>+?.N+22/1WHB5,-_T/+#[&VBDK[7
MR))H7\0JF&^,;**2A/GA.INHR->K8 (2)Z DSVU)F%@D[M^]$L8, <SPGHDC
M1$49VX\#6>)M#\C3PB'2N.5+G"#NHWM6,C6"^4*H>7.+E_B^B1F9DTR-8$H1
MVE6YE4M\RP0SQ&4S&<+((X \Z0N!&44_T7419@L!MO"ZY=RP;:3+.:!2::H\
MV"7,%T)\877+N<'*94XR?>6 L:)08^;6K>(;)M?(K&1J!,-)H>V46[>*;Y1
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MSU'3G5)JXGS^IO[1U*YJN6 !1T9^-(6L4_>#ZQ10XI[()S9\@K&>V'7&XK_
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MU74TER9G3()*T=FHR2K5NS,:!'*IMU_4GO?3UQN2-</#@L;7+?X'4$L#!!0
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MO19=C^\VBK?]_ +#$,W_ U!+ P04    " "N@5E0Z_^"KVX%  #W'0  &0
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M7;50RZP;)N@QJ",\I=X-$4!#K(-!>/ XP&9(Q-$CD@T1Y"]@%R$XT= (X)Y
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MXX+ 2:AI*N>LO\W[A:#M\%!YXVM9_ 502P,$%     @ KH%94&U62YKW P
M 1(  !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULC9C;<J,X$(9?A>)^
MC"0D$"G;57'.CJ<J-5.S>TULV::&@Q=P//OV(PXFT&IBW\2@?'_KE[I!0M-3
MEO\N]DJ5UI\D3HN9O2_+PXWC%.N]2L)BDAU4JO^SS?(D+/5MOG.*0Z["32U*
M8H<1XCE)&*7V?%JWO>7S:78LXRA5;[E5'),DS/]?J#@[S6QJGQM^1+M]634X
M\^DAW*F?JOQU>,OUG=-%V42)2HLH2ZU<;6?V+;U945X):N*?2)V*WK55#>4]
MRWY7-R^;F4TJ1RI6Z[(*$>J?#W6GXKB*I'W\UP:UNSXK8?_Z'/VQ'KP>S'M8
MJ+LL_C?:E/N9+6UKH[;A,2Y_9*=GU0Y(V%8[^I7Z4+'&*R>ZCW46%_5?:WTL
MRBQIHV@K2?BG^8W2^O?4QC_+< %K!:P3Z+Z_$KBMP/T4\"\%O!7P:P6B%8AK
M!5XK\*X5^*W OU8@6X&\5A"T@N!: 27GS)%/B?>UI$LVO;J7<[HI Q*G*:RZ
M4N_#,IQ/\^QDY<W#=@BK9YK>:)4.7K76M5__4U=KH5L_YCXG4^>CBM0RBX9A
M/<9E_I!9F@SM"$=;Z'PPU,>"&7HV[.'.)%P!7-R;#!\2#T@4)H?,H\EX8H@\
M869 F&>,"8;,"V8',,N+4_-ZV?#*1"@)\ RY>*6X=01W4"DC.>9X!%Y'X'T/
M#/A<-(RHF;09BO2Y"VK!I *?"S M]R;E!X0#Z@&AA.\#7X\FY7J$2)"K)Q.C
MS/-<\$0]FY@>9 !J]04)1H6$1;]$K#%**"P29&8#0GQ@;85T*CCK/>^#3 L\
MT\+(M _G?=DP7J\C8.7U(K$RB6^N-V+5PZUZB%50;DO/Z :=81-#9]C$J'"E
M1W#;/F[;1VR#^EGZ%V?X(K$R"<9PHQ(W*A&CX.%:RNLJV,30^36Q:G[EB.T
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MM[AWXVT9C6#[Z2&P^356_P!02P,$%     @ KH%94!C&:WUR P  V0\  !D
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MQZ+;3+N)XDU_4/"&TTK^%U!+ P04    " "N@5E0<;5CIHS,  "V& , %
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M"IFE!H'F7=16(A&4Q!:9O#,+JT^J9ZM%EZ@I&#C:EP5R9WQ+]/ RY801)%6
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MR!O:BI9G*7Q>QB97@@7NNP1TO[\! RQ9;A?YP8DL9U>_!A^R+G&I3G^,B@6
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MK-M*$"$YN;;F9Q,YFN2K#L>2KK-;%$*6%;>?J[I+-FH'3Y.PR3G#34VDG/,
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MG2,Y6^,D(?P]ZL[LWW@37LRZ$_O%<=4YJDI9M7_?[PZPQG# U@:W3&UO0H=
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M#4&>YZZ31/X_F3IW8_,@#OE9'4J]H<MW0D6ZA8 TTUXX&(T0:8:#<#Z8(M*
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M'.-,)"5G\.H?Y @,Q)L0PA) X0JKQ%@[&"J-HMH:T9<<FZ!FZ3;.?90?X$]
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M#6KK#5=;UB(AB7[#\_9;T4H!3;FK:D-UG-IU/Z3L'%,WA_O/!RZ1797#27+
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M%6XT;BV4X[W1173V[":&\5/;O;A)<RY=WRHVK'FIJ,#>8^PTG5)WE BYI13
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M.MCGG1*APT2IW["AL4('R1N>J]]K?((B0B.*"0 Z%.5KS%3G3DQ9:@U4Y'7
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MF_)7YEAK$WF;0OX=IZ+]N0 0T#-,,7/;+9G 9OI3UJ,PJCH[+HW5=;RI7F4
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M1, T&/:&X1@$JM\:",;)I!].QD0%QC.XE .\R*3:U<?KS^!9)'TCI"Z52Z/
M\5(@1.T0.ME-9T?]+&D,(" @UA'1@;7-;;6;5<M8#2]4ET>5F_O3@:34&*GQ
M[.I<VHU/1[V7@=8D@A/[PZG)EQ!#'IL0G1C4>+'1&]A\=:E8J<+*P*)EM2>V
M*88A A/%,4L=%F58PV=('J ?N/B,-#HO3"WDIH(N72EG#%3?*P1,FBDW.E*[
M+/QREZ:<CN2]Z&XY6B+QI0ZE!7D[MV'&9RX;Q=$F=L*K#9OX,BP[_Q#$% BU
MA$>X9S95)KKGB*<4?3C4/8D+2[!=BQM[XY:PD$]ER[D/C 8</]"+QPN#BA7S
M1:LE>28D6KM]J6H_SDE"H*ZZ!R3YD*VO>2QI( +JHPHTH?H*.C5S#-F_PV*V
MU_E%[@WHC9&KHM@TBJD^ARM<,@W[I"F)ET?P3KFAME).D6X*ORP$#="DT81I
M"L4VSJ2UH%'<S,8<&I"QMLU%9FI<U1I*,W)'C=(76F<FVOA"UICQK-77&EHM
MB ),K(X@:D4C@GXR(&Z(^%G$G&$B&I3H>/1GC8"IXUC$:S%",Y5QMG*Y/TV0
M1 F:C.]-X*_D3RAR:WIR2QDM*O6+=J <+P-"!(,>;,>-B+2>)F"SQM)T"G!+
M<O:X@IKX8EAI8+F*O5\G/=5G\AN[6;5F,$J6P@'3@"_"( E Q]17"B0 N+X8
M#,8*A>!WM@=4G^JY9&&RS=']LQ$VO"=X:&P-YO#'1*R&9G4+C,>FRG[J7M=7
MA**"G8L6TSS9H*<GFW.-3>H9@B!A/'\&0$9CW8KX^ 68W:J[UMH)Y3  AK/:
M L0VP^O0S74N4:=!OXD4]P_.LQ6S!A,5S("PB@O<3^,PQ+Z:921-)UV9. J-
M>\!&['?)5K@?4W6IGQ6E*88\D.5'B'BJ]( #*DNC6*VK-S%GX*LMK(6AC;HW
MVR><D*&$!(D$JRT,_<%N[1+HG>2/LY[&E8KI5K&O+D>N;[;KF/,1KR0>8#C#
MC)YHO<>(-X,E33>8)LM,9"([.U(-?SH8+^F._0QJ)B9MB"#9DOON22RV*S]&
ML"IV&[0S_3V6$FLF&J<6=:%\/9XP]TQCAK/Q+Z26".C,D[ WZ5&MFW!(\2V@
M+V %2C%#L/<=EYX)[R=!Q2G@X]D\. &=?XPB_ !TF887C>FY\NH@'(%.U@][
M6)$;*Y7.X/JL=F);\\2Q=;3]_ZO[%MXVDNW,O]+ :G8EH,FPFV\/$$ CVW-]
MXX<BV7<V"!9!BVK)S%"DEDU:HV!^_)Y759WJJFZV:-\D>Y&,*;*[GJ=.G>=W
M*AM2"><42U_14I+IA:U-CMX<2M$IFY=/YZCVO.%8&S7Y>3J8SB*K\)LUP^*Y
MQ&3(7>G4!W>^FK?(5KEO$N&(??NF4<GQM(&96-H: 54Y.:-#EMS)5(?>+=?-
MXU-7S,E(BR]/PF=@&\IF,YL-H21IG(18L?M10(;KM,^<$:T]E))1KJ6RDL!J
M/E!1 :"J_RBWF[;2,";'LUQ97['@B"[C'1Q5A)DKCG@5V+2#J!^4'T%555Z]
M1&: (2L!^D6QQ4-7N2=:H#(^OOF<B,OJ\LU5<OV7\ZLWI! ;U<!&TO4HCG<A
M42,K!"9->5D7#-%RVVB]:8W+Z\A,/NX?2L)G>:6'AW"U<* S8B3S 1PO/%79
M&(V"4_V@ O;8N)1C.C$*.JQN(3Q% ^%9V(Y4C?1R4\SZF &9X2!JYPP.^SDA
M.YJ*Z.OO'5J>=QV6;%;C6L'PX-9Z7?+IH!7^K1X89YJ4!%4526BG/<C3\6R4
MY/,IH=/D\R'\/4M>8^^D=;$FC2J[@7^18&H"#D (/9!)T3"&AMQ9.LK&+QN'
MF2?:JC''%E'Y9B# XK\#^+>5JD\P!8Y03/I#7*!!?YPWO>$6%-[)Z9T\HW=&
M\^2R:0-M&@((%5L&#>"<X*574G+D9837Z^AF*K*R)5O< 4"RC\>%7D-GUW 2
M;;VE:=_M4&RP>HEK*1-^E*7-RO0<]GU"SBN"0N=N^#1*JIAY:\*Q:3K%:F&R
M=O'J.(80C/(JB*;PGV<=-D_!\&NZ<7NW=2I=ZQ.J\FRE&=;ZG=..AT&C]_!I
MU$ZPSG_/YEI*(*?T!+G9[*^+9RO545P_&HPK!!/@<F70F5CI/L*")K-^$@=3
M,N8ZQE"^VV]I"6[+:K%=/D:@9A@Y@>1'S%!HVZSO]W*=>TNNH1M9*HZLDPS
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MRML^0V^[R%^2ODG5'DBT?3#QOHYLL%F-K(^FNH!8.X5H2LB\G^KX5/C=H9Y
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M@6#B-MO?S25]4WXM5G?L\F[H7*'ME%3#S P8U2%$H129V9$R=$A#MMDDA,C
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MCXCA8-_BC#3LTC8<_D\D/P%02P,$%     @ KH%94/$?G@2J!0  -3(   \
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M18<=KG*UW/\$'X+SP,7L2QEVV*METC%2\FAGE%R&JR_96ZZXK@7KH^L 8(H
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MP    !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( *Z!65 GZ(<.@@   +$    0              "  >D   !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ KH%94 B+Y,'N    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( *Z!65 $<([^,@(  'X'   8
M  "  6<1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "N
M@5E0G<E)GFD$  #C$P  &               @ '/$P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ KH%94"\/.L ^ @  B08  !@
M         ( !;A@  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( *Z!65#^4ZSN[P$  -L$   8              "  >(:  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "N@5E0?M#'M#T$  !3%
M&               @ $''0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ KH%94$4/4]QE!0  [AH  !@              ( !>B$  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( *Z!65#L*(^-L0$
M -(#   8              "  14G  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "N@5E07 _H^K4!  #2 P  &0              @ '\
M*   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( *Z!65"?
M8A90L $  -(#   9              "  >@J  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ KH%94)I  R2T 0  T@,  !D
M     ( !SRP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M" "N@5E0"S@%_K4!  #2 P  &0              @ &Z+@  >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *Z!65!<U4+>M@$  -(#   9
M              "  :8P  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ KH%94)XW5<NS 0  T@,  !D              ( !DS(  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "N@5E0NQHT6[0!
M  #2 P  &0              @ %]-   >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( *Z!65 >'V<QM0$  -(#   9              "
M 6@V  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ KH%9
M4.]/"$^S 0  T@,  !D              ( !5#@  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "N@5E0L!Y7+[0!  #0 P  &0
M        @ $^.@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( *Z!65 0.'*BM0$  -(#   9              "  2D\  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ KH%94&G'C)NZ @  >PL
M !D              ( !%3X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "N@5E0R.9"/-T!   !!0  &0              @ $&00
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *Z!65 CB(A6
MLP$  -(#   9              "  1I#  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ KH%94%[S)UKH 0  9@4  !D
M ( !!$4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "N
M@5E0Y>$A2K8!  #2 P  &0              @ $C1P  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *Z!65#!-R+?MP$  -(#   9
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M970S,"YX;6Q02P$"% ,4    " "N@5E07 ^9C](!  "<!   &0
M    @ $A4P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M *Z!65#<=L"^M@$  -(#   9              "  2I5  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ KH%94.R5_0D> P  CPT  !D
M             ( !%U<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "N@5E0%7B5%?$#  #.$0  &0              @ %L6@  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( *Z!65"@*G#+, ,
M ,(,   9              "  91>  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ KH%94+76?8Y_ P  6Q   !D              ( !
M^V$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "N@5E0
M8N+S@3,#  #!#   &0              @ &Q90  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( *Z!65 B/E;3Y0,  *X1   9
M      "  1MI  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ KH%94"IDY9=G @  Y0<  !D              ( !-VT  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "N@5E08<'7R5P%  "8'@
M&0              @ '5;P  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( *Z!65"&4M>H8 0  "X7   9              "  6AU  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ KH%94'L6.0@@
M @  ! 8  !D              ( !_WD  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "N@5E0L6#"1?,"  "X"P  &0
M@ %6?   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( *Z!
M65!H6\!\; (  #0(   9              "  8!_  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ KH%94!LK12<I @  9P8  !D
M         ( !(X(  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    " "N@5E0E)=;Y.T"  #L"@  &0              @ &#A   >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( *Z!65!.&$=^RP,  *D1
M   9              "  :>'  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L! A0#%     @ KH%94$,P8YPY @  W 8  !D              ( !J8L
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "N@5E0+L)Y
M4H($   >&   &0              @ $9C@  >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( *Z!65!YWY['K@,  #02   9
M  "  =*2  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MKH%94'TQO^<# @  7P4  !D              ( !MY8  'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "N@5E0R*KV/>\!  #U!   &0
M            @ 'QF   >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( *Z!65!%;J1O+@0  -H7   9              "  1>;  !X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ KH%94%B/"^2I @
M-@D  !D              ( !?)\  'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "N@5E0UP$P27,#  !D$   &0              @ %<
MH@  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( *Z!65!N
M%AP8]@$  .D$   9              "  0:F  !X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ KH%94! L]S]5 @  4 <  !D
M     ( !,Z@  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z!65"P<M?9A (  )@(   9              "
M ;VX  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ KH%9
M4$'NU.R? @  10D  !D              ( !>+L  'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " "N@5E0@GW"N  #   J"P  &0
M        @ %.O@  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( *Z!65!\EI@O] (  %\+   9              "  87!  !X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ KH%94+/VT%#W @  ;@L
M !D              ( !L,0  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " "N@5E0,TJ':E4"   Y!P  &0              @ '>QP
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( *Z!65!M5DN:
M]P,   $2   9              "  6K*  !X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ KH%94*G+D8GZ 0  'P4  !D
M ( !F,X  'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "N
M@5E0S'XV#Z<!  "9 P  &0              @ ')T   >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( *Z!65 8QFM]<@,  -D/   9
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M970W-2YX;6Q02P$"% ,4    " "N@5E0M;:[#4H"  "Y"   &0
M    @ %MX@  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (
M *Z!65!QM6.FC,P  +88 P 4              "  >[D  !X;"]S:&%R9613
M=')I;F=S+GAM;%!+ 0(4 Q0    ( *Z!65 ;/T8U5P(  %P,   -
M      "  :RQ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ KH%94/$?G@2J
M!0  -3(   \              ( !+K0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( *Z!65!.$:Y?:@(  (DM   :              "  06Z 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *Z!65#%X(*!%P(
M '(L   3              "  :>\ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !5 %4 11<  .^^ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820017680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830496208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Contractual Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 789,913<span></span>
</td>
<td class="nump">$ 626,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">522,551<span></span>
</td>
<td class="nump">153,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">$ 1,312,464<span></span>
</td>
<td class="nump">$ 780,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6824124000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember', window );">Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,464<span></span>
</td>
<td class="nump">228,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant lease improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember', window );">Built-To-Suit Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Build-to-suit lease period</a></td>
<td class="text">242 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Currently estimated amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage', window );">Annual increase percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod', window );">Payment commencement period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AreaOfRealEstatePropertyAvailableToLease', window );">Area of property available for lease (in squire feet) | $ / ft&#178;</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts', window );">Percentage of excess costs</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AreaOfRealEstatePropertyAvailableToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Real Estate Property, Available To Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AreaOfRealEstatePropertyAvailableToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822447904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">184,406<span></span>
</td>
<td class="nump">184,231<span></span>
</td>
<td class="nump">186,136<span></span>
</td>
<td class="nump">172,080<span></span>
</td>
<td class="nump">168,873<span></span>
</td>
<td class="nump">155,586<span></span>
</td>
<td class="nump">139,839<span></span>
</td>
<td class="nump">128,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">77,316<span></span>
</td>
<td class="nump">115,606<span></span>
</td>
<td class="nump">91,989<span></span>
</td>
<td class="nump">84,559<span></span>
</td>
<td class="nump">111,602<span></span>
</td>
<td class="nump">125,176<span></span>
</td>
<td class="nump">85,770<span></span>
</td>
<td class="nump">116,307<span></span>
</td>
<td class="nump">369,470<span></span>
</td>
<td class="nump">438,855<span></span>
</td>
<td class="nump">165,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 68,743<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 75,775<span></span>
</td>
<td class="nump">$ 360,089<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 115,857<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Income tax provision (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="num">$ (360,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="nump">$ 50,600<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 29,600<span></span>
</td>
<td class="nump">$ 42,600<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830334160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:56%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Lives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">up to 15 years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5 to 7 years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>74,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25,560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(17,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation and amortization expenses were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$8.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$4.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842506944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,731,439,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,393,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than May 4, 2020, in connection with the registrant&#8217;s 2020 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819936000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech and Daiichi Sankyo for other compounds and programs in our portfolio.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on the amount of collaboration revenues recognized during the years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Commercial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of 1) the expiration of patent claims related to cabozantinib, 2) the expiration of regulatory exclusivity covering cabozantinib or 3) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>ten years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the U.S. Food and Drug Administration (FDA) or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$210.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from Ipsen in 2016. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have achieved aggregate milestones of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$330.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to regulatory, development and sales-based progress by Ipsen since the inception of the collaboration agreement, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$55.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$140.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones achieved during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$79.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$470.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also receive royalties on the net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and going forward, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>22%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>26%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>22%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$30.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of annual net sales and a tiered royalty thereafter to</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>26%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these royalty tiers for Canada also reset each calendar year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>35%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding: CheckMate 9ER; CheckMate 040 (though Ipsen has opted not to co-fund the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); the dose escalation phase and first 20 expansion cohorts of COSMIC-021; and COSMIC-312.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$152.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$182.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$69.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$45.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#8220;&#8212;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;, below, for additional information related to the revenue recognition for this collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018 and May 2019, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of 1) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after first generic entry with respect to such product in Japan or 2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>six years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$50.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from Takeda in 2017. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have also achieved regulatory and development milestones in the aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$26.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> since the inception of the collaboration agreement, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones achieved during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had also determined that it was probable that we will earn a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone in the first quarter of 2020 for the anticipated January 2020 submission of a regulatory application </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to the Japanese MHLW for Manufacturing and Marketing Approval of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">cabozantinib as a treatment for patients in Japan with unresectable HCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">who progressed after prior systemic therapy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the collaboration agreement, as amended, as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are eligible to receive regulatory and development milestone payments from Takeda of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to first-line RCC and second-line HCC, including the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we expect to earn for the submission of a regulatory application in the first quarter of 2020 described above</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are also eligible to receive additional regulatory and development milestone payments, without limit, for additional potential future indications. We are further eligible to receive sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$155.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also receive </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>15%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>24%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on the initial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$300.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and following this initial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$300.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>30%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales thereafter; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>30%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>100%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate 9ER.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"/><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$24.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$18.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$14.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$18.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified two performance obligations for both the Ipsen and Takeda collaboration agreements: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on our evaluation of the collaboration agreements as of the date adoption of Topic 606, we determined that for both agreements, the up-front, nonrefundable payments, the milestones and royalties achieved as of December 31, 2017, and our estimate for the reimbursements of our research and development services performance obligation over the term of each agreement constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. In addition, the transaction price for the Ipsen collaboration agreement included a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we expected to achieve during the three months ended March 31, 2018. Other than the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone, variable consideration for both agreements related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the transaction price increased as a result of the achievement of various milestones. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Bristol-Myers Squibb Company (BMS)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate 9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. Under the terms of the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and we are sponsoring the COSMIC-313 trial and BMS is sponsoring the CheckMate 9ER and CheckMate 040 trials. The responsibility for the payment of costs for any further trials will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal trials in advanced non-small cell lung cancer, metastatic castration-resistant prostate cancer and RCC. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond the initial three planned phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, we continue to be required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of other collaboration revenues for sales by our collaboration partners. Such royalties were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$31.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$24.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In-Licensing Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Aurigene Discovery Technologies Limited (Aurigene) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>six</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$17.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>six</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs, including </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> pre-existing programs. We are also responsible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$32.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in research funding for the discovery and preclinical development work on these programs. During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$4.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in expense for the discovery and preclinical development funding commitment. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each option we decide to exercise, we will be required to pay an exercise fee of either </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, depending on the program, and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$148.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential development and regulatory milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$280.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential commercial milestone payments, as well as royalties on potential sales. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Iconic Therapeutics, Inc. (Iconic) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer, leveraging Iconic&#8217;s expertise in targeting tissue factor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology ADC program, in exchange for an upfront payment to Iconic of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a commitment for preclinical development funding. During the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$9.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in expense for the preclinical development funding commitment. Both the upfront payment and the accrual for the preclinical development funding commitment were included in research and development expenses in the accompanying Consolidated Statements of Income. If we exercise the option, we will be required to make an option exercise fee payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Iconic; we would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic would become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$190.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential development, regulatory and first-sale milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$262.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Invenra, Inc. (Invenra) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> technology platform, or with other platforms and formats at our option. As of December 31, 2019, we have initiated three additional discovery projects and two binder projects, and in total we incurred an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$4.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in expense during the years ended December 31, 2019 and 2018, respectively, in consideration of the upfront licensing and project initiation fees. Invenra is eligible to receive up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$131.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$43.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$325.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;for each B-Body project and four additional binder projects subject to an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for each project, as well as additional milestone payments and royalties for any products that arise from these efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">StemSynergy Therapeutics, Inc. (StemSynergy) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">), a component of the Wnt</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> signaling pathway implicated in key oncogenic processes. Under the terms of the a</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">greement,&#160;we&#160;will partner with </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We paid&#160;StemSynergy an upfront payment of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$3.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in initial research and development funding during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December&#160;31, 2018 and provided </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. StemSynergy is eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding on an as needed basis. StemSynergy will also be eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$56.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genentech</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits and losses on U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,615</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC for the years ended December 31, 2019 and 2018 were included collaboration revenues and losses on the U.S. commercialization of COTELLIC for the year ended December&#160;31, 2017 were included in selling, general and administrative expenses. The royalty revenues on ex-U.S. sales were included in Collaboration revenues for all periods presented. See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cobimetinib Profit Sharing and Royalty Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>50%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from the first </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$200.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of U.S. actual sales, decreasing to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>30%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from U.S. actual sales in excess of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$400.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Daiichi Sankyo</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019, Daiichi Sankyo had its first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have achieved milestones of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> each during the years ended December&#160;31, 2019 and 2018 for the approval and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are eligible to receive additional sales-based milestone payments of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$90.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Such revenues were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the year ended December 31, 2019. Daiichi Sankyo may terminate the agreement upon </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>90 days</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>0.5%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Other Collaborations &#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have evaluated our collaborations agreements with Genentech and Daiichi Sankyo and have determined that those collaboration agreements each have one performance obligation: the delivery of intellectual property licenses to the collaboration partner. We have further determined that the licenses we provided represent functional intellectual property that was transferred at a point in time, when the agreements were executed</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> prior to the adoption of Topic 606. Potential variable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones and therefore, any additional consideration earned and received from these collaborations will be fully recognized when the milestone is no longer constrained. Any variable consideration related to royalties and other sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred, and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6823396192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</a></td>
<td class="nump">3,770<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 324,782<span></span>
</td>
<td class="nump">$ 689,716<span></span>
</td>
<td class="nump">$ 154,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830374912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">COMMITMENTS<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Headquarters Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019 and August 2019, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>221,464</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space we have taken possession of as of December 31, 2019 (the Current Premises) under the amended Lease. We expect to take possession of the remainder of the space provided for under the August 2019 amendment on or prior to April 30, 2020, which will increase the space leased to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>228,941</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The term of the Lease continues through October 31, 2031 (the Lease Term). We have </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have made certain tenant improvements on the Initial Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. We were also provided an allowance of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the space we obtained under the April 2019 amendment which is expected to be received in 2020. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets included in other long-term assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41,835</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,739</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017 </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,189</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,944</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,661</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,935</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The 2017 amounts have not been adjusted for the adoption of Topic 842 and continue to be reported in accordance with the previous lease guidance, ASC Topic 840: </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;">Leases</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ending December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(13,685</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Future tenant improvement reimbursements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,739</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3.9%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>11.8 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Build-to-Suit Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>220,000</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The term of the Build-to-Suit Lease is for a period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>242</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in October 2021 (the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to an annual increase of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>sixty days</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To the extent that the total development costs of the New Premises exceeds </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$525</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per square foot, we will also pay </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>50%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such excess costs prior to the commencement of the Term, and may be required to secure such amount and the cost of the tenant improvements in excess of the allowance by providing a letter of credit or depositing such amounts in an account with the lessor&#8217;s lender prior to the start of construction.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Build-to-Suit Lease includes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>180</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that, under the guidance provided in Topic 842, we do not have control of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">New Premises</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the construction period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Therefore, we will not record a right-of-use asset or lease liability for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Build-to-Suit Lease</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> until the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lease Commencement Date</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will evaluate the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">classification the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Letters of Credit</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>None</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819937584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>four</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>Two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have made&#160;reclassifications&#160;to our prior years&#8217; Consolidated Balance Sheet and Consolidated Statements of Cash Flows to conform to the current year&#8217;s presentation. These&#160;reclassifications&#160;had no effect on total current assets, total assets, total operating cash flows, total investing cash flows or total financing cash flows.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the third quarter of 2019, we adopted ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 requires capitalized implementation costs to be expensed over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted ASU 2018-15 using the prospective transition method in the accompanying Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2019, we adopted ASU 2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income (loss) to accumulated deficit. In connection with the adoption of ASU 2018-02, we adopted the individual unit of account approach for releasing income tax effects from accumulated other comprehensive income (loss).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2019, we also adopted ASU 2017-08, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-08). ASU 2017-08 shortens the amortization period for certain callable debt securities held at a premium. Specifically, ASU 2017-08 requires the premium to be amortized to the earliest call date. ASU 2017-08 does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The adoption of ASU 2017-08 did not have a material impact on our Consolidated Financial Statements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income (expense), net in the accompanying Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of restricted cash </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents as short-term or long-term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">dependent upon the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">longer of the remaining term to maturity of the investment or the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">remaining term of the related restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We subject all of our investments to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record trade accounts receivable net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">have been insignificant.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>15 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We periodically review the carrying amount of goodwill for impairment (at least annually) and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. Historically, we assessed the recoverability of our goodwill on the last day of our third quarter. Beginning in 2019, we changed the date of our annual goodwill impairment assessment to the first day of our fourth quarter to allow for operational expediency. The change in goodwill impairment testing date does not represent a significant change to our accounting for goodwill</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value. We continue to operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We assess whether our collaboration agreements are subject to ASC 808:&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we assess whether the payments between us and our collaboration partner are subject to other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Topic 606. However, if we conclude that our collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, we present such payments as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Results for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while results for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have not been adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, ASC Topic 605: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 605). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: 1) identify the contract(s) with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations in the contract; and 5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>100%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2018 and 2017, the</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>50%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. This amount increased to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>70%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in 2019. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. Except for profit sharing arrangements, payments for product supply services </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and certain development cost reimbursements, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">each of these payment types were within the scope of Topic 606 during the years ended December 31, 2019 and 2018. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When such services are provided to a customer, and they are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenue for these services as the performance obligations are satisfied over time. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We account for such arrangements in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the years ending December 31, 2019 and 2018 and accordingly, those profits are recognized as collaboration revenues in the accompanying Consolidated Statements of Income. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as selling, general and administrative expenses in the accompanying Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Royalty and Sales-based Milestone Payments:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenue at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018 and 2017 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> amounts remaining related to previously expensed materials in our inventory balances as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and primarily include: (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees, funded research and milestone payments incurred for our in-licensing arrangements with our collaboration partners; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">becomes more certain. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development, regulatory or commercial milestone payments to collaboration partners are recorded as research and development costs when we determine such payments become probable.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the weighted average discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not to apply the recognition requirements of Topic 842 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for short-term leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Advertising</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Advertising expenses were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$17.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$14.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in sales, general and administrative expenses.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;awards, performance-based restricted&#160;stock&#160;awards (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Compensation-Stock&#160;Compensation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense relating to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax provision or benefit is computed under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. Some of these estimates are based on interpretations of existing tax laws or regulations. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the technical merits of the position</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income (expense), net in the accompanying Consolidated Statements of Income. Net foreign currency translational gains and losses were not material for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the FASB issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for us in the first quarter of 2020. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2016-13 on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820021808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selected unaudited quarterly financial data was as follows (in thousands, except per share data):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal 2019 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">March&#160;31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>215,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172,080</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>184,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>184,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>91,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>115,606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>75,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>97,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,743</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal 2018 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">March&#160;31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>213,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>228,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>139,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>155,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>168,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>116,307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>85,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>125,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>111,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>115,857</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>126,630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>360,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Total revenues for the quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 included </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$20.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$50.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$15.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> in milestone revenue, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$66.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$25.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$42.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$29.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> during the comparable periods in 2018. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as net product revenues less cost of goods sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Net income for the quarter ended December 31, 2018 included a </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$244.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods. </span></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843618240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues Disaggregated by Significant Customer) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0000939767-20-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-20-000035-xbrl.zip
M4$L#!!0    ( *Z!65!FE4ZHNAD  %<I 0 1    97AE;"TR,#(P,#$P,RYX
M<V3M/6ESXS:RW_,K^/SE3:I6XRN39*8RV9+/]<9C>RU-9M^G+8B$).Q0@ *
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M88P,M>XS9>.J@)T\"/PU".$&\&AP?+(9%[%C:\9%"+<-+MX?(FZ#J979;#G
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MA<&5P(D)]]SC7"_[Q<)4-6PCCO]DP:@:[WR=E6?B)WL?#T"3<.5K7DQ"A41
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M&R_U49=_G)^GQ:EHTT&A$*>*71'>3J^_Y!%\Q$-7?N/]<&(8((F$;0?;WOW
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M#A/.=N@Q4CY<KP@0UAF+?$F=L::^U^A@$NFV+B#-86S9M;B^B!P?).&<22B
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M'Y.2++*@:=S?!PTE*.T?TOPFR^^CU]'&!_G49]'31D^@<I(P[20*JFO -%:
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M=\SIQV4V_O,NFP4V+39V%!N^,)Z^B.BYH#!4+Y474'%B:'28,$KJ3=5R#X4
MIE):Z8XI.S$,54BHO.;..20!X.L, 05%U/@&N4Z[#T.MS(S#8:BG(=!G&.K)
M0J F_[DJ#)0^RW]/OZKQ.D-KK)6>9_/PQ_'!VK:UQDD\DUQA0P7A 3]IH>$E
M'RA6K,^JFDT"62O+P<M"+QV"U9=:\"E\[>I&3;*'@Z%5AYHG2ECBO L+SSA*
M.-/&B)(R!90=9JQKQUS,.@/N+8G&>43B2$FX 4O$>23A._WK(F>C?++XXR$J
M?:$] _*H:%3JGVBG):44>1>V8F.08Y84M#,$X8 *_+;#PI>G20<@#4% 2$,!
MV?9/F(%$> B( HA3K'FX_92T*ZWJ:ZR=&3A[$Y"Z( U!0!A #7>0HG^"%'$R
M7(.)8X8ICB1&OJ3= EI?0#ISX.IQ!ZD'4F]A/*5*OC$7Q%Q:V;S"A>5@OX1#
MA#!3WE!.:=@=$9%;6H44]5VX.RY%W=(%I4UP>GL/>S[5HY6(=[9/D+$^H*05
MYL!BJ3G"L*0-4XF&?25IB6\O'\=:1.IM2<,@;R%#$H+S,#_F\\SF:UOR407A
M5=N$ "<, ,AA*B@RE%!$"YHXD;Q!RM_.GL.;\>957'<S1'I3#2>3-<*CV8?1
M=/)N;D8/T^5H=EPE/-0O"4@YSX7   %AJ$;:ZY)6Q.@ HSK:Y7Z;Z/1X25C=
MKV:C\J%M1T+5*A>%:F,DVA.HPU) 5@C L!((\Q(##8=X66A90CI"JK\T$,M
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M\J6OM6$CIR/Q\TV=PQ@]-!NMG\LJN0Y4ZI\X+8F!3CD)<-@2K%9XNR] TR
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MU6I0/Y]W9T[ @Q"@-D'M2X!^R^;IXV^C_,]TZ5?SR?&M9W>'))S] D!!!)=
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M *X\P59"@W5 J*0. E=?A^_P%;I]AC?!I'>.^P#VXBZ=_)IE!Q^7=W=(#/"
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M0_&\7#!==ZMIO;).YJMG>7_ V@$'#/026"458 *11J5G$ RZ:5TB8@-:,]<
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MAK&S@+PI;R.-=?FNJ)?6K];5@MX4\]O]73%/#0E,<*F@$]QH+"$4SN'&&+9
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MU7D#>+VYM:_JIQU=Q]?]P0'!(T Y-$99RZ2U4$BWFS$@N/O-=V]MY'M;[KE
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M7!!E8/;-G8J$31?5JIZ4NJSORRY<;_.60)R)ZB=G GKA";11#6U@XXI;.9Z
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M2XG(B.Y91R!*&9$<+$YWK=X?"KY-,]A^/_WK8[$H__L__A]02P,$%     @
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M(1JEJ>L%$5HT%A;YYM.O%SV>YD?6+/Y)A:77_%=Y73Y4RS9Y<:@B=[?H_^4
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MN2ZKRJ(T J$#%.H W6QNF[_-F)Q.#61[=J(UU)_C"F:$J6%RUBY^)6GB!B2
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MM,OYP&SQ+1?GG87=9^B^9/=U?GZ-[N_7Q3*[6N<7?,#VL.4_^E+<%>W@K5[
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MTR"SK*7<A3NNG.UYEJ*!!GXH-MU9_[&63O5B9GFMU'JX1I\/MAZ!UB503'C
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MK,CV'W9S4RRVY6.Q?^CNZWQ;?"V$\]QN>Q?<MGMA76R_W7&NGY[]\BR@,8E
MED.&0IHS/A:+8$J2-$D0R5"L=(1T##R6ZXP.G!@S]2]I;I2?01\E+G(%AVLA
M42M)]NB/'PT6F+SG'EQX\ZW7AV[OQ<N_="%.'2Q&KV$,A.",#H\98#<T>U2/
MJ^FZD^:KQ\_!G'@"]3V,+$H(R7+F4P)9'&(*".HQYBE1N@EE7&26\\/O?[O^
MFW?S.DD<GEOF2E3O%4@]=XP<1[DLXFX([>03R72"[L55N1.]#6TB%&?RRC0A
M=R/#3.3[J=>K)XC P*S3'/43#Z7R0*[VOU/4LR3@0Y\P"BA+XBQ!- UAUJ,
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M."!Z)ZK,=0RY,TWJ))TZ<621;@?. ]GTKAJGT:H5]E^KI_EJ^\1^B+G)8A:
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MEX:TR8T1Y($C%7728-91==+QY#UUTF9'6IVZXNR5Y:Y:0W$,H(^2$,0!C3-
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M1M$U>;?JZTEEM\^PQG[*^69=KF_KJV+3)YYR@=9+6JYV'-\+- F(@Y@F"8$
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MI:I;&CP[K%XZWLAHF#9+LDKVM:@+_KMW7>&&\X3F*&5^'(0^8YD?D7Z.#+)
M7((D+UR*'VU9IWHTWHF^I:90JK3)"9)%QM3TYSVR)AK6/>?GC.)H$NF&P.B"
MKXPTIN%[CGXMU\7G;7%?SQ#S60!"&M"<QD'$TACWLU@0$U_JX1<SEB;:>R0
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M_MZW^8^B_JU<5YMR^]37<VB]?/XI[+]W_,>_%=N[BO_DD?]*>Q%&3G(_(B&
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M*ZJJ:F+UYEOO>W%;KM="*L7I\<;^B/GV_6B.D#Z-AG"2;/B!,IJM!"4=Q+]
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M^X:"_#]LV"I\\W-'Z1':Z V^S1"X*6B5'.-NX&1-0+WNGS9)\] %(^2G^WU
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MYPPG/8J$Q3[P*"6KMETKU!/<_J;A0\#RQ6MNK_G+6F+^*_B<);M1T!2S"0,
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M*8T9P@E88YJG9<%$1&*>-IUW2G@0X!AU1BA/$(9<' '\:)"F&%X382@EFMP
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MRPCCGX>WH_'FK"'FY6@?ED7OI19X5*JI7[;JJ78T6/4\%F>LW0BP$FC,*:=
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M;TS) >M%2B19#\,D3P[.VIP_M46WGOA#?$;UHYER3$D>)!*<1^T ](81ACC
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MY8P)*IG*DCH#:8HO0-^QM15;C4BB,UV53^?+>B3S966C_#X&@A]67KM[9=P
M+ZS40F/*@--&P9)MDG"3$F3&WA&W79LU)H[S3NKE$0IK#S/APNH3VB&#;,D+
M*Y,"A'KH/+1YB-<FWT]_9YF4(&-SW$Z9D<)S)@FSD@7%+VQY "4E,RE!DCT\
M'VD)$96O*FNR_51@>[$X[XJ@P?\KOS+%;!ZK?1]S47YHJ$P(*IR$5L0T8S2L
M:@E*"U<RYE,NS(\'X@G? !\/D0/H:YCS/<'BXROD%\4_8A43G5\7L6SX]_H
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MJO0\,.4PI592C]1,35GMJB9^%,_:E/7QE:4MP(IIR&2@W'ED ;1X,W=X3HG
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M:IPL2 !Y2S1!\6V1(3">F$FB$:(Z;%>5#.<3\J-*R97C!LJL%0&3!C$IG6<
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MPM<@1_+Z$5VGR"'Z:<G/VWP>8SN?3^S,$HIBB 2%B!D&L*1&*@J]80Y!#X6
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MUY[!,HF!M@A;YB1F5DGGK=AP1?"SR[O675Q7<USO[+'BX&%]MJ6&_[D83?-
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MPE)@RA@P #!5R@%RGE(#LX<9CQLT\/LKI,ZS>JW7M,XG^?6H4FJOYSTRJIU
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M.4 9X&;3] WK7#YVF(>Q2)UO;;'Y]YOY2T?CQW(V\^7BG\GB4.#CB6\*BF-
MH8TW#12YS(72HK*O"J=-3IK< )7K'$"\S-MHD='=;4O/YWQP6WK^<-!("AW)
M2O5YXC%M) *1>UH #1SUJIO^)UOX?%LW^8@B7K0;5]N:Y%_L7IGL[N%Z?TK$
MV:%A@6@H.3.8&<2(<4HZB2JF49^53W;RU6ULP&J0\9U!;'-;2'7!;FZ*J]7[
MFV<N[NG\:OIM%EFV:?7ST]9_"(!GOS1(!Z2UW'+&A/0H*B'QIPV7)+!B9,7?
M.@-F5P(9=KJDQXK22(:BC"*(@#2X8I_DUN:8K099LZDK>.5PN=/**N>W@CR
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MJ;[F9G&0P\&6@?!Y,9DOIYNK28TMX?GC01D#K=6(8>H(L%)XSW>HIC8G>6I
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M7*+U=(!K(5]JG>+_14OZER1^>4ZB^_%MNNE#M2'P&/B;^$;P7AK%3?POE50
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MS4JO/]G!&S>;+^5X83X4*5[\2JF*@"ZVOTK/'?("=SN1 *VCG$(()7+ 666
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MT6;QW&R[W.0CN>6W;VJYO+_;V/[C&?8L_7KWKN5OX^3K]B"FI-)1@\#6(0H
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M8?A$KS@?C'5>$P345'O.J68 &R65)=5IY%.JZ[BVPSXAV8(X!G**GW]2!XR
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M5\$MC8+1L4*H,86H*<[VBIY:W:R.C P,&^X(Q1PI8U#\'\=Z2Z^$T([L4M:
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MM96"0V6E!5M^8!XOB9U:PUNW=W:Y63;._ O83K<J>3L;ZO;E00)I-/#22*Y
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ME)(SA@50@@!C*TJI82-W!9\N\+(ESG9U0KPZX2.E%/:."5A(#QB14,3]"5N
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M:\M O&QO+1,WC]S[8[I_&XV!@$Y:2H!W #+.-X8/ZGP4]R"2\504R74ECEW
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M,,#8LG"Z@JN9++]&?J5_)7_Y]\GL)P5U,%IK?'#<44YX<K(KPX2VC,&*=L-
MIXZ?\>^3;<BD*SQN(LY2;.3/TJB;F1\ X?Y!P5N*,.+">TFQ4P9B)"HJ+94Y
MR!N0YV@8N&M,#)W=8R?3Q;\FL_OB$3_>S",7[A_MXX<NN'7&!RRLBKJMU9PJ
M*!6TQE7LI-[:G/CGD[U-8X=@&Q+IK$[)8G*=:I2N2ZML=8OEQ^*JB#MX7%-'
MT5AK?! 8*\4A4#*REL)(,]FI(5*QG#+> W)-#0.-;4BD*S3NO&WU=<%]0X(B
MQ&F'K76I:R030&F[4WVYRDH-'I#7:AB@:T@*O<=;U\==W5<$!2 PA +DB9*"
M$"I(93&(',UJ80!_>SCJAF/G2:7KF.PX\S>13_/;:=RQU7)9K);57QT]D6N_
M(S ?B::I&S>V'%JA)*F8S)#(:Z_ZVSVR)YR[:;%T9K/94X/HN3/QD-FFYBL"
M0YIP+[FE/N6S8T5!Y3UBDI@L8/YVH3PWW+0CE:YPN0U"WG2PF:]9\>_IZFM5
M(Z7^@7[:BP)RW$('<2JX1;&6%$&QXP8#677'!Y3W,@R,MBJ;[I"Z+.*WDI74
M1GIFY5HQV09^'=T\:XP.V@I!$6)"",\M(B9U(=S2C:W)*KWWVQ?S I--"Z0K
M(+XMHMI1O"TFR^($I\N!42%JS(!+:HSTQEK,F$2@HA/(K) '.* DFV$ KSE!
M]!" ;,KE*9Z^(R-#:K>(XKI2RA& @0 65#L]I\9G >^WJV5_N'(#PN@LZ&O;
MN[.X?MRT_?VW+=O>S%.B2%1]D\G@N/?EC+<%)Z4#'D$$B&*IXBN1E>+,A;!9
MJN)O9\SSB+#6!=2=,3QU<?X\^7&*,?SU(0%2A5'4?!&!*!+'E?65&98;:;/*
M>?_VP+PPAC<BA<X<TN6BF-[.S7T4X#Q.]U'1ZLBN]1]G:VZ=<&Z?_<Y@ #<:
M>* %9]0Y[I"I5&:.*/492$6_W3;//=<=B:F3/*7*]O_8[-];^M%>1T2-U**C
M8X."@'HLO!=< 0>3KJ6P\\@X@!1WM9)F.J;[9T?4+._:*Z\)\8[# 4UE$3E@
M6FBO/-QR@W(..NU5T46@7X/XJ.L^RV=[;UO N]20(6E\??>E;7=+H IJ):BQ
M'$* K, :<(@HTT13:'6M:A7MT&V+*-!X<"5Q'B#Q\6/!$F_CK#D4F$/C,:'(
M;:D17+!.Z[H/8TG7EF_9&%M[6[*?KKX6U_>SXOW-:W\[[G7, ::(.&,M!5RA
M>!$%#%*-"690^GK&@I8,*2^D\H**?>VC3WU%X,1*3[3F%&M%E3,.NXH+"(F1
M=.)L 17/K2'M,/S,JVG#G1^,L-;I.&LN+47,(ZI)-6?&QP:2YD7Y:M.'TYC:
M.A!J-WW0+AYA#F!I$?3:@DA^134"5N2D>@\(#&?*:D_3A]-XUJ:L3V_Z( 52
M7@!*O:= $X"8P=7<J<AS.0Y0WJ=*;&_3A]/XUJK,3V[Z0%2<-8N*K^5:(JDA
M=Z*:NU,HQY$RH'C%1F2>P;?>@[#U0^K'>:1A;HW1P;!4<C)>>;#7U*>*%$Q5
M=/.\,V% >&E=06B/Y;U#+<U[;[_!$T8'+*$55%OIL/1>(JV5KNC&VHRLC%&C
M2*B+LK.YW5U<U619?"UGUV_N4CW C8_F:&?F Z,"230J E.>%C4$*(W-EDX<
M+X CZ6S5BN1?!$TUQ>7C:-I;=_;NVWWDXL_;_?SZ4WFS^B<RYUCKY6,C ^$
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MI>Z>!-35L9GJ\KV_>33Q([4V7WT^*.:]26F;)NZZ&'.CB5_3IHVD?"S!TT,
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M+SV3;+YKJZ)F"QU#UR2E:TF\ZBB.HFF:8 +'/?XX6VKB"<?TY=]/0,%^NHL
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M[T^0;2F)DT/"9L.^-H1.7BM9I>L.S[#(H^-Z?E 3F@E[=Y.O),5]7_;9U/U
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M'GW@;](';3I>)4&@KVE,*6+T6%!>?;XIRA"213(SXZ\Q<)B5":'.3_*(T/Q
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M30W&V\Q<_'+840ML7!CWLL,>HW%>^Y^D(+0(GBKVL;2J%-0HF7IC5I"7#?8
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MMI;K&&NY7B7VWY(>RWFW0L@@HW_!J ?*@YDH4DVXA%F.M+*V;/0L45#Q"PC
M,!/<*7,/2^<AJ8V$(GMZN+"0(V7[V1\.Q[!0;T"\'Z,(WE0Z#O'NW#I_7SGW
M4#K!TR_%(1_+(4 "SB"61YRQPG_LML%*;U U9 <?!WE$IJ@%SNWK:N\*=I8(
MUTD+CD^SR$5"F&"</>I(,ZRL[PE3!9D70N]\Q$W# TDU\%U G!5N41<^/QC'
M8BA,#;$B*'I/9-FAF8EP3@M]J'V=T<(*:&6GB/PAM1L"%ZNU,1@81P')J2QS
MMG(=\CR0D.3*IA31/V KEAT1<KI&$="H1TX1MOE2\3BI J\TT!D-,"<G%1%6
MM-JPSLO^:M_<GAM?67EV\2L;1X>$NE+@76&+2>Q90/GIM!0C+@Z"53+8,R0_
MS(3*Y0TE]R+BR2C"(W?1HKQVL;3-Q66RIQ"T9R5(Y1U=ON.!Z&F=(!Y!RL_L
M@@!BX3S8.[!'L=>(MK*IE QB?!O$S+V/>JS"5V4!C,%);(:3.=VE3-*LO*"Y
M"[J((A^!+5U833_WY]CW?F!"<4QRGS@/(.9Y"/*$\7ZTVJ=)_;H<3/FD"96^
M!?+H3N%-V._FK'Q,N(<^-Z9*?%;]0.,[>2NF_( &/(S]B6(P?.C?T1-N.%=
MCTTRRL5X=,$K5!,DSX*?L,2%P64JW:AWB,M!FF>1[X2Y\Q:&EI!(A S<RY8\
MOK,&?M [NT)WP@K<).$,:F&_7[48DNNC(X$-D1CQ)C,1AW*T9)8VZ&)KB>V@
M1>EL55-> [E MF;-"7KER'=><OP]2PEE9D&E5+CB&F5FPTR9;MX)R;W/:R19
MNX:F#@]O4![W1H6"+)B6!2D+ $\K6]&"*,!]1\\LI0#&X=@;G(6$]$H@!$%
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M5+T&HWMKU<&Z)?-UD?E,P7(6F;8N;[Z=6V>2("RB]-:X?%/CLK8Y%+W'II5
MZS)N&MMAM:)F(T;D\T81+7&O"^BTAI"V)"Z72(_<D<\,RI;FWQ3\UT#4T1#^
MT,O*($1:PX:W[5P95T#XATWI.X.';U-GZI\NF#AARGWQDY3=L='RP 9,3/'_
M ZLR:P-T?G[89+])Z'[-VGP75LQ%%)Z5R-T*\ )H:D"V=+X1.F\=IFTZ3(T]
M9^@UGJW861.QWS2>TV]%S!9<J.+8=!NNV:KT0>5[,\3#YE3C?AV']WG=Z+N+
M&^MK*X'6Q@OV+\XU'@#KG6'9>2MUWMRPR3S7@R;@G8'Y-W;W.E@P;I!F78EI
MQ?8U'FRYOKP13DMG7**8N[B]_E5HN: U[P](R-<H6*-7'$[-3I&V\F@3U/\%
M%L@NM,.;C+'S0UN#L,'(V<V5<=W:CF\1#A['>"P@P*RW-XT5?&^K#C9#V,;M
M5RS_OCELVMX9P%MH3&#?EJ"HL+'J!4M+ZYNU&UL"7Y^=<A_CM?;C%*^#(EP"
M8AV$>M(2^09"!$)';2,$F[9A[N&'&%L(X5GSD+8=C:-AWI:AI?L-T3U+</^"
MI_I;%M@(]%W:EAE9("1C;(#2BSPJ\RGALP[9F54/2V1_;-EA W8] CXK+2X*
MGH YSB_:BJ=-H2(@3SZ].H.R1A\>0".(>S>B+9-CX!E$$KM3WHL&V..V]0-:
M/^! H'U-:(N!'A<E*8DR%P#S)#;MA9']H:7W-FMX2#"_B?KI6>HGR;AU>W>'
MQC_2IBS/&@_E'YW;^&FFE0S=0P4#M(G0G*Y"^BMVJ=?T%/I/S?^J&U^I!<WL
M7LMKFVU)PSU'7EU#& J :4>85:3-@H9D5<A4&4%F'UT;G.OLA+E\NV#MS8RP
M;@JA>=F\UQP]TCGMT@>^<='P;A&[M'2T#FSD[M?!D5.U\R%M\)6W7VQ):T.D
M1:->>TY9TY:6=Q-VDP6XRR,"W[@L7;W#[ALN]Q6]+5\SPFH\%]+=VGO*51#\
MUOTO3_)6B6MJD[>N7MU[U$;O37KD20M[Y$ER<X\\25INK+;(33K6_GF;J'5;
ML7O>^07VT3?/+XS;\\L+[O?SVR_<Y>T7^YK#?XRK<_NF;:JW4PANF^KM%CZL
M4L?8:W(/HKQ%S$X@YD7=#AMU4UN _0I4_$)"/XWP*K'2K8T''=W=?+L.>I32
M/>RV-)N$ZO_A0O\A"L9#]VY52.X I'9$+#?W"L/[O[_AB0#]T!OC[0PJZN0$
M7@,TK0D[3*FQ,P@HB13N_W#^R _\X4OD2POS]?4JE%KALVGATPJ<;0B<A^1#
MZ3=VUZ[,>1,ONTZQ7C2M'*AOT;.R;,JS;?&T[]N[J^[Y+]>VW0JGC2#":#2'
M\KOD/>R(=8:Q?'IW7Q22,&U9XRTEEV6>:9+.O4M)X-X')*1(>=^81WK;Y=3D
ML%I\OT%1U#,SS;BX-6Z-EXG!EZ236DE8*PG#*#RC(I"F,UNS;6=#3RV8-U1<
MGPF7'1(>C3C?BOPH;*>[:.KR)?[*E<6[3K"[!/S_ RY$SQ\/ST11XGJ^-PBB
MV.^MW.:L!?E+B[FY=]>  'BNT6!I*.L^FNN/E1G ]-KKC]OKCQ<4\[7%>]LO
MWFL]K+5UT_&340!.57AV'A+XB(]T5^3COJ_D6+4%DR^PD49D>!?#]_]:U;]J
MH?V*GEU79&BY=VT\>R-@K]9;M2TL-IEG \-)57]JL_L;E"_"77M@O)4N!POO
MMFQH:X9+$=<YMRXOSA<VTVW+R-^VC'RV95U;2?[V%:*'>3O/9N6WFY*_7N)Q
M[@DP=TQJ-Q=[BN]/.3_T@C'NGG.Y!/X3D#/W'D]D>^Y=])<;@F3Q[S@W'K92
M95T-ANJO_6HE3.M_'H; $3Z*Y1,MO,P?=IQKDQ"^()';^V/\@+?O!MFUI:WD
M6!MX,VG1UAMM,%CUJH*C5CY4'_[UVKB9WNA7KEFTKBW6R_F;?<NYPU'@]WV0
M&=49!TCO6Q ?\ 8_'==8&VV!]H$)+[R0'?RD;\;"5-[AQ\)V!#<U@;+;P23&
MYO7'$!_;$2R42E^[MX>H5G8&SFTZ9%O2?\F^W(<O^;<JW$OW@[>2?3,Q"+R$
MO14O;?SRX #?RO5=Q$M=ZGL2$@37/88MCD#V[\"95[P8#'YEG<0/]=KJ]ECK
M@<F.]@Z=;<!\>J_F*18=C +"A>0>?G\@'!YG2]+#%2$[@X16OFST3$<K638!
M;;,L/;(3];'KA\61>M+67K]]@BN- =;CMGYO-T1+ZXANSQ&]J-Z9?,ON3'Z'
M=_32;+N5WYS<JH>-^J[MC=6MH7E@8&ZUP2X(_"_$[5')?D&\'VWL<<TT?DV\
M<1R3,#TMAQZ3/\?N,!HGK-M>)MH/\N;IS8IMCZ3C)_\PQ?8VBL$.6@SLC!X\
M=AFQ,XAX1>^8%M2M[;?/&*DQ#+^1P&V0.(>C!#9)\]_#F"3$HYWH3J>'G(;-
M<-YW<=.6C>X]6-MLT#;"?15+\( %Q,X OC7]=DVBM*;?]DR_&_ V6\OO;2R_
MF2K$@/C1<!(E#.(T$!NE Q+#:OLIE_I),B9<-GJ(29_-"OF4#*._0 X,7] V
MOP5F&R/<&K0SB4QO\@/QP,''8C+T4[\M#WK[&S= 4$<A@CUV1Y,6W*UI>$""
MO,;Z,V K2/%NP-WBZ8B$\T/NVSA(:=TSK0CB;B>C6LFSG.C?>=&^B':V4@+$
MEO"R\I\=H.F] ?CK^CFVD%Z]8Q*K>Q;YF1Z-X N5,0%&#WPK05WL18,H3I-R
MM\>23^5A'UFJM,_ [_+AKV'*C>((ATE>:OUN:%U?6>^Y=WDS2?;.]Z=XM=DI
M]QW^_PO^0'4#^FX!Y_9(&!69V%-L!''*T</#IS6GR4ZYZ,&%W\/B]\I)D5/N
M'I<)RP5Q2G^,2!*-!NX]@5?\,0X]:G54OTEA,L@K=D*LV,FWDS7!Y$4!MH"C
MZ2 F9$X+3( F[,Q-HWB2PY-[]SW?T?_/WKLVMVTMVZ)_!95*;LEU2"Z];<?G
MI$J1Y40KENTM.3O[W"^W0!(4$9, %T!(9G[][='=\P6 HN2(3D)QK0^Q)!*8
MCYX]^S%Z-#]"ED@>AS9OP</J6U-[F%G@;:<L^7*]4];QME/6ME/6W5O4D,^F
M/'JO7"G-VTY93ZI3UE_OSEG+]?32W*9ZYW6:-Q[=@MY/X;7W#_:Y__I=^%_1
ML"INXBV<_>LQZ)U<G+]]NSE=S?_ZM;6:!(W*+3)23>]?Q5AU@!H>!FQ^NH^0
M3)FD6QWR".EQ\FZ2STE;X=<_92'_,3KD@4[3O;R W546YN&+FM'(OW!C?/DG
MYO>RQ0/Z_UK^%T[\0:9H?:YWF:91<]O:;$=> &<@/B3&N<([#5<F/ *'\M)'
M6^<V:;KSQ*X8^_(C\-@2\E'"*7DVK ;SA$,:>74]CO*JB,ZO/B*F<UW$T]ZJ
MX[*5H\?8#=,L:^/$B1W.?BXA0XE%OCL][YY^//NP%:VO)%I[Q\__\9)5SO*L
MS N2K/Z"L_1G59'/$GK'^^(ZSM(_1,!&Y.I>)F5"WNV8+=>/11+/IXBI(I[%
M\=R5<K?V6-,=AL!C!T/ECWC.]^F<OCMH9B5Y-,-DH(?T>_(#$AK"*<T=,F$2
ME5?5;):3F&37M,+7U40"TB<SNBC( ZYES39[";_YX?+T-.I&%V<?S]Y?;N[,
MO_GA/(O^74T6T?[NWE$GNDWH3&5YQ:[@+"]3)NDJDK*:S!D^(PO2B>)HUMI.
M;)!/9W$!$3H]^?$]??K__D\TSZ.$]$^.F@).A\](#!%UEMO"NIY8\MMQ'HWC
M&V!T9C3\A/\P3.F\T\O88DG*4O3 9)+?XD5SJP#D<?-HPIDBY%QF14KZXK_/
M?GI#DQ@D,Y)H&L X[:?TKY[.!MFO**7AT*>GZ-J:9,,9.BEVHF$R):W$^3#I
MB88<6<F:E-:LI#U,1_0#$CIHIJ$'BOXT)<5%7QE5$V39"AX^S?S#FRO68'9Q
M>M'',1IS#)'JPE]OXS)ZWCN,Z+WS<<D?AC)TJQD7TXA6LZ2E/.B]J'_.6VCZ
M8,__WJ3,_1'3(-,ICC8M\/M+WM*2>Y&%*R ;2I_AQ76/[T4D.5>THLFTGQ0B
M/F&P?YVG$XN&V_XLNYY@Y?]-1BT@%Y!06LL!V%=VWIW]^^+98X_&)#EF57^2
MEF,VA!)>I4DR3R Q\SB=M)V>49%/^<-&S&(:\:),PW/%N4>ZW^S7;I,BD<V;
M 0>;P?8B&0]NR*M\D";S!4L!SY^6XGW&E*B+:.?LZN+],]XAY'OX!/6B$^3%
MHMBA5>1 1=6L8XX%O]2<#<75-B0$@W]_10,OO?&E4"JT!?3.8S/8DRDM[L ;
M+*YK<P.YP9Y<G<I@CZ.3+*OH;Q=)(J>/EL:M.KWB:PC:6ZBFN1W?XTM3H #>
MR_G?WPL5@-67T&'I3:A=51?L'?>.0F60LQ"9+_@G%V\LXQ$V@13 B,05RXE-
M*N?5<,$K3;_@=H0JI61=8V2T^X $6&7+*J>$526[8AY'>]M (X@$??SEO.QM
M\H7Z7E:R'^O)Q@_#>!Z[\Z_'BR_,#O_FS>N3*)ZI,G9;:Y3ZW#=Q[[@\W9TH
M]QY6/\ZNT_PZH6-F,)A6R3C]871F&9W01P?0&1<GS^X]I& 0*6 7HO!JP\$U
MW)W'Q74B_B./9H-E8;E9B?6\^O7=YDZ=[<KW@WFNML'Q*M.2#X<N"TR1(@8D
MB)X^[$0DHUEW$O<3.BWQ %_KDAZ:DSKC>U9@KPW[,] _?%;**DOEQX8-2E?7
M39I7)1E%5<:RG0QKABD^AN[:!>OJ>=)%TG66YPB,EY^LC>H").3&0M&>3"8I
M'B-V7\WEHH&XJ\__]#,:QY#6#L&ZT\L3T@]A9 6/KAL)3?N +GZY2LV]SR_T
MMH5505GUR^0_5<(V87##XB%?XY;US+>&2?#X5RYF]H[TFC%<CWM&\M;M"8B]
MS6J3QI!F-^C5?@T_NQN7=,>6M.QP D*CV\IM3TS/FL< N0J%G2[J%[U]8PVH
M@7#4._;M _=0,N1;QO'XR_Z_RVIV1SCJCA#:;$Z;1@.J9C\\_K#N\'VPD'>X
M31V<LX.#[YH[8&RR_>_"M9:KUQI[^'&97=V)RG%^B[.,NY:^-8IO\B6*[6"W
M=U#;;3(A7RS9[E]G0U9O;:IWA2)Y+@+H:Y/ !7S^-]$GUK#Q%8M /1]?@(#O
MCSF \D),ZZJVP *S54_1.GV\['%$JY,->76&"=USN)RY;$;N!%Q+Y.:2/IBF
M\WE"3NWYY25 I;?C=(#8>S9*<2$%?F4R@J@./!_-"^ L53KLPMV"+@E2G]E9
MM'_!3*,7?4C$(L3 [*_%K%VMI(X;2NJ@56KEX)#U(RY'V]@B&1LK5WPX&(^G
MOD$'ZKP8EM>EJMQ7V+1V')_!@0M]F]+IZWGNGS1?&,BULX,9 X(L3L&@FG?S
MT8B>+D>+8W%['3Y,,FFK!E@!<,)$%4+@&5I["6,(QM<Z.%I&.MO8!-) RU>@
MQZZ!YYD>A[=(BV?:I@A)&^W?Y9S6UFSKF_YEOJFY!Q[%.6VSJCWNGK"6&T9V
MGD6O22CX.ME[Z9^"6XZQ324>#*.8?RH&L/DG,3D58];QM='1+#-2G[2\),V<
M/DJG:KYC3#/Z15DACZ0YCE[DRK<FY"CGHMHQ"*AW68^S4[<<=45 *YD6Y;P+
M6?%6!J-1IWB5'^$['1LLB\M]X\N$/+MREK"C%YV8$ZZ["]F$/&Q^8N:D%'O!
M=T*=1"'J70[B&3N<)'X5+1'G6?+)3:)*DJV.:&IJ#\]/S_W#.H.8TT7=![ZO
M^.1K4[HMQ%3@Q 44-%V$>3%G-Y;>,DXF9,DG$]HC%6UOC$X%C//H-J\F\/:A
ME5.^7,BIQ;[ZEN#3*U]YOBU?V9:O_.GRE<>3QVF.RCH3>>DG63)*Y\XQ-)G*
MVYQLMDER$[-+X:MI9XC=Z3^^6!:(>B'VZ# I!T7:-_Z,41M1-4\GJ::,[!5_
M=R*Y2*[C8CC!J\3028OHP^ONVSTV=JLR<'?8PH1)NB(S;1+0L$$R:]ZP9B7K
M-M>0-BYT,D_Z::;<!T;I;O!]+BE9-GZ"O&:[=>EN<#$T2[JXXDD5:UX 'BSN
M%KA<O&7)YYG)^Z-^U0AJ7LUIG9.RQ2GC+(2W>WACX .RO(5?,=GPYO-#80K%
MB$Z$M#(+W"L4Y-B,F]B-- -S7,0E$Z^UF(I/E,1DB/)JB!,T@M6:79?& >0!
M-Y:#0U1EF0]2GI7$"U%!FA2^^XWIDPM'J\(^M$GP9D.S)3T/1]58S4Z$(=R@
M[-8NDO?491"!:$?>\TRC0F9M=O2=S^QX9%HV*8"/RZ]LGSAS,,E"S_RL=9L:
M0G %S!0M>\S+)9_UU8?GJ)C@/\^%#C9M7I*R=QA/@"AA $EPO$55T NZC#.A
M#X@W*=H@33!F.A1F.R0KUJUF$*4]XQ9W@,'@X1T<?-?QLPG(<T20V6CG]2FM
M)0-$7GYGDW@TJ.XBB0OL!'\,'S@Z^(YV-+].,(B.(@JLDM;#!L-NY?FTAT$/
M*H\H[5?SI!YH ,)U[_FKDGR]]#\5HW60"3%^=ZAP:=$QB$2<IKI9&L866G0Q
M_08G/!.#UZ #((C)7&2HS51F>5"[N%QA&&^PKF[SO7ZF57W\T&CW:P1[H].S
MMV=7'\]/WF[NEM7SJ<_O =6SR]+A@,DJO%Z@)^EHSR;Q(.GG33/K9PO3&VH(
MCX-K:@O5T'AE7L2CA"-[F[P[=JUY599G$9N&"J[3=/@X.46-MGH[QSFFN68+
MYNE4'&\_U\ 7 -U! $2R&)A4 RP;";DA/>$FV$<D-I_-$HE FV0#XP'_'6<5
M)LS!,O&=OF1.RZ%SDB>3^%DZ#2Q--\*:#S*L"KD@Z&H&SEPM)W5-V/D Z,Q>
M7S]Q<35>0<.&C:%M?:*KQ10CJZ8R5T7-FHG2P[Z*M@.J<5V@1H$9?AFRT:X_
MKPY'AEG/S/(9H.1LNX]T [MJO:3%4$*E1L-T:DBXO5V7.&B>'97W%[W=X#-&
M_G?&\1]DMD>,>H]V>\^/7T4OC[Z3K-D0H601)#)$Z*_'!]W=WLO]5]'L_^SV
M=G</7SZSR0^#RYWF!1L1633,:9$T WQTUQ QS[W>R[;Q]:S)=_C=DF_N]LR?
M['=>URS#'5+?["/#O2"[A<S$#V0E(GDFU37&E-RY>OWLF1K XS2Y$83*,;W
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ML(%A-0]=".(X!5BW%]F!Q&0UT@)(NEV> -,,'549.2I&3QG]]]E/;SB2.4/
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M_N(0,%XXL]/FR_5UG(\@LQ%PR,>?MLR!'8_9) G+EM8A4=Q7<AK_SE010M!
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MA$ATI>G GU]]](AF[%T(/U.I9UL;*]3ZM-:;R7CS%')XOX$%ELN+%F#:-AS
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MN]<GS[SFTJ96S6"8/! CH+/6I.4G,C)7(=M+'E_B^8I0\%A&XBBCC_ML>7*
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M:V.W8?NAF$Y&6((."F^D>H2[7^ L 9@A'7;HS?-*0U%RQT3]/"Z&[MVFJ8[
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MP"Y=!.A,0I\C#7!P6HO<ZF14203-D#0RN'1:8)9PFFB2(_V=EOM$]SM\ANN
MIU@Y ZA%I#AS*?I"&F+7W.;7RQ6R6QL9H0>LZB>]^? H_0C-IS]5IONP;+H:
M-[]#+Z6?Y;"D^]L!4C[: RGW0,H_$)#R905B[.=LF[)BJYJ5@ZJ"IW7G%D3
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M1Q+$S[A_X3+-G@X!"34K,)_P84'&ZFPI2@XY.:F<ZG5T].Q6:L=IPF[-VLH
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MBHH+1K5<TP\2%*2Z?FFM*E@6ECGBOE)7RDVCD8[+E8?L'RXA#/N&,8#W]QC
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MV2DU)C CU3=" EE)T <S3D[*C)15+)H^5Y-.(UHQ9O*RWH3,B<0.LG)H",A
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M.>/R^[A?Y@)-F1>, ;8R9?F5J6-Q]J(E"<AO+@T+U1X\-6MAJV$B[\$%OS$
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M@N,?W>M&+[PF!#>33.C]U E5PB$Q'!L%IR44RV_GJ"56JU^ MB$_89Y^Q;7
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MXR3BDC%';WM<9SF;<N.DXO*0\.3XD*2%)SR*I8P-@'.0^4$8TZ1RI\O"CLP
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M+;P<3FPM2G"Q.-6D)EXP^SGFI$DF2MNO=M#"!OCX7VUQ@YPV"#LWU]N"5NF
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MEB=ANQ$%9@._7E'U14>@TE=4#ZK0#DIIW7A@0>KQ)U;#3?X+?A+HO/;0:F>
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MB,V&X_RP2A@%#B)$R:TD0D 72YHH(!.KX#01)CEFL"(&<>$+[":11(P5F7Z
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M/#K S]7 ZO#LO(&'?22I$,'#WA3E/!ILO_PGB1R\.WP4?&3B%@5?1E%1\(N
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M+>K:=+H),8ZJ!7P#M9=7QL*O4']U8A:&N!*+-K#RXSR1_'>.X1<I#9@G*;I
MNCP-W^&K3SX>@V-)*WEW<O;RY//I!ZW-./OT62]L*SK+,8)"I0WTT.0B23.2
MA).D3FP= M!HZS#BMBDK)E9 <-:;[B(6]@V5'\!4@/>:[*7)T7RUN]J*WN>F
MY7D*2VD02B.$Q! L,#"J=?+^T]NSDY<[@P%[L7K!W^;-AI[DJG/[\?CL)>BG
MD@H4EM'KSR>^)=DR6IH%&6^711AJ?%DGY3G%J2RKM6O5-TL3B)A"CL"0=U*2
MH8B>9R5=;^8K/#MOWX:E)]_#6A5;9R=G9"5/#%8Z8]0WG7+MB_?1RCI\$CY
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M!U1JZ@#+RCLPQFQ =W$&7;'#*@N#&7>NXX^X]V+><I9:JJ*[+/5=6<:&G\9
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M))V0&S7\.ED'3[MG=P?&%7G49'T:F-JWF^V=]LD^,N7I.+BM=$465*B7-W[
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M?0$'?=R*1UY#XWGS=6%/Q54#[S[T:4F:J#+W@*^7OB$;T5W^ED;-TJ0F2 A
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M5!Y..:+Z3DP(:O0^QGKM-9+FVBRJ,+IU N]/E5MVLTZ$[Y4>![6>(4=#CD=
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M8*$.1)MG'V.@%GV*<>Y*TM]J)8LY1]&R3!\I2W&ME/D3.JE56IS,&)R&2,H
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M1-OP#JOD]%9T1.C^0B:&9(D(MR'(D%HA7U,A5T'B!:I DW/Q\S+-Y7RB6+F
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MTS<$8QL\/4(%M8)IBC'$7ABB!!7$OP X[6BHW0'./OIV56)5-KPYYTMIK2W
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M%%%:$PJ<4M)A[5BPPSFCQC7RFQYG@)9T/2:YP#@QP!XZV&9\<3&8Q2'03]D
M;]%[<[WW_CSP$KYT:(LX-<CQ.'D[J/(XR8DS1B34-J8+-T^7;A97C?KQK"G<
M;#GJ/5N=?YT.?AH-AF$A)E?E@V@>5Q\5G('_>!#"R0W=6_EEBVY;G#)F7; \
M>9!?!Z5F!G/.M<=>>6\:YN?+Y/<>9;1N^7UV6LT.'3H>S\:]/\_'PZ GI]?=
M\,O_O1K,OKVV$_8N&[)[>^-I]W>Y?<B'R76BW3320I[]%?P( ,PNBTGVN1A>
ME7D&01Z,YVQZ7DQBGY&KV?EX$CZA7[4<&8VO_S"83J_*?DHH"BI3+/EK'#D
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ME*<,&VU( *V$T"(FI&@,L;I>\0!2NUAO5X=MUFM7LEPRDM)O=M&S3>"\ 6=
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M,?G#\O%.("_821QVLC^^.AV6Z\G@6\/=_W6=-[U=I$31HL;<4Q-NA,7N)U1
MH+06P8(!&#H.C6I4T 49VE!_6 1S -<0%GQX,SOK=^R P9"X94^XA<.ET=[,
M.J&--AY2&BP<;P*_(&>TTH"]B%O6? ;!),C!&IM1)[))9)/(IGVRD6!Q ",
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M<\T_!XF+22>Q5'-23F>302]FJ-_]>TI)>Y16,%C8Z HXA0ABSCA%@:6"<6&
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M4X4J$O @4%J="7S5-B>]:6$FY,;+[)M>IB9GV,&$ODRW<^.-_OW>R.F-OK#
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M&K\6.2;=O08#'@,"BQX3S5OGX;K3"RG5A"ZCA%<BQ4'IY6U,%#/@L44,P1_
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M@878,L*YF-9%+HO6GHHJ7*NE"B=);"M)0S-T/">,?!;S1%!%X&5^ZCZ *OB
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M*TIG>NVQL0DC 0,B-\,)78AC/ =VA0RU.A.[5M7JU_7RK 8*,Y;Y%4T#R+
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M<KJNJV7QP&ZZAY'T96L5S"EC9A!ZEI-: 0OB)'1=+TF"S+$S+S3Y5H'-(]J
M^*DXM:W4JOO>>(O9$]\?LI#EV>HO!Z"FO+9K&6CP3*GI>&G(HC@*F9F:D1G%
MS$V<E'FFR=WL.=DE^[BG@3T)_"%SK,=[.M[3H>ZI#C6+5\1DJ>>8,3.C+'2"
MR(JMQ',#,^6A_92Z\A[NI<<G/A\2?/KYJ[Z''#CZ>PY??N"=/NQB=-NQ.Z%L
M>YYKFP'/0%%FD6]QWTH3GH9>ZMAV%&ZA:#Q!O.3OGP:XY:X[\;TA,4^OI9%G
M*Y4/V?LW7FUYM1VM0T^8,=</TP (G_'$XRXW$R>*..>^XX?/,@XPR%UW@HEI
MCW=]O.L'?M=9U\LT ;$*IG5L^VG,/(>#.6T%60J"W E<9@^?]G /__8@=]L"
M.3ZH$?W\[O8]/=B;]28O0UW_4JWRN5'+"IW[G%\O\]!9?C=FU1K+71Z2>OBR
M0WQWW9'#"?4Y6J>OV,Y<.\B2V(D8<#XO2@+7#;PP<AV>\"3=IT4S (/CG@\<
M;DC@EUOIX7D&\EZ!DW%D;"-CNYFQN6;7.3IQL\"-F>4E@<6<U O#*'5#GGK,
MCQPGW&H!ME=[;@!.%S!G$MB#IBJ,G&[D=".G>YF<3L,("\TH-<V4A7%B,N:R
M($ MSC8=;J6VY>PG4JRLV2&<S<R>N/Z@B:@OD[,]/N+-82%7_%:LC&5=S=;3
M56LC&SGB5:Q6=7FZ7A4S8U5M@UHTQFD.=&Y4"&51&,U%N80E&O-J2@5HQT:,
MV NGLA[M(:]6KT28F&I=&]/>BY=YO5H4=?/__5M@6_[/QD61S_ZUAC_"WS;*
MNQX$M'/C*>T79DA\B._YT?*_3_)@3X"C-$92-N0H@T-8S(P0L4CRQ733)?)#
MP#,(/P:\$9Z:4E\@&/OC&8VF!@L7LVZDSP4L]VL1Y7/Z]78$FH0[&0^"V.-.
MZCA>S&T6*Z@<^#'2$&@RUS=MV_0\U[)XE+ D]A.!PQ;Z01*9!XY \P5N"LJ
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M3S6?]9+0DD%W $4<YD:B&-3BO<K@N:8A/JT@UMJ4H!T?1U$21KZ/!56AXUC
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MZR<<D&R/.&'\2P46#)'[MY4JWIYI!2VUD1>;?'.@MM-6#_%K?P&3H1?'*$*
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M"5Z-/-[H"11ZRO<2'_E10''"-=<DQ _"B(6^5#A:@GVTM!!;-7D]7SRC(K2
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M>JN.H#[X@>> Z6DUN]49H/942V?E*,YKOW)C**[4,].GS;%8,D'M9.8A)6&
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MIIVU<WDJ ESIT2VI]&'/;N75+7GHO/<5G.I5!I_QBQV.;$6-8<"43 +)>21
M^T](%'%]1(10L1&2Q#]@$5FY=KN)>>WG6/'.T0$(>>% 69=!NV2:@$NP[?"L
M_31S:$Z_YWR $EMYD1YIW2:+8!Q'./%C)&F,E/"H!RI++)$^)/TX62=&)^,J
M1OO-S5!_]ZM)D'U95:5!+7J)!C_JS1JF]R#T%O/ >_K[8F]4XC+A>G?3?*;-
M#X@?:?8R2876YS: CJ5M"JFRYY9#%X5S>P^R%-S@8%*4_K<'G&H-@]O=O]['
M;[[8RKUNXW'6$%[G:%\@_2V][0O#-V*Z;!$+<=IU@9E3-G1:1V([.79%M]T%
MQ[ Q@7_1-*27^M?K5+/&P+0YUF*V;'1L?_VA.FZGV;_G^=0>MYH.]6O*S/D]
MFE6;CDQ6 ZL'/D,8$4_(0-$H)D)R[/M2'YI8)<A;:U4U1%25L>1RMS^//V6S
MK_J\V96H:KQK\^&WG'Y$MDT_6M6:9H_Y1YHB'"TMAL\K1>N4.7%-.<B68?Y%
M/^5!55!6>RDD\90,).(>5A2%D8R$B+E PHL82OQ@KRKH'MGJ&:Z*0RB5AVP.
MR(*Z,V0<)I2$,J(T8C3RI RPYR5(1;X?".J+EZT>/T[Z.(3UO$_ZV$@>M9\%
M(9_$4<RDKY3B4H8HQI!0C%4DI:RA1O=3LGL0<B#+1H4FB;O)=%ADXW=_^Y]L
M.ME4A[L_X_/U]X'LOYHFD/OK6!GL8UG;'2M/63'KJFZ/<V>V2.):4W.[P_WK
M;9>U<4KK7D='L^_I:&YH<JE$M*@-E&*Q<Q8L\U(6V- ^<IA9'Y(I]DUGT%&K
M6&OZ%#8$9VXTP:/&OM;.K1]=V?!(RRJ;)K ZD:Q.;IVLL+<@)7*<34UTR[RP
M3/E8'G%6/^HNJSNS3S-7R@]M50<5@Z\:BO5/018P4.-E9@IC(:&W=SO1=YA4
M]OP&\N4@*;_EZW7A!ZVM#.:S?72A[^_AZ+N=YB"][+JGP\EMF6[];7*;#WK,
M8^>]7R>0; 4QS._I-+>=R2 -1YO':4, 9HOD4K0%9]6.<['7;2/"#RL/S]:K
M;_9U.,_*P4&JCMV>W.X09.[K?;LP [+-,PV^9WZ9#\"59IR@A1XU5*7/;^#M
M$&(J);CUA\)#)H/!?-IWM0[P*H-U8KSW8^<;M5ZR8CXPA5>&J^R$&V.':0%=
M9GHY3,)3JXZ@O6):PX/I65^M*\4NRU>7E[%L+7HY'YED2W/T_ _4F)1$6(=Q
M<UB8WFBB%>AI<RG/>U(/:,T&-O>I"K@9?Y!AM-6]4JMAK1I0^43G28(5[MG<
M>O!KFD!L8;GY(M.W-%EYXFZ&E*[A!+S:XYF>=CNMO\6@_?;:.W=G-:A2-$#>
M-6QC-<C54@N6L-!_%9>Y+9!?,Y^% WY-:FMJK*Y")4$@"$LH192J!$N!(\X"
M'B#%??W3.YO$^%8[NW[Z_"WN^5J;?5*WT _C[YHFC0S^,(ZR"XCFQ_^>Y[/[
M#T#_<_-+F!;7^GOX#_SV'2K99L5OXVEF8A1#DP%@__Q9<TSQBZG"?+!M*)8A
M49+2A"E*>9 PBN(RLU-&'#7:AL:!%^)8<!K11!$:$,1<VU 9>AQRALH*F*&<
M/?H]2UU'0_GU[SWY*>I]^/1?\==O'^-/W[XNX24MMFG=D,>ZS2B>,PG\C.SN
MUTOY0(_]'OS;:Y"E1:#11*TW"L3.XN^[;;&[DC,V=\U%8:@T-0O!@B@(]6XB
M5B4V2\R:77.]V ]]R3&+5>)S&4=^[,A?1)&49*EK[C.G5"_=FLD]-"_EA7$4
M41XJ[ O$*0J\R,TK")22C7GYOO"X(,B3""G?8XQP-R_]D-#W3[P;L#3'['B0
MC_(: ,@0-/S;R^H%[SM=IZ+HQ0M 29^8BBS0KK2:#89-J+44 #@W1Z]*1^:D
M_GJ=9;/*5K"ZQ-+=YJ<!Q)VU'F:J59N/^EJ6'-L:41A*8EH)@U[9=1;N.@L?
M3[/?M]-9^%!M&X^\H;!XAM 6.U14CKGU\-ON^/GZ:.F@G8@[TGGEI'.X)L0=
MZ;QRTNGZ#]N;C<EC\G07S+"NW]PS@/M/J=_<NMPAGS".LH V?#L(4R\.$S^.
M,*4(<15C;01[$<81]]52ZM!JCXR<A>ET"J;Z?Z6C^6+&KBN\V@&^/F:L3[WE
M3, ]]'=[$5KN^F8^X@CMY%@GQ]IRC(E&?Z6$^HIZ8>@A&H44^BT)&B<JII0E
ME.Q*CO&=R#&"_'X0O$BG\TZ.=7*LDV/'+<=X W.<8QI[L2389Q2'2J#$\RD2
M*!*AGT1+A1]/D&,?;/)VE VPV($L0YSTT4[[L;TR67;"?7._7D^FLS,#]/E
M]&^#QP-O\'CLU -_*![F7MV+(J9!& D_]L(@27 0*#_4G(RC*)(L\@-ON1RC
M&>\.H9_'$I;,,VPHJ(48Z@>[\F?\TRDT*'M++L.WP4"X!CR@0@1!S!(<2R42
M$@68AI:!5"B%OP* 8SL&>J+RWC%0QT"O@('\1@,105!(/#\A"E&EL&(ADTE
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MDP2U+3AH[RZ;9OKJ0D_,.-+U#4-]^?C*/.\^2Z=%+].S&O;*]=W5+,R":;:
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M- 8B/"JU&@NIC<0:&\^ 8'IED%[M"%=7#1[K<+B7<>_-1+B&VJZU*G7I55#
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MUC0^.6*+W(<&I3=@03C(N*PF*1M/@>/,<.PT=8(+2KC&RFE%I<,6UYL.5@U
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M]G@H&HN'9#4)Y&SPL*$^HEK:(XQN;J=! 5\*9<7 5CZZFMREXZPAUOMN[85
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MK%-RM^V(]U!(5RN4U%E>?UI0<LJQD6U+Z(X+-)Y(KI=+R?784,"\=I +1;7
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M 5)'BKCT\]DBD^M1OLQ O=:LV#NC_WV)R^/FOYSN4^;I/#RY0V:184*6?&=
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MVM[0=M+0=DMB2S6D3! @A<)0HJHZ5G#1VO)_NK;ORX6F X+;K-(] /0 <#8
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MF%4( @PU9490"@TKM5:$LK^-6KLBR=^/$8<0#  ^[9/0?7C8ZRAJ4&)K&EN
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MY)P.LIE''P?W^MO07P9J6ZZ )90H:!R@7GFA< 940;168K,M7Z^_'1U")72
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M5X:GUD(^B'\0P_&T+' .\O_%/\'G=)+F8O,ZMD1J([BT4B##%32RL+ 22$H
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MF+.(0D>$T\*R6#%GE=!,6F0H!X0\F+;O[&0+77F%;,/)EC?M@YR1GZI)LQ=
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M[NK:7];E[:+'WP-/^2>/3SM;8/(B#36CFY+Y>K0,+6N7JW[/8:%7]<%%J^#
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M[5%'+L;?T]<_0KU=>78B(*&?G;3T%/*!_A)^]3)2?,0[4'Z>Q[-15HC*ZCB
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M**!W-XYO;Y05K&X7?\O2W/ZL+YEX(%FY;>TX@0.!=]?>^9"8&,\@+]##S'G
M3*,HRRJ(G3:60J*%% (R:RJ809+PY\*,Z 1FZ$"P]J[(*:+,.89(C8V;/D[J
MXZ1^]<\J3JJJ3Z]G\\)6M6*D8?F)Q@;BGORS0W=/CM'[$+0.<A 6 %"L7#A9
M9)WAQ@'O?5"E(*6R71U[V_NH[,:/4H1V%N6@ 4=='L_O8Y@7LI(]!AP(!C0(
M[(EV1'.K )6:8L:UB!F!_H?6,K80/!L#N@E!/ ;@D\" KB.,HW R?EVE62LW
M(]0KW:E5VNA?;$^IUZ4C>GC:*WBMO8Q:K+WY)D+0V#*!,%&$RIA0H0$S6VKO
M^]ETN&,C3L0 [(?QZV#-^\G&1[UN5KHI07WV3$ : ^&XI)I3C*1DRDH<0X2\
MM8U=BT[@*;K9C7&%: !DIPV=#DXWGQ;"8W8,UO7+;)%,'F].][_=L!<&HD/>
MBS@6#K 2S'#-A0ICAR#D5,5,4D>DDH# 6%G'(7$$MRC [@&SG;D7%/@ 8:\]
MZ0Z33NO<4PP];O6X)6FC-904PG)EK(DI-3@61FK%,*+,&H95JZGF]KC5D>M%
M!@+O=6_U,'%K_XTVGT3YE4N%F66++0ZW.2>QT$Y8Z:@708AC%TZL!<ES&MC&
MX3;-I6+48<<49!(#IX0*'V406QX3\R _UL;[M+B]3O!LW'!V=3V;%B>OVYFE
MG(ZGHBT)!!;-3:XLG?A)^#:(OJ53_[5)?E@N&5V-I^-L$2[SO2!=F69YI\3\
MF)V937.]R2E_/@>BD*OJWN_R)H*#_HC=^ B.V$&T\8S=@WW&CNN,77^@;]?)
M+PC[$WTOVXWL%*2H/Q/5'\3KA>Y$A.[EVI_U0G>V0L>?QQ74Y=/\=[:\OF>1
M_83_T@IWZJ>X7KSZRT_P9S^2Y75?JUU\^<.:R'9/ +/S/;V=)4 W+?\Q;3!#
MB.K:K1@@KBF FG%%J;9",@.U0D)A+17>D-P,::Q[N1L[*=D29",K[U%O*A\4
M\!S2+DR/+\>++Z3>]*64,^F<L;%DE#JMH</&26X)03$4\+'X\E!'N2Y*S 90
MG'852P\X/>"<'."P>B,LL%"K&#@<(^=_0088 AEF&A!,K5F_':>FHT\^%DLF
MKMBEN;]Q7 <8@P?RQ)V: Z52ZT(>_U\R'^=[5IN"IZVK64^B:!5"7E>M LR<
MXU[I#-4T]N$ 5YQ(%@O*G66:W%7!:D[W$E+  4!=:M_!&O(3L-?GID.R;MXL
MH::<.$0H1!1@K 16&BF$N6.0M_NE;M"A';O-<,!8EP<S>J7JE:HCI4(-ZGFH
M8V^G'"-&.1H+(*3QCB*%0 N();G-2GX[$LUN*=@^W$0T0)"=@DZ=8Y+]<ZB7
M# [B.*_EBIZIBJ=]X@DB7!L^((A3E@NJH:)<004Y1@A*&S/JO<=6_%;-=%$T
MUZGG^)]T/ALEV67 4X$@^N6D@[:#TLY#M8FGKHBT-I9">7T#U/\##360:^LU
MTT=T F E'8\?HXA=NY^]9O::^<@ZCV/7W)\VJ6Z#>90R$$ZJ0&T4 LY)#60@
MY6&&*L1 VX;><75#*K3T<"NE+K*C&=RIQPL'".V.B?0)(E'KP'-D8@?NY<]G
MQC"V_GAR?B:C/^#7Q7;0V1WP@QC4>T9$:F<=-M1:1A$%RGG_QL9&QP@8CEI]
MK?>2J,8#P;JD*SK24WUGD)'KP:H'JPU@!64#K&0<.Q-;X6+J$4I!3E'X QM#
M5'S_>=.][@C0@:"@1Z\>O7K*^=.@G(<8B[J5JA;2.<0!T)RZ6$B$,+4,$\M1
M3'G+8;H_P'Q_EW.^XYB2#.29=+=80W^P_<GP-<? V\?R\V/XS8/>KQ&Y;A[,
M[_;XRJN__+[F?P\S,CSJ//G=P3>?]>[Y\JB]#NN.>N=35!]MWCHT]X_P*E?
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M@1X$#@,$<)TPU)Q +"B$''C+[PBGLMP@#.0-@CX=!-H;!L\# =SO&O0@T(-
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MTM;D:N\D4P#)QZI]5WD;+ <"=YDZ[M6^5_LS5WM>!S1<8,*\;6<.0^.<BK4
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ML$]B)H0LJ.&9<X11WJ?,4R.VLO*NOF)\-W]YYU"GR<;AAE%@""IT%\/#- (
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M>_7;'.?Q7E$93T=D[(K#>';T!7G5" F]!/8'7Q?F,5PKP7E\IGU0/[+YS%>
M;&7GVIJ&O-<\P0.C03S.<7)A?/L47@QJC(@)V]0)! X;N'[,HR@' ;<8&/X"
M-B1N%A+'$T7X8"TE_M(Z+PZE+J(H^0!\)A^TC[N9*X+9EK[ #1K6\?S<?JZ
M1'*($5<M3W/V%3S,49HKO'O^.!6$@T5(62@>Y\$RJ;S;/2H"#O-8U U=<"?
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M@\546S=J9(/%B@ (Z4/ZD#ZD#^E#^BI+WZD:V_^H%+10E0OUWW^Q-,U X94
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MH04,L5&.C2R>KD'/L5%C*4Q.>YM*20T\+23UTHQA<E+P$7&/1,QDN =+)4G
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MB)*1-%M$\+&&!?^,8O@(U$T::::D:T9,TW)KV400Y=0AD/D>T\F >A0C3SI
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M"_:VL]MEMQ$/M8RE"GFPLS.\?,/>3.-X?K2SLU@L.HO]CHHF.[?7.SC4VYU
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M&Z-;Y]7:O!NQIY@#RS:L_<CF6M1.M]=QJH2,'8 9F6X_ 17N^6JIL9)'#7M
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M!:DVNX2#:X*L!P7BFZRT#?P!8/ 8I2N9XZ97*\6\N=(2%Y\BB@M 'I8A.L_
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MGS'_QL#FFM:RX[)Y_(BQ+1L4$6>VS1[IBKZ+/1:->[S)[%##UJTQ.60E ,_
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M!.84-J.&]M"0H!E-/XB7HZ7-TON43#:@YKR@@K 43UFTZ3I#.J]CG\84 EH
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M$Q 6)1K#HN9II&99D$Q@AXZ3^0CV)ID6>+%:W$K@TM^8=.AN5W[#*S_6::[
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M8WVC9G0BI9ITNNLD[@F55WQ/QT\"<YWTE\KYZ8-%)_G(MV^F5\1//3V2'BP
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M_4HP+(VS*;3HL%'>Z%%:8#G.P4_#X.#Q_O-5\K26Q#-;]@S)1$2IWWS"]7'
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M"[Y$!E7*F!8Q,K4O6.+2*/M($H950"AB5\4<[\L-3(M%$G-7HD6J=UUZU/'
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M.LC'_OX8WO+UVT,)$KP_QG\15\1<82Z*ZH4I\I#B-"0HH8;9P=_UN-6IQ%S
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M$@$B6]GP5Y=6C(O,R;,!D<@MS-$#GEK$HS)$SO6[<^3;W8:'1G1/"0>JE-3
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MZ$#]K*1X6YF"SR:0OQ^]I 2?GB;&C:B%7Y86)V8B+S./10J#L:9.P!#?Q7A
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M''5IO3*. QLT%P4\1P#@(!!D#'!X+BT6]+HR<][1VN:4#9M'7DY2DGZQT\&
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MZ'SP=XA@'UV"JTY=@KM,O;/+H6?K+EL%UW(H*^9SZ;MRKV5?IKQNZD4^)0\
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M<LFR;H&4&+C[QRS915Z$O%699T"@A!.571F#==4U1OZ@S :)O!O3P5_Q_]L
MUYG4Q60O-WV\[S]]^N#CUKZ^Y[7,:;;AU$8_)RXE>5YR? \4XMU!1=R07AS;
M:%47*B0D7S07,#4:=S48WX(*.^DP\.+(-LR\%&'($M42?68!NZM4$^.3*QXK
MJ;JI; R-_F<*)NK8 [X5Z)$:^C0B9)NK!BME"W_:PI\Z@3^]Z!$*9PM_ZC'\
MZ2L<LQWGA_%8P "C8<21M,@@VM-[0PZDAAK.02W^<UI(NXIK.&WQ2)::?.1@
MO):+Z8Q5-\/@XOCR'7]]>'SX+C /RW; +T>N'V8J=1%%FW.UV(/*L$*/I)X=
M<P-X6@D+MFDC>U,BTJV,-* U=$2&0Q'#2<6=F*B$-$-3@\H874TX3 ><G#E+
M!28^<%6PU#@V?[#A1(+$06=90U,FXG6@& 9E^+FZ5N#\@A0.R=0A 1LPS@N-
M'B%=V!GZ1M"E&F'F%67N71+J63! ,=UQTDD2R].'C[(6&EW-EUA;SUX4#/3>
M%'8,"OJ.N!%9EHPCPC&4Q7B'/10F;66*?R7\S%(TP_"*DI$;2$K#/IH:=TD?
M+]70QX)?N6Q?#BX.SW8V'F_<T#:X[C@,'QN7WQKRTH%D.<#/<( 1&X/C$EOB
M6[ L&4]$>,:''B)EIX7'SN,(]XG14+X]234AL\-CY7],#&WP(E,=8W9<LP*6
M$5$).@/C*A4@:.6J&5@YH259"7=\(DB2Y45*Z-AR$LEERY2_0<_)/8/9"GXM
MX&YXK\HFK/R"CZG(JYN$(?ZFU0PKNAQ\#/7+"';!Q^#H_(T!^M#D[((B2G+:
MJ?#5*^\^! <^W+%Y,,GC.>>!6.R2*Z;ZH;1CJEGHJ#G$G=U2+$%>JD-%3J,-
M,G@X(^?V"3==Z>@TAZ5Q39=*AQ$,Y9Y(SJ^->=ZM*:T -6C& 4K5SC*QXDQJ
M3:H$RYE[Y$ TN<N*^N1=? 2HQ-N0_X2\6>^[G7X>_]VJO34>_K1I9G?: #;X
M)I%V8P;(_BH12DKG1Q.SD< . 6U<<@ZSZL4,.=.IA>2R7!UU]3,%K#OF,.:H
M")FL<AY+AKVG K5Q<]):>K-D_-&3 .+9$EV!TD-(;&09)1!-FDRBF2 :N+\F
M?9'9*LLV4LW#4GQ7H9[%0PGT'"I#VQGL"\382FE6)6G*Q@6#$WT4[:8)C3<E
M1QL7)/($P18QQZ(BB<)5-1*V/!<_](#M^*LW:*+O/WMQD+$5%A,"7^)RX 9G
MOJ%CX4%.A/Q:> 3[^[PM\IW'7<>_6Y:-]GKQ(9203MG$[V;G-YWT'VY._<,I
M*#/D@3"YS5//EJ%8>VL)P;V*D7:^P5U&9E1?=UK'Z1C#!K1R"BVFWTY3Q4K[
MXO "ME;(H#3_]+XC'_+]X6#S3A<R&6&J(Z+*?VJ_0ZING.PB%YF)LEG%L4)G
MGL#/U+5"HY7/*+6"#)4#0;Z_Y;MXC-JPS4Q3KV+)>Y]^PJN*;P(-X:^,0*P,
M+N4CS"UL:3@A-5:NJ;$ 8L3R;JN3=1VBJ,)N1,!'GY+JCB)**Q]7R8WFCMEP
M(DHH@]!7*-]3E;:]W:(\##5+8J\I](B"SO:DP0W2<MIP&SDT$@3J"V^T*'+G
MWC<'BV@2"6K$9UPO>Z!V':DCD#5.ZH5"^N.>(BQOOK(*&%:IRO"']<:%%.%6
M&7- M0I^ABL549,03C(Q(R)M^XQ7<2D]C-VP VHW1P<.PK0< ZI)Q>](U*#6
MCU7ZM;JH>W.=/-ZZC^+TJ5-Q8J(A\9,JI.ZN<:^$6M!&+ 5:R,EI@O[@%[]?
M''T>0.(K3?X/O_Q)A..-YU^4^>[:W5C$"G!4(F!24"YX47(5+:1E26Q8SJO6
MIR+RI5)\:8^S>H_(IA8X'*ZMV(EF;$L]2V]6F/R-7N\^Y^/]$ P=+'LCX&(+
MJMJ"JCH!5?W8(VS/%E3UG8"J-M/#H;75?%N_F:83:=O&8;4V#DUSMVWEL(8N
M FSZ;IL)?.5E[[9Y!/<FDO)L#W9SI]_M,U^9+8X9*DR"$>",KB# V!GU(PH&
MB")#-PWU".Y>!GZV/V)G: FCK& ZTODJUH?$+DD=MM-4H<NHABOY][T4H6[[
M49!9*<$-U@(V]$&QF2B9)=-2) 172&(NN?JHXU:>$NI79A;<2-FB2)$I@XII
MR#4PP,?5 CB<R36,9!3(L3&<EG$TE5J"1BMFN4?UT^!/,F6"K14SVV.E81(V
MZ2I:&,>UB1:DE\+:;2\,FR7B2$9DR.8M)JR2 H^0-B^9:IA[IMF0]"'FBG=6
MY"-KK][E0\[P-Y%HW<%(5N<;VW*-?:U.&Q6@:DU1K=HSVBD6Q?T#R^T#Y3$6
M_M%*>VB>^QWR@';;]T)EF32FL'%1;I!CR-G,_BKUR!%BITVTR6DZH)ICNF7\
M4:.DM(['O0F2@E*F7YJT1!2,:X92G+X_EM'IA1);$X%U7BNJ^TY,8]UKV24U
MQ:<$VB62M-NF%ARO-MY%L@>=,EQAO#5**EEYDQBE=3@\/J14GH5]K)9KQ_H6
M565I=.)+&M5"YN4?IG2EQ29#_9C"BTVPJ\,R\$%Y#'<9>51H0_M4!M!+NZQ;
MJF5_B><VK\N0!LGK$L6B-N5[WQNU7;< /&<-4X^3:.*=.4/8:].IN&YJ1JAW
M3("T;@MK!5M.0T-TV$QAF'V77(7=\N!Z-J771LV4,Y92:1*UXZ[1$J_[&"<W
M,QU.]5)01;FON&<<F%#,=X:M[)9BMJ7/*WNTE;@L5:RHL4<=OZQ-7G0';VDE
M7$LNBJ4=(V"%_H3A70&B2_K4Q7*7>#]? S3= [[9CN NFT8#;B8=][1M)3ZP
M]V&,6"Z"6%/>[0UB9&8*RQN&IOO+'42-0SX#*Y$^RG<TDWH-!3Z*_/D-<%;I
M;LBFN2XD)#O%.-!0<G4(=R@7.)0=J6#@?=70ES 9S? ,E^H.I$CR A4"Q2V=
M-55$7]EK:\DTK$#"MP-3_C[!@IUI_<:V-%5C:$_;?"6!B\9.VZF&N2^EJY(B
MSQ@W5;Y]$L Z4,_5",MS8(?AQ!9<+YIB[#<QWK&'9_%K8\0AYR43J%8,MR(H
M?=+/??FL;5\>PMAP5E1;ZP\'R_KBQ 7]YW124H^D-ZGO9QJ9P]$$\RB>>M?X
M8$_=)B*TIW%$JVWV^!V";(6]CG2UZ76*-Y4+KVPI\YUC&V0[:X0F'70O*(?G
MEZ=';T^"%VN,U7RM=SE]?WGR]NW)T>4?AV^#L_,/9R?GE_^]Q>QM,7N;P>S]
MU"/HV!:SM\7LK4V'O=C;;YL")."ELN)U>0:'V,+G)M8IIO>Y=P<.)3-,S'"J
MNV=ZA_YLEHRIB-OC?OWR(35,!NN<'OKD[0BZDT]Z%GV"0^6#69@U+K:].7/?
M-"TNRD-HVCG"(6@N8=_'WH *TJ_4-==0P#$V8]DA[^S38I9$$FQI?Z3?Q=/U
M[1R:3J-EAPZS; 7A3X;!>3*^TO!&]+^&"BK+8(EIC(@C&]VR\R,?#Z@>DWYH
MSNW,M3*5=BDP9QBHPB@P/I"N9#ZDE$&I<'+/I"L@1;5TEGL[12V=7_B!^;(R
M<OU)CPM#0C4I4O*['&N RSK)3X1KBA+!S(:>.1X$&PF3$E V9.RP)$N$7K3Y
M3!QH;^<O7[8AUL54+\:@&RP@O)F]CE_.2@@*E)G'4<%D6N1FVE4>LA-!J=DA
MY64)CY#1[ S+Z=V&N3Y3.<]73HL+8FQ'U4<%TH[%9-GJ0GOPG5=7'?1[7CF^
M=&6ET?*DS]88WM:K".BWH3=:WA?[@XJNJPQ[ TJ#Q^1I#/K -?LHZXOF-R!E
M4;[.J0I?"7:H)_R1?6=*HAUM6\?&K-NV["7]3'OJNPM]NV21G-+]"WE19XQ.
MT7\SNSTKXG*F!76(C9J[R_%^H)TD@H=Y.NF19O1Q,Y+*#01_6_O>[#-?88<%
MDV&(7B9<&CC.6G]DK(5@2TV5K1]_'DC60I'Z /V9P4N6FL693CG@/0U"1L.Z
MCY[@1U+\@7P8)L/(Z#BG/4BY>,UQ6)EHC!N-+=JC[5WO$\I\2!+?+O)G;MIH
MHMZYF5O3)L!#XV#I@^@7^Z^JJZN":002*FL#BZI5S#5:?'#(0=(@ .[\< V2
MZ( SMP(9O-%D.)#-H3\1CXIVISO_3=FEL=:X@)G?+C'5^A-, F?'X)M4<W72
MT.!<'+/X@A[)12H$[<WX$GJ,8'+A3T=(7GXFL4),4\Q_2;%\Z6NLI\\B&04F
M;*=F2"H=1;EI&^M8W[((UDZE_EUJ)57>5.WA#K&)#+&V*)VAR++AZCG$%],!
M#>];L7$:JO>62$(K^:SL3^'D*2HJD#)CDDM#O90AY_48M0VA4T13>,IHKZY&
MQPFWV34MCQFMAT"CAD1:SK2ORUZ#>N<VOT:E\286?I3 P/[#O/*2:U-$D!4C
M-  I(,Z@C"'!W(K85JY@0OY:SQ*N]UAMQ-ZR.TIQ@?IP/W63B!TC<664F:XR
M_.<D&N,X$VPAZ)FC%B0$JN TMOFDH9?^E16P-KSP5)-+4##>=J[3,6- O/YT
M>C)A(N.$34^\ ?'MV5OHD(S7. G&5RJ=-HG"D,F2K=7M@$<-Q:0\1>W3N!?\
M6=E+2\6 AE*1VT%$LK/C]H^AF.'SW4:=/FJ]**49;8E'F3!JV:KC-.AD\BJP
MKJ@M: %_)(ZRJW*BWF,ZJTB+!Z7U^21-!]KDSJDK;XJ%I7IKZ$:.9'W\X 2Y
MNM"!2$ #H_08#GM1>>6Y%6)J8U CE$CRZ#*%)A+BD_J4($UWOT29BSN:\!1C
M?DE1)@L.![L?2X_ALZYL[@UKTL%"P2M=SC$3^=<LN3&HD(B@/,FL<'@ ;O9$
M0]A#= /.)BH2*RJV?&=8EIP*[PJY<^HC0^[-^<.L>UX[>SK!S_QUDCG!@P].
M\)S/\@P66QM4"O\XM7+E#E._Q* ^+M]$9=)QU\[>1!AX\1JOYU.N^=;\RB!>
M\U&19KIE8G#2.7$Y3C+RJ(E]W]GOM2M$!NZP6I8=AKWUSY:8JX<CF*0D1O6R
M)O/TU.*AN-D8'2<HX514 LOJXA!M*\&BSQN8W"(DB$<(<NE^91'RS_BJ\!"R
M^6YC=LEHA%:2AB+=%_P'5L(U-GQ7>V5?R5=NBW^;\$NLYFP[-X1DZ-2G"_6U
M/?1DUUXE<%"/B6.)=$IB*GF\Z ].I'S9.H/@*[(+;<9*E&F5%;']!/A\D^ @
M&38<!1/;@&\4&>>8WEM%H;V/_,R]P@T<DXQ>K\\?7F@LZ7YNUG9RQ.,H6Q3Y
MNMS("J9J3#TPQ!=IXGM&P3+GT#VV<@M+=T2H*_\@JI@,TR0)@XDBQA%GEM()
M?,T'91AEJ@1-C$UK@GMN2F6L'_]XK&%!MRB@+0IH(RB@@\<] J-L44 ]1@&M
M4V7]\$O=ZD+]BZ8067"D2*P?5W(+N0$PG@G,^L%.05["Y(9X4-C^:JW'E4D<
M-"4+)%96AN+[,?;QSL:-DJ],^7%AX\:X1#*'Q)&PKHS991+,P8MF%G&,B\'B
M: Y7K>CN-:0ZARTXB>'2Q,VP) PN4KI"."WC>;KG8-H'PK<Y!1E8:!*$\AO8
M&S;\ N,%WH#$].&@O[79#<M4DG&8V6>>JU*!40D$^B-+UJ*/!1(O]@Z66.K2
M(88FXI!<(Y,K6WM2N19Z-Y:2<\[J85J_?()">[$$U*Q1.%)8JX_W\Z$+M@4=
MQ:K(-O,:XE#[+TNO48\Z>7$U%ANSJ[F=Y<0C+A;=6THRW!'P9A=TV();D5S'
MO7 K66(O;HITNRUABSK(CHTSR:5QXX&5 "]Q.8&<H?%<*MH%=:*%>(_P( ZC
M:@_#"5>:R9F4T:&D./&+_QRYWGWLE-]Y"SG6*,'G*L[[N9M;64%/XPG24=AD
M=^F80SF]O(K2T!P,Z]G4?30CVN&][ZDXNBMU:+4@UF!/:FK%UX229X2K])3;
M3N57V$],XRD\<#_$%KY.*"BQ-H\RU^HTXEZ!RA.-V^$=64S\VI*G@A.=H.&K
M;K!D<Z!BD_;O!%'N2_AZ*O<(@-!3<[@=95K5%,V&W;KDO 54K#^-9T4677LA
M+XL$9.GF(SBHCA:_:\,/4^4L8B-M7;J)5^/AGVHAVFH*5_N(1B^/7<$'V ='
ML>3DL5B2#Z%*RV&^X97R\J&E&N8TRF@O%WF=#'FG$:DM$$\#\>*!]U%TV[&/
M56%H<%36)+>-"-<O$MI&,.L72&QE9[4++3_X;HFU-_P2H:T@C1M$MH\2VQY[
MJ$I"F[>\)K&M E&:!/$^D8-YD3,N55(N5YI,$@Q0"5EW"62I+"L\T3]ER5",
MA1)T-;7../\> R@81$OBW45K)KY!NNLB[<%)2EV2AVCGH#=1?W(EPU1YX>4O
MVN#=-2#?&A$";3 C.ZY#:ITZ5U/BUQDGA&MBC&W)8.-9*"^T+(,=T21*<1/:
MVK]:5M6\O4.1\'"]?4MGGN#"I%,=#>HV&/ 2JSFF2AMK#==D#M*5+Z,<?CUF
M*J, Y$"MC<4!!":*?6\?"1NN)1>8)SE3*9A$O)F7'4>1F^JY-*ZL308)P3#P
M&\@OX8E0H/XG!!.URR;26A<;Z6(JN$YX0D@C+D5]$48]!$>]GGFD?!-'VV@O
MZ1S\_[G)B=Z)KJD&/WKI<[=2_U2UJ[\MUQE?[N.1N2$_6]2[$&Q:F&X[Y0I[
MM!2_DB0*_7X\4]&<J'RJ)ZH$IZDK]ZU$T0QQ;,"NMLXQ.L8V8]WA=K@2UM-@
M;N)&=EQL5#-'SU\M5$#'K]F^#EGOG\0("B1L;&BZ%T9A^=5,#.Y:QX5#']$P
MF@P%.R:,SK*%(#U'O>&;>[H0!&$<4Z:S=\8#6L2&/]+\<"B*4G[AZRT3=<"@
M+$%W)&YI@1>VU #CK5'<H'[9$HY29I^"Z6,[H!0#%=PN"HB=CT622R Z9-Q+
M+\W;]EC"L9[@(;A&5%Y<%D,6G%"#,Q2-V&YRQ]I3C!M'F6UXJZ8*T;6!T)F5
MD[%UF0UQ\*$GV":QZI_3QA)T1-#NJ*Z;CR8S*[>VHM_T>#()^!9)3.Q>NF5W
MEL-X7B%$I2J7U,?=%9BU]W;O81[+M[<D9)SNP/*RL2UOK<]> XIJI)E[S-Q8
M(%"K0!/O_0K&A^#O5O(@;/$%_])C<6,P&0EW606[]$P=M(7E0Q%2TYI;VP2F
MK4^I>?*.F*YYW&AL12'I.A]NEC>_K/6\3>M)@0,P]2ZN'/H%6"&DIPQ!=3>@
MR=P"R+8 LLT R/9[A&/: LBV +)5^Q[X(2\Y9JT*KEKZQD1XGZSHM(-:&^N4
M0Q"N0:(7$W!$D&TTLE2NHRB-GU4/ZBJ%1-N-HSE2MF<5:H_,%%Z5X GE5DDJ
ME$HB@M/=I$D\9?Y2S%5J>/M)0]C!>3L>8T:51;XA@C$TM0T<SY"" U#31>R9
M"WCO*ST+N;YRIFY!-P=W55)%SFFD4C*T^IA=!=N>&$NO@8RW5N9Z7WX-,8WH
MW"?!8.,"W!-3LU5QYL0FH=M;H\1CH_T<&<!\L'\4SNK-&7$6>QDN:F6DO6>'
MFG5A$VN.1POOQ.J\-XUZ8_G+5,FLR_E6+IM)9H:_PJ39'/2G!)-L[>G#I889
M%R22F<8<UE@5*57WME/D/5^@@EF\]\CME5]C\)LO&MS,5GO>MM5^)^38N<ZT
M2D'36<74P9X"#\'VN:!$  >4<#$K2I'*@256U39 $ZI2I<ZF3YX%?UP<!?AN
M+UX%^X\?!X.KSR1@7L&.VSU8=PW9%]B=:W!HOH@P^AX=ZJL;Y_D*=-$;>),W
MI^\/WQ^='KX-+D_.WUWT4!'\V$Z\VJ(H3R1YUP%:I"$#/(DF8,XM=(HB$ R>
M/?[WG<;C9-5+Y4BYH%@UG 68JKVC^Q$V<?=_[O%,2$:: DV9+8>D)_Q^<;1+
M,?AKC'@4H.)R1Q+?^B!?.\Z++ _D%D-K*]*=L>4[:#C,NO"=+6J;HSA^.6_K
MLPZEAPT=QL24@W>7&Q)<G&]&.'&>]%3OCFE9;4E(1J <M-['*LOY;B/;>M.5
MV-1ZVC#3@]]:$4=CL3R91(<L0KH)^ EC&1?4K;6T0 WM"?^X"'X]/#P+!K]J
M,"[(;#LDOANXZ-!1<YUQ?ZR9SG;0>#B-I=D6(;_?1%CJP+8"=E?""R[0AU%I
MF-4[CMC4OP@)'4M>+/X0 Y[PVL^"@>,?F5?[N4LS=P9VFTM>^)>@D3G#PGE,
MNF#.1U.!=ZF_B(F$PI/E$/4G3 Y.'S\/UXR2E',!G->IU4J5.XF06,OXLCU6
M('>@^4=P?MN0KI__?1N-*7A\IF[G!NO5R'OVC##OYFEOQ"U7UTD4FG1EF!0C
M,,KC.UJ3@)$.,HCT+8A6F2]F"3U:N$Q@]M <'>G\AN*8-MM@XL]\A7:-/?T(
M/2\5)47D6XL@,<VEJ[XW;>";)/UHLJ\\_SA9[E%-WF,_K=4?VRMQ_ *HE@.+
M9'S-UFLIX4$8HCN'83>6!#.JQQ4%L&I(IX8,/ G+W0\<^J6,_HZ1@I%G>P?P
MSTKE1S#H%H;N!KWFM7&(=#FU3%KNW/7V-B'#+$J9?H+=16'E27VR NIGZHI-
M&3NVTC)[W??P#M:IY(,<ET5(NNQCJ")'U*!'0C;TKS9U4U2%&"R*E(*$7DJP
M]II6_QN8PQDU@RSQZ=CZ,)X#*=$RQ5LLD-A'MA3ZNGL.!$Q9R6<R(]I81PM'
M+L1 C6'C^(3CC)=((B>UMS0V2A2#TH?M@6$[6C Z*@0Y9K1TRQPM%$\0 \_,
MK4(;0?Z ^V[!9Q&:)',5PI!IZ4PWV];Q\1.2,6SHY;VWQ&1KF=!>ZO36>JS7
M:OQQFE+#KV.<Y74J<- *)2B?XZ+A8+I0C]"^;"!E=4GB4J,R>[+7UL\9PM9$
M1X23L)35D.#=ZE]O8EOZ>JU3%0N\MDJZTJ 3F:TE_:A9&]E/F^>4-*A;-]2E
MKAFU@^&NKDY=NL=3J..JPV* +\23Z/'Z&3T.;A)'L6@<4_(S<L\XOG/RAZ9&
M]PJ4U^[H=I?_9?VOG+X$)XL"S\[9:S8<JEA7MCNE,D'N+*B358<G2DXJ$SPR
M./2;$JL$98H<W!<G9+AL4LTY["--0HP/S^A=6+4[SY;_)?DG@[5N&MD="KX!
M=--T2,GO7SGM?97<: 8WJWS9@RG_I!S(Q=1TB(& /P]+<6P;(# O;>#1 I$+
M+*9:X9&BQK?549;"(4BE9!VWLJ<MMFS+@A@6?>_=M AVBQ"4)S.9U&91#E!Y
M[ESG5PD7(QLGWN)HA-.M?2]4H.'B>F_A-UOXS6;@-P<]0H%LX3=;^,V*<F]C
MFR6\AO6,7, 13QIN0\\-B,69YGHR1O$W=$._E<8##=7]=!:QH3"^*MW5Q,Z:
M[B=$UB7NCLRZDF7>D5XZ6*W%-Z5H^2D9#C#65R;@NAY7JTGT^X'I;Z^_<8D!
M%&4[LVN94(ER-T16* *-%#\3WCW_56 OAK0AY&[MNCI=4+/QG=(+5<(JM02:
M3][L@;#"PI6KRIB"@>J4Z$(> Z_ 2['6T**L0!T5Y%#Q7-;.Y3P^ERD;RP3-
M2P/A>16F="XJE;K0!1&*E6SI<D"N89W-N/[(S(^JLU NX7"D"%3KC)";223T
M]EK-78F'*:MWOA.#\V)TP6]XN5TNI$&FK#MC5K_T8FVOXT?9W8O7:Q[FQ*C>
MJ3A=IH7>_6.Q3L5H4"I-69\&A[1Y@JP$D0<JU+X-/M_]5AP;(V7@CAF9E&2S
M1&T,-?X:6K\WS+3(<!^/B_82L-><:_\ 3GU:K(DN3B82:^!-);6OG@UU.PD.
M-I@R@6[[:P=:N+42((DH+X0@,(%!M*?WALS@"+>T_K\)4_#/,/M-=]^QX#\R
M!FNA/GP6PXB%SE/Y!PVS1>:.=H->@G>13"'N!1L8:,,>#.VSA%:.W]C$4<9X
M$&I+E5A[Z3V36J([)(Q::ZR2HPRW"<\9#@EZBD%9\+ -E/15("V_O%X8<BS;
M%*&Y1'(;-EXIP2UYB/D5W4CB9>6@R=?9<)LQ?%MAQ/]_>V_^U$:6IHW^?.]?
MD>&);P)N))3!NSU=<640MGHPT$B>ZHHO;GR1DHX@RU*F*A<PU='_^WVWL^4"
MV)989'7,N "E,D^>]5V>]WDZ)?@""UQF_&\-EX)*,RZ:0D_W"A\A3#"^4K)L
M$NZCR%ZAC#;0G"-"PF_0D!#&V]Y0LM"$GB$]')Z-:?HE%X //].&62OYP&BJ
M$/ 27-'4UI71!19[2CLI/$^W110\%G)#%Z9TBE&"T=7@M"YAQZZRP^C2($@^
MSV'J.Y2KG$21^FX*MK.-R;']#-95CN"A/#C'VNA ;P_S:30B+ O]D',UL^7B
MP#=&V/T(YG Z R\7+*<OL Y#O5TZK#Q\M;Q!G-"!JL8-Y1GF.U)[@9LO5NC:
M[.D(.BR>Q)@;8IY-$0G$"/T&WFV9I@TMA31;:,(G)P$/)^2,SW"2M33!K-!5
M37",KC<EM'K'(XBXI+QQ%EU@*Z[TC'0#X8VVKQ9FJC3+/ ;NG)>BN50OQY']
M=*ZA2)S\)8-()B^?5_QWD?"Y_K:P%M\KC)_ ]\[BA!8V+6%L%A\C,C@5V5N8
M/K2V"Z:2\?O/\?6&5W99FEOQ*:7W'#^\;"62.,3,<$!E5I?I-(1"$M4._N*8
MC=-X%AMV' 1-$ B/!ES+]#J7X.UX<[%DLWA#1BO$FK&E_B2Q<BTFBNR.">4B
MJ"S#,4&H/_SMBFEP1W7Y"[VJB;)&EU/AIZ31YN]?7A>8(<*6&5;>ZJ:QY_9U
MS^GG1G$U<VI093M/]LI,QP*V]GF?-<U[/2TU1LY8"V9F<V;:N;3I' F%H$IR
MI%%NI/MLB\+*$\2LTA\S%0]9<1?&B*.0(@%:>?[HMY(-5B:EPDP[KP)V@,;<
M2!V"Q/5Z87[E=L@%\=A^&FMSU,%D4;E78TK0643.,8!=+)YJ99>KF'ZD]ZWM
MO]S,'$V3X/S%?T'GK28U^[II(Z-1X75/XU+?Z9J4N2J-UWNN<^0:B27;U'M+
M\/Q0.<*;1U^.<-K=.S[=[P>=H_V@/_B\_WNPWQET5M"$?]->E7#*>_6RN(2-
M:-#U-CEN>G U070MQ*=)5JD%:,.'$=]%CLS0/8-#04U0EB."C?&*\'Z9CN=)
M0T+)I+-B!D+E63R#):US$GJ<@65,:I%6/#$,\B_Q=(I.JQJ=)_&?I=)W@",?
M?T;\>A:3UJ[H@QHD#1M!%/S+')V.U -6A7*8N$YQD9X1!Z(]/PR!D8T:FSU6
MJRM\2Z=NV(IH"E(CK +F-.*T.M2'<):=3".NQGP?IY'W1[;D',16JPFW&6S0
M"3WQ<V%\XFB$/55&((#-P:;V79>#9QP>$&P;,WB?3O )&M)VBHTQS,KF,UM7
M,&UC==$*$;ZNCPCP8XCZ.-(OU:K,DN+(T\(-$P0[.:13CD0S-\@DWC0J=171
MBF_:$>C';KFJ'?0EE$<AHHVGM7X(&T^Z2MZ4T%I!"/ZZ+I%?+KK09>E=5 _H
MI1-6Z[V^HR_,'>ZF.RI,VXOO$8UZNWV%.CL:3I<MM0-J&]!R.J+I%/]!H9"[
M%0:!5CA#TB ,PB>$(P_B'#BF;)I:;2(%Y-#C>6\*J$S,S<1?FL1'\H@\W#66
M;HVENQLLW;,5@G2ML70KC*6[>XNSM3[F,_M,"[<U5S'YWH[5DEZL!FO!G%^6
M%8]'<)EK4#]XGG\IQTAW; "J!4N,1V6L#4M7A=YU9.O6X0#7YJ8K;]'VP ;3
M]+N>20U?38[M=M"&S)MKK%NT&:AK%CI[R'RL"]IMY.5P<\H5\[;^O.+WM;&N
M-DV.ZUY,3Q(MUJ)=?H_QWG+<4Q#()[(CBY<G$?QHW3J7S&XCWFRI8(HS+X'J
ME7?9@J[X+S-?V6A77^?3-"X\.?*J9QQ-A?J88W_0!9%?/%5W'Z$7?K%TY6C&
M12-5<K@)#  PO+G2FB7WR!\ECFW.:EH4,U6.Z<B[WRXV\#=BZ!&25*#0%)%N
MQ-+K03_"0&7N1:MTN?>;[1<4=*K5@<,'H03Z.: DH4AR6TH<41HY#CO:-(E1
MS:565@D(&YDH--==P03BC3H.EB"ZJNBPHJ=2NTS39V;)=O#L!Z+<NN!-Q>/F
M6.X.<].N,K9L)S[:! &H#36R<%O<(J1JT(E :I%;)G!47PR^+&]97E23#9.P
M-69J5I_?, <3=G.UJF""4Y+=&1NA5%SUF(\.=2  ?+Y<S7#?D8KXFW9B MBI
M1$WBHF54;GB]4( P<P3Z%@+<D%!PE4''!^AP);4$)VD<\FN;2\"(QB(-?)26
ME*7C1?>G?L/2THA7WN[6.[7 Y"I44V<9[):$,23!$1)%TVR!MLQ1*F9;J0?W
M8&UE,#FX\\RC=>L;3XWFT;4DIP[$T<!,] T=( PG9'5_B980KSQ=5YM=Q()
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M<EZGK7(B5^@A.U>:M)534B,9)VGZ.%4,J3.M)^?5-M)[E(_CHWCSE>E ^(@
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M(K+CARS6G4?JJYCE<<#8OJU#Z&3<"<A9)*'V!_Q"PVCTY2Q#@W5+9O.$_D?
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M.VR([%;L 9XD/^;6/7Z7[2XFXVBI+IN>,_NR"^1OZ^N=IYM>\!%Y;E-U@>D
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MA*U[--6$:_7K=37A:E<3_E_ZEV$ZOOKU__ZO7\Z+V?37_Q]02P,$%     @
MKH%94 >\4U1=+@  4F0! !L   !E>&5L,C Q.3$R,S%E>&AI8FET,3 V,RYH
M=&WM7>M3VTJR_[S[5\S-UF[!+4$"(<D)9%-%P$G8)< %9[-;M^Z'L33&VLB2
M5P\(YZ^__9@9C63)/"+')O&'DX/UFE=/3S]^W?WFOPY/#_K_.NN)43Z.Q-GG
M=\='!^+)QM.G7YX?/'UZV#\4'_N?CL7.YK,MT4]EG(5YF,0R>OJT=_)$/!GE
M^63WZ=/KZ^O-Z^>;27KYM'_^%#^U\S1*DDQM!GGPY.T?W^"EMW_\PYN1D@'\
M_P]O_FMC0QPF?C%6<2[\5,E<!:+(POA2? E4]E5LB8T-^^1!,KE)P\M1+K:?
M;3\37Y+T:W@ES1-YF$?J;>_;*!R$^9NG_!,:>ZI;>S-(@INW;X+P2F3Y3:3^
M^F28Q/G&4([#Z&:W'XY5)D[4M3A/QC+>HWM9^+O:W7HVR?>P]_#FVS=2Q'(,
M[V:]5X>_[3Q_=7CP_MWK5\_WW[UZ\?+ER_V=5Z^>/]_9>OU\Z\G;-T\E_$=O
MF7],RU$8JXV1PK'L;FT_^_->KK[E&S(*+^/=2 WSZ>;?X)6FCA_ 6X,T]#)8
ME8U,I>&P_C+]O.;&!DD4P-?^5_RW^#_Q5W'0.^_O'YV(@].3]T>'O9/^T?ZQ
M.#IY?WK^:;]_=$HW\('>(5P5_8]'%P(HY?,G>-(3G_;/_PXWWOU+O#O?/_A[
MKW_AB8_[%^)=KW<B3C\=]?MXMW>P__FB)X[Z EY^=]K_*-:.UL7):1_>[_?.
ML<']DT.X"%>_G'X^QE>@V4]GO?Y1_^@?O>-_P4?//[W_#!U[KTD3KAT>71P<
MGU[T#C??/,4!FIEVYGN0.C\;9_[Y;W_>F\@@ 'K;&"1YGHQW?YM\<Q?#!\)4
M::?+\43WS.WU'4F#B)\OA'$ 7=M]_1+Z.V=B^<N?GF_O89][__QX] X6<NO9
MYLOG=QO G6?8'=3.;QT/"L>P]?+9WO2_'8]BSBMQ\?GL[+B'NT_T3V$[]AY7
M]_]V>@0]/S@^.CDZ@&U_WKOH[9\??!3['\Y[-*H';8K.^>5]-NCM4_OO(LO#
MX<V\";P_"C-A^CQ?HA-W7L?OV[' ==;RD1)_^=-OV]OE5OW.P=&;NV$.3_N-
MPRTFDTBA0-+-**#O6WOK E9G+ ,E9!P(VFP@Z(1QG@@U'"H_#Z_@5B:2H3A4
MOAH/5"JV?O- SMEZ+18P"3W;J4,0R3J=B,$-S8$<)R#D];ZI*/P69IXXBOU-
M(6'TD;R6J1)^DDZ25**8Z8DH\4DRE#G,RHLM\5&F@R05[^2-.)/IUVMYXXG]
M".2R0'KB8%^\WGGQ;,L3:S]XTO1@NIPN3[S?%!^3X1!DTGCC6()TZ@,U'.>!
M![-U<1UFF3M58B2O4'B6L0"FE"JX"W/V(57Q[Q+>2[,\E5FFQ-;V#DS41['S
M[-4SF,9,11Y^+/]=I1&NS@^>.1I4M].&HSB:9"H69R.9CF&N]B]PRM[#7/@C
M4"5NF;.7+\3_%#(4'Q2H,Z 9?$C23'GB]?;6,YBQI(B22S@&WH41S)>?%&D.
M*P6*D:]^]-S1(+N<NTTA^D!BP*+&&; HD>/)4G)% 60R@NN@ <I(1"J'!X$&
MY82Z^+L"PKP>*6!9*2ARQ.0$\B_4Z8I(I@+V+?Z>1$4J@>JRD8PB7 )%E\=*
MQK@8F<K%,$FA)?B0"H$'P'OA4,1)+@(UA",XL'> ;Y:/Z^;V+U-%W=W\*62*
MK>>+D-?.>P='_?WCB\ZZ;62A'Z&PW/9/LS[PY6/OO+=_T<5^\NSI1LR(&3<1
M>N7\E\)7:2Z!;O^6P 5Q ),:^K"USE6F9 J\RM*R".@47 H)P7:J4^$ YL-/
M@*4.D#<K9C4*3BZ1$$.!V]DDB3/@!4FLD"6,$Y05S)3E*? DDJ)@5I/Q((R9
MP^/+<G*C+4MF6;#5K5=[(K])$[BAQ%=X'@[',"83$GS]:YQ<Q\A??M"DZB4\
M@/'_+N,<1C704],-01I*(SM"AM-Y/0IA=E'@@BZI&!DV"&B6</.$3U+@TFGM
M%JW-U!$KUG[L5%'[G<W1=,M/WJYWILS@1/;E5Q!2]83YJLB);@^2\43&-RC6
M;78V@XWS]8-6AX?9(>UJB8Z8J-ZWF1@5(!4#"X@3/T)KM, ]@U9>V/ @PL'V
M#S)Q=KAQO+6HG;R?J]\3D(J@HUWNY#L*-?<XD>=LG9@+2<_OK&:N5CNF#^S!
MA$<*/G;,+'/J@'ZO!FDATQNQ_9H.Z)=B+2N0S9KG2&8%=17F.Q##-!F+/!PK
MY,?X?X\DV)^ "] T;MB9G8O(,!^F[W4P_4_>7K.&TD1;H*R,T:#AB#M(54.M
M'?D)GOX%/!&H*Q4E$Z(NE&O@"R#9C%7JAZAN\6MPPY49Z*FIQB]!/47J!"KC
M/AAI0'WS(Y",0# MY0+=[%1[JMK0=9)&P748 ,V2/(!]A\^IB>D67O@,NB*T
M>Y'#YN Y^)N$XVX14BL/O*_2%.6[FRX)\>&NA!5/OH4G>Z* 64BKBKTQ'1!9
M(\F2;-#%QFUB""&>!0)^R&XE\0GL"?@.;SPX%GP?[4\X&H7F$B12ZR#7QE"2
M@\@+#OOK7 T56K3(>HQ<0XTG$1U".>__%5EV3I:LR0^+E'325/VG"%-@;'2.
M5SDK3B@#)3I<:-X+5O$A21A7/DTB8_VJL;DIVJ@;R?;$XZ*2>:\PS _,5P;G
M6FH/6)Y3XC9H1# ,9PX[^?X+[.D+55KD_F$C5@;H@C!G=[NJH>EN>]K.P!Q[
MH$0RP&X8X5=O*"W[9$FDQ*1()PF(UM!"5@S&89ZSB?Y&3)+4%2X.R,P#7^IK
M&\]%7H ">"AS2>:B8H(OV(&;A;0]3,M1#D,@]DN64.1DDB97LG5'86>E;IQG
MQ;1?'E5MXN\>MO"X-MQC8,N-,@*O&_"_NM&O*G=/9)K'>,"C=]:*P]HDIMJ(
MX#H$:B82#P=%SOH;G0P1D%)D1':2YVL6RIG<F!D#?1RV"M)AB'IB@"3=MK%A
MA-<*7F@8*8DN*LN)JS4SJX=M]>DI91XETY#LK-174GSKP\?//L1+\U.X&$Y.
MOW@(HSCOO3\][\WOP,J9IZK+!!=CDJIQF*ER[L=%7B#[AT6RU_WD2L5PP#&!
MRHJ7K13&2_+3NPM7$2EO"'LJN<YVIZ6)&ACOP7ZX[=E+&<;0V[#IC8<B[J;)
MZ;?[=N&W[^L!3<$LYO[0.;D;)([_':7FTQ-YJ38&J9)?-^00&,NNC*[E3?;D
MD:WK4LSJPU&J"^)Z6YMMPSLX/3[>?W=ZSJCABX/3L]Z>>+=_\/</YZ>?3P[O
MSMX7,:BMME%=^,F$9-"J[7>@\FNEX@;_[J;HQ'#8X#C&4SP./!2,LT);/&I2
M0\UY2C_CH/!SL1:N-XHA(9)^. Q9"/G^GM/B!<K7$[5+<@(N,8V)O*IBOS-_
MFC[C2NO[6HH22LHV3CB/%F!?U+"8/LUOIZYQ@F6%L) D4;$_O+Z>"C260K*J
M-*T9Z?EB>D*78U*0G*GMMI;H["U'F'0H<2QO])'O4%B=+!D]-+U"J,'1 *C'
M2'5(FZ!,X= 0G_5CUVMJCFCAND53+0WONR\&:1&L>+N-%9^E29X >P.%_2I4
MUUI<9>(C!MVTD-EWH+_,B8L_YJ)0=XD'^T'KLR;7;Y-OOF=*$'8X#-$H95<;
M[2P$ &I>X-*BE!6#?RN?^(]#(=:,HSF186<;S,K^=M9O,AO0J_HK]1=9Y6&H
MUD6N8"# ;*%S:*("EK@&/#-0F9^&@U*S;S,$9>O0<U31F"6V#-&7*'%HQ&6N
M@D>G*Z\-YDHUO9#.0CN]B39"EK0Q2<.Q3.%[L*B$'PL'D7)]K8:+S**T-=72
MCG9]XJ<U <Y836\!0LD!#Q )]4RF>9=>3\^:$U@@@3F\P_R0E5>.&XRW!Q6!
M9A&3=9+$&W.<,$17'\4S"8VMVM4>6&L@39V!0 YA4D'6#C;%YSA"JSTMPG68
M*>,)(,B>=.U[^T4^2D!SO?%NXZU><T]X5P4*)3P$31JP=Q5Q>80AG0N7YHY*
MS;,3&1RH.E;H'Y'IS>-CP_Y<V;"V!?J(M(M4<*E-BJ0ID#]I/\U#'_CNRRFU
MP+J'5)YI&#\I*H99AQ$<?2HK73XUDC0\J&GOXAG<8)!ODQ>[=X3^:A+\\U83
MD?8]'&+X!GD?[RJ>UX:R[,$9/Y$P3@9]<G>3/@^\/K91/2 WQ1@D"-R>#GAF
M  T!0[>&^-0=8!I"QBA>M!BDUO,$C[+Y@/H#7$6?,))WN^;4*'OH&Q?X=,L]
M;!0T!#A-) J$E:>L\)BJ221]%1@IQO2D;-O%H#//JW2Y?+"4DQ[:E/6N5P?B
M>N*H$YE%$0)96EC [H^.$1FB2QU1?YV*G#]<J-#H1] ?SI7,DIBHI3=$XGW<
M(R-_;8<C(.I?R"! XNAP'(]/MINOBOUE9*!/K%&TLOH?'#8\A4SHDI:9+>-I
M93782YD&)?)+<]FZQ DZL3TUJP=,DQJ&LXBJ4P%D?(/?IG.R1&&E*E)7:%@/
M8\2,LW:U!FO@ITF6;=A# C$ ;B#XP#V"4%DTJN&ZX]N'MENA'VOF)"/<2?F.
MQI6N(US*'%5T)#>.KJ[Z3SL9L!W/B "^9,Q798*;Q'I63AN@*=J\@/JGMN\T
M:87KGDCBZ,8\#?L5J=?J=DVVH0:'2M_X,!CDHM<0D6&N*JZ^33"H'%J;H,J<
MXQY*TE)#;S% /J4N5+<7IHO@TX<G"']_P\,)HQ9!=]+X?7@3FD)RH:O) %@1
M+6IVC\;(M.,944P2,;HT6*$B9\J;IANI6!K89-.:\ Y+BISN!F'F1TE6I!K_
MYX\J+9L-^$#7RDI](.:YW>K+WS\[.S_]Q_[Q!:;V.CJ[Z)U0AJ[>/WO'1_\\
MND<T^"(&U>K+;]F]^]I#4.JBWW=V&/27-H>X&#WF[+CM K,/8/;"3..UTKJY
MPS"AJE.9&'U4( 6) 6P8S(@0A>-0A_94\;><+0\N:]-AH^ED!'/'MEN]C;W6
M?2P= Q@%L3UN!$$=0[%I IIGK1O%[=%['Z)D .MRZ(1HG448V$0'%^BNJ*6B
MT=!DK+C='T1,%I=7S3)3B;J7Z;%-_!0PP)CPC../J;]$"F2P- >X.[*\S$$"
M9YL-J<29FQOL<!ZLRJ9@U&8Q.$^'O)M(IF@]:)&<M*#FB;%,O[)(/DBE_U4A
MF'<$Q#% >%*BA8V!\F5!$@+2(IPZ(TK!B(P#FE#$!@E=@BD8KY,BPE?0FC]1
M>8A)H$!TP7CU81%A"I9) ?*$#]?T,7UGCV1MDI<KM>)<>K/=1?*9A0!.%]S\
MHI&9*[SK@O&N<W>D9#(,'M.QZ77QD3=9,3'O7JF4DH_H6<Z3R=X4 94?F.1/
MWL)TP?L=1 )99Z'U#9K@!3($7"9)((82CGC/R@-K(!M9B<")7ILA("%.<: T
M!(@/R68($(,8X&1#J\LD)_VZ! \UO'D+!NCV"#"T7F!T6UOOC;<?!EKJ"K6/
MM0F?M[>.<QP4>,(7:8:0Y:-9UHV,!(59<Y&TSX635X/-:9+-0)STLD"8\ETL
M%,BS)HH8EXW@6P$K[Z47MP(K]\W*6M&[(Q#[EZKI;T[Y3# U=0>=;=N)R',8
MG%#53F2J=D'/6]<P04SE,8MCS(0;LMMD;;#^8(Y#;;N\XN',(=NCV]J2B!]V
M-Z>#[_(,NJL,!..O$XLV,^5-V3"G8O^8VTU@(F48"1A^2F9GU(= S\A+[_-M
MVC.;K"DR%]XG-9VO3X=*V*!*4M.Y]]0-TO6=-=5H=>=CC">)UK7Y;,6%[L.%
M6L$AE:#LSLP,<^$Y&"L<^N&$M7--E-,[O9,\7Y6SN1IGCC$9#V47M82I%QK&
ML;VY)>0 ONA-!<FC"X-=0U<J,QESU;<)"I&4,K&2J$AB[F@V8C*4VGJ&Y! $
MNS1S-IOE-KA-R[FE;VJ0?RV^NH&K&E.I]98US1CFW )A)MZX2CA$)L>0*A12
MY/1<XE?=H!8S1\\W=];\]2D(&ZQ43=)1,3DPK-=$<QG](B8*L\Z-A@&-E=(9
M#]#L W.I:DOB&%[KJW,]2C1/K<YFR]PA-21)W!+MP_:@F@D4UN1*Q1JV[G1W
M>A;@#$WL5""OM2L$>G4<R&P&,M\L*I'D!LXR+ !T0#=&A[#PP]0O=,8;C;R^
MXT1AEN=(R2P7;(J;I&&2VH^81E9BYL_E]GK>ZO;Z<+Y_@B5LSGMG6-'@I$^Q
MK' !G5]?]L_Q]E&O=(HMS4(TCK+5#V:2%GY .,=<G%X($  N2GB1S.:/Q509
MV@P-0IM%AN&&HR<]!UA!7-KFX?#<-'-X)\<*5$-@ZJ"I>V*(H8C 1?R13"]9
M%DZ3&QGE-QMT2V?Q**5#XBE721A0NG9X,TB*0:X_1$<.L(64L^W= !.]H3,-
M1F2=[M9)A'YSP[G6&Q/WN-DW*E&61XY.>U9-QV&?Z2M_%"=1<GGC55U2,Q-V
ME$+^L4E@4GY(.Z?4?7U3ZVU)4& Z<%4;(T@]2N8S V>!F0;#3*]<U75YFTV@
M*:C$@6O, GDOS<Y=,H[>R$A:#0<7Y ="^NK:=^Z&;YDT:].R(B?^R\I>N"F
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M5!9JHS>M(S>H$0KE^# L(W,5*B=D8^@8K!V%R@TD@P&%J0L @9LZ@X:^]["
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MW?+&_FM/GG_ \_!.;91O!G;#\I5%]R-02P,$%     @ KH%94!8X*UF+ P
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MJ(98P3*+04!54#@$0H13CPMNE@C5F]AB>%K?6;=DD75G:ZE,6P"[R15*4I5
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MB)7_ZO<,;XJ!_3G'VY[]G<G1/U!+ P04    " "N@5E0C/DQ=5@(  #\(@
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M,C,Q97AH:6)I=#,R,2YH=&WM6O]3VDH0_[G]*[9TVM$9( E?K )E)H8XTJ?
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MD,WX)*1ENC-,M^B"+I/0.BA7LE0>IUZO:XK_*00L/4Q %B&OQEE(?!1%$'V
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M'#DI\"(14YX B?R:RX2/$U!9-^E8<1WC>S'(?V25!HOG=2*6H%#"*7XLT+[
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M&N4Z7BFC9(7/(,,P]Y-!:NE(X%!<HLTLL]!5<Q7<\;EDF57I9)]HIE4;C$?
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M*/K[37E!_]W'MT?T_Y <_Q]02P,$%     @ KH%94&'1*I%9$0$ PL8! !
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M.GOI-',+H1(N@ NT#K;_ND4S%F>+[XR2 _?MWIZL-]G.&&"<Z>S)6>4M46,
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M;&X%"N1_)>2?:8@'2$/^_L;=3@"-'AA&<\&41V5_1?,Z7!C0X!^QY6P SEU
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MY86+34Q' BT$2WDLFI8,M+ Z62MC12)GAF)A+.-'F'@L7(1("F2#9*.5Q6U
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M7S#^5//JO:\<O.3H)4GO-[^YB/MX705#+KJ^&K]^^B'VE^YL;-]PU4+HC^N
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MYE$YC8MCGE0C&J*S7(KCK6""Q9+7YSDF(-L7^=H&GF$CQ 3R%X84IV*VEYC
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M+07C@A+3*YG 1$$KPH92C:%Y4=YF4(KJ<%D^68Y&;U.CC]Q:3/.C&-S:;2P
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MJC"#'-5,(#_U12*)SW?CN[JC7C2[>.RS-@=*>YRTW8%C$5=9A'?9'-*WA_V
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MUUHGG;5GCAA,QV$H+S.S"-$"G3VG3Z54=#S]DWD\_SW.^R<>Y_WH!74 &&$
M'CJ(Z 7O3*OH7GR6)$G(?#0J9;NY%,74 =#+)_Z[D2,:O* 2W^,:/A7-1@&?
MWGO\<"[=6\]LT].A0\4D7B5)L+/ 1]):2[9.R3!=>,!F%"(F_J[R7>=,=%?J
M@]QTLZM[A5[:E9"8J5P-)#7 LH@1;WE/:I2L4&4FQ88R#&^>#-W<G:@2<^%
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M$ .]3H$G37I/T&:<VI0*KEV <".=H4/2SH,]I!>]U4*DV74!>>U^!D@7]<E
MQES;]%BTUFC$Y<(DD&/5XQV/T4>WH^7D/*+N3?( D<.8:/)"*JVW),\>]_7F
M)WK&XVR(O]$%(_WZ[,>*)A! .Z__S)E^][L,RF#1<7AE^IR!TZ;IB:5;.9$N
MTE=!@E./Q7[JX0E"+ (<$3!^MVMD2!)DL0/2OC$;S8+'+E7VK^]]WW:#]X9W
M0K7^%(X!XCCB) W:.HU19(!PP5B"/CM9SST!YD>7K?U<D-%4UF!2!%%X?ZJU
M^ [R6YK]/G6J-@OAFA.-,]_.<BM!RQ$0SJQ3OYL9__]0.VK5'D"$V;:=/@O
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M6N>9+OJ9=P<O14'?A!!'4^&'P[_>Y9=^S_/YB'Q(_B,-3GVS5W]$#?[,A81
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M7B%RYYS ^'+?0OZI#RU?$_2SMTMYMW3'D6,Z\U.=< ![-E(WK_S'9SC_ZO6
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MBI>-N\@ARN^=*?,8I3\H-CP7S:>$=C:\LB_#XBTX[HVT!Q7 'Z\W]L+=L;D
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M]L'C@DV.$3M"7-/.:9U6[ER;U#)DF6K<!;X'7X4E6AZH'3AQ[1 J.8<L0_,
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MX*+ %O+ Y,K:0&AL.3&)SQ]?P/P8>&)DUDE9RS3,L&*_+-S%&K'MZO[DP0T
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M9/"4G+>._L#;T%"B8N2)EJN#OO/5J)N]9%:O&2@-V6-2T_,?)V&3Y_FDG<M
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M:2LY^$F2N$>RHL$R%K;^1&MAFQKV14W\K>##$),@_>B[U54O.:\+3GR@^&1
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M'USXS947<I7LY]0_$UN_ZSN_$-AG&9RV?RC<9>>\@P.>80)65]!GWJ.*%83
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M5>(FCLKT/' A0BM&-Z;2U_=[RBN55Y>3/*JM26#C_]I@TIIKR/TTC,32I'4
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M;+=X89H6V1:"ED2P'MX>VN<S=;+3?+G3:BZ>J5_E4UE%8-VSW&'5SK"Q"AK
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M[F%72_\TP6&I$9-]41>]B,?#O*'!$%?;3!XC+^EA@*D_99_YTVSZR!92VY+
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MMIH0?YHQ];!J^&+"K;O\^28=?>?B)'3K[0=>Y_HZ<HN\59+!6]G.=P>XB3/
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MZUS2!?:+Y;5)0"S37-_I>UX2,,!H;(@ET.--D8P0"K!C.0<9(GO-FO;ZE9
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MEZ&G*G/-AXPK?2@$'<,7%M5I.*>G.-0(30(*P&J6;5M+I\]KGQE/=IMRH''
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M6]LTZ;2J3TXJQXQP(F>_-UU:#>4<?_K<*]@X<!2)<+)_U37E_*9[QON<UY*
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M2P$"% ,4    " "N@5E0"@)Z6E(J   QT $ %0              @ 'I&0
M97AE;"TR,#(P,#$P,U]C86PN>&UL4$L! A0#%     @ KH%94"!TO"W1:P
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M96PR,#$Y,3(S,3$P+6LN:'1M4$L! A0#%     @ KH%94/UM/Y%R!0  $68
M !L              ( !1+,& &5X96PR,#$Y,3(S,65X:&EB:70Q,#(Y+FAT
M;5!+ 0(4 Q0    ( *Z!65 G0]4[4A   #17   ;              "  >^X
M!@!E>&5L,C Q.3$R,S%E>&AI8FET,3 S-RYH=&U02P$"% ,4    " "N@5E0
M'*_4MVP9  #KB   &P              @ %ZR08 97AE;#(P,3DQ,C,Q97AH
M:6)I=#$P,SDN:'1M4$L! A0#%     @ KH%94(TSI^^;"P  ED<  !L
M         ( !'^,& &5X96PR,#$Y,3(S,65X:&EB:70Q,#4W+FAT;5!+ 0(4
M Q0    ( *Z!65 !5>=%Z-L  $)G!@ ;              "  ?/N!@!E>&5L
M,C Q.3$R,S%E>&AI8FET,3 V,BYH=&U02P$"% ,4    " "N@5E0![Q35%TN
M  !29 $ &P              @ $4RP< 97AE;#(P,3DQ,C,Q97AH:6)I=#$P
M-C,N:'1M4$L! A0#%     @ KH%94,]A:4P_ P  #1$  !H
M ( !JOD' &5X96PR,#$Y,3(S,65X:&EB:70R,3$N:'1M4$L! A0#%     @
MKH%94!8X*UF+ P  !PT  !H              ( !(?T' &5X96PR,#$Y,3(S
M,65X:&EB:70R,S$N:'1M4$L! A0#%     @ KH%94 )X%51/"   PB(  !H
M             ( !Y  ( &5X96PR,#$Y,3(S,65X:&EB:70S,3$N:'1M4$L!
M A0#%     @ KH%94(SY,758"   _"(  !H              ( !:PD( &5X
M96PR,#$Y,3(S,65X:&EB:70S,3(N:'1M4$L! A0#%     @ KH%94.=/A@GM
M!0  !B,  !H              ( !^Q$( &5X96PR,#$Y,3(S,65X:&EB:70S
M,C$N:'1M4$L! A0#%     @ KH%94!.L!(9M#@  XD0  !D
M ( !(!@( &5X96PR,#$Y,3(S,65X:&EB:70T,BYH=&U02P$"% ,4    " "N
M@5E08=$JD5D1 0#"Q@$ $               @ '$)@@ 97AE;&QO9V\Q.7$T
M+FIP9U!+ 0(4 Q0    ( *Z!65"4LVZ]7Y$  -PA 0 5              "
M 4LX"0!F:79E>65A<F-H87)T,C Q.2YJ<&=02P4&     !0 % !S!0  W<D)
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822512208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="nump">$ 40,626<span></span>
</td>
<td class="nump">$ 23,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">19,374<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 37,228<span></span>
</td>
<td class="nump">$ 27,511<span></span>
</td>
<td class="nump">$ 16,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6824963920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">$ 1,312,464<span></span>
</td>
<td class="nump">$ 780,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,347,664<span></span>
</td>
<td class="nump">844,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">1,312,464<span></span>
</td>
<td class="nump">780,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,345,197<span></span>
</td>
<td class="nump">796,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">389,573<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">389,573<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">756,226<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">756,226<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">166,665<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investment securities available-for-sale</a></td>
<td class="nump">166,665<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">32,733<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 32,733<span></span>
</td>
<td class="nump">$ 16,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819892816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Income Per Share (Narrative) (Details)<br> shares in Millions</strong></div></th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember', window );">2014 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820386144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Maturities of Operating Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Year Ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 4,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">4,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">4,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">5,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">41,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">66,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(13,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 50,739<span></span>
</td>
<td class="nump">$ 14,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827888688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 31.3<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830590800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Genentech) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Collaborative Arrangement, Income (Loss) From Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,615<span></span>
</td>
<td class="nump">8,084<span></span>
</td>
<td class="num">(2,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,679<span></span>
</td>
<td class="nump">$ 5,564<span></span>
</td>
<td class="nump">$ 6,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821243632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 65,131<span></span>
</td>
<td class="nump">$ 146,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">110,037<span></span>
</td>
<td class="nump">98,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">26,792<span></span>
</td>
<td class="nump">29,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified', window );">Stock-based compensation</a></td>
<td class="nump">14,966<span></span>
</td>
<td class="nump">11,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsLeasingArrangements', window );">Lease liabilities</a></td>
<td class="nump">11,211<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves not currently deductible</a></td>
<td class="nump">8,248<span></span>
</td>
<td class="nump">7,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">6,547<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">243,277<span></span>
</td>
<td class="nump">303,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(61,659)<span></span>
</td>
<td class="num">(58,112)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">181,618<span></span>
</td>
<td class="nump">245,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Lease right-of-use assets</a></td>
<td class="num">(9,244)<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(9,244)<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 172,374<span></span>
</td>
<td class="nump">$ 244,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortization of deferred stock compensation - non-qualified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825032240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Summary of All Stock Option Activity) (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of the year (in shares) | shares</a></td>
<td class="nump">22,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(3,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending of the year (in shares) | shares</a></td>
<td class="nump">20,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of the year (in shares) | shares</a></td>
<td class="nump">16,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">20.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">16.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">22.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at ending of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">9.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding at end of the year</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at end of the year</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding at end of the year | $</a></td>
<td class="nump">$ 169,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at end of the year | $</a></td>
<td class="nump">$ 167,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821331744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding stock options, unvested RSUs and ESPP contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded</a></td>
<td class="nump">9,111<span></span>
</td>
<td class="nump">3,968<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel2019123110-k.htm": {
   "axisCustom": 5,
   "axisStandard": 22,
   "contextCount": 290,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20200103_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20200103_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel2019123110-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20200103_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20200103_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20200103.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 641,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 30,
    "http://www.exelixis.com/20200103": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 39
   },
   "keyCustom": 70,
   "keyStandard": 393,
   "memberCustom": 58,
   "memberStandard": 39,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20200103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Collaboration Agreements",
     "role": "http://www.exelixis.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashAndInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Property and Equipment",
     "role": "http://www.exelixis.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Employee Benefit Plans",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Income Taxes",
     "role": "http://www.exelixis.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Commitments",
     "role": "http://www.exelixis.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Employee Benefit Plans (Tables)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansTables",
     "shortName": "Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.exelixis.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Commitments (Tables)",
     "role": "http://www.exelixis.com/role/CommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
     "shortName": "Revenues (Revenues by Disaggregated Category) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
     "shortName": "Revenues (Net Product Revenues Disaggregated by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CabometyxMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails",
     "shortName": "Revenues (Revenues Disaggregated by Significant Customer) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
     "shortName": "Revenues (Revenues Disaggregated by Geographic Region) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails",
     "shortName": "Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2017Q4Dec29",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Revenues Revenues (Contract Assets and Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails",
     "shortName": "Revenues Revenues (Contract Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:MilestonePaymentsEarned",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember",
      "decimals": "-5",
      "lang": null,
      "name": "exel:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:MilestonePaymentsEarned",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (Takeda Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:PeriodOfSpecificSalesVolumeThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
     "shortName": "Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementNumberOfPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
     "shortName": "Collaboration Agreements Collaboration Agreements (In-Licensing Collaborations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementNumberOfPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:ProjectInitiationFeePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (Invenra Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:ProjectInitiationFeePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:UpfrontAndMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:UpfrontAndMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403408 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
     "shortName": "Collaboration Agreements (Collaboration Revenues - Genentech) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember",
      "decimals": "-3",
      "lang": null,
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403409 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
     "shortName": "Collaboration Agreements (Other Collaborations, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember",
      "decimals": "-5",
      "lang": null,
      "name": "exel:CollaborativeArrangementAchievedMilestoneAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2017Q4Dec29",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Cash and Investments (Summary by Security Type) (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
     "shortName": "Cash and Investments (Summary by Security Type) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
     "shortName": "Cash and Investments (Gross Unrealized Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "investment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Cash and Investments (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "investment",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails",
     "shortName": "Cash and Investments (Summary by Contractual Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Property and Equipment (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Employee Benefit Plans (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails",
     "shortName": "Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
     "shortName": "Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408406 - Disclosure - Employee Benefit Plans (Summary of All Stock Option Activity) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails",
     "shortName": "Employee Benefit Plans (Summary of All Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408407 - Disclosure - Employee Benefit Plans (Summary of All RSU Activity) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails",
     "shortName": "Employee Benefit Plans (Summary of All RSU Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "lang": null,
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes (Components of Income Tax Expense (Benefit)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "D2018Q1Fiscal",
      "decimals": "-3",
      "lang": null,
      "name": "exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails",
     "shortName": "Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2016Q4Dec30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2016Q4Dec30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Net Income Per Share (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails",
     "shortName": "Net Income Per Share (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Commitments (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsNarrativeDetails",
     "shortName": "Commitments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Commitments (Balance Sheet Classification of Lease Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails",
     "shortName": "Commitments (Balance Sheet Classification of Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Commitments (Components of Lease Expense) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails",
     "shortName": "Commitments (Components of Lease Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Commitments (Maturities of Operating Lease Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments (Maturities of Operating Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails",
     "shortName": "Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019123110-k.htm",
      "contextRef": "I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - exel2019123110-k.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - exel2019123110-k.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 97,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accredo Health, Incorporated [Member]",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AdditionalDevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional Development And Regulatory Milestone [Member]",
        "label": "Additional Development And Regulatory Milestone [Member]",
        "terseLabel": "Additional Development and Regulatory Milestone"
       }
      }
     },
     "localname": "AdditionalDevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AdditionalUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional Upfront And Milestone Payments",
        "label": "Additional Upfront And Milestone Payments",
        "terseLabel": "Additional upfront and milestone payments"
       }
      }
     },
     "localname": "AdditionalUpfrontAndMilestonePayments",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AreaOfRealEstatePropertyAvailableToLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area Of Real Estate Property, Available To Lease",
        "label": "Area Of Real Estate Property, Available To Lease",
        "terseLabel": "Area of property available for lease (in squire feet)"
       }
      }
     },
     "localname": "AreaOfRealEstatePropertyAvailableToLease",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "exel_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Balance Sheet Classification of Lease Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_BuiltToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Built-To-Suit Lease [Member]",
        "label": "Built-To-Suit Lease [Member]",
        "terseLabel": "Built-To-Suit Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Total, Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementNumberOfPreexistingPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Preexisting Programs",
        "label": "Collaboration Agreement, Number Of Preexisting Programs",
        "terseLabel": "Collaboration agreement pre-existing programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPreexistingPrograms",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Programs",
        "label": "Collaboration Agreement, Number Of Programs",
        "terseLabel": "Collaboration agreement, number of programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPrograms",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "label": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "terseLabel": "Collaboration agreement option exercise fee payment, upon exercising option"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Collaboration agreement percent of royalty on net sale",
        "verboseLabel": "Cost of goods sold is related to product"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Research And Development Expense Accrued",
        "label": "Collaboration Agreement, Research And Development Expense Accrued",
        "terseLabel": "Expense for the discovery and preclinical development funding commitment"
       }
      }
     },
     "localname": "CollaborationAgreementResearchAndDevelopmentExpenseAccrued",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementResearchAndDevelopmentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Research And Development Obligation",
        "label": "Collaboration Agreement, Research And Development Obligation",
        "terseLabel": "Preclinical development work on these programs"
       }
      }
     },
     "localname": "CollaborationAgreementResearchAndDevelopmentObligation",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Termination Period",
        "label": "Collaboration Agreement, Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationPeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "label": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementWithIconicTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "label": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "terseLabel": "Collaboration Agreement With Iconic Therapeutics, Inc."
       }
      }
     },
     "localname": "CollaborationAgreementWithIconicTherapeuticsInc.Member",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreements, Upfront Payments",
        "label": "Collaboration Agreements, Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementwithDaiichiSankyoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "label": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "terseLabel": "Collaboration Agreement with Daiichi Sankyo"
       }
      }
     },
     "localname": "CollaborationAgreementwithDaiichiSankyoMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration, License [Member]",
        "label": "Collaboration, License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "CollaborationLicenseMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration revenues",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Collaboration [Member]",
        "label": "Collaboration, Other [Member]",
        "terseLabel": "Other collaboration revenues"
       }
      }
     },
     "localname": "CollaborationOtherMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationResearchAndDevelopmentServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration, Research And Development Service [Member]",
        "label": "Collaboration, Research And Development Service [Member]",
        "terseLabel": "Research and development service revenues"
       }
      }
     },
     "localname": "CollaborationResearchAndDevelopmentServiceMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAchievedMilestoneAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Achieved Milestone Amount",
        "label": "Collaborative Arrangement, Achieved Milestone Amount",
        "terseLabel": "Achieved milestone amount"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievedMilestoneAmount",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "label": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "terseLabel": "Collaboration period to achieve specified levels of commercial performance"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Collaborative Arrangement, Income (Loss) From Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount eligible for development and regulatory milestones under collaborations agreement.",
        "label": "Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "terseLabel": "Maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementWithInvenraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement With Invenra [Member]",
        "label": "Collaborative Arrangement With Invenra [Member]",
        "terseLabel": "Collaborative Arrangement With Invenra"
       }
      }
     },
     "localname": "CollaborativeArrangementWithInvenraMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementWithStemSynergyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement With StemSynergy [Member]",
        "label": "Collaborative Arrangement With StemSynergy [Member]",
        "terseLabel": "Collaborative Arrangement With StemSynergy"
       }
      }
     },
     "localname": "CollaborativeArrangementWithStemSynergyMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaborative Arrangements with Glaxo Smith Kline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithDaiichiSankyoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Daiichi Sankyo [Member]",
        "label": "Collaborative Arrangement with Daiichi Sankyo [Member]",
        "terseLabel": "Collaborative Arrangement with Daiichi Sankyo"
       }
      }
     },
     "localname": "CollaborativeArrangementwithDaiichiSankyoMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen",
        "verboseLabel": "Collaborative arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer Equipment And Software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets amortization of deferred stock compensation - non-qualified.",
        "label": "Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Leasing Arrangements",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Regulatory Milestone [Member]",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_DiplomatSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Diplomat Specialty Pharmacy [Member]",
        "label": "Diplomat Specialty Pharmacy [Member]",
        "terseLabel": "Diplomat Specialty Pharmacy"
       }
      }
     },
     "localname": "DiplomatSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_DiscoveryProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discovery Project [Member]",
        "label": "Discovery Project [Member]",
        "terseLabel": "Discovery Project"
       }
      }
     },
     "localname": "DiscoveryProjectMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EMAFilingAcceptanceHCCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EMA Filing Acceptance - HCC",
        "label": "EMA Filing Acceptance - HCC [Member]",
        "terseLabel": "EMA Filing Acceptance - HCC"
       }
      }
     },
     "localname": "EMAFilingAcceptanceHCCMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share Basic Diluted Other Disclosures [Abstract]",
        "label": "Earnings Per Share Basic Diluted Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicDilutedOtherDisclosuresAbstract",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_FinalTierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Final Tier[Member]",
        "label": "Final Tier [Member]",
        "terseLabel": "Final tier"
       }
      }
     },
     "localname": "FinalTierMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_FirstProductToReachMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First Product To Reach Market [Member]",
        "label": "First Product To Reach Market [Member]",
        "terseLabel": "First Product To Reach Market"
       }
      }
     },
     "localname": "FirstProductToReachMarketMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "Collaborative Arrangement with GlaxoSmithKline"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_GlobalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global [Member]",
        "label": "Global [Member]",
        "terseLabel": "Global"
       }
      }
     },
     "localname": "GlobalMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Headquarters Lease [Member]",
        "label": "Headquarters Lease [Member]",
        "terseLabel": "Headquarters Lease"
       }
      }
     },
     "localname": "HeadquartersLeaseMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_InitialMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial [Member]",
        "label": "Initial [Member]",
        "terseLabel": "Initial"
       }
      }
     },
     "localname": "InitialMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_InventoryManufacturedBeforeRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, Manufactured Before Regulatory Approval",
        "label": "Inventory, Manufactured Before Regulatory Approval",
        "terseLabel": "Materials in inventory balances"
       }
      }
     },
     "localname": "InventoryManufacturedBeforeRegulatoryApproval",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "negatedTerseLabel": "Future tenant improvement reimbursements",
        "terseLabel": "Future tenant improvement reimbursements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs",
        "terseLabel": "Percentage of excess costs"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "terseLabel": "Currently estimated amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "terseLabel": "Annual increase percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period",
        "terseLabel": "Payment commencement period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionOfPaymentsDueAbstract",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_MINNEBROMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MINNEBRO [Member]",
        "label": "MINNEBRO [Member]",
        "terseLabel": "MINNEBRO"
       }
      }
     },
     "localname": "MINNEBROMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount eligible for commercial milestones under collaborations agreement.",
        "label": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MedicarePartDFundingMandate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare Part D Funding Mandate",
        "label": "Medicare Part D Funding Mandate",
        "terseLabel": "Medicare Part D Funding Mandate"
       }
      }
     },
     "localname": "MedicarePartDFundingMandate",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_MilestoneObjectiveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Objective [Axis]",
        "label": "Milestone Objective [Axis]",
        "terseLabel": "Milestone Objective [Axis]"
       }
      }
     },
     "localname": "MilestoneObjectiveAxis",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_MilestoneObjectiveDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for MilestoneObjective [Axis]",
        "label": "Milestone Objective [Domain]",
        "terseLabel": "Milestone Objective [Domain]"
       }
      }
     },
     "localname": "MilestoneObjectiveDomain",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments Earned",
        "label": "Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MilestonePaymentsEarnedToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments Earned To Date",
        "label": "Milestone Payments Earned To Date",
        "terseLabel": "Milestone payments earned to date"
       }
      }
     },
     "localname": "MilestonePaymentsEarnedToDate",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NotProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Not Probable [Member]",
        "label": "Not Probable [Member]",
        "terseLabel": "Not Probable"
       }
      }
     },
     "localname": "NotProbableMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingAndFinanceLeasesLiabilityTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Leases, Liability - Total",
        "label": "Operating And Finance Leases, Liability - Total",
        "terseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeasesLiabilityTotal",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OperatingLeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Assets [Abstract]",
        "label": "Operating Lease Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAbstract",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liabilities [Abstract]",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeasesVariableLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesRentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Variable Lease Expense",
        "label": "Operating Leases, Variable Lease Expense",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "OperatingLeasesVariableLeaseExpense",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OperatingLossCarryforwardswithExpirationDates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Loss Carryforwards with Expiration Dates",
        "label": "Operating Loss Carryforwards with Expiration Dates",
        "terseLabel": "Operating loss carryforwards with expiration dates"
       }
      }
     },
     "localname": "OperatingLossCarryforwardswithExpirationDates",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of royalty on net sale.",
        "label": "Percent of royalty on net sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "PercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_PerformanceShareOptionsPSOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Share Options (PSO) [Member]",
        "label": "Performance Share Options (PSO) [Member]",
        "terseLabel": "Performance Share Options (PSO)"
       }
      }
     },
     "localname": "PerformanceShareOptionsPSOMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesAchievedBeforeDecember312020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "label": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "terseLabel": "Performance Shares, Achieved Before December 31, 2020"
       }
      }
     },
     "localname": "PerformanceSharesAchievedBeforeDecember312020Member",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesSecondProductApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Shares, Second Product Approval [Member]",
        "label": "Performance Shares, Second Product Approval [Member]",
        "terseLabel": "Performance Shares, Second Product Approval"
       }
      }
     },
     "localname": "PerformanceSharesSecondProductApprovalMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PeriodOfSpecificSalesVolumeThreshold": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period Of Specific Sales Volume, Threshold",
        "label": "Period Of Specific Sales Volume, Threshold",
        "terseLabel": "Sales volume period"
       }
      }
     },
     "localname": "PeriodOfSpecificSalesVolumeThreshold",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Commercialization [Member]",
        "label": "Product Commercialization [Member]",
        "terseLabel": "Product Commercialization"
       }
      }
     },
     "localname": "ProductCommercializationMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products Derived from Cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products Derived From Other Compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingAgreementPercentOfProfits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Sharing Agreement, Percent of Profits",
        "label": "Profit Sharing Agreement, Percent of Profits",
        "terseLabel": "Percent of profits"
       }
      }
     },
     "localname": "ProfitSharingAgreementPercentOfProfits",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ProfitSharingAgreementProfitThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Sharing Agreement, Profit Threshold",
        "label": "Profit Sharing Agreement, Profit Threshold",
        "terseLabel": "Profit threshold"
       }
      }
     },
     "localname": "ProfitSharingAgreementProfitThreshold",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ProfitSharingTierOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Sharing Tier One [Member]",
        "label": "Profit Sharing Tier One [Member]",
        "terseLabel": "Profit Sharing Tier One"
       }
      }
     },
     "localname": "ProfitSharingTierOneMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingTierThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Sharing Tier Three [Member]",
        "label": "Profit Sharing Tier Three [Member]",
        "terseLabel": "Profit Sharing Tier Three"
       }
      }
     },
     "localname": "ProfitSharingTierThreeMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingTierTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Sharing Tier Two [Member]",
        "label": "Profit Sharing Tier Two [Member]",
        "terseLabel": "Profit Sharing Tier Two"
       }
      }
     },
     "localname": "ProfitSharingTierTwoMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingTiersAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Sharing Tiers [Axis]",
        "label": "Profit Sharing Tiers [Axis]",
        "terseLabel": "Profit Sharing Tiers [Axis]"
       }
      }
     },
     "localname": "ProfitSharingTiersAxis",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ProfitSharingTiersDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Profit Sharing Tiers [Axis]",
        "label": "Profit Sharing Tiers [Domain]",
        "terseLabel": "Profit Sharing Tiers [Domain]"
       }
      }
     },
     "localname": "ProfitSharingTiersDomain",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProjectInitiationFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Project Initiation Fee Payment",
        "label": "Project Initiation Fee Payment",
        "terseLabel": "Project initiation fee"
       }
      }
     },
     "localname": "ProjectInitiationFeePayment",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "label": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "terseLabel": "Research and development arrangement performed for others, reimbursement for costs incurred, percent"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting From Discovery Efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTier": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Tier",
        "label": "Royalty Tier",
        "terseLabel": "Royalty tier"
       }
      }
     },
     "localname": "RoyaltyTier",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "royalty tier [Axis]",
        "label": "Royalty Tier [Axis]",
        "terseLabel": "Royalty Tier [Axis]"
       }
      }
     },
     "localname": "RoyaltyTierAxis",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_RoyaltytierDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for royalty tier [Axis]",
        "label": "royalty tier [Domain]",
        "terseLabel": "royalty tier [Domain]"
       }
      }
     },
     "localname": "RoyaltytierDomain",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_SalesRevenueDiscountExpectedtobeEarnedPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Revenue, Discount Expected to be Earned, Percent",
        "label": "Sales Revenue, Discount Expected to be Earned, Percent",
        "terseLabel": "Discount expected to be earned"
       }
      }
     },
     "localname": "SalesRevenueDiscountExpectedtobeEarnedPercent",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SalesRevenuePercentDiscountForPromptPayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Revenue, Percent Discount for Prompt Payment",
        "label": "Sales Revenue, Percent Discount for Prompt Payment",
        "terseLabel": "Percent discount for prompt payment"
       }
      }
     },
     "localname": "SalesRevenuePercentDiscountForPromptPayment",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released",
        "negatedTerseLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "terseLabel": "Additional shares to be earned (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Employees percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "terseLabel": "Exercise threshold, percentage of per share exercise price of the PSO"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "terseLabel": "Tenant lease improvements allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions",
        "terseLabel": "Change relating to prior year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments.",
        "label": "Upfront And Milestone Payments",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePayments",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront Payment(s)",
        "label": "Upfront Payment(s)",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_VestedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vested [Member]",
        "label": "Vested [Member]",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "VestedMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]",
        "label": "Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]",
        "terseLabel": "2014 Warrants"
       }
      }
     },
     "localname": "WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember",
     "nsuri": "http://www.exelixis.com/20200103",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r144",
      "r214",
      "r219",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r141",
      "r214",
      "r217",
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r143",
      "r214",
      "r218",
      "r398",
      "r404",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASU 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201609Member": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2016-09 [Member]",
        "terseLabel": "ASU 2016-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201609Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r195"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r51",
      "r55",
      "r56",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r227",
      "r229",
      "r276",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r229",
      "r260",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r140",
      "r372",
      "r387"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r48"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r154",
      "r172"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Investment securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r158",
      "r160",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r158",
      "r159",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r152",
      "r155",
      "r172"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total investment securities available-for-sale",
        "verboseLabel": "Total investment securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r231",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r29",
      "r90"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r91",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r90",
      "r96"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r345"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r103",
      "r207",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r101",
      "r207",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r200",
      "r378",
      "r393"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 304,831 and 299,876 at December 31, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r341",
      "r342",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r341",
      "r342",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r130",
      "r131",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred.",
        "label": "Construction in Progress Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment deemed to have been acquired in build-to-suit lease"
       }
      }
     },
     "localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r208",
      "r210",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r208",
      "r209",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Net contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r215"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "verboseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Adoption of Accounting Standards Update (ASU) No. 2016-09, Compensation\u2014Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r309",
      "r314"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r309",
      "r314"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r309",
      "r314"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r165",
      "r177",
      "r180"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "In an Unrealized Loss Position 12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r165",
      "r177"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r165",
      "r177",
      "r180"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "In an Unrealized Loss Position Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r165",
      "r177"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r162",
      "r173",
      "r180"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r163",
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r161",
      "r176",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r164",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r310",
      "r314"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r100",
      "r310",
      "r314"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r310",
      "r314"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r283",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r282",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r283",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r305",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r282",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Accruals and reserves not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r288",
      "r303"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r283",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses relating to stock match"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r88",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r88",
      "r138"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "verboseLabel": "Adjustments Due to the Adoption of Topic 606"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r108",
      "r112",
      "r114",
      "r115",
      "r116",
      "r119",
      "r380",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "netLabel": "Basic (in dollars per share)",
        "terseLabel": "Net income (loss) per share, basic (in dollars per share)",
        "verboseLabel": "Net income per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r108",
      "r112",
      "r114",
      "r115",
      "r116",
      "r119",
      "r380",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted (in dollars per share)",
        "terseLabel": "Net income (loss) per share, diluted (in dollars per share)",
        "verboseLabel": "Net income per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r289",
      "r290",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized compensation expense weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r335",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r335",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r335",
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r97",
      "r339",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r176",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r324",
      "r329",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r344",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r187",
      "r189"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r97",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r88",
      "r188",
      "r190",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charge on goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r292",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r139",
      "r315"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision (benefit)",
        "totalLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r97",
      "r286",
      "r287",
      "r298",
      "r299",
      "r304",
      "r316",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r285",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r99",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal income tax provision at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible interest"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r99",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r137",
      "r347",
      "r348",
      "r381"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r83",
      "r85",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r46",
      "r182"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r47",
      "r97",
      "r121",
      "r183",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "Cash and Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesRentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r364",
      "r366"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Build-to-suit lease period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r373",
      "r390"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r57",
      "r60",
      "r65",
      "r89",
      "r118",
      "r379",
      "r394"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r108",
      "r110"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income allocable to common stock - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income allocable to common stock - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations",
        "verboseLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r358",
      "r366"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Year Ending December 31,"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets included in other long-term assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r363",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average operating discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r362",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesRentExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r106",
      "r136",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r61",
      "r325",
      "r326",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r50",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "negatedTerseLabel": "Unrealized gains or losses on available-for-sale securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairment charges on available-for-sale securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r78",
      "r263"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r79",
      "r82",
      "r104"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r78",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Cash received from option exercises and purchases under the ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r32",
      "r194"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r196",
      "r392"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r97",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r17",
      "r23",
      "r391",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r281",
      "r408"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r97",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r10",
      "r96"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Short-term restricted cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r96",
      "r405"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in long-term investments"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r206",
      "r389"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation",
        "verboseLabel": "Transaction price allocated to our performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r229",
      "r259",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r229",
      "r259",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r24",
      "r25",
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Summary of All RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "verboseLabel": "Schedule of Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r96",
      "r371",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r231",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r237",
      "r248",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of All Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r297",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r128",
      "r130",
      "r131",
      "r132",
      "r341",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Revenues Disaggregated by Significant Customer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70",
      "r181"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Discount rate from market value on offering date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discount rate from market value on purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Instruments awarded (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Awards outstanding at end of period (in shares)",
        "periodStartLabel": "Awards outstanding at beginning of period (in shares)",
        "terseLabel": "Number of awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Awards outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Awards outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term, Awards outstanding at end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding at end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r239",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at ending of the year (in shares)",
        "periodStartLabel": "Options outstanding at beginning of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at ending of the year (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r228",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r228",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r97",
      "r231",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value, Awards outstanding at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllRsuActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Life of stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r254",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term, Exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options outstanding at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r374",
      "r375",
      "r377",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r202",
      "r203",
      "r323",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Outstanding stock options, unvested RSUs and ESPP contributions"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "verboseLabel": "Issuance of common stock on exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r205",
      "r206",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryOfAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock on exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r206",
      "r230",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r150"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r360",
      "r366"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r223",
      "r376",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedLabel": "Net income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "negatedLabel": "Adjustment to net income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r284",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Change relating to current year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Reductions based on the lapse of the applicable statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would reduce income tax provision and effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Income tax provision (benefit)",
        "verboseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r359",
      "r366"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Outstanding stock options, unvested RSUs and ESPP contributions (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r116"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r116"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118956092&loc=d3e12803-110250"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02(b))",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03(b))",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r412": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r413": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r414": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r415": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6820002944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:56%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Lives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">up to 15 years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5 to 7 years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,904</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>74,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25,560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(17,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830398768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits and losses on U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,615</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828081376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>690,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>154,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(367</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>690,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>690,070</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>302,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>297,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>293,588</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive effect of employee stock plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,415</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.06</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</a></td>
<td class="text">These potential common shares were as follows (in thousands):<span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Anti-dilutive securities and contingently issuable shares excluded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,645</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842887056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues by Disaggregated Category) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,621<span></span>
</td>
<td class="nump">738,529<span></span>
</td>
<td class="nump">402,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,671)<span></span>
</td>
<td class="num">(119,250)<span></span>
</td>
<td class="num">(53,561)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,950<span></span>
</td>
<td class="nump">619,279<span></span>
</td>
<td class="nump">349,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationLicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,299<span></span>
</td>
<td class="nump">192,188<span></span>
</td>
<td class="nump">96,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationResearchAndDevelopmentServiceMember', window );">Research and development service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,965<span></span>
</td>
<td class="nump">39,501<span></span>
</td>
<td class="nump">8,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationOtherMember', window );">Other collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,439)<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
<td class="num">(1,905)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,825<span></span>
</td>
<td class="nump">$ 234,547<span></span>
</td>
<td class="nump">$ 103,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationResearchAndDevelopmentServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationResearchAndDevelopmentServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825358176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 17,276<span></span>
</td>
<td class="nump">$ 9,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">193,791<span></span>
</td>
<td class="nump">119,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(188,714)<span></span>
</td>
<td class="num">(111,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">26,233<span></span>
</td>
<td class="nump">17,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">2,322<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">129,936<span></span>
</td>
<td class="nump">75,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">3,989<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(128,733)<span></span>
</td>
<td class="num">(74,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">7,514<span></span>
</td>
<td class="nump">2,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">3,038<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">15,605<span></span>
</td>
<td class="nump">13,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(15,035)<span></span>
</td>
<td class="num">(11,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">3,497<span></span>
</td>
<td class="nump">3,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">11,916<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">48,250<span></span>
</td>
<td class="nump">31,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(44,946)<span></span>
</td>
<td class="num">(24,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 15,222<span></span>
</td>
<td class="nump">$ 11,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6824500960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">304,831,000<span></span>
</td>
<td class="nump">299,876,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">304,831,000<span></span>
</td>
<td class="nump">299,876,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830336752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income before income taxes is derived solely from within the U.S. Our income tax provision (benefit) was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71,580</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(238,675</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71,002</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(244,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(237,978</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income tax provision for the year ended December 31, 2019 primarily relates to the utilization of federal net operating loss and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. The income tax benefit for the year ended December 31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California. The income tax provision for the year ended December 31, 2017 primarily related to state taxes in jurisdictions outside of California. Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2019, 2018 and 2017. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of the U.S. federal income tax provision (benefit) at the statutory federal income tax rates of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>34%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended December 31, 2019, 2018 and 2017, respectively, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to our income tax provision (benefit) was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax provision at statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>83,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>94,939</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>53,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(315,394</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(34,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(18,308</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(20,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible executive compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>982</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(237,978</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>65,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>146,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>110,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>98,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,966</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>303,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(61,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(58,112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>181,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>245,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,244</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,279</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>244,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2019, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December 31, 2019 and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, as well as considering the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">utilization of net operating losses and tax credits prior to their expiration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December 31, 2019 and 2018, we continue to carry a valuation allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$61.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$58.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, against our California state deferred tax assets. Prior to December 31, 2018, because of our history of operating losses, management believed that recognition of the deferred tax assets was not more likely than not (as defined in Topic 740) to be realized and, accordingly, had provided a full valuation allowance. The valuation allowance increased by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$3.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and decreased by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$360.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended December 31, 2019 and 2018, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had federal net operating loss carryforwards of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$225 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, of which approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$203 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> will expire in the years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2035</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and federal business tax credits of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$112 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which expire in the years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2039</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also had state net operating loss carryforwards of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$450 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which expire in the years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and California research and development tax credits of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$38 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which do not expire.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and concluded that an ownership change, as defined under Section 382, had not occurred. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>61,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(4,254</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not anticipate that the amount of unrecognized tax benefits existing as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> will significantly change over the next 12 months. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$79.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in unrecognized tax benefits, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$48.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would reduce our income tax provision and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. </span></div>We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2019 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843223376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 30, 2016</a></td>
<td class="nump">$ 89,318<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 2,072,591<span></span>
</td>
<td class="num">$ (416)<span></span>
</td>
<td class="num">$ (1,983,147)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,409<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">17,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock on exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock on exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 29, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 29, 2017</a></td>
<td class="nump">284,961<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">2,114,184<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">690,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</a></td>
<td class="num">(354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">13,411<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">13,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 40,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 28, 2018</a></td>
<td class="nump">299,876<span></span>
</td>
<td class="nump">299,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,168,217<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(880,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">321,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net unrealized gains (losses) on available-for-sale securities, net of tax impact of $(1,049), $156, and $0, respectively</a></td>
<td class="nump">3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,133<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">17,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Jan. 03, 2020</a></td>
<td class="nump">304,831<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 2,241,947<span></span>
</td>
<td class="nump">$ 3,069<span></span>
</td>
<td class="num">$ (559,351)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830357104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,345,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,347,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>796,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>844,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div>The carrying amount of our remaining financial assets and liabilities, which include cash and restricted cash, receivables and payables approximate their fair values due to the short-term nature.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6833496240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Balance Sheet Classification of Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets included in other long-term assets</a></td>
<td class="nump">$ 41,835<span></span>
</td>
<td class="nump">$ 5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in other current liabilities</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">48,011<span></span>
</td>
<td class="nump">12,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 50,739<span></span>
</td>
<td class="nump">$ 14,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822350560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 8.19<span></span>
</td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842997680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 74,452<span></span>
</td>
<td class="nump">$ 68,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(25,560)<span></span>
</td>
<td class="num">(17,309)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">48,892<span></span>
</td>
<td class="nump">50,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33,904<span></span>
</td>
<td class="nump">33,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17,338<span></span>
</td>
<td class="nump">15,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,053<span></span>
</td>
<td class="nump">12,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,904<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,253<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830374448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment charges on available-for-sale securities | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819607152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions', window );">Change relating to prior year provision</a></td>
<td class="num">$ (4,254)<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change relating to current year provision</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">17,378<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on the lapse of the applicable statutes of limitations</a></td>
<td class="num">$ (111)<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827888688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Income Tax Expense (Benefit)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">6,133<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">6,133<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">71,580<span></span>
</td>
<td class="num">(238,675)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(578)<span></span>
</td>
<td class="num">(5,436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">71,002<span></span>
</td>
<td class="num">(244,111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 77,097<span></span>
</td>
<td class="num">$ (237,978)<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6846401328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="nump">$ 50,600,000<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="nump">$ 42,600,000<span></span>
</td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="nump">$ 66,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">63,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">330,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">470,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="nump">152,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,900,000<span></span>
</td>
<td class="nump">$ 69,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="nump">24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Minimum | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Maximum | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845282800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Invenra Collaboration, Narrative) (Details) - Collaborative Arrangement With Invenra - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember', window );">Discovery Project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProjectInitiationFeePayment', window );">Project initiation fee</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember', window );">Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">131.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember', window );">Additional Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProjectInitiationFeePayment', window );">Project initiation fee</a></td>
<td class="nump">43.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember', window );">Product Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">$ 325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProjectInitiationFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project Initiation Fee Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProjectInitiationFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6726321104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 266,501<span></span>
</td>
<td class="nump">$ 314,775<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in long-term investments</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">$ 268,137<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
<td class="nump">$ 155,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830341984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income before income taxes is derived solely from within the U.S. Our income tax provision (benefit) was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71,580</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(238,675</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71,002</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(244,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(237,978</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of the U.S. federal income tax provision (benefit) at the statutory federal income tax rates of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>34%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended December 31, 2019, 2018 and 2017, respectively, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to our income tax provision (benefit) was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax provision at statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>83,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>94,939</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>53,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(315,394</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(34,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(18,308</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(20,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible executive compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>982</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(237,978</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Assets and Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>65,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>146,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit carryforwards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>110,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>98,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,966</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,547</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>303,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(61,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(58,112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>181,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>245,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,244</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,279</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>244,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>61,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(4,254</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829643056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,345,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,347,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>796,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>844,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6755602448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div>The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018 and fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017. For convenience, references in this report as of and for the fiscal years ended January 3, 2020, December 28, 2018 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the FASB issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for us in the first quarter of 2020. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for us in the first quarter of 2020. We are currently assessing the impact of ASU 2016-13 on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the third quarter of 2019, we adopted ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 requires capitalized implementation costs to be expensed over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted ASU 2018-15 using the prospective transition method in the accompanying Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2019, we adopted ASU 2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income (loss) to accumulated deficit. In connection with the adoption of ASU 2018-02, we adopted the individual unit of account approach for releasing income tax effects from accumulated other comprehensive income (loss).</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2019, we also adopted ASU 2017-08, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span> (ASU 2017-08). ASU 2017-08 shortens the amortization period for certain callable debt securities held at a premium. Specifically, ASU 2017-08 requires the premium to be amortized to the earliest call date. ASU 2017-08 does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income (expense), net in the accompanying Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of restricted cash </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents as short-term or long-term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">dependent upon the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">longer of the remaining term to maturity of the investment or the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">remaining term of the related restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We subject all of our investments to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record trade accounts receivable net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">have been insignificant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>15 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We periodically review the carrying amount of goodwill for impairment (at least annually) and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. Historically, we assessed the recoverability of our goodwill on the last day of our third quarter. Beginning in 2019, we changed the date of our annual goodwill impairment assessment to the first day of our fourth quarter to allow for operational expediency. The change in goodwill impairment testing date does not represent a significant change to our accounting for goodwill</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value. We continue to operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span> segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We assess whether our collaboration agreements are subject to ASC 808:&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we assess whether the payments between us and our collaboration partner are subject to other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Topic 606. However, if we conclude that our collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, we present such payments as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Results for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while results for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have not been adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, ASC Topic 605: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 605). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: 1) identify the contract(s) with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations in the contract; and 5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>100%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2018 and 2017, the</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>50%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. This amount increased to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>70%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in 2019. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. Except for profit sharing arrangements, payments for product supply services </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and certain development cost reimbursements, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">each of these payment types were within the scope of Topic 606 during the years ended December 31, 2019 and 2018. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When such services are provided to a customer, and they are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenue for these services as the performance obligations are satisfied over time. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We account for such arrangements in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the years ending December 31, 2019 and 2018 and accordingly, those profits are recognized as collaboration revenues in the accompanying Consolidated Statements of Income. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as selling, general and administrative expenses in the accompanying Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Royalty and Sales-based Milestone Payments:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenue at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</span></div>We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018 and 2017 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and primarily include: (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees, funded research and milestone payments incurred for our in-licensing arrangements with our collaboration partners; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">becomes more certain. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development, regulatory or commercial milestone payments to collaboration partners are recorded as research and development costs when we determine such payments become probable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the weighted average discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not to apply the recognition requirements of Topic 842 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for short-term leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Advertising</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Advertising expenses were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$17.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$14.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in sales, general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;awards, performance-based restricted&#160;stock&#160;awards (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Compensation-Stock&#160;Compensation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense relating to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax provision or benefit is computed under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. Some of these estimates are based on interpretations of existing tax laws or regulations. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the technical merits of the position</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Remeasurement</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</span></div>Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income (expense), net in the accompanying Consolidated Statements of Income. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845381152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 58,112<span></span>
</td>
<td class="nump">$ 61,659<span></span>
</td>
<td class="nump">$ 58,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">244,100<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="num">(360,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 76,060<span></span>
</td>
<td class="nump">79,078<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
<td class="nump">$ 79,342<span></span>
</td>
<td class="nump">$ 61,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLossCarryforwardswithExpirationDates', window );">Operating loss carryforwards with expiration dates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLossCarryforwardswithExpirationDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards with Expiration Dates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLossCarryforwardswithExpirationDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843777136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Summary of All RSU Activity) (Details) - RSUs<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">4,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">5,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(1,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares) | shares</a></td>
<td class="nump">8,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">19.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">17.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">18.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term, Awards outstanding at end of the year</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Awards outstanding at end of the year | $</a></td>
<td class="nump">$ 149,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845669664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Security Type) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investment securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,308,351<span></span>
</td>
<td class="nump">$ 781,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4,121<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,312,464<span></span>
</td>
<td class="nump">780,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">1,384,510<span></span>
</td>
<td class="nump">852,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</a></td>
<td class="nump">4,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Total, Fair Value</a></td>
<td class="nump">1,388,628<span></span>
</td>
<td class="nump">851,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investment securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">389,573<span></span>
</td>
<td class="nump">381,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">389,573<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investment securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">752,295<span></span>
</td>
<td class="nump">344,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">756,226<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investment securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">166,483<span></span>
</td>
<td class="nump">55,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">166,665<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">40,964<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">40,964<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">32,728<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 32,733<span></span>
</td>
<td class="nump">$ 16,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845760896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Takeda Collaboration, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="nump">$ 50,600,000<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="nump">$ 42,600,000<span></span>
</td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="nump">$ 66,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">63,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PeriodOfSpecificSalesVolumeThreshold', window );">Sales volume period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="nump">24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Global</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Minimum | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Maximum | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606 | EMA Filing Acceptance - HCC | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodOfSpecificSalesVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Specific Sales Volume, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodOfSpecificSalesVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830433584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details) - Collaborative Arrangement With StemSynergy - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AdditionalUpfrontAndMilestonePayments', window );">Additional upfront and milestone payments</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember', window );">First Product To Reach Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">$ 56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AdditionalUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Upfront And Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AdditionalUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843298592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>266,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>268,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>266,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>268,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Investments by Security Type</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investment securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>752,295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,308,351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,384,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,388,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investment securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>781,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>852,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>851,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on investment securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>236,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investment securities available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>789,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>626,711</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>522,551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819957408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selected unaudited quarterly financial data was as follows (in thousands, except per share data):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal 2019 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">March&#160;31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>215,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172,080</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>184,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>184,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>91,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>115,606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>75,775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>97,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,743</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal 2018 Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">March&#160;31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>213,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>228,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>139,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>155,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>168,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>116,307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>85,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>125,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>111,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>115,857</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>126,630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>360,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Total revenues for the quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 included </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$20.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$50.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$15.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> in milestone revenue, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$66.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$25.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$42.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$29.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> during the comparable periods in 2018. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as net product revenues less cost of goods sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Net income for the quarter ended December 31, 2018 included a </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>$244.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</span></div>The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6728257968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,569</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,626</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of All Stock Option Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options, including PSOs, during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.2 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>169,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options exercisable at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.6 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>167,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of All RSU Activity</a></td>
<td class="text">Activity for RSUs, including PSUs, during the <span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,842</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(357</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.2 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>149,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843777424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues (Contract Assets and Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">6,596,000<span></span>
</td>
<td class="nump">15,897,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">161,200,000<span></span>
</td>
<td class="nump">$ 198,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to our performance obligations</a></td>
<td class="nump">63,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to our performance obligations</a></td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830357104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets included in other long-term assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41,835</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,739</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017 </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,189</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,944</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,661</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,935</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The 2017 amounts have not been adjusted for the adoption of Topic 842 and continue to be reported in accordance with the previous lease guidance, ASC Topic 840: </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;">Leases</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ending December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(13,685</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Future tenant improvement reimbursements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,739</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6844093472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Net Product Revenues Disaggregated by Product) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,421<span></span>
</td>
<td class="nump">599,946<span></span>
</td>
<td class="nump">324,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,529<span></span>
</td>
<td class="nump">19,333<span></span>
</td>
<td class="nump">25,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759,950<span></span>
</td>
<td class="nump">$ 619,279<span></span>
</td>
<td class="nump">$ 349,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843240704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 266,501<span></span>
</td>
<td class="nump">$ 314,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">585,742<span></span>
</td>
<td class="nump">378,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">119,073<span></span>
</td>
<td class="nump">162,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">12,886<span></span>
</td>
<td class="nump">9,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">26,988<span></span>
</td>
<td class="nump">31,073<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,011,190<span></span>
</td>
<td class="nump">897,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">536,385<span></span>
</td>
<td class="nump">158,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">48,892<span></span>
</td>
<td class="nump">50,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">172,374<span></span>
</td>
<td class="nump">244,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">53,145<span></span>
</td>
<td class="nump">8,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,885,670<span></span>
</td>
<td class="nump">1,422,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,581<span></span>
</td>
<td class="nump">10,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">37,364<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">38,777<span></span>
</td>
<td class="nump">18,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">18,719<span></span>
</td>
<td class="nump">14,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">11,856<span></span>
</td>
<td class="nump">7,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">24,449<span></span>
</td>
<td class="nump">21,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">142,746<span></span>
</td>
<td class="nump">105,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">6,596<span></span>
</td>
<td class="nump">15,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">48,011<span></span>
</td>
<td class="nump">12,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiabilityTotal', window );">Long-term portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,347<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">199,700<span></span>
</td>
<td class="nump">134,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 304,831 and 299,876 at December 31, 2019 and 2018, respectively</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,241,947<span></span>
</td>
<td class="nump">2,168,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">3,069<span></span>
</td>
<td class="num">(701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(559,351)<span></span>
</td>
<td class="num">(880,363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,685,970<span></span>
</td>
<td class="nump">1,287,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,885,670<span></span>
</td>
<td class="nump">$ 1,422,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiabilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability - Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiabilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829660592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Incentive Plans and ESPP</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,569</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,626</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we granted stock options and RSUs, including PSOs and PSUs, to employees and directors. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>6,258,319</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Board of Directors (the Board) delegated responsibility for administration of our equity incentive plans to the Compensation Committee of the Board, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seven</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year life from the date of grant. Stock options issued prior to May 2011 have a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year life from the date of grant. RSUs granted to our employees and directors generally have a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term and a one-year vesting term, respectively. PSUs and PSOs granted pursuant to our equity incentive plans vest upon the achievement of a performance target or market condition, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>85%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the beginning of the offering period or</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>85%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the end of each</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">six</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">month purchase period. Compensation expense related to our ESPP was</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$2.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$2.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$1.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">for the years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. As of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, we had</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>4,238,999</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares available for issuance under our ESPP. Pursuant to the ESPP, we issued</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>483,009</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>330,492</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>434,523</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares of common stock at an average price per share of</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$12.60</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$15.74</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"><span>$11.20</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">during the years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Cash received</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from purchases under the ESPP for the years ended December 31, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$5.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$4.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value PSOs that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options, including PSOs:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered both implied and historical volatilities in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs, including the PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options, including PSOs, during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.2 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>169,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options exercisable at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.6 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>167,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$33.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options, including PSOs. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>2.2 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>308,365</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> PSOs to our President and Chief Executive Officer. In addition to the standard service conditions included in our other stock options, these PSOs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equal to or greater than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>125%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the per share exercise price of the PSO over a period of at least 30 consecutive calendar days. The stock-based compensation expense for the PSO is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total intrinsic value of stock options exercised during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$54.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$39.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$85.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Cash received from stock option exercises during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$17.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The total estimated fair value of stock options vested and recorded as expense during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$23.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$18.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$13.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Activity for RSUs, including PSUs, during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual&#160;</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,842</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(357</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.2 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>149,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$158.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including PSUs. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2.7 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2019, in connection with our long-term incentive compensation program, we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1,926,605</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> PSUs (the target amount) that will vest upon the achievement of a performance target related to a product approval by the FDA (the 2019 PSUs); employees may earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>150%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount, or an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>963,136</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, if the performance target is achieved before December 31, 2020 and may earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>200%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount, or up to an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1,926,605</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, if we receive a second product approval by December 31, 2021. During 2018 we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>693,131</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> PSUs that will vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we achieved two of the performance targets for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>281,238</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the 2018 PSUs and determined that it was probable that we would achieve one additional performance target for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>99,281</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional 2018 PSUs. As a result, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>141,004</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the 2018 PSUs have vested as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the remainder are expected to vest over various dates through November 2021. We recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$4.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense related to those 2018 PSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; the remaining unrecognized compensation expense for those 2018 PSUs was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total unrecognized compensation expense for both the 2019 PSUs and the remaining 2018 PSUs for which we have not yet determined that attainment of the performance target is probable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$80.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sponsor the 401(k) Plan under which we historically made matching contributions to our employees&#8217; 401(k) accounts in the form of our common stock. We recorded compensation expense related to the stock match of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$4.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$3.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Beginning in 2020, we will make matching contributions to our employees&#8217; 401(k) accounts in cash</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822713552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gains or losses on available-for-sale securities, tax impact</a></td>
<td class="num">$ (1,049)<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830476832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Cash and Investments</a></td>
<td class="text">CASH AND INVESTMENTS<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>266,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>268,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit and, during prior periods, a purchasing card program. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of restricted cash </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents as short-term or long-term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">dependent upon the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">longer of the remaining term to maturity of the investment or the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">remaining term of the related restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investment securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>752,295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,308,351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,384,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,388,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investment securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>781,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>852,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>851,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investment securities available-for-sale were insignificant during the years ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We manage credit risk </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">associated with our investment portfolio </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on investment securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>236,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>9</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>199</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investment securities in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investment securities available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>789,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>626,711</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>522,551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investment securities available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822128912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Components of Lease Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,844<span></span>
</td>
<td class="nump">$ 4,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeasesVariableLeaseExpense', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="nump">$ 5,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeasesVariableLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Variable Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeasesVariableLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830746192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">9,447<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">4,367<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">16,523<span></span>
</td>
<td class="nump">11,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">12,886<span></span>
</td>
<td class="nump">9,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 3,637<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819564416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Gross Unrealized Losses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 17,377<span></span>
</td>
<td class="nump">$ 271,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,809<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">17,377<span></span>
</td>
<td class="nump">320,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">14,529<span></span>
</td>
<td class="nump">236,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">14,529<span></span>
</td>
<td class="nump">275,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="nump">28,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="nump">37,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6846190128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="nump">6,258,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="nump">$ 40,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">1,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses relating to stock match</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Life of stock options granted</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 54,100<span></span>
</td>
<td class="nump">39,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="nump">23,400<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="nump">1,926,605<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="nump">5,842,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="nump">8,801,000<span></span>
</td>
<td class="nump">4,857,000<span></span>
</td>
<td class="nump">4,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,238,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate from market value on purchase date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount rate from market value on offering date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued (in shares)</a></td>
<td class="nump">483,009<span></span>
</td>
<td class="nump">330,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="nump">$ 15.74<span></span>
</td>
<td class="nump">$ 15.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember', window );">Performance Share Options (PSO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises', window );">Exercise threshold, percentage of per share exercise price of the PSO</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member', window );">Performance Shares, Achieved Before December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Employees percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Additional shares to be earned (in shares)</a></td>
<td class="nump">963,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesSecondProductApprovalMember', window );">Performance Shares, Second Product Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Employees percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Additional shares to be earned (in shares)</a></td>
<td class="nump">1,926,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_AchievedMember', window );">Achieved | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="nump">281,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_VestedMember', window );">Vested | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="nump">141,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_ProbableMember', window );">Probable | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="nump">99,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_NotProbableMember', window );">Not Probable | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 80,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesSecondProductApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesSecondProductApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_VestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_VestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_NotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_NotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
